_golden	chemical_id	chemical_name	disease_id	disease_name	form_sentence	original_job_id	pmid	relation_pair_id	sentence_id	uniq_id	verify_relationship_gold	verify_relationship_gold_reason
TRUE	D012701	"<span class=""chemical"">5-HT</span>"	D011605	"<span class=""disease"">psychotic disorders</span>"	"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered <span class=""chemical"">5-HT</span>6 receptors are involved in the pathophysiology of <span class=""disease"">psychotic disorders</span>."	762850.0	20705401.0	20705401_D012701_D011605		bcv_easy_68_sent_dev_set_762850	"no_relation
"	The receptors to 5-HT6 are related to psychotic disorders, not 5-HT itself.
TRUE	D010396	"<span class=""chemical"">D-penicillamine</span>"	D012594	"<span class=""disease"">localized scleroderma</span>"	"Case reports of 11 patients with severe, extensive <span class=""disease"">localized scleroderma</span> who were treated with <span class=""chemical"">D-penicillamine</span> are summarized in this article."	762850.0	2334179.0	2334179_D010396_D012594		bcv_easy_2399_sent_dev_set_762850	"no_relation
"	D-penicillamine was used to treat the patients.
TRUE	D015016	"<span class=""chemical"">yohimbine</span>"	D019964	"<span class=""disease"">affective disorders</span>"	"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or <span class=""disease"">affective disorders</span> who suffered sexual side effects after treatment with serotonin reuptake blockers were given <span class=""chemical"">yohimbine</span> on a p.r.n. basis in an open clinical trial."	762850.0	1535072.0	1535072_D015016_D019964		bcv_easy_642_sent_dev_set_762850	"no_relation
"	"The sentence says the affective disorders were caused by ""serotonin reuptake blockers"". Yohimbine was used to try and treat the patients."
TRUE	D002118	"<span class=""chemical"">calcium</span>"	D013035	"<span class=""disease"">muscle spasms</span>"	"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with <span class=""disease"">muscle spasms</span> and tetany which cannot be corrected by potassium and <span class=""chemical"">calcium</span> supplementation alone (1,2)."	762850.0	8492347.0	8492347_D002118_D013035		bcv_easy_1271_sent_dev_set_762850	"no_relation
"	The sentence says calcium supplementation cannot be used to treat muscle spasms and tetany.
TRUE	D064730	"<span class=""chemical"">dexrazoxane</span>"	D006402	"<span class=""disease"">hematologic toxicity</span>"	"Clinical trials in patients with brain metastases combining <span class=""chemical"">dexrazoxane</span> and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating <span class=""disease"">hematologic toxicity</span>."	762850.0	15897593.0	15897593_D064730_D006402		bcv_easy_2793_sent_dev_set_762850	"no_relation
"	Dexrazoxane is being used to try and make the patients better without making hematologic toxicity worse. The sentence does not say that dexrazoxane causes hematologic toxicity.
TRUE	D003404	"<span class=""chemical"">creatinine</span>"	D006973	"<span class=""disease"">hypertension</span>"	"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline <span class=""chemical"">creatinine</span>, low systolic blood pressure (<100 mm Hg), history of <span class=""disease"">hypertension</span>, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy."	762850.0	10539815.0	10539815_D003404_D006973		bcv_easy_306_sent_dev_set_762850	"no_relation
"	Creatinine and hypertension were studied as potential predictors of decreased renal (kidney) function.
TRUE	C071741	"<span class=""chemical"">remifentanil</span>"	D010146	"<span class=""disease"">pain</span>"	"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and <span class=""chemical"">remifentanil</span>, a significant reduction in propofol infusion <span class=""disease"">pain</span> was achieved without significant complications by prior administration of <span class=""chemical"">remifentanil</span> at a target Ce of 4 ng ml(-1)."	762850.0	18006530.0	18006530_C071741_D010146		bcv_easy_2437_sent_dev_set_762850	"no_relation
"	Remifentanil reduces the pain caused by propofol.
TRUE	C012052	"<span class=""chemical"">amisulpride</span>"	D006973	"<span class=""disease"">hypertensive</span>"	"CONCLUSIONS: As of March 24, 2005, this is the first reported case of <span class=""chemical"">amisulpride</span>- and tiapride-induced <span class=""disease"">hypertensive</span> crisis in a patient with pheochromocytoma."	762850.0	15811908.0	15811908_C012052_D006973		bcv_easy_808_sent_dev_set_762850	"yes_direct
"	This sentence talks about the first case of amisulpride induced hypertensive crisis.
TRUE	D002211	"<span class=""chemical"">capsaicin</span>"	D010146	"<span class=""disease"">painful</span>"	"A small amount of <span class=""chemical"">capsaicin</span> was administered subcutaneously in the right forehead to evoke a burning <span class=""disease"">painful</span> sensation in the first division of the trigeminal nerve."	762850.0	9514561.0	9514561_D002211_D010146		bcv_easy_2013_sent_dev_set_762850	"yes_direct
"	Capsaicin (the chemical that makes chilis spicy), when put under your skin, causes pain.
TRUE	D003630	"<span class=""chemical"">daunorubicin</span>"	D000163	"<span class=""disease"">AIDS</span>"	"We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal <span class=""chemical"">daunorubicin</span> (DaunoXome) in the treatment of <span class=""disease"">AIDS</span> related Kaposi's sarcoma."	762850.0	8305357.0	8305357_D003630_D000163		bcv_easy_125_sent_dev_set_762850	"no_relation
"	Daunorubicin is being studied as a way to treat AIDS related Kaposi's sarcoma.
TRUE	D000241	"<span class=""chemical"">adenosine</span>"	D059787|D059350	"<span class=""disease"">acute and chronic pain</span>"	"BACKGROUND: Preclinical studies of intrathecal <span class=""chemical"">adenosine</span> suggest it may be effective in the treatment of <span class=""disease"">acute and chronic pain</span> in humans, and preliminary studies in volunteers and patients with a Swedish formulation of <span class=""chemical"">adenosine</span> suggests it may be effective in hypersensitivity states but not with acute noxious stimulation."	762850.0	11752998.0	11752998_D000241_D059787|D059350		bcv_easy_3089_sent_dev_set_762850	"no_relation
"	Adenosine might be able to treat acute and chronic pain.
TRUE	D010830	"<span class=""chemical"">eserine</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"On the other hand, <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions evoked by carbachol and <span class=""chemical"">eserine</span> were not significantly changed by calcium chloride."	762850.0	6892185.0	6892185_D010830_D015878		bcv_easy_1548_sent_dev_set_762850	"yes_direct
"	Eserine and carbachol cause mydriasis.
TRUE	C084178	"<span class=""chemical"">telmisartan</span>"	D006973	"<span class=""disease"">hypertension</span>"	"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of <span class=""chemical"">telmisartan</span> and amlodipine versus amlodipine monotherapy in Indian adults with stage II <span class=""disease"">hypertension</span>."	762850.0	18201582.0	18201582_C084178_D006973		bcv_easy_2744_sent_dev_set_762850	"no_relation
"	Telmisartan is being used in patients with stage II hypertension. It seems it is being tested as a treatment.
TRUE	D004329	"<span class=""chemical"">droperidol</span>"	D004342	"<span class=""disease"">drug allergies</span>"	"We report the case of a previously healthy 19-year-old man with no known <span class=""disease"">drug allergies</span> in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of <span class=""chemical"">droperidol</span>."	762850.0	8599504.0	8599504_D004329_D004342		bcv_easy_1324_sent_dev_set_762850	"no_relation
"	Droperidol causes angioedema and tongue swelling, but the patient had no prior drug allergies.
TRUE	D006493	"<span class=""chemical"">heparin</span>"	D006470	"<span class=""disease"">hemorrhage</span>"	"Clinical manifestations of this disorder include <span class=""disease"">hemorrhage</span> or, more frequently, thromboembolic events in patients receiving <span class=""chemical"">heparin</span>."	762850.0	6615052.0	6615052_D006493_D006470		bcv_easy_3021_sent_dev_set_762850	"yes_direct
"	"The sentence does not follow the ""[chemical]-induced [other disease] causes [highlighted disease]"" structure, so  heparin-induced [other disease] causes hemorrhage is wrong. Patients developed hemorrhage after receiving heparin, so the correct choice is ""heparin directly contributes to or causes hemorrhage."""
TRUE	D014700	"<span class=""chemical"">Verapamil</span>"	D001281	"<span class=""disease"">AF</span>"	"RESULTS: <span class=""chemical"">Verapamil</span> caused <span class=""disease"">AF</span> promotion in six dogs, increasing mean duration of <span class=""disease"">AF</span> induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg."	762850.0	11282081.0	11282081_D014700_D001281		bcv_easy_1715_sent_dev_set_762850	"yes_direct
"	
TRUE	D004298	"<span class=""chemical"">dopamine</span>"	D002389	"<span class=""disease"">catatonia</span>"	"In the pinealectomized chick, pretreatment with <span class=""chemical"">dopamine</span> increased the duration of <span class=""disease"">catatonia</span> (DOC) after ketamine, but pretreatment with norepinephrine did not."	762850.0	6540303.0	6540303_D004298_D002389		bcv_easy_967_sent_dev_set_762850	"yes_direct
"	Dopamine made the duration of catatonia longer, which means dopamine made catatonia worse.
TRUE	D000082	"<span class=""chemical"">acetaminophen</span>"	D064420	"<span class=""disease"">toxicity</span>"	"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against <span class=""chemical"">acetaminophen</span>-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced <span class=""disease"">toxicity</span>."	762850.0	9067481.0	9067481_D000082_D064420		bcv_easy_2720_sent_dev_set_762850	"yes_direct
"	Five chemicals, including acetaminophen, induced (caused) toxicity.
TRUE	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"	D020521	"<span class=""disease"">stroke</span>"	"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, <span class=""disease"">stroke</span>, hypertension and heart failure during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."	762850.0	16586083.0	16586083_D016861_D020521		bcv_easy_291_sent_dev_set_762850	"yes_direct
"	Cyclooxygenase inhibitors cause four diseases including stroke.
TRUE	D000109	"<span class=""chemical"">acetylcholine</span>"	D023921	"<span class=""disease"">coronary artery stenosis</span>"	"Coronary spasm was induced by intracoronary injection of <span class=""chemical"">acetylcholine</span>, and no fixed <span class=""disease"">coronary artery stenosis</span> was documented on angiograms in all patients."	762850.0	11078231.0	11078231_D000109_D023921		bcv_easy_1807_sent_dev_set_762850	"no_relation
"	No fixed coronary artery stenosis was observed in patients who were injected with acetylcholine.
TRUE	D014147	"<span class=""chemical"">tramadol</span>"	D006212	"<span class=""disease"">hallucinations</span>"	"Fifty-six days after initiation of the treatment the patient presented <span class=""disease"">hallucinations</span> that only stopped after the withdrawal of psycho-active drugs and <span class=""chemical"">tramadol</span>."	762850.0	8766220.0	8766220_D014147_D006212		bcv_easy_1658_sent_dev_set_762850	"yes_direct
"	The hallucinations only went away after psycho-active drugs and tramadol were taken away.
TRUE	D000638	"<span class=""chemical"">Amiodarone</span>"	D011014	"<span class=""disease"">pneumonitis</span>"	"<span class=""chemical"">Amiodarone</span> is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being <span class=""disease"">pneumonitis</span>."	762850.0	1595783.0	1595783_D000638_D011014		bcv_easy_3183_sent_dev_set_762850	"yes_direct
"	Pneumonitis is a side effect of amiodarone.
TRUE	D017374	"<span class=""chemical"">paroxetine</span>"	D059350	"<span class=""disease"">chronic pain</span>"	"This drug was initiated in association with <span class=""chemical"">paroxetine</span> and dosulepine hydrochloride in a tetraparetic patient with <span class=""disease"">chronic pain</span>."	762850.0	8766220.0	8766220_D017374_D059350		bcv_easy_1657_sent_dev_set_762850	"no_relation
"	A patient with chronic pain was given paroxetine, but the sentence does not say paroxetine caused the pain.
TRUE	D002945	"<span class=""chemical"">cisplatin</span>"	D058186	"<span class=""disease"">acute renal injury</span>"	"The nephroprotective effect of coenzyme Q10 was investigated in mice with <span class=""disease"">acute renal injury</span> induced by a single i.p. injection of <span class=""chemical"">cisplatin</span> (5 mg/kg)."	762850.0	20510337.0	20510337_D002945_D058186		bcv_easy_1046_sent_dev_set_762850	"yes_direct
"	Acute renal injury was induced by cisplatin injection.
TRUE	D010878	"<span class=""chemical"">piperacillin</span>"	D006311	"<span class=""disease"">Ototoxicity</span>"	"<span class=""disease"">Ototoxicity</span> occurred in four (9.5%) of 42 netilmicin and <span class=""chemical"">piperacillin</span> and in 12 (22%) of 54 tobramycin and <span class=""chemical"">piperacillin</span>-treated patients."	762850.0	3535719.0	3535719_D010878_D006311		bcv_easy_773_sent_dev_set_762850	"yes_direct
"	Some of the patients receiving piperacillin developed ototoxicity.
TRUE	D010665	"<span class=""chemical"">PPA</span>"	D006973	"<span class=""disease"">hypertensive</span>"	"These results suggest that <span class=""chemical"">PPA</span>/caffeine can lead to cerebral hemorrhage in previously <span class=""disease"">hypertensive</span> animals when administered in greater than the allowed dosage."	762850.0	6695415.0	6695415_D010665_D006973		bcv_easy_1498_sent_dev_set_762850	"no_relation
"	"The ""previously"" implies that the animals already had hypertension before they were given PPA."
TRUE	D000666	"<span class=""chemical"">amphotericin B</span>"	D007008	"<span class=""disease"">hypokalemia</span>"	"Spironolactone: is it a novel drug for the prevention of <span class=""chemical"">amphotericin B</span>-related <span class=""disease"">hypokalemia</span> in cancer patients?"	762850.0	11868798.0	11868798_D000666_D007008		bcv_easy_1118_sent_dev_set_762850	"yes_direct
"	
TRUE	C034753	"<span class=""chemical"">benzylacyclouridine/BAU</span>"	D007970	"<span class=""disease"">leukopenia</span>"	"Because of the clinical toxicities associated with chronic Urd administration, the ability of <span class=""chemical"">benzylacyclouridine</span> (<span class=""chemical"">BAU</span>) to effect, in vivo, AZT-induced anemia and <span class=""disease"">leukopenia</span> was assessed."	762850.0	2257294.0	2257294_C034753_D007970		bcv_easy_2854_sent_dev_set_762850	"no_relation
"	"Leukopenia was caused by ""AZT""."
TRUE	D002083	"<span class=""chemical"">BHA</span>"	D010212	"<span class=""disease"">squamous cell papilloma</span>"	"In groups given 2% <span class=""chemical"">BHA</span>, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (<span class=""disease"">squamous cell papilloma</span> and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water."	762850.0	3131282.0	3131282_D002083_D010212		bcv_easy_24_sent_dev_set_762850	"yes_direct
"	Giving BHA together with RA caused squamous cell papillomas. Remember if a chemical only works in combination with other chemicals, then the correct choice is that the chemical can cause the disease.
TRUE	D013835	"<span class=""chemical"">TPP</span>"	D014899	"<span class=""disease"">Wernicke's encephalopathy</span>"	"We found that the above-mentioned patient and one of the diabetic kindreds with no history of <span class=""disease"">Wernicke's encephalopathy</span> had abnormal transketolase as determined by its Km for <span class=""chemical"">TPP</span>."	762850.0	3762968.0	3762968_D013835_D014899		bcv_easy_1369_sent_dev_set_762850	"no_relation
"	
TRUE	D004110	"<span class=""chemical"">diltiazem</span>"	D062787	"<span class=""disease"">overdose</span>"	"It should be considered early in cases of cardiac arrest after <span class=""chemical"">diltiazem</span> <span class=""disease"">overdose</span>."	762850.0	12101159.0	12101159_D004110_D062787		bcv_easy_834_sent_dev_set_762850	"yes_direct
"	You can overdose on the drug diltiazem.
TRUE	D012110	"<span class=""chemical"">Reserpine</span>"	D014202	"<span class=""disease"">tremor</span>"	"<span class=""chemical"">Reserpine</span> also produced <span class=""disease"">tremor</span> and catalepsy, which are signs suggestive of Parkinson's disease."	762850.0	11999899.0	11999899_D012110_D014202		bcv_easy_2175_sent_dev_set_762850	"yes_direct
"	
TRUE	C018370	"<span class=""chemical"">PREGS</span>"	D000647	"<span class=""disease"">amnesia</span>"	"The memory-enhancing effects of <span class=""chemical"">PREGS</span> and its analogs were tested in the passive avoidance task using the model of scopolamine-induced <span class=""disease"">amnesia</span>."	762850.0	11860495.0	11860495_C018370_D000647		bcv_easy_3086_sent_dev_set_762850	"no_relation
"	The amnesia was caused by scopolamine.
TRUE	D001590	"<span class=""chemical"">benztropine</span>"	D010302	"<span class=""disease"">parkinsonism</span>"	"In a 12-week controlled study ethopropazine was compared to <span class=""chemical"">benztropine</span> in the treatment of <span class=""disease"">parkinsonism</span> induced by fluphenazine enanthate in 60 schizophrenic outpatients."	762850.0	33969.0	33969_D001590_D010302		bcv_easy_2138_sent_dev_set_762850	"no_relation
"	Benztropine is being studied as a treatment for parkinsonism.
TRUE	D015119	"<span class=""chemical"">epsilon-aminocaproic acid</span>"	D012851	"<span class=""disease"">cerebral sinus thrombosis</span>"	"Although increased risk of thromboembolic disease has been reported during treatment with <span class=""chemical"">epsilon-aminocaproic acid</span>, <span class=""disease"">cerebral sinus thrombosis</span> has not been previously described."	762850.0	2339463.0	2339463_D015119_D012851		bcv_easy_43_sent_dev_set_762850	"no_relation
"	The sentence says no known cases of epsilon-aminocaproic acid causing cerebral sinus thrombosis existed before. Although we might want to say that this sentence is reporting the first case, the relation between epsilon-aminocaproic acid and cerebral sinus thrombosis is not explicit here.
TRUE	D010878	"<span class=""chemical"">piperacillin sodium</span>"	D007239	"<span class=""disease"">infections</span>"	"We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with <span class=""chemical"">piperacillin sodium</span> in 118 immunocompromised patients with presumed severe <span class=""disease"">infections</span>."	762850.0	3535719.0	3535719_D010878_D007239		bcv_easy_768_sent_dev_set_762850	"no_relation
"	The text seems to say that piperacillin sodium was being tested as a treatment.
TRUE	D004317	"<span class=""chemical"">ADR/adriamycin</span>"	D002318	"<span class=""disease"">cardiovascular toxicity</span>"	"The use of <span class=""chemical"">adriamycin</span> (<span class=""chemical"">ADR</span>) in cancer chemotherapy has been limited due to its cumulative <span class=""disease"">cardiovascular toxicity</span>."	762850.0	9952311.0	9952311_D004317_D002318		bcv_easy_1186_sent_dev_set_762850	"yes_direct
"	
TRUE	D013467	"<span class=""chemical"">sulindac</span>"	D007681	"<span class=""disease"">renal papillary necrosis/RPN</span>"	"A 31-year-old man with rheumatoid arthritis, who had previously been treated with <span class=""chemical"">sulindac</span>, fenoprofen calcium, high dose salicylates and gold salts, developed <span class=""disease"">renal papillary necrosis</span> (<span class=""disease"">RPN</span>) 4 months after institution of naproxen therapy."	762850.0	6699841.0	6699841_D013467_D007681		bcv_easy_840_sent_dev_set_762850	"no_relation
"	"The patient developed renal papillary necrosis only after starting naproxen therapy. The sentence says the man was ""previously treated with sulindac"", which implies that sulindac was not taken at the same time as naproxen."
TRUE	D010862	"<span class=""chemical"">pilocarpine</span>"	D012640	"<span class=""disease"">seizures</span>"	"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against <span class=""chemical"">pilocarpine</span> (416 mg/kg, s.c.)-induced limbic motor <span class=""disease"">seizures</span> and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.)."	762850.0	9121607.0	9121607_D010862_D012640		bcv_easy_2104_sent_dev_set_762850	"yes_direct
"	
TRUE	D000082	"<span class=""chemical"">paracetamol</span>"	D006525	"<span class=""disease"">viral hepatitis</span>"	"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <span class=""chemical"">paracetamol</span> overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to <span class=""disease"">viral hepatitis</span> whether or not they survived."	762850.0	7007443.0	7007443_D000082_D006525		bcv_easy_1359_sent_dev_set_762850	"no_relation
"	Paracetamol overdose causes fulminant hepatic (liver) failure. The text does not say what caused the viral hepatitis.
TRUE	D016202	"<span class=""chemical"">NMDA/N-methyl-D-aspartate</span>"	D012559	"<span class=""disease"">schizophrenia</span>"	"The glutamatergic <span class=""chemical"">N-methyl-D-aspartate</span> (<span class=""chemical"">NMDA</span>) receptor has been implicated in the pathophysiology of <span class=""disease"">schizophrenia</span>."	762850.0	20727411.0	20727411_D016202_D012559		bcv_easy_2627_sent_dev_set_762850	"no_relation
"	The NMDA receptor is involved in schizophrenia, not the chemical NMDA.
TRUE	D010396	"<span class=""chemical"">D-penicillamine</span>"	D008105	"<span class=""disease"">primary biliary cirrhosis</span>"	"A case of polymyositis in a patient with <span class=""disease"">primary biliary cirrhosis</span> treated with <span class=""chemical"">D-penicillamine</span>."	762850.0	8268147.0	8268147_D010396_D008105		bcv_easy_2535_sent_dev_set_762850	"no_relation
"	D-penicillamine seems to have been used to treat primary biliary cirrhosis.
TRUE	D011692	"<span class=""chemical"">puromycin aminonucleoside/PAN</span>"	D058186	"<span class=""disease"">Acute experimental models of renal damage</span>"	"<span class=""disease"">Acute experimental models of renal damage</span> to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), <span class=""chemical"">puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>), and 2-bromoethylamine (BEA), respectively."	762850.0	3653576.0	3653576_D011692_D058186		bcv_easy_1663_sent_dev_set_762850	"yes_direct
"	Three chemicals all produced acute experimental models of renal damage.
TRUE	D013619	"<span class=""chemical"">Tacrine</span>"	D012640	"<span class=""disease"">seizures</span>"	"<span class=""chemical"">Tacrine</span>, administered in LiCl pre-treated rats, induces electrocorticographic <span class=""disease"">seizures</span> and delayed hippocampal damage."	762850.0	19944736.0	19944736_D013619_D012640		bcv_easy_1618_sent_dev_set_762850	"yes_direct
"	
TRUE	D020123	"<span class=""chemical"">sirolimus</span>"	D011565	"<span class=""disease"">psoriasis</span>"	"Activated peripheral blood T cells from patients with <span class=""disease"">psoriasis</span> tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of <span class=""chemical"">sirolimus</span>."	762850.0	10328196.0	10328196_D020123_D011565		bcv_easy_3112_sent_dev_set_762850	"no_relation
"	Sirolimus made T cells undergo apoptosis (cell death) faster, but sirolimus is not stated to have caused psoriasis.
TRUE	C107135	"<span class=""chemical"">everolimus</span>"	D009190	"<span class=""disease"">MDS/myelodysplastic syndrome</span>"	"We report on a combination of <span class=""chemical"">everolimus</span> and tacrolimus in 24 patients (median age, 62 years) with either <span class=""disease"">myelodysplastic syndrome</span> (<span class=""disease"">MDS</span>; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors."	762850.0	19135948.0	19135948_C107135_D009190		bcv_easy_161_sent_dev_set_762850	"no_relation
"	Everolimus was used in patients with myelodysplastic syndrome, but the text does not say everolimus caused MDS.
TRUE	D013390	"<span class=""chemical"">succinylcholine</span>"	D063806	"<span class=""disease"">myalgia</span>"	"In conclusion, there is no evidence for an inflammatory origin of <span class=""chemical"">succinylcholine</span>-associated <span class=""disease"">myalgia</span>."	762850.0	12760988.0	12760988_D013390_D063806		bcv_easy_3068_sent_dev_set_762850	"yes_direct
"	"The sentence says that there is no evidence for an ""inflammatory origin"" of myalgia caused by succinylcholine. This does not mean that succinylcholine cannot cause myalgia."
TRUE	D000809	"<span class=""chemical"">angiotensin</span>"	D009404	"<span class=""disease"">NS/nephrotic syndrome</span>"	"Plasma concentration and urine excretion of the renin-<span class=""chemical"">angiotensin</span> system proteins are altered in rats with <span class=""disease"">nephrotic syndrome</span> (<span class=""disease"">NS</span>)."	762850.0	9154656.0	9154656_D000809_D009404		bcv_easy_2019_sent_dev_set_762850	"no_relation
"	The renin-angiotensin system protein levels were different in rats with nephrotic syndrome.
TRUE	C024224	"<span class=""chemical"">naloxazone</span>"	D007035	"<span class=""disease"">hypothermia</span>"	"Pretreatment with <span class=""chemical"">naloxazone</span> significantly blocked morphine analgesia, catalepsy and <span class=""disease"">hypothermia</span> at a dose which completely eliminated high-affinity binding in brain membranes."	762850.0	6308526.0	6308526_C024224_D007035		bcv_easy_2753_sent_dev_set_762850	"no_relation
"	Naloxazone made hypothermia better.
TRUE	C005618	"<span class=""chemical"">benzoylecgonine</span>"	D003693	"<span class=""disease"">EDDs</span>"	"<span class=""disease"">EDDs</span> had concentrations of cocaine and <span class=""chemical"">benzoylecgonine</span> in autopsy blood that were similar to those for controls."	762850.0	8988571.0	8988571_C005618_D003693		bcv_easy_3013_sent_dev_set_762850	"no_relation
"	
TRUE	D008625	"<span class=""chemical"">Tiopronin</span>"	D001172	"<span class=""disease"">RA</span>"	"Compared to healthy controls a lower DR5 frequency was observed in patients with <span class=""disease"">RA</span> except for the <span class=""chemical"">Tiopronin</span> related nephritis group."	762850.0	3084782.0	3084782_D008625_D001172		bcv_easy_3042_sent_dev_set_762850	"no_relation
"	
TRUE	D008094	"<span class=""chemical"">lithium</span>"	D014262	"<span class=""disease"">tricuspid regurgitation</span>"	"A newborn with massive <span class=""disease"">tricuspid regurgitation</span>, atrial flutter, congestive heart failure, and a high serum <span class=""chemical"">lithium</span> level is described."	762850.0	6794356.0	6794356_D008094_D014262		bcv_easy_2_sent_dev_set_762850	"no_relation
"	Although the newborn had both tricuspid regurgitation and high blood lithium levels, the sentence does not say that the lithium is what caused the tricuspid regurgitation.
TRUE	C020976	"<span class=""chemical"">azelastine</span>"	D013651	"<span class=""disease"">altered taste perception</span>"	"Drowsiness and <span class=""disease"">altered taste perception</span> were increased significantly over placebo only in the high-dose <span class=""chemical"">azelastine</span> group."	762850.0	3057041.0	3057041_C020976_D013651		bcv_easy_974_sent_dev_set_762850	"yes_direct
"	Azelastine caused drowsiness and altered taste perception whereas the placebo (no chemical given) did not.
TRUE	D011433	"<span class=""chemical"">propranolol</span>"	D011928	"<span class=""disease"">Raynaud's phenomenon</span>"	"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and <span class=""disease"">Raynaud's phenomenon</span> and dyspnoea in men and women taking <span class=""chemical"">propranolol</span>."	762850.0	6115999.0	6115999_D011433_D011928		bcv_easy_864_sent_dev_set_762850	"yes_direct
"	Raynaud's phenomenon is given as an example of an adverse reaction linked with drugs (in this case propranolol).
TRUE	D004837	"<span class=""chemical"">adrenaline</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"Intravenous pretreatment of the rats with diazepam, although causing no change in the <span class=""chemical"">adrenaline</span>-induced pressor effect, did enhance the <span class=""chemical"">adrenaline</span>-induced reflex <span class=""disease"">bradycardia</span>."	762850.0	2894433.0	2894433_D004837_D001919		bcv_easy_2376_sent_dev_set_762850	"yes_direct
"	
TRUE	D000431	"<span class=""chemical"">alcohol</span>"	D000437	"<span class=""disease"">alcohol abuse</span>"	"The patient had a history of <span class=""disease"">alcohol abuse</span>; <span class=""chemical"">alcohol</span> intake as well as withdrawal can also cause seizures."	762850.0	11573852.0	11573852_D000431_D000437		bcv_easy_102_sent_dev_set_762850	"no_relation
"	Alcohol is mentioned as something that might cause seizures. The sentence does not say that alcohol causes alcohol abuse!
TRUE	C047426	"<span class=""chemical"">venlafaxine</span>"	D020230	"<span class=""disease"">Serotonin syndrome</span>"	"<span class=""disease"">Serotonin syndrome</span> from <span class=""chemical"">venlafaxine</span>-tranylcypromine interaction."	762850.0	8888541.0	8888541_C047426_D020230		bcv_easy_2054_sent_dev_set_762850	"yes_direct
"	
TRUE	D013438	"<span class=""chemical"">thiol</span>"	D008175	"<span class=""disease"">lung cancer</span>"	"The protective effect of oral administration of the <span class=""chemical"">thiol</span> compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable <span class=""disease"">lung cancer</span> under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle."	762850.0	6402369.0	6402369_D013438_D008175		bcv_easy_3143_sent_dev_set_762850	"no_relation
"	The subject of the sentence is sodium 2-mercaptoethane sulphonate, not thiol.
TRUE	D006493	"<span class=""chemical"">heparin</span>"	D013923	"<span class=""disease"">thromboembolism</span>"	"MEASUREMENTS: Platelet counts, onset of objectively determined <span class=""disease"">thromboembolism</span>, results of <span class=""chemical"">heparin</span>-induced platelet factor 4 antibody tests, and outcomes."	762850.0	11827497.0	11827497_D006493_D013923		bcv_easy_2916_sent_dev_set_762850	"no_relation
"	The sentence lists some things that were measured.
TRUE	D007980	"<span class=""chemical"">L-dihydroxyphenylalanine</span>"	D020258	"<span class=""disease"">neurotoxicity</span>"	"Here we show that the recently reported ability of <span class=""chemical"">L-dihydroxyphenylalanine</span> to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA <span class=""disease"">neurotoxicity</span> is also confounded by drug effects on body temperature."	762850.0	20533999.0	20533999_D007980_D020258		bcv_easy_2637_sent_dev_set_762850	"no_relation
"	"Neurotoxicity was induced by ""METH""."
TRUE	D017963	"<span class=""chemical"">azithromycin</span>"	D006606	"<span class=""disease"">hiccups</span>"	"Possible <span class=""chemical"">azithromycin</span>-associated <span class=""disease"">hiccups</span>."	762850.0	15985056.0	15985056_D017963_D006606		bcv_easy_545_sent_dev_set_762850	"yes_direct
"	"The sentence suggests that azithromycin likely causes hiccups through the use of ""possible""."
TRUE	D015632	"<span class=""chemical"">MPTP</span>"	D010300	"<span class=""disease"">Parkinson's disease</span>"	"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of <span class=""disease"">Parkinson's disease</span> including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and <span class=""chemical"">MPTP</span>-treated non-human primate model."	762850.0	20973483.0	20973483_D015632_D010300		bcv_easy_265_sent_dev_set_762850	"no_relation
"	
TRUE	D016642	"<span class=""chemical"">bupropion</span>"	D012892	"<span class=""disease"">sleep deprivation</span>"	"This case report describes a generalized seizure associated with sustained-release <span class=""chemical"">bupropion</span> use and <span class=""disease"">sleep deprivation</span>."	762850.0	12745515.0	12745515_D016642_D012892		bcv_easy_2004_sent_dev_set_762850	"no_relation
"	The sentence says bupropion causes seizure and sleep deprivation causes seizure, but does not say bupropion causes sleep deprivation.
TRUE	D011034	"<span class=""chemical"">epipodophyllotoxin</span>"	D066126	"<span class=""disease"">cardiac toxicity</span>"	"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the <span class=""chemical"">epipodophyllotoxin</span> etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <span class=""disease"">cardiac toxicity</span> limit their use."	762850.0	15897593.0	15897593_D011034_D066126		bcv_easy_2770_sent_dev_set_762850	"no_relation
"	"The chemical ""etoposide"" is a kind of ""epipodophyllotoxin"". The sentence says that etoposide causes cardiac toxicity, but the sentence does not say all epipodophyllotoxins cause cardiac toxicity!"
TRUE	D002110	"<span class=""chemical"">caffeine</span>"	D001145	"<span class=""disease"">ventricular arrhythmias</span>"	"Although intravenous <span class=""chemical"">caffeine</span> is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious <span class=""disease"">ventricular arrhythmias</span>."	762850.0	18997632.0	18997632_D002110_D001145		bcv_easy_368_sent_dev_set_762850	"yes_direct
"	Serious ventricular arrhythmias can result from taking caffeine.
TRUE	D008790	"<span class=""chemical"">metoprolol</span>"	D006327	"<span class=""disease"">heart block</span>"	"A seventy-eight-year-old woman presented with complete <span class=""disease"">heart block</span> and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of <span class=""chemical"">metoprolol</span>."	762850.0	7785794.0	7785794_D008790_D006327		bcv_easy_2230_sent_dev_set_762850	"yes_direct
"	The woman developed a heart block after taking two chemicals together (verapamil and metoprolol).
TRUE	D004317	"<span class=""chemical"">doxorubicin</span>"	D006333	"<span class=""disease"">cardiac failure</span>"	"One of the patients developed <span class=""disease"">cardiac failure</span> after 30 mg m-2 MMC and only 150 mg m-2 <span class=""chemical"">doxorubicin</span>."	762850.0	3137399.0	3137399_D004317_D006333		bcv_easy_2589_sent_dev_set_762850	"yes_direct
"	
TRUE	D018818	"<span class=""chemical"">fenoldopam</span>"	D009369	"<span class=""disease"">tumor</span>"	"Arteritis induced in rats by vasodilators, <span class=""chemical"">fenoldopam</span> and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and <span class=""disease"">tumor</span> growth factor-beta1 (TGF-beta1)."	762850.0	12180796.0	12180796_D018818_D009369		bcv_easy_1109_sent_dev_set_762850	"no_relation
"	"Some rats which had been given fenoldopam were examined for a kind of protein (""tumor growth factor-beta1""). Here the word ""tumor"" is not being used to refer to the disease, but is rather part of the name of a protein (""tumor growth factor-beta1"")."
TRUE	D005047	"<span class=""chemical"">etoposide</span>"	D066126	"<span class=""disease"">cardiac toxicity</span>"	"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <span class=""chemical"">etoposide</span> are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <span class=""disease"">cardiac toxicity</span> limit their use."	762850.0	15897593.0	15897593_D005047_D066126		bcv_easy_2774_sent_dev_set_762850	"yes_direct
"	
TRUE	D008874	"<span class=""chemical"">midazolam</span>"	D006606	"<span class=""disease"">hiccups</span>"	"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (<span class=""chemical"">midazolam</span>) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <span class=""disease"">hiccups</span>."	762850.0	15985056.0	15985056_D008874_D006606		bcv_easy_554_sent_dev_set_762850	"yes_direct
"	"""Benzodiazepines"" are a category of chemicals. Midazolam is mentioned as a specific example of a ""benzodiazepine"" that is known to cause hiccups."
TRUE	D008775	"<span class=""chemical"">methylprednisolone</span>"	D006323	"<span class=""disease"">asystole</span>"	"We report a case of hypotension, bradycardia, and <span class=""disease"">asystole</span> after intravenous administration of high-dose <span class=""chemical"">methylprednisolone</span> in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode."	762850.0	10074612.0	10074612_D008775_D006323		bcv_easy_1727_sent_dev_set_762850	"yes_direct
"	Methylprednisolone caused three different diseases in this patient.
TRUE	D005045	"<span class=""chemical"">etomidate</span>"	D009207	"<span class=""disease"">myoclonus</span>"	"Remifentanil pretreatment reduces <span class=""disease"">myoclonus</span> after <span class=""chemical"">etomidate</span>."	762850.0	16563323.0	16563323_D005045_D009207		bcv_easy_523_sent_dev_set_762850	"yes_direct
"	Remifentanil makes myoclonus caused by etomidate better.
TRUE	C045645	"<span class=""chemical"">CLZ</span>"	D006261	"<span class=""disease"">headache</span>"	"Seven out of 12 subjects experienced <span class=""disease"">headache</span> of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of <span class=""chemical"">CLZ</span>."	762850.0	7596955.0	7596955_C045645_D006261		bcv_easy_202_sent_dev_set_762850	"yes_direct
"	Eating CLZ caused headaches in 7 of 12 patients.
TRUE	C037663	"<span class=""chemical"">ropivacaine</span>"	D012640	"<span class=""disease"">seizures</span>"	"The cumulative doses of levobupivacaine and <span class=""chemical"">ropivacaine</span> that produced <span class=""disease"">seizures</span> were similar and were larger than those of bupivacaine."	762850.0	11524350.0	11524350_C037663_D012640		bcv_easy_1454_sent_dev_set_762850	"yes_direct
"	
TRUE	D013739	"<span class=""chemical"">testosterone</span>"	D006966	"<span class=""disease"">hyperprolactinemia</span>"	"Serum <span class=""chemical"">testosterone</span> concentration increased with pubertal status but was not affected by <span class=""disease"">hyperprolactinemia</span>."	762850.0	20331935.0	20331935_D013739_D006966		bcv_easy_1924_sent_dev_set_762850	"no_relation
"	
TRUE	D002794	"<span class=""chemical"">choline</span>"	D000544	"<span class=""disease"">AD/Alzheimer's disease</span>"	"The <span class=""chemical"">choline</span> acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of <span class=""disease"">Alzheimer's disease</span> (<span class=""disease"">AD</span>)."	762850.0	16428827.0	16428827_D002794_D000544		bcv_easy_539_sent_dev_set_762850	"no_relation
"	"The ""choline acetyltransferase activator"" (a protein) and not ""choline"" itself is important to treating Alzheimer's disease."
TRUE	D004967	"<span class=""chemical"">oestrogen</span>"	D005705	"<span class=""disease"">gallbladder disease</span>"	"Long-term <span class=""chemical"">oestrogen</span>-only HT significantly increased the risk of venous thrombo-embolism, stroke and <span class=""disease"">gallbladder disease</span> (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer."	762850.0	19370593.0	19370593_D004967_D005705		bcv_easy_175_sent_dev_set_762850	"yes_direct
"	Oestrogen increased the risk of gallbladder disease.
TRUE	D002738	"<span class=""chemical"">chloroquine</span>"	D015354	"<span class=""disease"">deterioration of vision</span>"	"A 27-year old African woman with history of regular <span class=""chemical"">chloroquine</span> ingestion presented with progressive <span class=""disease"">deterioration of vision</span>, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks."	762850.0	1628552.0	1628552_D002738_D015354		bcv_easy_1438_sent_dev_set_762850	"yes_direct
"	
TRUE	D013629	"<span class=""chemical"">tamoxifen</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of <span class=""disease"">breast cancer</span>, the postulated protective effects of <span class=""chemical"">tamoxifen</span> are not yet apparent."	762850.0	9672273.0	9672273_D013629_D001943		bcv_easy_595_sent_dev_set_762850	"no_relation
"	Tamoxifen's protective (beneficial) effects on breast cancer are not yet clear according to this sentence.
TRUE	D011188	"<span class=""chemical"">potassium</span>"	D007008	"<span class=""disease"">hypokalemia</span>"	"In conclusion we found that thiazide diuretics cause <span class=""disease"">hypokalemia</span> and depletion of body <span class=""chemical"">potassium</span>."	762850.0	6942642.0	6942642_D011188_D007008		bcv_easy_998_sent_dev_set_762850	"no_relation
"	"Hypokalemia is caused by ""thiazide diuretics""."
TRUE	D012293	"<span class=""chemical"">rifampin</span>"	D014376	"<span class=""disease"">tuberculosis</span>"	"Light chain proteinuria and cellular mediated immunity in <span class=""chemical"">rifampin</span> treated patients with <span class=""disease"">tuberculosis</span>."	762850.0	804391.0	804391_D012293_D014376		bcv_easy_3185_sent_dev_set_762850	"no_relation
"	Rifampin was given to patients with tuberculosis, but the sentence does not say rifampin caused their tuberculosis.
TRUE	D006024	"<span class=""chemical"">glycopyrronium</span>"	D001919	"<span class=""disease"">bradycardias</span>"	"Use of <span class=""chemical"">glycopyrronium</span> 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced <span class=""disease"">bradycardias</span>."	762850.0	2917114.0	2917114_D006024_D001919		bcv_easy_39_sent_dev_set_762850	"no_relation
"	Glycopyrronium had a beneficial effect on bradycardias.
TRUE	D002998	"<span class=""chemical"">clonazepam</span>"	D009207	"<span class=""disease"">myoclonic jerks</span>"	"Of the benzodiazepines, <span class=""chemical"">clonazepam</span> (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the <span class=""disease"">myoclonic jerks</span>."	762850.0	6118280.0	6118280_D002998_D009207		bcv_easy_1583_sent_dev_set_762850	"no_relation
"	Clonazepam blocked myoclonic jerks.
TRUE	D004317	"<span class=""chemical"">doxorubicin</span>"	D009202	"<span class=""disease"">cardiomyopathy</span>"	"Dose-effect and structure-function relationships in <span class=""chemical"">doxorubicin</span> <span class=""disease"">cardiomyopathy</span>."	762850.0	7282516.0	7282516_D004317_D009202		bcv_easy_705_sent_dev_set_762850	"yes_direct
"	"The ""dose-effect"" and ""structure-function relationships"" refer to that between doxorubicin and cardiomyopathy. Therefore we can conclude that different doses of doxorubicin have different effects on cardiomyopathy, and that therefore doxorubicin causes cardiomyopathy."
TRUE	D003024	"<span class=""chemical"">clozapine</span>"	D013981	"<span class=""disease"">tic-like symptoms</span>"	"However, there are two case reports that show <span class=""disease"">tic-like symptoms</span>, including motor and phonic variants, occurring during treatment with quetiapine or <span class=""chemical"">clozapine</span>."	762850.0	16225977.0	16225977_D003024_D013981		bcv_easy_2976_sent_dev_set_762850	"yes_direct
"	Two reports showed that tic-like symptoms arose during clozapine treatment.
TRUE	C059896	"<span class=""chemical"">SC-48334</span>"	D007153	"<span class=""disease"">immunodeficiency</span>"	"The mean <span class=""chemical"">SC-48334</span> steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human <span class=""disease"">immunodeficiency</span> virus (HIV)."	762850.0	7905523.0	7905523_C059896_D007153		bcv_easy_2126_sent_dev_set_762850	"no_relation
"	"SC-48334 concentration was not high enough to inhibit ""human immunodeficiency virus"". Immunodeficiency is not discussed as a disease here. It is part of ""human immunodeficiency virus""."
TRUE	D010389	"<span class=""chemical"">pemoline</span>"	D062787	"<span class=""disease"">overdose</span>"	"The possibility of choreoathetoid movements should be considered in patients presenting after <span class=""chemical"">pemoline</span> <span class=""disease"">overdose</span>."	762850.0	9022662.0	9022662_D010389_D062787		bcv_easy_330_sent_dev_set_762850	"yes_direct
"	
TRUE	C033457	"<span class=""chemical"">Quinidine phenylethylbarbiturate</span>"	D056486	"<span class=""disease"">hepatitis</span>"	"<span class=""chemical"">Quinidine phenylethylbarbiturate</span>-induced fulminant <span class=""disease"">hepatitis</span> in a pregnant woman. A case report."	762850.0	3411101.0	3411101_C033457_D056486		bcv_easy_2695_sent_dev_set_762850	"yes_direct
"	Induced means caused.
TRUE	D000255	"<span class=""chemical"">ATP</span>"	D009765	"<span class=""disease"">obese</span>"	"In conclusion, HFD-induced <span class=""disease"">obese</span> rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial <span class=""chemical"">ATP</span> generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway."	762850.0	18674790.0	18674790_D000255_D009765		bcv_easy_491_sent_dev_set_762850	"no_relation
"	
TRUE	D017374	"<span class=""chemical"">paroxetine</span>"	D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"Possible <span class=""disease"">neuroleptic malignant syndrome</span> related to concomitant treatment with <span class=""chemical"">paroxetine</span> and alprazolam."	762850.0	16720068.0	16720068_D017374_D009459		bcv_easy_276_sent_dev_set_762850	"yes_direct
"	The sentence says that treatment with paroxetine and alprazolam possibly causes neuroleptic malignant syndrome.
TRUE	D003520	"<span class=""chemical"">Cyclophosphamide</span>"	D059265	"<span class=""disease"">visceral pain</span>"	"<span class=""chemical"">Cyclophosphamide</span>-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of <span class=""disease"">visceral pain</span>."	762850.0	10840460.0	10840460_D003520_D059265		bcv_easy_2866_sent_dev_set_762850	"no_relation
"	
TRUE	D005680	"<span class=""chemical"">gamma-aminobutyric acid/GABA</span>"	D007022	"<span class=""disease"">hypotension</span>"	"High doses of isoniazid increase <span class=""disease"">hypotension</span> induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain <span class=""chemical"">gamma-aminobutyric acid</span> (<span class=""chemical"">GABA</span>)."	762850.0	9915601.0	9915601_D005680_D007022		bcv_easy_1197_sent_dev_set_762850	"no_relation
"	"Hypotension is caused by ""vasodilators"" (chemicals that make blood vessels wider) and made worse by the chemical ""isoniazid""."
TRUE	D000319	"<span class=""chemical"">beta-adrenergic blocking drugs</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and <span class=""disease"">bradycardia</span> during combined therapy with verapamil and <span class=""chemical"">beta-adrenergic blocking drugs</span>."	762850.0	6127992.0	6127992_D000319_D001919		bcv_easy_851_sent_dev_set_762850	"yes_direct
"	
TRUE	D010068	"<span class=""chemical"">oxacillin</span>"	D013203|D016470	"<span class=""disease"">Staphylococcus aureus bacteremia</span>"	"A 67-year-old man who was treated with <span class=""chemical"">oxacillin</span> for one week because of <span class=""disease"">Staphylococcus aureus bacteremia</span>, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet."	762850.0	11337188.0	11337188_D010068_D013203|D016470		bcv_easy_2749_sent_dev_set_762850	"no_relation
"	Oxacillin was used to treat staphylococcus aureus bacteremia.
TRUE	D006046	"<span class=""chemical"">gold</span>"	D003872	"<span class=""disease"">dermatitis</span>"	"A strong association has been found between nephritis and <span class=""disease"">dermatitis</span> due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between <span class=""disease"">dermatitis</span> due to <span class=""chemical"">gold</span> thiosulphate and B35."	762850.0	3084782.0	3084782_D006046_D003872		bcv_easy_3040_sent_dev_set_762850	"no_relation
"	"""Gold"" is part of ""gold thiosulphate"", which is a very different chemical than ""gold""! Dermatitis is caused by ""gold thiosulphate"", not ""gold""."
TRUE	D008094	"<span class=""chemical"">Li</span>"	D001480	"<span class=""disease"">EPS</span>"	"Similarly, <span class=""disease"">EPS</span>-related adverse events with QTP + <span class=""chemical"">Li</span>/DVP (21.4%) were no different than with PBO + <span class=""chemical"">Li</span>/DVP (19.2%)."	762850.0	17042884.0	17042884_D008094_D001480		bcv_easy_227_sent_dev_set_762850	"no_relation
"	The EPS related events are no different when chemical QTP is given and when PBO is given. The sentence does not contain enough information to say that lithium (Li) causes EPS related adverse events.
TRUE	D012110	"<span class=""chemical"">reserpine</span>"	D014202	"<span class=""disease"">tremor</span>"	"Pretreatment with <span class=""chemical"">reserpine</span> (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in <span class=""disease"">tremor</span> and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of <span class=""chemical"">reserpine</span>."	762850.0	11999899.0	11999899_D012110_D014202		bcv_easy_2190_sent_dev_set_762850	"yes_direct
"	Giving reserpine 24 hours prior caused tremor.
TRUE	D014810	"<span class=""chemical"">Vitamin E</span>"	D009203	"<span class=""disease"">MI</span>"	"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, <span class=""chemical"">Vitamin E</span> and glutathione levels were altered in <span class=""disease"">MI</span> rats."	762850.0	16584858.0	16584858_D014810_D009203		bcv_easy_514_sent_dev_set_762850	"no_relation
"	Vitamin E levels were changed in MI rats.
TRUE	D005839	"<span class=""chemical"">gentamicin</span>"	D009956	"<span class=""disease"">tubular necrosis</span>"	"In Group II, P did not prevent <span class=""chemical"">gentamicin</span>-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and <span class=""disease"">tubular necrosis</span> score, 3.9 +/- 0.1)."	762850.0	2709684.0	2709684_D005839_D009956		bcv_easy_2614_sent_dev_set_762850	"no_relation
"	"The ""tubular necrosis score"" was a measurement used to quantify whether ""P"" prevented ""gentamicin-ARF"". The text never says ""gentamicin"" is related to ""tubular necrosis""."
TRUE	D043343	"<span class=""chemical"">TP</span>"	D011471	"<span class=""disease"">prostate cancer</span>"	"In L-W rats, <span class=""chemical"">TP</span> acted as a tumor enhancement agent, with primary emphasis on the development of <span class=""disease"">prostate cancer</span>."	762850.0	3461217.0	3461217_D043343_D011471		bcv_easy_3155_sent_dev_set_762850	"yes_direct
"	TP enhances tumors, especially the development of prostate cancer. Therefore we can conclude that TP can cause prostate cancer.
TRUE	D010672	"<span class=""chemical"">phenytoin</span>"	D011605	"<span class=""disease"">psychosis</span>"	"The case of a nonepileptic patient who developed <span class=""disease"">psychosis</span> following <span class=""chemical"">phenytoin</span> treatment for trigeminal neuralgia is described."	760841.0	14698717.0	14698717_D010672_D011605		bcv_easy_3152_sent_train_set_revised_760841	"yes_direct
"	The patient developed psychosis after receiving phenytoin.
TRUE	D001379	"<span class=""chemical"">azathioprine</span>"	D009369	"<span class=""disease"">cancers</span>"	"There have been several long-term studies of patients with rheumatoid arthritis treated with <span class=""chemical"">azathioprine</span> and cyclophosphamide and the incidence of most of the common <span class=""disease"">cancers</span> is not increased."	760841.0	3970039.0	3970039_D001379_D009369		bcv_easy_2200_sent_train_set_revised_760841	"no_relation
"	Azathioprine had no effect on cancer prevalence in the patients.
TRUE	D011433	"<span class=""chemical"">propranolol</span>"	D016584	"<span class=""disease"">panic disorders</span>"	"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and <span class=""chemical"">propranolol</span> (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with <span class=""disease"">panic disorders</span> and agoraphobia were investigated in a double-blind, randomized and crossover design."	760841.0	6387529.0	6387529_D011433_D016584		bcv_easy_174_sent_train_set_revised_760841	"no_relation
"	The sentence says that the effects of diazepam and propranolol on patients was investigated. The sentence does not state what the effect was.
TRUE	D004837	"<span class=""chemical"">adrenaline</span>"	D001281	"<span class=""disease"">atrial fibrillation</span>"	"An increase in blood pressure, accompanied by <span class=""disease"">atrial fibrillation</span>, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing <span class=""chemical"">adrenaline</span> 0.225 mg, for correction of Dupuytren's contracture."	760841.0	9698967.0	9698967_D004837_D001281		bcv_easy_762_sent_train_set_revised_760841	"yes_direct
"	Giving mepivacaine and adrenaline together caused the male patient to experience atrial fibrillation.
TRUE	D007654	"<span class=""chemical"">ketoconazole</span>"	D006973	"<span class=""disease"">hypertension</span>"	"In both cases normal plasma and urinary free cortisol levels had been achieved following <span class=""chemical"">ketoconazole</span> therapy, yet continuous blood pressure monitoring demonstrated <span class=""disease"">hypertension</span> 31 (patient 1) and 52 weeks (patient 2) after treatment."	760841.0	2632720.0	2632720_D007654_D006973		bcv_easy_58_sent_train_set_revised_760841	"yes_direct
"	Long-term patient monitoring showed that both patients had hypertension after receiving ketoconazole therapy.
TRUE	D002945	"<span class=""chemical"">cisplatin</span>"	D064420	"<span class=""disease"">toxicity</span>"	"We initiated a phase I/II trial to determine the response and <span class=""disease"">toxicity</span> of escalating paclitaxel doses combined with fixed-dose <span class=""chemical"">cisplatin</span> with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma."	760841.0	8643971.0	8643971_D002945_D064420		bcv_easy_2217_sent_train_set_revised_760841	"no_relation
"	The sentence says that the response and toxicity of paclitaxel with cisplatin was studied, but does not say what the result was.
TRUE	D012964	"<span class=""chemical"">na</span>"	D012640	"<span class=""disease"">Seizure</span>"	"METHODS: Cholinergic convulsant sensitivity was examined in alcohol-<span class=""chemical"">na</span>  ve Withdrawal <span class=""disease"">Seizure</span>-Prone (WSP) and-Resistant (WSR) mice."	760841.0	12198388.0	12198388_D012964_D012640		bcv_easy_847_sent_train_set_revised_760841	"no_relation
"	"""na"" does not represent a chemical in this context. There seems to be an error with ""alcohol-na ve"" since ""ve"" is not a word."
TRUE	D014031	"<span class=""chemical"">tobramycin sulfate</span>"	D006311	"<span class=""disease"">ototoxicity</span>"	"Gentamicin sulfate and <span class=""chemical"">tobramycin sulfate</span> continue to demonstrate <span class=""disease"">ototoxicity</span> and nephrotoxicity in both animal and clinical studies."	760841.0	7420681.0	7420681_D014031_D006311		bcv_easy_2055_sent_train_set_revised_760841	"yes_direct
"	Tobramycin sulfate causes ototoxicity in animals and humans.
TRUE	D014700	"<span class=""chemical"">Verapamil</span>"	D006973	"<span class=""disease"">hypertensive</span>"	"<span class=""chemical"">Verapamil</span> withdrawal as a possible cause of myocardial infarction in a <span class=""disease"">hypertensive</span> woman with a normal coronary angiogram."	760841.0	3173179.0	3173179_D014700_D006973		bcv_easy_1910_sent_train_set_revised_760841	"no_relation
"	Verapamil was used by a woman with hypertension, but the sentence does not say that verapamil causes hypertension.
TRUE	D002110	"<span class=""chemical"">caffeine</span>"	D014693	"<span class=""disease"">ventricular fibrillation</span>"	"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable <span class=""disease"">ventricular fibrillation</span> after consuming a ""natural energy"" guarana health drink containing a high concentration of <span class=""chemical"">caffeine</span>."	760841.0	11419773.0	11419773_D002110_D014693		bcv_easy_298_sent_train_set_revised_760841	"yes_direct
"	She developed ventricular fibrillation after consuming the health drink containing caffeine.
TRUE	D000082	"<span class=""chemical"">acetaminophen</span>"	D007676	"<span class=""disease"">ESRD</span>"	"The possibility that habitual use of <span class=""chemical"">acetaminophen</span> alone increases the risk of <span class=""disease"">ESRD</span> has not been clearly demonstrated, but cannot be dismissed."	760841.0	8669433.0	8669433_D000082_D007676		bcv_easy_698_sent_train_set_revised_760841	"no_relation
"	"The sentence says that it is not known whether acetaminophen causes ESRD, but that it is also not impossible. Therefore we do not know whether acetaminophen causes ESRD, and therefore the answer is that ""the sentence does not say that acetaminophen contributes to or causes ESRD""."
TRUE	D010862	"<span class=""chemical"">pilocarpine</span>"	D002544	"<span class=""disease"">Infarcts in substantia nigra pars reticulata</span>"	"<span class=""disease"">Infarcts in substantia nigra pars reticulata</span> were evoked by prolonged <span class=""chemical"">pilocarpine</span>-induced status epilepticus."	760841.0	8410052.0	8410052_D010862_D002544		bcv_easy_229_sent_train_set_revised_760841	"yes_indirect
"	"This sentence follows the structure of ""[chemical]-induced [other disease] causes [highlighted disease]"". Status epilepticus is what is actually causing ""infarcts in substantia nigra pars reticulata""."
TRUE	D000628	"<span class=""chemical"">aminophylline</span>"	D012131	"<span class=""disease"">respiratory failure</span>"	"The effects of <span class=""chemical"">aminophylline</span> on the ventricular fibrillation threshold during normal acid-base conditions and during <span class=""disease"">respiratory failure</span> were studied in anesthetized open chest dogs."	760841.0	234669.0	234669_D000628_D012131		bcv_easy_2792_sent_train_set_revised_760841	"no_relation
"	The sentence says that the effects were studied, but does not say if there were any effects.
TRUE	C027260	"<span class=""chemical"">4'-0-tetrahydropyranyladriamycin/Pirarubicin</span>"	D009369	"<span class=""disease"">tumors</span>"	"A Phase I study of intravenous (IV) bolus <span class=""chemical"">4'-0-tetrahydropyranyladriamycin</span> (<span class=""chemical"">Pirarubicin</span>) was done in 55 patients in good performance status with refractory <span class=""disease"">tumors</span>."	760841.0	2224762.0	2224762_C027260_D009369		bcv_easy_2221_sent_train_set_revised_760841	"no_relation
"	The study of Pirarubicin was done in patients with existing tumors, but there is no stated link between Pirarubicin and tumors.
TRUE	C558899	"<span class=""chemical"">lopinavir/ritonavir</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"One of the twins developed complete heart block and dilated cardiomyopathy related to <span class=""chemical"">lopinavir/ritonavir</span> therapy, a boosted protease-inhibitor agent, while the other twin developed mild <span class=""disease"">bradycardia</span>."	760841.0	19820426.0	19820426_C558899_D001919		bcv_easy_1711_sent_train_set_revised_760841	"yes_direct
"	The second twin developed bradycardia as a result of lopinavir/ritonavir.
TRUE	D011346	"<span class=""chemical"">prochlorperazine</span>"	D017109	"<span class=""disease"">akathisia</span>"	"Intravenous administration of <span class=""chemical"">prochlorperazine</span> by 15-minute infusion versus 2-minute bolus does not affect the incidence of <span class=""disease"">akathisia</span>: a prospective, randomized, controlled trial."	760841.0	11679859.0	11679859_D011346_D017109		bcv_easy_834_sent_train_set_revised_760841	"no_relation
"	Prochlorperazine has no effect on akathisia.
TRUE	D005283	"<span class=""chemical"">Fentanyl</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"<span class=""chemical"">Fentanyl</span> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and <span class=""disease"">bradycardia</span>."	760841.0	18544179.0	18544179_D005283_D001919		bcv_easy_2375_sent_train_set_revised_760841	"yes_direct
"	Fentanyl increased bradycardia.
TRUE	D003042	"<span class=""chemical"">cocaine</span>"	D005921	"<span class=""disease"">glomerulonephritis</span>"	"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic <span class=""disease"">glomerulonephritis</span>, and <span class=""chemical"">cocaine</span>-related acute renal failure."	760841.0	11391224.0	11391224_D003042_D005921		bcv_easy_814_sent_train_set_revised_760841	"no_relation
"	"Cocaine is causing ""acute renal failure"", not glomerulonephritis."
TRUE	D015740	"<span class=""chemical"">CGRP</span>"	D008881	"<span class=""disease"">migraine</span>"	"Plasma <span class=""chemical"">CGRP</span> concentration increased significantly (P<0.01) during the <span class=""disease"">migraine</span> attack and returned to baseline after the cessation of the <span class=""disease"">migraine</span>."	760841.0	14659530.0	14659530_D015740_D008881		bcv_easy_349_sent_train_set_revised_760841	"no_relation
"	"Here ""CGRP"" is part of ""Plasma CGRP concentration"". The migraine seemed to cause the increase in CGRP levels, and not the other way around."
TRUE	C106791	"<span class=""chemical"">telithromycin</span>"	D056486	"<span class=""disease"">toxic hepatitis/hepatitis</span>"	"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, <span class=""chemical"">telithromycin</span> was the probable cause of acute <span class=""disease"">hepatitis</span> in this patient, and pathological findings suggested drug-induced <span class=""disease"">toxic hepatitis</span>."	760841.0	17919553.0	17919553_C106791_D056486		bcv_easy_2550_sent_train_set_revised_760841	"yes_direct
"	Telithromycin was the likely cause of hepatitis in the patient.
TRUE	D001920	"<span class=""chemical"">bradykinin</span>"	D006973	"<span class=""disease"">hypertension</span>"	"Role of activation of <span class=""chemical"">bradykinin</span> B2 receptors in disruption of the blood-brain barrier during acute <span class=""disease"">hypertension</span>."	760841.0	8955532.0	8955532_D001920_D006973		bcv_easy_1892_sent_train_set_revised_760841	"no_relation
"	"Here ""bradykinin"" is part of ""bradykinin B2 receptors"", because the activated receptors are disrupting the blood-brain barrier somehow."
TRUE	D013390	"<span class=""chemical"">suxamethonium</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"Comparison of i.v. glycopyrrolate and atropine in the prevention of <span class=""disease"">bradycardia</span> and arrhythmias following repeated doses of <span class=""chemical"">suxamethonium</span> in children."	760841.0	6466532.0	6466532_D013390_D001919		bcv_easy_3049_sent_train_set_revised_760841	"yes_direct
"	Suxamethonium causes bradycardia, and the sentence says two other chemicals (glycopyrrolate and atropine) are being used to try and prevent the bradycardia.
TRUE	C060802	"<span class=""chemical"">fangchinoline</span>"	D013927	"<span class=""disease"">thrombosis</span>"	"Effects of tetrandrine and <span class=""chemical"">fangchinoline</span> on experimental <span class=""disease"">thrombosis</span> in mice and human platelet aggregation."	760841.0	10193204.0	10193204_C060802_D013927		bcv_easy_253_sent_train_set_revised_760841	"no_relation
"	The sentence is a fragment, and does not explicitly say that negative effects of fangchinoline exist, rather that the effects were tested.
TRUE	D004164	"<span class=""chemical"">bisphosphonate</span>"	D058186	"<span class=""disease"">acute renal failure</span>"	"Massive proteinuria and <span class=""disease"">acute renal failure</span> after oral <span class=""chemical"">bisphosphonate</span> (alendronate) administration in a patient with focal segmental glomerulosclerosis."	760841.0	18754075.0	18754075_D004164_D058186		bcv_easy_1641_sent_train_set_revised_760841	"yes_direct
"	Patient developed acute renal failure after taking bisphosphonate.
TRUE	D000082	"<span class=""chemical"">acetaminophen</span>"	D007676	"<span class=""disease"">chronic renal failure/ESRD</span>"	"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of <span class=""chemical"">acetaminophen</span> is also associated with <span class=""disease"">chronic renal failure</span> and <span class=""disease"">ESRD</span>, with a relative risk in the range of 2 to 4."	760841.0	8669433.0	8669433_D000082_D007676		bcv_easy_695_sent_train_set_revised_760841	"yes_direct
"	Habitual use of acetaminophen causes chronic renal failure.
TRUE	D009569	"<span class=""chemical"">NO</span>"	D009437	"<span class=""disease"">neuropathic pain</span>"	"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and <span class=""chemical"">NO</span> synthase inhibitors can be effective in alleviation of <span class=""disease"">neuropathic pain</span>, even in hospital care."	760841.0	19300402.0	19300402_D009569_D009437		bcv_easy_2907_sent_train_set_revised_760841	"no_relation
"	"The sentence says small doses of ""NO synthase inhibitors"" (a category of chemicals) removes neuropathic pain."
TRUE	D003520	"<span class=""chemical"">cyclophosphamide</span>"	D006973	"<span class=""disease"">hypertension</span>"	"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <span class=""chemical"">cyclophosphamide</span> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, <span class=""disease"">hypertension</span>, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation."	760841.0	15325671.0	15325671_D003520_D006973		bcv_easy_2919_sent_train_set_revised_760841	"no_relation
"	An analysis was done to see if congestive heart failure had anything to do with some pretreatment characteristics, including hypertension. The sentence never says what the conclusions of the analysis were, or whether cyclophosphamide causes hypertension.
TRUE	C524754	"<span class=""chemical"">maltolyl p-coumarate</span>"	D009410	"<span class=""disease"">neuronal death</span>"	"Taking these in vitro and in vivo results together, our study suggests that <span class=""chemical"">maltolyl p-coumarate</span> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <span class=""disease"">neuronal death</span> and progressive decline of cognitive function."	760841.0	17600377.0	17600377_C524754_D009410		bcv_easy_1560_sent_train_set_revised_760841	"no_relation
"	"Maltolyl p-coumarate is treating Alzheimer's disease, and not causing one of the symptoms (""neuronal death"") of Alzheimer's disease."
TRUE	D000109	"<span class=""chemical"">acetylcholine</span>"	D014202	"<span class=""disease"">tremors</span>"	"Binding of nicotine to nicotinic <span class=""chemical"">acetylcholine</span> receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and <span class=""disease"">tremors</span>, to seizures and death."	760841.0	15275829.0	15275829_D000109_D014202		bcv_easy_1512_sent_train_set_revised_760841	"no_relation
"	"Here ""acetylcholine"" is part of ""nicotinic acetylcholine receptors"". Nicotine binding to these receptors causes tremors, but acetylcholine itself does not."
TRUE	D012964	"<span class=""chemical"">na</span>"	D006509	"<span class=""disease"">HBV infected/HBV mono-infected</span>"	"Thirty-five lamivudine-<span class=""chemical"">na</span>  ve <span class=""disease"">HBV infected</span> patients with or without HIV co-infection were studied: 15 chronic <span class=""disease"">HBV mono-infected</span> patients and 20 HBV-HIV co-infected patients."	760841.0	17854040.0	17854040_D012964_D006509		bcv_easy_1578_sent_train_set_revised_760841	"no_relation
"	"""na"" is not being used as a chemical in this context, because ""ve"" is not a word. There seems to be a missing letter between ""na"" and ""ve""."
TRUE	D004837	"<span class=""chemical"">epinephrine/EP</span>"	D013927	"<span class=""disease"">thrombosis</span>"	"The present study was undertaken to investigate the effects of TET and FAN on the experimental <span class=""disease"">thrombosis</span> induced by collagen plus <span class=""chemical"">epinephrine</span> (<span class=""chemical"">EP</span>) in mice, and platelet aggregation and blood coagulation in vitro."	760841.0	10193204.0	10193204_D004837_D013927		bcv_easy_262_sent_train_set_revised_760841	"yes_direct
"	"Thrombosis was ""induced by"" (caused by) collagen and epinephrine."
TRUE	D006854	"<span class=""chemical"">hydrocortisone</span>"	D009202	"<span class=""disease"">myocardial injury</span>"	"Effects of acetylsalicylic acid, dipyridamole, and <span class=""chemical"">hydrocortisone</span> on epinephrine-induced <span class=""disease"">myocardial injury</span> in dogs."	760841.0	983936.0	983936_D006854_D009202		bcv_easy_1098_sent_train_set_revised_760841	"no_relation
"	"Myocardial injury is caused by ""epinephrine"". We do not know what the effect of hydrocortisone on myocardial injury is."
TRUE	D002784	"<span class=""chemical"">cholesterol</span>"	D003072	"<span class=""disease"">cognitive dysfunctions</span>"	"Therefore, DCE may prove to be a useful remedy for the management of <span class=""disease"">cognitive dysfunctions</span> on account of its multifarious beneficial effects such as, memory improving property, <span class=""chemical"">cholesterol</span> lowering property and anticholinesterase activity."	760841.0	16755009.0	16755009_D002784_D003072		bcv_easy_978_sent_train_set_revised_760841	"no_relation
"	"The sentence lists some ""beneficial effects"" of DCE, such as ""cholesterol lowering property"". The sentence does not say cholesterol causes cognitive dysfunctions."
TRUE	D012964	"<span class=""chemical"">sodium</span>"	D016055	"<span class=""disease"">volume retention</span>"	"Doxorubicin-induced nephropathy leads to epithelial <span class=""chemical"">sodium</span> channel (ENaC)-dependent <span class=""disease"">volume retention</span> and renal fibrosis."	760841.0	18768591.0	18768591_D012964_D016055		bcv_easy_1653_sent_train_set_revised_760841	"no_relation
"	"The sentence says nephropathy caused by doxorubicin leads to volume retention that is dependent on ""epithelial sodium channels"", a kind of protein. It does not say sodium causes volume retention."
TRUE	D002945	"<span class=""chemical"">cisplatin</span>"	D028361	"<span class=""disease"">mitochondrial toxicity</span>"	"In conclusion <span class=""disease"">mitochondrial toxicity</span> is an early common event both in paclitaxel and <span class=""chemical"">cisplatin</span> induced neurotoxicity."	760841.0	18809400.0	18809400_D002945_D028361		bcv_easy_2259_sent_train_set_revised_760841	"yes_indirect
"	"This sentence follows the ""[chemical]-induced [other disease] causes [highlighted disease]"" structure. Therefore the correct answer is ""cisplatin-induced [neurotoxicity] causes mitochondrial toxicity""."
TRUE	D009020	"<span class=""chemical"">morphine</span>"	D059787	"<span class=""disease"">acute pain</span>"	"Enhancement of <span class=""chemical"">morphine</span> antinociception by dextromethorphan was seen in both males and females in the <span class=""disease"">acute pain</span> models, with the magnitude of this effect being greater in males."	760841.0	18221780.0	18221780_D009020_D059787		bcv_easy_1595_sent_train_set_revised_760841	"no_relation
"	The effect was enhanced by dextromethorphan in a model of acute pain. The sentence does not say morphine causes acute pain. Fun fact: morphine is actually a very strong painkiller that is similar to opium and heroin.
TRUE	D016202	"<span class=""chemical"">NMDA</span>"	D059787	"<span class=""disease"">acute pain</span>"	"These findings demonstrate a sexually-dimorphic interaction between <span class=""chemical"">NMDA</span> antagonists and morphine in a persistent pain model that can be distinguished from those observed in <span class=""disease"">acute pain</span> models."	760841.0	18221780.0	18221780_D016202_D059787		bcv_easy_1597_sent_train_set_revised_760841	"no_relation
"	"""NMDA antagonists"" are interacting with morphine. The study is done in a ""acute pain"" model, but the sentence does not say that NMDA causes acute pain."
TRUE	D000431	"<span class=""chemical"">alcohol</span>"	D005483	"<span class=""disease"">flushing of the face</span>"	"In less than 1 hour after the ingestion of <span class=""chemical"">alcohol</span>, he developed malaise with <span class=""disease"">flushing of the face</span>, tachycardia, and dyspnea."	760841.0	19657887.0	19657887_D000431_D005483		bcv_easy_1805_sent_train_set_revised_760841	"yes_direct
"	Ingesting alcohol causes your face to flush (but you already knew that!).
TRUE	D004298	"<span class=""chemical"">dopamine</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the <span class=""disease"">bradycardia</span> of this agonist at peripheral <span class=""chemical"">dopamine</span> D2 receptors."	760841.0	10721819.0	10721819_D004298_D001919		bcv_easy_1391_sent_train_set_revised_760841	"no_relation
"	"Here ""dopamine"" is part of ""dopamine D2 receptors"", which is a kind of protein."
TRUE	D006220	"<span class=""chemical"">haloperidol</span>"	D011595	"<span class=""disease"">psychomotor agitation</span>"	"RESULTS: For the 60 patients who completed phase A, standard-dose <span class=""chemical"">haloperidol</span> was efficacious and superior to both low-dose <span class=""chemical"">haloperidol</span> and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on <span class=""disease"">psychomotor agitation</span>."	760841.0	9812111.0	9812111_D006220_D011595		bcv_easy_2042_sent_train_set_revised_760841	"no_relation
"	Haloperidol seemed to have a positive effect on psychomotor agitation.
TRUE	D005283	"<span class=""chemical"">fentanyl</span>"	D010149	"<span class=""disease"">postoperative pain</span>"	"CONCLUSION: As <span class=""chemical"">fentanyl</span> exacerbated postoperative nausea and vomiting without an improvement in <span class=""disease"">postoperative pain</span> and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery."	760841.0	18544179.0	18544179_D005283_D010149		bcv_easy_2381_sent_train_set_revised_760841	"no_relation
"	Fentanyl made postoperative nausea and vomiting worse, but did not improve postoperative pain. The sentence does not say that fentanyl originally caused the postoperative pain!
TRUE	D009582	"<span class=""chemical"">Nitrofurantoins</span>"	D000853	"<span class=""disease"">anophthalmia</span>"	"<span class=""chemical"">Nitrofurantoins</span> were associated with <span class=""disease"">anophthalmia</span> or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9)."	760841.0	19884587.0	19884587_D009582_D000853		bcv_easy_2185_sent_train_set_revised_760841	"yes_direct
"	Nitrofurantoins cause anophthalmia.
TRUE	D004177	"<span class=""chemical"">metamizol</span>"	D059350	"<span class=""disease"">chronic pain</span>"	"These findings show a significant interaction between morphine and <span class=""chemical"">metamizol</span> in chronically treated rats, suggesting that this combination could be useful for the treatment of <span class=""disease"">chronic pain</span>."	760841.0	12063090.0	12063090_D004177_D059350		bcv_easy_1462_sent_train_set_revised_760841	"no_relation
"	Metamizol is said to be useful for treating chronic pain.
TRUE	D007608	"<span class=""chemical"">kainic acid</span>"	D001930	"<span class=""disease"">hippocampal injury</span>"	"Estrogens protect ovariectomized rats from <span class=""disease"">hippocampal injury</span> induced by <span class=""chemical"">kainic acid</span>-induced status epilepticus (SE)."	760841.0	12757899.0	12757899_D007608_D001930		bcv_easy_1482_sent_train_set_revised_760841	"yes_indirect
"	"This follows the ""[chemical]-induced [other disease] caused [highlighted disease]"" format, so the correct answer is ""kainic acid-induced [status epilepticus] causes hippocampal injury""."
TRUE	D008775	"<span class=""chemical"">methylprednisolone</span>"	D020250	"<span class=""disease"">nausea, vomiting</span>"	"CONCLUSIONS: The administration of <span class=""chemical"">methylprednisolone</span> and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including <span class=""disease"">nausea, vomiting</span>, and headache."	760841.0	17466854.0	17466854_D008775_D020250		bcv_easy_1538_sent_train_set_revised_760841	"yes_direct
"	Methylprednisolone causes nausea and vomiting as a side effect.
TRUE	D002220	"<span class=""chemical"">carbamazepine</span>"	D051437	"<span class=""disease"">renal failure</span>"	"We report a patient in whom hypersensitivity to <span class=""chemical"">carbamazepine</span> presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and <span class=""disease"">renal failure</span>."	760841.0	2522601.0	2522601_D002220_D051437		bcv_easy_1930_sent_train_set_revised_760841	"yes_direct
"	Carbamazepine caused many diseases in this patient.
TRUE	D019386	"<span class=""chemical"">alendronate</span>"	D011507	"<span class=""disease"">proteinuria</span>"	"Massive <span class=""disease"">proteinuria</span> and acute renal failure after oral bisphosphonate (<span class=""chemical"">alendronate</span>) administration in a patient with focal segmental glomerulosclerosis."	760841.0	18754075.0	18754075_D019386_D011507		bcv_easy_1645_sent_train_set_revised_760841	"yes_direct
"	Patient developed proteinuria after taking alendronate.
TRUE	D002443	"<span class=""chemical"">ceftriaxone</span>"	D056486	"<span class=""disease"">hepatitis</span>"	"Acute <span class=""disease"">hepatitis</span>, autoimmune hemolytic anemia, and erythroblastocytopenia induced by <span class=""chemical"">ceftriaxone</span>."	760841.0	9625142.0	9625142_D002443_D056486		bcv_easy_241_sent_train_set_revised_760841	"yes_direct
"	Induced means caused by.
TRUE	D009568	"<span class=""chemical"">nitrendipine</span>"	D006978	"<span class=""disease"">renovascular hypertension</span>"	"The effect of a 6-week treatment with the calcium channel blocker <span class=""chemical"">nitrendipine</span> or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip <span class=""disease"">renovascular hypertension</span>."	760841.0	1639466.0	1639466_D009568_D006978		bcv_easy_3086_sent_train_set_revised_760841	"no_relation
"	The sentence gives no conclusion regarding the result of the study.
TRUE	C030852	"<span class=""chemical"">vinorelbine</span>"	D002289	"<span class=""disease"">nonsmall cell lung carcinoma</span>"	"Gemcitabine plus <span class=""chemical"">vinorelbine</span> in <span class=""disease"">nonsmall cell lung carcinoma</span> patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group."	760841.0	10526274.0	10526274_C030852_D002289		bcv_easy_269_sent_train_set_revised_760841	"no_relation
"	The sentence says vinorelbine was used in patients with lung carcinoma, but does not say whether vinorelbine is treating or causing the cancer.
TRUE	D005283	"<span class=""chemical"">fentanyl</span>"	D016055	"<span class=""disease"">retention of urine</span>"	"Bladder <span class=""disease"">retention of urine</span> as a result of continuous intravenous infusion of <span class=""chemical"">fentanyl</span>: 2 case reports."	760841.0	11581460.0	11581460_D005283_D016055		bcv_easy_299_sent_train_set_revised_760841	"yes_direct
"	Using fentanyl caused retention or urine.
TRUE	D018817	"<span class=""chemical"">MDMA</span>"	D003072	"<span class=""disease"">impaired social and emotional judgement processes</span>"	"<span class=""chemical"">MDMA</span> polydrug users show process-specific central executive impairments coupled with <span class=""disease"">impaired social and emotional judgement processes</span>."	760841.0	16574712.0	16574712_D018817_D003072		bcv_easy_371_sent_train_set_revised_760841	"yes_direct
"	People who take MDMA (and other drugs) develop impaired social and emotional judgement processes.
TRUE	D007980	"<span class=""chemical"">Levodopa</span>"	D004421	"<span class=""disease"">dystonia</span>"	"<span class=""chemical"">Levodopa</span>-induced oromandibular <span class=""disease"">dystonia</span> in progressive supranuclear palsy."	761593.0	12691807.0	12691807_D007980_D004421		bcv_easy_330_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008619	"<span class=""chemical"">mepivacaine</span>"	D009135	"<span class=""disease"">muscle damage</span>"	"In addition to <span class=""disease"">muscle damage</span>, severe damage was also seen in harderian glands, especially after exposure to <span class=""chemical"">mepivacaine</span> and lidocaine plus epinephrine."	761593.0	4038130.0	4038130_D008619_D009135		bcv_easy_395_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004917	"<span class=""chemical"">erythromycin</span>"	D008133	"<span class=""disease"">Prolongation of QT interval</span>"	"<span class=""disease"">Prolongation of QT interval</span>, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with <span class=""chemical"">erythromycin</span> or azole antifungal agents, but not with other CYP3A4 inhibitors."	761593.0	9545159.0	9545159_D004917_D008133		bcv_easy_258_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D014202	"<span class=""disease"">tremor</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions caused by <span class=""chemical"">carbachol</span> and eserine."	761593.0	6892185.0	6892185_D002217_D014202		bcv_easy_1055_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D017035	"<span class=""chemical"">pravastatin</span>"	D009220	"<span class=""disease"">inflammatory myopathy</span>"	"A case of acute <span class=""disease"">inflammatory myopathy</span> associated with the use of <span class=""chemical"">pravastatin</span>, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported."	761593.0	7604176.0	7604176_D017035_D009220		bcv_easy_809_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002119	"<span class=""chemical"">calcium carbon-ate</span>"	D053040	"<span class=""disease"">nephrolithiasis</span>"	"One case of acute hypercalcaemia and two of recurrent <span class=""disease"">nephrolithiasis</span> are reported in patients who had regularly consumed large amounts of <span class=""chemical"">calcium carbon-ate</span>-sodium bicarbonate powders for more than 20 years."	761593.0	625456.0	625456_D002119_D053040		bcv_easy_48_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004317	"<span class=""chemical"">adriamycin</span>"	D015470	"<span class=""disease"">acute myeloblastic leukemia</span>"	"1 of the 10 monkeys developed <span class=""disease"">acute myeloblastic leukemia</span> after receiving 324 mg/m2 of <span class=""chemical"">adriamycin</span>; the 10th monkey is alive and well 26 months after the last dose of drug."	761593.0	6769133.0	6769133_D004317_D015470		bcv_easy_941_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D001971	"<span class=""chemical"">bromocriptine</span>"	D011605	"<span class=""disease"">psychosis</span>"	"Two multigravida patients with no prior psychiatric history were seen with postpartum <span class=""disease"">psychosis</span>, having received <span class=""chemical"">bromocriptine</span> for inhibition of lactation."	761593.0	3686155.0	3686155_D001971_D011605		bcv_easy_558_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D006221	"<span class=""chemical"">halothane</span>"	D056486	"<span class=""disease"">hepatitis</span>"	"This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of <span class=""chemical"">halothane</span> <span class=""disease"">hepatitis</span> either alone or subsequent to <span class=""chemical"">halothane</span> administration."	761593.0	7647582.0	7647582_D006221_D056486		bcv_easy_919_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003520	"<span class=""chemical"">Cyclophosphamide</span>"	D001749	"<span class=""disease"">bladder tumor</span>"	"CONCLUSIONS: <span class=""chemical"">Cyclophosphamide</span> associated <span class=""disease"">bladder tumor</span> is an aggressive disease."	761593.0	8911359.0	8911359_D003520_D001749		bcv_easy_436_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008713	"<span class=""chemical"">methimazole</span>"	D011537	"<span class=""disease"">itching</span>"	"A 43-year-old woman had severe jaundice and <span class=""disease"">itching</span> 1 month after receiving <span class=""chemical"">methimazole</span> (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism."	761593.0	14982270.0	14982270_D008713_D011537		bcv_easy_546_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010830	"<span class=""chemical"">eserine</span>"	D014202	"<span class=""disease"">tremor</span>"	"On the other hand, mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions evoked by carbachol and <span class=""chemical"">eserine</span> were not significantly changed by calcium chloride."	761593.0	6892185.0	6892185_D010830_D014202		bcv_easy_1051_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D011441	"<span class=""chemical"">PTU/propylthiouracil</span>"	D014657	"<span class=""disease"">vasculitis</span>"	"The diagnosis of <span class=""chemical"">propylthiouracil</span> (<span class=""chemical"">PTU</span>)-associated <span class=""disease"">vasculitis</span> was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of <span class=""chemical"">PTU</span>."	761593.0	16418614.0	16418614_D011441_D014657		bcv_easy_94_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004837	"<span class=""chemical"">epinephrine</span>"	D017202	"<span class=""disease"">myocardial ischemia</span>"	"The role of <span class=""chemical"">epinephrine</span> in eliciting <span class=""disease"">myocardial ischemia</span> was examined in patients with coronary artery disease."	761593.0	3413271.0	3413271_D004837_D017202		bcv_easy_848_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C047781	"<span class=""chemical"">Lamotrigine</span>"	D009207	"<span class=""disease"">myoclonus</span>"	"<span class=""chemical"">Lamotrigine</span> associated with exacerbation or de novo <span class=""disease"">myoclonus</span> in idiopathic generalized epilepsies."	761593.0	16157917.0	16157917_C047781_D009207		bcv_easy_1005_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002110	"<span class=""chemical"">caffeine</span>"	D017180	"<span class=""disease"">ventricular tachycardia</span>"	"We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of <span class=""disease"">ventricular tachycardia</span> after <span class=""chemical"">caffeine</span> administration."	761593.0	18997632.0	18997632_D002110_D017180		bcv_easy_122_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014700	"<span class=""chemical"">verapamil</span>"	D007022	"<span class=""disease"">hypotension</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, <span class=""disease"">hypotension</span> and bradycardia during combined therapy with <span class=""chemical"">verapamil</span> and beta-adrenergic blocking drugs."	761593.0	6127992.0	6127992_D014700_D007022		bcv_easy_469_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005473	"<span class=""chemical"">fluoxetine</span>"	D062788	"<span class=""disease"">adenomyosis</span>"	"Histological studies revealed 11 cases of <span class=""disease"">adenomyosis</span>, all within the noncastrated group receiving <span class=""chemical"">fluoxetine</span>."	761593.0	9098464.0	9098464_D005473_D062788		bcv_easy_1036_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004656	"<span class=""chemical"">enalapril</span>"	D051437	"<span class=""disease"">decreased renal function</span>"	"Older age was associated with a greater risk of developing <span class=""disease"">decreased renal function</span> in both groups, but significantly more so in the <span class=""chemical"">enalapril</span> group (<span class=""chemical"">enalapril</span>: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with <span class=""chemical"">enalapril</span>; placebo: RR 1.18, 95% CI 1.12-1.25)."	761593.0	10539815.0	10539815_D004656_D051437		bcv_easy_765_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D017693	"<span class=""chemical"">sodium bicarbonate</span>"	D006934	"<span class=""disease"">hypercalcaemia</span>"	"One case of acute <span class=""disease"">hypercalcaemia</span> and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-<span class=""chemical"">sodium bicarbonate</span> powders for more than 20 years."	761593.0	625456.0	625456_D017693_D006934		bcv_easy_49_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C014282	"<span class=""chemical"">cirazoline</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"Both the pressor and <span class=""disease"">bradycardia</span> effects of <span class=""chemical"">cirazoline</span> were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4)."	761593.0	1355091.0	1355091_C014282_D001919		bcv_easy_1079_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000583	"<span class=""chemical"">amikacin</span>"	D007674	"<span class=""disease"">nephrotoxicity</span>"	"To evaluate <span class=""chemical"">amikacin</span>-associated <span class=""disease"">nephrotoxicity</span> in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center."	761593.0	18356633.0	18356633_D000583_D007674		bcv_easy_698_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010042	"<span class=""chemical"">ouabain</span>"	D001145	"<span class=""disease"">arrhythmia</span>"	"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and <span class=""chemical"">ouabain</span>-induced guinea pig <span class=""disease"">arrhythmia</span> models."	761593.0	19721134.0	19721134_D010042_D001145		bcv_easy_34_sent_work_dev_set_761593	"yes_direct
"	"Two animal models were used in this study. One was a rat model where arrhythmia was induced by ""aconitine"". The second was a guinea pig model induced by ""ouabain""."
TRUE	C019248	"<span class=""chemical"">Pamidronate</span>"	D006996	"<span class=""disease"">hypocalcemia</span>"	"<span class=""chemical"">Pamidronate</span> treatment is associated with considerable risk for <span class=""disease"">hypocalcemia</span>, even in cases of initially severe hypercalcemia."	761593.0	16006300.0	16006300_C019248_D006996		bcv_easy_709_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004977	"<span class=""chemical"">ethambutol</span>"	D009901	"<span class=""disease"">Bilateral optic neuropathy</span>"	"<span class=""disease"">Bilateral optic neuropathy</span> due to combined <span class=""chemical"">ethambutol</span> and isoniazid treatment."	761593.0	384871.0	384871_D004977_D009901		bcv_easy_570_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002110	"<span class=""chemical"">caffeine</span>"	D017180	"<span class=""disease"">ventricular tachycardia</span>"	"A case of <span class=""disease"">ventricular tachycardia</span> related to <span class=""chemical"">caffeine</span> pretreatment."	761593.0	18997632.0	18997632_D002110_D017180		bcv_easy_119_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008727	"<span class=""chemical"">methotrexate</span>"	D056784	"<span class=""disease"">leukoencephalopathy</span>"	"BACKGROUND: A transient <span class=""disease"">leukoencephalopathy</span> mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal <span class=""chemical"">methotrexate</span> for childhood leukaemia."	761593.0	17682013.0	17682013_D008727_D056784		bcv_easy_779_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C534628	"<span class=""chemical"">SCH 23390</span>"	D002375	"<span class=""disease"">catalepsy</span>"	"D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the <span class=""disease"">catalepsy</span> induced by fluphenazine, <span class=""chemical"">SCH 23390</span> or sulpiride."	761593.0	1687392.0	1687392_C534628_D002375		bcv_easy_861_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003630	"<span class=""chemical"">daunorubicin</span>"	D015431	"<span class=""disease"">weight loss</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and <span class=""disease"">weight loss</span> from <span class=""chemical"">daunorubicin</span> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <span class=""disease"">weight loss</span>, nor the in vitro cytotoxicity from doxorubicin."	761593.0	15897593.0	15897593_D003630_D015431		bcv_easy_983_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D009020	"<span class=""chemical"">morphine</span>"	D002375	"<span class=""disease"">cataleptic</span>"	"Pre-treatment with ketamine produced cross-tolerance to <span class=""chemical"">morphine</span>, whereas pretreatment with <span class=""chemical"">morphine</span> did not induce cross-tolerance to ketamine but rather augmented the <span class=""disease"">cataleptic</span> response; this augmentation was attributed to residual <span class=""chemical"">morphine</span> in the brain."	761593.0	2716967.0	2716967_D009020_D002375		bcv_easy_740_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C033457	"<span class=""chemical"">Quinidine phenylethylbarbiturate</span>"	D056486	"<span class=""disease"">hepatitis</span>"	"<span class=""chemical"">Quinidine phenylethylbarbiturate</span>-induced fulminant <span class=""disease"">hepatitis</span> in a pregnant woman. A case report."	761593.0	3411101.0	3411101_C033457_D056486		bcv_easy_1215_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D015742	"<span class=""chemical"">propofol</span>"	D010146	"<span class=""disease"">pain</span>"	"We hypothesized that <span class=""chemical"">propofol</span> infusion <span class=""disease"">pain</span> might be prevented by infusing remifentanil before starting the <span class=""chemical"">propofol</span> infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used."	761593.0	18006530.0	18006530_D015742_D010146		bcv_easy_5_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D013619	"<span class=""chemical"">Tacrine</span>"	D001930	"<span class=""disease"">hippocampal damage</span>"	"<span class=""chemical"">Tacrine</span>, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed <span class=""disease"">hippocampal damage</span>."	761593.0	19944736.0	19944736_D013619_D001930		bcv_easy_630_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D009543	"<span class=""chemical"">nifedipine/Adalat</span>"	D013684	"<span class=""disease"">telangiectasia</span>"	"Five months after starting <span class=""chemical"">nifedipine</span> (<span class=""chemical"">Adalat</span>), two patients developed photodistributed facial <span class=""disease"">telangiectasia</span>, which became more noticeable with time."	761593.0	8251368.0	8251368_D009543_D013684		bcv_easy_453_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014859	"<span class=""chemical"">warfarin</span>"	D018366	"<span class=""disease"">LV Cutaneous lesions</span>"	"The results of skin lesion biopsies were available in 3 patients, confirming <span class=""disease"">LV Cutaneous lesions</span> resolved in all patients after <span class=""chemical"">warfarin</span> was discontinued."	761593.0	16047871.0	16047871_D014859_D018366		bcv_easy_1184_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004837	"<span class=""chemical"">epinephrine</span>"	D017202	"<span class=""disease"">myocardial ischemia</span>"	"Both <span class=""chemical"">epinephrine</span> and exercise produced <span class=""disease"">myocardial ischemia</span> as evidenced by ST segment depression and angina."	761593.0	3413271.0	3413271_D004837_D017202		bcv_easy_852_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D009569	"<span class=""chemical"">nitric oxide/NO</span>"	D020326	"<span class=""disease"">migraine without aura</span>"	"In recent years, increasing evidence has suggested that the messenger molecule <span class=""chemical"">nitric oxide</span> (<span class=""chemical"">NO</span>) is involved in pain mechanisms of <span class=""disease"">migraine without aura</span>."	761593.0	10524660.0	10524660_D009569_D020326		bcv_easy_603_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D001971	"<span class=""chemical"">bromocriptine</span>"	D011605	"<span class=""disease"">psychosis</span>"	"These cases demonstrate that <span class=""chemical"">bromocriptine</span> may cause <span class=""disease"">psychosis</span> even when given in low doses."	761593.0	3686155.0	3686155_D001971_D011605		bcv_easy_561_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C092292	"<span class=""chemical"">ziprasidone</span>"	D009459	"<span class=""disease"">NMS</span>"	"This case is the earliest (second day of treatment) <span class=""disease"">NMS</span> due to <span class=""chemical"">ziprasidone</span> reported in the literature."	761593.0	17366349.0	17366349_C092292_D009459		bcv_easy_57_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003915	"<span class=""chemical"">DM</span>"	D003072	"<span class=""disease"">cognitive deterioration</span>"	"This report describes a case of <span class=""disease"">cognitive deterioration</span> resulting from prolonged use of <span class=""chemical"">DM</span>."	761593.0	7803371.0	7803371_D003915_D003072		bcv_easy_1243_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"	D006973	"<span class=""disease"">hypertension</span>"	"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, <span class=""disease"">hypertension</span> and heart failure during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."	761593.0	16586083.0	16586083_D016861_D006973		bcv_easy_1148_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> produced by <span class=""chemical"">carbachol</span> and eserine injected similarly was investigated."	761593.0	6892185.0	6892185_D002217_D004830		bcv_easy_1038_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007649	"<span class=""chemical"">ketamine</span>"	D002375	"<span class=""disease"">catalepsy</span>"	"Previous studies demonstrated that both <span class=""chemical"">ketamine</span> and morphine induced analgesia and <span class=""disease"">catalepsy</span> in the rat."	761593.0	2716967.0	2716967_D007649_D002375		bcv_easy_736_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010830	"<span class=""chemical"">eserine</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions caused by carbachol and <span class=""chemical"">eserine</span>."	761593.0	6892185.0	6892185_D010830_D015878		bcv_easy_1058_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014147	"<span class=""chemical"">tramadol</span>"	D006212	"<span class=""disease"">hallucinations</span>"	"Nightmares and <span class=""disease"">hallucinations</span> after long-term intake of <span class=""chemical"">tramadol</span> combined with antidepressants."	761593.0	8766220.0	8766220_D014147_D006212		bcv_easy_96_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000638	"<span class=""chemical"">amiodarone</span>"	D008103	"<span class=""disease"">cirrhosis of the liver</span>"	"It is concluded that solid evidence exists of hepatic injury due to <span class=""chemical"">amiodarone</span> treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular <span class=""disease"">cirrhosis of the liver</span>."	761593.0	3962737.0	3962737_D000638_D008103		bcv_easy_289_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D001556	"<span class=""chemical"">alpha-benzene hexachloride</span>"	D006528	"<span class=""disease"">hepatomas</span>"	"Peroxisomes in <span class=""disease"">hepatomas</span> and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm <span class=""chemical"">alpha-benzene hexachloride</span> were examined histochemically and electron microscopically."	761593.0	85485.0	85485_D001556_D006528		bcv_easy_379_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005283	"<span class=""chemical"">fentanyl</span>"	D009127	"<span class=""disease"">rigidity</span>"	"Post-operative <span class=""disease"">rigidity</span> after <span class=""chemical"">fentanyl</span> administration."	761593.0	3780697.0	3780697_D005283_D009127		bcv_easy_785_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005472	"<span class=""chemical"">5-fluorouracil</span>"	D056784	"<span class=""disease"">leukoencephalopathy</span>"	"RESULTS: We identified 27 reports of toxic <span class=""disease"">leukoencephalopathy</span> in patients treated with methotrexate (intrathecal, systemic), <span class=""chemical"">5-fluorouracil</span> and its derivative carmofur, and capecitabine."	761593.0	17682013.0	17682013_D005472_D056784		bcv_easy_783_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010830	"<span class=""chemical"">eserine</span>"	D014202	"<span class=""disease"">tremor</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions produced by carbachol and <span class=""chemical"">eserine</span> injected similarly was investigated."	761593.0	6892185.0	6892185_D010830_D014202		bcv_easy_1041_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D012293	"<span class=""chemical"">rifampicin</span>"	D058186	"<span class=""disease"">Acute renal failure</span>"	"<span class=""disease"">Acute renal failure</span> subsequent to the administration of <span class=""chemical"">rifampicin</span>. A follow-up study of cases reported earlier."	761593.0	982002.0	982002_D012293_D058186		bcv_easy_335_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010830	"<span class=""chemical"">eserine</span>"	D014202	"<span class=""disease"">tremor</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions caused by carbachol and <span class=""chemical"">eserine</span>."	761593.0	6892185.0	6892185_D010830_D014202		bcv_easy_1059_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003276	"<span class=""chemical"">oral contraceptives</span>"	D008113	"<span class=""disease"">liver tumors</span>"	"Etiologic factors in the pathogenesis of <span class=""disease"">liver tumors</span> associated with <span class=""chemical"">oral contraceptives</span>."	761593.0	188339.0	188339_D003276_D008113		bcv_easy_421_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004737	"<span class=""chemical"">enflurane</span>"	D056486	"<span class=""disease"">hepatic injury</span>"	"Two halogenated anesthetics, <span class=""chemical"">enflurane</span> and isoflurane, have been associated with an allergic-type <span class=""disease"">hepatic injury</span> both alone and following previous exposure to halothane."	761593.0	7647582.0	7647582_D004737_D056486		bcv_easy_910_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003975	"<span class=""chemical"">diazepam</span>"	D001259	"<span class=""disease"">incoordination</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and <span class=""chemical"">diazepam</span>-induced muscular <span class=""disease"">incoordination</span> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol."	761593.0	6323692.0	6323692_D003975_D001259		bcv_easy_372_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004837	"<span class=""chemical"">epinephrine</span>"	D017202	"<span class=""disease"">myocardial ischemia</span>"	"However, the mechanisms of <span class=""disease"">myocardial ischemia</span> induced by <span class=""chemical"">epinephrine</span> were significantly different from those of exercise."	761593.0	3413271.0	3413271_D004837_D017202		bcv_easy_853_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007649	"<span class=""chemical"">Ketamine</span>"	D011605	"<span class=""disease"">psychosis</span>"	"<span class=""chemical"">Ketamine</span> elicited <span class=""disease"">psychosis</span> like psychopathology."	761593.0	20727411.0	20727411_D007649_D011605		bcv_easy_225_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D015215	"<span class=""chemical"">AZT</span>"	D002311	"<span class=""disease"">cardiac dilation</span>"	"In contrast, <span class=""chemical"">AZT</span>-treated FasL Tg mice developed <span class=""disease"">cardiac dilation</span> and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles."	761593.0	17943461.0	17943461_D015215_D002311		bcv_easy_503_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010068	"<span class=""chemical"">oxacillin</span>"	D018366	"<span class=""disease"">Cutaneous leucocytoclastic vasculitis</span>"	"<span class=""disease"">Cutaneous leucocytoclastic vasculitis</span> associated with <span class=""chemical"">oxacillin</span>."	761593.0	11337188.0	11337188_D010068_D018366		bcv_easy_301_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004317	"<span class=""chemical"">doxorubicin/DXR/Adriamycin</span>"	D009202	"<span class=""disease"">cardiomyopathy/myocardial disease/CM</span>"	"The <span class=""disease"">cardiomyopathy</span> (<span class=""disease"">CM</span>) produced by the anticancer drug <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">DXR</span>) (<span class=""chemical"">Adriamycin</span>) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of <span class=""disease"">myocardial disease</span>."	761593.0	7282516.0	7282516_D004317_D009202		bcv_easy_59_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003915	"<span class=""chemical"">dextromethorphan</span>"	D003072	"<span class=""disease"">Cognitive deterioration</span>"	"<span class=""disease"">Cognitive deterioration</span> from long-term abuse of <span class=""chemical"">dextromethorphan</span>: a case report."	761593.0	7803371.0	7803371_D003915_D003072		bcv_easy_1242_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C047426	"<span class=""chemical"">venlafaxine</span>"	D020230	"<span class=""disease"">Serotonin syndrome</span>"	"<span class=""disease"">Serotonin syndrome</span> from <span class=""chemical"">venlafaxine</span>-tranylcypromine interaction."	761593.0	8888541.0	8888541_C047426_D020230		bcv_easy_1101_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D009288	"<span class=""chemical"">naproxen</span>"	D007681	"<span class=""disease"">renal papillary necrosis/RPN</span>"	"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed <span class=""disease"">renal papillary necrosis</span> (<span class=""disease"">RPN</span>) 4 months after institution of <span class=""chemical"">naproxen</span> therapy."	761593.0	6699841.0	6699841_D009288_D007681		bcv_easy_1253_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C076029	"<span class=""chemical"">olanzapine</span>"	D001714	"<span class=""disease"">Hypomania</span>"	"<span class=""disease"">Hypomania</span>-like syndrome induced by <span class=""chemical"">olanzapine</span>."	761593.0	10565806.0	10565806_C076029_D001714		bcv_easy_126_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000728	"<span class=""chemical"">androgen</span>"	D020181	"<span class=""disease"">obstructive sleep apnea syndrome</span>"	"Development of the <span class=""disease"">obstructive sleep apnea syndrome</span> must be considered a possible side effect of <span class=""chemical"">androgen</span> therapy."	761593.0	6732043.0	6732043_D000728_D020181		bcv_easy_1161_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005473	"<span class=""chemical"">fluoxetine hydrochloride</span>"	D006966	"<span class=""disease"">hyperprolactinemia</span>"	"A murine model of adenomyosis: the effects of <span class=""disease"">hyperprolactinemia</span> induced by <span class=""chemical"">fluoxetine hydrochloride</span>, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats."	761593.0	9098464.0	9098464_D005473_D006966		bcv_easy_1031_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D018967	"<span class=""chemical"">Risperidone</span>"	D010468	"<span class=""disease"">visual disturbances</span>"	"<span class=""chemical"">Risperidone</span>-associated, benign transient <span class=""disease"">visual disturbances</span> in schizophrenic patients with a past history of LSD abuse."	761593.0	12013711.0	12013711_D018967_D010468		bcv_easy_149_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005283	"<span class=""chemical"">fentanyl</span>"	D009127	"<span class=""disease"">rigidity</span>"	"A case of thoraco-abdominal <span class=""disease"">rigidity</span> leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of <span class=""chemical"">fentanyl</span>."	761593.0	3780697.0	3780697_D005283_D009127		bcv_easy_787_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D013619	"<span class=""chemical"">Tacrine</span>"	D012640	"<span class=""disease"">seizures</span>"	"<span class=""chemical"">Tacrine</span>, administered in LiCl pre-treated rats, induces electrocorticographic <span class=""disease"">seizures</span> and delayed hippocampal damage."	761593.0	19944736.0	19944736_D013619_D012640		bcv_easy_629_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004837	"<span class=""chemical"">epinephrine</span>"	D017202	"<span class=""disease"">myocardial ischemia</span>"	"Mechanisms of <span class=""disease"">myocardial ischemia</span> induced by <span class=""chemical"">epinephrine</span>: comparison with exercise-induced ischemia."	761593.0	3413271.0	3413271_D004837_D017202		bcv_easy_846_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004977	"<span class=""chemical"">Ethambutol</span>"	D014786	"<span class=""disease"">visual loss</span>"	"INTRODUCTION: <span class=""chemical"">Ethambutol</span> is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent <span class=""disease"">visual loss</span>."	761593.0	16710500.0	16710500_D004977_D014786		bcv_easy_339_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005047	"<span class=""chemical"">Etoposide</span>"	D009203	"<span class=""disease"">myocardial infarction</span>"	"<span class=""chemical"">Etoposide</span>-related <span class=""disease"">myocardial infarction</span>."	761593.0	7619765.0	7619765_D005047_D009203		bcv_easy_552_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014191	"<span class=""chemical"">tranylcypromine</span>"	D020230	"<span class=""disease"">serotonin syndrome</span>"	"We report a venlafaxine-MAOI interaction that resulted in the <span class=""disease"">serotonin syndrome</span> in a 23-y-old male who was taking <span class=""chemical"">tranylcypromine</span> for depression."	761593.0	8888541.0	8888541_D014191_D020230		bcv_easy_1109_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D018817	"<span class=""chemical"">MDMA</span>"	D008569	"<span class=""disease"">impaired memory functioning/memory impairments</span>"	"While the use of <span class=""chemical"">MDMA</span> in quantities that may be considered ""moderate"" is not associated with <span class=""disease"">impaired memory functioning</span>, heavy use of <span class=""chemical"">MDMA</span> use may lead to long lasting <span class=""disease"">memory impairments</span>."	761593.0	16574713.0	16574713_D018817_D008569		bcv_easy_317_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008012	"<span class=""chemical"">lidocaine</span>"	D012640	"<span class=""disease"">seizures</span>"	"Chronic carbamazepine inhibits the development of local anesthetic <span class=""disease"">seizures</span> kindled by cocaine and <span class=""chemical"">lidocaine</span>."	761593.0	2790457.0	2790457_D008012_D012640		bcv_easy_682_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008625	"<span class=""chemical"">Tiopronin</span>"	D009393	"<span class=""disease"">nephritis</span>"	"A strong association has been found between <span class=""disease"">nephritis</span> and dermatitis due to <span class=""chemical"">Tiopronin</span> (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35."	761593.0	3084782.0	3084782_D008625_D009393		bcv_easy_670_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000643	"<span class=""chemical"">NH4CL</span>"	D003128	"<span class=""disease"">coma</span>"	"Ammonia <span class=""disease"">coma</span> was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol <span class=""chemical"">NH4CL</span>."	761593.0	761833.0	761833_D000643_D003128		bcv_easy_457_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D017963	"<span class=""chemical"">azithromycin</span>"	D006606	"<span class=""disease"">hiccups</span>"	"Possible <span class=""chemical"">azithromycin</span>-associated <span class=""disease"">hiccups</span>."	761593.0	15985056.0	15985056_D017963_D006606		bcv_easy_815_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D013390	"<span class=""chemical"">succinylcholine</span>"	D001049	"<span class=""disease"">apnoea</span>"	"Fifteen patients demonstrating unexpected prolonged <span class=""disease"">apnoea</span> lasting several hours after <span class=""chemical"">succinylcholine</span> have been treated by a new preparation of human serum cholinesterase."	761593.0	871943.0	871943_D013390_D001049		bcv_easy_207_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000319	"<span class=""chemical"">beta-adrenergic blocking drugs</span>"	D006333	"<span class=""disease"">cardiac failure</span>"	"Three patients with ischaemic heart disease developed profound <span class=""disease"">cardiac failure</span>, hypotension and bradycardia during combined therapy with verapamil and <span class=""chemical"">beta-adrenergic blocking drugs</span>."	761593.0	6127992.0	6127992_D000319_D006333		bcv_easy_471_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C047426	"<span class=""chemical"">venlafaxine</span>"	D020230	"<span class=""disease"">serotonin syndrome</span>"	"We report a <span class=""chemical"">venlafaxine</span>-MAOI interaction that resulted in the <span class=""disease"">serotonin syndrome</span> in a 23-y-old male who was taking tranylcypromine for depression."	761593.0	8888541.0	8888541_C047426_D020230		bcv_easy_1110_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D006220	"<span class=""chemical"">Haloperidol</span>"	D003072	"<span class=""disease"">cognitive impairment</span>"	"CONCLUSION: <span class=""chemical"">Haloperidol</span> produced a clear profile of <span class=""disease"">cognitive impairment</span> that was not worsened by concomitant sertraline administration."	761593.0	8617710.0	8617710_D006220_D003072		bcv_easy_1194_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010830	"<span class=""chemical"">eserine</span>"	D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> caused by carbachol and <span class=""chemical"">eserine</span>."	761593.0	6892185.0	6892185_D010830_D004830		bcv_easy_1061_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004917	"<span class=""chemical"">erythromycin</span>"	D016171	"<span class=""disease"">torsades de pointes</span>"	"Prolongation of QT interval, <span class=""disease"">torsades de pointes</span>, and sudden cardiac death have been reported after concomitant administration with <span class=""chemical"">erythromycin</span> or azole antifungal agents, but not with other CYP3A4 inhibitors."	761593.0	9545159.0	9545159_D004917_D016171		bcv_easy_259_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004041	"<span class=""chemical"">fat</span>"	D009765	"<span class=""disease"">obesity</span>"	"In the current study, we investigated whether a physiological intervention by feeding 40% high <span class=""chemical"">fat</span> diet (HFD), which induces <span class=""disease"">obesity</span> in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity."	761593.0	18674790.0	18674790_D004041_D009765		bcv_easy_871_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D001971	"<span class=""chemical"">Bromocriptine</span>"	D011605	"<span class=""disease"">psychosis</span>"	"<span class=""chemical"">Bromocriptine</span> given in high doses has been associated with <span class=""disease"">psychosis</span> in patients receiving the drug for Parkinson's disease."	761593.0	3686155.0	3686155_D001971_D011605		bcv_easy_559_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007538	"<span class=""chemical"">isoniazid</span>"	D009901	"<span class=""disease"">Bilateral optic neuropathy</span>"	"<span class=""disease"">Bilateral optic neuropathy</span> due to combined ethambutol and <span class=""chemical"">isoniazid</span> treatment."	761593.0	384871.0	384871_D007538_D009901		bcv_easy_569_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004917	"<span class=""chemical"">erythromycin</span>"	D016757	"<span class=""disease"">sudden cardiac death</span>"	"Prolongation of QT interval, torsades de pointes, and <span class=""disease"">sudden cardiac death</span> have been reported after concomitant administration with <span class=""chemical"">erythromycin</span> or azole antifungal agents, but not with other CYP3A4 inhibitors."	761593.0	9545159.0	9545159_D004917_D016757		bcv_easy_257_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D016685	"<span class=""chemical"">Mitomycin C</span>"	D006463	"<span class=""disease"">Hemolytic Uremic Syndrome/HUS</span>"	"<span class=""chemical"">Mitomycin C</span> associated <span class=""disease"">Hemolytic Uremic Syndrome</span> (<span class=""disease"">HUS</span>) is a potentially fatal but uncommon condition that is not yet widely recognised."	761593.0	3108839.0	3108839_D016685_D006463		bcv_easy_798_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008775	"<span class=""chemical"">methylprednisolone</span>"	D006323	"<span class=""disease"">asystole</span>"	"Hypotension, bradycardia, and <span class=""disease"">asystole</span> after high-dose intravenous <span class=""chemical"">methylprednisolone</span> in a monitored patient."	761593.0	10074612.0	10074612_D008775_D006323		bcv_easy_1085_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014635	"<span class=""chemical"">sodium valproate/VPA</span>"	D007177	"<span class=""disease"">SIADH/syndrome of inappropriate secretion of antidiuretic hormone</span>"	"We report the case of a 62-year-old man who was administered <span class=""chemical"">sodium valproate</span> (<span class=""chemical"">VPA</span>) and who subsequently developed the <span class=""disease"">syndrome of inappropriate secretion of antidiuretic hormone</span> (<span class=""disease"">SIADH</span>)."	761593.0	11195262.0	11195262_D014635_D007177		bcv_easy_159_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014700	"<span class=""chemical"">verapamil</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and <span class=""disease"">bradycardia</span> during combined therapy with <span class=""chemical"">verapamil</span> and beta-adrenergic blocking drugs."	761593.0	6127992.0	6127992_D014700_D001919		bcv_easy_476_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D001556	"<span class=""chemical"">alpha-benzene hexachloride</span>"	D006528	"<span class=""disease"">hepatoma</span>"	"Changes in peroxisomes in preneoplastic liver and <span class=""disease"">hepatoma</span> of mice induced by <span class=""chemical"">alpha-benzene hexachloride</span>."	761593.0	85485.0	85485_D001556_D006528		bcv_easy_378_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D013866	"<span class=""chemical"">6-thioguanine</span>"	D006504	"<span class=""disease"">veno-occlusive disease of the liver</span>"	"Clinically reversible <span class=""disease"">veno-occlusive disease of the liver</span> developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with <span class=""chemical"">6-thioguanine</span>."	761593.0	7053705.0	7053705_D013866_D006504		bcv_easy_1213_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010672	"<span class=""chemical"">diphenylhydantoin/DPH</span>"	D002526	"<span class=""disease"">cerebellar dysfunction</span>"	"Among the common side effects of <span class=""chemical"">diphenylhydantoin</span> (<span class=""chemical"">DPH</span>) overdose, the most frequently encountered neurological signs are those of <span class=""disease"">cerebellar dysfunction</span>."	761593.0	430165.0	430165_D010672_D002526		bcv_easy_592_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C092292	"<span class=""chemical"">ziprasidone</span>"	D009459	"<span class=""disease"">NMS</span>"	"Although conventional neuroleptics are more frequently associated with <span class=""disease"">NMS</span>, atypical antipsychotic drugs like <span class=""chemical"">ziprasidone</span> may also be a cause."	761593.0	17366349.0	17366349_C092292_D009459		bcv_easy_54_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004317	"<span class=""chemical"">doxorubicin</span>"	D006331	"<span class=""disease"">cardiac dysfunction</span>"	"A LD(10) dose (8 mg <span class=""chemical"">doxorubicin</span>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, <span class=""disease"">cardiac dysfunction</span>, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."	761593.0	18674790.0	18674790_D004317_D006331		bcv_easy_875_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010672	"<span class=""chemical"">DPH</span>"	D010291	"<span class=""disease"">hemiparesis</span>"	"Two patients are presented who suffered progressive <span class=""disease"">hemiparesis</span> due to <span class=""chemical"">DPH</span> overdose."	761593.0	430165.0	430165_D010672_D010291		bcv_easy_595_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C092292	"<span class=""chemical"">ziprasidone</span>"	D009459	"<span class=""disease"">NMS</span>"	"The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of <span class=""disease"">NMS</span> after 2 days of treatment with an 80-mg/day dose of orally administrated <span class=""chemical"">ziprasidone</span>."	761593.0	17366349.0	17366349_C092292_D009459		bcv_easy_55_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007530	"<span class=""chemical"">Isoflurane</span>"	D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"CONCLUSIONS: <span class=""chemical"">Isoflurane</span>, a common anesthetic agent, can cause severe <span class=""disease"">cholestatic hepatitis</span>."	761593.0	11847945.0	11847945_D007530_D002779|D056486		bcv_easy_118_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000728	"<span class=""chemical"">androgen</span>"	D020181	"<span class=""disease"">obstructive sleep apnea</span>"	"A rechallenge with <span class=""chemical"">androgen</span> produced symptoms of <span class=""disease"">obstructive sleep apnea</span> that abated upon withdrawal of the hormone."	761593.0	6732043.0	6732043_D000728_D020181		bcv_easy_1159_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"	D009203	"<span class=""disease"">myocardial infarction</span>"	"Randomised clinical trials and observational studies have shown an increased risk of <span class=""disease"">myocardial infarction</span>, stroke, hypertension and heart failure during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."	761593.0	16586083.0	16586083_D016861_D009203		bcv_easy_1149_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010830	"<span class=""chemical"">eserine</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"On the other hand, <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions evoked by carbachol and <span class=""chemical"">eserine</span> were not significantly changed by calcium chloride."	761593.0	6892185.0	6892185_D010830_D015878		bcv_easy_1050_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D011718	"<span class=""chemical"">pyrazinamide</span>"	D000857	"<span class=""disease"">dysosmia</span>"	"Recurrent <span class=""disease"">dysosmia</span> induced by <span class=""chemical"">pyrazinamide</span>."	761593.0	19674115.0	19674115_D011718_D000857		bcv_easy_665_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002701	"<span class=""chemical"">chloramphenicol</span>"	D000741	"<span class=""disease"">aplastic anemia</span>"	"This was the second report of fatal <span class=""disease"">aplastic anemia</span> after topical treatment with <span class=""chemical"">chloramphenicol</span> for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported."	761593.0	7072798.0	7072798_D002701_D000741		bcv_easy_177_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010634	"<span class=""chemical"">PB</span>"	D008107	"<span class=""disease"">liver damage</span>"	"Our findings illustrate that <span class=""chemical"">PB</span> may be associated with chronic <span class=""disease"">liver damage</span>, which may lead to more serious and deleterious consequences."	761593.0	17574447.0	17574447_D010634_D008107		bcv_easy_1208_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014191	"<span class=""chemical"">tranylcypromine</span>"	D020230	"<span class=""disease"">Serotonin syndrome</span>"	"<span class=""disease"">Serotonin syndrome</span> from venlafaxine-<span class=""chemical"">tranylcypromine</span> interaction."	761593.0	8888541.0	8888541_D014191_D020230		bcv_easy_1100_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005476	"<span class=""chemical"">fluphenazine</span>"	D002375	"<span class=""disease"">catalepsy</span>"	"Dopamine antagonist <span class=""chemical"">fluphenazine</span>, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced <span class=""disease"">catalepsy</span>."	761593.0	1687392.0	1687392_D005476_D002375		bcv_easy_858_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D011718	"<span class=""chemical"">pyrazinamide</span>"	D000857	"<span class=""disease"">olfactory disorder</span>"	"We report a case of reversible <span class=""disease"">olfactory disorder</span> related to <span class=""chemical"">pyrazinamide</span> in a woman, with a positive rechallenge."	761593.0	19674115.0	19674115_D011718_D000857		bcv_easy_668_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010665	"<span class=""chemical"">Phenylpropanolamine/Dexatrim</span>"	D009203	"<span class=""disease"">myocardial infarction</span>"	"Case report: <span class=""chemical"">Dexatrim</span> (<span class=""chemical"">Phenylpropanolamine</span>) as a cause of <span class=""disease"">myocardial infarction</span>."	761593.0	12734532.0	12734532_D010665_D009203		bcv_easy_598_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"On the other hand, mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> evoked by <span class=""chemical"">carbachol</span> and eserine were not significantly changed by calcium chloride."	761593.0	6892185.0	6892185_D002217_D004830		bcv_easy_1048_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003276	"<span class=""chemical"">oral contraception</span>"	D002819	"<span class=""disease"">Chorea</span>"	"<span class=""disease"">Chorea</span> associated with <span class=""chemical"">oral contraception</span>."	761593.0	3123611.0	3123611_D003276_D002819		bcv_easy_388_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D018967	"<span class=""chemical"">risperidone</span>"	D010468	"<span class=""disease"">visual disturbances</span>"	"They both reported short episodes of transient <span class=""disease"">visual disturbances</span>, which appeared immediately after starting treatment with <span class=""chemical"">risperidone</span>."	761593.0	12013711.0	12013711_D018967_D010468		bcv_easy_155_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C047781	"<span class=""chemical"">LTG</span>"	D009207	"<span class=""disease"">MJ</span>"	"In three patients, <span class=""chemical"">LTG</span> exacerbated <span class=""disease"">MJ</span> in a dose-dependent manner with early aggravation during titration."	761593.0	16157917.0	16157917_C047781_D009207		bcv_easy_1008_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C047781	"<span class=""chemical"">LTG</span>"	D009207	"<span class=""disease"">myoclonic status/MJ</span>"	"In two patients, <span class=""chemical"">LTG</span> exacerbated <span class=""disease"">MJ</span> in a delayed but more severe manner, with <span class=""disease"">myoclonic status</span> that only ceased after <span class=""chemical"">LTG</span> withdrawal."	761593.0	16157917.0	16157917_C047781_D009207		bcv_easy_1010_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003520	"<span class=""chemical"">Cyclophosphamide</span>"	D001749	"<span class=""disease"">bladder cancer</span>"	"<span class=""chemical"">Cyclophosphamide</span> associated <span class=""disease"">bladder cancer</span>--a highly aggressive disease: analysis of 12 cases."	761593.0	8911359.0	8911359_D003520_D001749		bcv_easy_433_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D014202	"<span class=""disease"">tremor</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions produced by <span class=""chemical"">carbachol</span> and eserine injected similarly was investigated."	761593.0	6892185.0	6892185_D002217_D014202		bcv_easy_1037_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010396	"<span class=""chemical"">D-penicillamine</span>"	D017285	"<span class=""disease"">polymyositis</span>"	"We report a patient with primary biliary cirrhosis, who developed <span class=""disease"">polymyositis</span> while receiving <span class=""chemical"">D-penicillamine</span> therapy."	761593.0	8268147.0	8268147_D010396_D017285		bcv_easy_837_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002701	"<span class=""chemical"">chloramphenicol</span>"	D000741	"<span class=""disease"">aplastic anemia</span>"	"A 73-year-old woman died of <span class=""disease"">aplastic anemia</span> less than two months after undergoing cataract extraction and beginning topical therapy with <span class=""chemical"">chloramphenicol</span>."	761593.0	7072798.0	7072798_D002701_D000741		bcv_easy_174_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D001393	"<span class=""chemical"">azole</span>"	D016757	"<span class=""disease"">sudden cardiac death</span>"	"Prolongation of QT interval, torsades de pointes, and <span class=""disease"">sudden cardiac death</span> have been reported after concomitant administration with erythromycin or <span class=""chemical"">azole</span> antifungal agents, but not with other CYP3A4 inhibitors."	761593.0	9545159.0	9545159_D001393_D016757		bcv_easy_260_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008094	"<span class=""chemical"">lithium</span>"	D054537	"<span class=""disease"">atrioventricular (AV) block</span>"	"In the present case, complete <span class=""disease"">atrioventricular (AV) block</span> with syncopal attacks developed secondary to <span class=""chemical"">lithium</span> therapy, necessitating permanent pacemaker implantation."	761593.0	18441470.0	18441470_D008094_D054537		bcv_easy_531_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003907	"<span class=""chemical"">dexamethasone</span>"	D009422	"<span class=""disease"">neurological dysfunctions</span>"	"After <span class=""chemical"">dexamethasone</span> treatment, children showed a higher rate of minor <span class=""disease"">neurological dysfunctions</span>."	761593.0	15814210.0	15814210_D003907_D009422		bcv_easy_1259_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"	D006333	"<span class=""disease"">heart failure</span>"	"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and <span class=""disease"">heart failure</span> during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."	761593.0	16586083.0	16586083_D016861_D006333		bcv_easy_1146_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005839	"<span class=""chemical"">gentamicin</span>"	D058186	"<span class=""disease"">acute renal failure</span>"	"In this study we postulated that during <span class=""disease"">acute renal failure</span> induced by <span class=""chemical"">gentamicin</span> the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels."	761593.0	19893084.0	19893084_D005839_D058186		bcv_easy_324_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000324	"<span class=""chemical"">ACTH</span>"	D004421	"<span class=""disease"">dystonia</span>"	"A <span class=""disease"">dystonia</span>-like syndrome after neuropeptide (MSH/<span class=""chemical"">ACTH</span>) stimulation of the rat locus ceruleus."	761593.0	2840807.0	2840807_D000324_D004421		bcv_easy_492_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000728	"<span class=""chemical"">androgens</span>"	D020181	"<span class=""disease"">syndrome of obstructive sleep apnea</span>"	"We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the <span class=""disease"">syndrome of obstructive sleep apnea</span> while being administered exogenous <span class=""chemical"">androgens</span>."	761593.0	6732043.0	6732043_D000728_D020181		bcv_easy_1158_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D006220	"<span class=""chemical"">haloperidol</span>"	D003072	"<span class=""disease"">Impairment of cognitive function</span>"	"RESULTS: <span class=""disease"">Impairment of cognitive function</span> was observed 6 to 8 hours after administration of <span class=""chemical"">haloperidol</span> on Day 2 but was not evident 23 hours after dosing."	761593.0	8617710.0	8617710_D006220_D003072		bcv_easy_1193_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008094	"<span class=""chemical"">lithium</span>"	D012804	"<span class=""disease"">Sinus node dysfunction</span>"	"<span class=""disease"">Sinus node dysfunction</span> has been reported most frequently among the adverse cardiovascular effects of <span class=""chemical"">lithium</span>."	761593.0	18441470.0	18441470_D008094_D012804		bcv_easy_530_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014635	"<span class=""chemical"">sodium valproate</span>"	D007177	"<span class=""disease"">syndrome of inappropriate secretion of antidiuretic hormone</span>"	"Contribution of <span class=""chemical"">sodium valproate</span> to the <span class=""disease"">syndrome of inappropriate secretion of antidiuretic hormone</span>."	761593.0	11195262.0	11195262_D014635_D007177		bcv_easy_158_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008012	"<span class=""chemical"">lidocaine</span>"	D009135	"<span class=""disease"">muscle damage</span>"	"In addition to <span class=""disease"">muscle damage</span>, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and <span class=""chemical"">lidocaine</span> plus epinephrine."	761593.0	4038130.0	4038130_D008012_D009135		bcv_easy_397_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010396	"<span class=""chemical"">D-penicillamine</span>"	D005921	"<span class=""disease"">glomerulonephritis/RPGN</span>"	"A 67-year-old woman with rheumatoid arthritis presented rapidly progressive <span class=""disease"">glomerulonephritis</span> (<span class=""disease"">RPGN</span>) after 5 months of <span class=""chemical"">D-penicillamine</span> (250 mg/day) treatment."	761593.0	8267029.0	8267029_D010396_D005921		bcv_easy_499_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014700	"<span class=""chemical"">verapamil</span>"	D006333	"<span class=""disease"">cardiac failure</span>"	"Three patients with ischaemic heart disease developed profound <span class=""disease"">cardiac failure</span>, hypotension and bradycardia during combined therapy with <span class=""chemical"">verapamil</span> and beta-adrenergic blocking drugs."	761593.0	6127992.0	6127992_D014700_D006333		bcv_easy_473_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007530	"<span class=""chemical"">isoflurane</span>"	D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"Acute <span class=""disease"">cholestatic hepatitis</span> after exposure to <span class=""chemical"">isoflurane</span>."	761593.0	11847945.0	11847945_D007530_D002779|D056486		bcv_easy_115_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D015119	"<span class=""chemical"">epsilon-aminocaproic acid</span>"	D020225|D020227	"<span class=""disease"">sagittal and left transverse sinus thrombosis</span>"	"We describe a 42-year-old woman who developed superior <span class=""disease"">sagittal and left transverse sinus thrombosis</span> associated with prolonged <span class=""chemical"">epsilon-aminocaproic acid</span> therapy for menorrhagia."	761593.0	2339463.0	2339463_D015119_D020225|D020227		bcv_easy_209_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions caused by <span class=""chemical"">carbachol</span> and eserine."	761593.0	6892185.0	6892185_D002217_D015878		bcv_easy_1060_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014640	"<span class=""chemical"">vancomycin</span>"	D006311	"<span class=""disease"">ototoxicity</span>"	"Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and <span class=""disease"">ototoxicity</span> were confined to patients receiving an aminoglycoside plus <span class=""chemical"">vancomycin</span>."	761593.0	3934126.0	3934126_D014640_D006311		bcv_easy_1144_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002752	"<span class=""chemical"">chlorthalidone</span>"	D018879	"<span class=""disease"">ventricular ectopic beats</span>"	"Compared to amiloride treatment, the <span class=""chemical"">chlorthalidone</span> phase was associated with an increased frequency of <span class=""disease"">ventricular ectopic beats</span> (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation."	761593.0	3732088.0	3732088_D002752_D018879		bcv_easy_23_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002927	"<span class=""chemical"">cimetidine</span>"	D007172	"<span class=""disease"">impotence</span>"	"Sixty percent of the males developed breast changes or <span class=""disease"">impotence</span> while taking <span class=""chemical"">cimetidine</span> and in all cases these changes disappeared when <span class=""chemical"">cimetidine</span> was replaced by ranitidine."	761593.0	6150641.0	6150641_D002927_D007172		bcv_easy_326_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D016685	"<span class=""chemical"">MMC</span>"	D006333	"<span class=""disease"">cardiac failure</span>"	"One of the patients developed <span class=""disease"">cardiac failure</span> after 30 mg m-2 <span class=""chemical"">MMC</span> and only 150 mg m-2 doxorubicin."	761593.0	3137399.0	3137399_D016685_D006333		bcv_easy_1200_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D009288	"<span class=""chemical"">naproxen</span>"	D007681	"<span class=""disease"">Renal papillary necrosis</span>"	"<span class=""disease"">Renal papillary necrosis</span> due to <span class=""chemical"">naproxen</span>."	761593.0	6699841.0	6699841_D009288_D007681		bcv_easy_1244_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C019248	"<span class=""chemical"">pamidronate</span>"	D006996	"<span class=""disease"">hypocalcemia</span>"	"The 2 patients with the higher serum calcium concentrations received <span class=""chemical"">pamidronate</span> intravenously (60 and 30 mg, respectively), which caused severe <span class=""disease"">hypocalcemia</span>."	761593.0	16006300.0	16006300_C019248_D006996		bcv_easy_707_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000638	"<span class=""chemical"">amiodarone</span>"	D056486	"<span class=""disease"">hepatic injury</span>"	"It is concluded that solid evidence exists of <span class=""disease"">hepatic injury</span> due to <span class=""chemical"">amiodarone</span> treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver."	761593.0	3962737.0	3962737_D000638_D056486		bcv_easy_292_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D009074	"<span class=""chemical"">MSH</span>"	D004421	"<span class=""disease"">dystonia</span>"	"A <span class=""disease"">dystonia</span>-like syndrome after neuropeptide (<span class=""chemical"">MSH</span>/ACTH) stimulation of the rat locus ceruleus."	761593.0	2840807.0	2840807_D009074_D004421		bcv_easy_493_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004456	"<span class=""chemical"">echothiophate iodide</span>"	D018908	"<span class=""disease"">muscle weakness</span>"	"A patient developed a severe cholinergic syndrome from the use of <span class=""chemical"">echothiophate iodide</span> ophthalmic drops, presented with profound <span class=""disease"">muscle weakness</span> and was initially given the diagnosis of myasthenia gravis."	761593.0	7650771.0	7650771_D004456_D018908		bcv_easy_1165_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> caused by <span class=""chemical"">carbachol</span> and eserine."	761593.0	6892185.0	6892185_D002217_D004830		bcv_easy_1056_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010068	"<span class=""chemical"">oxacillin</span>"	D051437	"<span class=""disease"">renal failure</span>"	"A 67-year-old man who was treated with <span class=""chemical"">oxacillin</span> for one week because of Staphylococcus aureus bacteremia, developed <span class=""disease"">renal failure</span> and diffuse, symmetric, palpable purpuric lesions on his feet."	761593.0	11337188.0	11337188_D010068_D051437		bcv_easy_302_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D013874	"<span class=""chemical"">thiopental</span>"	D012133	"<span class=""disease"">respiratory paralysis</span>"	"GABA involvement in naloxone induced reversal of <span class=""disease"">respiratory paralysis</span> produced by <span class=""chemical"">thiopental</span>."	761593.0	2893236.0	2893236_D013874_D012133		bcv_easy_438_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008775	"<span class=""chemical"">methylprednisolone</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"We report a case of hypotension, <span class=""disease"">bradycardia</span>, and asystole after intravenous administration of high-dose <span class=""chemical"">methylprednisolone</span> in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode."	761593.0	10074612.0	10074612_D008775_D001919		bcv_easy_1089_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D011692	"<span class=""chemical"">PAN</span>"	D034141	"<span class=""disease"">hypoalbuminemia</span>"	"After 7 days, <span class=""chemical"">PAN</span> treatment induced significant proteinuria, <span class=""disease"">hypoalbuminemia</span>, decreased urinary sodium excretion, and extensive ascites."	761593.0	15075188.0	15075188_D011692_D034141		bcv_easy_1094_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C017367	"<span class=""chemical"">carmofur</span>"	D056784	"<span class=""disease"">leukoencephalopathy</span>"	"RESULTS: We identified 27 reports of toxic <span class=""disease"">leukoencephalopathy</span> in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative <span class=""chemical"">carmofur</span>, and capecitabine."	761593.0	17682013.0	17682013_C017367_D056784		bcv_easy_782_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D017693	"<span class=""chemical"">sodium bicarbonate</span>"	D053040	"<span class=""disease"">nephrolithiasis</span>"	"One case of acute hypercalcaemia and two of recurrent <span class=""disease"">nephrolithiasis</span> are reported in patients who had regularly consumed large amounts of calcium carbon-ate-<span class=""chemical"">sodium bicarbonate</span> powders for more than 20 years."	761593.0	625456.0	625456_D017693_D053040		bcv_easy_51_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005476	"<span class=""chemical"">fluphenazine</span>"	D002375	"<span class=""disease"">catalepsy</span>"	"D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the <span class=""disease"">catalepsy</span> induced by <span class=""chemical"">fluphenazine</span>, SCH 23390 or sulpiride."	761593.0	1687392.0	1687392_D005476_D002375		bcv_easy_862_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005047	"<span class=""chemical"">etoposide</span>"	D009203	"<span class=""disease"">myocardial infarction</span>"	"The occurrence of a <span class=""disease"">myocardial infarction</span> is reported after chemotherapy containing <span class=""chemical"">etoposide</span>, in a man with no risk factors for coronary heart disease."	761593.0	7619765.0	7619765_D005047_D009203		bcv_easy_554_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010068	"<span class=""chemical"">Oxacillin</span>"	D018366	"<span class=""disease"">leucocytoclastic vasculitis</span>"	"<span class=""chemical"">Oxacillin</span> should be included among the drugs that can cause <span class=""disease"">leucocytoclastic vasculitis</span>."	761593.0	11337188.0	11337188_D010068_D018366		bcv_easy_305_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010396	"<span class=""chemical"">Penicillamine</span>"	D005921	"<span class=""disease"">glomerulonephritis</span>"	"<span class=""chemical"">Penicillamine</span>-induced rapidly progressive <span class=""disease"">glomerulonephritis</span> in a patient with rheumatoid arthritis."	761593.0	8267029.0	8267029_D010396_D005921		bcv_easy_496_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D016685	"<span class=""chemical"">Mitomycin C</span>"	D006463	"<span class=""disease"">hemolytic uremic syndrome</span>"	"<span class=""chemical"">Mitomycin C</span> associated <span class=""disease"">hemolytic uremic syndrome</span>."	761593.0	3108839.0	3108839_D016685_D006463		bcv_easy_797_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions produced by <span class=""chemical"">carbachol</span> and eserine injected similarly was investigated."	761593.0	6892185.0	6892185_D002217_D015878		bcv_easy_1042_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005473	"<span class=""chemical"">Fluoxetine</span>"	D006966	"<span class=""disease"">hyperprolactinemia</span>"	"DESIGN: <span class=""chemical"">Fluoxetine</span>, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce <span class=""disease"">hyperprolactinemia</span>."	761593.0	9098464.0	9098464_D005473_D006966		bcv_easy_1034_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C056299	"<span class=""chemical"">Abbott-53693</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"On the other hand, the pressor effects of <span class=""chemical"">Abbott-53693</span> were similar in both groups of SHR, but the accompanying <span class=""disease"">bradycardia</span> was greater in SHR with chronic prazosin treatment than without such treatment."	761593.0	1355091.0	1355091_C056299_D001919		bcv_easy_1081_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D001971	"<span class=""chemical"">bromocriptine</span>"	D011605	"<span class=""disease"">psychosis</span>"	"Postpartum <span class=""disease"">psychosis</span> induced by <span class=""chemical"">bromocriptine</span>."	761593.0	3686155.0	3686155_D001971_D011605		bcv_easy_555_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004317	"<span class=""chemical"">doxorubicin</span>"	D006333	"<span class=""disease"">cardiac failure</span>"	"One of the patients developed <span class=""disease"">cardiac failure</span> after 30 mg m-2 MMC and only 150 mg m-2 <span class=""chemical"">doxorubicin</span>."	761593.0	3137399.0	3137399_D004317_D006333		bcv_easy_1199_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008727	"<span class=""chemical"">methotrexate</span>"	D056784	"<span class=""disease"">leukoencephalopathy</span>"	"RESULTS: We identified 27 reports of toxic <span class=""disease"">leukoencephalopathy</span> in patients treated with <span class=""chemical"">methotrexate</span> (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine."	761593.0	17682013.0	17682013_D008727_D056784		bcv_easy_781_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D013866	"<span class=""chemical"">6-thioguanine</span>"	D006504	"<span class=""disease"">Hepatic veno-occlusive disease</span>"	"<span class=""disease"">Hepatic veno-occlusive disease</span> caused by <span class=""chemical"">6-thioguanine</span>."	761593.0	7053705.0	7053705_D013866_D006504		bcv_easy_1211_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D015742	"<span class=""chemical"">propofol</span>"	D010146	"<span class=""disease"">pain</span>"	"Remifentanil-related complications were assessed during the remifentanil infusion, and <span class=""disease"">pain</span> caused by <span class=""chemical"">propofol</span> was evaluated using a four-point scale during the <span class=""chemical"">propofol</span> infusion."	761593.0	18006530.0	18006530_D015742_D010146		bcv_easy_8_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007530	"<span class=""chemical"">isoflurane</span>"	D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"OBJECTIVE: To report a case of acute <span class=""disease"">cholestatic hepatitis</span> following exposure to the inhalational anesthetic <span class=""chemical"">isoflurane</span>."	761593.0	11847945.0	11847945_D007530_D002779|D056486		bcv_easy_116_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D014202	"<span class=""disease"">tremor</span>"	"On the other hand, mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions evoked by <span class=""chemical"">carbachol</span> and eserine were not significantly changed by calcium chloride."	761593.0	6892185.0	6892185_D002217_D014202		bcv_easy_1047_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D017963	"<span class=""chemical"">azithromycin</span>"	D006606	"<span class=""disease"">hiccups</span>"	"CASE SUMMARY: A 76-year-old man presented with persistent <span class=""disease"">hiccups</span> after beginning <span class=""chemical"">azithromycin</span> for the treatment of pharyngitis."	761593.0	15985056.0	15985056_D017963_D006606		bcv_easy_817_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D015632	"<span class=""chemical"">MPTP</span>"	D020734	"<span class=""disease"">parkinsonian</span>"	"A group of four monkeys was rendered <span class=""disease"">parkinsonian</span> with the toxin <span class=""chemical"">MPTP</span>."	761593.0	8106150.0	8106150_D015632_D020734		bcv_easy_1113_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002217	"<span class=""chemical"">carbachol</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"On the other hand, <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions evoked by <span class=""chemical"">carbachol</span> and eserine were not significantly changed by calcium chloride."	761593.0	6892185.0	6892185_D002217_D015878		bcv_easy_1052_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D003276	"<span class=""chemical"">Oral Contraceptives</span>"	D008113	"<span class=""disease"">Liver Tumors</span>"	"The Registry for <span class=""disease"">Liver Tumors</span> Associated with <span class=""chemical"">Oral Contraceptives</span> at the University of California, Irvine, has clearly identified 27 cases."	761593.0	188339.0	188339_D003276_D008113		bcv_easy_424_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004298	"<span class=""chemical"">dopamine</span>"	D002389	"<span class=""disease"">catatonia</span>"	"In the pinealectomized chick, pretreatment with <span class=""chemical"">dopamine</span> increased the duration of <span class=""disease"">catatonia</span> (DOC) after ketamine, but pretreatment with norepinephrine did not."	761593.0	6540303.0	6540303_D004298_D002389		bcv_easy_485_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	D002637	"<span class=""disease"">chest pain</span>"	"We report a case of a patient with colon carcinoma and liver metastasis who presented <span class=""disease"">chest pain</span> after <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) administration."	761593.0	3952818.0	3952818_D005472_D002637		bcv_easy_997_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014635	"<span class=""chemical"">VPA</span>"	D007177	"<span class=""disease"">SIADH</span>"	"We consider this episode of <span class=""disease"">SIADH</span> to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of <span class=""chemical"">VPA</span>."	761593.0	11195262.0	11195262_D014635_D007177		bcv_easy_162_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D013629	"<span class=""chemical"">tamoxifen</span>"	D015228	"<span class=""disease"">hypertriglyceridaemia</span>"	"Compared with the placebo group, there was a significantly increased risk of vascular events and <span class=""disease"">hypertriglyceridaemia</span> among women on <span class=""chemical"">tamoxifen</span>."	761593.0	9672273.0	9672273_D013629_D015228		bcv_easy_313_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008012	"<span class=""chemical"">lidocaine</span>"	D012640	"<span class=""disease"">seizures</span>"	"Chronic oral CBZ inhibited the development of both <span class=""chemical"">lidocaine</span>- and cocaine-induced <span class=""disease"">seizures</span>, but had little effect on the fully developed local anesthetic <span class=""disease"">seizures</span>."	761593.0	2790457.0	2790457_D008012_D012640		bcv_easy_685_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008094	"<span class=""chemical"">Lithium</span>"	D011141	"<span class=""disease"">polyuria</span>"	"<span class=""chemical"">Lithium</span> induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but <span class=""disease"">polyuria</span> persisted in this patient for ten years after <span class=""chemical"">lithium</span> was stopped."	761593.0	9226773.0	9226773_D008094_D011141		bcv_easy_200_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D009543	"<span class=""chemical"">nifedipine</span>"	D013684	"<span class=""disease"">telangiectasia</span>"	"Photodistributed <span class=""chemical"">nifedipine</span>-induced facial <span class=""disease"">telangiectasia</span>."	761593.0	8251368.0	8251368_D009543_D013684		bcv_easy_452_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004656	"<span class=""chemical"">enalapril</span>"	D051437	"<span class=""disease"">decreased renal function</span>"	"Diuretic therapy was likewise associated with a greater risk of <span class=""disease"">decreased renal function</span> in the <span class=""chemical"">enalapril</span> group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66)."	761593.0	10539815.0	10539815_D004656_D051437		bcv_easy_767_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"	D020521	"<span class=""disease"">stroke</span>"	"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, <span class=""disease"">stroke</span>, hypertension and heart failure during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."	761593.0	16586083.0	16586083_D016861_D020521		bcv_easy_1147_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D005996	"<span class=""chemical"">Glyceryl trinitrate</span>"	D020326	"<span class=""disease"">migraine without aura</span>"	"<span class=""chemical"">Glyceryl trinitrate</span> induces attacks of <span class=""disease"">migraine without aura</span> in sufferers of migraine with aura."	761593.0	10524660.0	10524660_D005996_D020326		bcv_easy_601_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D014282	"<span class=""chemical"">trihexyphenidyl hydrochloride</span>"	D001919	"<span class=""disease"">Bradycardia</span>"	"<span class=""disease"">Bradycardia</span> due to <span class=""chemical"">trihexyphenidyl hydrochloride</span>."	761593.0	3769769.0	3769769_D014282_D001919		bcv_easy_250_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D016685	"<span class=""chemical"">mitomycin C</span>"	D051437	"<span class=""disease"">renal failure</span>"	"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive <span class=""disease"">renal failure</span> associated with <span class=""chemical"">mitomycin C</span> treatment and affects about 10% of patients treated with this agent."	761593.0	3108839.0	3108839_D016685_D051437		bcv_easy_800_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D011441	"<span class=""chemical"">PTU</span>"	D014657	"<span class=""disease"">vasculitis</span>"	"<span class=""chemical"">PTU</span>-associated <span class=""disease"">vasculitis</span> in a girl with Turner Syndrome and Graves' disease."	761593.0	16418614.0	16418614_D011441_D014657		bcv_easy_93_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000638	"<span class=""chemical"">amiodarone</span>"	D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"It is concluded that solid evidence exists of hepatic injury due to <span class=""chemical"">amiodarone</span> treatment, including steatosis, alterations resembling alcoholic hepatitis, <span class=""disease"">cholestatic hepatitis</span> and micronodular cirrhosis of the liver."	761593.0	3962737.0	3962737_D000638_D002779|D056486		bcv_easy_293_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004317	"<span class=""chemical"">ADR</span>"	D028361	"<span class=""disease"">mitochondrial structural and functional impairment</span>"	"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of <span class=""chemical"">ADR</span> on cardiovascular function involve <span class=""disease"">mitochondrial structural and functional impairment</span>."	761593.0	9952311.0	9952311_D004317_D028361		bcv_easy_796_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007069	"<span class=""chemical"">ifosfamide</span>"	D001002	"<span class=""disease"">anuria</span>"	"We strongly suspect that this lethal <span class=""disease"">anuria</span> was mainly due to <span class=""chemical"">ifosfamide</span>, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension."	761593.0	2320800.0	2320800_D007069_D001002		bcv_easy_411_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000319	"<span class=""chemical"">beta-adrenergic blocking drugs</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and <span class=""disease"">bradycardia</span> during combined therapy with verapamil and <span class=""chemical"">beta-adrenergic blocking drugs</span>."	761593.0	6127992.0	6127992_D000319_D001919		bcv_easy_472_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D008775	"<span class=""chemical"">methylprednisolone</span>"	D006323	"<span class=""disease"">asystole</span>"	"We report a case of hypotension, bradycardia, and <span class=""disease"">asystole</span> after intravenous administration of high-dose <span class=""chemical"">methylprednisolone</span> in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode."	761593.0	10074612.0	10074612_D008775_D006323		bcv_easy_1088_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000082	"<span class=""chemical"">paracetamol</span>"	D017114	"<span class=""disease"">fulminant hepatic failure</span>"	"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived <span class=""disease"">fulminant hepatic failure</span> after <span class=""chemical"">paracetamol</span> overdose, whereas activities were increased equally in patients with <span class=""disease"">fulminant hepatic failure</span> due to viral hepatitis whether or not they survived."	761593.0	7007443.0	7007443_D000082_D017114		bcv_easy_342_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D001393	"<span class=""chemical"">azole</span>"	D008133	"<span class=""disease"">Prolongation of QT interval</span>"	"<span class=""disease"">Prolongation of QT interval</span>, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or <span class=""chemical"">azole</span> antifungal agents, but not with other CYP3A4 inhibitors."	761593.0	9545159.0	9545159_D001393_D008133		bcv_easy_255_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000420	"<span class=""chemical"">Salbutamol</span>"	D013617	"<span class=""disease"">SIAT</span>"	"CONCLUSION: <span class=""chemical"">Salbutamol</span> is presented here as a possible trigger for <span class=""disease"">SIAT</span>."	761593.0	20552622.0	20552622_D000420_D013617		bcv_easy_45_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C092292	"<span class=""chemical"">ziprasidone</span>"	D009459	"<span class=""disease"">Neuroleptic malignant syndrome</span>"	"<span class=""disease"">Neuroleptic malignant syndrome</span> induced by <span class=""chemical"">ziprasidone</span> on the second day of treatment."	761593.0	17366349.0	17366349_C092292_D009459		bcv_easy_52_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007069	"<span class=""chemical"">ifosfamide</span>"	D001002	"<span class=""disease"">anuria</span>"	"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with <span class=""disease"">anuria</span>, the day after 5 g/m2 bolus <span class=""chemical"">ifosfamide</span>."	761593.0	2320800.0	2320800_D007069_D001002		bcv_easy_404_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D013874	"<span class=""chemical"">thiopental</span>"	D012133	"<span class=""disease"">respiratory paralysis</span>"	"These data suggest naloxone reverses <span class=""disease"">respiratory paralysis</span> produced by <span class=""chemical"">thiopental</span> and involves GABA in its action."	761593.0	2893236.0	2893236_D013874_D012133		bcv_easy_449_sent_work_dev_set_761593	"yes_direct
"	
TRUE	C056299	"<span class=""chemical"">Abbott-53693</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"The pressor responses and <span class=""disease"">bradycardia</span> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist <span class=""chemical"">Abbott-53693</span> (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment."	761593.0	1355091.0	1355091_C056299_D001919		bcv_easy_1074_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D000319	"<span class=""chemical"">beta-adrenergic blocking drugs</span>"	D007022	"<span class=""disease"">hypotension</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, <span class=""disease"">hypotension</span> and bradycardia during combined therapy with verapamil and <span class=""chemical"">beta-adrenergic blocking drugs</span>."	761593.0	6127992.0	6127992_D000319_D007022		bcv_easy_474_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D004977	"<span class=""chemical"">ethambutol</span>"	D009901	"<span class=""disease"">optic neuropathy</span>"	"CLINICAL PICTURE: Three patients with <span class=""chemical"">ethambutol</span>-associated toxic <span class=""disease"">optic neuropathy</span> are described."	761593.0	16710500.0	16710500_D004977_D009901		bcv_easy_340_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D002110	"<span class=""chemical"">caffeine</span>"	D018879	"<span class=""disease"">ventricular ectopy</span>"	"Intravenous <span class=""chemical"">caffeine</span> is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign <span class=""disease"">ventricular ectopy</span>."	761593.0	18997632.0	18997632_D002110_D018879		bcv_easy_120_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D009627	"<span class=""chemical"">nomifensine</span>"	D006948	"<span class=""disease"">hyperactivity</span>"	"The <span class=""disease"">hyperactivity</span> induced by <span class=""chemical"">nomifensine</span> in mice remained unaffected by fluvoxamine."	761593.0	2576810.0	2576810_D009627_D006948		bcv_easy_1178_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D010396	"<span class=""chemical"">D-penicillamine</span>"	D017285	"<span class=""disease"">Polymyositis</span>"	"<span class=""disease"">Polymyositis</span>/dermatomyositis can develop as one of the autoimmune complications of <span class=""chemical"">D-penicillamine</span> treatment, but its exact pathogenesis remains unclear."	761593.0	8268147.0	8268147_D010396_D017285		bcv_easy_836_sent_work_dev_set_761593	"yes_direct
"	
TRUE	D007660	"<span class=""chemical"">Ketoprofen</span>"	D013345	"<span class=""disease"">SAH</span>"	"<span class=""chemical"">Ketoprofen</span> but not acetaminophen impaired platelet function in patients with <span class=""disease"">SAH</span>."	761593.0	10414674.0	10414674_D007660_D013345		bcv_easy_901_sent_work_dev_set_761593	"no_relation
"	
TRUE	C012655	"<span class=""chemical"">nimesulide</span>"	D014581	"<span class=""disease"">urticaria</span>"	"In this study we investigated tolerability and reliability of <span class=""chemical"">nimesulide</span> and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced <span class=""disease"">urticaria</span>/angioedema."	761593.0	11694026.0	11694026_C012655_D014581		bcv_easy_641_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000082	"<span class=""chemical"">paracetamol</span>"	D001744	"<span class=""disease"">bladder calculi</span>"	"Additionally, 20 to 25% of <span class=""chemical"">paracetamol</span>-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of <span class=""disease"">bladder calculi</span>."	761593.0	4090988.0	4090988_D000082_D001744		bcv_easy_282_sent_work_dev_set_761593	"no_relation
"	
TRUE	D010830	"<span class=""chemical"">physostigmine</span>"	D004409	"<span class=""disease"">dyskinetic</span>"	"Several drugs, including clonidine, <span class=""chemical"">physostigmine</span>, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the <span class=""disease"">dyskinetic</span> movements but at the cost of a return of parkinsonian symptomatology."	761593.0	8106150.0	8106150_D010830_D004409		bcv_easy_1121_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004317	"<span class=""chemical"">doxorubicin</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated <span class=""chemical"">doxorubicin</span> and cyclophosphamide compared with conventional <span class=""chemical"">doxorubicin</span> and cyclophosphamide in a randomized, multicenter trial of metastatic <span class=""disease"">breast cancer</span>."	761593.0	11230490.0	11230490_D004317_D001943		bcv_easy_130_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014147	"<span class=""chemical"">Tramadol</span>"	D009369	"<span class=""disease"">cancer</span>"	"<span class=""chemical"">Tramadol</span> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat <span class=""disease"">cancer</span> pain and chronic non malignant pain."	761593.0	8766220.0	8766220_D014147_D009369		bcv_easy_98_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004008	"<span class=""chemical"">diclofenac sodium</span>"	D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"Gastrointestinal tolerability of etoricoxib in <span class=""disease"">rheumatoid arthritis</span> patients: results of the etoricoxib vs <span class=""chemical"">diclofenac sodium</span> gastrointestinal tolerability and effectiveness trial (EDGE-II)."	761593.0	17965424.0	17965424_D004008_D001172		bcv_easy_924_sent_work_dev_set_761593	"no_relation
"	
TRUE	D011188	"<span class=""chemical"">potassium</span>"	D003327	"<span class=""disease"">coronary disease</span>"	"Diuretics, <span class=""chemical"">potassium</span> and arrhythmias in hypertensive <span class=""disease"">coronary disease</span>."	761593.0	3732088.0	3732088_D011188_D003327		bcv_easy_13_sent_work_dev_set_761593	"no_relation
"	
TRUE	C422649	"<span class=""chemical"">etoricoxib</span>"	D001172	"<span class=""disease"">RA</span>"	"PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with <span class=""disease"">RA</span> were enrolled and received <span class=""chemical"">etoricoxib</span> 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054)."	761593.0	17965424.0	17965424_C422649_D001172		bcv_easy_927_sent_work_dev_set_761593	"no_relation
"	
TRUE	C004742	"<span class=""chemical"">daidzein</span>"	D000647	"<span class=""disease"">amnesia</span>"	"Administration of <span class=""chemical"">daidzein</span> (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced <span class=""disease"">amnesia</span>, according to the results of a Y-maze test."	761593.0	16428827.0	16428827_C004742_D000647		bcv_easy_66_sent_work_dev_set_761593	"no_relation
"	
TRUE	D015647	"<span class=""chemical"">SKF 38393</span>"	D002375	"<span class=""disease"">catalepsy</span>"	"D-1 agonist <span class=""chemical"">SKF 38393</span> or D-2 agonist quinpirole decreased the <span class=""disease"">catalepsy</span> induced by fluphenazine, SCH 23390 or sulpiride."	761593.0	1687392.0	1687392_D015647_D002375		bcv_easy_863_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003520	"<span class=""chemical"">cyclophosphamide</span>"	D001943	"<span class=""disease"">MBC</span>"	"PATIENTS AND METHODS: Two hundred ninety-seven patients with <span class=""disease"">MBC</span> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of <span class=""chemical"">cyclophosphamide</span> (C), every 3 weeks until disease progression or unacceptable toxicity."	761593.0	11230490.0	11230490_D003520_D001943		bcv_easy_140_sent_work_dev_set_761593	"no_relation
"	
TRUE	D015215	"<span class=""chemical"">AZT</span>"	D000163	"<span class=""disease"">AIDS</span>"	"We have used a murine model of <span class=""disease"">AIDS</span>, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if <span class=""chemical"">AZT</span>-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO)."	761593.0	2004015.0	2004015_D015215_D000163		bcv_easy_215_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007660	"<span class=""chemical"">ketoprofen</span>"	D013345	"<span class=""disease"">aneurysmal subarachnoid hemorrhage/SAH</span>"	"Patients with <span class=""disease"">aneurysmal subarachnoid hemorrhage</span> (<span class=""disease"">SAH</span>) were randomized to receive either <span class=""chemical"">ketoprofen</span>, 100 mg, three times a day (<span class=""chemical"">ketoprofen</span> group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal <span class=""disease"">SAH</span>."	761593.0	10414674.0	10414674_D007660_D013345		bcv_easy_894_sent_work_dev_set_761593	"no_relation
"	
TRUE	C065179	"<span class=""chemical"">Atorvastatin</span>"	D006973	"<span class=""disease"">hypertension</span>"	"<span class=""chemical"">Atorvastatin</span> prevented and reversed dexamethasone-induced <span class=""disease"">hypertension</span> in the rat."	761593.0	16820346.0	16820346_C065179_D006973		bcv_easy_69_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000082	"<span class=""chemical"">paracetamol</span>"	D006525	"<span class=""disease"">viral hepatitis</span>"	"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <span class=""chemical"">paracetamol</span> overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to <span class=""disease"">viral hepatitis</span> whether or not they survived."	761593.0	7007443.0	7007443_D000082_D006525		bcv_easy_344_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002118	"<span class=""chemical"">calcium</span>"	D003866	"<span class=""disease"">depression</span>"	"Addition of excess <span class=""chemical"">calcium</span> reversed the <span class=""disease"">depression</span> in both tissues, but <span class=""chemical"">calcium</span>-independent catecholamine release by acetaldehyde was not blocked by NH4Ac."	761593.0	6323692.0	6323692_D002118_D003866		bcv_easy_364_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005680	"<span class=""chemical"">GABA</span>"	D012133	"<span class=""disease"">respiratory paralysis</span>"	"Naloxone (2.5 mg/kg, i.v.) reversed <span class=""disease"">respiratory paralysis</span>, glutamate and <span class=""chemical"">GABA</span> levels to control values in brain stem and cortex with no changes in caudate or cerebellum."	761593.0	2893236.0	2893236_D005680_D012133		bcv_easy_446_sent_work_dev_set_761593	"no_relation
"	
TRUE	D017311	"<span class=""chemical"">amlodipine</span>"	D006973	"<span class=""disease"">hypertension</span>"	"OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + <span class=""chemical"">amlodipine</span> 5 mg (T+A) compared with <span class=""chemical"">amlodipine</span> 5-mg monotherapy (A) in adult Indian patients with stage II <span class=""disease"">hypertension</span>."	761593.0	18201582.0	18201582_D017311_D006973		bcv_easy_888_sent_work_dev_set_761593	"no_relation
"	
TRUE	D001058	"<span class=""chemical"">Apomorphine</span>"	D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Apomorphine</span> was the first dopaminergic drug ever used to treat symptoms of <span class=""disease"">Parkinson's disease</span>."	761593.0	11009181.0	11009181_D001058_D010300		bcv_easy_190_sent_work_dev_set_761593	"no_relation
"	
TRUE	C012655	"<span class=""chemical"">nimesulide</span>"	D014581	"<span class=""disease"">urticaria</span>"	"A single-placebo-controlled oral challenge procedure with <span class=""chemical"">nimesulide</span> or paracetamol was applied to 829 patients with a history of NSAID-induced <span class=""disease"">urticaria</span>/angioedema."	761593.0	11694026.0	11694026_C012655_D014581		bcv_easy_645_sent_work_dev_set_761593	"no_relation
"	
TRUE	D011224	"<span class=""chemical"">prazosin</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"The pressor responses and <span class=""disease"">bradycardia</span> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic <span class=""chemical"">prazosin</span> pretreatment."	761593.0	1355091.0	1355091_D011224_D001919		bcv_easy_1075_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002216	"<span class=""chemical"">captopril</span>"	D011507	"<span class=""disease"">proteinuria</span>"	"Also, <span class=""chemical"">captopril</span> treatment failed to potentiate or facilitate development of massive <span class=""disease"">proteinuria</span> invoked by puromycin aminonucleoside in SHR."	761593.0	6454943.0	6454943_D002216_D011507		bcv_easy_589_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002220	"<span class=""chemical"">CBZ</span>"	D012640	"<span class=""disease"">seizure</span>"	"Chronic <span class=""chemical"">CBZ</span> also decreased the incidence of <span class=""disease"">seizure</span>-related mortality in the cocaine-injected rats."	761593.0	2790457.0	2790457_D002220_D012640		bcv_easy_686_sent_work_dev_set_761593	"no_relation
"	
TRUE	D012964	"<span class=""chemical"">sodium</span>"	D034141	"<span class=""disease"">hypoalbuminemia</span>"	"After 7 days, PAN treatment induced significant proteinuria, <span class=""disease"">hypoalbuminemia</span>, decreased urinary <span class=""chemical"">sodium</span> excretion, and extensive ascites."	761593.0	15075188.0	15075188_D012964_D034141		bcv_easy_1097_sent_work_dev_set_761593	"no_relation
"	
TRUE	D012254	"<span class=""chemical"">ribavirin</span>"	D000257	"<span class=""disease"">adenovirus disease</span>"	"Although intravenous <span class=""chemical"">ribavirin</span> was not effective for all children with severe <span class=""disease"">adenovirus disease</span> in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection."	761593.0	12093990.0	12093990_D012254_D000257		bcv_easy_246_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013629	"<span class=""chemical"">tamoxifen</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of <span class=""disease"">breast cancer</span>, the postulated protective effects of <span class=""chemical"">tamoxifen</span> are not yet apparent."	761593.0	9672273.0	9672273_D013629_D001943		bcv_easy_314_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007980	"<span class=""chemical"">L-dopa</span>"	D003128	"<span class=""disease"">coma</span>"	"Bilateral nephrectomy eliminated the beneficial effect of <span class=""chemical"">L-dopa</span> on blood and brain ammonia and the ammonia <span class=""disease"">coma</span> was not prevented."	761593.0	761833.0	761833_D007980_D003128		bcv_easy_463_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009020	"<span class=""chemical"">Morphine</span>"	D001523	"<span class=""disease"">behavioral disorders</span>"	"<span class=""chemical"">Morphine</span> dose-dependently reversed these <span class=""disease"">behavioral disorders</span>."	761593.0	10840460.0	10840460_D009020_D001523		bcv_easy_320_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008687	"<span class=""chemical"">metformin</span>"	D014652	"<span class=""disease"">vascular dysfunction</span>"	"The antidiabetic drug <span class=""chemical"">metformin</span> can diminish apoptosis induced by oxidative stress in endothelial cells and prevent <span class=""disease"">vascular dysfunction</span> even in nondiabetic patients."	761593.0	20164825.0	20164825_D008687_D014652		bcv_easy_268_sent_work_dev_set_761593	"no_relation
"	
TRUE	D017374	"<span class=""chemical"">paroxetine</span>"	D059350	"<span class=""disease"">chronic pain</span>"	"This drug was initiated in association with <span class=""chemical"">paroxetine</span> and dosulepine hydrochloride in a tetraparetic patient with <span class=""disease"">chronic pain</span>."	761593.0	8766220.0	8766220_D017374_D059350		bcv_easy_100_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003520	"<span class=""chemical"">cyclophosphamide</span>"	D066126	"<span class=""disease"">cardiotoxicity</span>"	"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing <span class=""disease"">cardiotoxicity</span> and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with <span class=""chemical"">cyclophosphamide</span> as first-line therapy for MBC."	761593.0	11230490.0	11230490_D003520_D066126		bcv_easy_142_sent_work_dev_set_761593	"no_relation
"	
TRUE	C032151	"<span class=""chemical"">cibenzoline</span>"	D001145	"<span class=""disease"">ventricular arrhythmias</span>"	"Antiarrhythmic plasma concentrations of <span class=""chemical"">cibenzoline</span> on canine <span class=""disease"">ventricular arrhythmias</span>."	761593.0	2435991.0	2435991_C032151_D001145		bcv_easy_425_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002220	"<span class=""chemical"">CBZ</span>"	D012640	"<span class=""disease"">seizures</span>"	"Repeated i.p. injection of <span class=""chemical"">CBZ</span> (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled <span class=""disease"">seizures</span>."	761593.0	2790457.0	2790457_D002220_D012640		bcv_easy_689_sent_work_dev_set_761593	"no_relation
"	
TRUE	D011224	"<span class=""chemical"">prazosin</span>"	D009127	"<span class=""disease"">muscular rigidity</span>"	"Such an induced <span class=""disease"">muscular rigidity</span> by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, <span class=""chemical"">prazosin</span>."	761593.0	2564649.0	2564649_D011224_D009127		bcv_easy_1162_sent_work_dev_set_761593	"no_relation
"	
TRUE	D010433	"<span class=""chemical"">metrazol</span>"	D000699	"<span class=""disease"">analgesia</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine <span class=""disease"">analgesia</span>- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of <span class=""chemical"">metrazol</span>."	761593.0	6323692.0	6323692_D010433_D000699		bcv_easy_376_sent_work_dev_set_761593	"no_relation
"	
TRUE	D001262	"<span class=""chemical"">atenolol</span>"	D001145	"<span class=""disease"">arrhythmia</span>"	"The <span class=""disease"">arrhythmia</span> resolved after therapy with <span class=""chemical"">atenolol</span>, but recurred a year later."	761593.0	20552622.0	20552622_D001262_D001145		bcv_easy_43_sent_work_dev_set_761593	"no_relation
"	
TRUE	D006493	"<span class=""chemical"">Unfractionated heparin sodium/UFH</span>"	D013927	"<span class=""disease"">thrombosis</span>"	"BACKGROUND: <span class=""chemical"">Unfractionated heparin sodium</span> (<span class=""chemical"">UFH</span>) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent <span class=""disease"">thrombosis</span> after liver transplantation."	761593.0	18589141.0	18589141_D006493_D013927		bcv_easy_491_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008687	"<span class=""chemical"">metformin</span>"	D007674	"<span class=""disease"">nephrotoxicity</span>"	"Thus, our study suggests that pleiotropic effects of <span class=""chemical"">metformin</span> can lessen gentamicin <span class=""disease"">nephrotoxicity</span> and improve mitochondrial homeostasis."	761593.0	20164825.0	20164825_D008687_D007674		bcv_easy_273_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004052	"<span class=""chemical"">diethylnitrosamine</span>"	D063646	"<span class=""disease"">carcinogenic</span>"	"Anti-<span class=""disease"">carcinogenic</span> action of phenobarbital given simultaneously with <span class=""chemical"">diethylnitrosamine</span> in the rat."	761593.0	3780814.0	3780814_D004052_D063646		bcv_easy_712_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000086	"<span class=""chemical"">acetazolamide</span>"	D007674	"<span class=""disease"">renal impairment</span>"	"Acute confusion induced by <span class=""chemical"">acetazolamide</span> is a well known adverse drug reaction in patients with <span class=""disease"">renal impairment</span>."	761593.0	10692744.0	10692744_D000086_D007674		bcv_easy_989_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004298	"<span class=""chemical"">dopamine</span>"	D003128	"<span class=""disease"">coma</span>"	"Thus, the reduction in blood and brain ammonia and the prevention of ammonia <span class=""disease"">coma</span> after L-dopa, can be accounted for by the peripheral effect of <span class=""chemical"">dopamine</span> on renal function rather than its central action."	761593.0	761833.0	761833_D004298_D003128		bcv_easy_465_sent_work_dev_set_761593	"no_relation
"	
TRUE	D012254	"<span class=""chemical"">ribavirin</span>"	D006482	"<span class=""disease"">infection with hemorrhagic fever viruses</span>"	"Intravenous <span class=""chemical"">ribavirin</span> is the treatment of choice for <span class=""disease"">infection with hemorrhagic fever viruses</span>."	761593.0	12093990.0	12093990_D012254_D006482		bcv_easy_238_sent_work_dev_set_761593	"no_relation
"	
TRUE	D015725	"<span class=""chemical"">fluconazole</span>"	D001145	"<span class=""disease"">ventricular arrhythmias</span>"	"Serial electrocardiographic monitoring may be considered when <span class=""chemical"">fluconazole</span> is administered in patients who are at risk for <span class=""disease"">ventricular arrhythmias</span>."	761593.0	11302406.0	11302406_D015725_D001145		bcv_easy_544_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000082	"<span class=""chemical"">acetaminophen</span>"	D013345	"<span class=""disease"">SAH</span>"	"Ketoprofen but not <span class=""chemical"">acetaminophen</span> impaired platelet function in patients with <span class=""disease"">SAH</span>."	761593.0	10414674.0	10414674_D000082_D013345		bcv_easy_902_sent_work_dev_set_761593	"no_relation
"	
TRUE	D017035	"<span class=""chemical"">pravastatin</span>"	D006937	"<span class=""disease"">hypercholesterolemia</span>"	"He assumed <span class=""chemical"">pravastatin</span> (20 mg/day) because of <span class=""disease"">hypercholesterolemia</span>."	761593.0	7604176.0	7604176_D017035_D006937		bcv_easy_810_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013792	"<span class=""chemical"">thalidomide</span>"	D002292	"<span class=""disease"">renal cell carcinoma</span>"	"CONCLUSION: These results are consistent with a low level of activity of <span class=""chemical"">thalidomide</span> in <span class=""disease"">renal cell carcinoma</span>."	761593.0	12448656.0	12448656_D013792_D002292		bcv_easy_386_sent_work_dev_set_761593	"no_relation
"	
TRUE	C018370	"<span class=""chemical"">pregnenolone sulphate</span>"	D000647	"<span class=""disease"">amnesic</span>"	"Steroid structure and pharmacological properties determine the anti-<span class=""disease"">amnesic</span> effects of <span class=""chemical"">pregnenolone sulphate</span> in the passive avoidance task in rats."	761593.0	11860495.0	11860495_C018370_D000647		bcv_easy_1227_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007980	"<span class=""chemical"">levodopa</span>"	D010300	"<span class=""disease"">idiopathic Parkinson's disease</span>"	"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced <span class=""chemical"">levodopa</span>-induced peak dose involuntary movements in 16 patients with <span class=""disease"">idiopathic Parkinson's disease</span>."	761593.0	458486.0	458486_D007980_D010300		bcv_easy_109_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014269	"<span class=""chemical"">trifluoroacetyl</span>"	D056486	"<span class=""disease"">hepatitis</span>"	"An antibody response to a protein-bound biotransformation product (<span class=""chemical"">trifluoroacetyl</span> adduct) has been detected on halothane <span class=""disease"">hepatitis</span> patients."	761593.0	7647582.0	7647582_D014269_D056486		bcv_easy_913_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003520	"<span class=""chemical"">cyclophosphamide</span>"	D007674	"<span class=""disease"">renal involvement</span>"	"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with <span class=""disease"">renal involvement</span> and undergone periods of treatment with azathioprine and <span class=""chemical"">cyclophosphamide</span>."	761593.0	12739036.0	12739036_D003520_D007674		bcv_easy_296_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004052	"<span class=""chemical"">diethylnitrosamine/DEN</span>"	D063646	"<span class=""disease"">carcinogenesis</span>"	"The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on <span class=""disease"">carcinogenesis</span> when it is administered simultaneously with <span class=""chemical"">diethylnitrosamine</span> (<span class=""chemical"">DEN</span>: 10 mg/kg/day)."	761593.0	3780814.0	3780814_D004052_D063646		bcv_easy_714_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005492	"<span class=""chemical"">folic acid</span>"	D064420	"<span class=""disease"">toxicity</span>"	"This observation prompted a Phase I clinical study of lometrexol given with <span class=""chemical"">folic acid</span> supplementation which has confirmed that the <span class=""disease"">toxicity</span> of lometrexol can be markedly reduced by <span class=""chemical"">folic acid</span> supplementation."	761593.0	8958188.0	8958188_D005492_D064420		bcv_easy_185_sent_work_dev_set_761593	"no_relation
"	
TRUE	C095756	"<span class=""chemical"">AIDA</span>"	D009127	"<span class=""disease"">muscle rigidity</span>"	"<span class=""chemical"">AIDA</span> in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced <span class=""disease"">muscle rigidity</span>."	761593.0	12231232.0	12231232_C095756_D009127		bcv_easy_479_sent_work_dev_set_761593	"no_relation
"	
TRUE	C507346	"<span class=""chemical"">AMN082</span>"	D018476	"<span class=""disease"">akinetic</span>"	"In a more complex task commonly used to evaluate major <span class=""disease"">akinetic</span> symptoms of PD patients, 5 mg/kg <span class=""chemical"">AMN082</span> reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats."	761593.0	19940105.0	19940105_C507346_D018476		bcv_easy_1238_sent_work_dev_set_761593	"no_relation
"	
TRUE	D006046	"<span class=""chemical"">gold</span>"	D009393	"<span class=""disease"">nephritis</span>"	"A strong association has been found between <span class=""disease"">nephritis</span> and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to <span class=""chemical"">gold</span> thiosulphate and B35."	761593.0	3084782.0	3084782_D006046_D009393		bcv_easy_674_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007649	"<span class=""chemical"">Ketamine</span>"	D012559	"<span class=""disease"">schizophrenia</span>"	"<span class=""chemical"">Ketamine</span> induces activation changes in healthy subjects similar to those observed in patients with <span class=""disease"">schizophrenia</span>, particularly in frontal and temporal brain regions."	761593.0	20727411.0	20727411_D007649_D012559		bcv_easy_226_sent_work_dev_set_761593	"no_relation
"	
TRUE	D010634	"<span class=""chemical"">PB</span>"	D009369	"<span class=""disease"">tumor</span>"	"In DEN + <span class=""chemical"">PB</span> treated rats, the survival was prolonged and the <span class=""disease"">tumor</span> incidence decreased as compared with the results obtained by DEN alone."	761593.0	3780814.0	3780814_D010634_D009369		bcv_easy_720_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007650	"<span class=""chemical"">Ketanserin</span>"	D009127	"<span class=""disease"">muscle rigidity</span>"	"<span class=""chemical"">Ketanserin</span> pretreatment reverses alfentanil-induced <span class=""disease"">muscle rigidity</span>."	761593.0	3115150.0	3115150_D007650_D009127		bcv_easy_228_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009270	"<span class=""chemical"">Naloxone</span>"	D012133	"<span class=""disease"">respiratory paralysis</span>"	"<span class=""chemical"">Naloxone</span> (2.5 mg/kg, i.v.) reversed <span class=""disease"">respiratory paralysis</span>, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum."	761593.0	2893236.0	2893236_D009270_D012133		bcv_easy_447_sent_work_dev_set_761593	"no_relation
"	
TRUE	D001379	"<span class=""chemical"">azathioprine</span>"	D007674	"<span class=""disease"">renal involvement</span>"	"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with <span class=""disease"">renal involvement</span> and undergone periods of treatment with <span class=""chemical"">azathioprine</span> and cyclophosphamide."	761593.0	12739036.0	12739036_D001379_D007674		bcv_easy_297_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014031	"<span class=""chemical"">tobramicyn</span>"	D064420	"<span class=""disease"">toxicity</span>"	"OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of <span class=""chemical"">tobramicyn</span> on steady-state serum concentrations and <span class=""disease"">toxicity</span>."	761593.0	9875685.0	9875685_D014031_D064420		bcv_easy_1026_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005492	"<span class=""chemical"">folic acid</span>"	D064420	"<span class=""disease"">toxicity</span>"	"Preclinical murine studies demonstrated that the <span class=""disease"">toxicity</span> of lometrexol can be prevented by low dose <span class=""chemical"">folic acid</span> administration, i.e. for 7 days prior to and 7 days following a single bolus dose."	761593.0	8958188.0	8958188_D005492_D064420		bcv_easy_183_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002216	"<span class=""chemical"">captopril</span>"	D006973	"<span class=""disease"">hypertensive</span>"	"Contribution of the sympathetic nervous system to salt-sensitivity in lifetime <span class=""chemical"">captopril</span>-treated spontaneously <span class=""disease"">hypertensive</span> rats."	761593.0	8586822.0	8586822_D002216_D006973		bcv_easy_1188_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013467	"<span class=""chemical"">sulindac</span>"	D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 31-year-old man with <span class=""disease"">rheumatoid arthritis</span>, who had previously been treated with <span class=""chemical"">sulindac</span>, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy."	761593.0	6699841.0	6699841_D013467_D001172		bcv_easy_1250_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000638	"<span class=""chemical"">amiodarone</span>"	D017180	"<span class=""disease"">VT</span>"	"Six percent of the patients had a nonfatal recurrence of <span class=""disease"">VT</span> and were successfully managed by continuing <span class=""chemical"">amiodarone</span> at a higher dose or by the addition of a conventional antiarrhythmic drug."	761593.0	6637851.0	6637851_D000638_D017180		bcv_easy_1018_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014635	"<span class=""chemical"">VPA</span>"	D004830	"<span class=""disease"">tonic-clonic convulsions</span>"	"He had been taking <span class=""chemical"">VPA</span> for treatment of idiopathic generalized <span class=""disease"">tonic-clonic convulsions</span> since he was 56 years old."	761593.0	11195262.0	11195262_D014635_D004830		bcv_easy_160_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000617	"<span class=""chemical"">aminoglycoside</span>"	D006402|D009369	"<span class=""disease"">hematologic/oncologic disorder</span>"	"Forty patients with a diagnosis consistent with a <span class=""disease"">hematologic/oncologic disorder</span> that required treatment with an <span class=""chemical"">aminoglycoside</span> were randomized to either conventional or extended-interval amikacin."	761593.0	18356633.0	18356633_D000617_D006402|D009369		bcv_easy_699_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003630	"<span class=""chemical"">daunorubicin</span>"	D001855	"<span class=""disease"">myelosuppression</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced <span class=""disease"">myelosuppression</span> and weight loss from <span class=""chemical"">daunorubicin</span> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <span class=""disease"">myelosuppression</span>, weight loss, nor the in vitro cytotoxicity from doxorubicin."	761593.0	15897593.0	15897593_D003630_D001855		bcv_easy_977_sent_work_dev_set_761593	"yes_direct
"	Daunorubicin causes weight loss and myelosuppression. Dexrazoxane made the myelosuppression and weight loss better.
TRUE	D064730	"<span class=""chemical"">dexrazoxane</span>"	D009362	"<span class=""disease"">metastases</span>"	"Clinical trials in patients with brain <span class=""disease"">metastases</span> combining <span class=""chemical"">dexrazoxane</span> and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity."	761593.0	15897593.0	15897593_D064730_D009362		bcv_easy_985_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002122	"<span class=""chemical"">calcium chloride</span>"	D014202	"<span class=""disease"">tremor</span>"	"The effect of <span class=""chemical"">calcium chloride</span> injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated."	761593.0	6892185.0	6892185_D002122_D014202		bcv_easy_1044_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000583	"<span class=""chemical"">Amikacin</span>"	D009503	"<span class=""disease"">febrile neutropenia</span>"	"<span class=""chemical"">Amikacin</span> is an aminoglycoside commonly used to provide empirical double gram-negative treatment for <span class=""disease"">febrile neutropenia</span> and other suspected infections."	761593.0	18356633.0	18356633_D000583_D009503		bcv_easy_694_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014282	"<span class=""chemical"">trihexyphenidyl hydrochloride</span>"	D012559	"<span class=""disease"">schizophrenic</span>"	"A chronic <span class=""disease"">schizophrenic</span> patient was treated with an anticholinergic drug, <span class=""chemical"">trihexyphenidyl hydrochloride</span>."	761593.0	3769769.0	3769769_D014282_D012559		bcv_easy_251_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003520	"<span class=""chemical"">cyclophosphamide</span>"	D008180	"<span class=""disease"">systemic lupus erythematosus/SLE</span>"	"Since 1989, she had been suffering from <span class=""disease"">systemic lupus erythematosus</span> (<span class=""disease"">SLE</span>) with renal involvement and undergone periods of treatment with azathioprine and <span class=""chemical"">cyclophosphamide</span>."	761593.0	12739036.0	12739036_D003520_D008180		bcv_easy_295_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005557	"<span class=""chemical"">formalin</span>"	D010146	"<span class=""disease"">pain</span>"	"Their ester prodrugs 6 and 8 were orally active in three models of <span class=""disease"">pain</span>: reversal of <span class=""chemical"">formalin</span>-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia."	761593.0	15974569.0	15974569_D005557_D010146		bcv_easy_420_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002110	"<span class=""chemical"">caffeine</span>"	D006331	"<span class=""disease"">cardiac disease</span>"	"We describe a patient with no previous history of <span class=""disease"">cardiac disease</span> or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after <span class=""chemical"">caffeine</span> administration."	761593.0	18997632.0	18997632_D002110_D006331		bcv_easy_124_sent_work_dev_set_761593	"no_relation
"	
TRUE	C400082	"<span class=""chemical"">bortezomib</span>"	D009101	"<span class=""disease"">MM</span>"	"The results suggest that <span class=""chemical"">bortezomib</span> in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed <span class=""disease"">MM</span> that warrants further investigation."	761593.0	19274460.0	19274460_C400082_D009101		bcv_easy_578_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007980	"<span class=""chemical"">L-dopa</span>"	D003128	"<span class=""disease"">coma</span>"	"This <span class=""disease"">coma</span> was prevented with 1.68 mmol <span class=""chemical"">L-dopa</span> given by gastric intubation 15 minutes before the ammonium salt injection."	761593.0	761833.0	761833_D007980_D003128		bcv_easy_460_sent_work_dev_set_761593	"no_relation
"	
TRUE	D011899	"<span class=""chemical"">ranitidine</span>"	D007172	"<span class=""disease"">impotence</span>"	"Sixty percent of the males developed breast changes or <span class=""disease"">impotence</span> while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by <span class=""chemical"">ranitidine</span>."	761593.0	6150641.0	6150641_D011899_D007172		bcv_easy_325_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005996	"<span class=""chemical"">Glyceryl trinitrate</span>"	D020325	"<span class=""disease"">migraine with aura</span>"	"<span class=""chemical"">Glyceryl trinitrate</span> induces attacks of migraine without aura in sufferers of <span class=""disease"">migraine with aura</span>."	761593.0	10524660.0	10524660_D005996_D020325		bcv_easy_600_sent_work_dev_set_761593	"no_relation
"	
TRUE	C018370	"<span class=""chemical"">PREGS</span>"	D000647	"<span class=""disease"">amnesic</span>"	"Moreover, <span class=""chemical"">PREGS</span> is able to reverse the <span class=""disease"">amnesic</span>-like effects of NMDAR and GABA(A)R ligands."	761593.0	11860495.0	11860495_C018370_D000647		bcv_easy_1229_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	D009362	"<span class=""disease"">metastasis</span>"	"We report a case of a patient with colon carcinoma and liver <span class=""disease"">metastasis</span> who presented chest pain after <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) administration."	761593.0	3952818.0	3952818_D005472_D009362		bcv_easy_996_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002122	"<span class=""chemical"">calcium chloride</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"On the other hand, <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by <span class=""chemical"">calcium chloride</span>."	761593.0	6892185.0	6892185_D002122_D015878		bcv_easy_1049_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003520	"<span class=""chemical"">cyclophosphamide</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and <span class=""chemical"">cyclophosphamide</span> compared with conventional doxorubicin and <span class=""chemical"">cyclophosphamide</span> in a randomized, multicenter trial of metastatic <span class=""disease"">breast cancer</span>."	761593.0	11230490.0	11230490_D003520_D001943		bcv_easy_131_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000638	"<span class=""chemical"">Amiodarone</span>"	D017180	"<span class=""disease"">VT/ventricular tachycardia</span>"	"<span class=""chemical"">Amiodarone</span> was administered to 154 patients who had sustained, symptomatic <span class=""disease"">ventricular tachycardia</span> (<span class=""disease"">VT</span>) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs."	761593.0	6637851.0	6637851_D000638_D017180		bcv_easy_1014_sent_work_dev_set_761593	"no_relation
"	
TRUE	C047781	"<span class=""chemical"">LTG/lamotrigine</span>"	C562694	"<span class=""disease"">IGE/idiopathic generalized epilepsies</span>"	"Five patients with <span class=""disease"">idiopathic generalized epilepsies</span> (<span class=""disease"">IGE</span>) treated with <span class=""chemical"">lamotrigine</span> (<span class=""chemical"">LTG</span>) experienced exacerbation or de novo appearance of myoclonic jerks (MJ)."	761593.0	16157917.0	16157917_C047781_C562694		bcv_easy_1006_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008713	"<span class=""chemical"">methimazole</span>"	D006980	"<span class=""disease"">hyperthyroidism</span>"	"A 43-year-old woman had severe jaundice and itching 1 month after receiving <span class=""chemical"">methimazole</span> (10 mg tid) and propranolol (20 mg tid) for treatment of <span class=""disease"">hyperthyroidism</span>."	761593.0	14982270.0	14982270_D008713_D006980		bcv_easy_550_sent_work_dev_set_761593	"no_relation
"	
TRUE	C004742	"<span class=""chemical"">Daidzein</span>"	D000647	"<span class=""disease"">amnesia</span>"	"<span class=""chemical"">Daidzein</span> activates choline acetyltransferase from MC-IXC cells and improves drug-induced <span class=""disease"">amnesia</span>."	761593.0	16428827.0	16428827_C004742_D000647		bcv_easy_62_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005557	"<span class=""chemical"">formalin</span>"	D006930	"<span class=""disease"">thermal hyperalgesia/mechanical hyperalgesia</span>"	"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of <span class=""chemical"">formalin</span>-induced paw licking, carrageenan-induced <span class=""disease"">thermal hyperalgesia</span>, and capsaicin-induced <span class=""disease"">mechanical hyperalgesia</span>."	761593.0	15974569.0	15974569_D005557_D006930		bcv_easy_419_sent_work_dev_set_761593	"no_relation
"	
TRUE	D020117	"<span class=""chemical"">Cisapride</span>"	D015835	"<span class=""disease"">gastrointestinal motility disorders</span>"	"<span class=""chemical"">Cisapride</span>, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of <span class=""disease"">gastrointestinal motility disorders</span>."	761593.0	9545159.0	9545159_D020117_D015835		bcv_easy_254_sent_work_dev_set_761593	"no_relation
"	
TRUE	D015215	"<span class=""chemical"">AZT</span>"	D000163	"<span class=""disease"">AIDS</span>"	"<span class=""chemical"">AZT</span> has induced a macrocytic anemia in <span class=""disease"">AIDS</span> patients on long term <span class=""chemical"">AZT</span> therapy."	761593.0	9209318.0	9209318_D015215_D000163		bcv_easy_906_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013835	"<span class=""chemical"">thiamine pyrophosphate/TPP</span>"	D003920	"<span class=""disease"">diabetic</span>"	"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a <span class=""disease"">diabetic</span> patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for <span class=""chemical"">thiamine pyrophosphate</span> (<span class=""chemical"">TPP</span>)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome."	761593.0	3762968.0	3762968_D013835_D003920		bcv_easy_729_sent_work_dev_set_761593	"no_relation
"	
TRUE	C009166	"<span class=""chemical"">retinyl acetate</span>"	D013274	"<span class=""disease"">forestomach carcinogenesis</span>"	"Co-carcinogenic effect of <span class=""chemical"">retinyl acetate</span> on <span class=""disease"">forestomach carcinogenesis</span> of male F344 rats induced with butylated hydroxyanisole."	761593.0	3131282.0	3131282_C009166_D013274		bcv_easy_347_sent_work_dev_set_761593	"no_relation
"	
TRUE	C097949	"<span class=""chemical"">1,25-dihydroxyvitamin D</span>"	D058186	"<span class=""disease"">acute renal insufficiency</span>"	"RESULTS: The 3 patients had <span class=""disease"">acute renal insufficiency</span>, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and <span class=""chemical"">1,25-dihydroxyvitamin D</span> concentrations."	761593.0	16006300.0	16006300_C097949_D058186		bcv_easy_705_sent_work_dev_set_761593	"no_relation
"	
TRUE	C071741	"<span class=""chemical"">Remifentanil</span>"	D010146	"<span class=""disease"">pain</span>"	"<span class=""chemical"">Remifentanil</span>-related complications were assessed during the <span class=""chemical"">remifentanil</span> infusion, and <span class=""disease"">pain</span> caused by propofol was evaluated using a four-point scale during the propofol infusion."	761593.0	18006530.0	18006530_C071741_D010146		bcv_easy_9_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000617	"<span class=""chemical"">aminoglycoside</span>"	D009503	"<span class=""disease"">febrile neutropenia</span>"	"Amikacin is an <span class=""chemical"">aminoglycoside</span> commonly used to provide empirical double gram-negative treatment for <span class=""disease"">febrile neutropenia</span> and other suspected infections."	761593.0	18356633.0	18356633_D000617_D009503		bcv_easy_695_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002122	"<span class=""chemical"">calcium chloride</span>"	D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"On the other hand, mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> evoked by carbachol and eserine were not significantly changed by <span class=""chemical"">calcium chloride</span>."	761593.0	6892185.0	6892185_D002122_D004830		bcv_easy_1054_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008687	"<span class=""chemical"">Metformin</span>"	D058186	"<span class=""disease"">acute renal failure</span>"	"<span class=""chemical"">Metformin</span> treatment fully blocked gentamicin-mediated <span class=""disease"">acute renal failure</span>."	761593.0	20164825.0	20164825_D008687_D058186		bcv_easy_271_sent_work_dev_set_761593	"no_relation
"	
TRUE	C037689	"<span class=""chemical"">benzamide</span>"	D010300	"<span class=""disease"">idiopathic Parkinson's disease</span>"	"Tiapride, a substituted <span class=""chemical"">benzamide</span> derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with <span class=""disease"">idiopathic Parkinson's disease</span>."	761593.0	458486.0	458486_C037689_D010300		bcv_easy_103_sent_work_dev_set_761593	"no_relation
"	
TRUE	D006046	"<span class=""chemical"">gold</span>"	D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 31-year-old man with <span class=""disease"">rheumatoid arthritis</span>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and <span class=""chemical"">gold</span> salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy."	761593.0	6699841.0	6699841_D006046_D001172		bcv_easy_1245_sent_work_dev_set_761593	"no_relation
"	
TRUE	D018967	"<span class=""chemical"">risperidone</span>"	D001480	"<span class=""disease"">EPS</span>"	"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed <span class=""disease"">EPS</span> with classic antipsychotics, were successfully treated with <span class=""chemical"">risperidone</span>."	761593.0	12013711.0	12013711_D018967_D001480		bcv_easy_151_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002752	"<span class=""chemical"">chlorthalidone</span>"	D003324	"<span class=""disease"">coronary artery disease</span>"	"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known <span class=""disease"">coronary artery disease</span> after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (<span class=""chemical"">chlorthalidone</span>) in a randomised study."	761593.0	3732088.0	3732088_D002752_D003324		bcv_easy_20_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003345	"<span class=""chemical"">corticosterone</span>"	D009422	"<span class=""disease"">neuropathy</span>"	"Although low concentrations (less than or equal to 50 ppm) of <span class=""chemical"">corticosterone</span> had beneficial effects on TOTP-induced <span class=""disease"">neuropathy</span>, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP."	761593.0	3961813.0	3961813_D003345_D009422		bcv_easy_520_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009543	"<span class=""chemical"">nifedipine</span>"	D000788	"<span class=""disease"">Prinzmetal's angina</span>"	"Clinical electrocardiographic evolution was similar to that observed in <span class=""disease"">Prinzmetal's angina</span>, and chest pain promptly resolved with <span class=""chemical"">nifedipine</span>."	761593.0	3952818.0	3952818_D009543_D000788		bcv_easy_999_sent_work_dev_set_761593	"no_relation
"	
TRUE	C507346	"<span class=""chemical"">AMN082</span>"	D010300	"<span class=""disease"">PD</span>"	"In a more complex task commonly used to evaluate major akinetic symptoms of <span class=""disease"">PD</span> patients, 5 mg/kg <span class=""chemical"">AMN082</span> reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats."	761593.0	19940105.0	19940105_C507346_D010300		bcv_easy_1239_sent_work_dev_set_761593	"no_relation
"	
TRUE	C422649	"<span class=""chemical"">etoricoxib</span>"	D005767	"<span class=""disease"">GI AEs</span>"	"The cumulative discontinuation rate due to <span class=""disease"">GI AEs</span> was significantly lower with <span class=""chemical"">etoricoxib</span> than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001))."	761593.0	17965424.0	17965424_C422649_D005767		bcv_easy_930_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009599	"<span class=""chemical"">nitroprusside</span>"	D007511	"<span class=""disease"">ischemia</span>"	"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before <span class=""disease"">ischemia</span>, the other receiving 650 micrograms/kg b.w. of the hypotensive drug <span class=""chemical"">nitroprusside</span> at a flow rate of 103 microliters/min intravenously during <span class=""disease"">ischemia</span>, although in this latter group malondialdehyde was significantly higher."	761593.0	7710775.0	7710775_D009599_D007511		bcv_easy_950_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004317	"<span class=""chemical"">doxorubicin</span>"	D066126	"<span class=""disease"">cardiotoxicity</span>"	"Reduced <span class=""disease"">cardiotoxicity</span> and preserved antitumor efficacy of liposome-encapsulated <span class=""chemical"">doxorubicin</span> and cyclophosphamide compared with conventional <span class=""chemical"">doxorubicin</span> and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer."	761593.0	11230490.0	11230490_D004317_D066126		bcv_easy_132_sent_work_dev_set_761593	"no_relation
"	
TRUE	D001262	"<span class=""chemical"">atenolol</span>"	D001145	"<span class=""disease"">arrhythmia</span>"	"After stopping the beta-agonist, and after a week with the <span class=""chemical"">atenolol</span>, the <span class=""disease"">arrhythmia</span> disappeared."	761593.0	20552622.0	20552622_D001262_D001145		bcv_easy_44_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007980	"<span class=""chemical"">L-dopa</span>"	D020734	"<span class=""disease"">parkinsonian</span>"	"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of <span class=""disease"">parkinsonian</span> patients on <span class=""chemical"">L-dopa</span> medication, the first one without <span class=""chemical"">L-dopa</span> induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects."	761593.0	9549528.0	9549528_D007980_D020734		bcv_easy_891_sent_work_dev_set_761593	"no_relation
"	
TRUE	D064704	"<span class=""chemical"">levofloxacin</span>"	D012852	"<span class=""disease"">sinusitis</span>"	"PURPOSE: To evaluate the efficacy and safety of <span class=""chemical"">levofloxacin</span> (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial <span class=""disease"">sinusitis</span>."	761593.0	9564988.0	9564988_D064704_D012852		bcv_easy_679_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002945	"<span class=""chemical"">cisplatin</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"A sixty-year-old woman with advanced <span class=""disease"">breast cancer</span>, previously treated with <span class=""chemical"">cisplatin</span>, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide."	761593.0	2320800.0	2320800_D002945_D001943		bcv_easy_407_sent_work_dev_set_761593	"no_relation
"	
TRUE	D063325	"<span class=""chemical"">Tiapride</span>"	D004409	"<span class=""disease"">involuntary movements</span>"	"<span class=""chemical"">Tiapride</span>, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose <span class=""disease"">involuntary movements</span> in 16 patients with idiopathic Parkinson's disease."	761593.0	458486.0	458486_D063325_D004409		bcv_easy_108_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003520	"<span class=""chemical"">cyclophosphamide</span>"	D009101	"<span class=""disease"">myeloma</span>"	"DSMM XI study: dose definition for intravenous <span class=""chemical"">cyclophosphamide</span> in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed <span class=""disease"">myeloma</span>."	761593.0	19274460.0	19274460_D003520_D009101		bcv_easy_573_sent_work_dev_set_761593	"no_relation
"	
TRUE	D018698	"<span class=""chemical"">glutamate</span>"	D020336	"<span class=""disease"">spastic paraparesis</span>"	"These data indicate that IT morphine induces <span class=""disease"">spastic paraparesis</span> with a concomitant increase in CSF <span class=""chemical"">glutamate</span>, which is involved in NMDA receptor activation."	761593.0	15673851.0	15673851_D018698_D020336		bcv_easy_88_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008790	"<span class=""chemical"">metoprolol</span>"	D017202	"<span class=""disease"">myocardial ischemia</span>"	"CONCLUSION: During dobutamine stress testing, <span class=""chemical"">metoprolol</span> attenuates or eliminates evidence of <span class=""disease"">myocardial ischemia</span>."	761593.0	11079278.0	11079278_D008790_D017202		bcv_easy_1187_sent_work_dev_set_761593	"no_relation
"	
TRUE	D012254	"<span class=""chemical"">ribavirin</span>"	D007239	"<span class=""disease"">infection</span>"	"Although intravenous <span class=""chemical"">ribavirin</span> was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the <span class=""disease"">infection</span>."	761593.0	12093990.0	12093990_D012254_D007239		bcv_easy_247_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007980	"<span class=""chemical"">Levodopa</span>"	D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Levodopa</span>-induced dyskinesias have been reported in <span class=""disease"">Parkinson's disease</span> and multiple system atrophy."	761593.0	12691807.0	12691807_D007980_D010300		bcv_easy_333_sent_work_dev_set_761593	"no_relation
"	
TRUE	C032151	"<span class=""chemical"">Cibenzoline</span>"	D001145	"<span class=""disease"">arrhythmias</span>"	"<span class=""chemical"">Cibenzoline</span> suppressed all the <span class=""disease"">arrhythmias</span>, and the minimum effective plasma concentrations for <span class=""disease"">arrhythmias</span> induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7)."	761593.0	2435991.0	2435991_C032151_D001145		bcv_easy_429_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007660	"<span class=""chemical"">ketoprofen</span>"	D017542	"<span class=""disease"">aneurysmal</span>"	"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either <span class=""chemical"">ketoprofen</span>, 100 mg, three times a day (<span class=""chemical"">ketoprofen</span> group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of <span class=""disease"">aneurysmal</span> SAH."	761593.0	10414674.0	10414674_D007660_D017542		bcv_easy_893_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008687	"<span class=""chemical"">Metformin</span>"	D007674	"<span class=""disease"">nephropathy</span>"	"<span class=""chemical"">Metformin</span> prevents experimental gentamicin-induced <span class=""disease"">nephropathy</span> by a mitochondria-dependent pathway."	761593.0	20164825.0	20164825_D008687_D007674		bcv_easy_267_sent_work_dev_set_761593	"no_relation
"	
TRUE	D020117	"<span class=""chemical"">cisapride</span>"	D006973	"<span class=""disease"">hypertension</span>"	"A possible drug interaction occurred in a 45-year-old woman who was taking <span class=""chemical"">cisapride</span> for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for <span class=""disease"">hypertension</span>."	761593.0	9545159.0	9545159_D020117_D006973		bcv_easy_262_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002939	"<span class=""chemical"">ciprofloxacin</span>"	D009369	"<span class=""disease"">cancer</span>"	"Five patients with <span class=""disease"">cancer</span> who developed acute renal failure that followed treatment with <span class=""chemical"">ciprofloxacin</span> are described and an additional 15 cases reported in the literature are reviewed."	761593.0	8494478.0	8494478_D002939_D009369		bcv_easy_845_sent_work_dev_set_761593	"no_relation
"	
TRUE	D016291	"<span class=""chemical"">MK-801</span>"	D004409	"<span class=""disease"">dyskinetic</span>"	"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and <span class=""chemical"">MK-801</span>, markedly reduced the <span class=""disease"">dyskinetic</span> movements but at the cost of a return of parkinsonian symptomatology."	761593.0	8106150.0	8106150_D016291_D004409		bcv_easy_1120_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004317	"<span class=""chemical"">doxorubicin</span>"	D009765	"<span class=""disease"">obese</span>"	"In conclusion, HFD-induced <span class=""disease"">obese</span> rats are highly sensitized to <span class=""chemical"">doxorubicin</span>-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway."	761593.0	18674790.0	18674790_D004317_D009765		bcv_easy_883_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002927	"<span class=""chemical"">cimetidine</span>"	D056486|D006402	"<span class=""disease"">hepatic or hematologic toxicity</span>"	"Treatment with high doses of <span class=""chemical"">cimetidine</span> (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with <span class=""disease"">hepatic or hematologic toxicity</span> or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with <span class=""chemical"">cimetidine</span> therapy."	761593.0	6150641.0	6150641_D002927_D056486|D006402		bcv_easy_327_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014147	"<span class=""chemical"">Tramadol</span>"	D010146	"<span class=""disease"">pain</span>"	"<span class=""chemical"">Tramadol</span> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer <span class=""disease"">pain</span> and chronic non malignant <span class=""disease"">pain</span>."	761593.0	8766220.0	8766220_D014147_D010146		bcv_easy_97_sent_work_dev_set_761593	"no_relation
"	
TRUE	D015647	"<span class=""chemical"">SKF 38393</span>"	D002375	"<span class=""disease"">catalepsy</span>"	"Combination of <span class=""chemical"">SKF 38393</span> with quinpirole did not cause potentiated inhibitory effect on <span class=""disease"">catalepsy</span> induced by dopamine antagonists."	761593.0	1687392.0	1687392_D015647_D002375		bcv_easy_867_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000082	"<span class=""chemical"">paracetamol</span>"	D014581	"<span class=""disease"">urticaria</span>"	"Taken together, our results confirm the good tolerability of nimesulide and <span class=""chemical"">paracetamol</span> in patients who experienced <span class=""disease"">urticaria</span>/angioedema caused by NSAIDs."	761593.0	11694026.0	11694026_D000082_D014581		bcv_easy_648_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005492	"<span class=""chemical"">folic acid</span>"	D064420	"<span class=""disease"">toxicity</span>"	"Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by <span class=""chemical"">folic acid</span> administration indicating that supplementation is unlikely to reduce <span class=""disease"">toxicity</span> by enhancing lometrexol plasma clearance."	761593.0	8958188.0	8958188_D005492_D064420		bcv_easy_188_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004317	"<span class=""chemical"">Doxorubicin</span>"	D009765	"<span class=""disease"">OB</span>"	"<span class=""chemical"">Doxorubicin</span> toxicokinetics studies revealed no change in accumulation of <span class=""chemical"">doxorubicin</span> and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and <span class=""disease"">OB</span> hearts."	761593.0	18674790.0	18674790_D004317_D009765		bcv_easy_878_sent_work_dev_set_761593	"no_relation
"	
TRUE	C053571	"<span class=""chemical"">iopentol</span>"	D014693	"<span class=""disease"">ventricular fibrillation</span>"	"Frequencies of <span class=""disease"">ventricular fibrillation</span> were significantly lower (p less than 0.05) after <span class=""chemical"">iopentol</span> (0%) and iohexol (3%) than after metrizoate (22%)."	761593.0	2980315.0	2980315_C053571_D014693		bcv_easy_167_sent_work_dev_set_761593	"no_relation
"	
TRUE	D064730	"<span class=""chemical"">dexrazoxane</span>"	D015431	"<span class=""disease"">weight loss</span>"	"RESULTS: Nontoxic doses of <span class=""chemical"">dexrazoxane</span> reduced myelosuppression and <span class=""disease"">weight loss</span> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <span class=""chemical"">dexrazoxane</span> neither reduced myelosuppression, <span class=""disease"">weight loss</span>, nor the in vitro cytotoxicity from doxorubicin."	761593.0	15897593.0	15897593_D064730_D015431		bcv_easy_976_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008774	"<span class=""chemical"">methylphenidate</span>"	D000544	"<span class=""disease"">Alzheimer's disease</span>"	"An 82-year-old man with treatment-resistant depression and early <span class=""disease"">Alzheimer's disease</span> was started on <span class=""chemical"">methylphenidate</span>."	761593.0	12907924.0	12907924_D008774_D000544		bcv_easy_399_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004656	"<span class=""chemical"">enalapril</span>"	D018487	"<span class=""disease"">Left Ventricular Dysfunction</span>"	"METHOD: We analyzed data from the Studies of <span class=""disease"">Left Ventricular Dysfunction</span> (SOLVD), a randomized, double-blind, placebo-controlled trial of <span class=""chemical"">enalapril</span> for the treatment of CHF."	761593.0	10539815.0	10539815_D004656_D018487		bcv_easy_753_sent_work_dev_set_761593	"no_relation
"	
TRUE	C400082	"<span class=""chemical"">bortezomib</span>"	D009101	"<span class=""disease"">MM/multiple myeloma</span>"	"A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with <span class=""chemical"">bortezomib</span> and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed <span class=""disease"">multiple myeloma</span> (<span class=""disease"">MM</span>)."	761593.0	19274460.0	19274460_C400082_D009101		bcv_easy_575_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009288	"<span class=""chemical"">naproxen</span>"	D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 31-year-old man with <span class=""disease"">rheumatoid arthritis</span>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of <span class=""chemical"">naproxen</span> therapy."	761593.0	6699841.0	6699841_D009288_D001172		bcv_easy_1254_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013629	"<span class=""chemical"">tamoxifen</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of <span class=""chemical"">tamoxifen</span> in women (mainly in Italy) who did not have <span class=""disease"">breast cancer</span> and who had had a hysterectomy."	761593.0	9672273.0	9672273_D013629_D001943		bcv_easy_309_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004008	"<span class=""chemical"">diclofenac</span>"	D004487	"<span class=""disease"">oedema</span>"	"The incidence of discontinuations for hypertension-related and <span class=""disease"">oedema</span>-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <span class=""chemical"">diclofenac</span> (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for <span class=""disease"">oedema</span>)."	761593.0	17965424.0	17965424_D004008_D004487		bcv_easy_931_sent_work_dev_set_761593	"no_relation
"	
TRUE	D001379	"<span class=""chemical"">azathioprine</span>"	D008180	"<span class=""disease"">systemic lupus erythematosus/SLE</span>"	"Since 1989, she had been suffering from <span class=""disease"">systemic lupus erythematosus</span> (<span class=""disease"">SLE</span>) with renal involvement and undergone periods of treatment with <span class=""chemical"">azathioprine</span> and cyclophosphamide."	761593.0	12739036.0	12739036_D001379_D008180		bcv_easy_298_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008238	"<span class=""chemical"">LSD</span>"	D001480	"<span class=""disease"">EPS</span>"	"Two schizophrenic patients, who had a prior history of <span class=""chemical"">LSD</span> abuse and who had previously developed <span class=""disease"">EPS</span> with classic antipsychotics, were successfully treated with risperidone."	761593.0	12013711.0	12013711_D008238_D001480		bcv_easy_153_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004317	"<span class=""chemical"">ADR/adriamycin</span>"	D009369	"<span class=""disease"">cancer</span>"	"The use of <span class=""chemical"">adriamycin</span> (<span class=""chemical"">ADR</span>) in <span class=""disease"">cancer</span> chemotherapy has been limited due to its cumulative cardiovascular toxicity."	761593.0	9952311.0	9952311_D004317_D009369		bcv_easy_792_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002122	"<span class=""chemical"">calcium chloride</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"The effect of <span class=""chemical"">calcium chloride</span> injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated."	761593.0	6892185.0	6892185_D002122_D015878		bcv_easy_1039_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009270	"<span class=""chemical"">naloxone</span>"	D002375	"<span class=""disease"">catalepsy</span>"	"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced <span class=""disease"">catalepsy</span>, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for <span class=""chemical"">naloxone</span> would argue against an action at a single opioid site."	761593.0	2716967.0	2716967_D009270_D002375		bcv_easy_744_sent_work_dev_set_761593	"no_relation
"	
TRUE	D015119	"<span class=""chemical"">epsilon-aminocaproic acid</span>"	D008595	"<span class=""disease"">menorrhagia</span>"	"We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged <span class=""chemical"">epsilon-aminocaproic acid</span> therapy for <span class=""disease"">menorrhagia</span>."	761593.0	2339463.0	2339463_D015119_D008595		bcv_easy_210_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013467	"<span class=""chemical"">sulindac</span>"	D007674	"<span class=""disease"">renal toxicity</span>"	"We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of <span class=""chemical"">sulindac</span> in patients who have experienced <span class=""disease"">renal toxicity</span> from other antiinflammatory agents."	761593.0	6699841.0	6699841_D013467_D007674		bcv_easy_1255_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009270	"<span class=""chemical"">naloxone</span>"	D012133	"<span class=""disease"">respiratory paralysis</span>"	"GABA involvement in <span class=""chemical"">naloxone</span> induced reversal of <span class=""disease"">respiratory paralysis</span> produced by thiopental."	761593.0	2893236.0	2893236_D009270_D012133		bcv_easy_439_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002794	"<span class=""chemical"">choline</span>"	D000647	"<span class=""disease"">amnesia</span>"	"Daidzein activates <span class=""chemical"">choline</span> acetyltransferase from MC-IXC cells and improves drug-induced <span class=""disease"">amnesia</span>."	761593.0	16428827.0	16428827_D002794_D000647		bcv_easy_61_sent_work_dev_set_761593	"no_relation
"	
TRUE	D017373	"<span class=""chemical"">CPA/cyproterone acetate</span>"	D054556	"<span class=""disease"">venous thromboembolism/VTE</span>"	"OBJECTIVE: To achieve absolute risk estimates of <span class=""disease"">venous thromboembolism</span> (<span class=""disease"">VTE</span>) among women on <span class=""chemical"">cyproterone acetate</span> plus ethinylestradiol (<span class=""chemical"">CPA</span>/EE), and among women on combined oral contraceptives (COCs)."	761593.0	12851669.0	12851669_D017373_D054556		bcv_easy_656_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000662	"<span class=""chemical"">amphetamines</span>"	D012640	"<span class=""disease"">seizure</span>"	"CONCLUSIONS: During this study period, routine plasma screening for cocaine and <span class=""chemical"">amphetamines</span> in adult <span class=""disease"">seizure</span> patients had a low yield."	761593.0	11185967.0	11185967_D000662_D012640		bcv_easy_568_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000638	"<span class=""chemical"">amiodarone</span>"	D014693	"<span class=""disease"">ventricular fibrillation/VF</span>"	"Sixty-nine percent of patients continued treatment with <span class=""chemical"">amiodarone</span> and had no recurrence of symptomatic VT or <span class=""disease"">ventricular fibrillation</span> (<span class=""disease"">VF</span>) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2)."	761593.0	6637851.0	6637851_D000638_D014693		bcv_easy_1017_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002701	"<span class=""chemical"">chloramphenicol</span>"	D002386	"<span class=""disease"">cataract</span>"	"A 73-year-old woman died of aplastic anemia less than two months after undergoing <span class=""disease"">cataract</span> extraction and beginning topical therapy with <span class=""chemical"">chloramphenicol</span>."	761593.0	7072798.0	7072798_D002701_D002386		bcv_easy_173_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007530	"<span class=""chemical"">isoflurane</span>"	D004342	"<span class=""disease"">hypersensitivity</span>"	"This study was performed to determine cross-reactivity between enflurane and <span class=""chemical"">isoflurane</span> with the <span class=""disease"">hypersensitivity</span> induced by halothane."	761593.0	7647582.0	7647582_D007530_D004342		bcv_easy_915_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004656	"<span class=""chemical"">enalapril</span>"	D006333	"<span class=""disease"">CHF</span>"	"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of <span class=""chemical"">enalapril</span> for the treatment of <span class=""disease"">CHF</span>."	761593.0	10539815.0	10539815_D004656_D006333		bcv_easy_754_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009270	"<span class=""chemical"">naloxone</span>"	D012133	"<span class=""disease"">respiratory paralysis</span>"	"These data suggest <span class=""chemical"">naloxone</span> reverses <span class=""disease"">respiratory paralysis</span> produced by thiopental and involves GABA in its action."	761593.0	2893236.0	2893236_D009270_D012133		bcv_easy_451_sent_work_dev_set_761593	"no_relation
"	
TRUE	D011441	"<span class=""chemical"">PTU</span>"	D014424	"<span class=""disease"">Turner Syndrome</span>"	"<span class=""chemical"">PTU</span>-associated vasculitis in a girl with <span class=""disease"">Turner Syndrome</span> and Graves' disease."	761593.0	16418614.0	16418614_D011441_D014424		bcv_easy_92_sent_work_dev_set_761593	"no_relation
"	
TRUE	C065179	"<span class=""chemical"">atorvastatin</span>"	D006973	"<span class=""disease"">hypertension</span>"	"Thus, <span class=""chemical"">atorvastatin</span> prevented and reversed dexamethasone-induced <span class=""disease"">hypertension</span> in the rat."	761593.0	16820346.0	16820346_C065179_D006973		bcv_easy_73_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002216	"<span class=""chemical"">captopril</span>"	D011507	"<span class=""disease"">proteinuria</span>"	"Effect of <span class=""chemical"">captopril</span> on pre-existing and aminonucleoside-induced <span class=""disease"">proteinuria</span> in spontaneously hypertensive rats."	761593.0	6454943.0	6454943_D002216_D011507		bcv_easy_582_sent_work_dev_set_761593	"no_relation
"	
TRUE	C059262	"<span class=""chemical"">cidofovir</span>"	D000257	"<span class=""disease"">adenovirus infection</span>"	"The use of <span class=""chemical"">cidofovir</span> in severe <span class=""disease"">adenovirus infection</span> has been limited by adverse effects, the most significant of which is nephrotoxicity."	761593.0	12093990.0	12093990_C059262_D000257		bcv_easy_241_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004308	"<span class=""chemical"">dosulepine hydrochloride</span>"	D059350	"<span class=""disease"">chronic pain</span>"	"This drug was initiated in association with paroxetine and <span class=""chemical"">dosulepine hydrochloride</span> in a tetraparetic patient with <span class=""disease"">chronic pain</span>."	761593.0	8766220.0	8766220_D004308_D059350		bcv_easy_99_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000109	"<span class=""chemical"">ACh/acetylcholine</span>"	D000544	"<span class=""disease"">AD/Alzheimer's disease</span>"	"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <span class=""chemical"">acetylcholine</span> (<span class=""chemical"">ACh</span>), is an important factor in the treatment of <span class=""disease"">Alzheimer's disease</span> (<span class=""disease"">AD</span>)."	761593.0	16428827.0	16428827_D000109_D000544		bcv_easy_64_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013629	"<span class=""chemical"">tamoxifen</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"There is a statistically significant reduction of <span class=""disease"">breast cancer</span> among women receiving <span class=""chemical"">tamoxifen</span> who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of <span class=""disease"">breast cancer</span> compared with one case among 362 women allocated to <span class=""chemical"">tamoxifen</span>."	761593.0	9672273.0	9672273_D013629_D001943		bcv_easy_311_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004052	"<span class=""chemical"">DEN</span>"	D009369	"<span class=""disease"">tumor</span>"	"In <span class=""chemical"">DEN</span> + PB treated rats, the survival was prolonged and the <span class=""disease"">tumor</span> incidence decreased as compared with the results obtained by <span class=""chemical"">DEN</span> alone."	761593.0	3780814.0	3780814_D004052_D009369		bcv_easy_719_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013629	"<span class=""chemical"">tamoxifen</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"Prevention of <span class=""disease"">breast cancer</span> with <span class=""chemical"">tamoxifen</span>: preliminary findings from the Italian randomised trial among hysterectomised women. Italian <span class=""chemical"">Tamoxifen</span> Prevention Study."	761593.0	9672273.0	9672273_D013629_D001943		bcv_easy_306_sent_work_dev_set_761593	"no_relation
"	
TRUE	C012655	"<span class=""chemical"">nimesulide</span>"	D014581	"<span class=""disease"">urticaria</span>"	"Tolerability of <span class=""chemical"">nimesulide</span> and paracetamol in patients with NSAID-induced <span class=""disease"">urticaria</span>/angioedema."	761593.0	11694026.0	11694026_C012655_D014581		bcv_easy_637_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000638	"<span class=""chemical"">amiodarone</span>"	D017180	"<span class=""disease"">VT</span>"	"Sixty-nine percent of patients continued treatment with <span class=""chemical"">amiodarone</span> and had no recurrence of symptomatic <span class=""disease"">VT</span> or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2)."	761593.0	6637851.0	6637851_D000638_D017180		bcv_easy_1016_sent_work_dev_set_761593	"no_relation
"	
TRUE	D001058	"<span class=""chemical"">Apomorphine</span>"	D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Apomorphine</span>: an underutilized therapy for <span class=""disease"">Parkinson's disease</span>."	761593.0	11009181.0	11009181_D001058_D010300		bcv_easy_189_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014443	"<span class=""chemical"">tyrosine</span>"	D009410	"<span class=""disease"">degeneration of dopaminergic neurons</span>"	"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, <span class=""chemical"">tyrosine</span> hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the <span class=""disease"">degeneration of dopaminergic neurons</span> and increased iron content in the SN of iron dextran overloaded animals."	761593.0	17490790.0	17490790_D014443_D009410		bcv_easy_776_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002216	"<span class=""chemical"">captopril</span>"	D011507	"<span class=""disease"">proteinuria</span>"	"Oral administration of <span class=""chemical"">captopril</span> at 100 mg/kg for 14 days failed to aggravate <span class=""disease"">proteinuria</span> pre-existing in SHR."	761593.0	6454943.0	6454943_D002216_D011507		bcv_easy_588_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013835	"<span class=""chemical"">thiamine pyrophosphate/TPP</span>"	D014899	"<span class=""disease"">Wernicke's encephalopathy</span>"	"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed <span class=""disease"">Wernicke's encephalopathy</span> when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for <span class=""chemical"">thiamine pyrophosphate</span> (<span class=""chemical"">TPP</span>)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome."	761593.0	3762968.0	3762968_D013835_D014899		bcv_easy_723_sent_work_dev_set_761593	"no_relation
"	
TRUE	D003975	"<span class=""chemical"">Diazepam</span>"	D006212	"<span class=""disease"">hallucinations</span>"	"<span class=""chemical"">Diazepam</span>, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative <span class=""disease"">hallucinations</span>."	761593.0	12091028.0	12091028_D003975_D006212		bcv_easy_991_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008687	"<span class=""chemical"">metformin</span>"	D007674	"<span class=""disease"">kidney dysfunction</span>"	"These in vivo markers of <span class=""disease"">kidney dysfunction</span> and their correction by <span class=""chemical"">metformin</span> were complemented by in vitro studies of mitochondrial function."	761593.0	20164825.0	20164825_D008687_D007674		bcv_easy_272_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013629	"<span class=""chemical"">Tamoxifen</span>"	D001943	"<span class=""disease"">breast cancer</span>"	"BACKGROUND: <span class=""chemical"">Tamoxifen</span> is a candidate chemopreventive agent in <span class=""disease"">breast cancer</span>, although the drug may be associated with the development of endometrial cancer."	761593.0	9672273.0	9672273_D013629_D001943		bcv_easy_308_sent_work_dev_set_761593	"no_relation
"	
TRUE	D012254	"<span class=""chemical"">ribavirin</span>"	D000257	"<span class=""disease"">adenovirus disease</span>"	"DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous <span class=""chemical"">ribavirin</span> for documented severe <span class=""disease"">adenovirus disease</span>."	761593.0	12093990.0	12093990_D012254_D000257		bcv_easy_243_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014191	"<span class=""chemical"">tranylcypromine</span>"	D003866	"<span class=""disease"">depression</span>"	"We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking <span class=""chemical"">tranylcypromine</span> for <span class=""disease"">depression</span>."	761593.0	8888541.0	8888541_D014191_D003866		bcv_easy_1107_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004656	"<span class=""chemical"">enalapril</span>"	D003920	"<span class=""disease"">diabetes</span>"	"By multivariate analysis, in both the placebo and <span class=""chemical"">enalapril</span> groups older age, diuretic therapy, and <span class=""disease"">diabetes</span> were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective."	761593.0	10539815.0	10539815_D004656_D003920		bcv_easy_761_sent_work_dev_set_761593	"no_relation
"	
TRUE	D010396	"<span class=""chemical"">D-penicillamine</span>"	D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 67-year-old woman with <span class=""disease"">rheumatoid arthritis</span> presented rapidly progressive glomerulonephritis (RPGN) after 5 months of <span class=""chemical"">D-penicillamine</span> (250 mg/day) treatment."	761593.0	8267029.0	8267029_D010396_D001172		bcv_easy_498_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002122	"<span class=""chemical"">calcium chloride</span>"	D015878	"<span class=""disease"">mydriasis</span>"	"It is apparent that <span class=""chemical"">calcium chloride</span> can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions caused by carbachol and eserine."	761593.0	6892185.0	6892185_D002122_D015878		bcv_easy_1057_sent_work_dev_set_761593	"no_relation
"	
TRUE	D014635	"<span class=""chemical"">Valproate</span>"	D006423	"<span class=""disease"">homonymous hemianopsia</span>"	"Complications were observed in two patients: one had a left <span class=""disease"">homonymous hemianopsia</span> after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with <span class=""chemical"">Valproate</span> 1000 mg/day."	761593.0	19234905.0	19234905_D014635_D006423		bcv_easy_201_sent_work_dev_set_761593	"no_relation
"	
TRUE	D015215	"<span class=""chemical"">azidothymidine</span>"	C565469	"<span class=""disease"">immunodeficient</span>"	"Sensitivity of erythroid progenitor colonies to erythropoietin in <span class=""chemical"">azidothymidine</span> treated <span class=""disease"">immunodeficient</span> mice."	761593.0	2004015.0	2004015_D015215_C565469		bcv_easy_213_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009270	"<span class=""chemical"">naloxone</span>"	D007022	"<span class=""disease"">hypotension</span>"	"Our experience demonstrates a possible role of <span class=""chemical"">naloxone</span> in the reversal of <span class=""disease"">hypotension</span> resulting from captopril."	761593.0	1928887.0	1928887_D009270_D007022		bcv_easy_514_sent_work_dev_set_761593	"no_relation
"	
TRUE	D000617	"<span class=""chemical"">aminoglycoside</span>"	D013924	"<span class=""disease"">Thrombophlebitis</span>"	"<span class=""disease"">Thrombophlebitis</span> occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an <span class=""chemical"">aminoglycoside</span> plus vancomycin."	761593.0	3934126.0	3934126_D000617_D013924		bcv_easy_1143_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008727	"<span class=""chemical"">methotrexate</span>"	D007938	"<span class=""disease"">leukaemia</span>"	"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal <span class=""chemical"">methotrexate</span> for childhood <span class=""disease"">leukaemia</span>."	761593.0	17682013.0	17682013_D008727_D007938		bcv_easy_780_sent_work_dev_set_761593	"no_relation
"	
TRUE	D013999	"<span class=""chemical"">timolol</span>"	D007008	"<span class=""disease"">hypokalemia</span>"	"The beta adrenergic blocking drug, <span class=""chemical"">timolol</span>, tended to correct the <span class=""disease"">hypokalemia</span> of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant."	761593.0	326460.0	326460_D013999_D007008		bcv_easy_394_sent_work_dev_set_761593	"no_relation
"	
TRUE	D004110	"<span class=""chemical"">diltiazem</span>"	D005764	"<span class=""disease"">gastroesophageal reflux disorder</span>"	"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for <span class=""disease"">gastroesophageal reflux disorder</span> and <span class=""chemical"">diltiazem</span>, an agent that has inhibitory effect on CYP3A4, for hypertension."	761593.0	9545159.0	9545159_D004110_D005764		bcv_easy_264_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009270	"<span class=""chemical"">naloxone</span>"	D012133	"<span class=""disease"">respiratory paralysis</span>"	"In this study <span class=""chemical"">naloxone</span> reversed <span class=""disease"">respiratory paralysis</span> induced by thiopental in rats."	761593.0	2893236.0	2893236_D009270_D012133		bcv_easy_441_sent_work_dev_set_761593	"no_relation
"	
TRUE	D005680	"<span class=""chemical"">GABA</span>"	D012133	"<span class=""disease"">respiratory paralysis</span>"	"These data suggest naloxone reverses <span class=""disease"">respiratory paralysis</span> produced by thiopental and involves <span class=""chemical"">GABA</span> in its action."	761593.0	2893236.0	2893236_D005680_D012133		bcv_easy_450_sent_work_dev_set_761593	"no_relation
"	
TRUE	D015742	"<span class=""chemical"">propofol</span>"	D008305	"<span class=""disease"">malignant hyperthermia</span>"	"Anesthesia was continued uneventfully with <span class=""chemical"">propofol</span> infusion while all facilities were available to detect and treat <span class=""disease"">malignant hyperthermia</span>."	761593.0	15893386.0	15893386_D015742_D008305		bcv_easy_1225_sent_work_dev_set_761593	"no_relation
"	
TRUE	C422649	"<span class=""chemical"">Etoricoxib</span>"	D005767	"<span class=""disease"">GI AEs</span>"	"CONCLUSIONS: <span class=""chemical"">Etoricoxib</span> 90 mg demonstrated a significantly lower risk for discontinuing treatment due to <span class=""disease"">GI AEs</span> compared with diclofenac 150 mg."	761593.0	17965424.0	17965424_C422649_D005767		bcv_easy_936_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008094	"<span class=""chemical"">lithium</span>"	D001714	"<span class=""disease"">bipolar disorder</span>"	"PATIENTS: One hundred and one patients (28 men and 73 women) with <span class=""disease"">bipolar disorder</span> receiving <span class=""chemical"">lithium</span> maintenance therapy ranging from 1 year's to 32 years' duration."	761593.0	10354657.0	10354657_D008094_D001714		bcv_easy_1132_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008774	"<span class=""chemical"">methylphenidate</span>"	D061218	"<span class=""disease"">treatment-resistant depression</span>"	"An 82-year-old man with <span class=""disease"">treatment-resistant depression</span> and early Alzheimer's disease was started on <span class=""chemical"">methylphenidate</span>."	761593.0	12907924.0	12907924_D008774_D061218		bcv_easy_398_sent_work_dev_set_761593	"no_relation
"	
TRUE	D011224	"<span class=""chemical"">prazosin</span>"	D001919	"<span class=""disease"">bradycardia</span>"	"Furthermore, the <span class=""disease"">bradycardia</span> that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic <span class=""chemical"">prazosin</span> treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)"	761593.0	1355091.0	1355091_D011224_D001919		bcv_easy_1082_sent_work_dev_set_761593	"no_relation
"	
TRUE	D007980	"<span class=""chemical"">levodopa</span>"	D018476	"<span class=""disease"">bradykinesia</span>"	"Pallidal stimulation improves <span class=""disease"">bradykinesia</span> and rigidity to a minor extent; however, its strength seems to be in improving <span class=""chemical"">levodopa</span>-induced dyskinesias."	761593.0	15096016.0	15096016_D007980_D018476		bcv_easy_842_sent_work_dev_set_761593	"no_relation
"	
TRUE	D010396	"<span class=""chemical"">Penicillamine</span>"	D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"<span class=""chemical"">Penicillamine</span>-induced rapidly progressive glomerulonephritis in a patient with <span class=""disease"">rheumatoid arthritis</span>."	761593.0	8267029.0	8267029_D010396_D001172		bcv_easy_497_sent_work_dev_set_761593	"no_relation
"	
TRUE	D002118	"<span class=""chemical"">calcium</span>"	D003329	"<span class=""disease"">coronary spasm</span>"	"These data suggest that <span class=""disease"">coronary spasm</span> may be the cause of cardiotoxicity due to 5-FU, and that <span class=""chemical"">calcium</span> antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity."	761593.0	3952818.0	3952818_D002118_D003329		bcv_easy_1002_sent_work_dev_set_761593	"no_relation
"	
TRUE	C018824	"<span class=""chemical"">NH4Ac</span>"	D003866	"<span class=""disease"">depression</span>"	"Addition of excess calcium reversed the <span class=""disease"">depression</span> in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by <span class=""chemical"">NH4Ac</span>."	761593.0	6323692.0	6323692_C018824_D003866		bcv_easy_362_sent_work_dev_set_761593	"no_relation
"	
TRUE	D009705	"<span class=""chemical"">nucleosides</span>"	D002545	"<span class=""disease"">cerebral ischemia</span>"	"Time dependence of plasma malondialdehyde, oxypurines, and <span class=""chemical"">nucleosides</span> during incomplete <span class=""disease"">cerebral ischemia</span> in the rat."	761593.0	7710775.0	7710775_D009705_D002545		bcv_easy_944_sent_work_dev_set_761593	"no_relation
"	
TRUE	D008784	"<span class=""chemical"">methysergide</span>"	D004409	"<span class=""disease"">dyskinetic</span>"	"Several drugs, including clonidine, physostigmine, <span class=""chemical"">methysergide</span>, 5-MDOT, propranolol, and MK-801, markedly reduced the <span class=""disease"">dyskinetic</span> movements but at the cost of a return of parkinsonian symptomatology."	761593.0	8106150.0	8106150_D008784_D004409		bcv_easy_1116_sent_work_dev_set_761593	"no_relation
"	
TRUE	D011899	"<span class=""chemical"">ranitidine</span>"	D056486|D006402	"<span class=""disease"">hepatic or hematologic toxicity</span>"	"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or <span class=""chemical"">ranitidine</span> (two to 31 months; median, 14 months) was not associated with <span class=""disease"">hepatic or hematologic toxicity</span> or alterations of serum gastrin concentrations, but <span class=""chemical"">ranitidine</span> therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy."	761593.0	6150641.0	6150641_D011899_D056486|D006402		bcv_easy_328_sent_work_dev_set_761593	"no_relation
"	
	MESH:D015738	"<span class=""chemical"">Famotidine</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"<span class=""chemical"">Famotidine</span>-associated <span class=""disease"">delirium</span>. A series of six cases."		0.0	0_MESH:D015738_MESH:D003693	0_0	bcv_final_eval_easy_0		
	MESH:D006632	"<span class=""chemical"">histamine</span>"	MESH:D014456	"<span class=""disease"">ulcers</span>"	"Famotidine is a <span class=""chemical"">histamine</span> H2-receptor antagonist used in inpatient settings for prevention of stress <span class=""disease"">ulcers</span> and is showing increasing popularity because of its low cost."		0.0	0_MESH:D006632_MESH:D014456	0_1	bcv_final_eval_easy_1		
	MESH:D015738	"<span class=""chemical"">Famotidine</span>"	MESH:D014456	"<span class=""disease"">ulcers</span>"	"<span class=""chemical"">Famotidine</span> is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress <span class=""disease"">ulcers</span> and is showing increasing popularity because of its low cost."		0.0	0_MESH:D015738_MESH:D014456	0_1	bcv_final_eval_easy_2		
	MESH:D015738	"<span class=""chemical"">famotidine</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"Although all of the currently available H2-receptor antagonists have shown the propensity to cause <span class=""disease"">delirium</span>, only two previously reported cases have been associated with <span class=""chemical"">famotidine</span>."		0.0	0_MESH:D015738_MESH:D003693	0_2	bcv_final_eval_easy_3		
	MESH:D015738	"<span class=""chemical"">famotidine</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"The authors report on six cases of <span class=""chemical"">famotidine</span>-associated <span class=""disease"">delirium</span> in hospitalized patients who cleared completely upon removal of <span class=""chemical"">famotidine</span>."		0.0	0_MESH:D015738_MESH:D003693	0_3	bcv_final_eval_easy_4		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Indomethacin induced <span class=""disease"">hypotension</span> in <span class=""chemical"">sodium</span> and volume depleted rats."		1.0	1_MESH:D012964_MESH:D007022	1_0	bcv_final_eval_easy_5		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D007674	"<span class=""disease"">scleroderma renal crisis</span>"	"Late-onset <span class=""disease"">scleroderma renal crisis</span> induced by <span class=""chemical"">tacrolimus</span> and prednisolone: a case report."		2.0	2_MESH:D016559_MESH:D007674	2_0	bcv_final_eval_easy_6		
	MESH:D011239	"<span class=""chemical"">prednisolone</span>"	MESH:D007674	"<span class=""disease"">scleroderma renal crisis</span>"	"Late-onset <span class=""disease"">scleroderma renal crisis</span> induced by tacrolimus and <span class=""chemical"">prednisolone</span>: a case report."		2.0	2_MESH:D011239_MESH:D007674	2_0	bcv_final_eval_easy_7		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D012595	"<span class=""disease"">SSc</span>"	"Furthermore, there have been reports of thrombotic microangiopathy precipitated by <span class=""chemical"">cyclosporine</span> in patients with <span class=""disease"">SSc</span>."		2.0	2_MESH:D016572_MESH:D012595	2_3	bcv_final_eval_easy_8		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D057049	"<span class=""disease"">thrombotic microangiopathy</span>"	"Furthermore, there have been reports of <span class=""disease"">thrombotic microangiopathy</span> precipitated by <span class=""chemical"">cyclosporine</span> in patients with SSc."		2.0	2_MESH:D016572_MESH:D057049	2_3	bcv_final_eval_easy_9		
	MESH:D000305	"<span class=""chemical"">corticosteroids</span>"	MESH:D007674	"<span class=""disease"">SRC</span>"	"In this article, we report a patient with <span class=""disease"">SRC</span> induced by tacrolimus and <span class=""chemical"">corticosteroids</span>."		2.0	2_MESH:D000305_MESH:D007674	2_4	bcv_final_eval_easy_10		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D007674	"<span class=""disease"">SRC</span>"	"In this article, we report a patient with <span class=""disease"">SRC</span> induced by <span class=""chemical"">tacrolimus</span> and corticosteroids."		2.0	2_MESH:D016559_MESH:D007674	2_4	bcv_final_eval_easy_11		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D012595	"<span class=""disease"">SSc</span>"	"The aim of this work is to call attention to the risk of <span class=""chemical"">tacrolimus</span> use in patients with <span class=""disease"">SSc</span>."		2.0	2_MESH:D016559_MESH:D012595	2_5	bcv_final_eval_easy_12		
	MESH:D008694	"<span class=""chemical"">methamphetamine</span>"	MESH:D001523	"<span class=""disease"">Axis I psychiatric disorders</span>"	"Patients with the diagnosis of <span class=""chemical"">methamphetamine</span> based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for <span class=""chemical"">methamphetamine</span>-induced psychosis and other <span class=""disease"">Axis I psychiatric disorders</span>."		3.0	3_MESH:D008694_MESH:D001523	3_4	bcv_final_eval_easy_13		
	MESH:D008694	"<span class=""chemical"">methamphetamine</span>"	MESH:D001714	"<span class=""disease"">bipolar disorder</span>"	"Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), <span class=""disease"">bipolar disorder</span> (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy <span class=""chemical"">methamphetamine</span> uses were significantly associated with lifetime <span class=""chemical"">methamphetamine</span>-induced psychosis after adjusted for other factors."		3.0	3_MESH:D008694_MESH:D001714	3_7	bcv_final_eval_easy_14		
	MESH:D008694	"<span class=""chemical"">methamphetamine</span>"	MESH:D000987	"<span class=""disease"">antisocial personality disorder</span>"	"Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), <span class=""disease"">antisocial personality disorder</span> (OR=12.619, 95 CI=6.702-23.759) and heavy <span class=""chemical"">methamphetamine</span> uses were significantly associated with lifetime <span class=""chemical"">methamphetamine</span>-induced psychosis after adjusted for other factors."		3.0	3_MESH:D008694_MESH:D000987	3_7	bcv_final_eval_easy_15		
	MESH:D008694	"<span class=""chemical"">methamphetamine</span>"	MESH:D003866	"<span class=""disease"">depressive disorder</span>"	"Co-morbid major <span class=""disease"">depressive disorder</span> (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy <span class=""chemical"">methamphetamine</span> uses were significantly associated with lifetime <span class=""chemical"">methamphetamine</span>-induced psychosis after adjusted for other factors."		3.0	3_MESH:D008694_MESH:D003866	3_7	bcv_final_eval_easy_16		
	MESH:D008694	"<span class=""chemical"">methamphetamine</span>"	MESH:D000987	"<span class=""disease"">, antisocial personality</span>"	"It was associated with co-morbid affective disorder<span class=""disease"">, antisocial personality</span>, and heavy <span class=""chemical"">methamphetamine</span> use."		3.0	3_MESH:D008694_MESH:D000987	3_10	bcv_final_eval_easy_17		
	MESH:D008694	"<span class=""chemical"">methamphetamine</span>"	MESH:D011618	"<span class=""disease"">psychotic symptoms</span>"	"It is recommended that all cases of <span class=""chemical"">methamphetamine</span> dependence should be screened for <span class=""disease"">psychotic symptoms</span>."		3.0	3_MESH:D008694_MESH:D011618	3_11	bcv_final_eval_easy_18		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D004409	"<span class=""disease"">LIDs/levodopa-induced dyskinesias</span>"	"The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and <span class=""chemical""></span><span class=""disease"">levodopa</span>-induced dyskinesias (<span class=""disease"">LIDs</span>) is severely impaired."		4.0	4_MESH:D007980_MESH:D004409	4_1	bcv_final_eval_easy_19		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease/PD</span>"	"The plasticity of primary motor cortex (M1) in patients with <span class=""disease"">Parkinson's disease</span> (<span class=""disease"">PD</span>) and <span class=""chemical"">levodopa</span>-induced dyskinesias (LIDs) is severely impaired."		4.0	4_MESH:D007980_MESH:D010300	4_1	bcv_final_eval_easy_20		
	MESH:D003520	"<span class=""chemical"">Cyclophosphamide</span>"	MESH:D010146	"<span class=""disease"">pain behaviors</span>"	"RESULTS: <span class=""chemical"">Cyclophosphamide</span> treatment increased the spontaneous <span class=""disease"">pain behaviors</span> scores."		5.0	5_MESH:D003520_MESH:D010146	5_8	bcv_final_eval_easy_21		
	MESH:C055162	"<span class=""chemical"">clopidogrel</span>"	MESH:D056486	"<span class=""disease"">hepatitis</span>"	"Acute <span class=""disease"">hepatitis</span> associated with <span class=""chemical"">clopidogrel</span>: a case report and review of the literature."		6.0	6_MESH:C055162_MESH:D056486	6_0	bcv_final_eval_easy_22		
	MESH:C055162	"<span class=""chemical"">clopidogrel</span>"	MESH:D056486	"<span class=""disease"">hepatitis</span>"	"We describe a case of <span class=""chemical"">clopidogrel</span>-related acute <span class=""disease"">hepatitis</span>."		6.0	6_MESH:C055162_MESH:D056486	6_2	bcv_final_eval_easy_23		
	MESH:C055162	"<span class=""chemical"">clopidogrel</span>"	MESH:D056486	"<span class=""disease"">hepatic injury</span>"	"In conclusion, we believe that physicians should carefully consider the risk of drug-induced <span class=""disease"">hepatic injury</span> when <span class=""chemical"">clopidogrel</span> is prescribed."		6.0	6_MESH:C055162_MESH:D056486	6_5	bcv_final_eval_easy_24		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D009101	"<span class=""disease"">multiple myeloma</span>"	"Bortezomib and <span class=""chemical"">dexamethasone</span> as salvage therapy in patients with relapsed/refractory <span class=""disease"">multiple myeloma</span>: analysis of long-term clinical outcomes."		7.0	7_MESH:D003907_MESH:D009101	7_0	bcv_final_eval_easy_25		
	MESH:C400082	"<span class=""chemical"">Bortezomib</span>"	MESH:D009101	"<span class=""disease"">multiple myeloma</span>"	"<span class=""chemical"">Bortezomib</span> and dexamethasone as salvage therapy in patients with relapsed/refractory <span class=""disease"">multiple myeloma</span>: analysis of long-term clinical outcomes."		7.0	7_MESH:C400082_MESH:D009101	7_0	bcv_final_eval_easy_26		
	MESH:D003907	"<span class=""chemical"">dex/dexamethasone</span>"	MESH:D009101	"<span class=""disease"">MM/multiple myeloma</span>"	"Bortezomib (bort)-<span class=""chemical"">dexamethasone</span> (<span class=""chemical"">dex</span>) is an effective therapy for relapsed/refractory (R/R) <span class=""disease"">multiple myeloma</span> (<span class=""disease"">MM</span>)."		7.0	7_MESH:D003907_MESH:D009101	7_1	bcv_final_eval_easy_27		
	MESH:C400082	"<span class=""chemical"">Bortezomib</span>"	MESH:D009101	"<span class=""disease"">MM/multiple myeloma</span>"	"<span class=""chemical"">Bortezomib</span> (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) <span class=""disease"">multiple myeloma</span> (<span class=""disease"">MM</span>)."		7.0	7_MESH:C400082_MESH:D009101	7_1	bcv_final_eval_easy_28		
	MESH:D003907	"<span class=""chemical"">dex</span>"	MESH:D009101	"<span class=""disease"">MM</span>"	"This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and <span class=""chemical"">dex</span> (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R <span class=""disease"">MM</span> after prior autologous stem cell transplantation or conventional chemotherapy."		7.0	7_MESH:D003907_MESH:D009101	7_2	bcv_final_eval_easy_29		
	MESH:D003907	"<span class=""chemical"">dex</span>"	MESH:D011475	"<span class=""disease"">OS</span>"	"Prolonged PFS and <span class=""disease"">OS</span> were observed in patients achieving CR and receiving bort-<span class=""chemical"">dex</span> a single line of prior therapy."		7.0	7_MESH:D003907_MESH:D011475	7_10	bcv_final_eval_easy_30		
	MESH:C006780	"<span class=""chemical"">Bisphenol A</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"Pubertal exposure to <span class=""chemical"">Bisphenol A</span> increases <span class=""disease"">anxiety</span>-like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice."		8.0	8_MESH:C006780_MESH:D001008	8_0	bcv_final_eval_easy_31		
	MESH:C006780	"<span class=""chemical"">BPA</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"Results from our behavioral phenotyping indicated that <span class=""disease"">anxiety</span>-like behavior was increased in mice exposed to <span class=""chemical"">BPA</span>."		8.0	8_MESH:C006780_MESH:D001008	8_7	bcv_final_eval_easy_32		
	MESH:C006780	"<span class=""chemical"">BPA</span>"	MESH:D007029	"<span class=""disease"">hypothalamus</span>"	"AChE activity was significantly decreased in the hippocampus of mice with <span class=""chemical"">BPA</span> compared to control mice, whereas no difference was found in the prefrontal cortex, <span class=""disease"">hypothalamus</span> and cerebellum."		8.0	8_MESH:C006780_MESH:D007029	8_8	bcv_final_eval_easy_33		
	MESH:C006780	"<span class=""chemical"">BPA</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"Our findings showed that pubertal <span class=""chemical"">BPA</span> exposure increased <span class=""disease"">anxiety</span>-like behavior, which may be associated with decreased AChE activity of the hippocampus in adult male mice."		8.0	8_MESH:C006780_MESH:D001008	8_9	bcv_final_eval_easy_34		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D009101	"<span class=""disease"">myeloma</span>"	"""Real-world"" data on the efficacy and safety of lenalidomide and <span class=""chemical"">dexamethasone</span> in patients with relapsed/refractory multiple <span class=""disease"">myeloma</span> who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group."		10.0	10_MESH:D003907_MESH:D009101	10_0	bcv_final_eval_easy_35		
	MESH:C467567	"<span class=""chemical"">lenalidomide</span>"	MESH:D009101	"<span class=""disease"">myeloma</span>"	"""Real-world"" data on the efficacy and safety of <span class=""chemical"">lenalidomide</span> and dexamethasone in patients with relapsed/refractory multiple <span class=""disease"">myeloma</span> who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group."		10.0	10_MESH:C467567_MESH:D009101	10_0	bcv_final_eval_easy_36		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D009101	"<span class=""disease"">myeloma</span>"	"Lenalidomide and <span class=""chemical"">dexamethasone</span> (RD) is a standard of care for relapsed/refractory multiple <span class=""disease"">myeloma</span> (RRMM), but there is limited published data on its efficacy and safety in the ""real world"" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition."		10.0	10_MESH:D003907_MESH:D009101	10_1	bcv_final_eval_easy_37		
	MESH:C467567	"<span class=""chemical"">Lenalidomide</span>"	MESH:D009101	"<span class=""disease"">myeloma</span>"	"<span class=""chemical"">Lenalidomide</span> and dexamethasone (RD) is a standard of care for relapsed/refractory multiple <span class=""disease"">myeloma</span> (RRMM), but there is limited published data on its efficacy and safety in the ""real world"" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition."		10.0	10_MESH:C467567_MESH:D009101	10_1	bcv_final_eval_easy_38		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"Risk factors and predictors of <span class=""chemical"">levodopa</span>-induced dyskinesia among multiethnic Malaysians with <span class=""disease"">Parkinson's disease</span>."		12.0	12_MESH:D007980_MESH:D010300	12_0	bcv_final_eval_easy_39		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease/PD</span>"	"Chronic pulsatile <span class=""chemical"">levodopa</span> therapy for <span class=""disease"">Parkinson's disease</span> (<span class=""disease"">PD</span>) leads to the development of motor fluctuations and dyskinesia."		12.0	12_MESH:D007980_MESH:D010300	12_1	bcv_final_eval_easy_40		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">PD</span>"	"We studied the prevalence and predictors of <span class=""chemical"">levodopa</span>-induced dyskinesia among multiethnic Malaysian patients with <span class=""disease"">PD</span>."		12.0	12_MESH:D007980_MESH:D010300	12_2	bcv_final_eval_easy_41		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">PD</span>"	"METHODS: This is a cross-sectional study involving 95 patients with <span class=""disease"">PD</span> on uninterrupted <span class=""chemical"">levodopa</span> therapy for at least 6 months."		12.0	12_MESH:D007980_MESH:D010300	12_3	bcv_final_eval_easy_42		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D004194	"<span class=""disease"">longer disease duration</span>"	"Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of <span class=""chemical"">levodopa</span> therapy ( p < 0.001), <span class=""disease"">longer disease duration</span> ( p < 0.001), higher total daily <span class=""chemical"">levodopa</span> dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia."		12.0	12_MESH:D007980_MESH:D004194	12_12	bcv_final_eval_easy_43		
	MESH:C107135	"<span class=""chemical"">everolimus</span>"	MESH:D009101	"<span class=""disease"">AL amyloidosis</span>"	"An unexpected diagnosis in a renal-transplant patient with proteinuria treated with <span class=""chemical"">everolimus</span>: <span class=""disease"">AL amyloidosis</span>."		13.0	13_MESH:C107135_MESH:D009101	13_0	bcv_final_eval_easy_44		
	MESH:C107135	"<span class=""chemical"">everolimus</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"An unexpected diagnosis in a renal-transplant patient with <span class=""disease"">proteinuria</span> treated with <span class=""chemical"">everolimus</span>: AL amyloidosis."		13.0	13_MESH:C107135_MESH:D011507	13_0	bcv_final_eval_easy_45		
	MESH:D020123	"<span class=""chemical"">rapamycin</span>"	MESH:D011507	"<span class=""disease"">Proteinuria</span>"	"<span class=""disease"">Proteinuria</span> is an expected complication in transplant patients treated with mammalian target of <span class=""chemical"">rapamycin</span> inhibitors (mTOR-i)."		13.0	13_MESH:D020123_MESH:D011507	13_1	bcv_final_eval_easy_46		
	MESH:C107135	"<span class=""chemical"">everolimus</span>"	MESH:D010265	"<span class=""disease"">monoclonal gammapathy</span>"	"In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant <span class=""disease"">monoclonal gammapathy</span> of undetermined significance who developed proteinuria after conversion from tacrolimus to <span class=""chemical"">everolimus</span>."		13.0	13_MESH:C107135_MESH:D010265	13_3	bcv_final_eval_easy_47		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D000686	"<span class=""disease"">amyloidosis</span>"	"In this case we report the unexpected diagnosis of <span class=""disease"">amyloidosis</span> in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from <span class=""chemical"">tacrolimus</span> to everolimus."		13.0	13_MESH:D016559_MESH:D000686	13_3	bcv_final_eval_easy_48		
	MESH:C107135	"<span class=""chemical"">everolimus</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed <span class=""disease"">proteinuria</span> after conversion from tacrolimus to <span class=""chemical"">everolimus</span>."		13.0	13_MESH:C107135_MESH:D011507	13_3	bcv_final_eval_easy_49		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D010265	"<span class=""disease"">monoclonal gammapathy</span>"	"In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant <span class=""disease"">monoclonal gammapathy</span> of undetermined significance who developed proteinuria after conversion from <span class=""chemical"">tacrolimus</span> to everolimus."		13.0	13_MESH:D016559_MESH:D010265	13_3	bcv_final_eval_easy_50		
	MESH:C107135	"<span class=""chemical"">everolimus</span>"	MESH:D000686	"<span class=""disease"">amyloidosis</span>"	"In this case we report the unexpected diagnosis of <span class=""disease"">amyloidosis</span> in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to <span class=""chemical"">everolimus</span>."		13.0	13_MESH:C107135_MESH:D000686	13_3	bcv_final_eval_easy_51		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed <span class=""disease"">proteinuria</span> after conversion from <span class=""chemical"">tacrolimus</span> to everolimus."		13.0	13_MESH:D016559_MESH:D011507	13_3	bcv_final_eval_easy_52		
	MESH:C418563	"<span class=""chemical"">tenofovir disoproxil fumarate</span>"	MESH:D007674	"<span class=""disease"">kidney injury</span>"	"An investigation of the pattern of <span class=""disease"">kidney injury</span> in HIV-positive persons exposed to <span class=""chemical"">tenofovir disoproxil fumarate</span>: an examination of a large population database (MHRA database)."		14.0	14_MESH:C418563_MESH:D007674	14_0	bcv_final_eval_easy_53		
	MESH:C096918	"<span class=""chemical"">tenofovir</span>"	MESH:D007674	"<span class=""disease"">kidney syndromes</span>"	"The potential for <span class=""chemical"">tenofovir</span> to cause a range of <span class=""disease"">kidney syndromes</span> has been established from mechanistic and randomised clinical trials."		14.0	14_MESH:C096918_MESH:D007674	14_1	bcv_final_eval_easy_54		
	MESH:D013874	"<span class=""chemical"">thiopentone</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"The use of <span class=""chemical"">thiopentone</span> was significantly associated with an eight-fold-higher risk for <span class=""disease"">delirium</span> compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02)."		15.0	15_MESH:D013874_MESH:D003693	15_9	bcv_final_eval_easy_55		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"The use of thiopentone was significantly associated with an eight-fold-higher risk for <span class=""disease"">delirium</span> compared to <span class=""chemical"">propofol</span> (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02)."		15.0	15_MESH:D015742_MESH:D003693	15_9	bcv_final_eval_easy_56		
	MESH:D008694	"<span class=""chemical"">methamphetamine</span>"	MESH:D003866	"<span class=""disease"">depressive</span>"	"A single neurotoxic dose of <span class=""chemical"">methamphetamine</span> induces a long-lasting <span class=""disease"">depressive</span>-like behaviour in mice."		16.0	16_MESH:D008694_MESH:D003866	16_0	bcv_final_eval_easy_57		
	MESH:D008694	"<span class=""chemical"">Methamphetamine/METH</span>"	MESH:D003866	"<span class=""disease"">depressive symptoms</span>"	"<span class=""chemical"">Methamphetamine</span> (<span class=""chemical"">METH</span>) triggers a disruption of the monoaminergic system and <span class=""chemical"">METH</span> abuse leads to negative emotional states including <span class=""disease"">depressive symptoms</span> during drug withdrawal."		16.0	16_MESH:D008694_MESH:D003866	16_1	bcv_final_eval_easy_58		
	MESH:D008694	"<span class=""chemical"">METH</span>"	MESH:D003866	"<span class=""disease"">depressive phenotype</span>"	"However, it is currently unknown if the acute toxic dosage of <span class=""chemical"">METH</span> also causes a long-lasting <span class=""disease"">depressive phenotype</span> and persistent monoaminergic deficits."		16.0	16_MESH:D008694_MESH:D003866	16_2	bcv_final_eval_easy_59		
	MESH:D008694	"<span class=""chemical"">METH</span>"	MESH:D003866	"<span class=""disease"">depressive</span>"	"Thus, we now assessed the <span class=""disease"">depressive</span>-like behaviour in mice at early and long-term periods following a single high <span class=""chemical"">METH</span> dose (30 mg/kg, i.p.)."		16.0	16_MESH:D008694_MESH:D003866	16_3	bcv_final_eval_easy_60		
	MESH:D014443	"<span class=""chemical"">tyrosine</span>"	MESH:D003866	"<span class=""disease"">depressive</span>"	"This <span class=""disease"">depressive</span>-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, <span class=""chemical"">tyrosine</span> hydroxylase and serotonin, observed at both 3 and 49 days post-administration."		16.0	16_MESH:D014443_MESH:D003866	16_6	bcv_final_eval_easy_61		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D003866	"<span class=""disease"">depressive</span>"	"This <span class=""disease"">depressive</span>-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of <span class=""chemical"">dopamine</span>, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration."		16.0	16_MESH:D004298_MESH:D003866	16_6	bcv_final_eval_easy_62		
	MESH:D008694	"<span class=""chemical"">METH</span>"	MESH:D003866	"<span class=""disease"">depressive</span>"	"This <span class=""disease"">depressive</span>-like profile induced by <span class=""chemical"">METH</span> was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration."		16.0	16_MESH:D008694_MESH:D003866	16_6	bcv_final_eval_easy_63		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D003866	"<span class=""disease"">depressive</span>"	"This <span class=""disease"">depressive</span>-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and <span class=""chemical"">serotonin</span>, observed at both 3 and 49 days post-administration."		16.0	16_MESH:D012701_MESH:D003866	16_6	bcv_final_eval_easy_64		
	MESH:D015102	"<span class=""chemical"">DOPAC</span>"	MESH:D003866	"<span class=""disease"">depressive</span>"	"This <span class=""disease"">depressive</span>-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, <span class=""chemical"">DOPAC</span> and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration."		16.0	16_MESH:D015102_MESH:D003866	16_6	bcv_final_eval_easy_65		
	MESH:D008694	"<span class=""chemical"">METH</span>"	MESH:D003866	"<span class=""disease"">depressive</span>"	"These findings demonstrate for the first time that a single high dose of <span class=""chemical"">METH</span> induces long-lasting <span class=""disease"">depressive</span>-like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis."		16.0	16_MESH:D008694_MESH:D003866	16_8	bcv_final_eval_easy_66		
	MESH:C098010	"<span class=""chemical"">linezolid</span>"	MESH:D054062	"<span class=""disease"">loss of vision</span>"	"We describe a case of progressive <span class=""disease"">loss of vision</span> associated with <span class=""chemical"">linezolid</span> therapy."		17.0	17_MESH:C098010_MESH:D054062	17_3	bcv_final_eval_easy_67		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D014376	"<span class=""disease"">tuberculous</span>"	"A 45-year-old male patient who was on treatment with multiple second-line anti-<span class=""disease"">tuberculous</span> drugs including linezolid and <span class=""chemical"">ethambutol</span> for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes."		17.0	17_MESH:D004977_MESH:D014376	17_4	bcv_final_eval_easy_68		
	MESH:C098010	"<span class=""chemical"">linezolid</span>"	MESH:D018088	"<span class=""disease"">drug-resistant tuberculosis</span>"	"A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including <span class=""chemical"">linezolid</span> and ethambutol for extensively <span class=""disease"">drug-resistant tuberculosis</span> (XDR-TB) presented to us with painless progressive loss of vision in both eyes."		17.0	17_MESH:C098010_MESH:D018088	17_4	bcv_final_eval_easy_69		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D054908	"<span class=""disease"">XDR-TB</span>"	"A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and <span class=""chemical"">ethambutol</span> for extensively drug-resistant tuberculosis (<span class=""disease"">XDR-TB</span>) presented to us with painless progressive loss of vision in both eyes."		17.0	17_MESH:D004977_MESH:D054908	17_4	bcv_final_eval_easy_70		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D054062	"<span class=""disease"">loss of vision</span>"	"A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and <span class=""chemical"">ethambutol</span> for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive <span class=""disease"">loss of vision</span> in both eyes."		17.0	17_MESH:D004977_MESH:D054062	17_4	bcv_final_eval_easy_71		
	MESH:C098010	"<span class=""chemical"">linezolid</span>"	MESH:D014376	"<span class=""disease"">tuberculous</span>"	"A 45-year-old male patient who was on treatment with multiple second-line anti-<span class=""disease"">tuberculous</span> drugs including <span class=""chemical"">linezolid</span> and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes."		17.0	17_MESH:C098010_MESH:D014376	17_4	bcv_final_eval_easy_72		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D018088	"<span class=""disease"">drug-resistant tuberculosis</span>"	"A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and <span class=""chemical"">ethambutol</span> for extensively <span class=""disease"">drug-resistant tuberculosis</span> (XDR-TB) presented to us with painless progressive loss of vision in both eyes."		17.0	17_MESH:D004977_MESH:D018088	17_4	bcv_final_eval_easy_73		
	MESH:C098010	"<span class=""chemical"">linezolid</span>"	MESH:D054062	"<span class=""disease"">loss of vision</span>"	"A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including <span class=""chemical"">linezolid</span> and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive <span class=""disease"">loss of vision</span> in both eyes."		17.0	17_MESH:C098010_MESH:D054062	17_4	bcv_final_eval_easy_74		
	MESH:C098010	"<span class=""chemical"">linezolid</span>"	MESH:D054908	"<span class=""disease"">XDR-TB</span>"	"A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including <span class=""chemical"">linezolid</span> and ethambutol for extensively drug-resistant tuberculosis (<span class=""disease"">XDR-TB</span>) presented to us with painless progressive loss of vision in both eyes."		17.0	17_MESH:C098010_MESH:D054908	17_4	bcv_final_eval_easy_75		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D014786	"<span class=""disease"">Deterioration of vision</span>"	"<span class=""disease"">Deterioration of vision</span> occurred despite withdrawal of <span class=""chemical"">ethambutol</span>."		17.0	17_MESH:D004977_MESH:D014786	17_7	bcv_final_eval_easy_76		
	MESH:C098010	"<span class=""chemical"">linezolid</span>"	MESH:D014786	"<span class=""disease"">improvement of vision</span>"	"Discontinuation of <span class=""chemical"">linezolid</span> resulted in marked <span class=""disease"">improvement of vision</span>."		17.0	17_MESH:C098010_MESH:D014786	17_8	bcv_final_eval_easy_77		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D066126	"<span class=""disease"">cardiac toxicity</span>"	"Resuscitation with lipid, <span class=""chemical"">epinephrine</span>, or both in levobupivacaine-induced <span class=""disease"">cardiac toxicity</span> in newborn piglets."		18.0	18_MESH:D004837_MESH:D066126	18_0	bcv_final_eval_easy_78		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: The optimal dosing regimens of lipid emulsion, <span class=""chemical"">epinephrine</span>, or both are not yet determined in neonates in cases of local anaesthetic systemic <span class=""disease"">toxicity</span> (LAST)."		18.0	18_MESH:D004837_MESH:D064420	18_1	bcv_final_eval_easy_79		
	MESH:C476513	"<span class=""chemical"">levobupivacaine</span>"	MESH:D002318	"<span class=""disease"">cardiovascular collapse</span>"	"METHODS: Newborn piglets received <span class=""chemical"">levobupivacaine</span> until <span class=""disease"">cardiovascular collapse</span> occurred."		18.0	18_MESH:C476513_MESH:D002318	18_2	bcv_final_eval_easy_80		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:C566094	"<span class=""disease"">HIT type II</span>"	"The impact of immune-mediated <span class=""chemical"">heparin</span>-induced thrombocytopenia type II (<span class=""disease"">HIT type II</span>) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results."		19.0	19_MESH:D006493_MESH:C566094	19_2	bcv_final_eval_easy_81		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:C566094	"<span class=""disease"">HIT type II</span>"	"For further reduction of <span class=""disease"">HIT type II</span>, the use of intravenous <span class=""chemical"">heparin</span> should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight <span class=""chemical"">heparin</span> after normalization of platelet count."		19.0	19_MESH:D006493_MESH:C566094	19_10	bcv_final_eval_easy_82		
	MESH:C089750	"<span class=""chemical"">Zolmitriptan</span>"	MESH:D054549	"<span class=""disease"">Takotsubo syndrome/apical ballooning syndrome</span>"	"<span class=""disease"">Takotsubo syndrome</span> (or <span class=""disease"">apical ballooning syndrome</span>) secondary to <span class=""chemical"">Zolmitriptan</span>."		20.0	20_MESH:C089750_MESH:D054549	20_0	bcv_final_eval_easy_83		
	MESH:C089750	"<span class=""chemical"">zolmitriptan</span>"	MESH:D008881	"<span class=""disease"">migraines</span>"	"Detailed history obtained retrospectively revealed that the patient took <span class=""chemical"">zolmitriptan</span> sparingly only when she had <span class=""disease"">migraines</span>."		20.0	20_MESH:C089750_MESH:D008881	20_4	bcv_final_eval_easy_84		
	MESH:C089750	"<span class=""chemical"">zolmitriptan</span>"	MESH:D006261	"<span class=""disease"">headache</span>"	"But before this event, she was taking <span class=""chemical"">zolmitriptan</span> 2-3 times daily for several days because of a persistent migraine <span class=""disease"">headache</span>."		20.0	20_MESH:C089750_MESH:D006261	20_5	bcv_final_eval_easy_85		
	MESH:C089750	"<span class=""chemical"">zolmitriptan</span>"	MESH:D008881	"<span class=""disease"">migraine</span>"	"But before this event, she was taking <span class=""chemical"">zolmitriptan</span> 2-3 times daily for several days because of a persistent <span class=""disease"">migraine</span> headache."		20.0	20_MESH:C089750_MESH:D008881	20_5	bcv_final_eval_easy_86		
	MESH:C089750	"<span class=""chemical"">zolmitriptan</span>"	MESH:D003324	"<span class=""disease"">coronary artery</span>"	"Extensive literature search revealed multiple cases of <span class=""disease"">coronary artery</span> vasospasm secondary to <span class=""chemical"">zolmitriptan</span>, but none of the cases were associated with TS."		20.0	20_MESH:C089750_MESH:D003324	20_8	bcv_final_eval_easy_87		
	MESH:C089750	"<span class=""chemical"">zolmitriptan</span>"	MESH:D054549	"<span class=""disease"">TS</span>"	"Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to <span class=""chemical"">zolmitriptan</span>, but none of the cases were associated with <span class=""disease"">TS</span>."		20.0	20_MESH:C089750_MESH:D054549	20_8	bcv_final_eval_easy_88		
	MESH:D018817	"<span class=""chemical"">MDMA/3,4-methylenedioxymethamphetamine/ecstasy</span>"	MESH:D003866	"<span class=""disease"">Depression</span>"	"<span class=""disease"">Depression</span>, impulsiveness, sleep, and memory in past and present polydrug users of <span class=""chemical"">3,4-methylenedioxymethamphetamine</span> (<span class=""chemical"">MDMA</span>, <span class=""chemical"">ecstasy</span>)."		21.0	21_MESH:D018817_MESH:D003866	21_0	bcv_final_eval_easy_89		
	MESH:D018817	"<span class=""chemical"">MDMA/3,4-methylenedioxymethamphetamine/ecstasy</span>"	MESH:D007174	"<span class=""disease"">impulsiveness</span>"	"Depression, <span class=""disease"">impulsiveness</span>, sleep, and memory in past and present polydrug users of <span class=""chemical"">3,4-methylenedioxymethamphetamine</span> (<span class=""chemical"">MDMA</span>, <span class=""chemical"">ecstasy</span>)."		21.0	21_MESH:D018817_MESH:D007174	21_0	bcv_final_eval_easy_90		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D003072	"<span class=""disease"">increased impairment</span>"	"Compared with present <span class=""chemical"">ecstasy</span> users, the past users showed no change for ten measures, <span class=""disease"">increased impairment</span> for two measures, and improvement on just one measure."		21.0	21_MESH:D018817_MESH:D003072	21_8	bcv_final_eval_easy_91		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of <span class=""disease"">depression</span>, impulsiveness, and sleep disturbance, the prognosis for the current generation of <span class=""chemical"">ecstasy</span> users is a major cause for concern."		21.0	21_MESH:D018817_MESH:D003866	21_9	bcv_final_eval_easy_92		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D012893	"<span class=""disease"">sleep disturbance</span>"	"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and <span class=""disease"">sleep disturbance</span>, the prognosis for the current generation of <span class=""chemical"">ecstasy</span> users is a major cause for concern."		21.0	21_MESH:D018817_MESH:D012893	21_9	bcv_final_eval_easy_93		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D008569	"<span class=""disease"">impaired memory</span>"	"CONCLUSIONS: Given this record of <span class=""disease"">impaired memory</span> and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of <span class=""chemical"">ecstasy</span> users is a major cause for concern."		21.0	21_MESH:D018817_MESH:D008569	21_9	bcv_final_eval_easy_94		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D007174	"<span class=""disease"">impulsiveness</span>"	"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, <span class=""disease"">impulsiveness</span>, and sleep disturbance, the prognosis for the current generation of <span class=""chemical"">ecstasy</span> users is a major cause for concern."		21.0	21_MESH:D018817_MESH:D007174	21_9	bcv_final_eval_easy_95		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"Association of common genetic variants of HOMER1 gene with <span class=""chemical"">levodopa</span> adverse effects in <span class=""disease"">Parkinson's disease</span> patients."		22.0	22_MESH:D007980_MESH:D010300	22_0	bcv_final_eval_easy_96		
	MESH:D007980	"<span class=""chemical"">Levodopa</span>"	MESH:D004409	"<span class=""disease"">dyskinesia</span>"	"<span class=""chemical"">Levodopa</span> is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, <span class=""disease"">dyskinesia</span> and visual hallucinations."		22.0	22_MESH:D007980_MESH:D004409	22_1	bcv_final_eval_easy_97		
	MESH:D007980	"<span class=""chemical"">Levodopa</span>"	MESH:D006212	"<span class=""disease"">visual hallucinations</span>"	"<span class=""chemical"">Levodopa</span> is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and <span class=""disease"">visual hallucinations</span>."		22.0	22_MESH:D007980_MESH:D006212	22_1	bcv_final_eval_easy_98		
	MESH:D007980	"<span class=""chemical"">Levodopa</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Levodopa</span> is the most effective symptomatic therapy for <span class=""disease"">Parkinson's disease</span>, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations."		22.0	22_MESH:D007980_MESH:D010300	22_1	bcv_final_eval_easy_99		
	MESH:C029036	"<span class=""chemical"">Crocin</span>"	MESH:D006949	"<span class=""disease"">hyperlipemia</span>"	"<span class=""chemical"">Crocin</span> reduced inhibition of ERK activation and diazinon-induced <span class=""disease"">hyperlipemia</span> and increased levels of LDLr transcript."		23.0	23_MESH:C029036_MESH:D006949	23_12	bcv_final_eval_easy_100		
	MESH:C029036	"<span class=""chemical"">Crocin</span>"	MESH:D006949	"<span class=""disease"">hyperlipemia</span>"	"CONCLUSIONS: <span class=""chemical"">Crocin</span> may be considered as a novel protective agent in diazinon-induced <span class=""disease"">hyperlipemia</span> through modulating of ERK pathway and increase of LDLr expression."		23.0	23_MESH:C029036_MESH:D006949	23_13	bcv_final_eval_easy_101		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D006689	"<span class=""disease"">HL</span>"	"Gemcitabine and <span class=""chemical"">cisplatin</span> have activity in <span class=""disease"">HL</span>, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting."		24.0	24_MESH:D002945_MESH:D006689	24_4	bcv_final_eval_easy_102		
	MESH:C056507	"<span class=""chemical"">Gemcitabine</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"<span class=""chemical"">Gemcitabine</span> and cisplatin have activity in HL, non-overlapping <span class=""disease"">toxicity</span> with first-line chemotherapeutics, and may be delivered in an outpatient setting."		24.0	24_MESH:C056507_MESH:D064420	24_4	bcv_final_eval_easy_103		
	MESH:C056507	"<span class=""chemical"">Gemcitabine</span>"	MESH:D006689	"<span class=""disease"">HL</span>"	"<span class=""chemical"">Gemcitabine</span> and cisplatin have activity in <span class=""disease"">HL</span>, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting."		24.0	24_MESH:C056507_MESH:D006689	24_4	bcv_final_eval_easy_104		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Gemcitabine and <span class=""chemical"">cisplatin</span> have activity in HL, non-overlapping <span class=""disease"">toxicity</span> with first-line chemotherapeutics, and may be delivered in an outpatient setting."		24.0	24_MESH:D002945_MESH:D064420	24_4	bcv_final_eval_easy_105		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D006689	"<span class=""disease"">HL</span>"	"In this retrospective single-centre analysis, patients with relapsed or refractory <span class=""disease"">HL</span> treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and <span class=""chemical"">cisplatin</span> 100 mg/m(2) D15, every 28 days (GEM-P) were included."		24.0	24_MESH:D002945_MESH:D006689	24_5	bcv_final_eval_easy_106		
	MESH:C056507	"<span class=""chemical"">gemcitabine</span>"	MESH:D006689	"<span class=""disease"">HL</span>"	"In this retrospective single-centre analysis, patients with relapsed or refractory <span class=""disease"">HL</span> treated with <span class=""chemical"">gemcitabine</span> 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included."		24.0	24_MESH:C056507_MESH:D006689	24_5	bcv_final_eval_easy_107		
	MESH:D008775	"<span class=""chemical"">methylprednisolone</span>"	MESH:D006689	"<span class=""disease"">HL</span>"	"In this retrospective single-centre analysis, patients with relapsed or refractory <span class=""disease"">HL</span> treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; <span class=""chemical"">methylprednisolone</span> 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included."		24.0	24_MESH:D008775_MESH:D006689	24_5	bcv_final_eval_easy_108		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D020018	"<span class=""disease"">psychological distress</span>"	"Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and <span class=""disease"">psychological distress</span> in recreational <span class=""chemical"">ecstasy</span> polydrug users."		25.0	25_MESH:D018817_MESH:D020018	25_0	bcv_final_eval_easy_109		
	MESH:D018817	"<span class=""chemical"">Ecstasy/MDMA</span>"	MESH:D008107	"<span class=""disease"">psychobiological dysfunction</span>"	"RATIONALE: <span class=""chemical"">Ecstasy</span> (<span class=""chemical"">MDMA</span>) is a psychostimulant drug which is increasingly associated with <span class=""disease"">psychobiological dysfunction</span>."		25.0	25_MESH:D018817_MESH:D008107	25_1	bcv_final_eval_easy_110		
	MESH:D006854	"<span class=""chemical"">cortisol</span>"	MESH:D020018	"<span class=""disease"">psychological distress</span>"	"OBJECTIVES: The current study is the first to explore the effects of ecstasy-polydrug use on <span class=""disease"">psychological distress</span> and basal functioning of the HPA axis through assessing the secretion of <span class=""chemical"">cortisol</span> across the diurnal period."		25.0	25_MESH:D006854_MESH:D020018	25_3	bcv_final_eval_easy_111		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D020018	"<span class=""disease"">psychological distress</span>"	"OBJECTIVES: The current study is the first to explore the effects of <span class=""chemical"">ecstasy</span>-polydrug use on <span class=""disease"">psychological distress</span> and basal functioning of the HPA axis through assessing the secretion of cortisol across the diurnal period."		25.0	25_MESH:D018817_MESH:D020018	25_3	bcv_final_eval_easy_112		
	MESH:D006854	"<span class=""chemical"">cortisol</span>"	MESH:D020018	"<span class=""disease"">psychological distress</span>"	"METHOD: Seventy-six participants (21 nonusers, 29 light ecstasy-polydrug users, 26 heavy ecstasy-polydrug users) completed a substance use inventory and measures of <span class=""disease"">psychological distress</span> at baseline, then two consecutive days of <span class=""chemical"">cortisol</span> sampling (on awakening, 30 min post awakening, between 1400 and 1600 hours and pre bedtime)."		25.0	25_MESH:D006854_MESH:D020018	25_4	bcv_final_eval_easy_113		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D020018	"<span class=""disease"">psychological distress</span>"	"METHOD: Seventy-six participants (21 nonusers, 29 light <span class=""chemical"">ecstasy</span>-polydrug users, 26 heavy <span class=""chemical"">ecstasy</span>-polydrug users) completed a substance use inventory and measures of <span class=""disease"">psychological distress</span> at baseline, then two consecutive days of cortisol sampling (on awakening, 30 min post awakening, between 1400 and 1600 hours and pre bedtime)."		25.0	25_MESH:D018817_MESH:D020018	25_4	bcv_final_eval_easy_114		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"CONCLUSIONS: The increases in <span class=""disease"">anxiety</span> and depression are in line with previous observations in recreational <span class=""chemical"">ecstasy</span>-polydrug users."		25.0	25_MESH:D018817_MESH:D001008	25_10	bcv_final_eval_easy_115		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"CONCLUSIONS: The increases in anxiety and <span class=""disease"">depression</span> are in line with previous observations in recreational <span class=""chemical"">ecstasy</span>-polydrug users."		25.0	25_MESH:D018817_MESH:D003866	25_10	bcv_final_eval_easy_116		
	MESH:D006854	"<span class=""chemical"">cortisol</span>"	MESH:D006966	"<span class=""disease"">hypersecretion</span>"	"Dysregulated diurnal <span class=""chemical"">cortisol</span> may be indicative of inappropriate anticipation of forthcoming demands and <span class=""disease"">hypersecretion</span> may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy."		25.0	25_MESH:D006854_MESH:D006966	25_11	bcv_final_eval_easy_117		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D006966	"<span class=""disease"">hypersecretion</span>"	"Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and <span class=""disease"">hypersecretion</span> may lead to the increased psychological and physical morbidity associated with heavy recreational use of <span class=""chemical"">ecstasy</span>."		25.0	25_MESH:D018817_MESH:D006966	25_11	bcv_final_eval_easy_118		
	MESH:D007069	"<span class=""chemical"">Ifosfamide</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"<span class=""chemical"">Ifosfamide</span> related <span class=""disease"">encephalopathy</span>: the need for a timely EEG evaluation."		26.0	26_MESH:D007069_MESH:D001927	26_0	bcv_final_eval_easy_119		
	MESH:D007069	"<span class=""chemical"">Ifosfamide</span>"	MESH:D009369	"<span class=""disease"">cancers/testicular cancers</span>"	"BACKGROUND: <span class=""chemical"">Ifosfamide</span> is an alkylating agent useful in the treatment of a wide range of <span class=""disease"">cancers</span> including sarcomas, lymphoma, gynecologic and <span class=""disease"">testicular cancers</span>."		26.0	26_MESH:D007069_MESH:D009369	26_1	bcv_final_eval_easy_120		
	MESH:D007069	"<span class=""chemical"">Ifosfamide</span>"	MESH:D012509	"<span class=""disease"">sarcomas</span>"	"BACKGROUND: <span class=""chemical"">Ifosfamide</span> is an alkylating agent useful in the treatment of a wide range of cancers including <span class=""disease"">sarcomas</span>, lymphoma, gynecologic and testicular cancers."		26.0	26_MESH:D007069_MESH:D012509	26_1	bcv_final_eval_easy_121		
	MESH:D007069	"<span class=""chemical"">Ifosfamide</span>"	MESH:D008223	"<span class=""disease"">lymphoma</span>"	"BACKGROUND: <span class=""chemical"">Ifosfamide</span> is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, <span class=""disease"">lymphoma</span>, gynecologic and testicular cancers."		26.0	26_MESH:D007069_MESH:D008223	26_1	bcv_final_eval_easy_122		
	MESH:D007069	"<span class=""chemical"">ifosfamide</span>"	MESH:D001927	"<span class=""disease"">Encephalopathy</span>"	"<span class=""disease"">Encephalopathy</span> has been reported in 10-40% of patients receiving high-dose IV <span class=""chemical"">ifosfamide</span>."		26.0	26_MESH:D007069_MESH:D001927	26_2	bcv_final_eval_easy_123		
	MESH:D007069	"<span class=""chemical"">ifosfamide</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"OBJECTIVE: To highlight the role of electroencephalogram (EEG) in the early detection and management of <span class=""chemical"">ifosfamide</span> related <span class=""disease"">encephalopathy</span>."		26.0	26_MESH:D007069_MESH:D001927	26_3	bcv_final_eval_easy_124		
	MESH:D007069	"<span class=""chemical"">ifosfamide</span>"	MESH:D009369	"<span class=""disease"">Cancer</span>"	"METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson <span class=""disease"">Cancer</span> Center between years 2009 and 2012, who developed <span class=""chemical"">ifosfamide</span> related acute encephalopathy."		26.0	26_MESH:D007069_MESH:D009369	26_4	bcv_final_eval_easy_125		
	MESH:D007069	"<span class=""chemical"">ifosfamide</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed <span class=""chemical"">ifosfamide</span> related acute <span class=""disease"">encephalopathy</span>."		26.0	26_MESH:D007069_MESH:D001927	26_4	bcv_final_eval_easy_126		
	MESH:D007069	"<span class=""chemical"">ifosfamide</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"RESULTS: All five patients experienced symptoms of <span class=""disease"">encephalopathy</span> soon after (within 12 h-2 days) receiving <span class=""chemical"">ifosfamide</span>."		26.0	26_MESH:D007069_MESH:D001927	26_5	bcv_final_eval_easy_127		
	MESH:D007069	"<span class=""chemical"">ifosfamide</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"CONCLUSIONS: Severity of <span class=""chemical"">ifosfamide</span> related <span class=""disease"">encephalopathy</span> correlates with EEG changes."		26.0	26_MESH:D007069_MESH:D001927	26_10	bcv_final_eval_easy_128		
	MESH:D007069	"<span class=""chemical"">ifosfamide</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"We suggest a timely EEG evaluation for patients receiving <span class=""chemical"">ifosfamide</span> who develop features of <span class=""disease"">encephalopathy</span>."		26.0	26_MESH:D007069_MESH:D001927	26_11	bcv_final_eval_easy_129		
	MESH:D002857	"<span class=""chemical"">Cr</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"<span class=""disease"">CIN</span> was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of <span class=""chemical"">Cr</span> to 25 % over baseline."		27.0	27_MESH:D002857_MESH:D007674	27_5	bcv_final_eval_easy_130		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"<span class=""disease"">CIN</span> was defined as an increase in serum <span class=""chemical"">creatinine</span> (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline."		27.0	27_MESH:D003404_MESH:D007674	27_5	bcv_final_eval_easy_131		
	MESH:C051890	"<span class=""chemical"">irinotecan</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"<span class=""disease"">CIN</span> was significantly more after treatment with bevacizumab/<span class=""chemical"">irinotecan</span> (P = 0.021) and in patients with hypertension (P = 0.044)."		27.0	27_MESH:C051890_MESH:D007674	27_10	bcv_final_eval_easy_132		
	MESH:C051890	"<span class=""chemical"">irinotecan</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"CIN was significantly more after treatment with bevacizumab/<span class=""chemical"">irinotecan</span> (P = 0.021) and in patients with <span class=""disease"">hypertension</span> (P = 0.044)."		27.0	27_MESH:C051890_MESH:D006973	27_10	bcv_final_eval_easy_133		
	MESH:C051890	"<span class=""chemical"">irinotecan</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"Hypertension and the combination of bevacizumab/<span class=""chemical"">irinotecan</span> may be additional risk factors for <span class=""disease"">CIN</span> development."		27.0	27_MESH:C051890_MESH:D007674	27_13	bcv_final_eval_easy_134		
	MESH:C051890	"<span class=""chemical"">irinotecan</span>"	MESH:D006973	"<span class=""disease"">Hypertension</span>"	"<span class=""disease"">Hypertension</span> and the combination of bevacizumab/<span class=""chemical"">irinotecan</span> may be additional risk factors for CIN development."		27.0	27_MESH:C051890_MESH:D006973	27_13	bcv_final_eval_easy_135		
	MESH:C086816	"<span class=""chemical"">desvenlafaxine</span>"	MESH:D007177	"<span class=""disease"">inappropriate antidiuretic hormone secretion</span>"	"Syndrome of <span class=""disease"">inappropriate antidiuretic hormone secretion</span> associated with <span class=""chemical"">desvenlafaxine</span>."		28.0	28_MESH:C086816_MESH:D007177	28_0	bcv_final_eval_easy_136		
	MESH:C086816	"<span class=""chemical"">desvenlafaxine</span>"	MESH:D007177	"<span class=""disease"">SIADH/syndrome of inappropriate anti-diuretic hormone</span>"	"OBJECTIVE: To report a case of <span class=""disease"">syndrome of inappropriate anti-diuretic hormone</span> (<span class=""disease"">SIADH</span>) secretion associated with <span class=""chemical"">desvenlafaxine</span>."		28.0	28_MESH:C086816_MESH:D007177	28_1	bcv_final_eval_easy_137		
	MESH:C086816	"<span class=""chemical"">desvenlafaxine</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"Her medications included <span class=""chemical"">desvenlafaxine</span>, and symptoms included <span class=""disease"">nausea</span>, anxiety and confusion."		28.0	28_MESH:C086816_MESH:D009325	28_3	bcv_final_eval_easy_138		
	MESH:C086816	"<span class=""chemical"">desvenlafaxine</span>"	MESH:D003221	"<span class=""disease"">confusion</span>"	"Her medications included <span class=""chemical"">desvenlafaxine</span>, and symptoms included nausea, anxiety and <span class=""disease"">confusion</span>."		28.0	28_MESH:C086816_MESH:D003221	28_3	bcv_final_eval_easy_139		
	MESH:C086816	"<span class=""chemical"">desvenlafaxine</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"Her medications included <span class=""chemical"">desvenlafaxine</span>, and symptoms included nausea, <span class=""disease"">anxiety</span> and confusion."		28.0	28_MESH:C086816_MESH:D001008	28_3	bcv_final_eval_easy_140		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D007177	"<span class=""disease"">SIADH</span>"	"The serum <span class=""chemical"">sodium</span> at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine <span class=""chemical"">sodium</span> 63 mmol/L, consistent with a diagnosis of <span class=""disease"">SIADH</span>."		28.0	28_MESH:D012964_MESH:D007177	28_4	bcv_final_eval_easy_141		
	MESH:C086816	"<span class=""chemical"">desvenlafaxine</span>"	MESH:D007010	"<span class=""disease"">hyponatremia</span>"	"This case report suggests that <span class=""chemical"">desvenlafaxine</span> might cause clinically significant <span class=""disease"">hyponatremia</span>."		28.0	28_MESH:C086816_MESH:D007010	28_9	bcv_final_eval_easy_142		
	MESH:D004317	"<span class=""chemical"">DOX</span>"	MESH:D006331	"<span class=""disease"">cardiac disarrangement</span>"	"Single dose of <span class=""chemical"">DOX</span> was associated with increased <span class=""disease"">cardiac disarrangement</span>, necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP."		29.0	29_MESH:D004317_MESH:D006331	29_5	bcv_final_eval_easy_143		
	MESH:D004317	"<span class=""chemical"">DOX</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Single dose of <span class=""chemical"">DOX</span> was associated with increased cardiac disarrangement, <span class=""disease"">necrosis</span>, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP."		29.0	29_MESH:D004317_MESH:D009336	29_5	bcv_final_eval_easy_144		
	MESH:D016559	"<span class=""chemical"">Tacrolimus</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">Tacrolimus</span>-related <span class=""disease"">seizure</span> after pediatric liver transplantation--a single-center experience."		30.0	30_MESH:D016559_MESH:D012640	30_0	bcv_final_eval_easy_145		
	MESH:D001663	"<span class=""chemical"">bilirubin</span>"	MESH:D008107	"<span class=""disease"">liver disease</span>"	"Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage <span class=""disease"">liver disease</span> score before surgery, Child-Pugh score before surgery, serum total <span class=""chemical"">bilirubin</span> after surgery, and trough TAC level."		30.0	30_MESH:D001663_MESH:D008107	30_7	bcv_final_eval_easy_146		
	MESH:D001663	"<span class=""chemical"">bilirubin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Univariate analysis showed that the risk factors associated with <span class=""disease"">seizures</span> after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total <span class=""chemical"">bilirubin</span> after surgery, and trough TAC level."		30.0	30_MESH:D001663_MESH:D012640	30_7	bcv_final_eval_easy_147		
	MESH:D016559	"<span class=""chemical"">TAC</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Univariate analysis showed that the risk factors associated with <span class=""disease"">seizures</span> after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough <span class=""chemical"">TAC</span> level."		30.0	30_MESH:D016559_MESH:D012640	30_7	bcv_final_eval_easy_148		
	MESH:D016559	"<span class=""chemical"">TAC</span>"	MESH:D008107	"<span class=""disease"">liver disease</span>"	"Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage <span class=""disease"">liver disease</span> score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough <span class=""chemical"">TAC</span> level."		30.0	30_MESH:D016559_MESH:D008107	30_7	bcv_final_eval_easy_149		
	MESH:D016559	"<span class=""chemical"">TAC</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Multivariate analysis showed that trough <span class=""chemical"">TAC</span> level was the only independent risk factor associated with the <span class=""disease"">seizures</span>."		30.0	30_MESH:D016559_MESH:D012640	30_8	bcv_final_eval_easy_150		
	MESH:D016559	"<span class=""chemical"">TAC</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"High trough <span class=""chemical"">TAC</span> level was the predominant factor that contributed to <span class=""disease"">seizures</span> in the early post-operative period after pediatric LT."		30.0	30_MESH:D016559_MESH:D012640	30_10	bcv_final_eval_easy_151		
	MESH:D016559	"<span class=""chemical"">TAC</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for <span class=""chemical"">TAC</span>-related <span class=""disease"">seizures</span>."		30.0	30_MESH:D016559_MESH:D012640	30_11	bcv_final_eval_easy_152		
	MESH:D047310	"<span class=""chemical"">apigenin</span>"	MESH:D000647	"<span class=""disease"">amnesia</span>"	"Furthermore, <span class=""chemical"">apigenin</span> did not prevent the <span class=""disease"">amnesia</span> induced by scopolamine (1mg/kg, i.p., 30 min before the acquisition)."		31.0	31_MESH:D047310_MESH:D000647	31_3	bcv_final_eval_easy_153		
	MESH:D012601	"<span class=""chemical"">scopolamine</span>"	MESH:D000647	"<span class=""disease"">amnesia</span>"	"Furthermore, apigenin did not prevent the <span class=""disease"">amnesia</span> induced by <span class=""chemical"">scopolamine</span> (1mg/kg, i.p., 30 min before the acquisition)."		31.0	31_MESH:D012601_MESH:D000647	31_3	bcv_final_eval_easy_154		
	MESH:D013311	"<span class=""chemical"">Streptozotocin</span>"	MESH:D020258	"<span class=""disease"">synaptic neurotoxicity</span>"	"Glial activation and post-<span class=""disease"">synaptic neurotoxicity</span>: the key events in <span class=""chemical"">Streptozotocin</span> (ICV) induced memory impairment in rats."		33.0	33_MESH:D013311_MESH:D020258	33_0	bcv_final_eval_easy_155		
	MESH:D013311	"<span class=""chemical"">Streptozotocin/STZ</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"In the present study the role of glial activation and post synaptic <span class=""disease"">toxicity</span> in ICV <span class=""chemical"">Streptozotocin</span> (<span class=""chemical"">STZ</span>) induced memory impaired rats was explored."		33.0	33_MESH:D013311_MESH:D064420	33_1	bcv_final_eval_easy_156		
	MESH:D013311	"<span class=""chemical"">STZ</span>"	MESH:D020258	"<span class=""disease"">synaptic neurotoxicity</span>"	"<span class=""chemical"">STZ</span> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post <span class=""disease"">synaptic neurotoxicity</span>."		33.0	33_MESH:D013311_MESH:D020258	33_6	bcv_final_eval_easy_157		
	MESH:D007052	"<span class=""chemical"">Ibuprofen</span>"	MESH:D020258	"<span class=""disease"">synaptic neurotoxicity</span>"	"Oral treatment with Memantine (10mg/kg) and <span class=""chemical"">Ibuprofen</span> (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post <span class=""disease"">synaptic neurotoxicity</span> in rat brain."		33.0	33_MESH:D007052_MESH:D020258	33_7	bcv_final_eval_easy_158		
	MESH:D008559	"<span class=""chemical"">Memantine</span>"	MESH:D020258	"<span class=""disease"">synaptic neurotoxicity</span>"	"Oral treatment with <span class=""chemical"">Memantine</span> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post <span class=""disease"">synaptic neurotoxicity</span> in rat brain."		33.0	33_MESH:D008559_MESH:D020258	33_7	bcv_final_eval_easy_159		
	MESH:D013311	"<span class=""chemical"">STZ</span>"	MESH:D020258	"<span class=""disease"">synaptic neurotoxicity</span>"	"Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <span class=""chemical"">STZ</span> induced glial activation, apoptotic cell death and post <span class=""disease"">synaptic neurotoxicity</span> in rat brain."		33.0	33_MESH:D013311_MESH:D020258	33_7	bcv_final_eval_easy_160		
	MESH:D013311	"<span class=""chemical"">STZ</span>"	MESH:D020258	"<span class=""disease"">synaptic neurotoxicity</span>"	"Present study clearly suggests that glial activation and post <span class=""disease"">synaptic neurotoxicity</span> are the key factors in <span class=""chemical"">STZ</span> induced memory impairment and neuronal cell death."		33.0	33_MESH:D013311_MESH:D020258	33_13	bcv_final_eval_easy_161		
	MESH:D004110	"<span class=""chemical"">diltiazem</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Comparison of effects of isotonic sodium chloride with <span class=""chemical"">diltiazem</span> in prevention of contrast-induced <span class=""disease"">nephropathy</span>."		34.0	34_MESH:D004110_MESH:D007674	34_0	bcv_final_eval_easy_162		
	MESH:D017693	"<span class=""chemical"">sodium bicarbonate</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with <span class=""chemical"">sodium bicarbonate</span> infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing <span class=""disease"">CIN</span>."		34.0	34_MESH:D017693_MESH:D007674	34_2	bcv_final_eval_easy_163		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a <span class=""chemical"">calcium</span> channel blocker, in preventing <span class=""disease"">CIN</span>."		34.0	34_MESH:D002118_MESH:D007674	34_2	bcv_final_eval_easy_164		
	MESH:D004110	"<span class=""chemical"">diltiazem</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with <span class=""chemical"">diltiazem</span>, a calcium channel blocker, in preventing <span class=""disease"">CIN</span>."		34.0	34_MESH:D004110_MESH:D007674	34_2	bcv_final_eval_easy_165		
	MESH:D017693	"<span class=""chemical"">sodium bicarbonate</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"CONCLUSION: There was no significant difference between isotonic sodium chloride, <span class=""chemical"">sodium bicarbonate</span> and isotonic sodium chloride with diltiazem application in prevention of <span class=""disease"">CIN</span>."		34.0	34_MESH:D017693_MESH:D007674	34_11	bcv_final_eval_easy_166		
	MESH:D004110	"<span class=""chemical"">diltiazem</span>"	MESH:D007674	"<span class=""disease"">CIN</span>"	"CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with <span class=""chemical"">diltiazem</span> application in prevention of <span class=""disease"">CIN</span>."		34.0	34_MESH:D004110_MESH:D007674	34_11	bcv_final_eval_easy_167		
	MESH:C527967	"<span class=""chemical"">P9605</span>"	MESH:D054198	"<span class=""disease"">acute lymphoblastic leukemia</span>"	"Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) <span class=""chemical"">P9605</span> (standard risk) and P9201 (lesser risk) <span class=""disease"">acute lymphoblastic leukemia</span> protocols (ACCL0131): a methotrexate consequence? A report from the Children's Oncology Group."		35.0	35_MESH:C527967_MESH:D054198	35_0	bcv_final_eval_easy_168		
	MESH:D008727	"<span class=""chemical"">methotrexate/MTX</span>"	MESH:D054198	"<span class=""disease"">acute lymphoblastic leukemia</span>"	"Concerns about long-term <span class=""chemical"">methotrexate</span> (<span class=""chemical"">MTX</span>) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic <span class=""chemical"">MTX</span> administration in children with <span class=""disease"">acute lymphoblastic leukemia</span>."		35.0	35_MESH:D008727_MESH:D054198	35_1	bcv_final_eval_easy_169		
	MESH:D008727	"<span class=""chemical"">methotrexate/MTX</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"Concerns about long-term <span class=""chemical"">methotrexate</span> (<span class=""chemical"">MTX</span>) <span class=""disease"">neurotoxicity</span> in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic <span class=""chemical"">MTX</span> administration in children with acute lymphoblastic leukemia."		35.0	35_MESH:D008727_MESH:D020258	35_1	bcv_final_eval_easy_170		
	MESH:D014148	"<span class=""chemical"">Tranexamic acid</span>"	MESH:D051437	"<span class=""disease"">renal failure</span>"	"<span class=""chemical"">Tranexamic acid</span> overdosage-induced generalized seizure in <span class=""disease"">renal failure</span>."		36.0	36_MESH:D014148_MESH:D051437	36_0	bcv_final_eval_easy_171		
	MESH:D014148	"<span class=""chemical"">Tranexamic acid</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">Tranexamic acid</span> overdosage-induced generalized <span class=""disease"">seizure</span> in renal failure."		36.0	36_MESH:D014148_MESH:D012640	36_0	bcv_final_eval_easy_172		
	MESH:D014148	"<span class=""chemical"">Tranexamic acid</span>"	MESH:D006470	"<span class=""disease"">bleeding</span>"	"<span class=""chemical"">Tranexamic acid</span> (TNA) 1 g 8-hourly was administered to her to control <span class=""disease"">bleeding</span> per vaginum."		36.0	36_MESH:D014148_MESH:D006470	36_4	bcv_final_eval_easy_173		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D002318	"<span class=""disease"">cardiovascular depression</span>"	"Pre-treatment of bupivacaine-induced <span class=""disease"">cardiovascular depression</span> using different lipid formulations of <span class=""chemical"">propofol</span>."		37.0	37_MESH:D015742_MESH:D002318	37_0	bcv_final_eval_easy_174		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <span class=""chemical"">propofol</span> may alleviate bupivacaine-induced <span class=""disease"">cardiotoxicity</span>."		37.0	37_MESH:D015742_MESH:D066126	37_1	bcv_final_eval_easy_175		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The aim of this study is to investigate the effects of <span class=""chemical"">propofol</span> in intralipid or medialipid emulsions on bupivacaine-induced <span class=""disease"">cardiotoxicity</span>."		37.0	37_MESH:D015742_MESH:D066126	37_2	bcv_final_eval_easy_176		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D006323	"<span class=""disease"">asystole</span>"	"We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to <span class=""disease"">asystole</span> and total amount of <span class=""chemical"">bupivacaine</span> consumption."		37.0	37_MESH:D002045_MESH:D006323	37_5	bcv_final_eval_easy_177		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D001145	"<span class=""disease"">dysrhythmia</span>"	"We recorded time to first <span class=""disease"">dysrhythmia</span> occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of <span class=""chemical"">bupivacaine</span> consumption."		37.0	37_MESH:D002045_MESH:D001145	37_5	bcv_final_eval_easy_178		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"CONCLUSION: We conclude that pre-treatment with <span class=""chemical"">propofol</span> in intralipid, compared with <span class=""chemical"">propofol</span> in medialipid or saline, delayed the onset of bupivacaine-induced <span class=""disease"">cardiotoxic</span> effects as well as reduced plasma bupivacaine levels."		37.0	37_MESH:D015742_MESH:D066126	37_11	bcv_final_eval_easy_179		
	MESH:C065180	"<span class=""chemical"">Fluvastatin</span>"	MESH:D056486	"<span class=""disease"">Liver Injury</span>"	"Drug-Induced Acute <span class=""disease"">Liver Injury</span> Within 12 Hours After <span class=""chemical"">Fluvastatin</span> Therapy."		38.0	38_MESH:C065180_MESH:D056486	38_0	bcv_final_eval_easy_180		
	MESH:D019821	"<span class=""chemical"">statins</span>"	MESH:D056486	"<span class=""disease"">drug-induced liver injury</span>"	"Although <span class=""chemical"">statins</span> are generally well-tolerated drugs, recent cases of <span class=""disease"">drug-induced liver injury</span> associated with their use have been reported."		38.0	38_MESH:D019821_MESH:D056486	38_1	bcv_final_eval_easy_181		
	MESH:C065180	"<span class=""chemical"">fluvastatin</span>"	MESH:D008107	"<span class=""disease"">liver damage</span>"	"A 52-year-old Chinese man reported with <span class=""disease"">liver damage</span>, which appeared 12 hours after beginning treatment with <span class=""chemical"">fluvastatin</span>."		38.0	38_MESH:C065180_MESH:D008107	38_2	bcv_final_eval_easy_182		
	MESH:D015725	"<span class=""chemical"">Fluconazole</span>"	MESH:D013921	"<span class=""disease"">thrombocytopenia</span>"	"<span class=""chemical"">Fluconazole</span> associated agranulocytosis and <span class=""disease"">thrombocytopenia</span>."		39.0	39_MESH:D015725_MESH:D013921	39_0	bcv_final_eval_easy_183		
	MESH:D015725	"<span class=""chemical"">Fluconazole</span>"	MESH:D000380	"<span class=""disease"">agranulocytosis</span>"	"<span class=""chemical"">Fluconazole</span> associated <span class=""disease"">agranulocytosis</span> and thrombocytopenia."		39.0	39_MESH:D015725_MESH:D000380	39_0	bcv_final_eval_easy_184		
	MESH:D015725	"<span class=""chemical"">fluconazole</span>"	MESH:D013921	"<span class=""disease"">thrombocytopenia</span>"	"CASE: We describe a second case of <span class=""chemical"">fluconazole</span> associated agranulocytosis with <span class=""disease"">thrombocytopenia</span> and recovery upon discontinuation of therapy."		39.0	39_MESH:D015725_MESH:D013921	39_1	bcv_final_eval_easy_185		
	MESH:D015725	"<span class=""chemical"">fluconazole</span>"	MESH:D000380	"<span class=""disease"">agranulocytosis</span>"	"CASE: We describe a second case of <span class=""chemical"">fluconazole</span> associated <span class=""disease"">agranulocytosis</span> with thrombocytopenia and recovery upon discontinuation of therapy."		39.0	39_MESH:D015725_MESH:D000380	39_1	bcv_final_eval_easy_186		
	MESH:D015725	"<span class=""chemical"">fluconazole</span>"	MESH:D013921	"<span class=""disease"">thrombocytopenia</span>"	"CONCLUSION: According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and <span class=""disease"">thrombocytopenia</span> occurred as a result of therapy with <span class=""chemical"">fluconazole</span> is probable, with a total of six points."		39.0	39_MESH:D015725_MESH:D013921	39_4	bcv_final_eval_easy_187		
	MESH:D015725	"<span class=""chemical"">fluconazole</span>"	MESH:D000380	"<span class=""disease"">agranulocytosis</span>"	"CONCLUSION: According to Naranjo's algorithm the likelihood that our patient's <span class=""disease"">agranulocytosis</span> and thrombocytopenia occurred as a result of therapy with <span class=""chemical"">fluconazole</span> is probable, with a total of six points."		39.0	39_MESH:D015725_MESH:D000380	39_4	bcv_final_eval_easy_188		
	MESH:D015725	"<span class=""chemical"">fluconazole</span>"	MESH:D001855	"<span class=""disease"">bone marrow suppression</span>"	"In particular the temporal relationship of <span class=""disease"">bone marrow suppression</span> to the initiation of <span class=""chemical"">fluconazole</span> and the abatement of symptoms that rapidly reversed immediately following discontinuation."		39.0	39_MESH:D015725_MESH:D001855	39_6	bcv_final_eval_easy_189		
	MESH:D015251	"<span class=""chemical"">epirubicin</span>"	MESH:D006331	"<span class=""disease"">cardiac dysfunction</span>"	"AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future <span class=""disease"">cardiac dysfunction</span> in patients after <span class=""chemical"">epirubicin</span> exposure."		40.0	40_MESH:D015251_MESH:D006331	40_1	bcv_final_eval_easy_190		
	MESH:D015251	"<span class=""chemical"">epirubicin</span>"	MESH:D009202	"<span class=""disease"">myocardial strain</span>"	"AIMS: To investigate whether alterations of <span class=""disease"">myocardial strain</span> and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after <span class=""chemical"">epirubicin</span> exposure."		40.0	40_MESH:D015251_MESH:D009202	40_1	bcv_final_eval_easy_191		
	MESH:D015251	"<span class=""chemical"">epirubicin</span>"	MESH:D008228	"<span class=""disease"">non-Hodgkin lymphoma</span>"	"METHODS: Seventy-five patients with <span class=""disease"">non-Hodgkin lymphoma</span> treated with <span class=""chemical"">epirubicin</span> were studied."		40.0	40_MESH:D015251_MESH:D008228	40_2	bcv_final_eval_easy_192		
	MESH:D018943	"<span class=""chemical"">anthracycline</span>"	MESH:D006331	"<span class=""disease"">cardiac dysfunction</span>"	"CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict <span class=""disease"">cardiac dysfunction</span> in patients receiving <span class=""chemical"">anthracycline</span>-based chemotherapy."		40.0	40_MESH:D018943_MESH:D006331	40_12	bcv_final_eval_easy_193		
	MESH:D005283	"<span class=""chemical"">Fentanyl</span>"	MESH:D009207	"<span class=""disease"">myoclonus</span>"	"Prevention of etomidate-induced <span class=""disease"">myoclonus</span>: which is superior: <span class=""chemical"">Fentanyl</span>, midazolam, or a combination? A Retrospective comparative study."		41.0	41_MESH:D005283_MESH:D009207	41_0	bcv_final_eval_easy_194		
	MESH:D008874	"<span class=""chemical"">midazolam</span>"	MESH:D009207	"<span class=""disease"">myoclonus</span>"	"Prevention of etomidate-induced <span class=""disease"">myoclonus</span>: which is superior: Fentanyl, <span class=""chemical"">midazolam</span>, or a combination? A Retrospective comparative study."		41.0	41_MESH:D008874_MESH:D009207	41_0	bcv_final_eval_easy_195		
	MESH:D005283	"<span class=""chemical"">fentanyl</span>"	MESH:D009207	"<span class=""disease"">myoclonus</span>"	"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of <span class=""chemical"">fentanyl</span>, midazolam, and a combination of <span class=""chemical"">fentanyl</span> and midazolam to prevent etomidate-induced <span class=""disease"">myoclonus</span>."		41.0	41_MESH:D005283_MESH:D009207	41_1	bcv_final_eval_easy_196		
	MESH:D008874	"<span class=""chemical"">midazolam</span>"	MESH:D009207	"<span class=""disease"">myoclonus</span>"	"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, <span class=""chemical"">midazolam</span>, and a combination of fentanyl and <span class=""chemical"">midazolam</span> to prevent etomidate-induced <span class=""disease"">myoclonus</span>."		41.0	41_MESH:D008874_MESH:D009207	41_1	bcv_final_eval_easy_197		
	MESH:D005045	"<span class=""chemical"">etomidate</span>"	MESH:D009069	"<span class=""disease"">Myoclonic movements</span>"	"<span class=""disease"">Myoclonic movements</span> are evaluated, which were observed and graded according to clinical severity during the 2 minutes after <span class=""chemical"">etomidate</span> injection."		41.0	41_MESH:D005045_MESH:D009069	41_5	bcv_final_eval_easy_198		
	MESH:D005045	"<span class=""chemical"">etomidate</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"The severity of <span class=""disease"">pain</span> due to <span class=""chemical"">etomidate</span> injection, mean arterial pressure, heart rate, and adverse effects were also evaluated."		41.0	41_MESH:D005045_MESH:D010146	41_6	bcv_final_eval_easy_199		
	MESH:D005283	"<span class=""chemical"">fentanyl</span>"	MESH:D009207	"<span class=""disease"">myoclonus</span>"	"CONCLUSIONS: We conclude that pretreatment with <span class=""chemical"">fentanyl</span> or combination of <span class=""chemical"">fentanyl</span> and midazolam was effective in preventing etomidate-induced <span class=""disease"">myoclonus</span>."		41.0	41_MESH:D005283_MESH:D009207	41_8	bcv_final_eval_easy_200		
	MESH:D008874	"<span class=""chemical"">midazolam</span>"	MESH:D009207	"<span class=""disease"">myoclonus</span>"	"CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and <span class=""chemical"">midazolam</span> was effective in preventing etomidate-induced <span class=""disease"">myoclonus</span>."		41.0	41_MESH:D008874_MESH:D009207	41_8	bcv_final_eval_easy_201		
	MESH:D010758	"<span class=""chemical"">phosphorus</span>"	MESH:D011041	"<span class=""disease"">phosphorus poisoning</span>"	"Cholestatic presentation of yellow <span class=""chemical""></span><span class=""disease"">phosphorus</span> poisoning."		42.0	42_MESH:D010758_MESH:D011041	42_0	bcv_final_eval_easy_202		
	MESH:D010758	"<span class=""chemical"">phosphorus</span>"	MESH:D056486	"<span class=""disease"">hepatitis</span>"	"Poisoning with yellow <span class=""chemical"">phosphorus</span> classically manifests with acute <span class=""disease"">hepatitis</span> leading to acute liver failure which may need liver transplantation."		42.0	42_MESH:D010758_MESH:D056486	42_2	bcv_final_eval_easy_203		
	MESH:D010758	"<span class=""chemical"">phosphorus</span>"	MESH:D017114	"<span class=""disease"">acute liver failure</span>"	"Poisoning with yellow <span class=""chemical"">phosphorus</span> classically manifests with acute hepatitis leading to <span class=""disease"">acute liver failure</span> which may need liver transplantation."		42.0	42_MESH:D010758_MESH:D017114	42_2	bcv_final_eval_easy_204		
	MESH:D010758	"<span class=""chemical"">phosphorus</span>"	MESH:D011041	"<span class=""disease"">phosphorus poisoning</span>"	"We present a case of yellow <span class=""chemical""></span><span class=""disease"">phosphorus</span> poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow <span class=""chemical"">phosphorus</span> hepatotoxicity."		42.0	42_MESH:D010758_MESH:D011041	42_3	bcv_final_eval_easy_205		
	MESH:D010758	"<span class=""chemical"">phosphorus</span>"	MESH:D002779	"<span class=""disease"">cholestasis</span>"	"We present a case of yellow <span class=""chemical"">phosphorus</span> poisoning in which a patient presented with florid clinical features of <span class=""disease"">cholestasis</span> highlighting the fact that <span class=""disease"">cholestasis</span> can rarely be a presenting feature of yellow <span class=""chemical"">phosphorus</span> hepatotoxicity."		42.0	42_MESH:D010758_MESH:D002779	42_3	bcv_final_eval_easy_206		
	MESH:D020927	"<span class=""chemical"">dexmedetomidine</span>"	MESH:D019462	"<span class=""disease"">Vasovagal syncope</span>"	"<span class=""disease"">Vasovagal syncope</span> and severe bradycardia following intranasal <span class=""chemical"">dexmedetomidine</span> for pediatric procedural sedation."		43.0	43_MESH:D020927_MESH:D019462	43_0	bcv_final_eval_easy_207		
	MESH:D020927	"<span class=""chemical"">dexmedetomidine</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"Vasovagal syncope and severe <span class=""disease"">bradycardia</span> following intranasal <span class=""chemical"">dexmedetomidine</span> for pediatric procedural sedation."		43.0	43_MESH:D020927_MESH:D001919	43_0	bcv_final_eval_easy_208		
	MESH:D020927	"<span class=""chemical"">dexmedetomidine</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"We report syncope and <span class=""disease"">bradycardia</span> in an 11-year-old girl following administration of intranasal <span class=""chemical"">dexmedetomidine</span> for sedation for a voiding cystourethrogram."		43.0	43_MESH:D020927_MESH:D001919	43_1	bcv_final_eval_easy_209		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:D011595	"<span class=""disease"">agitation</span>"	"Paradoxical severe <span class=""disease"">agitation</span> induced by add-on high-doses <span class=""chemical"">quetiapine</span> in schizo-affective disorder."		44.0	44_MESH:C069541_MESH:D011595	44_0	bcv_final_eval_easy_210		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:D019964	"<span class=""disease"">schizo-affective disorder</span>"	"Paradoxical severe agitation induced by add-on high-doses <span class=""chemical"">quetiapine</span> in <span class=""disease"">schizo-affective disorder</span>."		44.0	44_MESH:C069541_MESH:D019964	44_0	bcv_final_eval_easy_211		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D019964	"<span class=""disease"">schizo-affective disorder</span>"	"We report the case of a 35-year-old patient suffering from <span class=""disease"">schizo-affective disorder</span> since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and <span class=""chemical"">lithium</span> (1200 mg/day) (serum <span class=""chemical"">lithium</span>=0.85 mEq/l)."		44.0	44_MESH:D008094_MESH:D019964	44_1	bcv_final_eval_easy_212		
	MESH:D003006	"<span class=""chemical"">zuclopenthixol</span>"	MESH:D019964	"<span class=""disease"">schizo-affective disorder</span>"	"We report the case of a 35-year-old patient suffering from <span class=""disease"">schizo-affective disorder</span> since the age of 19 years, treated by a combination of first-generation antipsychotics, <span class=""chemical"">zuclopenthixol</span> (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l)."		44.0	44_MESH:D003006_MESH:D019964	44_1	bcv_final_eval_easy_213		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:D001523	"<span class=""disease"">aggressiveness</span>"	"Within the 48 h following the gradual introduction of <span class=""chemical"">quetiapine</span> (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of <span class=""disease"">aggressiveness</span> or personality disorder."		44.0	44_MESH:C069541_MESH:D001523	44_3	bcv_final_eval_easy_214		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:D011595	"<span class=""disease"">agitation</span>"	"Within the 48 h following the gradual introduction of <span class=""chemical"">quetiapine</span> (up to 600 mg/day), the patient presented severe <span class=""disease"">agitation</span> without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder."		44.0	44_MESH:C069541_MESH:D011595	44_3	bcv_final_eval_easy_215		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:D010554	"<span class=""disease"">personality disorder</span>"	"Within the 48 h following the gradual introduction of <span class=""chemical"">quetiapine</span> (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or <span class=""disease"">personality disorder</span>."		44.0	44_MESH:C069541_MESH:D010554	44_3	bcv_final_eval_easy_216		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:D011595	"<span class=""disease"">agitation</span>"	"The withdrawal and the gradual reintroduction of <span class=""chemical"">quetiapine</span> 2 weeks later, which led to another severe <span class=""disease"">agitation</span>, enabled us to attribute the <span class=""disease"">agitation</span> specifically to <span class=""chemical"">quetiapine</span>."		44.0	44_MESH:C069541_MESH:D011595	44_5	bcv_final_eval_easy_217		
	MESH:D003907	"<span class=""chemical"">Dexamethasone</span>"	MESH:D001835	"<span class=""disease"">decreased thymus and body weights</span>"	"<span class=""chemical"">Dexamethasone</span> significantly increased SBP and plasma H2O2 level and <span class=""disease"">decreased thymus and body weights</span>."		45.0	45_MESH:D003907_MESH:D001835	45_10	bcv_final_eval_easy_218		
	MESH:D006861	"<span class=""chemical"">H2O2</span>"	MESH:D001835	"<span class=""disease"">decreased thymus and body weights</span>"	"Dexamethasone significantly increased SBP and plasma <span class=""chemical"">H2O2</span> level and <span class=""disease"">decreased thymus and body weights</span>."		45.0	45_MESH:D006861_MESH:D001835	45_10	bcv_final_eval_easy_219		
	MESH:D006861	"<span class=""chemical"">H2O2</span>"	MESH:D015431	"<span class=""disease"">weight loss</span>"	"LF prevented body <span class=""disease"">weight loss</span> and significantly reduced the elevated plasma <span class=""chemical"">H2O2</span> and increased FRAP values."		45.0	45_MESH:D006861_MESH:D015431	45_12	bcv_final_eval_easy_220		
	MESH:D014148	"<span class=""chemical"">tranexamic acid</span>"	MESH:D012640	"<span class=""disease"">seizures/convulsive</span>"	"The association between <span class=""chemical"">tranexamic acid</span> and <span class=""disease"">convulsive</span> <span class=""disease"">seizures</span> after cardiac surgery: a multivariate analysis in 11 529 patients."		46.0	46_MESH:D014148_MESH:D012640	46_0	bcv_final_eval_easy_221		
	MESH:D014148	"<span class=""chemical"">tranexamic acid</span>"	MESH:D006333	"<span class=""disease"">congestive heart failure</span>"	"Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, <span class=""disease"">congestive heart failure</span>, deep hypothermic circulatory arrest, duration of aortic cross-clamp and <span class=""chemical"">tranexamic acid</span>."		46.0	46_MESH:D014148_MESH:D006333	46_8	bcv_final_eval_easy_222		
	MESH:D014148	"<span class=""chemical"">tranexamic acid</span>"	MESH:D006323	"<span class=""disease"">circulatory arrest</span>"	"Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic <span class=""disease"">circulatory arrest</span>, duration of aortic cross-clamp and <span class=""chemical"">tranexamic acid</span>."		46.0	46_MESH:D014148_MESH:D006323	46_8	bcv_final_eval_easy_223		
	MESH:D014148	"<span class=""chemical"">tranexamic acid</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Independent predictors of postoperative <span class=""disease"">seizures</span> included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and <span class=""chemical"">tranexamic acid</span>."		46.0	46_MESH:D014148_MESH:D012640	46_8	bcv_final_eval_easy_224		
	MESH:D014148	"<span class=""chemical"">tranexamic acid</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"When tested in a multivariate regression analysis, <span class=""chemical"">tranexamic acid</span> was a strong independent predictor of <span class=""disease"">seizures</span> (OR 14.3, 95% CI 5.5-36.7; p < 0.001)."		46.0	46_MESH:D014148_MESH:D012640	46_9	bcv_final_eval_easy_225		
	MESH:D014148	"<span class=""chemical"">tranexamic acid</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"As <span class=""chemical"">tranexamic acid</span> is the only modifiable factor, its administration, particularly in doses exceeding 80 mg.kg(-1), should be weighed against the risk of postoperative <span class=""disease"">seizures</span>."		46.0	46_MESH:D014148_MESH:D012640	46_13	bcv_final_eval_easy_226		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D012893	"<span class=""disease"">sleep-related impairments</span>"	"Previous studies indicate that <span class=""chemical"">ecstasy</span> users have marked and persistent neurocognitive and <span class=""disease"">sleep-related impairments</span>."		47.0	47_MESH:D018817_MESH:D012893	47_2	bcv_final_eval_easy_227		
	MESH:D018817	"<span class=""chemical"">ecstasy</span>"	MESH:D008569	"<span class=""disease"">memory impairments</span>"	"We suggest that <span class=""chemical"">ecstasy</span>-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation <span class=""disease"">memory impairments</span> in regular <span class=""chemical"">ecstasy</span> users."		47.0	47_MESH:D018817_MESH:D008569	47_8	bcv_final_eval_easy_228		
	MESH:D014635	"<span class=""chemical"">valproate</span>"	MESH:D010291	"<span class=""disease"">unilateral hemiparesis</span>"	"In the preceding months, the patient had a number of admissions with transient <span class=""disease"">unilateral hemiparesis</span> with facial droop, and had been started on <span class=""chemical"">valproate</span> for presumed hemiplegic migraine."		48.0	48_MESH:D014635_MESH:D010291	48_2	bcv_final_eval_easy_229		
	MESH:D014635	"<span class=""chemical"">valproate</span>"	MESH:D008881	"<span class=""disease"">hemiplegic migraine</span>"	"In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on <span class=""chemical"">valproate</span> for presumed <span class=""disease"">hemiplegic migraine</span>."		48.0	48_MESH:D014635_MESH:D008881	48_2	bcv_final_eval_easy_230		
	MESH:D016202	"<span class=""chemical"">NMDA/N-methyl-D-aspartate</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"EEG undertaken during inpatient stay showed changes consistent with <span class=""disease"">encephalopathy</span>, and low titre <span class=""chemical"">N-methyl-D-aspartate</span> (<span class=""chemical"">NMDA</span>) receptor antibodies were present in this patient."		48.0	48_MESH:D016202_MESH:D001927	48_5	bcv_final_eval_easy_231		
	MESH:D016202	"<span class=""chemical"">NMDA</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"The possible aetiologies of valproate-induced <span class=""disease"">encephalopathy</span> and <span class=""chemical"">NMDA</span> receptor-associated encephalitis present a diagnostic dilemma."		48.0	48_MESH:D016202_MESH:D001927	48_6	bcv_final_eval_easy_232		
	MESH:D014635	"<span class=""chemical"">valproate</span>"	MESH:D004660	"<span class=""disease"">encephalitis</span>"	"The possible aetiologies of <span class=""chemical"">valproate</span>-induced encephalopathy and NMDA receptor-associated <span class=""disease"">encephalitis</span> present a diagnostic dilemma."		48.0	48_MESH:D014635_MESH:D004660	48_6	bcv_final_eval_easy_233		
	MESH:D016202	"<span class=""chemical"">NMDA</span>"	MESH:D004660	"<span class=""disease"">encephalitis</span>"	"The possible aetiologies of valproate-induced encephalopathy and <span class=""chemical"">NMDA</span> receptor-associated <span class=""disease"">encephalitis</span> present a diagnostic dilemma."		48.0	48_MESH:D016202_MESH:D004660	48_6	bcv_final_eval_easy_234		
	MESH:D008614	"<span class=""chemical"">pethidine</span>"	MESH:D002526	"<span class=""disease"">Cerebellar and oculomotor dysfunction</span>"	"<span class=""disease"">Cerebellar and oculomotor dysfunction</span> induced by rapid infusion of <span class=""chemical"">pethidine</span>."		49.0	49_MESH:D008614_MESH:D002526	49_0	bcv_final_eval_easy_235		
	MESH:D008614	"<span class=""chemical"">Pethidine</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"<span class=""chemical"">Pethidine</span> is an opioid that gains its popularity for the effective <span class=""disease"">pain</span> control through acting on the opioid-receptors."		49.0	49_MESH:D008614_MESH:D010146	49_1	bcv_final_eval_easy_236		
	MESH:C002752	"<span class=""chemical"">norpethidine</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"In patients with impaired renal and liver function, and those who need long-term <span class=""disease"">pain</span> control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <span class=""chemical"">norpethidine</span>, resulting in irritability and seizure attack."		49.0	49_MESH:C002752_MESH:D010146	49_4	bcv_final_eval_easy_237		
	MESH:D008614	"<span class=""chemical"">pethidine</span>"	MESH:D001523	"<span class=""disease"">irritability</span>"	"In patients with impaired renal and liver function, and those who need long-term pain control, <span class=""chemical"">pethidine</span> may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in <span class=""disease"">irritability</span> and seizure attack."		49.0	49_MESH:D008614_MESH:D001523	49_4	bcv_final_eval_easy_238		
	MESH:D008614	"<span class=""chemical"">pethidine</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"In patients with impaired renal and liver function, and those who need long-term pain control, <span class=""chemical"">pethidine</span> may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and <span class=""disease"">seizure</span> attack."		49.0	49_MESH:D008614_MESH:D012640	49_4	bcv_final_eval_easy_239		
	MESH:D008614	"<span class=""chemical"">pethidine</span>"	MESH:D051437	"<span class=""disease"">impaired renal and liver function</span>"	"In patients with <span class=""disease"">impaired renal and liver function</span>, and those who need long-term pain control, <span class=""chemical"">pethidine</span> may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack."		49.0	49_MESH:D008614_MESH:D051437	49_4	bcv_final_eval_easy_240		
	MESH:C002752	"<span class=""chemical"">norpethidine</span>"	MESH:D051437	"<span class=""disease"">impaired renal and liver function</span>"	"In patients with <span class=""disease"">impaired renal and liver function</span>, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <span class=""chemical"">norpethidine</span>, resulting in irritability and seizure attack."		49.0	49_MESH:C002752_MESH:D051437	49_4	bcv_final_eval_easy_241		
	MESH:D008614	"<span class=""chemical"">pethidine</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"In patients with impaired renal and liver function, and those who need long-term <span class=""disease"">pain</span> control, <span class=""chemical"">pethidine</span> may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack."		49.0	49_MESH:D008614_MESH:D010146	49_4	bcv_final_eval_easy_242		
	MESH:C002752	"<span class=""chemical"">norpethidine</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <span class=""chemical"">norpethidine</span>, resulting in irritability and <span class=""disease"">seizure</span> attack."		49.0	49_MESH:C002752_MESH:D012640	49_4	bcv_final_eval_easy_243		
	MESH:C002752	"<span class=""chemical"">norpethidine</span>"	MESH:D001523	"<span class=""disease"">irritability</span>"	"In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <span class=""chemical"">norpethidine</span>, resulting in <span class=""disease"">irritability</span> and seizure attack."		49.0	49_MESH:C002752_MESH:D001523	49_4	bcv_final_eval_easy_244		
	MESH:D007654	"<span class=""chemical"">ketoconazole</span>"	MESH:D003875	"<span class=""disease"">eruption</span>"	"A 27-year-old male patient presented with a maculopapular <span class=""disease"">eruption</span> on the flexural areas and buttocks after using oral <span class=""chemical"">ketoconazole</span>."		50.0	50_MESH:D007654_MESH:D003875	50_1	bcv_final_eval_easy_245		
	MESH:C042288	"<span class=""chemical"">Pilsicainide</span>"	MESH:D003643	"<span class=""disease"">Cardiac Death</span>"	"A Case of Sudden <span class=""disease"">Cardiac Death</span> due to <span class=""chemical"">Pilsicainide</span>-Induced Torsades de Pointes."		51.0	51_MESH:C042288_MESH:D003643	51_0	bcv_final_eval_easy_246		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D016757	"<span class=""disease"">sudden cardiac death</span>"	"An 84-year-old male received oral pilsicainide, a pure <span class=""chemical"">sodium</span> channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed <span class=""disease"">sudden cardiac death</span> two days later."		51.0	51_MESH:D012964_MESH:D016757	51_1	bcv_final_eval_easy_247		
	MESH:C042288	"<span class=""chemical"">pilsicainide</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"An 84-year-old male received oral <span class=""chemical"">pilsicainide</span>, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal <span class=""disease"">atrial fibrillation</span> to a sinus rhythm; the patient developed sudden cardiac death two days later."		51.0	51_MESH:C042288_MESH:D001281	51_1	bcv_final_eval_easy_248		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"An 84-year-old male received oral pilsicainide, a pure <span class=""chemical"">sodium</span> channel blocker with slow recovery kinetics, to convert his paroxysmal <span class=""disease"">atrial fibrillation</span> to a sinus rhythm; the patient developed sudden cardiac death two days later."		51.0	51_MESH:D012964_MESH:D001281	51_1	bcv_final_eval_easy_249		
	MESH:C042288	"<span class=""chemical"">pilsicainide</span>"	MESH:D016757	"<span class=""disease"">sudden cardiac death</span>"	"An 84-year-old male received oral <span class=""chemical"">pilsicainide</span>, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed <span class=""disease"">sudden cardiac death</span> two days later."		51.0	51_MESH:C042288_MESH:D016757	51_1	bcv_final_eval_easy_250		
	MESH:C042288	"<span class=""chemical"">pilsicainide</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"Although the oral administration of class IC drugs, including <span class=""chemical"">pilsicainide</span>, is effective to terminate <span class=""disease"">atrial fibrillation</span>, careful consideration must be taken before giving these drugs to octogenarians."		51.0	51_MESH:C042288_MESH:D001281	51_5	bcv_final_eval_easy_251		
	MESH:D014212	"<span class=""chemical"">All-trans retinoic acid</span>"	MESH:D015473	"<span class=""disease"">acute promyelocytic leukemia</span>"	"<span class=""chemical"">All-trans retinoic acid</span>-induced inflammatory myositis in a patient with <span class=""disease"">acute promyelocytic leukemia</span>."		52.0	52_MESH:D014212_MESH:D015473	52_0	bcv_final_eval_easy_252		
	MESH:D014212	"<span class=""chemical"">ATRA/All-trans retinoic acid</span>"	MESH:D015473	"<span class=""disease"">APL/acute promyelocytic leukemia</span>"	"<span class=""chemical"">All-trans retinoic acid</span> (<span class=""chemical"">ATRA</span>), a component of standard therapy for <span class=""disease"">acute promyelocytic leukemia</span> (<span class=""disease"">APL</span>), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement."		52.0	52_MESH:D014212_MESH:D015473	52_1	bcv_final_eval_easy_253		
	MESH:D008130	"<span class=""chemical"">lomustine</span>"	MESH:D008223	"<span class=""disease"">lymphoma</span>"	"Tolerability of <span class=""chemical"">lomustine</span> in combination with cyclophosphamide in dogs with <span class=""disease"">lymphoma</span>."		53.0	53_MESH:D008130_MESH:D008223	53_0	bcv_final_eval_easy_254		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D008223	"<span class=""disease"">lymphoma</span>"	"Tolerability of lomustine in combination with <span class=""chemical"">cyclophosphamide</span> in dogs with <span class=""disease"">lymphoma</span>."		53.0	53_MESH:D003520_MESH:D008223	53_0	bcv_final_eval_easy_255		
	MESH:D008130	"<span class=""chemical"">CCNU/lomustine</span>"	MESH:D008223	"<span class=""disease"">lymphoma</span>"	"This retrospective study describes toxicity associated with a protocol of <span class=""chemical"">lomustine</span> (<span class=""chemical"">CCNU</span>) and cyclophosphamide (CTX) in dogs with <span class=""disease"">lymphoma</span>."		53.0	53_MESH:D008130_MESH:D008223	53_1	bcv_final_eval_easy_256		
	MESH:D008130	"<span class=""chemical"">CCNU/lomustine</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"This retrospective study describes <span class=""disease"">toxicity</span> associated with a protocol of <span class=""chemical"">lomustine</span> (<span class=""chemical"">CCNU</span>) and cyclophosphamide (CTX) in dogs with lymphoma."		53.0	53_MESH:D008130_MESH:D064420	53_1	bcv_final_eval_easy_257		
	MESH:D003520	"<span class=""chemical"">CTX/cyclophosphamide</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"This retrospective study describes <span class=""disease"">toxicity</span> associated with a protocol of lomustine (CCNU) and <span class=""chemical"">cyclophosphamide</span> (<span class=""chemical"">CTX</span>) in dogs with lymphoma."		53.0	53_MESH:D003520_MESH:D064420	53_1	bcv_final_eval_easy_258		
	MESH:D003520	"<span class=""chemical"">CTX/cyclophosphamide</span>"	MESH:D008223	"<span class=""disease"">lymphoma</span>"	"This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and <span class=""chemical"">cyclophosphamide</span> (<span class=""chemical"">CTX</span>) in dogs with <span class=""disease"">lymphoma</span>."		53.0	53_MESH:D003520_MESH:D008223	53_1	bcv_final_eval_easy_259		
	MESH:D008130	"<span class=""chemical"">CCNU</span>"	MESH:D009503	"<span class=""disease"">Neutropenia</span>"	"<span class=""disease"">Neutropenia</span> was the principal toxic effect, and the overall frequency of grade 4 <span class=""disease"">neutropenia</span> after the first treatment of <span class=""chemical"">CCNU</span>/CTX was 30% (95% confidence interval, 19-43%)."		53.0	53_MESH:D008130_MESH:D009503	53_4	bcv_final_eval_easy_260		
	MESH:D003520	"<span class=""chemical"">CTX</span>"	MESH:D009503	"<span class=""disease"">Neutropenia</span>"	"<span class=""disease"">Neutropenia</span> was the principal toxic effect, and the overall frequency of grade 4 <span class=""disease"">neutropenia</span> after the first treatment of CCNU/<span class=""chemical"">CTX</span> was 30% (95% confidence interval, 19-43%)."		53.0	53_MESH:D003520_MESH:D009503	53_4	bcv_final_eval_easy_261		
	MESH:D008130	"<span class=""chemical"">CCNU</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"On the basis of the findings reported herein, a dose of 60 mg/m(2) of <span class=""chemical"">CCNU</span> combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in <span class=""disease"">tumor</span>-bearing dogs."		53.0	53_MESH:D008130_MESH:D009369	53_9	bcv_final_eval_easy_262		
	MESH:D003520	"<span class=""chemical"">CTX</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of <span class=""chemical"">CTX</span> (divided over 5 days) q 4 wk is tolerable in <span class=""disease"">tumor</span>-bearing dogs."		53.0	53_MESH:D003520_MESH:D009369	53_9	bcv_final_eval_easy_263		
	MESH:C104457	"<span class=""chemical"">Nelarabine</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"<span class=""chemical"">Nelarabine</span> <span class=""disease"">neurotoxicity</span> with concurrent intrathecal chemotherapy: Case report and review of literature."		54.0	54_MESH:C104457_MESH:D020258	54_0	bcv_final_eval_easy_264		
	MESH:C104457	"<span class=""chemical"">nelarabine</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"Severe <span class=""chemical"">nelarabine</span> <span class=""disease"">neurotoxicity</span> in a patient who received concurrent intrathecal (IT) chemotherapy is reported."		54.0	54_MESH:C104457_MESH:D020258	54_1	bcv_final_eval_easy_265		
	MESH:C104457	"<span class=""chemical"">nelarabine</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"To our knowledge, this is the first published case report of severe <span class=""disease"">neurotoxicity</span> caused by <span class=""chemical"">nelarabine</span> in a patient who received concurrent IT chemotherapy."		54.0	54_MESH:C104457_MESH:D020258	54_15	bcv_final_eval_easy_266		
	MESH:D014635	"<span class=""chemical"">Valproate</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"<span class=""chemical"">Valproate</span>-induced hyperammonemic <span class=""disease"">encephalopathy</span> in a renal transplanted patient."		55.0	55_MESH:D014635_MESH:D001927	55_0	bcv_final_eval_easy_267		
	MESH:D014635	"<span class=""chemical"">Valproate</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"<span class=""chemical"">Valproate</span>-induced hyperammonemic <span class=""disease"">encephalopathy</span> is an uncommon but serious effect of <span class=""chemical"">valproate</span> treatment."		55.0	55_MESH:D014635_MESH:D001927	55_3	bcv_final_eval_easy_268		
	MESH:D014635	"<span class=""chemical"">valproate</span>"	MESH:D003244	"<span class=""disease"">impaired consciousness</span>"	"Here, we describe the case of a 15-year-old girl who was on a long-term therapy with <span class=""chemical"">valproate</span> due to epilepsy and revealed <span class=""disease"">impaired consciousness</span> with hyperammonemia 12 days after renal transplantation."		55.0	55_MESH:D014635_MESH:D003244	55_4	bcv_final_eval_easy_269		
	MESH:D014635	"<span class=""chemical"">valproate</span>"	MESH:D022124	"<span class=""disease"">hyperammonemia</span>"	"Here, we describe the case of a 15-year-old girl who was on a long-term therapy with <span class=""chemical"">valproate</span> due to epilepsy and revealed impaired consciousness with <span class=""disease"">hyperammonemia</span> 12 days after renal transplantation."		55.0	55_MESH:D014635_MESH:D022124	55_4	bcv_final_eval_easy_270		
	MESH:D014635	"<span class=""chemical"">valproate</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"Here, we describe the case of a 15-year-old girl who was on a long-term therapy with <span class=""chemical"">valproate</span> due to <span class=""disease"">epilepsy</span> and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation."		55.0	55_MESH:D014635_MESH:D004827	55_4	bcv_final_eval_easy_271		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D005208	"<span class=""disease"">Necrotising fasciitis</span>"	"<span class=""disease"">Necrotising fasciitis</span> after bortezomib and <span class=""chemical"">dexamethasone</span>-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia."		56.0	56_MESH:D003907_MESH:D005208	56_0	bcv_final_eval_easy_272		
	MESH:C400082	"<span class=""chemical"">bortezomib</span>"	MESH:D008258	"<span class=""disease"">Waldenstrom macroglobulinaemia</span>"	"Necrotising fasciitis after <span class=""chemical"">bortezomib</span> and dexamethasone-containing regimen in an elderly patient of <span class=""disease"">Waldenstrom macroglobulinaemia</span>."		56.0	56_MESH:C400082_MESH:D008258	56_0	bcv_final_eval_easy_273		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D008258	"<span class=""disease"">Waldenstrom macroglobulinaemia</span>"	"Necrotising fasciitis after bortezomib and <span class=""chemical"">dexamethasone</span>-containing regimen in an elderly patient of <span class=""disease"">Waldenstrom macroglobulinaemia</span>."		56.0	56_MESH:D003907_MESH:D008258	56_0	bcv_final_eval_easy_274		
	MESH:C400082	"<span class=""chemical"">bortezomib</span>"	MESH:D005208	"<span class=""disease"">Necrotising fasciitis</span>"	"<span class=""disease"">Necrotising fasciitis</span> after <span class=""chemical"">bortezomib</span> and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia."		56.0	56_MESH:C400082_MESH:D005208	56_0	bcv_final_eval_easy_275		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D001424	"<span class=""disease"">bacterial infections</span>"	"Bortezomib and high-dose <span class=""chemical"">dexamethasone</span>-containing regimens are considered to be generally tolerable with few severe <span class=""disease"">bacterial infections</span> in patients with B-cell malignancies."		56.0	56_MESH:D003907_MESH:D001424	56_1	bcv_final_eval_easy_276		
	MESH:C400082	"<span class=""chemical"">Bortezomib</span>"	MESH:D001424	"<span class=""disease"">bacterial infections</span>"	"<span class=""chemical"">Bortezomib</span> and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe <span class=""disease"">bacterial infections</span> in patients with B-cell malignancies."		56.0	56_MESH:C400082_MESH:D001424	56_1	bcv_final_eval_easy_277		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D005208	"<span class=""disease"">fasciitis</span>"	"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising <span class=""disease"">fasciitis</span> without neutropenia after the combination treatment with bortezomib, high-dose <span class=""chemical"">dexamethasone</span> and rituximab."		56.0	56_MESH:D003907_MESH:D005208	56_3	bcv_final_eval_easy_278		
	MESH:C400082	"<span class=""chemical"">bortezomib</span>"	MESH:D005208	"<span class=""disease"">fasciitis</span>"	"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising <span class=""disease"">fasciitis</span> without neutropenia after the combination treatment with <span class=""chemical"">bortezomib</span>, high-dose dexamethasone and rituximab."		56.0	56_MESH:C400082_MESH:D005208	56_3	bcv_final_eval_easy_279		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D009503	"<span class=""disease"">neutropenia</span>"	"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without <span class=""disease"">neutropenia</span> after the combination treatment with bortezomib, high-dose <span class=""chemical"">dexamethasone</span> and rituximab."		56.0	56_MESH:D003907_MESH:D009503	56_3	bcv_final_eval_easy_280		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D008258	"<span class=""disease"">Waldenstrom macroglobulinaemia</span>"	"We report a case of a 76-year-old man with <span class=""disease"">Waldenstrom macroglobulinaemia</span> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <span class=""chemical"">dexamethasone</span> and rituximab."		56.0	56_MESH:D003907_MESH:D008258	56_3	bcv_final_eval_easy_281		
	MESH:C400082	"<span class=""chemical"">bortezomib</span>"	MESH:D009503	"<span class=""disease"">neutropenia</span>"	"We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without <span class=""disease"">neutropenia</span> after the combination treatment with <span class=""chemical"">bortezomib</span>, high-dose dexamethasone and rituximab."		56.0	56_MESH:C400082_MESH:D009503	56_3	bcv_final_eval_easy_282		
	MESH:C400082	"<span class=""chemical"">bortezomib</span>"	MESH:D008258	"<span class=""disease"">Waldenstrom macroglobulinaemia</span>"	"We report a case of a 76-year-old man with <span class=""disease"">Waldenstrom macroglobulinaemia</span> who suffered necrotising fasciitis without neutropenia after the combination treatment with <span class=""chemical"">bortezomib</span>, high-dose dexamethasone and rituximab."		56.0	56_MESH:C400082_MESH:D008258	56_3	bcv_final_eval_easy_283		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D001424	"<span class=""disease"">bacterial infections</span>"	"Physicians should recognise the possibility of fatal <span class=""disease"">bacterial infections</span> related to bortezomib plus high-dose <span class=""chemical"">dexamethasone</span> in elderly patients, and we believe this case warrants further investigation."		56.0	56_MESH:D003907_MESH:D001424	56_5	bcv_final_eval_easy_284		
	MESH:C400082	"<span class=""chemical"">bortezomib</span>"	MESH:D001424	"<span class=""disease"">bacterial infections</span>"	"Physicians should recognise the possibility of fatal <span class=""disease"">bacterial infections</span> related to <span class=""chemical"">bortezomib</span> plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation."		56.0	56_MESH:C400082_MESH:D001424	56_5	bcv_final_eval_easy_285		
	MESH:D004317	"<span class=""chemical"">doxorubicin/DOX</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"In this study, we have utilized a rat model of progressive <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">DOX</span>)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this <span class=""disease"">toxicity</span>."		57.0	57_MESH:D004317_MESH:D064420	57_2	bcv_final_eval_easy_286		
	MESH:D005682	"<span class=""chemical"">gadolinium</span>"	MESH:D008107	"<span class=""disease"">diastolic dysfunction</span>"	"Troponin I levels positively correlated with delayed and peak <span class=""chemical"">gadolinium</span> contrast enhancement, histopathological grading, and <span class=""disease"">diastolic dysfunction</span>."		57.0	57_MESH:D005682_MESH:D008107	57_9	bcv_final_eval_easy_287		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia/allodynia</span>"	"Intradermal glutamate and <span class=""chemical"">capsaicin</span> injections: intra- and interindividual variability of provoked <span class=""disease"">hyperalgesia</span> and <span class=""disease"">allodynia</span>."		58.0	58_MESH:D002211_MESH:D006930	58_0	bcv_final_eval_easy_288		
	MESH:D018698	"<span class=""chemical"">glutamate</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia/allodynia</span>"	"Intradermal <span class=""chemical"">glutamate</span> and capsaicin injections: intra- and interindividual variability of provoked <span class=""disease"">hyperalgesia</span> and <span class=""disease"">allodynia</span>."		58.0	58_MESH:D018698_MESH:D006930	58_0	bcv_final_eval_easy_289		
	MESH:D018698	"<span class=""chemical"">glutamate</span>"	MESH:D010146	"<span class=""disease"">pain disorders/experimental pain</span>"	"Intradermal injections of <span class=""chemical"">glutamate</span> and capsaicin are attractive to use in human <span class=""disease"">experimental pain</span> models because hyperalgesia and allodynia mimic isolated aspects of clinical <span class=""disease"">pain disorders</span>."		58.0	58_MESH:D018698_MESH:D010146	58_1	bcv_final_eval_easy_290		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D010146	"<span class=""disease"">pain disorders/experimental pain</span>"	"Intradermal injections of glutamate and <span class=""chemical"">capsaicin</span> are attractive to use in human <span class=""disease"">experimental pain</span> models because hyperalgesia and allodynia mimic isolated aspects of clinical <span class=""disease"">pain disorders</span>."		58.0	58_MESH:D002211_MESH:D010146	58_1	bcv_final_eval_easy_291		
	MESH:D018698	"<span class=""chemical"">glutamate</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia/allodynia</span>"	"Intradermal injections of <span class=""chemical"">glutamate</span> and capsaicin are attractive to use in human experimental pain models because <span class=""disease"">hyperalgesia</span> and <span class=""disease"">allodynia</span> mimic isolated aspects of clinical pain disorders."		58.0	58_MESH:D018698_MESH:D006930	58_1	bcv_final_eval_easy_292		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia/allodynia</span>"	"Intradermal injections of glutamate and <span class=""chemical"">capsaicin</span> are attractive to use in human experimental pain models because <span class=""disease"">hyperalgesia</span> and <span class=""disease"">allodynia</span> mimic isolated aspects of clinical pain disorders."		58.0	58_MESH:D002211_MESH:D006930	58_1	bcv_final_eval_easy_293		
	MESH:D018698	"<span class=""chemical"">glutamate</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia</span>"	"Secondary pinprick <span class=""disease"">hyperalgesia</span> was observed as a marked increase in the visual analogue scale (VAS) response to von Frey gauges 60 and 100 g (P < 0.001) after <span class=""chemical"">glutamate</span> injection."		58.0	58_MESH:D018698_MESH:D006930	58_8	bcv_final_eval_easy_294		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia</span>"	"For <span class=""chemical"">capsaicin</span>, secondary pinprick <span class=""disease"">hyperalgesia</span> was detected with all von Frey gauges (P < 0.001)."		58.0	58_MESH:D002211_MESH:D006930	58_9	bcv_final_eval_easy_295		
	MESH:D018698	"<span class=""chemical"">Glutamate</span>"	MESH:D020521	"<span class=""disease"">brush strokes</span>"	"<span class=""chemical"">Glutamate</span> evoked reproducible VAS response to all von Frey gauges (ICC > 0.60) and <span class=""disease"">brush strokes</span> (ICC > 0.83)."		58.0	58_MESH:D018698_MESH:D020521	58_10	bcv_final_eval_easy_296		
	MESH:D002211	"<span class=""chemical"">Capsaicin</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia/allodynia</span>"	"<span class=""chemical"">Capsaicin</span> injection was reproducible for secondary <span class=""disease"">hyperalgesia</span> (ICC > 0.70) and <span class=""disease"">allodynia</span> (ICC > 0.71)."		58.0	58_MESH:D002211_MESH:D006930	58_11	bcv_final_eval_easy_297		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D006930	"<span class=""disease"">hyperalgesic</span>"	"In conclusion, glutamate and <span class=""chemical"">capsaicin</span> yield reproducible <span class=""disease"">hyperalgesic</span> and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena."		58.0	58_MESH:D002211_MESH:D006930	58_13	bcv_final_eval_easy_298		
	MESH:D018698	"<span class=""chemical"">glutamate</span>"	MESH:D006930	"<span class=""disease"">hyperalgesic</span>"	"In conclusion, <span class=""chemical"">glutamate</span> and capsaicin yield reproducible <span class=""disease"">hyperalgesic</span> and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena."		58.0	58_MESH:D018698_MESH:D006930	58_13	bcv_final_eval_easy_299		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D009410	"<span class=""disease"">axonal degeneration</span>"	"Treatment of WT mice with topical ocular 0.1% <span class=""chemical"">dexamethasone</span> led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and <span class=""disease"">axonal degeneration</span>, resembling glucocorticoid-induced glaucoma in human patients."		59.0	59_MESH:D003907_MESH:D009410	59_5	bcv_final_eval_easy_300		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D028361	"<span class=""disease"">structural loss of retinal ganglion</span>"	"Treatment of WT mice with topical ocular 0.1% <span class=""chemical"">dexamethasone</span> led to elevation of intraocular pressure (IOP), functional and <span class=""disease"">structural loss of retinal ganglion</span> cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients."		59.0	59_MESH:D003907_MESH:D028361	59_5	bcv_final_eval_easy_301		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D005901	"<span class=""disease"">glaucoma</span>"	"Treatment of WT mice with topical ocular 0.1% <span class=""chemical"">dexamethasone</span> led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced <span class=""disease"">glaucoma</span> in human patients."		59.0	59_MESH:D003907_MESH:D005901	59_5	bcv_final_eval_easy_302		
	MESH:D003907	"<span class=""chemical"">Dexamethasone</span>"	MESH:D002872	"<span class=""disease"">Chop deletion</span>"	"<span class=""chemical"">Dexamethasone</span> induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and <span class=""disease"">Chop deletion</span> reduced ER stress in these tissues and prevented <span class=""chemical"">dexamethasone</span>-induced ocular hypertension."		59.0	59_MESH:D003907_MESH:D002872	59_8	bcv_final_eval_easy_303		
	MESH:C075773	"<span class=""chemical"">sodium 4-phenylbutyrate</span>"	MESH:D006973	"<span class=""disease"">ocular hypertension</span>"	"Furthermore, reduction of ER stress in the TM with <span class=""chemical"">sodium 4-phenylbutyrate</span> prevented dexamethasone-induced <span class=""disease"">ocular hypertension</span> in WT mice."		59.0	59_MESH:C075773_MESH:D006973	59_9	bcv_final_eval_easy_304		
	MESH:D036145	"<span class=""chemical"">ginsenosides</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia</span>"	"Effects of <span class=""chemical"">ginsenosides</span> on opioid-induced <span class=""disease"">hyperalgesia</span> in mice."		60.0	60_MESH:D036145_MESH:D006930	60_0	bcv_final_eval_easy_305		
	MESH:D020927	"<span class=""chemical"">dexmedetomidine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"CONCLUSIONS: Severe <span class=""disease"">hypotension</span> and bradycardia occur at similar prevalence in neurocritical care patients who receive <span class=""chemical"">dexmedetomidine</span> or propofol."		61.0	61_MESH:D020927_MESH:D007022	61_12	bcv_final_eval_easy_306		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"CONCLUSIONS: Severe <span class=""disease"">hypotension</span> and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <span class=""chemical"">propofol</span>."		61.0	61_MESH:D015742_MESH:D007022	61_12	bcv_final_eval_easy_307		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"CONCLUSIONS: Severe hypotension and <span class=""disease"">bradycardia</span> occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <span class=""chemical"">propofol</span>."		61.0	61_MESH:D015742_MESH:D001919	61_12	bcv_final_eval_easy_308		
	MESH:D020927	"<span class=""chemical"">dexmedetomidine</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"CONCLUSIONS: Severe hypotension and <span class=""disease"">bradycardia</span> occur at similar prevalence in neurocritical care patients who receive <span class=""chemical"">dexmedetomidine</span> or propofol."		61.0	61_MESH:D020927_MESH:D001919	61_12	bcv_final_eval_easy_309		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in <span class=""chemical"">doxorubicin</span>-induced cardiotoxicity in rats with <span class=""disease"">breast cancer</span>."		62.0	62_MESH:D004317_MESH:D001943	62_0	bcv_final_eval_easy_310		
	MESH:C005975	"<span class=""chemical"">Hydroxytyrosol</span>"	MESH:D028361	"<span class=""disease"">mitochondrial dysfunction</span>"	"<span class=""chemical"">Hydroxytyrosol</span> ameliorates oxidative stress and <span class=""disease"">mitochondrial dysfunction</span> in doxorubicin-induced cardiotoxicity in rats with breast cancer."		62.0	62_MESH:C005975_MESH:D028361	62_0	bcv_final_eval_easy_311		
	MESH:C005975	"<span class=""chemical"">Hydroxytyrosol</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"<span class=""chemical"">Hydroxytyrosol</span> ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced <span class=""disease"">cardiotoxicity</span> in rats with breast cancer."		62.0	62_MESH:C005975_MESH:D066126	62_0	bcv_final_eval_easy_312		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D028361	"<span class=""disease"">mitochondrial dysfunction</span>"	"Hydroxytyrosol ameliorates oxidative stress and <span class=""disease"">mitochondrial dysfunction</span> in <span class=""chemical"">doxorubicin</span>-induced cardiotoxicity in rats with breast cancer."		62.0	62_MESH:D004317_MESH:D028361	62_0	bcv_final_eval_easy_313		
	MESH:C005975	"<span class=""chemical"">Hydroxytyrosol</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"<span class=""chemical"">Hydroxytyrosol</span> ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with <span class=""disease"">breast cancer</span>."		62.0	62_MESH:C005975_MESH:D001943	62_0	bcv_final_eval_easy_314		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D002318	"<span class=""disease"">cardiovascular disease</span>"	"Oxidative stress is involved in several processes including cancer, aging and <span class=""disease"">cardiovascular disease</span>, and has been shown to potentiate the therapeutic effect of drugs such as <span class=""chemical"">doxorubicin</span>."		62.0	62_MESH:D004317_MESH:D002318	62_1	bcv_final_eval_easy_315		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"Oxidative stress is involved in several processes including <span class=""disease"">cancer</span>, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as <span class=""chemical"">doxorubicin</span>."		62.0	62_MESH:D004317_MESH:D009369	62_1	bcv_final_eval_easy_316		
	MESH:D004317	"<span class=""chemical"">Doxorubicin</span>"	MESH:D028361	"<span class=""disease"">mitochondrial dysfunction</span>"	"<span class=""chemical"">Doxorubicin</span> causes significant cardiotoxicity characterized by marked increases in oxidative stress and <span class=""disease"">mitochondrial dysfunction</span>."		62.0	62_MESH:D004317_MESH:D028361	62_2	bcv_final_eval_easy_317		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"Herein, we investigate whether <span class=""chemical"">doxorubicin</span>-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with <span class=""disease"">breast cancer</span>."		62.0	62_MESH:D004317_MESH:D001943	62_3	bcv_final_eval_easy_318		
	MESH:C005975	"<span class=""chemical"">hydroxytyrosol</span>"	MESH:D066126	"<span class=""disease"">cardiac toxicity</span>"	"Herein, we investigate whether doxorubicin-associated chronic <span class=""disease"">cardiac toxicity</span> can be ameliorated with the antioxidant <span class=""chemical"">hydroxytyrosol</span> in rats with breast cancer."		62.0	62_MESH:C005975_MESH:D066126	62_3	bcv_final_eval_easy_319		
	MESH:C005975	"<span class=""chemical"">hydroxytyrosol</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant <span class=""chemical"">hydroxytyrosol</span> in rats with <span class=""disease"">breast cancer</span>."		62.0	62_MESH:C005975_MESH:D001943	62_3	bcv_final_eval_easy_320		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D001943	"<span class=""disease"">breast tumors</span>"	"Thirty-six rats bearing <span class=""disease"">breast tumors</span> induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), <span class=""chemical"">doxorubicin</span> (1mg/kg/week), and <span class=""chemical"">doxorubicin</span> plus hydroxytyrosol."		62.0	62_MESH:D004317_MESH:D001943	62_4	bcv_final_eval_easy_321		
	MESH:C005975	"<span class=""chemical"">hydroxytyrosol</span>"	MESH:D001943	"<span class=""disease"">breast tumors</span>"	"Thirty-six rats bearing <span class=""disease"">breast tumors</span> induced chemically were divided into 4 groups: control, <span class=""chemical"">hydroxytyrosol</span> (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus <span class=""chemical"">hydroxytyrosol</span>."		62.0	62_MESH:C005975_MESH:D001943	62_4	bcv_final_eval_easy_322		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D006331	"<span class=""disease"">cardiac disturbances</span>"	"Hydroxytyrosol improved the <span class=""disease"">cardiac disturbances</span> enhanced by <span class=""chemical"">doxorubicin</span> by significantly reducing the percentage of altered mitochondria and oxidative damage."		62.0	62_MESH:D004317_MESH:D006331	62_6	bcv_final_eval_easy_323		
	MESH:C005975	"<span class=""chemical"">Hydroxytyrosol</span>"	MESH:D006331	"<span class=""disease"">cardiac disturbances</span>"	"<span class=""chemical"">Hydroxytyrosol</span> improved the <span class=""disease"">cardiac disturbances</span> enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage."		62.0	62_MESH:C005975_MESH:D006331	62_6	bcv_final_eval_easy_324		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D012131	"<span class=""disease"">respiratory failure</span>"	"A 62-year-old man was found to have bradycardia, hypothermia and <span class=""disease"">respiratory failure</span> 3 weeks after initiation of <span class=""chemical"">amiodarone</span> therapy for atrial fibrillation."		63.0	63_MESH:D000638_MESH:D012131	63_1	bcv_final_eval_easy_325		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"A 62-year-old man was found to have <span class=""disease"">bradycardia</span>, hypothermia and respiratory failure 3 weeks after initiation of <span class=""chemical"">amiodarone</span> therapy for atrial fibrillation."		63.0	63_MESH:D000638_MESH:D001919	63_1	bcv_final_eval_easy_326		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D007035	"<span class=""disease"">hypothermia</span>"	"A 62-year-old man was found to have bradycardia, <span class=""disease"">hypothermia</span> and respiratory failure 3 weeks after initiation of <span class=""chemical"">amiodarone</span> therapy for atrial fibrillation."		63.0	63_MESH:D000638_MESH:D007035	63_1	bcv_final_eval_easy_327		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of <span class=""chemical"">amiodarone</span> therapy for <span class=""disease"">atrial fibrillation</span>."		63.0	63_MESH:D000638_MESH:D001281	63_1	bcv_final_eval_easy_328		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"The only two cases of <span class=""chemical"">amiodarone</span>-induced myxoedema coma in the literature report patient <span class=""disease"">death</span> despite supportive therapy and thyroid hormone replacement."		63.0	63_MESH:D000638_MESH:D003643	63_8	bcv_final_eval_easy_329		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D013959	"<span class=""disease"">subclinical thyroid disease</span>"	"This case represents the most thoroughly investigated case of <span class=""chemical"">amiodarone</span>-induced myxoedema coma with a history significant for <span class=""disease"">subclinical thyroid disease</span>."		63.0	63_MESH:D000638_MESH:D013959	63_9	bcv_final_eval_easy_330		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013921	"<span class=""disease"">heparin-induced thrombocytopenia with thrombosis</span>"	"Use of <span class=""chemical"">argatroban</span> and catheter-directed thrombolysis with alteplase in an oncology patient with <span class=""disease"">heparin-induced thrombocytopenia with thrombosis</span>."		64.0	64_MESH:C031942_MESH:D013921	64_0	bcv_final_eval_easy_331		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013921	"<span class=""disease"">heparin-induced thrombocytopenia with thrombosis/HITT</span>"	"PURPOSE: The case of an oncology patient who developed <span class=""disease"">heparin-induced thrombocytopenia with thrombosis</span> (<span class=""disease"">HITT</span>) and was treated with <span class=""chemical"">argatroban</span> plus catheter-directed thrombolysis (CDT) with alteplase is presented."		64.0	64_MESH:C031942_MESH:D013921	64_1	bcv_final_eval_easy_332		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D007674	"<span class=""disease"">renal amyloidosis</span>"	"SUMMARY: A 63-year-old Caucasian man with <span class=""disease"">renal amyloidosis</span> undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to <span class=""chemical"">heparin</span>-induced thrombocytopenia."		64.0	64_MESH:D006493_MESH:D007674	64_2	bcv_final_eval_easy_333		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D020246	"<span class=""disease"">DVT/deep venous thrombosis</span>"	"SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity <span class=""disease"">deep venous thrombosis</span> (<span class=""disease"">DVT</span>) and pulmonary embolism secondary to <span class=""chemical"">heparin</span>-induced thrombocytopenia."		64.0	64_MESH:D006493_MESH:D020246	64_2	bcv_final_eval_easy_334		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D011655	"<span class=""disease"">pulmonary embolism</span>"	"SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and <span class=""disease"">pulmonary embolism</span> secondary to <span class=""chemical"">heparin</span>-induced thrombocytopenia."		64.0	64_MESH:D006493_MESH:D011655	64_2	bcv_final_eval_easy_335		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D004844	"<span class=""disease"">epistaxis</span>"	"The <span class=""disease"">epistaxis</span> resolved the next day, and the patient was restarted on <span class=""chemical"">argatroban</span>."		64.0	64_MESH:C031942_MESH:D004844	64_6	bcv_final_eval_easy_336		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013479	"<span class=""disease"">SVC syndrome</span>"	"CONCLUSION: A 63-year-old man with renal amyloidosis and <span class=""disease"">SVC syndrome</span> secondary to HITT was successfully treated with <span class=""chemical"">argatroban</span> and CDT with alteplase."		64.0	64_MESH:C031942_MESH:D013479	64_11	bcv_final_eval_easy_337		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D007674	"<span class=""disease"">renal amyloidosis</span>"	"CONCLUSION: A 63-year-old man with <span class=""disease"">renal amyloidosis</span> and SVC syndrome secondary to HITT was successfully treated with <span class=""chemical"">argatroban</span> and CDT with alteplase."		64.0	64_MESH:C031942_MESH:D007674	64_11	bcv_final_eval_easy_338		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013921	"<span class=""disease"">HITT</span>"	"CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to <span class=""disease"">HITT</span> was successfully treated with <span class=""chemical"">argatroban</span> and CDT with alteplase."		64.0	64_MESH:C031942_MESH:D013921	64_11	bcv_final_eval_easy_339		
	MESH:D003687	"<span class=""chemical"">dehydroepiandrosterone</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"Effects of <span class=""chemical"">dehydroepiandrosterone</span> in amphetamine-induced <span class=""disease"">schizophrenia</span> models in mice."		65.0	65_MESH:D003687_MESH:D012559	65_0	bcv_final_eval_easy_340		
	MESH:D003687	"<span class=""chemical"">dehydroepiandrosterone/DHEA</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"OBJECTIVE: To examine the effects of <span class=""chemical"">dehydroepiandrosterone</span> (<span class=""chemical"">DHEA</span>) on animal models of <span class=""disease"">schizophrenia</span>."		65.0	65_MESH:D003687_MESH:D012559	65_1	bcv_final_eval_easy_341		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Amphetamine (3 mg/kg ip) induced hyper locomotion, <span class=""chemical"">apomorphine</span> (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced <span class=""disease"">catalepsy</span> tests were used as animal models of schizophrenia."		65.0	65_MESH:D001058_MESH:D002375	65_4	bcv_final_eval_easy_342		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D006948	"<span class=""disease"">hyper</span>"	"Amphetamine (3 mg/kg ip) induced <span class=""disease"">hyper</span> locomotion, <span class=""chemical"">apomorphine</span> (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia."		65.0	65_MESH:D001058_MESH:D006948	65_4	bcv_final_eval_easy_343		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"Amphetamine (3 mg/kg ip) induced hyper locomotion, <span class=""chemical"">apomorphine</span> (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of <span class=""disease"">schizophrenia</span>."		65.0	65_MESH:D001058_MESH:D012559	65_4	bcv_final_eval_easy_344		
	MESH:D000661	"<span class=""chemical"">Amphetamine</span>"	MESH:D006948	"<span class=""disease"">hyper</span>"	"<span class=""chemical"">Amphetamine</span> (3 mg/kg ip) induced <span class=""disease"">hyper</span> locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia."		65.0	65_MESH:D000661_MESH:D006948	65_4	bcv_final_eval_easy_345		
	MESH:D000661	"<span class=""chemical"">Amphetamine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"<span class=""chemical"">Amphetamine</span> (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced <span class=""disease"">catalepsy</span> tests were used as animal models of schizophrenia."		65.0	65_MESH:D000661_MESH:D002375	65_4	bcv_final_eval_easy_346		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and <span class=""chemical"">haloperidol</span> (1.5 mg/kg sc) induced catalepsy tests were used as animal models of <span class=""disease"">schizophrenia</span>."		65.0	65_MESH:D006220_MESH:D012559	65_4	bcv_final_eval_easy_347		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D006948	"<span class=""disease"">hyper</span>"	"Amphetamine (3 mg/kg ip) induced <span class=""disease"">hyper</span> locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and <span class=""chemical"">haloperidol</span> (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia."		65.0	65_MESH:D006220_MESH:D006948	65_4	bcv_final_eval_easy_348		
	MESH:D003687	"<span class=""chemical"">DHEA</span>"	MESH:D001523	"<span class=""disease"">DHEA reduced locomotor activity</span>"	"CONCLUSION: We observed that <span class=""chemical""></span><span class=""disease"">DHEA</span> reduced locomotor activity and increased catalepsy at both doses, while it had no effect on climbing behavior."		65.0	65_MESH:D003687_MESH:D001523	65_11	bcv_final_eval_easy_349		
	MESH:D003687	"<span class=""chemical"">DHEA</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"CONCLUSION: We observed that <span class=""chemical"">DHEA</span> reduced locomotor activity and increased <span class=""disease"">catalepsy</span> at both doses, while it had no effect on climbing behavior."		65.0	65_MESH:D003687_MESH:D002375	65_11	bcv_final_eval_easy_350		
	MESH:D003687	"<span class=""chemical"">DHEA</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"We suggest that <span class=""chemical"">DHEA</span> displays typical neuroleptic-like effects, and may be used in the treatment of <span class=""disease"">schizophrenia</span>."		65.0	65_MESH:D003687_MESH:D012559	65_12	bcv_final_eval_easy_351		
	MESH:D003687	"<span class=""chemical"">DHEA</span>"	MESH:D009459	"<span class=""disease"">neuroleptic</span>"	"We suggest that <span class=""chemical"">DHEA</span> displays typical <span class=""disease"">neuroleptic</span>-like effects, and may be used in the treatment of schizophrenia."		65.0	65_MESH:D003687_MESH:D009459	65_12	bcv_final_eval_easy_352		
	MESH:D016593	"<span class=""chemical"">Terfenadine</span>"	MESH:D016171	"<span class=""disease"">Torsade de Pointes/TdP</span>"	"Finally, the IKr blockers, <span class=""chemical"">Terfenadine</span> and Citalopram, which are reported to cause <span class=""disease"">Torsade de Pointes</span> (<span class=""disease"">TdP</span>) in clinical practice, produced early afterdepolarization (EAD)."		66.0	66_MESH:D016593_MESH:D016171	66_7	bcv_final_eval_easy_353		
	MESH:D015283	"<span class=""chemical"">Citalopram</span>"	MESH:D016171	"<span class=""disease"">Torsade de Pointes/TdP</span>"	"Finally, the IKr blockers, Terfenadine and <span class=""chemical"">Citalopram</span>, which are reported to cause <span class=""disease"">Torsade de Pointes</span> (<span class=""disease"">TdP</span>) in clinical practice, produced early afterdepolarization (EAD)."		66.0	66_MESH:D015283_MESH:D016171	66_7	bcv_final_eval_easy_354		
	MESH:C083440	"<span class=""chemical"">S-23121</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: S-53482 and <span class=""chemical"">S-23121</span> are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental <span class=""disease"">toxicity</span> studies."		67.0	67_MESH:C083440_MESH:D064420	67_1	bcv_final_eval_easy_355		
	MESH:C106487	"<span class=""chemical"">S-53482</span>"	MESH:D006345	"<span class=""disease"">ventricular septal defects</span>"	"BACKGROUND: <span class=""chemical"">S-53482</span> and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly <span class=""disease"">ventricular septal defects</span> and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies."		67.0	67_MESH:C106487_MESH:D006345	67_1	bcv_final_eval_easy_356		
	MESH:C083440	"<span class=""chemical"">S-23121</span>"	MESH:D006130	"<span class=""disease"">growth retardation</span>"	"BACKGROUND: S-53482 and <span class=""chemical"">S-23121</span> are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and <span class=""disease"">growth retardation</span> in rats in conventional oral developmental toxicity studies."		67.0	67_MESH:C083440_MESH:D006130	67_1	bcv_final_eval_easy_357		
	MESH:C083440	"<span class=""chemical"">S-23121</span>"	MESH:D006345	"<span class=""disease"">ventricular septal defects</span>"	"BACKGROUND: S-53482 and <span class=""chemical"">S-23121</span> are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly <span class=""disease"">ventricular septal defects</span> and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies."		67.0	67_MESH:C083440_MESH:D006345	67_1	bcv_final_eval_easy_358		
	MESH:C106487	"<span class=""chemical"">S-53482</span>"	MESH:D006130	"<span class=""disease"">growth retardation</span>"	"BACKGROUND: <span class=""chemical"">S-53482</span> and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and <span class=""disease"">growth retardation</span> in rats in conventional oral developmental toxicity studies."		67.0	67_MESH:C106487_MESH:D006130	67_1	bcv_final_eval_easy_359		
	MESH:C106487	"<span class=""chemical"">S-53482</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: <span class=""chemical"">S-53482</span> and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental <span class=""disease"">toxicity</span> studies."		67.0	67_MESH:C106487_MESH:D064420	67_1	bcv_final_eval_easy_360		
	MESH:C106487	"<span class=""chemical"">S-53482</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"RESULTS: Dermal exposure of rats to <span class=""chemical"">S-53482</span> at 300 mg/kg produced patterns of developmental <span class=""disease"">toxicity</span> similar to those resulting from oral exposure."		67.0	67_MESH:C106487_MESH:D064420	67_5	bcv_final_eval_easy_361		
	MESH:C083440	"<span class=""chemical"">S-23121</span>"	MESH:D003643	"<span class=""disease"">embryonic death</span>"	"Dermal administration of <span class=""chemical"">S-23121</span> at 800 mg/kg resulted in an increased incidence of <span class=""disease"">embryonic death</span> and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to <span class=""chemical"">S-23121</span>."		67.0	67_MESH:C083440_MESH:D003643	67_7	bcv_final_eval_easy_362		
	MESH:C083440	"<span class=""chemical"">S-23121</span>"	MESH:D006345	"<span class=""disease"">ventricular septal defect</span>"	"Dermal administration of <span class=""chemical"">S-23121</span> at 800 mg/kg resulted in an increased incidence of embryonic death and <span class=""disease"">ventricular septal defect</span>, but retarded fetal growth was not observed as it was following oral exposure to <span class=""chemical"">S-23121</span>."		67.0	67_MESH:C083440_MESH:D006345	67_7	bcv_final_eval_easy_363		
	MESH:D002945	"<span class=""chemical"">Cisplatin</span>"	MESH:D007674	"<span class=""disease"">Renal Toxicity</span>"	"Rates of <span class=""disease"">Renal Toxicity</span> in Cancer Patients Receiving <span class=""chemical"">Cisplatin</span> With and Without Mannitol."		68.0	68_MESH:D002945_MESH:D007674	68_0	bcv_final_eval_easy_364		
	MESH:D002945	"<span class=""chemical"">Cisplatin</span>"	MESH:D009369	"<span class=""disease"">Cancer</span>"	"Rates of Renal Toxicity in <span class=""disease"">Cancer</span> Patients Receiving <span class=""chemical"">Cisplatin</span> With and Without Mannitol."		68.0	68_MESH:D002945_MESH:D009369	68_0	bcv_final_eval_easy_365		
	MESH:D008353	"<span class=""chemical"">Mannitol</span>"	MESH:D009369	"<span class=""disease"">Cancer</span>"	"Rates of Renal Toxicity in <span class=""disease"">Cancer</span> Patients Receiving Cisplatin With and Without <span class=""chemical"">Mannitol</span>."		68.0	68_MESH:D008353_MESH:D009369	68_0	bcv_final_eval_easy_366		
	MESH:D008353	"<span class=""chemical"">Mannitol</span>"	MESH:D007674	"<span class=""disease"">Renal Toxicity</span>"	"Rates of <span class=""disease"">Renal Toxicity</span> in Cancer Patients Receiving Cisplatin With and Without <span class=""chemical"">Mannitol</span>."		68.0	68_MESH:D008353_MESH:D007674	68_0	bcv_final_eval_easy_367		
	MESH:D008353	"<span class=""chemical"">mannitol</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"There are many strategies to prevent this <span class=""disease"">toxicity</span>, including the use of <span class=""chemical"">mannitol</span> as a nephroprotectant in combination with hydration."		68.0	68_MESH:D008353_MESH:D064420	68_3	bcv_final_eval_easy_368		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"OBJECTIVE: We aimed to evaluate the rates of <span class=""chemical"">cisplatin</span>-induced nephrotoxicity in <span class=""disease"">cancer</span> patients receiving single-agent <span class=""chemical"">cisplatin</span> with and without mannitol."		68.0	68_MESH:D002945_MESH:D009369	68_4	bcv_final_eval_easy_369		
	MESH:D008353	"<span class=""chemical"">mannitol</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in <span class=""disease"">cancer</span> patients receiving single-agent cisplatin with and without <span class=""chemical"">mannitol</span>."		68.0	68_MESH:D008353_MESH:D009369	68_4	bcv_final_eval_easy_370		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"Data were collected on adult <span class=""disease"">cancer</span> patients receiving single-agent <span class=""chemical"">cisplatin</span> as an outpatient from January 2011 to September 2012."		68.0	68_MESH:D002945_MESH:D009369	68_6	bcv_final_eval_easy_371		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D006258	"<span class=""disease"">head and neck cancer</span>"	"RESULTS: We evaluated 143 patients who received single-agent <span class=""chemical"">cisplatin</span>; 97.2% of patients had <span class=""disease"">head and neck cancer</span> as their primary malignancy."		68.0	68_MESH:D002945_MESH:D006258	68_8	bcv_final_eval_easy_372		
	MESH:D008353	"<span class=""chemical"">mannitol</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with <span class=""disease"">hypertension</span> are at the greatest risk of nephrotoxicity and would benefit from the addition of <span class=""chemical"">mannitol</span>."		68.0	68_MESH:D008353_MESH:D006973	68_12	bcv_final_eval_easy_373		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) <span class=""chemical"">cisplatin</span> every 3 weeks and those with <span class=""disease"">hypertension</span> are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol."		68.0	68_MESH:D002945_MESH:D006973	68_12	bcv_final_eval_easy_374		
	MESH:D010433	"<span class=""chemical"">pentylenetetrazole</span>"	MESH:D008569	"<span class=""disease"">memory impairments</span>"	"Metformin protects against seizures, learning and <span class=""disease"">memory impairments</span> and oxidative damage induced by <span class=""chemical"">pentylenetetrazole</span>-induced kindling in mice."		69.0	69_MESH:D010433_MESH:D008569	69_0	bcv_final_eval_easy_375		
	MESH:D008687	"<span class=""chemical"">Metformin</span>"	MESH:D008569	"<span class=""disease"">memory impairments</span>"	"<span class=""chemical"">Metformin</span> protects against seizures, learning and <span class=""disease"">memory impairments</span> and oxidative damage induced by pentylenetetrazole-induced kindling in mice."		69.0	69_MESH:D008687_MESH:D008569	69_0	bcv_final_eval_easy_376		
	MESH:D008687	"<span class=""chemical"">Metformin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"<span class=""chemical"">Metformin</span> protects against <span class=""disease"">seizures</span>, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice."		69.0	69_MESH:D008687_MESH:D012640	69_0	bcv_final_eval_easy_377		
	MESH:D010433	"<span class=""chemical"">pentylenetetrazole</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Metformin protects against <span class=""disease"">seizures</span>, learning and memory impairments and oxidative damage induced by <span class=""chemical"">pentylenetetrazole</span>-induced kindling in mice."		69.0	69_MESH:D010433_MESH:D012640	69_0	bcv_final_eval_easy_378		
	MESH:D010433	"<span class=""chemical"">pentylenetetrazole</span>"	MESH:D003072	"<span class=""disease"">cognitive impairment</span>"	"This study was designed to evaluate the ameliorative effects of metformin on seizures, <span class=""disease"">cognitive impairment</span> and brain oxidative stress markers observed in <span class=""chemical"">pentylenetetrazole</span>-induced kindling animals."		69.0	69_MESH:D010433_MESH:D003072	69_6	bcv_final_eval_easy_379		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D003072	"<span class=""disease"">cognitive impairment</span>"	"This study was designed to evaluate the ameliorative effects of <span class=""chemical"">metformin</span> on seizures, <span class=""disease"">cognitive impairment</span> and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals."		69.0	69_MESH:D008687_MESH:D003072	69_6	bcv_final_eval_easy_380		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"This study was designed to evaluate the ameliorative effects of <span class=""chemical"">metformin</span> on <span class=""disease"">seizures</span>, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals."		69.0	69_MESH:D008687_MESH:D012640	69_6	bcv_final_eval_easy_381		
	MESH:D010433	"<span class=""chemical"">pentylenetetrazole</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"This study was designed to evaluate the ameliorative effects of metformin on <span class=""disease"">seizures</span>, cognitive impairment and brain oxidative stress markers observed in <span class=""chemical"">pentylenetetrazole</span>-induced kindling animals."		69.0	69_MESH:D010433_MESH:D012640	69_6	bcv_final_eval_easy_382		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D003072	"<span class=""disease"">cognitive impairment</span>"	"We found that <span class=""chemical"">metformin</span> suppressed the progression of kindling, ameliorated the <span class=""disease"">cognitive impairment</span> and decreased brain oxidative stress."		69.0	69_MESH:D008687_MESH:D003072	69_9	bcv_final_eval_easy_383		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D003072	"<span class=""disease"">cognitive impairment</span>"	"Thus the present study concluded that <span class=""chemical"">metformin</span> may be a potential agent for the treatment of epilepsy as well as a protective medicine against <span class=""disease"">cognitive impairment</span> induced by seizures."		69.0	69_MESH:D008687_MESH:D003072	69_10	bcv_final_eval_easy_384		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Thus the present study concluded that <span class=""chemical"">metformin</span> may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by <span class=""disease"">seizures</span>."		69.0	69_MESH:D008687_MESH:D012640	69_10	bcv_final_eval_easy_385		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"Thus the present study concluded that <span class=""chemical"">metformin</span> may be a potential agent for the treatment of <span class=""disease"">epilepsy</span> as well as a protective medicine against cognitive impairment induced by seizures."		69.0	69_MESH:D008687_MESH:D004827	69_10	bcv_final_eval_easy_386		
	MESH:D018943	"<span class=""chemical"">anthracycline</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"P53 inhibition exacerbates late-stage <span class=""chemical"">anthracycline</span> <span class=""disease"">cardiotoxicity</span>."		70.0	70_MESH:D018943_MESH:D066126	70_0	bcv_final_eval_easy_387		
	MESH:D004317	"<span class=""chemical"">Doxorubicin/DOX</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"AIMS: <span class=""chemical"">Doxorubicin</span> (<span class=""chemical"">DOX</span>) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage <span class=""disease"">cardiotoxicity</span>."		70.0	70_MESH:D004317_MESH:D066126	70_1	bcv_final_eval_easy_388		
	MESH:D004317	"<span class=""chemical"">Doxorubicin/DOX</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"AIMS: <span class=""chemical"">Doxorubicin</span> (<span class=""chemical"">DOX</span>) is an effective anti-<span class=""disease"">cancer</span> therapeutic, but is associated with both acute and late-stage cardiotoxicity."		70.0	70_MESH:D004317_MESH:D009369	70_1	bcv_final_eval_easy_389		
	MESH:D004317	"<span class=""chemical"">DOX</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Here, the impact of p53 inhibition on acute vs. late-stage <span class=""chemical"">DOX</span> <span class=""disease"">cardiotoxicity</span> was examined in a juvenile model."		70.0	70_MESH:D004317_MESH:D066126	70_3	bcv_final_eval_easy_390		
	MESH:D008795	"<span class=""chemical"">metronidazole</span>"	MESH:D064420	"<span class=""disease"">metronidazole toxicity</span>"	"The diagnosis of <span class=""chemical""></span><span class=""disease"">metronidazole</span> toxicity was made by the MRI findings and supported clinically."		71.0	71_MESH:D008795_MESH:D064420	71_4	bcv_final_eval_easy_391		
	MESH:D000157	"<span class=""chemical"">Aconitine</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"<span class=""chemical"">Aconitine</span>-induced Ca2+ overload causes <span class=""disease"">arrhythmia</span> and triggers apoptosis through p38 MAPK signaling pathway in rats."		72.0	72_MESH:D000157_MESH:D001145	72_0	bcv_final_eval_easy_392		
	MESH:D012964	"<span class=""chemical"">Na(+)</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Emerging evidence indicates that voltage-dependent <span class=""chemical"">Na(+)</span> channels have pivotal roles in the <span class=""disease"">cardiotoxicity</span> of aconitine."		72.0	72_MESH:D012964_MESH:D066126	72_2	bcv_final_eval_easy_393		
	MESH:D000157	"<span class=""chemical"">aconitine</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the <span class=""disease"">cardiotoxicity</span> of <span class=""chemical"">aconitine</span>."		72.0	72_MESH:D000157_MESH:D066126	72_2	bcv_final_eval_easy_394		
	MESH:D000157	"<span class=""chemical"">aconitine</span>"	MESH:D011041	"<span class=""disease"">poisoning</span>"	"However, no reports are available on the role of Ca(2+) in <span class=""chemical"">aconitine</span> <span class=""disease"">poisoning</span>."		72.0	72_MESH:D000157_MESH:D011041	72_3	bcv_final_eval_easy_395		
	MESH:D000157	"<span class=""chemical"">aconitine</span>"	MESH:D011041	"<span class=""disease"">poisoning</span>"	"In this study, we explored the importance of pathological Ca(2+) signaling in <span class=""chemical"">aconitine</span> <span class=""disease"">poisoning</span> in vitro and in vivo."		72.0	72_MESH:D000157_MESH:D011041	72_4	bcv_final_eval_easy_396		
	MESH:D000157	"<span class=""chemical"">aconitine</span>"	MESH:D064420	"<span class=""disease"">cytotoxicity</span>"	"To investigate effects of <span class=""chemical"">aconitine</span> on myocardial injury, we performed <span class=""disease"">cytotoxicity</span> assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats."		72.0	72_MESH:D000157_MESH:D064420	72_6	bcv_final_eval_easy_397		
	MESH:D019344	"<span class=""chemical"">lactate</span>"	MESH:D064420	"<span class=""disease"">cytotoxicity</span>"	"To investigate effects of aconitine on myocardial injury, we performed <span class=""disease"">cytotoxicity</span> assay in neonatal rat ventricular myocytes (NRVMs), as well as measured <span class=""chemical"">lactate</span> dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats."		72.0	72_MESH:D019344_MESH:D064420	72_6	bcv_final_eval_easy_398		
	MESH:D000157	"<span class=""chemical"">aconitine</span>"	MESH:D009202	"<span class=""disease"">myocardial injury</span>"	"To investigate effects of <span class=""chemical"">aconitine</span> on <span class=""disease"">myocardial injury</span>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats."		72.0	72_MESH:D000157_MESH:D009202	72_6	bcv_final_eval_easy_399		
	MESH:D019344	"<span class=""chemical"">lactate</span>"	MESH:D009202	"<span class=""disease"">myocardial injury</span>"	"To investigate effects of aconitine on <span class=""disease"">myocardial injury</span>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured <span class=""chemical"">lactate</span> dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats."		72.0	72_MESH:D019344_MESH:D009202	72_6	bcv_final_eval_easy_400		
	MESH:D000157	"<span class=""chemical"">aconitine</span>"	MESH:D009202	"<span class=""disease"">myocardial injury</span>"	"The results showed that <span class=""chemical"">aconitine</span> resulted in <span class=""disease"">myocardial injury</span> and reduced NRVMs viability dose-dependently."		72.0	72_MESH:D000157_MESH:D009202	72_7	bcv_final_eval_easy_401		
	MESH:D000157	"<span class=""chemical"">aconitine</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"Hence, our results suggest that <span class=""chemical"">aconitine</span> significantly aggravates Ca(2+) overload and causes <span class=""disease"">arrhythmia</span> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase."		72.0	72_MESH:D000157_MESH:D001145	72_13	bcv_final_eval_easy_402		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Chronic treatment with <span class=""chemical"">metformin</span> suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following <span class=""disease"">myocardial infarction</span>."		73.0	73_MESH:D008687_MESH:D009203	73_0	bcv_final_eval_easy_403		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D018487	"<span class=""disease"">left ventricular dysfunction</span>"	"Chronic treatment with <span class=""chemical"">metformin</span> suppresses toll-like receptor 4 signaling and attenuates <span class=""disease"">left ventricular dysfunction</span> following myocardial infarction."		73.0	73_MESH:D008687_MESH:D018487	73_0	bcv_final_eval_easy_404		
	MESH:D000667	"<span class=""chemical"">AMP</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Acute treatment with metformin has a protective effect in <span class=""disease"">myocardial infarction</span> by suppression of inflammatory responses due to activation of <span class=""chemical"">AMP</span>-activated protein kinase (AMPK)."		73.0	73_MESH:D000667_MESH:D009203	73_1	bcv_final_eval_easy_405		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Acute treatment with <span class=""chemical"">metformin</span> has a protective effect in <span class=""disease"">myocardial infarction</span> by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK)."		73.0	73_MESH:D008687_MESH:D009203	73_1	bcv_final_eval_easy_406		
	MESH:D000667	"<span class=""chemical"">AMP</span>"	MESH:D007249	"<span class=""disease"">inflammatory</span>"	"Acute treatment with metformin has a protective effect in myocardial infarction by suppression of <span class=""disease"">inflammatory</span> responses due to activation of <span class=""chemical"">AMP</span>-activated protein kinase (AMPK)."		73.0	73_MESH:D000667_MESH:D007249	73_1	bcv_final_eval_easy_407		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D007249	"<span class=""disease"">inflammatory</span>"	"Acute treatment with <span class=""chemical"">metformin</span> has a protective effect in myocardial infarction by suppression of <span class=""disease"">inflammatory</span> responses due to activation of AMP-activated protein kinase (AMPK)."		73.0	73_MESH:D008687_MESH:D007249	73_1	bcv_final_eval_easy_408		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"In the present study, the effect of chronic pre-treatment with <span class=""chemical"">metformin</span> on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following <span class=""disease"">myocardial infarction</span> and their relation with AMPK were assessed."		73.0	73_MESH:D008687_MESH:D009203	73_2	bcv_final_eval_easy_409		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D006331	"<span class=""disease"">cardiac dysfunction</span>"	"In the present study, the effect of chronic pre-treatment with <span class=""chemical"">metformin</span> on <span class=""disease"">cardiac dysfunction</span> and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed."		73.0	73_MESH:D008687_MESH:D006331	73_2	bcv_final_eval_easy_410		
	MESH:D007545	"<span class=""chemical"">Isoproterenol</span>"	MESH:D009203	"<span class=""disease"">acute myocardial infarction</span>"	"<span class=""chemical"">Isoproterenol</span> (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce <span class=""disease"">acute myocardial infarction</span>."		73.0	73_MESH:D007545_MESH:D009203	73_4	bcv_final_eval_easy_411		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D018487	"<span class=""disease"">left ventricular dysfunction</span>"	"The <span class=""disease"">left ventricular dysfunction</span> was significantly lower in the groups treated with 25 and 50mg/kg of <span class=""chemical"">metformin</span>."		73.0	73_MESH:D008687_MESH:D018487	73_6	bcv_final_eval_easy_412		
	MESH:D007545	"<span class=""chemical"">isoproterenol</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Metfromin markedly lowered <span class=""chemical"">isoproterenol</span>-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), <span class=""disease"">tumor</span> necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues."		73.0	73_MESH:D007545_MESH:D009369	73_7	bcv_final_eval_easy_413		
	MESH:D007545	"<span class=""chemical"">isoproterenol</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Metfromin markedly lowered <span class=""chemical"">isoproterenol</span>-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor <span class=""disease"">necrosis</span> factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues."		73.0	73_MESH:D007545_MESH:D009336	73_7	bcv_final_eval_easy_414		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction cardiac dysfunction</span>"	"Chronic pre-treatment with <span class=""chemical"">metformin</span> reduces post-<span class=""disease"">myocardial infarction cardiac dysfunction</span> and suppresses inflammatory responses, possibly through inhibition of TLR4 activities."		73.0	73_MESH:D008687_MESH:D009203	73_11	bcv_final_eval_easy_415		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D007249	"<span class=""disease"">inflammatory</span>"	"Chronic pre-treatment with <span class=""chemical"">metformin</span> reduces post-myocardial infarction cardiac dysfunction and suppresses <span class=""disease"">inflammatory</span> responses, possibly through inhibition of TLR4 activities."		73.0	73_MESH:D008687_MESH:D007249	73_11	bcv_final_eval_easy_416		
	MESH:D063325	"<span class=""chemical"">tiapride</span>"	MESH:D009459	"<span class=""disease"">Neuroleptic malignant syndrome</span>"	"<span class=""disease"">Neuroleptic malignant syndrome</span> induced by combination therapy with tetrabenazine and <span class=""chemical"">tiapride</span> in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer."		74.0	74_MESH:D063325_MESH:D009459	74_0	bcv_final_eval_easy_417		
	MESH:D013747	"<span class=""chemical"">tetrabenazine</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"Neuroleptic malignant syndrome induced by combination therapy with <span class=""chemical"">tetrabenazine</span> and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent <span class=""disease"">breast cancer</span>."		74.0	74_MESH:D013747_MESH:D001943	74_0	bcv_final_eval_easy_418		
	MESH:D063325	"<span class=""chemical"">tiapride</span>"	MESH:D006816	"<span class=""disease"">Huntington's disease</span>"	"Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and <span class=""chemical"">tiapride</span> in a Japanese patient with <span class=""disease"">Huntington's disease</span> at the terminal stage of recurrent breast cancer."		74.0	74_MESH:D063325_MESH:D006816	74_0	bcv_final_eval_easy_419		
	MESH:D063325	"<span class=""chemical"">tiapride</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and <span class=""chemical"">tiapride</span> in a Japanese patient with Huntington's disease at the terminal stage of recurrent <span class=""disease"">breast cancer</span>."		74.0	74_MESH:D063325_MESH:D001943	74_0	bcv_final_eval_easy_420		
	MESH:D013747	"<span class=""chemical"">tetrabenazine</span>"	MESH:D006816	"<span class=""disease"">Huntington's disease</span>"	"Neuroleptic malignant syndrome induced by combination therapy with <span class=""chemical"">tetrabenazine</span> and tiapride in a Japanese patient with <span class=""disease"">Huntington's disease</span> at the terminal stage of recurrent breast cancer."		74.0	74_MESH:D013747_MESH:D006816	74_0	bcv_final_eval_easy_421		
	MESH:D013747	"<span class=""chemical"">tetrabenazine</span>"	MESH:D009459	"<span class=""disease"">Neuroleptic malignant syndrome</span>"	"<span class=""disease"">Neuroleptic malignant syndrome</span> induced by combination therapy with <span class=""chemical"">tetrabenazine</span> and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer."		74.0	74_MESH:D013747_MESH:D009459	74_0	bcv_final_eval_easy_422		
	MESH:D063325	"<span class=""chemical"">tiapride</span>"	MESH:D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"We herein describe the case of an 81-year-old Japanese woman with <span class=""disease"">neuroleptic malignant syndrome</span> that occurred 36 days after the initiation of combination therapy with <span class=""chemical"">tiapride</span> (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease."		74.0	74_MESH:D063325_MESH:D009459	74_1	bcv_final_eval_easy_423		
	MESH:D013747	"<span class=""chemical"">tetrabenazine</span>"	MESH:D006816	"<span class=""disease"">Huntington's disease</span>"	"We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and <span class=""chemical"">tetrabenazine</span> (12.5 mg/day) for <span class=""disease"">Huntington's disease</span>."		74.0	74_MESH:D013747_MESH:D006816	74_1	bcv_final_eval_easy_424		
	MESH:D013747	"<span class=""chemical"">tetrabenazine</span>"	MESH:D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"We herein describe the case of an 81-year-old Japanese woman with <span class=""disease"">neuroleptic malignant syndrome</span> that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and <span class=""chemical"">tetrabenazine</span> (12.5 mg/day) for Huntington's disease."		74.0	74_MESH:D013747_MESH:D009459	74_1	bcv_final_eval_easy_425		
	MESH:D063325	"<span class=""chemical"">tiapride</span>"	MESH:D006816	"<span class=""disease"">Huntington's disease</span>"	"We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with <span class=""chemical"">tiapride</span> (75 mg/day) and tetrabenazine (12.5 mg/day) for <span class=""disease"">Huntington's disease</span>."		74.0	74_MESH:D063325_MESH:D006816	74_1	bcv_final_eval_easy_426		
	MESH:D063325	"<span class=""chemical"">tiapride</span>"	MESH:D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"To the best of our knowledge, the occurrence of <span class=""disease"">neuroleptic malignant syndrome</span> due to combination therapy with tetrabenazine and <span class=""chemical"">tiapride</span> has not been previously reported."		74.0	74_MESH:D063325_MESH:D009459	74_4	bcv_final_eval_easy_427		
	MESH:D013747	"<span class=""chemical"">tetrabenazine</span>"	MESH:D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"To the best of our knowledge, the occurrence of <span class=""disease"">neuroleptic malignant syndrome</span> due to combination therapy with <span class=""chemical"">tetrabenazine</span> and tiapride has not been previously reported."		74.0	74_MESH:D013747_MESH:D009459	74_4	bcv_final_eval_easy_428		
	MESH:D008790	"<span class=""chemical"">metoprolol</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"A <span class=""chemical"">metoprolol</span>-terbinafine combination induced <span class=""disease"">bradycardia</span>."		75.0	75_MESH:D008790_MESH:D001919	75_0	bcv_final_eval_easy_429		
	MESH:C041359	"<span class=""chemical"">terbinafine</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"A metoprolol-<span class=""chemical"">terbinafine</span> combination induced <span class=""disease"">bradycardia</span>."		75.0	75_MESH:C041359_MESH:D001919	75_0	bcv_final_eval_easy_430		
	MESH:D008790	"<span class=""chemical"">metoprolol</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"To report a sinus <span class=""disease"">bradycardia</span> induced by <span class=""chemical"">metoprolol</span> and terbinafine drug-drug interaction and its management."		75.0	75_MESH:D008790_MESH:D001919	75_1	bcv_final_eval_easy_431		
	MESH:C041359	"<span class=""chemical"">terbinafine</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"To report a sinus <span class=""disease"">bradycardia</span> induced by metoprolol and <span class=""chemical"">terbinafine</span> drug-drug interaction and its management."		75.0	75_MESH:C041359_MESH:D001919	75_1	bcv_final_eval_easy_432		
	MESH:D008790	"<span class=""chemical"">metoprolol</span>"	MESH:D003324	"<span class=""disease"">coronary artery disease</span>"	"A 63 year-old Caucasian man on <span class=""chemical"">metoprolol</span> 200 mg/day for stable <span class=""disease"">coronary artery disease</span> was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis."		75.0	75_MESH:D008790_MESH:D003324	75_2	bcv_final_eval_easy_433		
	MESH:C041359	"<span class=""chemical"">terbinafine</span>"	MESH:D003324	"<span class=""disease"">coronary artery disease</span>"	"A 63 year-old Caucasian man on metoprolol 200 mg/day for stable <span class=""disease"">coronary artery disease</span> was prescribed a 90-day course of oral <span class=""chemical"">terbinafine</span> 250 mg/day for onychomycosis."		75.0	75_MESH:C041359_MESH:D003324	75_2	bcv_final_eval_easy_434		
	MESH:C041359	"<span class=""chemical"">terbinafine</span>"	MESH:D014009	"<span class=""disease"">onychomycosis</span>"	"A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral <span class=""chemical"">terbinafine</span> 250 mg/day for <span class=""disease"">onychomycosis</span>."		75.0	75_MESH:C041359_MESH:D014009	75_2	bcv_final_eval_easy_435		
	MESH:D008790	"<span class=""chemical"">metoprolol</span>"	MESH:D014009	"<span class=""disease"">onychomycosis</span>"	"A 63 year-old Caucasian man on <span class=""chemical"">metoprolol</span> 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for <span class=""disease"">onychomycosis</span>."		75.0	75_MESH:D008790_MESH:D014009	75_2	bcv_final_eval_easy_436		
	MESH:C041359	"<span class=""chemical"">terbinafine</span>"	MESH:D003221	"<span class=""disease"">confusion</span>"	"On the 49th day of <span class=""chemical"">terbinafine</span> therapy, he was brought to the emergency room for a decrease of his global health status, <span class=""disease"">confusion</span> and falls."		75.0	75_MESH:C041359_MESH:D003221	75_3	bcv_final_eval_easy_437		
	MESH:D008790	"<span class=""chemical"">metoprolol</span>"	MESH:D064420	"<span class=""disease"">adverse drug reaction</span>"	"A score of 7 on the Naranjo <span class=""disease"">adverse drug reaction</span> probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between <span class=""chemical"">metoprolol</span> and terbinafine."		75.0	75_MESH:D008790_MESH:D064420	75_5	bcv_final_eval_easy_438		
	MESH:C041359	"<span class=""chemical"">terbinafine</span>"	MESH:D064420	"<span class=""disease"">adverse drug reaction</span>"	"A score of 7 on the Naranjo <span class=""disease"">adverse drug reaction</span> probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and <span class=""chemical"">terbinafine</span>."		75.0	75_MESH:C041359_MESH:D064420	75_5	bcv_final_eval_easy_439		
	MESH:C041359	"<span class=""chemical"">terbinafine</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus <span class=""disease"">bradycardia</span> and the drug interaction between metoprolol and <span class=""chemical"">terbinafine</span>."		75.0	75_MESH:C041359_MESH:D001919	75_5	bcv_final_eval_easy_440		
	MESH:D008790	"<span class=""chemical"">metoprolol</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus <span class=""disease"">bradycardia</span> and the drug interaction between <span class=""chemical"">metoprolol</span> and terbinafine."		75.0	75_MESH:D008790_MESH:D001919	75_5	bcv_final_eval_easy_441		
	MESH:D008790	"<span class=""chemical"">metoprolol</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"By inhibiting the cytochrome P450 2D6, terbinafine had decreased <span class=""chemical"">metoprolol</span>'s clearance, leading in <span class=""chemical"">metoprolol</span> accumulation which has resulted in clinically significant sinus <span class=""disease"">bradycardia</span>."		75.0	75_MESH:D008790_MESH:D001919	75_8	bcv_final_eval_easy_442		
	MESH:C041359	"<span class=""chemical"">terbinafine</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"By inhibiting the cytochrome P450 2D6, <span class=""chemical"">terbinafine</span> had decreased metoprolol's clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus <span class=""disease"">bradycardia</span>."		75.0	75_MESH:C041359_MESH:D001919	75_8	bcv_final_eval_easy_443		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D010523	"<span class=""disease"">peripheral neuropathy</span>"	"Optochiasmatic and <span class=""disease"">peripheral neuropathy</span> due to <span class=""chemical"">ethambutol</span> overtreatment."		76.0	76_MESH:D004977_MESH:D010523	76_0	bcv_final_eval_easy_444		
	MESH:D004977	"<span class=""chemical"">Ethambutol</span>"	MESH:D011115	"<span class=""disease"">polyneuropathy</span>"	"<span class=""chemical"">Ethambutol</span> is known to cause optic neuropathy and, more rarely, axonal <span class=""disease"">polyneuropathy</span>."		76.0	76_MESH:D004977_MESH:D011115	76_1	bcv_final_eval_easy_445		
	MESH:D004977	"<span class=""chemical"">Ethambutol</span>"	MESH:D009901	"<span class=""disease"">optic neuropathy</span>"	"<span class=""chemical"">Ethambutol</span> is known to cause <span class=""disease"">optic neuropathy</span> and, more rarely, axonal polyneuropathy."		76.0	76_MESH:D004977_MESH:D009901	76_1	bcv_final_eval_easy_446		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D014786	"<span class=""disease"">visual loss</span>"	"We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed <span class=""disease"">visual loss</span> and paresthesias after 11 weeks of exposure to a supratherapeutic dose of <span class=""chemical"">ethambutol</span>."		76.0	76_MESH:D004977_MESH:D014786	76_2	bcv_final_eval_easy_447		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"This case demonstrates the selective vulnerability of the anterior visual pathways and peripheral nerves to <span class=""chemical"">ethambutol</span> <span class=""disease"">toxicity</span>."		76.0	76_MESH:D004977_MESH:D064420	76_3	bcv_final_eval_easy_448		
	MESH:D013739	"<span class=""chemical"">Testosterone</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"<span class=""chemical"">Testosterone</span> ameliorates streptozotocin-induced <span class=""disease"">memory impairment</span> in male rats."		77.0	77_MESH:D013739_MESH:D008569	77_0	bcv_final_eval_easy_449		
	MESH:D013739	"<span class=""chemical"">testosterone</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"AIM: To study the effects of <span class=""chemical"">testosterone</span> on streptozotocin (STZ)-induced <span class=""disease"">memory impairment</span> in male rats."		77.0	77_MESH:D013739_MESH:D008569	77_1	bcv_final_eval_easy_450		
	MESH:D005485	"<span class=""chemical"">flutamide</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"Administration of <span class=""chemical"">flutamide</span>, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced <span class=""disease"">memory impairment</span>."		77.0	77_MESH:D005485_MESH:D008569	77_7	bcv_final_eval_easy_451		
	MESH:D013739	"<span class=""chemical"">testosterone</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the <span class=""chemical"">testosterone</span> replacement in improving STZ- and castration-induced <span class=""disease"">memory impairment</span>."		77.0	77_MESH:D013739_MESH:D008569	77_7	bcv_final_eval_easy_452		
	MESH:D013629	"<span class=""chemical"">tamoxifen</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"Administration of flutamide, letrozole or <span class=""chemical"">tamoxifen</span> significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced <span class=""disease"">memory impairment</span>."		77.0	77_MESH:D013629_MESH:D008569	77_7	bcv_final_eval_easy_453		
	MESH:C067431	"<span class=""chemical"">letrozole</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"Administration of flutamide, <span class=""chemical"">letrozole</span> or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced <span class=""disease"">memory impairment</span>."		77.0	77_MESH:C067431_MESH:D008569	77_7	bcv_final_eval_easy_454		
	MESH:D013739	"<span class=""chemical"">Testosterone</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"CONCLUSION: <span class=""chemical"">Testosterone</span> administration ameliorates STZ- and castration-induced <span class=""disease"">memory impairment</span> in male Wistar rats."		77.0	77_MESH:D013739_MESH:D008569	77_8	bcv_final_eval_easy_455		
	MESH:C573355	"<span class=""chemical"">GFC</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"The present study aimed to evaluate the <span class=""chemical"">GFC</span> effects at doses of 25, 50 or 75 mg/kg on <span class=""disease"">seizure</span> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <span class=""disease"">seizures</span>."		78.0	78_MESH:C573355_MESH:D012640	78_4	bcv_final_eval_easy_456		
	MESH:D018698	"<span class=""chemical"">glutamine</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on <span class=""disease"">seizure</span> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), <span class=""chemical"">glutamine</span>, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <span class=""disease"">seizures</span>."		78.0	78_MESH:D018698_MESH:D012640	78_4	bcv_final_eval_easy_457		
	MESH:D005680	"<span class=""chemical"">GABA</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on <span class=""disease"">seizure</span> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (<span class=""chemical"">GABA</span>), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <span class=""disease"">seizures</span>."		78.0	78_MESH:D005680_MESH:D012640	78_4	bcv_final_eval_easy_458		
	MESH:D005978	"<span class=""chemical"">glutathione</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on <span class=""disease"">seizure</span> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and <span class=""chemical"">glutathione</span>) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <span class=""disease"">seizures</span>."		78.0	78_MESH:D005978_MESH:D012640	78_4	bcv_final_eval_easy_459		
	MESH:D001224	"<span class=""chemical"">aspartate</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on <span class=""disease"">seizure</span> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, <span class=""chemical"">aspartate</span> and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <span class=""disease"">seizures</span>."		78.0	78_MESH:D001224_MESH:D012640	78_4	bcv_final_eval_easy_460		
	MESH:D000596	"<span class=""chemical"">amino acid</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on <span class=""disease"">seizure</span> parameters to determine their anticonvulsant activity and its effects on <span class=""chemical"">amino acid</span> (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <span class=""disease"">seizures</span>."		78.0	78_MESH:D000596_MESH:D012640	78_4	bcv_final_eval_easy_461		
	MESH:C573355	"<span class=""chemical"">GFC</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">GFC</span> produced an increased latency to first <span class=""disease"">seizure</span>, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice."		78.0	78_MESH:C573355_MESH:D012640	78_5	bcv_final_eval_easy_462		
	MESH:C573355	"<span class=""chemical"">GFC</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"The results indicate that <span class=""chemical"">GFC</span> can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced <span class=""disease"">status epilepticus</span>, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals."		78.0	78_MESH:C573355_MESH:D013226	78_9	bcv_final_eval_easy_463		
	MESH:C573355	"<span class=""chemical"">GFC</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"The results indicate that <span class=""chemical"">GFC</span> can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first <span class=""disease"">seizure</span> and decrease in mortality rate of animals."		78.0	78_MESH:C573355_MESH:D012640	78_9	bcv_final_eval_easy_464		
	MESH:D019821	"<span class=""chemical"">simvastatin</span>"	MESH:D012206	"<span class=""disease"">Rhabdomyolysis</span>"	"<span class=""disease"">Rhabdomyolysis</span> in a hepatitis C virus infected patient treated with telaprevir and <span class=""chemical"">simvastatin</span>."		80.0	80_MESH:D019821_MESH:D012206	80_0	bcv_final_eval_easy_465		
	MESH:C486464	"<span class=""chemical"">telaprevir</span>"	MESH:D012206	"<span class=""disease"">Rhabdomyolysis</span>"	"<span class=""disease"">Rhabdomyolysis</span> in a hepatitis C virus infected patient treated with <span class=""chemical"">telaprevir</span> and simvastatin."		80.0	80_MESH:C486464_MESH:D012206	80_0	bcv_final_eval_easy_466		
	MESH:C486464	"<span class=""chemical"">telaprevir</span>"	MESH:D006526	"<span class=""disease"">a hepatitis C virus infected</span>"	"Rhabdomyolysis in <span class=""disease"">a hepatitis C virus infected</span> patient treated with <span class=""chemical"">telaprevir</span> and simvastatin."		80.0	80_MESH:C486464_MESH:D006526	80_0	bcv_final_eval_easy_467		
	MESH:D019821	"<span class=""chemical"">simvastatin</span>"	MESH:D006526	"<span class=""disease"">a hepatitis C virus infected</span>"	"Rhabdomyolysis in <span class=""disease"">a hepatitis C virus infected</span> patient treated with telaprevir and <span class=""chemical"">simvastatin</span>."		80.0	80_MESH:D019821_MESH:D006526	80_0	bcv_final_eval_easy_468		
	MESH:C417083	"<span class=""chemical"">pegylated interferon</span>"	MESH:D019698	"<span class=""disease"">chronic hepatitis C virus infection</span>"	"A 46-year old man with a <span class=""disease"">chronic hepatitis C virus infection</span> received triple therapy with ribavirin, <span class=""chemical"">pegylated interferon</span> and telaprevir."		80.0	80_MESH:C417083_MESH:D019698	80_1	bcv_final_eval_easy_469		
	MESH:C486464	"<span class=""chemical"">telaprevir</span>"	MESH:D019698	"<span class=""disease"">chronic hepatitis C virus infection</span>"	"A 46-year old man with a <span class=""disease"">chronic hepatitis C virus infection</span> received triple therapy with ribavirin, pegylated interferon and <span class=""chemical"">telaprevir</span>."		80.0	80_MESH:C486464_MESH:D019698	80_1	bcv_final_eval_easy_470		
	MESH:D012254	"<span class=""chemical"">ribavirin</span>"	MESH:D019698	"<span class=""disease"">chronic hepatitis C virus infection</span>"	"A 46-year old man with a <span class=""disease"">chronic hepatitis C virus infection</span> received triple therapy with <span class=""chemical"">ribavirin</span>, pegylated interferon and telaprevir."		80.0	80_MESH:D012254_MESH:D019698	80_1	bcv_final_eval_easy_471		
	MESH:D019821	"<span class=""chemical"">simvastatin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"At admission <span class=""chemical"">simvastatin</span> and all antiviral drugs were discontinued because <span class=""disease"">toxicity</span> due to a drug-drug interaction was suspected."		80.0	80_MESH:D019821_MESH:D064420	80_4	bcv_final_eval_easy_472		
	MESH:D019821	"<span class=""chemical"">Simvastatin</span>"	MESH:D064420	"<span class=""disease"">muscle toxicity</span>"	"<span class=""chemical"">Simvastatin</span> plasma concentration increased 30 times in this patient and statin induced <span class=""disease"">muscle toxicity</span> is related to the concentration of the statin in blood."		80.0	80_MESH:D019821_MESH:D064420	80_10	bcv_final_eval_easy_473		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D009101	"<span class=""disease"">multiple myeloma</span>"	"Combination of bortezomib, thalidomide, and <span class=""chemical"">dexamethasone</span> (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic <span class=""disease"">multiple myeloma</span> in Japanese patients."		81.0	81_MESH:D003907_MESH:D009101	81_0	bcv_final_eval_easy_474		
	MESH:C400082	"<span class=""chemical"">bortezomib</span>"	MESH:D009101	"<span class=""disease"">multiple myeloma</span>"	"Combination of <span class=""chemical"">bortezomib</span>, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic <span class=""disease"">multiple myeloma</span> in Japanese patients."		81.0	81_MESH:C400082_MESH:D009101	81_0	bcv_final_eval_easy_475		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D009101	"<span class=""disease"">multiple myeloma</span>"	"Combination of bortezomib, <span class=""chemical"">thalidomide</span>, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic <span class=""disease"">multiple myeloma</span> in Japanese patients."		81.0	81_MESH:D013792_MESH:D009101	81_0	bcv_final_eval_easy_476		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D009101	"<span class=""disease"">MM</span>"	"In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and <span class=""chemical"">dexamethasone</span> (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed <span class=""disease"">MM</span>."		81.0	81_MESH:D003907_MESH:D009101	81_2	bcv_final_eval_easy_477		
	MESH:C400082	"<span class=""chemical"">bortezomib</span>"	MESH:D009101	"<span class=""disease"">MM</span>"	"In this study, we retrospectively analyzed the safety and efficacy of combination regimen of <span class=""chemical"">bortezomib</span>, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed <span class=""disease"">MM</span>."		81.0	81_MESH:C400082_MESH:D009101	81_2	bcv_final_eval_easy_478		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D009101	"<span class=""disease"">MM</span>"	"In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, <span class=""chemical"">thalidomide</span>, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed <span class=""disease"">MM</span>."		81.0	81_MESH:D013792_MESH:D009101	81_2	bcv_final_eval_easy_479		
	MESH:D020123	"<span class=""chemical"">sirolimus</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Conversion to <span class=""chemical"">sirolimus</span> ameliorates cyclosporine-induced <span class=""disease"">nephropathy</span> in the rat: focus on serum, urine, gene, and protein renal expression biomarkers."		82.0	82_MESH:D020123_MESH:D007674	82_0	bcv_final_eval_easy_480		
	MESH:D020123	"<span class=""chemical"">sirolimus/SRL</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Protocols of conversion from cyclosporin A (CsA) to <span class=""chemical"">sirolimus</span> (<span class=""chemical"">SRL</span>) have been widely used in immunotherapy after transplantation to prevent CsA-induced <span class=""disease"">nephropathy</span>, but the molecular mechanisms underlying these protocols remain nuclear."		82.0	82_MESH:D020123_MESH:D007674	82_1	bcv_final_eval_easy_481		
	MESH:D006416	"<span class=""chemical"">hematoxylin</span>"	MESH:D007674	"<span class=""disease"">Renal lesions</span>"	"<span class=""disease"">Renal lesions</span> were analyzed in <span class=""chemical"">hematoxylin</span> and eosin, periodic acid-Schiff, and Masson's trichrome stains."		82.0	82_MESH:D006416_MESH:D007674	82_5	bcv_final_eval_easy_482		
	MESH:D004801	"<span class=""chemical"">eosin</span>"	MESH:D007674	"<span class=""disease"">Renal lesions</span>"	"<span class=""disease"">Renal lesions</span> were analyzed in hematoxylin and <span class=""chemical"">eosin</span>, periodic acid-Schiff, and Masson's trichrome stains."		82.0	82_MESH:D004801_MESH:D007674	82_5	bcv_final_eval_easy_483		
	MESH:D020123	"<span class=""chemical"">SRL</span>"	MESH:D007674	"<span class=""disease"">renal impairment</span>"	"<span class=""chemical"">SRL</span>-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of <span class=""disease"">renal impairment</span>."		82.0	82_MESH:D020123_MESH:D007674	82_6	bcv_final_eval_easy_484		
	MESH:D020123	"<span class=""chemical"">SRL</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"<span class=""chemical"">SRL</span>-treated rats presented <span class=""disease"">proteinuria</span> and NGAL (serum and urinary) as the best markers of renal impairment."		82.0	82_MESH:D020123_MESH:D011507	82_6	bcv_final_eval_easy_485		
	MESH:D020123	"<span class=""chemical"">SRL</span>"	MESH:D007674	"<span class=""disease"">renal damage evolution</span>"	"Conversion to <span class=""chemical"">SRL</span> prevented CsA-induced <span class=""disease"">renal damage evolution</span> (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to <span class=""chemical"">SRL</span>."		82.0	82_MESH:D020123_MESH:D007674	82_9	bcv_final_eval_easy_486		
	MESH:D014508	"<span class=""chemical"">urea</span>"	MESH:D058186	"<span class=""disease"">acute kidney injury</span>"	"Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce <span class=""disease"">acute kidney injury</span> due its ability to negatively affect renal function, augment serum levels of creatinine and <span class=""chemical"">urea</span>, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a)."		83.0	83_MESH:D014508_MESH:D058186	83_1	bcv_final_eval_easy_487		
	MESH:D002945	"<span class=""chemical"">Cisplatin</span>"	MESH:D007683	"<span class=""disease"">acute tubular necrosis</span>"	"<span class=""chemical"">Cisplatin</span> treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the <span class=""disease"">acute tubular necrosis</span> score and up-regulate cytokines (e.g., IL-1b and TNF-a)."		83.0	83_MESH:D002945_MESH:D007683	83_1	bcv_final_eval_easy_488		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D007683	"<span class=""disease"">acute tubular necrosis</span>"	"Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of <span class=""chemical"">creatinine</span> and urea, increase the <span class=""disease"">acute tubular necrosis</span> score and up-regulate cytokines (e.g., IL-1b and TNF-a)."		83.0	83_MESH:D003404_MESH:D007683	83_1	bcv_final_eval_easy_489		
	MESH:D014508	"<span class=""chemical"">urea</span>"	MESH:D007683	"<span class=""disease"">acute tubular necrosis</span>"	"Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and <span class=""chemical"">urea</span>, increase the <span class=""disease"">acute tubular necrosis</span> score and up-regulate cytokines (e.g., IL-1b and TNF-a)."		83.0	83_MESH:D014508_MESH:D007683	83_1	bcv_final_eval_easy_490		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D058186	"<span class=""disease"">acute kidney injury</span>"	"Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce <span class=""disease"">acute kidney injury</span> due its ability to negatively affect renal function, augment serum levels of <span class=""chemical"">creatinine</span> and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a)."		83.0	83_MESH:D003404_MESH:D058186	83_1	bcv_final_eval_easy_491		
	MESH:D005446	"<span class=""chemical"">fluocinolone acetonide</span>"	MESH:C537630	"<span class=""disease"">birdshot retinochoroidopathy</span>"	"Safety and efficacy of <span class=""chemical"">fluocinolone acetonide</span> intravitreal implant (0.59 mg) in <span class=""disease"">birdshot retinochoroidopathy</span>."		84.0	84_MESH:D005446_MESH:C537630	84_0	bcv_final_eval_easy_492		
	MESH:D005446	"<span class=""chemical"">fluocinolone acetonide</span>"	MESH:C537630	"<span class=""disease"">birdshot retinochoroidopathy</span>"	"PURPOSE: To report the treatment outcomes of the <span class=""chemical"">fluocinolone acetonide</span> intravitreal implant (0.59 mg) in patients with <span class=""disease"">birdshot retinochoroidopathy</span> whose disease is refractory or intolerant to conventional immunomodulatory therapy."		84.0	84_MESH:D005446_MESH:C537630	84_1	bcv_final_eval_easy_493		
	MESH:D005446	"<span class=""chemical"">fluocinolone acetonide</span>"	MESH:D007249	"<span class=""disease"">inflammation</span>"	"CONCLUSION: The data suggest that <span class=""chemical"">fluocinolone acetonide</span> implant (0.59 mg) helps to control <span class=""disease"">inflammation</span> in otherwise treatment-refractory cases of birdshot retinochoroidopathy."		84.0	84_MESH:D005446_MESH:D007249	84_13	bcv_final_eval_easy_494		
	MESH:D005446	"<span class=""chemical"">fluocinolone acetonide</span>"	MESH:C537630	"<span class=""disease"">birdshot retinochoroidopathy</span>"	"CONCLUSION: The data suggest that <span class=""chemical"">fluocinolone acetonide</span> implant (0.59 mg) helps to control inflammation in otherwise treatment-refractory cases of <span class=""disease"">birdshot retinochoroidopathy</span>."		84.0	84_MESH:D005446_MESH:C537630	84_13	bcv_final_eval_easy_495		
	MESH:C061870	"<span class=""chemical"">rocuronium</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"Optimal precurarizing dose of <span class=""chemical"">rocuronium</span> to decrease fasciculation and <span class=""disease"">myalgia</span> following succinylcholine administration."		85.0	85_MESH:C061870_MESH:D063806	85_0	bcv_final_eval_easy_496		
	MESH:D013390	"<span class=""chemical"">succinylcholine</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"Optimal precurarizing dose of rocuronium to decrease fasciculation and <span class=""disease"">myalgia</span> following <span class=""chemical"">succinylcholine</span> administration."		85.0	85_MESH:D013390_MESH:D063806	85_0	bcv_final_eval_easy_497		
	MESH:C061870	"<span class=""chemical"">rocuronium</span>"	MESH:D005207	"<span class=""disease"">fasciculation</span>"	"Optimal precurarizing dose of <span class=""chemical"">rocuronium</span> to decrease <span class=""disease"">fasciculation</span> and myalgia following succinylcholine administration."		85.0	85_MESH:C061870_MESH:D005207	85_0	bcv_final_eval_easy_498		
	MESH:D013390	"<span class=""chemical"">Succinylcholine</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"BACKGROUND: <span class=""chemical"">Succinylcholine</span> commonly produces frequent adverse effects, including muscle fasciculation and <span class=""disease"">myalgia</span>."		85.0	85_MESH:D013390_MESH:D063806	85_1	bcv_final_eval_easy_499		
	MESH:C061870	"<span class=""chemical"">rocuronium</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"The current study identified the optimal dose of <span class=""chemical"">rocuronium</span> to prevent succinylcholine-induced fasciculation and <span class=""disease"">myalgia</span> and evaluated the influence of <span class=""chemical"">rocuronium</span> on the speed of onset produced by succinylcholine."		85.0	85_MESH:C061870_MESH:D063806	85_2	bcv_final_eval_easy_500		
	MESH:D013390	"<span class=""chemical"">succinylcholine</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"The current study identified the optimal dose of rocuronium to prevent <span class=""chemical"">succinylcholine</span>-induced fasciculation and <span class=""disease"">myalgia</span> and evaluated the influence of rocuronium on the speed of onset produced by <span class=""chemical"">succinylcholine</span>."		85.0	85_MESH:D013390_MESH:D063806	85_2	bcv_final_eval_easy_501		
	MESH:C061870	"<span class=""chemical"">rocuronium</span>"	MESH:D005207	"<span class=""disease"">fasciculation</span>"	"The current study identified the optimal dose of <span class=""chemical"">rocuronium</span> to prevent succinylcholine-induced <span class=""disease"">fasciculation</span> and myalgia and evaluated the influence of <span class=""chemical"">rocuronium</span> on the speed of onset produced by succinylcholine."		85.0	85_MESH:C061870_MESH:D005207	85_2	bcv_final_eval_easy_502		
	MESH:D013390	"<span class=""chemical"">succinylcholine</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"All patients received <span class=""chemical"">succinylcholine</span> 1.5 mg/kg at 2 minutes after the precurarization, and were assessed the incidence and severity of fasciculations, while <span class=""disease"">myalgia</span> was assessed at 24 hours after surgery."		85.0	85_MESH:D013390_MESH:D063806	85_6	bcv_final_eval_easy_503		
	MESH:C061870	"<span class=""chemical"">rocuronium</span>"	MESH:D005207	"<span class=""disease"">muscle fasciculation</span>"	"RESULTS: The incidence and severity of visible <span class=""disease"">muscle fasciculation</span> was significantly less with increasing the amount of precurarizing dose of <span class=""chemical"">rocuronium</span> (P < 0.001)."		85.0	85_MESH:C061870_MESH:D005207	85_7	bcv_final_eval_easy_504		
	MESH:C061870	"<span class=""chemical"">rocuronium</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"Those of <span class=""disease"">myalgia</span> tend to decrease according to increasing the amount of precurarizing dose of <span class=""chemical"">rocuronium</span>, but there was no significance (P = 0.072)."		85.0	85_MESH:C061870_MESH:D063806	85_8	bcv_final_eval_easy_505		
	MESH:C061870	"<span class=""chemical"">rocuronium</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"CONCLUSIONS: Precurarization with 0.04 mg/kg <span class=""chemical"">rocuronium</span> was the optimal dose considering the reduction in the incidence and severity of fasciculation and <span class=""disease"">myalgia</span> with acceptable onset time, and the safe and effective precurarization."		85.0	85_MESH:C061870_MESH:D063806	85_10	bcv_final_eval_easy_506		
	MESH:C061870	"<span class=""chemical"">rocuronium</span>"	MESH:D005207	"<span class=""disease"">fasciculation</span>"	"CONCLUSIONS: Precurarization with 0.04 mg/kg <span class=""chemical"">rocuronium</span> was the optimal dose considering the reduction in the incidence and severity of <span class=""disease"">fasciculation</span> and myalgia with acceptable onset time, and the safe and effective precurarization."		85.0	85_MESH:C061870_MESH:D005207	85_10	bcv_final_eval_easy_507		
	MESH:D017311	"<span class=""chemical"">amlodipine</span>"	MESH:D012678	"<span class=""disease"">loss of taste sensation</span>"	"We report a case about a female with essential hypertension on drug treatment with <span class=""chemical"">amlodipine</span> developed <span class=""disease"">loss of taste sensation</span>."		87.0	87_MESH:D017311_MESH:D012678	87_3	bcv_final_eval_easy_508		
	MESH:D017311	"<span class=""chemical"">amlodipine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"We report a case about a female with essential <span class=""disease"">hypertension</span> on drug treatment with <span class=""chemical"">amlodipine</span> developed loss of taste sensation."		87.0	87_MESH:D017311_MESH:D006973	87_3	bcv_final_eval_easy_509		
	MESH:D019821	"<span class=""chemical"">simvastatin</span>"	MESH:D012206	"<span class=""disease"">Rhabdomyolysis</span>"	"<span class=""disease"">Rhabdomyolysis</span> in association with <span class=""chemical"">simvastatin</span> and dosage increment in clarithromycin."		88.0	88_MESH:D019821_MESH:D012206	88_0	bcv_final_eval_easy_510		
	MESH:D017291	"<span class=""chemical"">clarithromycin</span>"	MESH:D012206	"<span class=""disease"">Rhabdomyolysis</span>"	"<span class=""disease"">Rhabdomyolysis</span> in association with simvastatin and dosage increment in <span class=""chemical"">clarithromycin</span>."		88.0	88_MESH:D017291_MESH:D012206	88_0	bcv_final_eval_easy_511		
	MESH:D017291	"<span class=""chemical"">clarithromycin</span>"	MESH:D012206	"<span class=""disease"">rhabdomyolysis</span>"	"This particular case is of interest as <span class=""disease"">rhabdomyolysis</span> only occurred after an increase in the dose of <span class=""chemical"">clarithromycin</span>."		88.0	88_MESH:D017291_MESH:D012206	88_2	bcv_final_eval_easy_512		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D034381	"<span class=""disease"">loss of activity</span>"	"Characterization of a novel BCHE ""silent"" allele: point mutation (p.Val204Asp) causes <span class=""disease"">loss of activity</span> and prolonged apnea with <span class=""chemical"">suxamethonium</span>."		89.0	89_MESH:D013390_MESH:D034381	89_0	bcv_final_eval_easy_513		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D001049	"<span class=""disease"">apnea</span>"	"Characterization of a novel BCHE ""silent"" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged <span class=""disease"">apnea</span> with <span class=""chemical"">suxamethonium</span>."		89.0	89_MESH:D013390_MESH:D001049	89_0	bcv_final_eval_easy_514		
	MESH:C049430	"<span class=""chemical"">mivacurium</span>"	MESH:C537417	"<span class=""disease"">Butyrylcholinesterase deficiency</span>"	"<span class=""disease"">Butyrylcholinesterase deficiency</span> is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or <span class=""chemical"">mivacurium</span>) in patients who have mutations in the BCHE gene."		89.0	89_MESH:C049430_MESH:C537417	89_1	bcv_final_eval_easy_515		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:C537417	"<span class=""disease"">Butyrylcholinesterase deficiency</span>"	"<span class=""disease"">Butyrylcholinesterase deficiency</span> is characterized by prolonged apnea after the use of muscle relaxants (<span class=""chemical"">suxamethonium</span> or mivacurium) in patients who have mutations in the BCHE gene."		89.0	89_MESH:D013390_MESH:C537417	89_1	bcv_final_eval_easy_516		
	MESH:C049430	"<span class=""chemical"">mivacurium</span>"	MESH:D001049	"<span class=""disease"">apnea</span>"	"Butyrylcholinesterase deficiency is characterized by prolonged <span class=""disease"">apnea</span> after the use of muscle relaxants (suxamethonium or <span class=""chemical"">mivacurium</span>) in patients who have mutations in the BCHE gene."		89.0	89_MESH:C049430_MESH:D001049	89_1	bcv_final_eval_easy_517		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D001049	"<span class=""disease"">apnea</span>"	"Butyrylcholinesterase deficiency is characterized by prolonged <span class=""disease"">apnea</span> after the use of muscle relaxants (<span class=""chemical"">suxamethonium</span> or mivacurium) in patients who have mutations in the BCHE gene."		89.0	89_MESH:D013390_MESH:D001049	89_1	bcv_final_eval_easy_518		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D008133	"<span class=""disease"">prolonged neuromuscular block</span>"	"Here, we report a case of <span class=""disease"">prolonged neuromuscular block</span> after administration of <span class=""chemical"">suxamethonium</span> leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp)."		89.0	89_MESH:D013390_MESH:D008133	89_2	bcv_final_eval_easy_519		
	MESH:D006859	"<span class=""chemical"">hydrogen</span>"	MESH:C567116	"<span class=""disease"">MD/Molecular dynamic</span>"	"<span class=""disease"">Molecular dynamic</span> (<span class=""disease"">MD</span>) simulations showed that the overall effect of the mutation p.Val204Asp is disruption of <span class=""chemical"">hydrogen</span> bonding between Gln223 and Glu441, leading Ser198 and His438 to move away from each other with subsequent disruption of the catalytic triad functionality regardless of the type of substrate."		89.0	89_MESH:D006859_MESH:C567116	89_8	bcv_final_eval_easy_520		
	MESH:C039726	"<span class=""chemical"">artesunate</span>"	MESH:D000740	"<span class=""disease"">anemia</span>"	"Delayed <span class=""disease"">anemia</span> after treatment with injectable <span class=""chemical"">artesunate</span> in the Democratic Republic of the Congo: a manageable issue."		90.0	90_MESH:C039726_MESH:D000740	90_0	bcv_final_eval_easy_521		
	MESH:C039726	"<span class=""chemical"">artesunate</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"Cases of delayed hemolytic anemia have been described after treatment with injectable <span class=""chemical"">artesunate</span>, the current World Health Organization (WHO)-recommended first-line drug for the treatment of severe <span class=""disease"">malaria</span>."		90.0	90_MESH:C039726_MESH:D008288	90_1	bcv_final_eval_easy_522		
	MESH:C039726	"<span class=""chemical"">artesunate</span>"	MESH:D000743	"<span class=""disease"">hemolytic anemia</span>"	"Cases of delayed <span class=""disease"">hemolytic anemia</span> have been described after treatment with injectable <span class=""chemical"">artesunate</span>, the current World Health Organization (WHO)-recommended first-line drug for the treatment of severe malaria."		90.0	90_MESH:C039726_MESH:D000743	90_1	bcv_final_eval_easy_523		
	MESH:C039726	"<span class=""chemical"">artesunate</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"A total of 350 patients (215 [61.4%] < 5 years of age and 135 [38.6%] > 5 years of age) were followed-up after treatment with injectable <span class=""chemical"">artesunate</span> for severe <span class=""disease"">malaria</span> in hospitals and health centers of the Democratic Republic of the Congo."		90.0	90_MESH:C039726_MESH:D008288	90_2	bcv_final_eval_easy_524		
	MESH:D001622	"<span class=""chemical"">betaine</span>"	MESH:D009202	"<span class=""disease"">myocardial injury</span>"	"Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by <span class=""chemical"">betaine</span> attenuates isoproterenol-induced acute <span class=""disease"">myocardial injury</span> in rats."		91.0	91_MESH:D001622_MESH:D009202	91_0	bcv_final_eval_easy_525		
	MESH:D001622	"<span class=""chemical"">betaine</span>"	MESH:D017202	"<span class=""disease"">acute myocardial ischemia</span>"	"The present study was designed to investigate the cardioprotective effects of <span class=""chemical"">betaine</span> on <span class=""disease"">acute myocardial ischemia</span> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect."		91.0	91_MESH:D001622_MESH:D017202	91_1	bcv_final_eval_easy_526		
	MESH:D001622	"<span class=""chemical"">betaine</span>"	MESH:D009202	"<span class=""disease"">myocardial damage</span>"	"The protective role of <span class=""chemical"">betaine</span> on <span class=""disease"">myocardial damage</span> was further confirmed by histopathological examination."		91.0	91_MESH:D001622_MESH:D009202	91_8	bcv_final_eval_easy_527		
	MESH:D001622	"<span class=""chemical"">betaine</span>"	MESH:D017202	"<span class=""disease"">acute myocardial ischemia</span>"	"In summary, our results showed that <span class=""chemical"">betaine</span> pretreatment attenuated isoproterenol-induced <span class=""disease"">acute myocardial ischemia</span> via the regulation of STAT3 and apoptotic pathways."		91.0	91_MESH:D001622_MESH:D017202	91_9	bcv_final_eval_easy_528		
	MESH:C069541	"<span class=""chemical"">Quetiapine</span>"	MESH:D001714	"<span class=""disease"">bipolar</span>"	"<span class=""chemical"">Quetiapine</span>-induced neutropenia in a <span class=""disease"">bipolar</span> patient with hepatocellular carcinoma."		92.0	92_MESH:C069541_MESH:D001714	92_0	bcv_final_eval_easy_529		
	MESH:C069541	"<span class=""chemical"">Quetiapine</span>"	MESH:D006528	"<span class=""disease"">hepatocellular carcinoma</span>"	"<span class=""chemical"">Quetiapine</span>-induced neutropenia in a bipolar patient with <span class=""disease"">hepatocellular carcinoma</span>."		92.0	92_MESH:C069541_MESH:D006528	92_0	bcv_final_eval_easy_530		
	MESH:D003024	"<span class=""chemical"">clozapine</span>"	MESH:D006402	"<span class=""disease"">blood dyscrasias</span>"	"OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to <span class=""chemical"">clozapine</span>, which has the highest risk of causing <span class=""disease"">blood dyscrasias</span>, especially neutropenia."		92.0	92_MESH:D003024_MESH:D006402	92_1	bcv_final_eval_easy_531		
	MESH:C069541	"<span class=""chemical"">Quetiapine</span>"	MESH:D006402	"<span class=""disease"">blood dyscrasias</span>"	"OBJECTIVE: <span class=""chemical"">Quetiapine</span> is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing <span class=""disease"">blood dyscrasias</span>, especially neutropenia."		92.0	92_MESH:C069541_MESH:D006402	92_1	bcv_final_eval_easy_532		
	MESH:D003024	"<span class=""chemical"">clozapine</span>"	MESH:D009503	"<span class=""disease"">neutropenia</span>"	"OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to <span class=""chemical"">clozapine</span>, which has the highest risk of causing blood dyscrasias, especially <span class=""disease"">neutropenia</span>."		92.0	92_MESH:D003024_MESH:D009503	92_1	bcv_final_eval_easy_533		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:D006528	"<span class=""disease"">hepatocellular carcinoma</span>"	"A case of a patient with <span class=""disease"">hepatocellular carcinoma</span> that developed neutropenia after treatment with <span class=""chemical"">quetiapine</span> is described here."		92.0	92_MESH:C069541_MESH:D006528	92_3	bcv_final_eval_easy_534		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:C536227	"<span class=""disease"">leucopenia</span>"	"She developed <span class=""disease"">leucopenia</span> after being treated with <span class=""chemical"">quetiapine</span>."		92.0	92_MESH:C069541_MESH:C536227	92_5	bcv_final_eval_easy_535		
	MESH:C069541	"<span class=""chemical"">quetiapine</span>"	MESH:D008107	"<span class=""disease"">Hepatic dysfunction</span>"	"<span class=""disease"">Hepatic dysfunction</span> may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to <span class=""chemical"">quetiapine</span>."		92.0	92_MESH:C069541_MESH:D008107	92_8	bcv_final_eval_easy_536		
	MESH:D013256	"<span class=""chemical"">steroid</span>"	MESH:D009422	"<span class=""disease"">neuropathy</span>"	"Lateral antebrachial cutaneous <span class=""disease"">neuropathy</span> after <span class=""chemical"">steroid</span> injection at lateral epicondyle."		93.0	93_MESH:D013256_MESH:D009422	93_0	bcv_final_eval_easy_537		
	MESH:D013256	"<span class=""chemical"">steroid</span>"	MESH:D013716	"<span class=""disease"">lateral epicondylitis</span>"	"BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a <span class=""chemical"">steroid</span> injection in the lateral epicondyle to treat <span class=""disease"">lateral epicondylitis</span> in a 40-year-old woman."		93.0	93_MESH:D013256_MESH:D013716	93_1	bcv_final_eval_easy_538		
	MESH:D013256	"<span class=""chemical"">steroid</span>"	MESH:D009422	"<span class=""disease"">neuropathy</span>"	"BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous <span class=""disease"">neuropathy</span> (LACNP) that occurred after a <span class=""chemical"">steroid</span> injection in the lateral epicondyle to treat lateral epicondylitis in a 40-year-old woman."		93.0	93_MESH:D013256_MESH:D009422	93_1	bcv_final_eval_easy_539		
	MESH:D013256	"<span class=""chemical"">steroid</span>"	MESH:D012678	"<span class=""disease"">decreased sensation</span>"	"MATERIAL AND METHOD: A 40-year-old woman presented with <span class=""disease"">decreased sensation</span> and paresthesia over her right lateral forearm; the paresthesia had occurred after a <span class=""chemical"">steroid</span> injection in the right lateral epicondyle 3 months before."		93.0	93_MESH:D013256_MESH:D012678	93_2	bcv_final_eval_easy_540		
	MESH:D013256	"<span class=""chemical"">steroid</span>"	MESH:D013716	"<span class=""disease"">lateral epicondylitis</span>"	"CONCLUSION: This report describes the case of a woman with LACNP that developed after a <span class=""chemical"">steroid</span> injection for the treatment of <span class=""disease"">lateral epicondylitis</span>."		93.0	93_MESH:D013256_MESH:D013716	93_8	bcv_final_eval_easy_541		
	MESH:D003474	"<span class=""chemical"">curcumin</span>"	MESH:D007674	"<span class=""disease"">renal injury</span>"	"The potential protective effect of the dietary antioxidant <span class=""chemical"">curcumin</span> (120 mg/Kg/day for 6 days) against the <span class=""disease"">renal injury</span> induced by maleate was evaluated."		94.0	94_MESH:D003474_MESH:D007674	94_1	bcv_final_eval_easy_542		
	MESH:C030272	"<span class=""chemical"">maleate</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"Tubular <span class=""disease"">proteinuria</span> and oxidative stress were induced by a single injection of <span class=""chemical"">maleate</span> (400 mg/kg) in rats."		94.0	94_MESH:C030272_MESH:D011507	94_2	bcv_final_eval_easy_543		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, <span class=""chemical"">glucose</span>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of <span class=""disease"">necrosis</span> and apoptosis of tubular cells on 24 h."		94.0	94_MESH:D005947_MESH:D009336	94_3	bcv_final_eval_easy_544		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D007674	"<span class=""disease"">kidney injury/renal injury</span>"	"Maleate-induced <span class=""disease"">renal injury</span> included increase in renal vascular resistance and in the urinary excretion of total protein, <span class=""chemical"">glucose</span>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <span class=""disease"">kidney injury</span> molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h."		94.0	94_MESH:D005947_MESH:D007674	94_3	bcv_final_eval_easy_545		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D007674	"<span class=""disease"">kidney injury/renal injury</span>"	"Maleate-induced <span class=""disease"">renal injury</span> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <span class=""chemical"">sodium</span>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <span class=""disease"">kidney injury</span> molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h."		94.0	94_MESH:D012964_MESH:D007674	94_3	bcv_final_eval_easy_546		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <span class=""chemical"">sodium</span>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of <span class=""disease"">necrosis</span> and apoptosis of tubular cells on 24 h."		94.0	94_MESH:D012964_MESH:D009336	94_3	bcv_final_eval_easy_547		
	MESH:C030272	"<span class=""chemical"">Maleate</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"<span class=""chemical"">Maleate</span>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of <span class=""disease"">necrosis</span> and apoptosis of tubular cells on 24 h."		94.0	94_MESH:C030272_MESH:D009336	94_3	bcv_final_eval_easy_548		
	MESH:D003474	"<span class=""chemical"">curcumin</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"It is concluded that <span class=""chemical"">curcumin</span> is able to attenuate in vivo maleate-induced <span class=""disease"">nephropathy</span> and in vitro cell damage."		94.0	94_MESH:D003474_MESH:D007674	94_10	bcv_final_eval_easy_549		
	MESH:D003976	"<span class=""chemical"">diazinon</span>"	MESH:D009369	"<span class=""disease"">tumours</span>"	"Incidence of solid <span class=""disease"">tumours</span> among pesticide applicators exposed to the organophosphate insecticide <span class=""chemical"">diazinon</span> in the Agricultural Health Study: an updated analysis."		95.0	95_MESH:D003976_MESH:D009369	95_0	bcv_final_eval_easy_550		
	MESH:D010755	"<span class=""chemical"">organophosphate</span>"	MESH:D009369	"<span class=""disease"">tumours</span>"	"Incidence of solid <span class=""disease"">tumours</span> among pesticide applicators exposed to the <span class=""chemical"">organophosphate</span> insecticide diazinon in the Agricultural Health Study: an updated analysis."		95.0	95_MESH:D010755_MESH:D009369	95_0	bcv_final_eval_easy_551		
	MESH:D003976	"<span class=""chemical"">Diazinon</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"OBJECTIVE: <span class=""chemical"">Diazinon</span>, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined <span class=""chemical"">diazinon</span>-associated <span class=""disease"">cancer</span> risk."		95.0	95_MESH:D003976_MESH:D009369	95_1	bcv_final_eval_easy_552		
	MESH:D010755	"<span class=""chemical"">organophosphate</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"OBJECTIVE: Diazinon, a common <span class=""chemical"">organophosphate</span> insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated <span class=""disease"">cancer</span> risk."		95.0	95_MESH:D010755_MESH:D009369	95_1	bcv_final_eval_easy_553		
	MESH:D003976	"<span class=""chemical"">Diazinon</span>"	MESH:D008175	"<span class=""disease"">lung cancer</span>"	"OBJECTIVE: <span class=""chemical"">Diazinon</span>, a common organophosphate insecticide with genotoxic properties, was previously associated with <span class=""disease"">lung cancer</span> in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined <span class=""chemical"">diazinon</span>-associated cancer risk."		95.0	95_MESH:D003976_MESH:D008175	95_1	bcv_final_eval_easy_554		
	MESH:D010755	"<span class=""chemical"">organophosphate</span>"	MESH:D008175	"<span class=""disease"">lung cancer</span>"	"OBJECTIVE: Diazinon, a common <span class=""chemical"">organophosphate</span> insecticide with genotoxic properties, was previously associated with <span class=""disease"">lung cancer</span> in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk."		95.0	95_MESH:D010755_MESH:D008175	95_1	bcv_final_eval_easy_555		
	MESH:D003976	"<span class=""chemical"">diazinon</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"We used updated <span class=""chemical"">diazinon</span> exposure and <span class=""disease"">cancer</span> incidence information to evaluate solid tumour risk in the AHS."		95.0	95_MESH:D003976_MESH:D009369	95_2	bcv_final_eval_easy_556		
	MESH:D003976	"<span class=""chemical"">diazinon</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime <span class=""chemical"">diazinon</span> use at enrolment (1993-1997) and follow-up (1998-2005); <span class=""disease"">cancer</span> incidence was assessed through 2010(North Carolina)/2011(Iowa)."		95.0	95_MESH:D003976_MESH:D009369	95_3	bcv_final_eval_easy_557		
	MESH:D003976	"<span class=""chemical"">diazinon</span>"	MESH:D008175	"<span class=""disease"">lung cancer</span>"	"RESULTS: We observed elevated <span class=""disease"">lung cancer</span> risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of <span class=""chemical"">diazinon</span> use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08)."		95.0	95_MESH:D003976_MESH:D008175	95_5	bcv_final_eval_easy_558		
	MESH:D003976	"<span class=""chemical"">diazinon</span>"	MESH:D008175	"<span class=""disease"">lung cancer</span>"	"CONCLUSIONS: Our updated evaluation of <span class=""chemical"">diazinon</span> provides additional evidence of an association with <span class=""disease"">lung cancer</span> risk."		95.0	95_MESH:D003976_MESH:D008175	95_7	bcv_final_eval_easy_559		
	MESH:D010126	"<span class=""chemical"">Ozone</span>"	MESH:D010300	"<span class=""disease"">Parkinson's Disease</span>"	"Associations of <span class=""chemical"">Ozone</span> and PM2.5 Concentrations With <span class=""disease"">Parkinson's Disease</span> Among Participants in the Agricultural Health Study."		96.0	96_MESH:D010126_MESH:D010300	96_0	bcv_final_eval_easy_560		
	MESH:D010126	"<span class=""chemical"">ozone</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"OBJECTIVE: This study describes associations of <span class=""chemical"">ozone</span> and fine particulate matter with <span class=""disease"">Parkinson's disease</span> observed among farmers in North Carolina and Iowa."		96.0	96_MESH:D010126_MESH:D010300	96_1	bcv_final_eval_easy_561		
	MESH:D010126	"<span class=""chemical"">ozone</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"RESULTS: We observed positive associations of <span class=""disease"">Parkinson's disease</span> with <span class=""chemical"">ozone</span> (odds ratio = 1.39; 95% CI: 0.98 to 1.98) and fine particulate matter (odds ratio = 1.34; 95% CI: 0.93 to 1.93) in North Carolina but not in Iowa."		96.0	96_MESH:D010126_MESH:D010300	96_4	bcv_final_eval_easy_562		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D005921	"<span class=""disease"">glomerulosclerosis</span>"	"Low functional programming of renal AT2R mediates the developmental origin of <span class=""disease"">glomerulosclerosis</span> in adult offspring induced by prenatal <span class=""chemical"">caffeine</span> exposure."		97.0	97_MESH:D002110_MESH:D005921	97_0	bcv_final_eval_easy_563		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D005317	"<span class=""disease"">intrauterine growth retardation/IUGR</span>"	"UNASSIGNED: Our previous study has indicated that prenatal <span class=""chemical"">caffeine</span> exposure (PCE) could induce <span class=""disease"">intrauterine growth retardation</span> (<span class=""disease"">IUGR</span>) of offspring."		97.0	97_MESH:D002110_MESH:D005317	97_1	bcv_final_eval_easy_564		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial <span class=""disease"">fibrosis</span>, accompanied by elevated levels of serum <span class=""chemical"">creatinine</span> and urine protein."		97.0	97_MESH:D003404_MESH:D005355	97_6	bcv_final_eval_easy_565		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D005921	"<span class=""disease"">glomerulosclerosis</span>"	"The results revealed that the adult offspring kidneys in the PCE group exhibited <span class=""disease"">glomerulosclerosis</span> as well as interstitial fibrosis, accompanied by elevated levels of serum <span class=""chemical"">creatinine</span> and urine protein."		97.0	97_MESH:D003404_MESH:D005921	97_6	bcv_final_eval_easy_566		
	MESH:C031763	"<span class=""chemical"">1,3-Butadiene</span>"	MESH:D015464	"<span class=""disease"">CML</span>"	"<span class=""chemical"">1,3-Butadiene</span>, <span class=""disease"">CML</span> and the t(9:22) translocation: A reality check."		98.0	98_MESH:C031763_MESH:D015464	98_0	bcv_final_eval_easy_567		
	MESH:C031763	"<span class=""chemical"">1,3-butadiene</span>"	MESH:D015464	"<span class=""disease"">chronic myeloid leukemia/CML</span>"	"UNASSIGNED: Epidemiological studies of <span class=""chemical"">1,3-butadiene</span> have suggest that exposures to humans are associated with <span class=""disease"">chronic myeloid leukemia</span> (<span class=""disease"">CML</span>)."		98.0	98_MESH:C031763_MESH:D015464	98_1	bcv_final_eval_easy_568		
	MESH:C051786	"<span class=""chemical"">metolachlor</span>"	MESH:D009369	"<span class=""disease"">Cancer</span>"	"<span class=""disease"">Cancer</span> incidence and <span class=""chemical"">metolachlor</span> use in the Agricultural Health Study: An update."		99.0	99_MESH:C051786_MESH:D009369	99_0	bcv_final_eval_easy_569		
	MESH:C051786	"<span class=""chemical"">metolachlor</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"We evaluated <span class=""disease"">cancer</span> incidence through 2010/2011 (NC/IA) for 49,616 applicators, 53% of whom reported ever using <span class=""chemical"">metolachlor</span>."		99.0	99_MESH:C051786_MESH:D009369	99_5	bcv_final_eval_easy_570		
	MESH:C051786	"<span class=""chemical"">metolachlor</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"We used Poisson regression to evaluate relations between two metrics of <span class=""chemical"">metolachlor</span> use (lifetime days, intensity-weighted lifetime days) and <span class=""disease"">cancer</span> incidence."		99.0	99_MESH:C051786_MESH:D009369	99_6	bcv_final_eval_easy_571		
	MESH:C051786	"<span class=""chemical"">metolachlor</span>"	MESH:D009369	"<span class=""disease"">cancers</span>"	"We saw no association between <span class=""chemical"">metolachlor</span> use and incidence of all <span class=""disease"">cancers</span> combined (n = 5,701 with a 5-year lag) or most site-specific <span class=""disease"">cancers</span>."		99.0	99_MESH:C051786_MESH:D009369	99_7	bcv_final_eval_easy_572		
	MESH:C051786	"<span class=""chemical"">metolachlor</span>"	MESH:D008175	"<span class=""disease"">increased lung cancer</span>"	"An earlier suggestion of <span class=""disease"">increased lung cancer</span> risk at high levels of <span class=""chemical"">metolachlor</span> use in this cohort was not confirmed in this update."		99.0	99_MESH:C051786_MESH:D008175	99_11	bcv_final_eval_easy_573		
	MESH:C051786	"<span class=""chemical"">metolachlor</span>"	MESH:D008113	"<span class=""disease"">liver cancer/liver neoplasms</span>"	"This suggestion of an association between <span class=""chemical"">metolachlor</span> and <span class=""disease"">liver cancer</span> among pesticide applicators is a novel finding and echoes observation of increased <span class=""disease"">liver neoplasms</span> in some animal studies."		99.0	99_MESH:C051786_MESH:D008113	99_12	bcv_final_eval_easy_574		
	MESH:C051786	"<span class=""chemical"">metolachlor</span>"	MESH:D008224	"<span class=""disease"">follicular cell lymphoma</span>"	"However, our findings for both liver cancer and <span class=""disease"">follicular cell lymphoma</span> warrant follow-up to better differentiate effects of <span class=""chemical"">metolachlor</span> use from other factors."		99.0	99_MESH:C051786_MESH:D008224	99_13	bcv_final_eval_easy_575		
	MESH:C051786	"<span class=""chemical"">metolachlor</span>"	MESH:D008113	"<span class=""disease"">liver cancer</span>"	"However, our findings for both <span class=""disease"">liver cancer</span> and follicular cell lymphoma warrant follow-up to better differentiate effects of <span class=""chemical"">metolachlor</span> use from other factors."		99.0	99_MESH:C051786_MESH:D008113	99_13	bcv_final_eval_easy_576		
	MESH:C024986	"<span class=""chemical"">BaCl2</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"Four types of experimental <span class=""disease"">arrhythmia</span> are used--with <span class=""chemical"">BaCl2</span>, with chloroform-adrenaline, with strophantine G and with aconitine."		101.0	101_MESH:C024986_MESH:D001145	101_2	bcv_final_eval_easy_577		
	MESH:D002725	"<span class=""chemical"">chloroform</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"Four types of experimental <span class=""disease"">arrhythmia</span> are used--with BaCl2, with <span class=""chemical"">chloroform</span>-adrenaline, with strophantine G and with aconitine."		101.0	101_MESH:D002725_MESH:D001145	101_2	bcv_final_eval_easy_578		
	MESH:D004837	"<span class=""chemical"">adrenaline</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"Four types of experimental <span class=""disease"">arrhythmia</span> are used--with BaCl2, with chloroform-<span class=""chemical"">adrenaline</span>, with strophantine G and with aconitine."		101.0	101_MESH:D004837_MESH:D001145	101_2	bcv_final_eval_easy_579		
	MESH:D000157	"<span class=""chemical"">aconitine</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"Four types of experimental <span class=""disease"">arrhythmia</span> are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with <span class=""chemical"">aconitine</span>."		101.0	101_MESH:D000157_MESH:D001145	101_2	bcv_final_eval_easy_580		
	MESH:D002725	"<span class=""chemical"">chloroform</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"The compound manifests antiarrhythmic activity in all models of experimental <span class=""disease"">arrhythmia</span> used, causing greatest inhibition on the <span class=""disease"">arrhythmia</span> induced by <span class=""chemical"">chloroform</span>-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent)."		101.0	101_MESH:D002725_MESH:D001145	101_4	bcv_final_eval_easy_581		
	MESH:C024986	"<span class=""chemical"">BaCl2</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"The compound manifests antiarrhythmic activity in all models of experimental <span class=""disease"">arrhythmia</span> used, causing greatest inhibition on the <span class=""disease"">arrhythmia</span> induced by chloroform-adrenaline (in 90 per cent) and with <span class=""chemical"">BaCl2</span> (in 84 per cent)."		101.0	101_MESH:C024986_MESH:D001145	101_4	bcv_final_eval_easy_582		
	MESH:D004837	"<span class=""chemical"">adrenaline</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"The compound manifests antiarrhythmic activity in all models of experimental <span class=""disease"">arrhythmia</span> used, causing greatest inhibition on the <span class=""disease"">arrhythmia</span> induced by chloroform-<span class=""chemical"">adrenaline</span> (in 90 per cent) and with BaCl2 (in 84 per cent)."		101.0	101_MESH:D004837_MESH:D001145	101_4	bcv_final_eval_easy_583		
	MESH:D014810	"<span class=""chemical"">vitamin E</span>"	MESH:D009135	"<span class=""disease"">Myopathy</span>"	"<span class=""disease"">Myopathy</span> due to lack of <span class=""chemical"">vitamin E</span> and <span class=""disease"">myopathy</span> induced by certain viruses have much in common anatomically and pathologically with the human form."		102.0	102_MESH:D014810_MESH:D009135	102_3	bcv_final_eval_easy_584		
	MESH:D014810	"<span class=""chemical"">vitamin E</span>"	MESH:D009136	"<span class=""disease"">myodystrophy</span>"	"The authors induced <span class=""disease"">myodystrophy</span> in the rat by giving it a diet lacking in <span class=""chemical"">vitamin E</span>."		102.0	102_MESH:D014810_MESH:D009136	102_4	bcv_final_eval_easy_585		
	MESH:D014810	"<span class=""chemical"">vitamin E</span>"	MESH:C536100	"<span class=""disease"">myopathic</span>"	"The encouraging results obtained in various authoratative departments in <span class=""disease"">myopathic</span> patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered <span class=""disease"">myopathic</span> by a diet deficient in <span class=""chemical"">vitamin E</span>."		102.0	102_MESH:D014810_MESH:C536100	102_7	bcv_final_eval_easy_586		
	MESH:D013256	"<span class=""chemical"">steroids</span>"	MESH:C536100	"<span class=""disease"">myopathic</span>"	"The encouraging results obtained in various authoratative departments in <span class=""disease"">myopathic</span> patients by using anabolizing <span class=""chemical"">steroids</span> have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered <span class=""disease"">myopathic</span> by a diet deficient in vitamin E."		102.0	102_MESH:D013256_MESH:C536100	102_7	bcv_final_eval_easy_587		
	MESH:D008696	"<span class=""chemical"">Dianabol</span>"	MESH:C536100	"<span class=""disease"">myopathic</span>"	"The encouraging results obtained in various authoratative departments in <span class=""disease"">myopathic</span> patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (<span class=""chemical"">Dianabol</span>, CIBA) at high doses in rats rendered <span class=""disease"">myopathic</span> by a diet deficient in vitamin E."		102.0	102_MESH:D008696_MESH:C536100	102_7	bcv_final_eval_easy_588		
	MESH:D014810	"<span class=""chemical"">vitamin E</span>"	MESH:D014947	"<span class=""disease"">dystrophic injurious</span>"	"The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the ""regeneration"" of the muscle tissue; and finally because the <span class=""disease"">dystrophic injurious</span> agent is certainly not the lack of <span class=""chemical"">vitamin E</span> but something as yet unknown."		102.0	102_MESH:D014810_MESH:D014947	102_9	bcv_final_eval_easy_589		
	MESH:D014810	"<span class=""chemical"">vitamin E</span>"	MESH:D017695	"<span class=""disease"">tissue injury</span>"	"The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the <span class=""disease"">tissue injury</span> too often occurs at an irreversible stage vis-a-vis the ""regeneration"" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of <span class=""chemical"">vitamin E</span> but something as yet unknown."		102.0	102_MESH:D014810_MESH:D017695	102_9	bcv_final_eval_easy_590		
	MESH:D014810	"<span class=""chemical"">vitamin E</span>"	MESH:D004194	"<span class=""disease"">myopathic disease</span>"	"The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental <span class=""disease"">myopathic disease</span>, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the ""regeneration"" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of <span class=""chemical"">vitamin E</span> but something as yet unknown."		102.0	102_MESH:D014810_MESH:D004194	102_9	bcv_final_eval_easy_591		
	MESH:D013256	"<span class=""chemical"">steroids</span>"	MESH:D004194	"<span class=""disease"">myopathic disease</span>"	"The authors conclude by affirming the undoubted efficacy of the anabolizing <span class=""chemical"">steroids</span> in experimental <span class=""disease"">myopathic disease</span>, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the ""regeneration"" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown."		102.0	102_MESH:D013256_MESH:D004194	102_9	bcv_final_eval_easy_592		
	MESH:D013256	"<span class=""chemical"">steroids</span>"	MESH:D017695	"<span class=""disease"">tissue injury</span>"	"The authors conclude by affirming the undoubted efficacy of the anabolizing <span class=""chemical"">steroids</span> in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the <span class=""disease"">tissue injury</span> too often occurs at an irreversible stage vis-a-vis the ""regeneration"" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown."		102.0	102_MESH:D013256_MESH:D017695	102_9	bcv_final_eval_easy_593		
	MESH:D013256	"<span class=""chemical"">steroids</span>"	MESH:D014947	"<span class=""disease"">dystrophic injurious</span>"	"The authors conclude by affirming the undoubted efficacy of the anabolizing <span class=""chemical"">steroids</span> in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the ""regeneration"" of the muscle tissue; and finally because the <span class=""disease"">dystrophic injurious</span> agent is certainly not the lack of vitamin E but something as yet unknown."		102.0	102_MESH:D013256_MESH:D014947	102_9	bcv_final_eval_easy_594		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002806	"<span class=""disease"">chondrodysplasia punctata/stippled epiphyses</span>"	"The baby showed <span class=""chemical"">warfarin</span>-induced embryopathy with nasal hypoplasia and <span class=""disease"">stippled epiphyses</span> (<span class=""disease"">chondrodysplasia punctata</span>)."		103.0	103_MESH:D014859_MESH:D002806	103_5	bcv_final_eval_easy_595		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:C562568	"<span class=""disease"">hypoplasia</span>"	"The baby showed <span class=""chemical"">warfarin</span>-induced embryopathy with nasal <span class=""disease"">hypoplasia</span> and stippled epiphyses (chondrodysplasia punctata)."		103.0	103_MESH:D014859_MESH:C562568	103_5	bcv_final_eval_easy_596		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002806	"<span class=""disease"">stippled epiphyses</span>"	"Nasal hypoplasia with or without <span class=""disease"">stippled epiphyses</span> has now been reported in 11 infants born to mothers treated with <span class=""chemical"">warfarin</span> during the first trimester, and a causal association is probable."		103.0	103_MESH:D014859_MESH:D002806	103_6	bcv_final_eval_easy_597		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:C562568	"<span class=""disease"">hypoplasia</span>"	"Nasal <span class=""disease"">hypoplasia</span> with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with <span class=""chemical"">warfarin</span> during the first trimester, and a causal association is probable."		103.0	103_MESH:D014859_MESH:C562568	103_6	bcv_final_eval_easy_598		
	MESH:D017275	"<span class=""chemical"">Isradipine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"<span class=""chemical"">Isradipine</span> treatment for <span class=""disease"">hypertension</span> in general practice in Hong Kong."		104.0	104_MESH:D017275_MESH:D006973	104_0	bcv_final_eval_easy_599		
	MESH:D017275	"<span class=""chemical"">isradipine</span>"	MESH:D004244	"<span class=""disease"">dizziness</span>"	"The main side-effects were headache, <span class=""disease"">dizziness</span>, palpitation and flushing and these were not more frequent than reported in other studies with <span class=""chemical"">isradipine</span> or with placebo."		104.0	104_MESH:D017275_MESH:D004244	104_4	bcv_final_eval_easy_600		
	MESH:D017275	"<span class=""chemical"">isradipine</span>"	MESH:D006261	"<span class=""disease"">headache</span>"	"The main side-effects were <span class=""disease"">headache</span>, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with <span class=""chemical"">isradipine</span> or with placebo."		104.0	104_MESH:D017275_MESH:D006261	104_4	bcv_final_eval_easy_601		
	MESH:D000420	"<span class=""chemical"">salbutamol</span>"	MESH:D058545	"<span class=""disease"">high dose inhaled salbutamol</span>"	"Tachyphylaxis to systemic but not to airway responses during prolonged therapy with <span class=""disease"">high dose inhaled </span><span class=""chemical"">salbutamol</span> in asthmatics."		105.0	105_MESH:D000420_MESH:D058545	105_0	bcv_final_eval_easy_602		
	MESH:D000420	"<span class=""chemical"">salbutamol</span>"	MESH:D001249	"<span class=""disease"">asthma</span>"	"High doses of inhaled <span class=""chemical"">salbutamol</span> produce substantial improvements in airway response in patients with <span class=""disease"">asthma</span>, and are associated with dose-dependent systemic beta-adrenoceptor responses."		105.0	105_MESH:D000420_MESH:D001249	105_1	bcv_final_eval_easy_603		
	MESH:D000420	"<span class=""chemical"">salbutamol</span>"	MESH:D058545	"<span class=""disease"">high dose inhaled salbutamol</span>"	"The purpose of the present study was to investigate whether tachyphylaxis occurs during prolonged treatment with <span class=""disease"">high dose inhaled </span><span class=""chemical"">salbutamol</span>."		105.0	105_MESH:D000420_MESH:D058545	105_2	bcv_final_eval_easy_604		
	MESH:D000420	"<span class=""chemical"">salbutamol</span>"	MESH:D013224	"<span class=""disease"">asthmatic</span>"	"Twelve <span class=""disease"">asthmatic</span> patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled <span class=""chemical"">salbutamol</span> (HDS), 4,000 micrograms daily, low dose inhaled <span class=""chemical"">salbutamol</span> (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design."		105.0	105_MESH:D000420_MESH:D013224	105_3	bcv_final_eval_easy_605		
	MESH:D000420	"<span class=""chemical"">salbutamol</span>"	MESH:D058545	"<span class=""disease"">high dose inhaled salbutamol/HDS</span>"	"Twelve asthmatic patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with <span class=""disease"">high dose inhaled </span><span class=""chemical"">salbutamol</span> (<span class=""disease"">HDS</span>), 4,000 micrograms daily, low dose inhaled <span class=""chemical"">salbutamol</span> (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design."		105.0	105_MESH:D000420_MESH:D058545	105_3	bcv_final_eval_easy_606		
	MESH:D011188	"<span class=""chemical"">K</span>"	MESH:D014202	"<span class=""disease"">tremor</span>"	"At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), <span class=""disease"">tremor</span>, and metabolic (<span class=""chemical"">K</span>, Glu) responses were measured at each step (from 100 to 4,000 micrograms)."		105.0	105_MESH:D011188_MESH:D014202	105_5	bcv_final_eval_easy_607		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">panic disorders</span>"	"Increased anxiogenic effects of <span class=""chemical"">caffeine</span> in <span class=""disease"">panic disorders</span>."		106.0	106_MESH:D002110_MESH:D016584	106_0	bcv_final_eval_easy_608		
	MESH:D008734	"<span class=""chemical"">MHPG</span>"	MESH:D016584	"<span class=""disease"">panic disorder/panic</span>"	"The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (<span class=""chemical"">MHPG</span>) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with <span class=""disease"">panic</span> attacks or <span class=""disease"">panic disorder</span>."		106.0	106_MESH:D008734_MESH:D016584	106_1	bcv_final_eval_easy_609		
	MESH:D006854	"<span class=""chemical"">cortisol</span>"	MESH:D016584	"<span class=""disease"">panic disorder/panic</span>"	"The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and <span class=""chemical"">cortisol</span> were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with <span class=""disease"">panic</span> attacks or <span class=""disease"">panic disorder</span>."		106.0	106_MESH:D006854_MESH:D016584	106_1	bcv_final_eval_easy_610		
	MESH:D006854	"<span class=""chemical"">cortisol</span>"	MESH:D000379	"<span class=""disease"">agoraphobia</span>"	"The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and <span class=""chemical"">cortisol</span> were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for <span class=""disease"">agoraphobia</span> with panic attacks or panic disorder."		106.0	106_MESH:D006854_MESH:D000379	106_1	bcv_final_eval_easy_611		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">panic disorder/panic</span>"	"The effects of oral administration of <span class=""chemical"">caffeine</span> (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with <span class=""disease"">panic</span> attacks or <span class=""disease"">panic disorder</span>."		106.0	106_MESH:D002110_MESH:D016584	106_1	bcv_final_eval_easy_612		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D000379	"<span class=""disease"">agoraphobia</span>"	"The effects of oral administration of <span class=""chemical"">caffeine</span> (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for <span class=""disease"">agoraphobia</span> with panic attacks or panic disorder."		106.0	106_MESH:D002110_MESH:D000379	106_1	bcv_final_eval_easy_613		
	MESH:D008734	"<span class=""chemical"">MHPG</span>"	MESH:D000379	"<span class=""disease"">agoraphobia</span>"	"The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (<span class=""chemical"">MHPG</span>) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for <span class=""disease"">agoraphobia</span> with panic attacks or panic disorder."		106.0	106_MESH:D008734_MESH:D000379	106_1	bcv_final_eval_easy_614		
	MESH:D002110	"<span class=""chemical"">Caffeine</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"<span class=""chemical"">Caffeine</span> produced significantly greater increases in subject-rated <span class=""disease"">anxiety</span>, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects."		106.0	106_MESH:D002110_MESH:D001008	106_2	bcv_final_eval_easy_615		
	MESH:D002110	"<span class=""chemical"">Caffeine</span>"	MESH:D014202	"<span class=""disease"">tremors</span>"	"<span class=""chemical"">Caffeine</span> produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and <span class=""disease"">tremors</span> in the patients compared with healthy subjects."		106.0	106_MESH:D002110_MESH:D014202	106_2	bcv_final_eval_easy_616		
	MESH:D002110	"<span class=""chemical"">Caffeine</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"<span class=""chemical"">Caffeine</span> produced significantly greater increases in subject-rated anxiety, nervousness, fear, <span class=""disease"">nausea</span>, palpitations, restlessness, and tremors in the patients compared with healthy subjects."		106.0	106_MESH:D002110_MESH:D009325	106_2	bcv_final_eval_easy_617		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">panic</span>"	"Seventy-one percent of the patients reported that the behavioral effects of <span class=""chemical"">caffeine</span> were similar to those experienced during <span class=""disease"">panic</span> attacks."		106.0	106_MESH:D002110_MESH:D016584	106_4	bcv_final_eval_easy_618		
	MESH:D000241	"<span class=""chemical"">adenosine</span>"	MESH:D016584	"<span class=""disease"">panic disorder</span>"	"Because caffeine is an <span class=""chemical"">adenosine</span> receptor antagonist, these results suggest that some <span class=""disease"">panic disorder</span> patients may have abnormalities in neuronal systems involving <span class=""chemical"">adenosine</span>."		106.0	106_MESH:D000241_MESH:D016584	106_7	bcv_final_eval_easy_619		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">panic disorder</span>"	"Because <span class=""chemical"">caffeine</span> is an adenosine receptor antagonist, these results suggest that some <span class=""disease"">panic disorder</span> patients may have abnormalities in neuronal systems involving adenosine."		106.0	106_MESH:D002110_MESH:D016584	106_7	bcv_final_eval_easy_620		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D001008	"<span class=""disease"">anxiety disorders</span>"	"Patients with <span class=""disease"">anxiety disorders</span> may benefit by avoiding <span class=""chemical"">caffeine</span>-containing foods and beverages."		106.0	106_MESH:D002110_MESH:D001008	106_8	bcv_final_eval_easy_621		
	MESH:D003035	"<span class=""chemical"">cobalt</span>"	MESH:D009202	"<span class=""disease"">cardiomyopathy</span>"	"In the first, <span class=""chemical"">cobalt</span> <span class=""disease"">cardiomyopathy</span> was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05)."		107.0	107_MESH:D003035_MESH:D009202	107_3	bcv_final_eval_easy_622		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D064420	"<span class=""disease"">toxic</span>"	"Interstrain variation in acute <span class=""disease"">toxic</span> response to <span class=""chemical"">caffeine</span> among inbred mice."		108.0	108_MESH:D002110_MESH:D064420	108_0	bcv_final_eval_easy_623		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D064420	"<span class=""disease"">toxic</span>"	"Acute <span class=""disease"">toxic</span> dosage-dependent behavioral effects of <span class=""chemical"">caffeine</span> were compared in adult males from seven inbred mouse strains (A/J, BALB/cJ, CBA/J, C3H/HeJ, C57BL/6J, DBA/2J, SWR/J)."		108.0	108_MESH:D002110_MESH:D064420	108_1	bcv_final_eval_easy_624		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress-induced lethality, <span class=""disease"">death</span> without external stress--were scored at various <span class=""chemical"">caffeine</span> doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions."		108.0	108_MESH:D002110_MESH:D003643	108_3	bcv_final_eval_easy_625		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Five phenotypic characteristics--locomotor activity, righting ability, clonic <span class=""disease"">seizure</span> induction, stress-induced lethality, death without external stress--were scored at various <span class=""chemical"">caffeine</span> doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions."		108.0	108_MESH:D002110_MESH:D012640	108_3	bcv_final_eval_easy_626		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D064420	"<span class=""disease"">toxic</span>"	"By any single behavioral criterion or a combination of these criteria, marked differences in response to <span class=""disease"">toxic</span> <span class=""chemical"">caffeine</span> doses were observed between strains."		108.0	108_MESH:D002110_MESH:D064420	108_10	bcv_final_eval_easy_627		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D007674	"<span class=""disease"">carcinoma of the renal pelvis</span>"	"Invasive <span class=""disease"">carcinoma of the renal pelvis</span> following <span class=""chemical"">cyclophosphamide</span> therapy for nonmalignant disease."		109.0	109_MESH:D003520_MESH:D007674	109_0	bcv_final_eval_easy_628		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D020293	"<span class=""disease"">cerebral vasculitis</span>"	"A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih <span class=""chemical"">cyclophosphamide</span> for <span class=""disease"">cerebral vasculitis</span>."		109.0	109_MESH:D003520_MESH:D020293	109_1	bcv_final_eval_easy_629		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D006417	"<span class=""disease"">hematuria</span>"	"A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross <span class=""disease"">hematuria</span> after being treated for five years wtih <span class=""chemical"">cyclophosphamide</span> for cerebral vasculitis."		109.0	109_MESH:D003520_MESH:D006417	109_1	bcv_final_eval_easy_630		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:C537373	"<span class=""disease"">ureterovesical junction obstruction</span>"	"A 47-year-old woman with right hydroureteronephrosis due to <span class=""disease"">ureterovesical junction obstruction</span> had gross hematuria after being treated for five years wtih <span class=""chemical"">cyclophosphamide</span> for cerebral vasculitis."		109.0	109_MESH:D003520_MESH:C537373	109_1	bcv_final_eval_easy_631		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D002277	"<span class=""disease"">carcinoma</span>"	"Although the ability of <span class=""chemical"">cyclophosphamide</span> to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade <span class=""disease"">carcinoma</span> is well known, it is less widely appreciated that it is also associated with <span class=""disease"">carcinoma</span> of the urinary tract."		109.0	109_MESH:D003520_MESH:D002277	109_4	bcv_final_eval_easy_632		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D003556	"<span class=""disease"">hemorrhagic cystitis</span>"	"Although the ability of <span class=""chemical"">cyclophosphamide</span> to cause <span class=""disease"">hemorrhagic cystitis</span> and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract."		109.0	109_MESH:D003520_MESH:D003556	109_4	bcv_final_eval_easy_633		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D007674	"<span class=""disease"">carcinoma of the renal pelvis</span>"	"The present case is the first <span class=""disease"">carcinoma of the renal pelvis</span> reported in association with <span class=""chemical"">cyclophosphamide</span> treatment."		109.0	109_MESH:D003520_MESH:D007674	109_6	bcv_final_eval_easy_634		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D014571	"<span class=""disease"">urinary tract cancer</span>"	"It is the third <span class=""disease"">urinary tract cancer</span> reported in association with <span class=""chemical"">cyclophosphamide</span> treatment for nonmalignant disease."		109.0	109_MESH:D003520_MESH:D014571	109_7	bcv_final_eval_easy_635		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"The association of the <span class=""disease"">tumor</span> with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to <span class=""chemical"">cyclophosphamide</span>."		109.0	109_MESH:D003520_MESH:D009369	109_8	bcv_final_eval_easy_636		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D014647	"<span class=""disease"">stasis</span>"	"The association of the tumor with preexisting hydroureteronephrosis suggests that <span class=""disease"">stasis</span> prolonged and intensified exposure of upper urinary tract epithelium to <span class=""chemical"">cyclophosphamide</span>."		109.0	109_MESH:D003520_MESH:D014647	109_8	bcv_final_eval_easy_637		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:C536483	"<span class=""disease"">for obstructive uropathy</span>"	"Patients who are candidates for long-term <span class=""chemical"">cyclophosphamide</span> treatment should be routinely evaluated <span class=""disease"">for obstructive uropathy</span>."		109.0	109_MESH:D003520_MESH:C536483	109_9	bcv_final_eval_easy_638		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"A pilot study to assess the safety of <span class=""chemical"">dobutamine</span> stress echocardiography in the emergency department evaluation of cocaine-associated <span class=""disease"">chest pain</span>."		111.0	111_MESH:D004280_MESH:D002637	111_0	bcv_final_eval_easy_639		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span>."		111.0	111_MESH:D003042_MESH:D002637	111_0	bcv_final_eval_easy_640		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">Chest pain</span>"	"STUDY OBJECTIVE: <span class=""disease"">Chest pain</span> in the setting of <span class=""chemical"">cocaine</span> use poses a diagnostic dilemma."		111.0	111_MESH:D003042_MESH:D002637	111_1	bcv_final_eval_easy_641		
	MESH:D004280	"<span class=""chemical"">Dobutamine</span>"	MESH:D006331	"<span class=""disease"">cardiac ischemia</span>"	"<span class=""chemical"">Dobutamine</span> stress echocardiography (DSE) is a widely available and sensitive test for evaluating <span class=""disease"">cardiac ischemia</span>."		111.0	111_MESH:D004280_MESH:D006331	111_2	bcv_final_eval_easy_642		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"Because of the theoretical concern regarding administration of <span class=""chemical"">dobutamine</span> in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated <span class=""disease"">chest pain</span>."		111.0	111_MESH:D004280_MESH:D002637	111_3	bcv_final_eval_easy_643		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"Because of the theoretical concern regarding administration of dobutamine in the setting of <span class=""chemical"">cocaine</span> use, we conducted a pilot study to assess the safety of DSE in emergency department patients with <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span>."		111.0	111_MESH:D003042_MESH:D002637	111_3	bcv_final_eval_easy_644		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"Patients were eligible for DSE if they had used <span class=""chemical"">cocaine</span> within 24 hours preceding the onset of <span class=""disease"">chest pain</span> and had a normal ECG and tropinin I level."		111.0	111_MESH:D003042_MESH:D002637	111_5	bcv_final_eval_easy_645		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D064420	"<span class=""disease"">cocaine toxicity</span>"	"Patients exhibiting signs of continuing <span class=""chemical""></span><span class=""disease"">cocaine</span> toxicity were excluded from the study."		111.0	111_MESH:D003042_MESH:D064420	111_6	bcv_final_eval_easy_646		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"CONCLUSION: No exaggerated adrenergic response was detected when <span class=""chemical"">dobutamine</span> was administered to patients with cocaine-related <span class=""disease"">chest pain</span>."		111.0	111_MESH:D004280_MESH:D002637	111_13	bcv_final_eval_easy_647		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with <span class=""chemical"">cocaine</span>-related <span class=""disease"">chest pain</span>."		111.0	111_MESH:D003042_MESH:D002637	111_13	bcv_final_eval_easy_648		
	MESH:D004077	"<span class=""chemical"">digoxin</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including <span class=""disease"">hypokalemia</span> and <span class=""chemical"">digoxin</span> excess."		112.0	112_MESH:D004077_MESH:D007008	112_2	bcv_final_eval_easy_649		
	MESH:D004077	"<span class=""chemical"">digoxin</span>"	MESH:D016171	"<span class=""disease"">TdP</span>"	"Consistent with other reports this case of <span class=""disease"">TdP</span> occurred in the context of multiple exacerbating factors including hypokalemia and <span class=""chemical"">digoxin</span> excess."		112.0	112_MESH:D004077_MESH:D016171	112_2	bcv_final_eval_easy_650		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"In the absence of <span class=""chemical"">amiodarone</span> therapy, a second bladder irrigation did not induce TdP despite <span class=""disease"">hypokalemia</span> and hypomagnesemia."		112.0	112_MESH:D000638_MESH:D007008	112_6	bcv_final_eval_easy_651		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:C537153	"<span class=""disease"">hypomagnesemia</span>"	"In the absence of <span class=""chemical"">amiodarone</span> therapy, a second bladder irrigation did not induce TdP despite hypokalemia and <span class=""disease"">hypomagnesemia</span>."		112.0	112_MESH:D000638_MESH:C537153	112_6	bcv_final_eval_easy_652		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D058186	"<span class=""disease"">ARI/Acute renal insufficiency</span>"	"<span class=""disease"">Acute renal insufficiency</span> (<span class=""disease"">ARI</span>) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum <span class=""chemical"">creatinine</span> level that is greater than 50% of baseline immediately after conditioning."		113.0	113_MESH:D003404_MESH:D058186	113_7	bcv_final_eval_easy_653		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D003072	"<span class=""disease"">Impaired fear recognition</span>"	"<span class=""disease"">Impaired fear recognition</span> in regular recreational <span class=""chemical"">cocaine</span> users."		114.0	114_MESH:D003042_MESH:D003072	114_0	bcv_final_eval_easy_654		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D014456	"<span class=""disease"">ulcers</span>"	"Corneal <span class=""disease"">ulcers</span> associated with aerosolized crack <span class=""chemical"">cocaine</span> use."		115.0	115_MESH:D003042_MESH:D014456	115_0	bcv_final_eval_easy_655		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D014456	"<span class=""disease"">ulcers</span>"	"RESULTS: Four patients with corneal <span class=""disease"">ulcers</span> associated with crack <span class=""chemical"">cocaine</span> use were reviewed."		115.0	115_MESH:D003042_MESH:D014456	115_4	bcv_final_eval_easy_656		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D014456	"<span class=""disease"">ulcers</span>"	"CONCLUSIONS: Aerosolized crack <span class=""chemical"">cocaine</span> use can be associated with the development of corneal <span class=""disease"">ulcers</span>."		115.0	115_MESH:D003042_MESH:D014456	115_10	bcv_final_eval_easy_657		
	MESH:C026098	"<span class=""chemical"">Levetiracetam</span>"	MESH:C562694	"<span class=""disease"">idiopathic epilepsy</span>"	"<span class=""chemical"">Levetiracetam</span> as an adjunct to phenobarbital treatment in cats with suspected <span class=""disease"">idiopathic epilepsy</span>."		116.0	116_MESH:C026098_MESH:C562694	116_0	bcv_final_eval_easy_658		
	MESH:D010634	"<span class=""chemical"">phenobarbital</span>"	MESH:C562694	"<span class=""disease"">idiopathic epilepsy</span>"	"Levetiracetam as an adjunct to <span class=""chemical"">phenobarbital</span> treatment in cats with suspected <span class=""disease"">idiopathic epilepsy</span>."		116.0	116_MESH:D010634_MESH:C562694	116_0	bcv_final_eval_easy_659		
	MESH:C026098	"<span class=""chemical"">levetiracetam</span>"	MESH:C562694	"<span class=""disease"">idiopathic epilepsy</span>"	"OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral <span class=""chemical"">levetiracetam</span> administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected <span class=""disease"">idiopathic epilepsy</span>."		116.0	116_MESH:C026098_MESH:C562694	116_1	bcv_final_eval_easy_660		
	MESH:D010634	"<span class=""chemical"">phenobarbital</span>"	MESH:C562694	"<span class=""disease"">idiopathic epilepsy</span>"	"OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to <span class=""chemical"">phenobarbital</span> treatment in cats with poorly controlled suspected <span class=""disease"">idiopathic epilepsy</span>."		116.0	116_MESH:D010634_MESH:C562694	116_1	bcv_final_eval_easy_661		
	MESH:D010634	"<span class=""chemical"">phenobarbital</span>"	MESH:C562694	"<span class=""disease"">idiopathic epilepsy</span>"	"ANIMALS: 12 cats suspected to have <span class=""disease"">idiopathic epilepsy</span> that was poorly controlled with <span class=""chemical"">phenobarbital</span> or that had unacceptable adverse effects when treated with <span class=""chemical"">phenobarbital</span>."		116.0	116_MESH:D010634_MESH:C562694	116_3	bcv_final_eval_easy_662		
	MESH:C026098	"<span class=""chemical"">levetiracetam</span>"	MESH:D012640	"<span class=""disease"">Seizure</span>"	"<span class=""disease"">Seizure</span> frequencies before and after initiation of <span class=""chemical"">levetiracetam</span> treatment were compared, and adverse effects were recorded."		116.0	116_MESH:C026098_MESH:D012640	116_6	bcv_final_eval_easy_663		
	MESH:C026098	"<span class=""chemical"">levetiracetam</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"Median <span class=""disease"">seizure</span> frequency prior to treatment with <span class=""chemical"">levetiracetam</span> (2.1 <span class=""disease"">seizures</span>/mo) was significantly higher than median <span class=""disease"">seizure</span> frequency after initiation of <span class=""chemical"">levetiracetam</span> treatment (0.42 <span class=""disease"">seizures</span>/mo), and 7 of 10 cats were classified as having responded to <span class=""chemical"">levetiracetam</span> treatment (ie, reduction in <span class=""disease"">seizure</span> frequency of >or=50%)."		116.0	116_MESH:C026098_MESH:D012640	116_8	bcv_final_eval_easy_664		
	MESH:C026098	"<span class=""chemical"">levetiracetam</span>"	MESH:C562694	"<span class=""disease"">idiopathic epilepsy</span>"	"CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that <span class=""chemical"">levetiracetam</span> is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with <span class=""disease"">idiopathic epilepsy</span>."		116.0	116_MESH:C026098_MESH:C562694	116_10	bcv_final_eval_easy_665		
	MESH:D010634	"<span class=""chemical"">phenobarbital</span>"	MESH:C562694	"<span class=""disease"">idiopathic epilepsy</span>"	"CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to <span class=""chemical"">phenobarbital</span> treatment in cats with <span class=""disease"">idiopathic epilepsy</span>."		116.0	116_MESH:D010634_MESH:C562694	116_10	bcv_final_eval_easy_666		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D002543	"<span class=""disease"">haemorrhagic infarction</span>"	"Bilateral <span class=""disease"">haemorrhagic infarction</span> of the globus pallidus after cocaine and <span class=""chemical"">alcohol</span> intoxication."		117.0	117_MESH:D000431_MESH:D002543	117_0	bcv_final_eval_easy_667		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002543	"<span class=""disease"">haemorrhagic infarction</span>"	"Bilateral <span class=""disease"">haemorrhagic infarction</span> of the globus pallidus after <span class=""chemical"">cocaine</span> and alcohol intoxication."		117.0	117_MESH:D003042_MESH:D002543	117_0	bcv_final_eval_easy_668		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D000435	"<span class=""disease"">alcohol intoxication</span>"	"Bilateral haemorrhagic infarction of the globus pallidus after <span class=""chemical"">cocaine</span> and <span class=""disease"">alcohol intoxication</span>."		117.0	117_MESH:D003042_MESH:D000435	117_0	bcv_final_eval_easy_669		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D000435	"<span class=""disease"">alcohol intoxication</span>"	"Bilateral haemorrhagic infarction of the globus pallidus after cocaine and <span class=""chemical""></span><span class=""disease"">alcohol</span> intoxication."		117.0	117_MESH:D000431_MESH:D000435	117_0	bcv_final_eval_easy_670		
	MESH:D003042	"<span class=""chemical"">Cocaine</span>"	MESH:D020521	"<span class=""disease"">haemorrhagic stroke</span>"	"<span class=""chemical"">Cocaine</span> is a risk factor for both ischemic and <span class=""disease"">haemorrhagic stroke</span>."		117.0	117_MESH:D003042_MESH:D020521	117_1	bcv_final_eval_easy_671		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D007511	"<span class=""disease"">ischemia</span>"	"We present the case of a 31-year-old man with bilateral <span class=""disease"">ischemia</span> of the globus pallidus after excessive alcohol and intranasal <span class=""chemical"">cocaine</span> use."		117.0	117_MESH:D003042_MESH:D007511	117_2	bcv_final_eval_easy_672		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D007511	"<span class=""disease"">ischemia</span>"	"We present the case of a 31-year-old man with bilateral <span class=""disease"">ischemia</span> of the globus pallidus after excessive <span class=""chemical"">alcohol</span> and intranasal cocaine use."		117.0	117_MESH:D000431_MESH:D007511	117_2	bcv_final_eval_easy_673		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D007238	"<span class=""disease"">Bilateral basal ganglia infarcts</span>"	"<span class=""disease"">Bilateral basal ganglia infarcts</span> after the use of cocaine, without concurrent <span class=""chemical"">heroin</span> use, have never been reported."		117.0	117_MESH:D003932_MESH:D007238	117_4	bcv_final_eval_easy_674		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D007238	"<span class=""disease"">Bilateral basal ganglia infarcts</span>"	"<span class=""disease"">Bilateral basal ganglia infarcts</span> after the use of <span class=""chemical"">cocaine</span>, without concurrent heroin use, have never been reported."		117.0	117_MESH:D003042_MESH:D007238	117_4	bcv_final_eval_easy_675		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002543	"<span class=""disease"">cerebral hypoperfusion</span>"	"In our patient, transient cardiac arrhythmia or respiratory dysfunction related to <span class=""chemical"">cocaine</span> and/or ethanol use were the most likely causes of <span class=""disease"">cerebral hypoperfusion</span>."		117.0	117_MESH:D003042_MESH:D002543	117_5	bcv_final_eval_easy_676		
	MESH:D000431	"<span class=""chemical"">ethanol</span>"	MESH:D002543	"<span class=""disease"">cerebral hypoperfusion</span>"	"In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or <span class=""chemical"">ethanol</span> use were the most likely causes of <span class=""disease"">cerebral hypoperfusion</span>."		117.0	117_MESH:D000431_MESH:D002543	117_5	bcv_final_eval_easy_677		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D012131	"<span class=""disease"">respiratory dysfunction</span>"	"In our patient, transient cardiac arrhythmia or <span class=""disease"">respiratory dysfunction</span> related to <span class=""chemical"">cocaine</span> and/or ethanol use were the most likely causes of cerebral hypoperfusion."		117.0	117_MESH:D003042_MESH:D012131	117_5	bcv_final_eval_easy_678		
	MESH:D000431	"<span class=""chemical"">ethanol</span>"	MESH:D012131	"<span class=""disease"">respiratory dysfunction</span>"	"In our patient, transient cardiac arrhythmia or <span class=""disease"">respiratory dysfunction</span> related to cocaine and/or <span class=""chemical"">ethanol</span> use were the most likely causes of cerebral hypoperfusion."		117.0	117_MESH:D000431_MESH:D012131	117_5	bcv_final_eval_easy_679		
	MESH:D000431	"<span class=""chemical"">ethanol</span>"	MESH:D001145	"<span class=""disease"">cardiac arrhythmia</span>"	"In our patient, transient <span class=""disease"">cardiac arrhythmia</span> or respiratory dysfunction related to cocaine and/or <span class=""chemical"">ethanol</span> use were the most likely causes of cerebral hypoperfusion."		117.0	117_MESH:D000431_MESH:D001145	117_5	bcv_final_eval_easy_680		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D001145	"<span class=""disease"">cardiac arrhythmia</span>"	"In our patient, transient <span class=""disease"">cardiac arrhythmia</span> or respiratory dysfunction related to <span class=""chemical"">cocaine</span> and/or ethanol use were the most likely causes of cerebral hypoperfusion."		117.0	117_MESH:D003042_MESH:D001145	117_5	bcv_final_eval_easy_681		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D058186	"<span class=""disease"">Acute renal failure</span>"	"<span class=""disease"">Acute renal failure</span> after high-dose <span class=""chemical"">methotrexate</span> therapy in a patient with ileostomy."		118.0	118_MESH:D008727_MESH:D058186	118_0	bcv_final_eval_easy_682		
	MESH:D008727	"<span class=""chemical"">methotrexate/MTX</span>"	MESH:D002051	"<span class=""disease"">Burkitt lymphoma</span>"	"High-dose <span class=""chemical"">methotrexate</span> (HD-<span class=""chemical"">MTX</span>) is an important treatment for <span class=""disease"">Burkitt lymphoma</span>, but can cause hepatic and renal toxicity when its clearance is delayed."		118.0	118_MESH:D008727_MESH:D002051	118_1	bcv_final_eval_easy_683		
	MESH:D008727	"<span class=""chemical"">methotrexate/MTX</span>"	MESH:D007674	"<span class=""disease"">renal toxicity</span>"	"High-dose <span class=""chemical"">methotrexate</span> (HD-<span class=""chemical"">MTX</span>) is an important treatment for Burkitt lymphoma, but can cause hepatic and <span class=""disease"">renal toxicity</span> when its clearance is delayed."		118.0	118_MESH:D008727_MESH:D007674	118_1	bcv_final_eval_easy_684		
	MESH:D008727	"<span class=""chemical"">MTX</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"Subsequent HD-<span class=""chemical"">MTX</span> therapy caused <span class=""disease"">acute renal failure</span> that required continuous hemodialysis."		118.0	118_MESH:D008727_MESH:D058186	118_5	bcv_final_eval_easy_685		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002546	"<span class=""disease"">TIA</span>"	"RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/<span class=""disease"">TIA</span>, MB were more frequent in ICH vs IS/<span class=""disease"">TIA</span> in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <span class=""chemical"">warfarin</span> users (P difference=0.01)."		119.0	119_MESH:D014859_MESH:D002546	119_5	bcv_final_eval_easy_686		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002543	"<span class=""disease"">ICH</span>"	"RESULTS: In a pooled analysis of 1460 <span class=""disease"">ICH</span> and 3817 IS/TIA, MB were more frequent in <span class=""disease"">ICH</span> vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <span class=""chemical"">warfarin</span> users (P difference=0.01)."		119.0	119_MESH:D014859_MESH:D002543	119_5	bcv_final_eval_easy_687		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002544	"<span class=""disease"">IS</span>"	"RESULTS: In a pooled analysis of 1460 ICH and 3817 <span class=""disease"">IS</span>/TIA, MB were more frequent in ICH vs <span class=""disease"">IS</span>/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <span class=""chemical"">warfarin</span> users (P difference=0.01)."		119.0	119_MESH:D014859_MESH:D002544	119_5	bcv_final_eval_easy_688		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002546	"<span class=""disease"">TIA</span>"	"There was also an excess of MB in <span class=""chemical"">warfarin</span> users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in <span class=""chemical"">warfarin</span> users with IS/<span class=""disease"">TIA</span> (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01)."		119.0	119_MESH:D014859_MESH:D002546	119_6	bcv_final_eval_easy_689		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002543	"<span class=""disease"">ICH</span>"	"There was also an excess of MB in <span class=""chemical"">warfarin</span> users vs nonusers with <span class=""disease"">ICH</span> (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in <span class=""chemical"">warfarin</span> users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01)."		119.0	119_MESH:D014859_MESH:D002543	119_6	bcv_final_eval_easy_690		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002544	"<span class=""disease"">IS</span>"	"There was also an excess of MB in <span class=""chemical"">warfarin</span> users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in <span class=""chemical"">warfarin</span> users with <span class=""disease"">IS</span>/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01)."		119.0	119_MESH:D014859_MESH:D002544	119_6	bcv_final_eval_easy_691		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002543	"<span class=""disease"">ICH</span>"	"CONCLUSIONS: The excess of MB in <span class=""chemical"">warfarin</span> users with <span class=""disease"">ICH</span> compared to other groups suggests that MB increase the risk of <span class=""chemical"">warfarin</span>-associated <span class=""disease"">ICH</span>."		119.0	119_MESH:D014859_MESH:D002543	119_9	bcv_final_eval_easy_692		
	MESH:D014700	"<span class=""chemical"">Verapamil</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"<span class=""chemical"">Verapamil</span> stimulation test in <span class=""disease"">hyperprolactinemia</span>: loss of prolactin response in anatomic or functional stalk effect."		120.0	120_MESH:D014700_MESH:D006966	120_0	bcv_final_eval_easy_693		
	MESH:D014700	"<span class=""chemical"">Verapamil</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"AIM: <span class=""chemical"">Verapamil</span> stimulation test was previously investigated as a tool for differential diagnosis of <span class=""disease"">hyperprolactinemia</span>, but with conflicting results."		120.0	120_MESH:D014700_MESH:D006966	120_1	bcv_final_eval_easy_694		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"Prolactin responses to <span class=""chemical"">verapamil</span> in 65 female patients (age: 29.9 +/- 8.1 years) with <span class=""disease"">hyperprolactinemia</span> were tested in a descriptive, matched case-control study."		120.0	120_MESH:D014700_MESH:D006966	120_4	bcv_final_eval_easy_695		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D015175	"<span class=""disease"">microprolactinoma/macroprolactinoma</span>"	"RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), <span class=""disease"">macroprolactinoma</span> (N. 8, PRL: 7%), <span class=""disease"">microprolactinoma</span> (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and <span class=""chemical"">risperidone</span>-induced hyperprolactinemia (N. 7, PRL: 3%)."		120.0	120_MESH:D018967_MESH:D015175	120_7	bcv_final_eval_easy_696		
	MESH:D014700	"<span class=""chemical"">Verapamil</span>"	MESH:D015175	"<span class=""disease"">microprolactinoma/macroprolactinoma</span>"	"RESULTS: <span class=""chemical"">Verapamil</span> significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), <span class=""disease"">macroprolactinoma</span> (N. 8, PRL: 7%), <span class=""disease"">microprolactinoma</span> (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%)."		120.0	120_MESH:D014700_MESH:D015175	120_7	bcv_final_eval_easy_697		
	MESH:D014700	"<span class=""chemical"">Verapamil</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"RESULTS: <span class=""chemical"">Verapamil</span> significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced <span class=""disease"">hyperprolactinemia</span> (N. 7, PRL: 3%)."		120.0	120_MESH:D014700_MESH:D006966	120_7	bcv_final_eval_easy_698		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"ROC curve analysis revealed that unresponsiveness to <span class=""chemical"">verapamil</span> defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone-induced <span class=""disease"">hyperprolactinemia</span>, respectively."		120.0	120_MESH:D014700_MESH:D006966	120_8	bcv_final_eval_easy_699		
	MESH:D014700	"<span class=""chemical"">Verapamil</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"CONCLUSION: <span class=""chemical"">Verapamil</span> responsiveness is not a reliable finding for the differential diagnosis of <span class=""disease"">hyperprolactinemia</span>."		120.0	120_MESH:D014700_MESH:D006966	120_9	bcv_final_eval_easy_700		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"However, <span class=""chemical"">verapamil</span> unresponsiveness discriminates stalk effect (i.e., anatomically or functionally inhibited dopaminergic tonus) from other causes of <span class=""disease"">hyperprolactinemia</span> with varying degrees of responsiveness."		120.0	120_MESH:D014700_MESH:D006966	120_10	bcv_final_eval_easy_701		
	MESH:C009695	"<span class=""chemical"">xylometazoline</span>"	MESH:D000699	"<span class=""disease"">analgesia</span>"	"The effect of clonidine, naphazoline and <span class=""chemical"">xylometazoline</span> on <span class=""disease"">analgesia</span> induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats."		121.0	121_MESH:C009695_MESH:D000699	121_1	bcv_final_eval_easy_702		
	MESH:D003061	"<span class=""chemical"">codeine</span>"	MESH:D000699	"<span class=""disease"">analgesia</span>"	"The effect of clonidine, naphazoline and xylometazoline on <span class=""disease"">analgesia</span> induced by morphine, <span class=""chemical"">codeine</span>, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats."		121.0	121_MESH:D003061_MESH:D000699	121_1	bcv_final_eval_easy_703		
	MESH:D003000	"<span class=""chemical"">clonidine</span>"	MESH:D000699	"<span class=""disease"">analgesia</span>"	"The effect of <span class=""chemical"">clonidine</span>, naphazoline and xylometazoline on <span class=""disease"">analgesia</span> induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats."		121.0	121_MESH:D003000_MESH:D000699	121_1	bcv_final_eval_easy_704		
	MESH:D010423	"<span class=""chemical"">pentazocine</span>"	MESH:D000699	"<span class=""disease"">analgesia</span>"	"The effect of clonidine, naphazoline and xylometazoline on <span class=""disease"">analgesia</span> induced by morphine, codeine, fentanyl and <span class=""chemical"">pentazocine</span>, and on cataleptic effect of morphine, codine and fentanyl was studied in rats."		121.0	121_MESH:D010423_MESH:D000699	121_1	bcv_final_eval_easy_705		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D000699	"<span class=""disease"">analgesia</span>"	"The effect of clonidine, naphazoline and xylometazoline on <span class=""disease"">analgesia</span> induced by <span class=""chemical"">morphine</span>, codeine, fentanyl and pentazocine, and on cataleptic effect of <span class=""chemical"">morphine</span>, codine and fentanyl was studied in rats."		121.0	121_MESH:D009020_MESH:D000699	121_1	bcv_final_eval_easy_706		
	MESH:D009278	"<span class=""chemical"">naphazoline</span>"	MESH:D000699	"<span class=""disease"">analgesia</span>"	"The effect of clonidine, <span class=""chemical"">naphazoline</span> and xylometazoline on <span class=""disease"">analgesia</span> induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats."		121.0	121_MESH:D009278_MESH:D000699	121_1	bcv_final_eval_easy_707		
	MESH:D005283	"<span class=""chemical"">fentanyl</span>"	MESH:D000699	"<span class=""disease"">analgesia</span>"	"The effect of clonidine, naphazoline and xylometazoline on <span class=""disease"">analgesia</span> induced by morphine, codeine, <span class=""chemical"">fentanyl</span> and pentazocine, and on cataleptic effect of morphine, codine and <span class=""chemical"">fentanyl</span> was studied in rats."		121.0	121_MESH:D005283_MESH:D000699	121_1	bcv_final_eval_easy_708		
	MESH:D005283	"<span class=""chemical"">fentanyl</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced <span class=""disease"">catalepsy</span> induced by morphine and <span class=""chemical"">fentanyl</span>."		121.0	121_MESH:D005283_MESH:D002375	121_3	bcv_final_eval_easy_709		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced <span class=""disease"">catalepsy</span> induced by <span class=""chemical"">morphine</span> and fentanyl."		121.0	121_MESH:D009020_MESH:D002375	121_3	bcv_final_eval_easy_710		
	MESH:D003061	"<span class=""chemical"">Codeine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"<span class=""chemical"">Codeine</span> <span class=""disease"">catalepsy</span> was increased by clonidine and decreased by naphazoline and xylometazoline."		121.0	121_MESH:D003061_MESH:D002375	121_4	bcv_final_eval_easy_711		
	MESH:D009278	"<span class=""chemical"">naphazoline</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Codeine <span class=""disease"">catalepsy</span> was increased by clonidine and decreased by <span class=""chemical"">naphazoline</span> and xylometazoline."		121.0	121_MESH:D009278_MESH:D002375	121_4	bcv_final_eval_easy_712		
	MESH:C009695	"<span class=""chemical"">xylometazoline</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Codeine <span class=""disease"">catalepsy</span> was increased by clonidine and decreased by naphazoline and <span class=""chemical"">xylometazoline</span>."		121.0	121_MESH:C009695_MESH:D002375	121_4	bcv_final_eval_easy_713		
	MESH:D003000	"<span class=""chemical"">clonidine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Codeine <span class=""disease"">catalepsy</span> was increased by <span class=""chemical"">clonidine</span> and decreased by naphazoline and xylometazoline."		121.0	121_MESH:D003000_MESH:D002375	121_4	bcv_final_eval_easy_714		
	MESH:D009640	"<span class=""chemical"">norethisterone</span>"	MESH:D006965	"<span class=""disease"">cystic hyperplasia/atypical hyperplasia</span>"	"Two courses of 21 days of 5 mg <span class=""chemical"">norethisterone</span> daily caused reversion to normal in all 57 cases of <span class=""disease"">cystic hyperplasia</span> and 6 of the 8 cases of <span class=""disease"">atypical hyperplasia</span>."		123.0	123_MESH:D009640_MESH:D006965	123_3	bcv_final_eval_easy_715		
	MESH:D011372	"<span class=""chemical"">progestagen</span>"	MESH:D016889	"<span class=""disease"">endometrial hyperplasia or carcinoma</span>"	"Cyclical low-dose oestrogen therapy with 7--13 days of <span class=""chemical"">progestagen</span> does not seem to increase the risk of <span class=""disease"">endometrial hyperplasia or carcinoma</span>."		123.0	123_MESH:D011372_MESH:D016889	123_5	bcv_final_eval_easy_716		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D012010	"<span class=""disease"">red cell aplasia</span>"	"Pure <span class=""disease"">red cell aplasia</span>, toxic dermatitis and lymphadenopathy in a patient taking <span class=""chemical"">diphenylhydantoin</span>."		124.0	124_MESH:D010672_MESH:D012010	124_0	bcv_final_eval_easy_717		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D003872	"<span class=""disease"">dermatitis</span>"	"Pure red cell aplasia, toxic <span class=""disease"">dermatitis</span> and lymphadenopathy in a patient taking <span class=""chemical"">diphenylhydantoin</span>."		124.0	124_MESH:D010672_MESH:D003872	124_0	bcv_final_eval_easy_718		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D008206	"<span class=""disease"">lymphadenopathy</span>"	"Pure red cell aplasia, toxic dermatitis and <span class=""disease"">lymphadenopathy</span> in a patient taking <span class=""chemical"">diphenylhydantoin</span>."		124.0	124_MESH:D010672_MESH:D008206	124_0	bcv_final_eval_easy_719		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D012010	"<span class=""disease"">red cell aplasia</span>"	"A patient taking <span class=""chemical"">diphenylhydantoin</span> for 3 weeks developed a generalized skin rash, lymphadenopathy and pure <span class=""disease"">red cell aplasia</span>."		124.0	124_MESH:D010672_MESH:D012010	124_1	bcv_final_eval_easy_720		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D005076	"<span class=""disease"">skin rash</span>"	"A patient taking <span class=""chemical"">diphenylhydantoin</span> for 3 weeks developed a generalized <span class=""disease"">skin rash</span>, lymphadenopathy and pure red cell aplasia."		124.0	124_MESH:D010672_MESH:D005076	124_1	bcv_final_eval_easy_721		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D008206	"<span class=""disease"">lymphadenopathy</span>"	"A patient taking <span class=""chemical"">diphenylhydantoin</span> for 3 weeks developed a generalized skin rash, <span class=""disease"">lymphadenopathy</span> and pure red cell aplasia."		124.0	124_MESH:D010672_MESH:D008206	124_1	bcv_final_eval_easy_722		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D005076	"<span class=""disease"">Skin rash</span>"	"<span class=""disease"">Skin rash</span> is a well-known complication of <span class=""chemical"">diphenylhydantoin</span> treatment as is benign and malignant lymphadenopathy."		124.0	124_MESH:D010672_MESH:D005076	124_3	bcv_final_eval_easy_723		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D008206	"<span class=""disease"">lymphadenopathy</span>"	"Skin rash is a well-known complication of <span class=""chemical"">diphenylhydantoin</span> treatment as is benign and malignant <span class=""disease"">lymphadenopathy</span>."		124.0	124_MESH:D010672_MESH:D008206	124_3	bcv_final_eval_easy_724		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D012010	"<span class=""disease"">red cell aplasia</span>"	"Pure <span class=""disease"">red cell aplasia</span> associated with <span class=""chemical"">diphenylhydantoin</span> medication has been reported in 3 patients."		124.0	124_MESH:D010672_MESH:D012010	124_4	bcv_final_eval_easy_725		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D012010	"<span class=""disease"">red cell aplasia</span>"	"In this patient the time relation between the ingestion of <span class=""chemical"">diphenylhydantoin</span> and the occurrence of the skin rash, lymphadenopathy and pure <span class=""disease"">red cell aplasia</span> is very suggestive of a direct connection."		124.0	124_MESH:D010672_MESH:D012010	124_6	bcv_final_eval_easy_726		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D005076	"<span class=""disease"">skin rash</span>"	"In this patient the time relation between the ingestion of <span class=""chemical"">diphenylhydantoin</span> and the occurrence of the <span class=""disease"">skin rash</span>, lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection."		124.0	124_MESH:D010672_MESH:D005076	124_6	bcv_final_eval_easy_727		
	MESH:D010672	"<span class=""chemical"">diphenylhydantoin</span>"	MESH:D008206	"<span class=""disease"">lymphadenopathy</span>"	"In this patient the time relation between the ingestion of <span class=""chemical"">diphenylhydantoin</span> and the occurrence of the skin rash, <span class=""disease"">lymphadenopathy</span> and pure red cell aplasia is very suggestive of a direct connection."		124.0	124_MESH:D010672_MESH:D008206	124_6	bcv_final_eval_easy_728		
	MESH:D002228	"<span class=""chemical"">carbenicillin</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"Continuous infusion tobramycin combined with <span class=""chemical"">carbenicillin</span> for infections in <span class=""disease"">cancer</span> patients."		125.0	125_MESH:D002228_MESH:D009369	125_0	bcv_final_eval_easy_729		
	MESH:D014031	"<span class=""chemical"">tobramycin</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"Continuous infusion <span class=""chemical"">tobramycin</span> combined with carbenicillin for infections in <span class=""disease"">cancer</span> patients."		125.0	125_MESH:D014031_MESH:D009369	125_0	bcv_final_eval_easy_730		
	MESH:D002228	"<span class=""chemical"">carbenicillin</span>"	MESH:D007239	"<span class=""disease"">infections</span>"	"Continuous infusion tobramycin combined with <span class=""chemical"">carbenicillin</span> for <span class=""disease"">infections</span> in cancer patients."		125.0	125_MESH:D002228_MESH:D007239	125_0	bcv_final_eval_easy_731		
	MESH:D014031	"<span class=""chemical"">tobramycin</span>"	MESH:D007239	"<span class=""disease"">infections</span>"	"Continuous infusion <span class=""chemical"">tobramycin</span> combined with carbenicillin for <span class=""disease"">infections</span> in cancer patients."		125.0	125_MESH:D014031_MESH:D007239	125_0	bcv_final_eval_easy_732		
	MESH:D002228	"<span class=""chemical"">carbenicillin</span>"	MESH:D009503	"<span class=""disease"">neutropenia</span>"	"To overcome the adverse effects of <span class=""disease"">neutropenia</span>, tobramycin was given by continuous infusion and combined with intermittent <span class=""chemical"">carbenicillin</span>."		125.0	125_MESH:D002228_MESH:D009503	125_3	bcv_final_eval_easy_733		
	MESH:D014031	"<span class=""chemical"">tobramycin</span>"	MESH:D009503	"<span class=""disease"">neutropenia</span>"	"To overcome the adverse effects of <span class=""disease"">neutropenia</span>, <span class=""chemical"">tobramycin</span> was given by continuous infusion and combined with intermittent carbenicillin."		125.0	125_MESH:D014031_MESH:D009503	125_3	bcv_final_eval_easy_734		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D053099	"<span class=""disease"">azotemia</span>"	"Major <span class=""disease"">azotemia</span> (serum <span class=""chemical"">creatinine</span> greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%."		125.0	125_MESH:D003404_MESH:D053099	125_13	bcv_final_eval_easy_735		
	MESH:D014031	"<span class=""chemical"">tobramycin</span>"	MESH:D053099	"<span class=""disease"">Azotemia</span>"	"<span class=""disease"">Azotemia</span> was not related to duration of therapy or serum <span class=""chemical"">tobramycin</span> concentration."		125.0	125_MESH:D014031_MESH:D053099	125_14	bcv_final_eval_easy_736		
	MESH:D000614	"<span class=""chemical"">aminocaproic acid</span>"	MESH:D013345	"<span class=""disease"">subarachnoid hemorrhage</span>"	"Recurrent <span class=""disease"">subarachnoid hemorrhage</span> associated with <span class=""chemical"">aminocaproic acid</span> therapy and acute renal artery thrombosis. Case report."		126.0	126_MESH:D000614_MESH:D013345	126_0	bcv_final_eval_easy_737		
	MESH:D000614	"<span class=""chemical"">aminocaproic acid</span>"	MESH:D058186	"<span class=""disease"">acute renal artery thrombosis</span>"	"Recurrent subarachnoid hemorrhage associated with <span class=""chemical"">aminocaproic acid</span> therapy and <span class=""disease"">acute renal artery thrombosis</span>. Case report."		126.0	126_MESH:D000614_MESH:D058186	126_0	bcv_final_eval_easy_738		
	MESH:D015119	"<span class=""chemical"">Epsilon aminocaproic acid/EACA</span>"	MESH:D013345	"<span class=""disease"">subarachnoid hemorrhage/SAH</span>"	"<span class=""chemical"">Epsilon aminocaproic acid</span> (<span class=""chemical"">EACA</span>) has been used to prevent rebleeding in patients with <span class=""disease"">subarachnoid hemorrhage</span> (<span class=""disease"">SAH</span>)."		126.0	126_MESH:D015119_MESH:D013345	126_1	bcv_final_eval_easy_739		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D013927	"<span class=""disease"">thrombotic</span>"	"Although this agent does decrease the frequency of rebleeding, several reports have described <span class=""disease"">thrombotic</span> complications of <span class=""chemical"">EACA</span> therapy."		126.0	126_MESH:D015119_MESH:D013927	126_2	bcv_final_eval_easy_740		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D013923	"<span class=""disease"">thromboembolic</span>"	"These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <span class=""chemical"">EACA</span>, or other <span class=""disease"">thromboembolic</span> phenomena."		126.0	126_MESH:D015119_MESH:D013923	126_3	bcv_final_eval_easy_741		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D020767	"<span class=""disease"">intracranial vascular thrombosis</span>"	"These complications have included clinical deterioration and <span class=""disease"">intracranial vascular thrombosis</span> in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <span class=""chemical"">EACA</span>, or other thromboembolic phenomena."		126.0	126_MESH:D015119_MESH:D020767	126_3	bcv_final_eval_easy_742		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D013345	"<span class=""disease"">SAH</span>"	"These complications have included clinical deterioration and intracranial vascular thrombosis in patients with <span class=""disease"">SAH</span>, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <span class=""chemical"">EACA</span>, or other thromboembolic phenomena."		126.0	126_MESH:D015119_MESH:D013345	126_3	bcv_final_eval_easy_743		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D004211	"<span class=""disease"">intravascular coagulation</span>"	"Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <span class=""chemical"">EACA</span> should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated <span class=""disease"">intravascular coagulation</span> or other ""consumption coagulopathies."" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery."		126.0	126_MESH:D015119_MESH:D004211	126_4	bcv_final_eval_easy_744		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D001778	"<span class=""disease"">consumption coagulopathies</span>"	"Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <span class=""chemical"">EACA</span> should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other ""<span class=""disease"">consumption coagulopathies</span>."" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery."		126.0	126_MESH:D015119_MESH:D001778	126_4	bcv_final_eval_easy_745		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D013927	"<span class=""disease"">thrombosis</span>"	"Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <span class=""chemical"">EACA</span> should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other ""consumption coagulopathies."" This report describes subtotal infarction of the kidney due to <span class=""disease"">thrombosis</span> of a normal renal artery."		126.0	126_MESH:D015119_MESH:D013927	126_4	bcv_final_eval_easy_746		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D007238	"<span class=""disease"">infarction of the kidney</span>"	"Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <span class=""chemical"">EACA</span> should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other ""consumption coagulopathies."" This report describes subtotal <span class=""disease"">infarction of the kidney</span> due to thrombosis of a normal renal artery."		126.0	126_MESH:D015119_MESH:D007238	126_4	bcv_final_eval_easy_747		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:C565017	"<span class=""disease"">fibrinolytic disorders</span>"	"Since intravascular fibrin thrombi are often observed in patients with <span class=""disease"">fibrinolytic disorders</span>, <span class=""chemical"">EACA</span> should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other ""consumption coagulopathies."" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery."		126.0	126_MESH:D015119_MESH:C565017	126_4	bcv_final_eval_easy_748		
	MESH:D015119	"<span class=""chemical"">EACA</span>"	MESH:D013345	"<span class=""disease"">SAH</span>"	"This occlusion occurred after <span class=""chemical"">EACA</span> therapy in a patient with <span class=""disease"">SAH</span> and histopathological documentation of recurrent <span class=""disease"">SAH</span>."		126.0	126_MESH:D015119_MESH:D013345	126_5	bcv_final_eval_easy_749		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D011086	"<span class=""disease"">polycythemia</span>"	"We conclude that previously reported hypoglycemia, hyperbilirubinemia, <span class=""disease"">polycythemia</span>, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic <span class=""chemical"">propranolol</span> therapy."		127.0	127_MESH:D011433_MESH:D011086	127_7	bcv_final_eval_easy_750		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D001049	"<span class=""disease"">apnea</span>"	"We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal <span class=""disease"">apnea</span>, and bradycardia are not invariable and cannot be statistically correlated with chronic <span class=""chemical"">propranolol</span> therapy."		127.0	127_MESH:D011433_MESH:D001049	127_7	bcv_final_eval_easy_751		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D007003	"<span class=""disease"">hypoglycemia</span>"	"We conclude that previously reported <span class=""disease"">hypoglycemia</span>, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic <span class=""chemical"">propranolol</span> therapy."		127.0	127_MESH:D011433_MESH:D007003	127_7	bcv_final_eval_easy_752		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D006932	"<span class=""disease"">hyperbilirubinemia</span>"	"We conclude that previously reported hypoglycemia, <span class=""disease"">hyperbilirubinemia</span>, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic <span class=""chemical"">propranolol</span> therapy."		127.0	127_MESH:D011433_MESH:D006932	127_7	bcv_final_eval_easy_753		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and <span class=""disease"">bradycardia</span> are not invariable and cannot be statistically correlated with chronic <span class=""chemical"">propranolol</span> therapy."		127.0	127_MESH:D011433_MESH:D001919	127_7	bcv_final_eval_easy_754		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D007022	"<span class=""disease"">idiopathic orthostatic hypotension</span>"	"Use of <span class=""chemical"">propranolol</span> in the treatment of <span class=""disease"">idiopathic orthostatic hypotension</span>."		128.0	128_MESH:D011433_MESH:D007022	128_0	bcv_final_eval_easy_755		
	MESH:D002395	"<span class=""chemical"">catecholamines</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"They all exhibited markedly reduced plasma <span class=""chemical"">catecholamines</span> and plasma renin activity in both recumbent and upright positions and had marked <span class=""disease"">hypersensitivity</span> to the pressor effects of infused norepinephrine."		128.0	128_MESH:D002395_MESH:D004342	128_2	bcv_final_eval_easy_756		
	MESH:D009638	"<span class=""chemical"">norepinephrine</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked <span class=""disease"">hypersensitivity</span> to the pressor effects of infused <span class=""chemical"">norepinephrine</span>."		128.0	128_MESH:D009638_MESH:D004342	128_2	bcv_final_eval_easy_757		
	MESH:D011433	"<span class=""chemical"">propanolol</span>"	MESH:D006973	"<span class=""disease"">increases in supine and upright blood pressure</span>"	"Treatment with <span class=""chemical"">propanolol</span> administered intravenously (1-5 mg) produced <span class=""disease"">increases in supine and upright blood pressure</span> in 4 of the 5 individuals with rises ranging from 11/6 to 22/11 mmHg."		128.0	128_MESH:D011433_MESH:D006973	128_3	bcv_final_eval_easy_758		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"In 1 patient, marked <span class=""disease"">hypertension</span> was induced by <span class=""chemical"">propranolol</span> and the drug had to be withdrawn."		128.0	128_MESH:D011433_MESH:D006973	128_5	bcv_final_eval_easy_759		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D007022	"<span class=""disease"">idiopathic orthostatic hypotension</span>"	"The studies suggest that <span class=""chemical"">propranolol</span> is a useful drug in selected patients with severe <span class=""disease"">idiopathic orthostatic hypotension</span>."		128.0	128_MESH:D011433_MESH:D007022	128_9	bcv_final_eval_easy_760		
	MESH:D005280	"<span class=""chemical"">fenoterol</span>"	MESH:D014202	"<span class=""disease"">tremor</span>"	"After the end of <span class=""chemical"">fenoterol</span>-hydrobromide infusion, <span class=""disease"">tremor</span> amplitudes decreased significantly faster than those following ritodrin-HCl infusion."		130.0	130_MESH:D005280_MESH:D014202	130_8	bcv_final_eval_easy_761		
	MESH:C000873	"<span class=""chemical"">methylprednisolone acetate</span>"	MESH:D001766	"<span class=""disease"">blindness</span>"	"Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with <span class=""disease"">blindness</span> following head and neck soft-tissue injection with <span class=""chemical"">methylprednisolone acetate</span> in combination with lidocaine, epinephrine, or penicillin are reported."		131.0	131_MESH:C000873_MESH:D001766	131_1	bcv_final_eval_easy_762		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D001766	"<span class=""disease"">blindness</span>"	"Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with <span class=""disease"">blindness</span> following head and neck soft-tissue injection with methylprednisolone acetate in combination with <span class=""chemical"">lidocaine</span>, epinephrine, or penicillin are reported."		131.0	131_MESH:D008012_MESH:D001766	131_1	bcv_final_eval_easy_763		
	MESH:D010406	"<span class=""chemical"">penicillin</span>"	MESH:D001766	"<span class=""disease"">blindness</span>"	"Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with <span class=""disease"">blindness</span> following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or <span class=""chemical"">penicillin</span> are reported."		131.0	131_MESH:D010406_MESH:D001766	131_1	bcv_final_eval_easy_764		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D001766	"<span class=""disease"">blindness</span>"	"Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with <span class=""disease"">blindness</span> following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, <span class=""chemical"">epinephrine</span>, or penicillin are reported."		131.0	131_MESH:D004837_MESH:D001766	131_1	bcv_final_eval_easy_765		
	MESH:D002512	"<span class=""chemical"">Cephalothin</span>"	MESH:D000743	"<span class=""disease"">hemolytic anemia</span>"	"<span class=""chemical"">Cephalothin</span>-induced immune <span class=""disease"">hemolytic anemia</span>."		132.0	132_MESH:D002512_MESH:D000743	132_0	bcv_final_eval_easy_766		
	MESH:D002512	"<span class=""chemical"">cephalothin</span>"	MESH:D007674	"<span class=""disease"">renal disease</span>"	"A patient with <span class=""disease"">renal disease</span> developed Coombs-positive hemolytic anemia while receiving <span class=""chemical"">cephalothin</span> therapy."		132.0	132_MESH:D002512_MESH:D007674	132_1	bcv_final_eval_easy_767		
	MESH:D002512	"<span class=""chemical"">cephalothin</span>"	MESH:D000743	"<span class=""disease"">hemolytic anemia</span>"	"A patient with renal disease developed Coombs-positive <span class=""disease"">hemolytic anemia</span> while receiving <span class=""chemical"">cephalothin</span> therapy."		132.0	132_MESH:D002512_MESH:D000743	132_1	bcv_final_eval_easy_768		
	MESH:D007980	"<span class=""chemical"">L-dopa</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"Kaliuretic effect of <span class=""chemical"">L-dopa</span> treatment in <span class=""disease"">parkinsonian</span> patients."		133.0	133_MESH:D007980_MESH:D010300	133_0	bcv_final_eval_easy_769		
	MESH:D007980	"<span class=""chemical"">L-dopa</span>"	MESH:D007008	"<span class=""disease"">Hypokalemia</span>"	"<span class=""disease"">Hypokalemia</span>, sometimes severe, was observed in some <span class=""chemical"">L-dopa</span>-treated parkinsonian patients."		133.0	133_MESH:D007980_MESH:D007008	133_1	bcv_final_eval_easy_770		
	MESH:D007980	"<span class=""chemical"">L-dopa</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"Hypokalemia, sometimes severe, was observed in some <span class=""chemical"">L-dopa</span>-treated <span class=""disease"">parkinsonian</span> patients."		133.0	133_MESH:D007980_MESH:D010300	133_1	bcv_final_eval_easy_771		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"The influence of L-dopa on the renal excretion of <span class=""chemical"">potassium</span> was studied in 3 patients with <span class=""disease"">hypokalemia</span> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of <span class=""chemical"">potassium</span> and sodium as well as urinary excretion of <span class=""chemical"">potassium</span>, sodium and aldosterone."		133.0	133_MESH:D011188_MESH:D007008	133_2	bcv_final_eval_easy_772		
	MESH:D007980	"<span class=""chemical"">L-dopa</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"The influence of <span class=""chemical"">L-dopa</span> on the renal excretion of potassium was studied in 3 patients with <span class=""disease"">hypokalemia</span> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone."		133.0	133_MESH:D007980_MESH:D007008	133_2	bcv_final_eval_easy_773		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with <span class=""disease"">hypokalemia</span> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and <span class=""chemical"">sodium</span> as well as urinary excretion of potassium, <span class=""chemical"">sodium</span> and aldosterone."		133.0	133_MESH:D012964_MESH:D007008	133_2	bcv_final_eval_easy_774		
	MESH:D000450	"<span class=""chemical"">aldosterone</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with <span class=""disease"">hypokalemia</span> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and <span class=""chemical"">aldosterone</span>."		133.0	133_MESH:D000450_MESH:D007008	133_2	bcv_final_eval_easy_775		
	MESH:D007980	"<span class=""chemical"">L-Dopa</span>"	MESH:D020514	"<span class=""disease"">hypokalemic</span>"	"<span class=""chemical"">L-Dopa</span> intake was found to cause an increased excretion of potassium, and sometimes also of sodium, in the <span class=""disease"">hypokalemic</span> but not in the normokalemic patients."		133.0	133_MESH:D007980_MESH:D020514	133_3	bcv_final_eval_easy_776		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D020514	"<span class=""disease"">hypokalemic</span>"	"L-Dopa intake was found to cause an increased excretion of <span class=""chemical"">potassium</span>, and sometimes also of sodium, in the <span class=""disease"">hypokalemic</span> but not in the normokalemic patients."		133.0	133_MESH:D011188_MESH:D020514	133_3	bcv_final_eval_easy_777		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D020514	"<span class=""disease"">hypokalemic</span>"	"L-Dopa intake was found to cause an increased excretion of potassium, and sometimes also of <span class=""chemical"">sodium</span>, in the <span class=""disease"">hypokalemic</span> but not in the normokalemic patients."		133.0	133_MESH:D012964_MESH:D020514	133_3	bcv_final_eval_easy_778		
	MESH:D010672	"<span class=""chemical"">Phenytoin</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"<span class=""chemical"">Phenytoin</span> <span class=""disease"">encephalopathy</span> as probable idiosyncratic reaction: case report."		134.0	134_MESH:D010672_MESH:D001927	134_0	bcv_final_eval_easy_779		
	MESH:D010672	"<span class=""chemical"">phenytoin/DPH</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"A case of <span class=""chemical"">phenytoin</span> (<span class=""chemical"">DPH</span>) encephalopathy with increasing <span class=""disease"">seizures</span> and EEG and mental changes is described."		134.0	134_MESH:D010672_MESH:D012640	134_1	bcv_final_eval_easy_780		
	MESH:D010672	"<span class=""chemical"">phenytoin/DPH</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"A case of <span class=""chemical"">phenytoin</span> (<span class=""chemical"">DPH</span>) <span class=""disease"">encephalopathy</span> with increasing seizures and EEG and mental changes is described."		134.0	134_MESH:D010672_MESH:D001927	134_1	bcv_final_eval_easy_781		
	MESH:D010672	"<span class=""chemical"">DPH</span>"	MESH:D005076	"<span class=""disease"">retarded morbilliform rash</span>"	"In fact the concentration of free <span class=""chemical"">DPH</span> was normal, the patient presented a <span class=""disease"">retarded morbilliform rash</span> during <span class=""chemical"">DPH</span> treatment, the protidogram was normal, and an intradermic <span class=""chemical"">DPH</span> injection had no local effect."		134.0	134_MESH:D010672_MESH:D005076	134_4	bcv_final_eval_easy_782		
	MESH:D010672	"<span class=""chemical"">DPH</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The authors conclude that in a patient starting <span class=""chemical"">DPH</span> treatment an unexpected increase in <span class=""disease"">seizures</span>, with EEG and mental changes occurring simultaneously, should alert the physician to the possible need for eliminating <span class=""chemical"">DPH</span> from the therapeutic regimen, even if plasma concentrations are low."		134.0	134_MESH:D010672_MESH:D012640	134_5	bcv_final_eval_easy_783		
	MESH:D007545	"<span class=""chemical"">isoproterenol</span>"	MESH:D007238	"<span class=""disease"">infarction</span>"	"The results indicated that exercise reduced the mortality associated with the effects of large dosages of <span class=""chemical"">isoproterenol</span> but had little on the severity of the <span class=""disease"">infarction</span>."		135.0	135_MESH:D007545_MESH:D007238	135_9	bcv_final_eval_easy_784		
	MESH:D000617	"<span class=""chemical"">aminoglycoside</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"Dehydrated rats regularly develop <span class=""disease"">acute renal failure</span> following single injection of <span class=""chemical"">aminoglycoside</span> antibiotics combined with dextran or of antibiotics only."		136.0	136_MESH:D000617_MESH:D058186	136_1	bcv_final_eval_easy_785		
	MESH:D007612	"<span class=""chemical"">kanamycin</span>"	MESH:D051437	"<span class=""disease"">renal failure</span>"	"Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against <span class=""disease"">renal failure</span> induced by <span class=""chemical"">kanamycin</span>-dextran."		136.0	136_MESH:D007612_MESH:D051437	136_2	bcv_final_eval_easy_786		
	MESH:D000617	"<span class=""chemical"">aminoglycoside</span>"	MESH:D007674	"<span class=""disease"">renal damage</span>"	"D-Glucarates were effective against <span class=""disease"">renal damage</span> induced by peptide antibiotics as well as various <span class=""chemical"">aminoglycoside</span> antibitocis."		136.0	136_MESH:D000617_MESH:D007674	136_4	bcv_final_eval_easy_787		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D010264	"<span class=""disease"">Paraplegia</span>"	"<span class=""disease"">Paraplegia</span> following intrathecal <span class=""chemical"">methotrexate</span>: report of a case and review of the literature."		137.0	137_MESH:D008727_MESH:D010264	137_0	bcv_final_eval_easy_788		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D010264	"<span class=""disease"">paraplegia</span>"	"A patient who developed <span class=""disease"">paraplegia</span> following the intrathecal instillation of <span class=""chemical"">methotrexate</span> is discribed."		137.0	137_MESH:D008727_MESH:D010264	137_1	bcv_final_eval_easy_789		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D002493	"<span class=""disease"">central nervous system leukemia</span>"	"The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of <span class=""disease"">central nervous system leukemia</span>, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high <span class=""chemical"">methotrexate</span> doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available <span class=""chemical"">methotrexate</span> preparations and diluents; and the use of <span class=""chemical"">methotrexate</span> diluents of unphysiologic pH, ionic content and osmolarity."		137.0	137_MESH:D008727_MESH:D002493	137_3	bcv_final_eval_easy_790		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high <span class=""chemical"">methotrexate</span> doses based on body surface area calculations in older children and adults; the presence of <span class=""disease"">neurotoxic</span> preservatives in commercially available <span class=""chemical"">methotrexate</span> preparations and diluents; and the use of <span class=""chemical"">methotrexate</span> diluents of unphysiologic pH, ionic content and osmolarity."		137.0	137_MESH:D008727_MESH:D020258	137_3	bcv_final_eval_easy_791		
	MESH:D005492	"<span class=""chemical"">folate</span>"	MESH:C562799	"<span class=""disease"">folate deficiency</span>"	"The role of methotrexate contaminants, local <span class=""chemical""></span><span class=""disease"">folate</span> deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear."		137.0	137_MESH:D005492_MESH:C562799	137_4	bcv_final_eval_easy_792		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"The role of <span class=""chemical"">methotrexate</span> contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal <span class=""chemical"">methotrexate</span> <span class=""disease"">toxicity</span> is unclear."		137.0	137_MESH:D008727_MESH:D064420	137_4	bcv_final_eval_easy_793		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:C562799	"<span class=""disease"">folate deficiency</span>"	"The role of <span class=""chemical"">methotrexate</span> contaminants, local <span class=""disease"">folate deficiency</span>, and cranial irradiation in the pathogenesis of intrathecal <span class=""chemical"">methotrexate</span> toxicity is unclear."		137.0	137_MESH:D008727_MESH:C562799	137_4	bcv_final_eval_easy_794		
	MESH:D005492	"<span class=""chemical"">folate</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"The role of methotrexate contaminants, local <span class=""chemical"">folate</span> deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate <span class=""disease"">toxicity</span> is unclear."		137.0	137_MESH:D005492_MESH:D064420	137_4	bcv_final_eval_easy_795		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D015174	"<span class=""disease"">epidural leakage</span>"	"The incidence of neurotoxicity may be reduced by employing lower doses of <span class=""chemical"">methotrexate</span> in the presence of central nervous system leukemia, in older children and adults, and in the presence of <span class=""disease"">epidural leakage</span>."		137.0	137_MESH:D008727_MESH:D015174	137_5	bcv_final_eval_easy_796		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D002493	"<span class=""disease"">central nervous system leukemia</span>"	"The incidence of neurotoxicity may be reduced by employing lower doses of <span class=""chemical"">methotrexate</span> in the presence of <span class=""disease"">central nervous system leukemia</span>, in older children and adults, and in the presence of epidural leakage."		137.0	137_MESH:D008727_MESH:D002493	137_5	bcv_final_eval_easy_797		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"The incidence of <span class=""disease"">neurotoxicity</span> may be reduced by employing lower doses of <span class=""chemical"">methotrexate</span> in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage."		137.0	137_MESH:D008727_MESH:D020258	137_5	bcv_final_eval_easy_798		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"Periodic monitoring of cerebruspinal fluid <span class=""chemical"">methotrexate</span> levels may be predictive of the development of serious <span class=""disease"">neurotoxicity</span>."		137.0	137_MESH:D008727_MESH:D020258	137_7	bcv_final_eval_easy_799		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while <span class=""chemical"">propranolol</span> (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the <span class=""disease"">tachycardia</span> following i.c. carbachol (1 mug)."		138.0	138_MESH:D011433_MESH:D013610	138_2	bcv_final_eval_easy_800		
	MESH:D018738	"<span class=""chemical"">hexamethonium</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), <span class=""chemical"">hexamethonium</span> (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the <span class=""disease"">tachycardia</span> following i.c. carbachol (1 mug)."		138.0	138_MESH:D018738_MESH:D013610	138_2	bcv_final_eval_easy_801		
	MESH:D010646	"<span class=""chemical"">phentolamine</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or <span class=""chemical"">phentolamine</span> (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the <span class=""disease"">tachycardia</span> following i.c. carbachol (1 mug)."		138.0	138_MESH:D010646_MESH:D013610	138_2	bcv_final_eval_easy_802		
	MESH:D006145	"<span class=""chemical"">guanethidine</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"This response was significantly reduced by the intravenous (i.v.) injection of <span class=""chemical"">guanethidine</span> (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the <span class=""disease"">tachycardia</span> following i.c. carbachol (1 mug)."		138.0	138_MESH:D006145_MESH:D013610	138_2	bcv_final_eval_easy_803		
	MESH:D002217	"<span class=""chemical"">carbachol</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the <span class=""disease"">tachycardia</span> following i.c. <span class=""chemical"">carbachol</span> (1 mug)."		138.0	138_MESH:D002217_MESH:D013610	138_2	bcv_final_eval_easy_804		
	MESH:D003891	"<span class=""chemical"">desmethylimipramine</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. <span class=""chemical"">desmethylimipramine</span> (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the <span class=""disease"">tachycardia</span> following i.c. carbachol (1 mug)."		138.0	138_MESH:D003891_MESH:D013610	138_2	bcv_final_eval_easy_805		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D006030	"<span class=""disease"">glucosuria</span>"	"The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated <span class=""chemical"">glucose</span> tolerance curve and, occasionally, <span class=""disease"">glucosuria</span>."		139.0	139_MESH:D005947_MESH:D006030	139_1	bcv_final_eval_easy_806		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D018149	"<span class=""disease"">elevated glucose tolerance curve</span>"	"The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an <span class=""disease"">elevated </span><span class=""chemical"">glucose</span> tolerance curve and, occasionally, glucosuria."		139.0	139_MESH:D005947_MESH:D018149	139_1	bcv_final_eval_easy_807		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D006943	"<span class=""disease"">hyperglycemia</span>"	"The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in <span class=""disease"">hyperglycemia</span>, an elevated <span class=""chemical"">glucose</span> tolerance curve and, occasionally, glucosuria."		139.0	139_MESH:D005947_MESH:D006943	139_1	bcv_final_eval_easy_808		
	MESH:D013752	"<span class=""chemical"">tetracycline</span>"	MESH:D005234	"<span class=""disease"">Fatty liver</span>"	"<span class=""disease"">Fatty liver</span> induced by <span class=""chemical"">tetracycline</span> in the rat. Dose-response relationships and effect of sex."		140.0	140_MESH:D013752_MESH:D005234	140_0	bcv_final_eval_easy_809		
	MESH:D013752	"<span class=""chemical"">tetracycline</span>"	MESH:D005234	"<span class=""disease"">fatty liver</span>"	"Dose-response relationships, biochemical mechanisms, and sex differences in the experimental <span class=""disease"">fatty liver</span> induced by <span class=""chemical"">tetracycline</span> were studied in the intact rat and with the isolated perfused rat liver in vitro."		140.0	140_MESH:D013752_MESH:D005234	140_1	bcv_final_eval_easy_810		
	MESH:D013752	"<span class=""chemical"">tetracycline</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of <span class=""chemical"">tetracycline</span> and both accumulation of triglyceride in the liver and <span class=""disease"">depression</span> of output of triglyceride by livers from male and female rats."		140.0	140_MESH:D013752_MESH:D003866	140_3	bcv_final_eval_easy_811		
	MESH:D019301	"<span class=""chemical"">oleic acid</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"With provision of adequate <span class=""chemical"">oleic acid</span> as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and <span class=""disease"">depression</span> of output of triglyceride by livers from male and female rats."		140.0	140_MESH:D019301_MESH:D003866	140_3	bcv_final_eval_easy_812		
	MESH:D013752	"<span class=""chemical"">tetracycline</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of <span class=""chemical"">tetracycline</span> on <span class=""disease"">depression</span> of output of triglyceride under these experimental conditions."		140.0	140_MESH:D013752_MESH:D003866	140_6	bcv_final_eval_easy_813		
	MESH:D013752	"<span class=""chemical"">tetracycline</span>"	MESH:D005234	"<span class=""disease"">fatty liver</span>"	"Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich <span class=""disease"">fatty liver</span> in response to <span class=""chemical"">tetracycline</span>."		140.0	140_MESH:D013752_MESH:D005234	140_8	bcv_final_eval_easy_814		
	MESH:D014750	"<span class=""chemical"">Vincristine</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"<span class=""chemical"">Vincristine</span> was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and <span class=""disease"">death</span>."		141.0	141_MESH:D014750_MESH:D003643	141_1	bcv_final_eval_easy_815		
	MESH:D014750	"<span class=""chemical"">Vincristine</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"<span class=""chemical"">Vincristine</span> was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by <span class=""disease"">encephalopathy</span> and death."		141.0	141_MESH:D014750_MESH:D001927	141_1	bcv_final_eval_easy_816		
	MESH:D014750	"<span class=""chemical"">Vincristine</span>"	MESH:D015417	"<span class=""disease"">sensory and motor dysfunction</span>"	"<span class=""chemical"">Vincristine</span> was accidentally given intrathecally to a child with leukaemia, producing <span class=""disease"">sensory and motor dysfunction</span> followed by encephalopathy and death."		141.0	141_MESH:D014750_MESH:D015417	141_1	bcv_final_eval_easy_817		
	MESH:D014750	"<span class=""chemical"">Vincristine</span>"	MESH:D007938	"<span class=""disease"">leukaemia</span>"	"<span class=""chemical"">Vincristine</span> was accidentally given intrathecally to a child with <span class=""disease"">leukaemia</span>, producing sensory and motor dysfunction followed by encephalopathy and death."		141.0	141_MESH:D014750_MESH:D007938	141_1	bcv_final_eval_easy_818		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"Potentiation of <span class=""chemical"">bupivacaine</span> <span class=""disease"">arrhythmia</span> in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level."		142.0	142_MESH:D002045_MESH:D001145	142_9	bcv_final_eval_easy_819		
	MESH:D003676	"<span class=""chemical"">desferrioxamine</span>"	MESH:D058186	"<span class=""disease"">Acute renal failure</span>"	"<span class=""disease"">Acute renal failure</span> occurring during intravenous <span class=""chemical"">desferrioxamine</span> therapy: recovery after haemodialysis."		143.0	143_MESH:D003676_MESH:D058186	143_0	bcv_final_eval_easy_820		
	MESH:D003676	"<span class=""chemical"">desferrioxamine/DFX</span>"	MESH:D013789	"<span class=""disease"">thalassemia</span>"	"A patient with transfusion-dependent <span class=""disease"">thalassemia</span> was undergoing home intravenous <span class=""chemical"">desferrioxamine</span> (<span class=""chemical"">DFX</span>) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy."		143.0	143_MESH:D003676_MESH:D013789	143_1	bcv_final_eval_easy_821		
	MESH:D003676	"<span class=""chemical"">desferrioxamine</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive <span class=""disease"">acute renal failure</span> caused by <span class=""chemical"">desferrioxamine</span>."		143.0	143_MESH:D003676_MESH:D058186	143_4	bcv_final_eval_easy_822		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"Neuroleptic-associated <span class=""disease"">hyperprolactinemia</span>. Can it be treated with <span class=""chemical"">bromocriptine</span>?"		144.0	144_MESH:D001971_MESH:D006966	144_0	bcv_final_eval_easy_823		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D001523	"<span class=""disease"">psychiatric</span>"	"Six stable <span class=""disease"">psychiatric</span> outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with <span class=""chemical"">bromocriptine</span>."		144.0	144_MESH:D001971_MESH:D001523	144_1	bcv_final_eval_easy_824		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D000568	"<span class=""disease"">amenorrhea</span>"	"Six stable psychiatric outpatients with hyperprolactinemia and <span class=""disease"">amenorrhea</span>/oligomenorrhea associated with their neuroleptic medications were treated with <span class=""chemical"">bromocriptine</span>."		144.0	144_MESH:D001971_MESH:D000568	144_1	bcv_final_eval_easy_825		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"Six stable psychiatric outpatients with <span class=""disease"">hyperprolactinemia</span> and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with <span class=""chemical"">bromocriptine</span>."		144.0	144_MESH:D001971_MESH:D006966	144_1	bcv_final_eval_easy_826		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D009839	"<span class=""disease"">oligomenorrhea</span>"	"Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/<span class=""disease"">oligomenorrhea</span> associated with their neuroleptic medications were treated with <span class=""chemical"">bromocriptine</span>."		144.0	144_MESH:D001971_MESH:D009839	144_1	bcv_final_eval_easy_827		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D001523	"<span class=""disease"">psychiatric</span>"	"One woman, however, developed worsened <span class=""disease"">psychiatric</span> symptoms while taking <span class=""chemical"">bromocriptine</span>, and it was discontinued."		144.0	144_MESH:D001971_MESH:D001523	144_3	bcv_final_eval_easy_828		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D005687	"<span class=""disease"">galactorrhea</span>"	"This suggests that <span class=""chemical"">bromocriptine</span> should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/<span class=""disease"">galactorrhea</span>."		144.0	144_MESH:D001971_MESH:D005687	144_5	bcv_final_eval_easy_829		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D000568	"<span class=""disease"">amenorrhea</span>"	"This suggests that <span class=""chemical"">bromocriptine</span> should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and <span class=""disease"">amenorrhea</span>/galactorrhea."		144.0	144_MESH:D001971_MESH:D000568	144_5	bcv_final_eval_easy_830		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"This suggests that <span class=""chemical"">bromocriptine</span> should be further evaluated as potential therapy for neuroleptic-associated <span class=""disease"">hyperprolactinemia</span> and amenorrhea/galactorrhea."		144.0	144_MESH:D001971_MESH:D006966	144_5	bcv_final_eval_easy_831		
	MESH:D007538	"<span class=""chemical"">isoniazid</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the <span class=""disease"">convulsions</span> induced by <span class=""chemical"">isoniazid</span> (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)"		146.0	146_MESH:D007538_MESH:D012640	146_8	bcv_final_eval_easy_832		
	MESH:C036150	"<span class=""chemical"">beta-carboline</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"Moreover, 0.05 mg/kg of this <span class=""chemical"">beta-carboline</span> reduced markedly the increase of [35S]TBPS binding and the <span class=""disease"">convulsions</span> induced by isoniazid (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)"		146.0	146_MESH:C036150_MESH:D012640	146_8	bcv_final_eval_easy_833		
	MESH:D001971	"<span class=""chemical"">bromocriptine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Recurrent <span class=""disease"">myocardial infarction</span> in a postpartum patient receiving <span class=""chemical"">bromocriptine</span>."		147.0	147_MESH:D001971_MESH:D009203	147_0	bcv_final_eval_easy_834		
	MESH:D001971	"<span class=""chemical"">Bromocriptine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"<span class=""chemical"">Bromocriptine</span> has been implicated in several previous case reports of <span class=""disease"">myocardial infarction</span> in the puerperium."		147.0	147_MESH:D001971_MESH:D009203	147_3	bcv_final_eval_easy_835		
	MESH:D002220	"<span class=""chemical"">CBZ/carbamazepine</span>"	MESH:D020820	"<span class=""disease"">asterixis</span>"	"In this report we present four patients treated with a combination of different psychotropic drugs, in whom <span class=""disease"">asterixis</span> was triggered either by adding <span class=""chemical"">carbamazepine</span> (<span class=""chemical"">CBZ</span>) to a treatment regimen, or by increasing its dosage."		148.0	148_MESH:D002220_MESH:D020820	148_2	bcv_final_eval_easy_836		
	MESH:D002220	"<span class=""chemical"">CBZ</span>"	MESH:D020820	"<span class=""disease"">asterixis</span>"	"We consider <span class=""disease"">asterixis</span> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <span class=""chemical"">CBZ</span>."		148.0	148_MESH:D002220_MESH:D020820	148_4	bcv_final_eval_easy_837		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D020820	"<span class=""disease"">asterixis</span>"	"We consider <span class=""disease"">asterixis</span> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as <span class=""chemical"">lithium</span> or clozapine are used in combination with CBZ."		148.0	148_MESH:D008094_MESH:D020820	148_4	bcv_final_eval_easy_838		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"We consider asterixis to be an easily overlooked sign of <span class=""disease"">neurotoxicity</span>, which may occur even at low or moderate dosage levels, if certain drugs as <span class=""chemical"">lithium</span> or clozapine are used in combination with CBZ."		148.0	148_MESH:D008094_MESH:D020258	148_4	bcv_final_eval_easy_839		
	MESH:D003024	"<span class=""chemical"">clozapine</span>"	MESH:D020820	"<span class=""disease"">asterixis</span>"	"We consider <span class=""disease"">asterixis</span> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <span class=""chemical"">clozapine</span> are used in combination with CBZ."		148.0	148_MESH:D003024_MESH:D020820	148_4	bcv_final_eval_easy_840		
	MESH:D002220	"<span class=""chemical"">CBZ</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"We consider asterixis to be an easily overlooked sign of <span class=""disease"">neurotoxicity</span>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <span class=""chemical"">CBZ</span>."		148.0	148_MESH:D002220_MESH:D020258	148_4	bcv_final_eval_easy_841		
	MESH:D003024	"<span class=""chemical"">clozapine</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"We consider asterixis to be an easily overlooked sign of <span class=""disease"">neurotoxicity</span>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <span class=""chemical"">clozapine</span> are used in combination with CBZ."		148.0	148_MESH:D003024_MESH:D020258	148_4	bcv_final_eval_easy_842		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"Pharmacodynamics of the <span class=""disease"">hypotensive</span> effect of <span class=""chemical"">levodopa</span> in parkinsonian patients."		149.0	149_MESH:D007980_MESH:D007022	149_0	bcv_final_eval_easy_843		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"Pharmacodynamics of the hypotensive effect of <span class=""chemical"">levodopa</span> in <span class=""disease"">parkinsonian</span> patients."		149.0	149_MESH:D007980_MESH:D010300	149_0	bcv_final_eval_easy_844		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"Blood pressure effects of i.v. <span class=""chemical"">levodopa</span> were examined in <span class=""disease"">parkinsonian</span> patients with stable and fluctuating responses to <span class=""chemical"">levodopa</span>."		149.0	149_MESH:D007980_MESH:D010300	149_1	bcv_final_eval_easy_845		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"The magnitude of the <span class=""disease"">hypotensive</span> effect of <span class=""chemical"">levodopa</span> was concentration dependent and was fit to an Emax model in fluctuating responders."		149.0	149_MESH:D007980_MESH:D007022	149_2	bcv_final_eval_easy_846		
	MESH:D000596	"<span class=""chemical"">LNAA/amino acid</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"Phenylalanine, a large neutral <span class=""chemical"">amino acid</span> (<span class=""chemical"">LNAA</span>) competing with levodopa for transport across the blood-brain barrier, reduced the <span class=""disease"">hypotensive</span> and antiparkinsonian effects of levodopa."		149.0	149_MESH:D000596_MESH:D007022	149_6	bcv_final_eval_easy_847		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"Phenylalanine, a large neutral amino acid (LNAA) competing with <span class=""chemical"">levodopa</span> for transport across the blood-brain barrier, reduced the <span class=""disease"">hypotensive</span> and antiparkinsonian effects of <span class=""chemical"">levodopa</span>."		149.0	149_MESH:D007980_MESH:D007022	149_6	bcv_final_eval_easy_848		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"We conclude that <span class=""chemical"">levodopa</span> has a central <span class=""disease"">hypotensive</span> action that parallels the motor effects in fluctuating patients."		149.0	149_MESH:D007980_MESH:D007022	149_7	bcv_final_eval_easy_849		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007177	"<span class=""disease"">Syndrome of inappropriate secretion of antidiuretic hormone</span>"	"<span class=""disease"">Syndrome of inappropriate secretion of antidiuretic hormone</span> after infusional <span class=""chemical"">vincristine</span>."		150.0	150_MESH:D014750_MESH:D007177	150_0	bcv_final_eval_easy_850		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D009101	"<span class=""disease"">myeloma</span>"	"A 77-year-old woman with refractory multiple <span class=""disease"">myeloma</span> was treated with a 4-day continuous intravenous infusion of <span class=""chemical"">vincristine</span> and doxorubicin and 4 days of oral dexamethasone."		150.0	150_MESH:D014750_MESH:D009101	150_1	bcv_final_eval_easy_851		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009101	"<span class=""disease"">myeloma</span>"	"A 77-year-old woman with refractory multiple <span class=""disease"">myeloma</span> was treated with a 4-day continuous intravenous infusion of vincristine and <span class=""chemical"">doxorubicin</span> and 4 days of oral dexamethasone."		150.0	150_MESH:D004317_MESH:D009101	150_1	bcv_final_eval_easy_852		
	MESH:D003907	"<span class=""chemical"">dexamethasone</span>"	MESH:D009101	"<span class=""disease"">myeloma</span>"	"A 77-year-old woman with refractory multiple <span class=""disease"">myeloma</span> was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral <span class=""chemical"">dexamethasone</span>."		150.0	150_MESH:D003907_MESH:D009101	150_1	bcv_final_eval_easy_853		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007177	"<span class=""disease"">syndrome of inappropriate secretion of antidiuretic hormone</span>"	"Evaluation revealed the <span class=""disease"">syndrome of inappropriate secretion of antidiuretic hormone</span>, which was attributed to the <span class=""chemical"">vincristine</span> infusion."		150.0	150_MESH:D014750_MESH:D007177	150_3	bcv_final_eval_easy_854		
	MESH:D004077	"<span class=""chemical"">digoxin</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"In patients with <span class=""disease"">atrial fibrillation</span> <span class=""chemical"">digoxin</span> is beneficial for ventricular rate control."		151.0	151_MESH:D004077_MESH:D001281	151_2	bcv_final_eval_easy_855		
	MESH:D004077	"<span class=""chemical"">digoxin</span>"	MESH:D001145	"<span class=""disease"">arrhythmias</span>"	"Also, <span class=""chemical"">digoxin</span> has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing <span class=""disease"">arrhythmias</span>."		151.0	151_MESH:D004077_MESH:D001145	151_5	bcv_final_eval_easy_856		
	MESH:D004077	"<span class=""chemical"">digoxin</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction/MI</span>"	"Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that <span class=""chemical"">digoxin</span> may increase mortality after <span class=""disease"">myocardial infarction</span> (<span class=""disease"">MI</span>)."		151.0	151_MESH:D004077_MESH:D009203	151_10	bcv_final_eval_easy_857		
	MESH:D012293	"<span class=""chemical"">rifampin</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"Intravascular hemolysis and <span class=""disease"">acute renal failure</span> following intermittent <span class=""chemical"">rifampin</span> therapy."		152.0	152_MESH:D012293_MESH:D058186	152_0	bcv_final_eval_easy_858		
	MESH:D012293	"<span class=""chemical"">rifampin</span>"	MESH:D006461	"<span class=""disease"">Intravascular hemolysis</span>"	"<span class=""disease"">Intravascular hemolysis</span> and acute renal failure following intermittent <span class=""chemical"">rifampin</span> therapy."		152.0	152_MESH:D012293_MESH:D006461	152_0	bcv_final_eval_easy_859		
	MESH:D012293	"<span class=""chemical"">rifampin</span>"	MESH:D051437	"<span class=""disease"">Renal failure</span>"	"<span class=""disease"">Renal failure</span> is a rare complication associated with the use of <span class=""chemical"">rifampin</span>."		152.0	152_MESH:D012293_MESH:D051437	152_1	bcv_final_eval_easy_860		
	MESH:D012293	"<span class=""chemical"">rifampin</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"Intravascular hemolysis leading to <span class=""disease"">acute renal failure</span> following <span class=""chemical"">rifampin</span> therapy is extremely rare."		152.0	152_MESH:D012293_MESH:D058186	152_2	bcv_final_eval_easy_861		
	MESH:D012293	"<span class=""chemical"">rifampin</span>"	MESH:D006461	"<span class=""disease"">Intravascular hemolysis</span>"	"<span class=""disease"">Intravascular hemolysis</span> leading to acute renal failure following <span class=""chemical"">rifampin</span> therapy is extremely rare."		152.0	152_MESH:D012293_MESH:D006461	152_2	bcv_final_eval_easy_862		
	MESH:D012293	"<span class=""chemical"">rifampin</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"Two patients with leprosy who developed hemolysis and <span class=""disease"">acute renal failure</span> following <span class=""chemical"">rifampin</span> are reported."		152.0	152_MESH:D012293_MESH:D058186	152_3	bcv_final_eval_easy_863		
	MESH:D012293	"<span class=""chemical"">rifampin</span>"	MESH:D007918	"<span class=""disease"">leprosy</span>"	"Two patients with <span class=""disease"">leprosy</span> who developed hemolysis and acute renal failure following <span class=""chemical"">rifampin</span> are reported."		152.0	152_MESH:D012293_MESH:D007918	152_3	bcv_final_eval_easy_864		
	MESH:D012293	"<span class=""chemical"">rifampin</span>"	MESH:D006461	"<span class=""disease"">hemolysis</span>"	"Two patients with leprosy who developed <span class=""disease"">hemolysis</span> and acute renal failure following <span class=""chemical"">rifampin</span> are reported."		152.0	152_MESH:D012293_MESH:D006461	152_3	bcv_final_eval_easy_865		
	MESH:D015215	"<span class=""chemical"">zidovudine</span>"	MESH:D000163	"<span class=""disease"">AIDS</span>"	"A case of acute hepatitis induced by <span class=""chemical"">zidovudine</span> in a 38-year-old patient with <span class=""disease"">AIDS</span> is presented."		153.0	153_MESH:D015215_MESH:D000163	153_1	bcv_final_eval_easy_866		
	MESH:D014859	"<span class=""chemical"">coumadin</span>"	MESH:D020758	"<span class=""disease"">hematomyelia</span>"	"Thoracic <span class=""disease"">hematomyelia</span> secondary to <span class=""chemical"">coumadin</span> anticoagulant therapy: a case report."		154.0	154_MESH:D014859_MESH:D020758	154_0	bcv_final_eval_easy_867		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"Fluoxetine, a selective <span class=""chemical"">serotonin</span> reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent <span class=""disease"">depression</span>."		155.0	155_MESH:D012701_MESH:D003866	155_1	bcv_final_eval_easy_868		
	MESH:D005473	"<span class=""chemical"">Fluoxetine</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"<span class=""chemical"">Fluoxetine</span>, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent <span class=""disease"">depression</span>."		155.0	155_MESH:D005473_MESH:D003866	155_1	bcv_final_eval_easy_869		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D003866	"<span class=""disease"">depressed</span>"	"The cases of five <span class=""disease"">depressed</span> adolescents, 14-16 years of age, who developed mania during pharmacotherapy with <span class=""chemical"">fluoxetine</span>, are reported here."		155.0	155_MESH:D005473_MESH:D003866	155_3	bcv_final_eval_easy_870		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D003866	"<span class=""disease"">instability; major depression</span>"	"Apparent risk factors for the development of mania or hypomania during <span class=""chemical"">fluoxetine</span> pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective <span class=""disease"">instability; major depression</span> with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder."		155.0	155_MESH:D005473_MESH:D003866	155_4	bcv_final_eval_easy_871		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D011618	"<span class=""disease"">psychotic</span>"	"Apparent risk factors for the development of mania or hypomania during <span class=""chemical"">fluoxetine</span> pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with <span class=""disease"">psychotic</span> features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder."		155.0	155_MESH:D005473_MESH:D011618	155_4	bcv_final_eval_easy_872		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity disorder</span>"	"Apparent risk factors for the development of mania or hypomania during <span class=""chemical"">fluoxetine</span> pharmacotherapy in this population were the combination of attention-deficit <span class=""disease"">hyperactivity disorder</span> and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder."		155.0	155_MESH:D005473_MESH:D006948	155_4	bcv_final_eval_easy_873		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D019964	"<span class=""disease"">affective disorder</span>"	"Apparent risk factors for the development of mania or hypomania during <span class=""chemical"">fluoxetine</span> pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of <span class=""disease"">affective disorder</span>, especially bipolar disorder; and a diagnosis of bipolar disorder."		155.0	155_MESH:D005473_MESH:D019964	155_4	bcv_final_eval_easy_874		
	MESH:D015248	"<span class=""chemical"">Gemfibrozil</span>"	MESH:D006951	"<span class=""disease"">hyperlipoproteinemias</span>"	"<span class=""chemical"">Gemfibrozil</span>-lovastatin therapy for primary <span class=""disease"">hyperlipoproteinemias</span>."		156.0	156_MESH:D015248_MESH:D006951	156_0	bcv_final_eval_easy_875		
	MESH:D008148	"<span class=""chemical"">lovastatin</span>"	MESH:D006951	"<span class=""disease"">hyperlipoproteinemias</span>"	"Gemfibrozil-<span class=""chemical"">lovastatin</span> therapy for primary <span class=""disease"">hyperlipoproteinemias</span>."		156.0	156_MESH:D008148_MESH:D006951	156_0	bcv_final_eval_easy_876		
	MESH:D003401	"<span class=""chemical"">creatine</span>"	MESH:D009220	"<span class=""disease"">Myositis</span>"	"<span class=""disease"">Myositis</span>, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high <span class=""chemical"">creatine</span> phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)"		156.0	156_MESH:D003401_MESH:D009220	156_7	bcv_final_eval_easy_877		
	MESH:D003401	"<span class=""chemical"">creatine</span>"	MESH:D012206	"<span class=""disease"">rhabdomyolysis</span>"	"Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high <span class=""chemical"">creatine</span> phosphokinase (769 U/liter); no patients had <span class=""disease"">rhabdomyolysis</span> or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)"		156.0	156_MESH:D003401_MESH:D012206	156_7	bcv_final_eval_easy_878		
	MESH:D003401	"<span class=""chemical"">creatine</span>"	MESH:D009212	"<span class=""disease"">myoglobinuria</span>"	"Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high <span class=""chemical"">creatine</span> phosphokinase (769 U/liter); no patients had rhabdomyolysis or <span class=""disease"">myoglobinuria</span>.(ABSTRACT TRUNCATED AT 250 WORDS)"		156.0	156_MESH:D003401_MESH:D009212	156_7	bcv_final_eval_easy_879		
	MESH:D000728	"<span class=""chemical"">androgens</span>"	MESH:D005199	"<span class=""disease"">Fanconi's anemia</span>"	"The case of an 11-year-old boy is reported who was known to have <span class=""disease"">Fanconi's anemia</span> for 3 years and was treated with <span class=""chemical"">androgens</span>, corticosteroids and transfusions."		157.0	157_MESH:D000728_MESH:D005199	157_1	bcv_final_eval_easy_880		
	MESH:D000305	"<span class=""chemical"">corticosteroids</span>"	MESH:D005199	"<span class=""disease"">Fanconi's anemia</span>"	"The case of an 11-year-old boy is reported who was known to have <span class=""disease"">Fanconi's anemia</span> for 3 years and was treated with androgens, <span class=""chemical"">corticosteroids</span> and transfusions."		157.0	157_MESH:D000305_MESH:D005199	157_1	bcv_final_eval_easy_881		
	MESH:D014294	"<span class=""chemical"">trimethaphan</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"The <span class=""chemical"">trimethaphan</span>-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a <span class=""disease"">tachycardia</span> in sham rats (+33 +/- 12 beats per minute) 1 day postlesion."		158.0	158_MESH:D014294_MESH:D013610	158_8	bcv_final_eval_easy_882		
	MESH:D014294	"<span class=""chemical"">trimethaphan</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"The <span class=""chemical"">trimethaphan</span>-induced hypotension was accompanied by a significant <span class=""disease"">bradycardia</span> in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion."		158.0	158_MESH:D014294_MESH:D001919	158_8	bcv_final_eval_easy_883		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D009410	"<span class=""disease"">neuronal damage</span>"	"Nissl-staining and antibodies against the neuron-specific <span class=""chemical"">calcium</span>-binding protein, parvalbumin, served to detect <span class=""disease"">neuronal damage</span> in SNR."		159.0	159_MESH:D002118_MESH:D009410	159_6	bcv_final_eval_easy_884		
	MESH:C032976	"<span class=""chemical"">N-(2-hydroxypropyl)methacrylamide</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Reduced <span class=""disease"">cardiotoxicity</span> of doxorubicin given in the form of <span class=""chemical"">N-(2-hydroxypropyl)methacrylamide</span> conjugates: and experimental study in the rat."		160.0	160_MESH:C032976_MESH:D066126	160_0	bcv_final_eval_easy_885		
	MESH:C032976	"<span class=""chemical"">N-(2-hydroxypropyl)methacrylamide</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"A rat model was used to evaluate the general acute <span class=""disease"">toxicity</span> and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three <span class=""chemical"">N-(2-hydroxypropyl)methacrylamide</span> (HPMA) copolymer conjugates."		160.0	160_MESH:C032976_MESH:D064420	160_1	bcv_final_eval_easy_886		
	MESH:C032976	"<span class=""chemical"">N-(2-hydroxypropyl)methacrylamide</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"A rat model was used to evaluate the general acute toxicity and the late <span class=""disease"">cardiotoxicity</span> of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three <span class=""chemical"">N-(2-hydroxypropyl)methacrylamide</span> (HPMA) copolymer conjugates."		160.0	160_MESH:C032976_MESH:D066126	160_1	bcv_final_eval_easy_887		
	MESH:C032802	"<span class=""chemical"">HPMA</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"A rat model was used to evaluate the general acute toxicity and the late <span class=""disease"">cardiotoxicity</span> of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (<span class=""chemical"">HPMA</span>) copolymer conjugates."		160.0	160_MESH:C032802_MESH:D066126	160_1	bcv_final_eval_easy_888		
	MESH:C032802	"<span class=""chemical"">HPMA</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"A rat model was used to evaluate the general acute <span class=""disease"">toxicity</span> and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (<span class=""chemical"">HPMA</span>) copolymer conjugates."		160.0	160_MESH:C032802_MESH:D064420	160_1	bcv_final_eval_easy_889		
	MESH:D004317	"<span class=""chemical"">doxorubicin/DOX</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"A rat model was used to evaluate the general acute <span class=""disease"">toxicity</span> and the late cardiotoxicity of 4 mg/kg <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">DOX</span>) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates."		160.0	160_MESH:D004317_MESH:D064420	160_1	bcv_final_eval_easy_890		
	MESH:C032802	"<span class=""chemical"">HPMA</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Throughout the study (20 weeks), deaths related to <span class=""disease"">cardiotoxicity</span> were observed only in animals that received either free DOX or the mixture of <span class=""chemical"">HPMA</span> copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced <span class=""disease"">cardiotoxicity</span>."		160.0	160_MESH:C032802_MESH:D066126	160_6	bcv_final_eval_easy_891		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D009437	"<span class=""disease"">post-herpetic neuralgia</span>"	"Topical 0.025% <span class=""chemical"">capsaicin</span> in chronic <span class=""disease"">post-herpetic neuralgia</span>: efficacy, predictors of response and long-term course."		161.0	161_MESH:D002211_MESH:D009437	161_0	bcv_final_eval_easy_892		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D009437	"<span class=""disease"">post-herpetic neuralgia/PHN</span>"	"In order to evaluate the efficacy, time-course of action and predictors of response to topical <span class=""chemical"">capsaicin</span>, 39 patients with chronic <span class=""disease"">post-herpetic neuralgia</span> (<span class=""disease"">PHN</span>), median duration 24 months, were treated with 0.025% <span class=""chemical"">capsaicin</span> cream for 8 weeks."		161.0	161_MESH:D002211_MESH:D009437	161_1	bcv_final_eval_easy_893		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D008413	"<span class=""disease"">mastitis</span>"	"Nineteen patients (48.7%) substantially improved after the 8-week trial; 5 (12.8%) discontinued therapy due to side-effects such as intolerable <span class=""chemical"">capsaicin</span>-induced burning sensations (4) or <span class=""disease"">mastitis</span> (1); 15 (38.5%) reported no benefit."		161.0	161_MESH:D002211_MESH:D008413	161_4	bcv_final_eval_easy_894		
	MESH:D002211	"<span class=""chemical"">capsaicin</span>"	MESH:D009437	"<span class=""disease"">PHN</span>"	"If confirmed in controlled trials, the long-term results of this open, non-randomized study might indicate that the analgesic effect of <span class=""chemical"">capsaicin</span> in <span class=""disease"">PHN</span> is mediated by both interference with neuropeptide metabolism and morphological changes (perhaps degeneration) of nociceptive afferents."		161.0	161_MESH:D002211_MESH:D009437	161_9	bcv_final_eval_easy_895		
	MESH:D012701	"<span class=""chemical"">Serotonin</span>"	MESH:D010259	"<span class=""disease"">paranoia</span>"	"<span class=""chemical"">Serotonin</span> reuptake inhibitors, <span class=""disease"">paranoia</span>, and the ventral basal ganglia."		162.0	162_MESH:D012701_MESH:D010259	162_0	bcv_final_eval_easy_896		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D001714	"<span class=""disease"">bipolarity</span>"	"Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, <span class=""disease"">bipolarity</span>, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with <span class=""chemical"">serotonin</span> reuptake inhibitors."		162.0	162_MESH:D012701_MESH:D001714	162_4	bcv_final_eval_easy_897		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D003866	"<span class=""disease"">depressive disorders</span>"	"Complicated <span class=""disease"">depressive disorders</span> (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with <span class=""chemical"">serotonin</span> reuptake inhibitors."		162.0	162_MESH:D012701_MESH:D003866	162_4	bcv_final_eval_easy_898		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D011605	"<span class=""disease"">psychosis</span>"	"Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, <span class=""disease"">psychosis</span>, bipolarity, and secondary onset in the course of a primary <span class=""disease"">psychosis</span>) may present particular vulnerability to paranoid exacerbations associated with <span class=""chemical"">serotonin</span> reuptake inhibitors."		162.0	162_MESH:D012701_MESH:D011605	162_4	bcv_final_eval_easy_899		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D010259	"<span class=""disease"">paranoia</span>"	"Although the pharmacology and neurobiology of <span class=""disease"">paranoia</span> remain cryptic, several mechanisms, including 5HT3 receptor-mediated <span class=""chemical"">dopamine</span> release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon."		162.0	162_MESH:D004298_MESH:D010259	162_5	bcv_final_eval_easy_900		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D010259	"<span class=""disease"">paranoia</span>"	"These cases call attention to possible paranoid exacerbations with <span class=""chemical"">serotonin</span> reuptake blockers in select patients and raise neurobiological considerations regarding <span class=""disease"">paranoia</span>."		162.0	162_MESH:D012701_MESH:D010259	162_6	bcv_final_eval_easy_901		
	MESH:D004049	"<span class=""chemical"">diethylcarbamazine</span>"	MESH:D004660	"<span class=""disease"">encephalitis</span>"	"Five cases of <span class=""disease"">encephalitis</span> during treatment of loiasis with <span class=""chemical"">diethylcarbamazine</span>."		163.0	163_MESH:D004049_MESH:D004660	163_0	bcv_final_eval_easy_902		
	MESH:D004049	"<span class=""chemical"">diethylcarbamazine</span>"	MESH:D008118	"<span class=""disease"">loiasis</span>"	"Five cases of encephalitis during treatment of <span class=""disease"">loiasis</span> with <span class=""chemical"">diethylcarbamazine</span>."		163.0	163_MESH:D004049_MESH:D008118	163_0	bcv_final_eval_easy_903		
	MESH:D004049	"<span class=""chemical"">diethylcarbamazine/DEC</span>"	MESH:D004660	"<span class=""disease"">encephalitis</span>"	"Five cases of <span class=""disease"">encephalitis</span> following treatment with <span class=""chemical"">diethylcarbamazine</span> (<span class=""chemical"">DEC</span>) were observed in Congolese patients with Loa loa filariasis."		163.0	163_MESH:D004049_MESH:D004660	163_1	bcv_final_eval_easy_904		
	MESH:D004049	"<span class=""chemical"">diethylcarbamazine/DEC</span>"	MESH:D005368	"<span class=""disease"">Loa loa filariasis</span>"	"Five cases of encephalitis following treatment with <span class=""chemical"">diethylcarbamazine</span> (<span class=""chemical"">DEC</span>) were observed in Congolese patients with <span class=""disease"">Loa loa filariasis</span>."		163.0	163_MESH:D004049_MESH:D005368	163_1	bcv_final_eval_easy_905		
	MESH:D016595	"<span class=""chemical"">Misoprostol</span>"	MESH:D006261	"<span class=""disease"">headache</span>"	"<span class=""chemical"">Misoprostol</span> has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and <span class=""disease"">headache</span>."		164.0	164_MESH:D016595_MESH:D006261	164_1	bcv_final_eval_easy_906		
	MESH:D016595	"<span class=""chemical"">Misoprostol</span>"	MESH:D005767	"<span class=""disease"">gastrointestinal symptoms</span>"	"<span class=""chemical"">Misoprostol</span> has been associated with adverse reactions, including <span class=""disease"">gastrointestinal symptoms</span>, gynecologic problems, and headache."		164.0	164_MESH:D016595_MESH:D005767	164_1	bcv_final_eval_easy_907		
	MESH:D016595	"<span class=""chemical"">misoprostol</span>"	MESH:D003221	"<span class=""disease"">confused</span>"	"We present a case in which an 89-year-old woman in a long-term care facility became <span class=""disease"">confused</span> after the initiation of <span class=""chemical"">misoprostol</span> therapy."		164.0	164_MESH:D016595_MESH:D003221	164_3	bcv_final_eval_easy_908		
	MESH:D016595	"<span class=""chemical"">misoprostol</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"Her <span class=""disease"">delirium</span> significantly improved after <span class=""chemical"">misoprostol</span> was discontinued and her mental status returned to normal within a week."		164.0	164_MESH:D016595_MESH:D003693	164_5	bcv_final_eval_easy_909		
	MESH:D016595	"<span class=""chemical"">misoprostol</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"Because no other factors related to this patient changed significantly, the <span class=""disease"">delirium</span> experienced by this patient possibly resulted from <span class=""chemical"">misoprostol</span> therapy."		164.0	164_MESH:D016595_MESH:D003693	164_6	bcv_final_eval_easy_910		
	MESH:D005978	"<span class=""chemical"">glutathione</span>"	MESH:D015427	"<span class=""disease"">intestinal ischemia-reperfusion injury</span>"	"There was no change in hepatic tissue total <span class=""chemical"">glutathione</span> following <span class=""disease"">intestinal ischemia-reperfusion injury</span>."		165.0	165_MESH:D005978_MESH:D015427	165_6	bcv_final_eval_easy_911		
	MESH:D002927	"<span class=""chemical"">cimetidine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"We conclude that an H1 antagonist may be useful in preventing <span class=""disease"">hypotension</span> caused by iv <span class=""chemical"">cimetidine</span>, since the vasodilating activity of <span class=""chemical"">cimetidine</span> is mediated, in part, through the H1 receptor."		166.0	166_MESH:D002927_MESH:D007022	166_9	bcv_final_eval_easy_912		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D058186	"<span class=""disease"">Acute renal failure</span>"	"<span class=""disease"">Acute renal failure</span> due to <span class=""chemical"">rifampicin</span>."		167.0	167_MESH:D012293_MESH:D058186	167_0	bcv_final_eval_easy_913		
	MESH:D012293	"<span class=""chemical"">Rifampicin</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"<span class=""chemical"">Rifampicin</span> was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like <span class=""disease"">nausea</span>, vomiting and fever with chills and rigors."		167.0	167_MESH:D012293_MESH:D009325	167_2	bcv_final_eval_easy_914		
	MESH:D012293	"<span class=""chemical"">Rifampicin</span>"	MESH:D012298	"<span class=""disease"">rigors</span>"	"<span class=""chemical"">Rifampicin</span> was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and fever with chills and <span class=""disease"">rigors</span>."		167.0	167_MESH:D012293_MESH:D012298	167_2	bcv_final_eval_easy_915		
	MESH:D012293	"<span class=""chemical"">Rifampicin</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"<span class=""chemical"">Rifampicin</span> was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, <span class=""disease"">vomiting</span> and fever with chills and rigors."		167.0	167_MESH:D012293_MESH:D014839	167_2	bcv_final_eval_easy_916		
	MESH:D013852	"<span class=""chemical"">thiotepa</span>"	MESH:D064420	"<span class=""disease"">neurologic toxicity</span>"	"Two cases of severe delayed <span class=""disease"">neurologic toxicity</span> related to the administration of intrathecal (IT) combination chemotherapy including <span class=""chemical"">thiotepa</span> (TSPA) are presented."		168.0	168_MESH:D013852_MESH:D064420	168_1	bcv_final_eval_easy_917		
	MESH:D003561	"<span class=""chemical"">ara-C</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"In spite of the fact that TSPA is a useful IT agent, its combination with MTX, <span class=""chemical"">ara-C</span> and radiotherapy could cause severe <span class=""disease"">neurotoxicity</span>."		168.0	168_MESH:D003561_MESH:D020258	168_5	bcv_final_eval_easy_918		
	MESH:D008727	"<span class=""chemical"">MTX</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"In spite of the fact that TSPA is a useful IT agent, its combination with <span class=""chemical"">MTX</span>, ara-C and radiotherapy could cause severe <span class=""disease"">neurotoxicity</span>."		168.0	168_MESH:D008727_MESH:D020258	168_5	bcv_final_eval_easy_919		
	MESH:D005996	"<span class=""chemical"">Nitroglycerin</span>"	MESH:D006331	"<span class=""disease"">cardiac or systemic hemodynamic parameter</span>"	"<span class=""chemical"">Nitroglycerin</span>, up to 0.3 micrograms/kg, selectively increased circumflex artery diameter (CxAD) without simultaneously affecting any other <span class=""disease"">cardiac or systemic hemodynamic parameter</span>."		169.0	169_MESH:D005996_MESH:D006331	169_2	bcv_final_eval_easy_920		
	MESH:D020110	"<span class=""chemical"">pinacidil</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and <span class=""chemical"">pinacidil</span> were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced <span class=""disease"">tachycardia</span> was abolished."		169.0	169_MESH:D020110_MESH:D013610	169_5	bcv_final_eval_easy_921		
	MESH:D020110	"<span class=""chemical"">pinacidil</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Vasodilation of large and small coronary vessels and <span class=""disease"">hypotension</span> induced by cromakalim and <span class=""chemical"">pinacidil</span> were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished."		169.0	169_MESH:D020110_MESH:D007022	169_5	bcv_final_eval_easy_922		
	MESH:D008528	"<span class=""chemical"">Mefenamic acid</span>"	MESH:D051437	"<span class=""disease"">renal failure</span>"	"<span class=""chemical"">Mefenamic acid</span>-induced neutropenia and <span class=""disease"">renal failure</span> in elderly females with hypothyroidism."		170.0	170_MESH:D008528_MESH:D051437	170_0	bcv_final_eval_easy_923		
	MESH:D008528	"<span class=""chemical"">Mefenamic acid</span>"	MESH:D007037	"<span class=""disease"">hypothyroidism</span>"	"<span class=""chemical"">Mefenamic acid</span>-induced neutropenia and renal failure in elderly females with <span class=""disease"">hypothyroidism</span>."		170.0	170_MESH:D008528_MESH:D007037	170_0	bcv_final_eval_easy_924		
	MESH:D008528	"<span class=""chemical"">mefenamic acid</span>"	MESH:D051437	"<span class=""disease"">renal failure</span>"	"We report <span class=""chemical"">mefenamic acid</span>-induced non-oliguric <span class=""disease"">renal failure</span> and severe neutropenia occurring simultaneously in two elderly females."		170.0	170_MESH:D008528_MESH:D051437	170_1	bcv_final_eval_easy_925		
	MESH:D008528	"<span class=""chemical"">mefenamic acid</span>"	MESH:D007037	"<span class=""disease"">hypothyroid/hypothyroidism</span>"	"However, it would seem prudent not to use <span class=""chemical"">mefenamic acid</span> in <span class=""disease"">hypothyroid</span> patients until the <span class=""disease"">hypothyroidism</span> has been corrected."		170.0	170_MESH:D008528_MESH:D007037	170_4	bcv_final_eval_easy_926		
	MESH:D002119	"<span class=""chemical"">calcium carbonate</span>"	MESH:D006934	"<span class=""disease"">hypercalcemia</span>"	"Etiology of <span class=""disease"">hypercalcemia</span> in hemodialysis patients on <span class=""chemical"">calcium carbonate</span> therapy."		171.0	171_MESH:D002119_MESH:D006934	171_0	bcv_final_eval_easy_927		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D006934	"<span class=""disease"">hypercalcemia</span>"	"In order to identify risk factors associated with the development of <span class=""disease"">hypercalcemia</span>, indirect parameters of intestinal <span class=""chemical"">calcium</span> reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of renal disease."		171.0	171_MESH:D002118_MESH:D006934	171_2	bcv_final_eval_easy_928		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D007674	"<span class=""disease"">renal disease</span>"	"In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal <span class=""chemical"">calcium</span> reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of <span class=""disease"">renal disease</span>."		171.0	171_MESH:D002118_MESH:D007674	171_2	bcv_final_eval_easy_929		
	MESH:D008750	"<span class=""chemical"">Methyldopa</span>"	MESH:D013575	"<span class=""disease"">syncope</span>"	"<span class=""chemical"">Methyldopa</span>-induced hemolytic anemia in a 15 year old presenting as near-<span class=""disease"">syncope</span>."		172.0	172_MESH:D008750_MESH:D013575	172_0	bcv_final_eval_easy_930		
	MESH:D008750	"<span class=""chemical"">Methyldopa</span>"	MESH:D000744	"<span class=""disease"">autoimmune hemolytic anemia</span>"	"<span class=""chemical"">Methyldopa</span> causes an <span class=""disease"">autoimmune hemolytic anemia</span> in a small percentage of patients who take the drug."		172.0	172_MESH:D008750_MESH:D000744	172_2	bcv_final_eval_easy_931		
	MESH:D008750	"<span class=""chemical"">methyldopa</span>"	MESH:D013575	"<span class=""disease"">syncope</span>"	"We report a case of <span class=""chemical"">methyldopa</span>-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-<span class=""disease"">syncope</span>."		172.0	172_MESH:D008750_MESH:D013575	172_3	bcv_final_eval_easy_932		
	MESH:D008750	"<span class=""chemical"">methyldopa</span>"	MESH:D014947	"<span class=""disease"">trauma</span>"	"The boy had been treated with intravenous <span class=""chemical"">methyldopa</span> during a <span class=""disease"">trauma</span> admission seven weeks prior to presentation."		172.0	172_MESH:D008750_MESH:D014947	172_4	bcv_final_eval_easy_933		
	MESH:D003613	"<span class=""chemical"">danazol</span>"	MESH:D054179	"<span class=""disease"">hereditary angioedema</span>"	"The long-term safety of <span class=""chemical"">danazol</span> in women with <span class=""disease"">hereditary angioedema</span>."		173.0	173_MESH:D003613_MESH:D054179	173_0	bcv_final_eval_easy_934		
	MESH:D003613	"<span class=""chemical"">danazol</span>"	MESH:D054179	"<span class=""disease"">hereditary angioedema</span>"	"We therefore investigated the long-term safety of <span class=""chemical"">danazol</span> by performing a retrospective chart review of 60 female patients with <span class=""disease"">hereditary angioedema</span> treated with <span class=""chemical"">danazol</span> for a continuous period of 6 months or longer."		173.0	173_MESH:D003613_MESH:D054179	173_2	bcv_final_eval_easy_935		
	MESH:C048279	"<span class=""chemical"">CHP</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"There was a direct relationship between <span class=""chemical"">CHP</span> concentration and patients' ratings of <span class=""disease"">pain</span> on an analogue scale."		174.0	174_MESH:C048279_MESH:D010146	174_7	bcv_final_eval_easy_936		
	MESH:C048279	"<span class=""chemical"">CHP</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"The 0.25 per cent <span class=""chemical"">CHP</span> cream was closest to AgSD in <span class=""disease"">pain</span> tolerance; however, none of the treatments differed statistically from AgSD or from each other."		174.0	174_MESH:C048279_MESH:D010146	174_8	bcv_final_eval_easy_937		
	MESH:D002066	"<span class=""chemical"">busulfan</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"Dose-dependent <span class=""disease"">neurotoxicity</span> of high-dose <span class=""chemical"">busulfan</span> in children: a clinical and pharmacological study."		175.0	175_MESH:D002066_MESH:D020258	175_0	bcv_final_eval_easy_938		
	MESH:D002066	"<span class=""chemical"">Busulfan</span>"	MESH:D020258	"<span class=""disease"">neurotoxic/neurotoxicity</span>"	"<span class=""chemical"">Busulfan</span> is known to be <span class=""disease"">neurotoxic</span> in animals and humans, but its acute <span class=""disease"">neurotoxicity</span> remains poorly characterized in children."		175.0	175_MESH:D002066_MESH:D020258	175_1	bcv_final_eval_easy_939		
	MESH:D002066	"<span class=""chemical"">busulfan</span>"	MESH:D001932	"<span class=""disease"">brain tumors</span>"	"We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose <span class=""chemical"">busulfan</span> in combined chemotherapy before bone marrow transplantation for malignant solid tumors, <span class=""disease"">brain tumors</span> excluded."		175.0	175_MESH:D002066_MESH:D001932	175_2	bcv_final_eval_easy_940		
	MESH:D002066	"<span class=""chemical"">busulfan</span>"	MESH:D009369	"<span class=""disease"">tumors</span>"	"We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose <span class=""chemical"">busulfan</span> in combined chemotherapy before bone marrow transplantation for malignant solid <span class=""disease"">tumors</span>, brain tumors excluded."		175.0	175_MESH:D002066_MESH:D009369	175_2	bcv_final_eval_easy_941		
	MESH:D002066	"<span class=""chemical"">busulfan</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Ninety-six patients were not given anticonvulsive prophylaxis; 7 (7.5%) developed <span class=""disease"">seizures</span> during the 4 days of the <span class=""chemical"">busulfan</span> course or within 24 h after the last dosing."		175.0	175_MESH:D002066_MESH:D012640	175_6	bcv_final_eval_easy_942		
	MESH:D002066	"<span class=""chemical"">busulfan</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"When the total <span class=""chemical"">busulfan</span> dose was taken into account, there was a significant difference in terms of <span class=""disease"">neurotoxicity</span> incidence among patients under 16 mg/kg (1 of 57, 1.7%) and patients under 600 mg/m2 (6 of 39, 15.4%) (P less than 0.02)."		175.0	175_MESH:D002066_MESH:D020258	175_7	bcv_final_eval_easy_943		
	MESH:D002066	"<span class=""chemical"">Busulfan</span>"	MESH:D002493	"<span class=""disease"">central nervous system disease</span>"	"<span class=""chemical"">Busulfan</span> levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without <span class=""disease"">central nervous system disease</span> under 600 mg/m2 <span class=""chemical"">busulfan</span> with clonazepam:<span class=""chemical"">busulfan</span> cerebrospinal fluid:plasma ratio was 1.39."		175.0	175_MESH:D002066_MESH:D002493	175_9	bcv_final_eval_easy_944		
	MESH:D002998	"<span class=""chemical"">clonazepam</span>"	MESH:D002493	"<span class=""disease"">central nervous system disease</span>"	"Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without <span class=""disease"">central nervous system disease</span> under 600 mg/m2 busulfan with <span class=""chemical"">clonazepam</span>:busulfan cerebrospinal fluid:plasma ratio was 1.39."		175.0	175_MESH:D002998_MESH:D002493	175_9	bcv_final_eval_easy_945		
	MESH:D002066	"<span class=""chemical"">busulfan</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"This study shows that <span class=""chemical"">busulfan</span> <span class=""disease"">neurotoxicity</span> is dose-dependent in children and efficiently prevented by clonazepam."		175.0	175_MESH:D002066_MESH:D020258	175_11	bcv_final_eval_easy_946		
	MESH:D002998	"<span class=""chemical"">clonazepam</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"This study shows that busulfan <span class=""disease"">neurotoxicity</span> is dose-dependent in children and efficiently prevented by <span class=""chemical"">clonazepam</span>."		175.0	175_MESH:D002998_MESH:D020258	175_11	bcv_final_eval_easy_947		
	MESH:D002066	"<span class=""chemical"">busulfan</span>"	MESH:D020258	"<span class=""disease"">increased neurotoxicity/neurotoxicity</span>"	"A <span class=""chemical"">busulfan</span> dose calculated on the basis of body surface area, resulting in higher doses in young children, was followed by <span class=""disease"">increased neurotoxicity</span>, close to <span class=""disease"">neurotoxicity</span> incidence observed in adults."		175.0	175_MESH:D002066_MESH:D020258	175_12	bcv_final_eval_easy_948		
	MESH:D006632	"<span class=""chemical"">Histamine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"<span class=""chemical"">Histamine</span> antagonists and d-tubocurarine-induced <span class=""disease"">hypotension</span> in cardiac surgical patients."		176.0	176_MESH:D006632_MESH:D007022	176_0	bcv_final_eval_easy_949		
	MESH:D001556	"<span class=""chemical"">gamma-hexachlorocyclohexane/Lindane</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"<span class=""chemical"">Lindane</span> (<span class=""chemical"">gamma-hexachlorocyclohexane</span>) is an organochlorine insecticide with known <span class=""disease"">neurotoxic</span> effects."		177.0	177_MESH:D001556_MESH:D020258	177_1	bcv_final_eval_easy_950		
	MESH:D001556	"<span class=""chemical"">lindane</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"We studied the effect of <span class=""chemical"">lindane</span> (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of <span class=""disease"">seizures</span>."		177.0	177_MESH:D001556_MESH:D012640	177_3	bcv_final_eval_easy_951		
	MESH:D005680	"<span class=""chemical"">GABA</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of <span class=""chemical"">GABA</span>, dopamine and its metabolites in 7 brain areas at the onset of <span class=""disease"">seizures</span>."		177.0	177_MESH:D005680_MESH:D012640	177_3	bcv_final_eval_easy_952		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, <span class=""chemical"">dopamine</span> and its metabolites in 7 brain areas at the onset of <span class=""disease"">seizures</span>."		177.0	177_MESH:D004298_MESH:D012640	177_3	bcv_final_eval_easy_953		
	MESH:D001556	"<span class=""chemical"">lindane</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"All animals suffered tonic <span class=""disease"">convulsions</span> at 18.3 +/- 1.4 min after <span class=""chemical"">lindane</span> administration."		177.0	177_MESH:D001556_MESH:D012640	177_4	bcv_final_eval_easy_954		
	MESH:D008713	"<span class=""chemical"">methimazole</span>"	MESH:D056486	"<span class=""disease"">hepatitis</span>"	"Two cases of propylthiouracil-associated acute <span class=""disease"">hepatitis</span>, one case of fatal <span class=""chemical"">methimazole</span>-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described."		178.0	178_MESH:D008713_MESH:D056486	178_1	bcv_final_eval_easy_955		
	MESH:D011441	"<span class=""chemical"">propylthiouracil</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Two cases of <span class=""chemical"">propylthiouracil</span>-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular <span class=""disease"">necrosis</span> and one case of <span class=""chemical"">propylthiouracil</span>-associated lupus-like syndrome are described."		178.0	178_MESH:D011441_MESH:D009336	178_1	bcv_final_eval_easy_956		
	MESH:D008713	"<span class=""chemical"">methimazole</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Two cases of propylthiouracil-associated acute hepatitis, one case of fatal <span class=""chemical"">methimazole</span>-associated hepatocellular <span class=""disease"">necrosis</span> and one case of propylthiouracil-associated lupus-like syndrome are described."		178.0	178_MESH:D008713_MESH:D009336	178_1	bcv_final_eval_easy_957		
	MESH:D008713	"<span class=""chemical"">methimazole</span>"	MESH:D008180	"<span class=""disease"">lupus-like syndrome</span>"	"Two cases of propylthiouracil-associated acute hepatitis, one case of fatal <span class=""chemical"">methimazole</span>-associated hepatocellular necrosis and one case of propylthiouracil-associated <span class=""disease"">lupus-like syndrome</span> are described."		178.0	178_MESH:D008713_MESH:D008180	178_1	bcv_final_eval_easy_958		
	MESH:D011441	"<span class=""chemical"">propylthiouracil</span>"	MESH:D056486	"<span class=""disease"">hepatitis</span>"	"Two cases of <span class=""chemical"">propylthiouracil</span>-associated acute <span class=""disease"">hepatitis</span>, one case of fatal methimazole-associated hepatocellular necrosis and one case of <span class=""chemical"">propylthiouracil</span>-associated lupus-like syndrome are described."		178.0	178_MESH:D011441_MESH:D056486	178_1	bcv_final_eval_easy_959		
	MESH:D011441	"<span class=""chemical"">propylthiouracil</span>"	MESH:D008180	"<span class=""disease"">lupus-like syndrome</span>"	"Two cases of <span class=""chemical"">propylthiouracil</span>-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of <span class=""chemical"">propylthiouracil</span>-associated <span class=""disease"">lupus-like syndrome</span> are described."		178.0	178_MESH:D011441_MESH:D008180	178_1	bcv_final_eval_easy_960		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"Anticonvulsant actions of <span class=""chemical"">MK-801</span> on the lithium-pilocarpine model of <span class=""disease"">status epilepticus</span> in rats."		179.0	179_MESH:D016291_MESH:D013226	179_0	bcv_final_eval_easy_961		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"Anticonvulsant actions of MK-801 on the lithium-<span class=""chemical"">pilocarpine</span> model of <span class=""disease"">status epilepticus</span> in rats."		179.0	179_MESH:D010862_MESH:D013226	179_0	bcv_final_eval_easy_962		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"Anticonvulsant actions of MK-801 on the <span class=""chemical"">lithium</span>-pilocarpine model of <span class=""disease"">status epilepticus</span> in rats."		179.0	179_MESH:D008094_MESH:D013226	179_0	bcv_final_eval_easy_963		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">MK-801</span>, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two <span class=""disease"">seizure</span> models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone."		179.0	179_MESH:D016291_MESH:D012640	179_1	bcv_final_eval_easy_964		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two <span class=""disease"">seizure</span> models, coadministration of lithium and <span class=""chemical"">pilocarpine</span> and administration of a high dose of <span class=""chemical"">pilocarpine</span> alone."		179.0	179_MESH:D010862_MESH:D012640	179_1	bcv_final_eval_easy_965		
	MESH:D016202	"<span class=""chemical"">NMDA/N-methyl-D-aspartate</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"MK-801, a noncompetitive <span class=""chemical"">N-methyl-D-aspartate</span> (<span class=""chemical"">NMDA</span>) receptor antagonist, was tested for anticonvulsant effects in rats using two <span class=""disease"">seizure</span> models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone."		179.0	179_MESH:D016202_MESH:D012640	179_1	bcv_final_eval_easy_966		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two <span class=""disease"">seizure</span> models, coadministration of <span class=""chemical"">lithium</span> and pilocarpine and administration of a high dose of pilocarpine alone."		179.0	179_MESH:D008094_MESH:D012640	179_1	bcv_final_eval_easy_967		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"First, pretreatment with <span class=""chemical"">MK-801</span> produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control <span class=""disease"">seizures</span> in these two models."		179.0	179_MESH:D016291_MESH:D012640	179_3	bcv_final_eval_easy_968		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-<span class=""chemical"">pilocarpine</span> model but not with rats treated with <span class=""chemical"">pilocarpine</span> alone, suggesting that different biochemical mechanisms control <span class=""disease"">seizures</span> in these two models."		179.0	179_MESH:D010862_MESH:D012640	179_3	bcv_final_eval_easy_969		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the <span class=""chemical"">lithium</span>-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control <span class=""disease"">seizures</span> in these two models."		179.0	179_MESH:D008094_MESH:D012640	179_3	bcv_final_eval_easy_970		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Second, the anticonvulsant effect of <span class=""chemical"">MK-801</span> in the lithium-pilocarpine model only occurred after initial periods of <span class=""disease"">seizure</span> activity."		179.0	179_MESH:D016291_MESH:D012640	179_4	bcv_final_eval_easy_971		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Second, the anticonvulsant effect of MK-801 in the lithium-<span class=""chemical"">pilocarpine</span> model only occurred after initial periods of <span class=""disease"">seizure</span> activity."		179.0	179_MESH:D010862_MESH:D012640	179_4	bcv_final_eval_easy_972		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Second, the anticonvulsant effect of MK-801 in the <span class=""chemical"">lithium</span>-pilocarpine model only occurred after initial periods of <span class=""disease"">seizure</span> activity."		179.0	179_MESH:D008094_MESH:D012640	179_4	bcv_final_eval_easy_973		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Third, although it is relatively easy to block <span class=""disease"">seizures</span> induced by <span class=""chemical"">lithium</span> and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the <span class=""disease"">seizures</span>."		179.0	179_MESH:D008094_MESH:D012640	179_6	bcv_final_eval_easy_974		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"Third, although it is relatively easy to block seizures induced by lithium and <span class=""chemical"">pilocarpine</span> by administration of anticonvulsants prior to <span class=""chemical"">pilocarpine</span>, it is more difficult to terminate ongoing <span class=""disease"">status epilepticus</span> and block the lethality of the seizures."		179.0	179_MESH:D010862_MESH:D013226	179_6	bcv_final_eval_easy_975		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Third, although it is relatively easy to block <span class=""disease"">seizures</span> induced by lithium and <span class=""chemical"">pilocarpine</span> by administration of anticonvulsants prior to <span class=""chemical"">pilocarpine</span>, it is more difficult to terminate ongoing status epilepticus and block the lethality of the <span class=""disease"">seizures</span>."		179.0	179_MESH:D010862_MESH:D012640	179_6	bcv_final_eval_easy_976		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"Third, although it is relatively easy to block seizures induced by <span class=""chemical"">lithium</span> and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing <span class=""disease"">status epilepticus</span> and block the lethality of the seizures."		179.0	179_MESH:D008094_MESH:D013226	179_6	bcv_final_eval_easy_977		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Administration of <span class=""chemical"">MK-801</span> 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral <span class=""disease"">seizure</span> activity and greatly enhanced the survival rate."		179.0	179_MESH:D016291_MESH:D012640	179_7	bcv_final_eval_easy_978		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"Administration of MK-801 30 or 60 min after <span class=""chemical"">pilocarpine</span>, i.e., during <span class=""disease"">status epilepticus</span>, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate."		179.0	179_MESH:D010862_MESH:D013226	179_7	bcv_final_eval_easy_979		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Administration of MK-801 30 or 60 min after <span class=""chemical"">pilocarpine</span>, i.e., during status epilepticus, gradually reduced electrical and behavioral <span class=""disease"">seizure</span> activity and greatly enhanced the survival rate."		179.0	179_MESH:D010862_MESH:D012640	179_7	bcv_final_eval_easy_980		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"Administration of <span class=""chemical"">MK-801</span> 30 or 60 min after pilocarpine, i.e., during <span class=""disease"">status epilepticus</span>, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate."		179.0	179_MESH:D016291_MESH:D013226	179_7	bcv_final_eval_easy_981		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"These results suggest that activation of NMDA receptors plays an important role in status epilepticus and <span class=""disease"">brain damage</span> in the <span class=""chemical"">lithium</span>-pilocarpine model."		179.0	179_MESH:D008094_MESH:D001927	179_8	bcv_final_eval_easy_982		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"These results suggest that activation of NMDA receptors plays an important role in status epilepticus and <span class=""disease"">brain damage</span> in the lithium-<span class=""chemical"">pilocarpine</span> model."		179.0	179_MESH:D010862_MESH:D001927	179_8	bcv_final_eval_easy_983		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"These results suggest that activation of NMDA receptors plays an important role in <span class=""disease"">status epilepticus</span> and brain damage in the <span class=""chemical"">lithium</span>-pilocarpine model."		179.0	179_MESH:D008094_MESH:D013226	179_8	bcv_final_eval_easy_984		
	MESH:D016202	"<span class=""chemical"">NMDA</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"These results suggest that activation of <span class=""chemical"">NMDA</span> receptors plays an important role in <span class=""disease"">status epilepticus</span> and brain damage in the lithium-pilocarpine model."		179.0	179_MESH:D016202_MESH:D013226	179_8	bcv_final_eval_easy_985		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"These results suggest that activation of NMDA receptors plays an important role in <span class=""disease"">status epilepticus</span> and brain damage in the lithium-<span class=""chemical"">pilocarpine</span> model."		179.0	179_MESH:D010862_MESH:D013226	179_8	bcv_final_eval_easy_986		
	MESH:D016202	"<span class=""chemical"">NMDA</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"These results suggest that activation of <span class=""chemical"">NMDA</span> receptors plays an important role in status epilepticus and <span class=""disease"">brain damage</span> in the lithium-pilocarpine model."		179.0	179_MESH:D016202_MESH:D001927	179_8	bcv_final_eval_easy_987		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"This was further supported by results showing that nonconvulsive doses of NMDA and <span class=""chemical"">pilocarpine</span> were synergistic, resulting in <span class=""disease"">status epilepticus</span> and subsequent mortality."		179.0	179_MESH:D010862_MESH:D013226	179_9	bcv_final_eval_easy_988		
	MESH:D016202	"<span class=""chemical"">NMDA</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"This was further supported by results showing that nonconvulsive doses of <span class=""chemical"">NMDA</span> and pilocarpine were synergistic, resulting in <span class=""disease"">status epilepticus</span> and subsequent mortality."		179.0	179_MESH:D016202_MESH:D013226	179_9	bcv_final_eval_easy_989		
	MESH:D009543	"<span class=""chemical"">Nifedipine</span>"	MESH:D001342	"<span class=""disease"">autonomic neuropathy</span>"	"<span class=""chemical"">Nifedipine</span> induced bradycardia in a patient with <span class=""disease"">autonomic neuropathy</span>."		180.0	180_MESH:D009543_MESH:D001342	180_0	bcv_final_eval_easy_990		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D001282	"<span class=""disease"">atrial flutter</span>"	"He was found to have <span class=""disease"">atrial flutter</span> at a ventricular rate of 70/min which slowed down to 30-40/min when <span class=""chemical"">nifedipine</span> (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min."		180.0	180_MESH:D009543_MESH:D001282	180_2	bcv_final_eval_easy_991		
	MESH:D000661	"<span class=""chemical"">amphetamine</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"In this model, toxic effects were induced by intraperitoneal (i.p.) injection of <span class=""chemical"">amphetamine</span> 75 mg/kg (100% <span class=""disease"">death</span> rate) or cocaine 70 mg/kg (82% <span class=""disease"">death</span> rate)."		181.0	181_MESH:D000661_MESH:D003643	181_2	bcv_final_eval_easy_992		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"In this model, toxic effects were induced by intraperitoneal (i.p.) injection of amphetamine 75 mg/kg (100% <span class=""disease"">death</span> rate) or <span class=""chemical"">cocaine</span> 70 mg/kg (82% <span class=""disease"">death</span> rate)."		181.0	181_MESH:D003042_MESH:D003643	181_2	bcv_final_eval_easy_993		
	MESH:D006220	"<span class=""chemical"">Haloperidol</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"<span class=""chemical"">Haloperidol</span> failed to prevent amphetamine-induced <span class=""disease"">seizures</span>, but did lower the mortality rate at most doses tested."		181.0	181_MESH:D006220_MESH:D012640	181_3	bcv_final_eval_easy_994		
	MESH:D006220	"<span class=""chemical"">Haloperidol</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"<span class=""chemical"">Haloperidol</span> decreased the incidence of cocaine-induced <span class=""disease"">seizures</span> at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose."		181.0	181_MESH:D006220_MESH:D012640	181_4	bcv_final_eval_easy_995		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"These data suggest a protective role for the central <span class=""chemical"">dopamine</span> blocker haloperidol against <span class=""disease"">death</span> from high-dose amphetamine exposure without reducing the incidence of seizures."		181.0	181_MESH:D004298_MESH:D003643	181_5	bcv_final_eval_easy_996		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"These data suggest a protective role for the central dopamine blocker <span class=""chemical"">haloperidol</span> against death from high-dose amphetamine exposure without reducing the incidence of <span class=""disease"">seizures</span>."		181.0	181_MESH:D006220_MESH:D012640	181_5	bcv_final_eval_easy_997		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"These data suggest a protective role for the central <span class=""chemical"">dopamine</span> blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of <span class=""disease"">seizures</span>."		181.0	181_MESH:D004298_MESH:D012640	181_5	bcv_final_eval_easy_998		
	MESH:D000661	"<span class=""chemical"">amphetamine</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"These data suggest a protective role for the central dopamine blocker haloperidol against <span class=""disease"">death</span> from high-dose <span class=""chemical"">amphetamine</span> exposure without reducing the incidence of seizures."		181.0	181_MESH:D000661_MESH:D003643	181_5	bcv_final_eval_easy_999		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"These data suggest a protective role for the central dopamine blocker <span class=""chemical"">haloperidol</span> against <span class=""disease"">death</span> from high-dose amphetamine exposure without reducing the incidence of seizures."		181.0	181_MESH:D006220_MESH:D003643	181_5	bcv_final_eval_easy_1000		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"In contrast, <span class=""chemical"">haloperidol</span> demonstrated an ability to reduce cocaine-induced <span class=""disease"">seizures</span> without significantly reducing mortality."		181.0	181_MESH:D006220_MESH:D012640	181_6	bcv_final_eval_easy_1001		
	MESH:D004967	"<span class=""chemical"">estrogen</span>"	MESH:D007674	"<span class=""disease"">renal carcinomas</span>"	"Autoradiographic evidence of <span class=""chemical"">estrogen</span> binding sites in nuclei of diethylstilbesterol induced hamster <span class=""disease"">renal carcinomas</span>."		182.0	182_MESH:D004967_MESH:D007674	182_0	bcv_final_eval_easy_1002		
	MESH:D004967	"<span class=""chemical"">Estrogen</span>"	MESH:D007674	"<span class=""disease"">renal carcinomas</span>"	"<span class=""chemical"">Estrogen</span> binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced <span class=""disease"">renal carcinomas</span> in three hamsters."		182.0	182_MESH:D004967_MESH:D007674	182_1	bcv_final_eval_easy_1003		
	MESH:D012834	"<span class=""chemical"">silver</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of <span class=""disease"">tumor</span> cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced <span class=""chemical"">silver</span> grains over nuclei than cytoplasm of these cells."		182.0	182_MESH:D012834_MESH:D009369	182_2	bcv_final_eval_easy_1004		
	MESH:D004967	"<span class=""chemical"">estrogen</span>"	MESH:D007674	"<span class=""disease"">renal carcinomas</span>"	"This is the first published report documenting the preferential in vivo binding of <span class=""chemical"">estrogen</span> to nuclei of cells in <span class=""chemical"">estrogen</span> induced hamster <span class=""disease"">renal carcinomas</span>."		182.0	182_MESH:D004967_MESH:D007674	182_4	bcv_final_eval_easy_1005		
	MESH:C036432	"<span class=""chemical"">biperiden lactate</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg <span class=""chemical"">biperiden lactate</span> led to a long-lasting paradoxical reaction characterized by considerable <span class=""disease"">bradycardia</span>, dysarthria, and dysphagia."		183.0	183_MESH:C036432_MESH:D001919	183_1	bcv_final_eval_easy_1006		
	MESH:C036432	"<span class=""chemical"">biperiden lactate</span>"	MESH:D014277	"<span class=""disease"">postzosteric trigeminal neuralgia</span>"	"In a 38-year-old male patient suffering from a severe <span class=""disease"">postzosteric trigeminal neuralgia</span>, intravenous application of 10 mg <span class=""chemical"">biperiden lactate</span> led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia."		183.0	183_MESH:C036432_MESH:D014277	183_1	bcv_final_eval_easy_1007		
	MESH:C036432	"<span class=""chemical"">biperiden lactate</span>"	MESH:D003680	"<span class=""disease"">dysphagia</span>"	"In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg <span class=""chemical"">biperiden lactate</span> led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and <span class=""disease"">dysphagia</span>."		183.0	183_MESH:C036432_MESH:D003680	183_1	bcv_final_eval_easy_1008		
	MESH:C036432	"<span class=""chemical"">biperiden lactate</span>"	MESH:D004401	"<span class=""disease"">dysarthria</span>"	"In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg <span class=""chemical"">biperiden lactate</span> led to a long-lasting paradoxical reaction characterized by considerable bradycardia, <span class=""disease"">dysarthria</span>, and dysphagia."		183.0	183_MESH:C036432_MESH:D004401	183_1	bcv_final_eval_easy_1009		
	MESH:D001285	"<span class=""chemical"">atropine</span>"	MESH:D001919	"<span class=""disease"">Bradycardia</span>"	"<span class=""disease"">Bradycardia</span> induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of <span class=""chemical"">atropine</span>-like drugs on muscarine receptors."		183.0	183_MESH:D001285_MESH:D001919	183_3	bcv_final_eval_easy_1010		
	MESH:D001712	"<span class=""chemical"">biperiden</span>"	MESH:D001919	"<span class=""disease"">Bradycardia</span>"	"<span class=""disease"">Bradycardia</span> induced by <span class=""chemical"">biperiden</span> is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors."		183.0	183_MESH:D001712_MESH:D001919	183_3	bcv_final_eval_easy_1011		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Deliberate <span class=""disease"">hypotension</span> induced by labetalol with <span class=""chemical"">halothane</span>, enflurane or isoflurane for middle-ear surgery."		184.0	184_MESH:D006221_MESH:D007022	184_0	bcv_final_eval_easy_1012		
	MESH:D007741	"<span class=""chemical"">labetalol</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Deliberate <span class=""disease"">hypotension</span> induced by <span class=""chemical"">labetalol</span> with halothane, enflurane or isoflurane for middle-ear surgery."		184.0	184_MESH:D007741_MESH:D007022	184_0	bcv_final_eval_easy_1013		
	MESH:D007530	"<span class=""chemical"">isoflurane</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Deliberate <span class=""disease"">hypotension</span> induced by labetalol with halothane, enflurane or <span class=""chemical"">isoflurane</span> for middle-ear surgery."		184.0	184_MESH:D007530_MESH:D007022	184_0	bcv_final_eval_easy_1014		
	MESH:D004737	"<span class=""chemical"">enflurane</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Deliberate <span class=""disease"">hypotension</span> induced by labetalol with halothane, <span class=""chemical"">enflurane</span> or isoflurane for middle-ear surgery."		184.0	184_MESH:D004737_MESH:D007022	184_0	bcv_final_eval_easy_1015		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a <span class=""disease"">hypotensive</span> agent in combination with inhalation anaesthetics (<span class=""chemical"">halothane</span>, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery."		184.0	184_MESH:D006221_MESH:D007022	184_1	bcv_final_eval_easy_1016		
	MESH:D007741	"<span class=""chemical"">labetalol</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"The feasibility of using <span class=""chemical"">labetalol</span>, an alpha- and beta-adrenergic blocking agent, as a <span class=""disease"">hypotensive</span> agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery."		184.0	184_MESH:D007741_MESH:D007022	184_1	bcv_final_eval_easy_1017		
	MESH:D007530	"<span class=""chemical"">isoflurane</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a <span class=""disease"">hypotensive</span> agent in combination with inhalation anaesthetics (halothane, enflurane or <span class=""chemical"">isoflurane</span>) was studied in 23 adult patients undergoing middle-ear surgery."		184.0	184_MESH:D007530_MESH:D007022	184_1	bcv_final_eval_easy_1018		
	MESH:D004737	"<span class=""chemical"">enflurane</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a <span class=""disease"">hypotensive</span> agent in combination with inhalation anaesthetics (halothane, <span class=""chemical"">enflurane</span> or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery."		184.0	184_MESH:D004737_MESH:D007022	184_1	bcv_final_eval_easy_1019		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"During <span class=""disease"">hypotension</span>, the serum <span class=""chemical"">creatinine</span> concentration rose significantly in all groups from the values before <span class=""disease"">hypotension</span> and returned postoperatively to the initial level in the other groups, except the isoflurane group."		184.0	184_MESH:D003404_MESH:D007022	184_8	bcv_final_eval_easy_1020		
	MESH:D007530	"<span class=""chemical"">isoflurane</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"During <span class=""disease"">hypotension</span>, the serum creatinine concentration rose significantly in all groups from the values before <span class=""disease"">hypotension</span> and returned postoperatively to the initial level in the other groups, except the <span class=""chemical"">isoflurane</span> group."		184.0	184_MESH:D007530_MESH:D007022	184_8	bcv_final_eval_easy_1021		
	MESH:D007741	"<span class=""chemical"">labetalol</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"These results indicate that <span class=""chemical"">labetalol</span> induces easily adjustable <span class=""disease"">hypotension</span> without compensatory tachycardia and rebound hypertension."		184.0	184_MESH:D007741_MESH:D007022	184_10	bcv_final_eval_easy_1022		
	MESH:D007741	"<span class=""chemical"">labetalol</span>"	MESH:D013610	"<span class=""disease"">compensatory tachycardia</span>"	"These results indicate that <span class=""chemical"">labetalol</span> induces easily adjustable hypotension without <span class=""disease"">compensatory tachycardia</span> and rebound hypertension."		184.0	184_MESH:D007741_MESH:D013610	184_10	bcv_final_eval_easy_1023		
	MESH:D007741	"<span class=""chemical"">labetalol</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"These results indicate that <span class=""chemical"">labetalol</span> induces easily adjustable hypotension without compensatory tachycardia and rebound <span class=""disease"">hypertension</span>."		184.0	184_MESH:D007741_MESH:D006973	184_10	bcv_final_eval_easy_1024		
	MESH:D019793	"<span class=""chemical"">fluorescein</span>"	MESH:D012640	"<span class=""disease"">Convulsion</span>"	"<span class=""disease"">Convulsion</span> following intravenous <span class=""chemical"">fluorescein</span> angiography."		185.0	185_MESH:D019793_MESH:D012640	185_0	bcv_final_eval_easy_1025		
	MESH:D019793	"<span class=""chemical"">fluorescein</span>"	MESH:D012640	"<span class=""disease"">Tonic-clonic seizures</span>"	"<span class=""disease"">Tonic-clonic seizures</span> followed intravenous <span class=""chemical"">fluorescein</span> injection for fundus angiography in a 47-year-old male."		185.0	185_MESH:D019793_MESH:D012640	185_1	bcv_final_eval_easy_1026		
	MESH:C043114	"<span class=""chemical"">ACC-9653</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"<span class=""chemical"">ACC-9653</span> and phenytoin sodium have equivalent anticonvulsant activity against <span class=""disease"">seizures</span> induced by maximal electroshock (MES) in mice following i.p., oral, or i.v. administration."		186.0	186_MESH:C043114_MESH:D012640	186_3	bcv_final_eval_easy_1027		
	MESH:C043114	"<span class=""chemical"">ACC-9653</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"<span class=""chemical"">ACC-9653</span> and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced <span class=""disease"">ventricular tachycardia</span> in anesthetized dogs."		186.0	186_MESH:C043114_MESH:D017180	186_6	bcv_final_eval_easy_1028		
	MESH:C043114	"<span class=""chemical"">ACC-9653</span>"	MESH:D001145	"<span class=""disease"">arrhythmia</span>"	"The total doses of <span class=""chemical"">ACC-9653</span> or phenytoin sodium necessary to convert the <span class=""disease"">arrhythmia</span> to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively."		186.0	186_MESH:C043114_MESH:D001145	186_7	bcv_final_eval_easy_1029		
	MESH:C043114	"<span class=""chemical"">ACC-9653</span>"	MESH:D007022	"<span class=""disease"">reductions in diastolic blood pressure</span>"	"The <span class=""chemical"">ACC-9653</span> and phenytoin sodium treatments produced similar marked <span class=""disease"">reductions in diastolic blood pressure</span> and contractile force (LVdP/dt)."		186.0	186_MESH:C043114_MESH:D007022	186_10	bcv_final_eval_easy_1030		
	MESH:C043114	"<span class=""chemical"">ACC-9653</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Acute <span class=""disease"">toxicity</span> studies of <span class=""chemical"">ACC-9653</span> and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i.v., i.m., and i.p. routes of administration."		186.0	186_MESH:C043114_MESH:D064420	186_12	bcv_final_eval_easy_1031		
	MESH:D010672	"<span class=""chemical"">phenytoin</span>"	MESH:D017093	"<span class=""disease"">hepatic failure</span>"	"A 61 year old female developed fatal <span class=""disease"">hepatic failure</span> after <span class=""chemical"">phenytoin</span> administration."		187.0	187_MESH:D010672_MESH:D017093	187_1	bcv_final_eval_easy_1032		
	MESH:D006632	"<span class=""chemical"">histamine</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"Blockade of <span class=""chemical"">histamine</span> H1 receptors may reduce mortality in pertussis immunization-induced <span class=""disease"">encephalopathy</span> in mice."		188.0	188_MESH:D006632_MESH:D001927	188_4	bcv_final_eval_easy_1033		
	MESH:D004837	"<span class=""chemical"">adrenaline</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Support for <span class=""chemical"">adrenaline</span>-<span class=""disease"">hypertension</span> hypothesis: 18 hour pressor effect after 6 hours <span class=""chemical"">adrenaline</span> infusion."		189.0	189_MESH:D004837_MESH:D006973	189_0	bcv_final_eval_easy_1034		
	MESH:D004837	"<span class=""chemical"">adrenaline</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"These findings are strong support for the <span class=""chemical"">adrenaline</span>-<span class=""disease"">hypertension</span> hypothesis in man."		189.0	189_MESH:D004837_MESH:D006973	189_6	bcv_final_eval_easy_1035		
	MESH:D000241	"<span class=""chemical"">Adenosine</span>"	MESH:D058186	"<span class=""disease"">acute renal failure/ARF</span>"	"<span class=""chemical"">Adenosine</span> antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of <span class=""disease"">acute renal failure</span> (<span class=""disease"">ARF</span>)."		190.0	190_MESH:D000241_MESH:D058186	190_1	bcv_final_eval_easy_1036		
	MESH:C028322	"<span class=""chemical"">8-phenyltheophylline</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists <span class=""chemical"">8-phenyltheophylline</span>, theophylline and enprofylline, were examined in rats developing <span class=""disease"">acute renal failure</span> after 4 daily injections of gentamicin (200 mg kg-1)."		190.0	190_MESH:C028322_MESH:D058186	190_2	bcv_final_eval_easy_1037		
	MESH:C034347	"<span class=""chemical"">enprofylline</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and <span class=""chemical"">enprofylline</span>, were examined in rats developing <span class=""disease"">acute renal failure</span> after 4 daily injections of gentamicin (200 mg kg-1)."		190.0	190_MESH:C034347_MESH:D058186	190_2	bcv_final_eval_easy_1038		
	MESH:D000241	"<span class=""chemical"">adenosine</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"In the present study, the effects of three alkylxanthines with different potencies as <span class=""chemical"">adenosine</span> antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing <span class=""disease"">acute renal failure</span> after 4 daily injections of gentamicin (200 mg kg-1)."		190.0	190_MESH:D000241_MESH:D058186	190_2	bcv_final_eval_easy_1039		
	MESH:D013806	"<span class=""chemical"">theophylline</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, <span class=""chemical"">theophylline</span> and enprofylline, were examined in rats developing <span class=""disease"">acute renal failure</span> after 4 daily injections of gentamicin (200 mg kg-1)."		190.0	190_MESH:D013806_MESH:D058186	190_2	bcv_final_eval_easy_1040		
	MESH:D014508	"<span class=""chemical"">urea</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Renal function was assessed by biochemical (plasma <span class=""chemical"">urea</span> and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of <span class=""disease"">necrosis</span>) indices."		190.0	190_MESH:D014508_MESH:D009336	190_3	bcv_final_eval_easy_1041		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Renal function was assessed by biochemical (plasma urea and <span class=""chemical"">creatinine</span>), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of <span class=""disease"">necrosis</span>) indices."		190.0	190_MESH:D003404_MESH:D009336	190_3	bcv_final_eval_easy_1042		
	MESH:D000241	"<span class=""chemical"">adenosine</span>"	MESH:D058186	"<span class=""disease"">ARF</span>"	"The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that <span class=""chemical"">adenosine</span> plays little, if any, pathophysiological role in gentamicin-induced <span class=""disease"">ARF</span>."		190.0	190_MESH:D000241_MESH:D058186	190_6	bcv_final_eval_easy_1043		
	MESH:D015474	"<span class=""chemical"">Isotretinoin</span>"	MESH:D000013	"<span class=""disease"">congenital abnormalities</span>"	"<span class=""chemical"">Isotretinoin</span> is contraindicated in pregnancy because of the many reported <span class=""disease"">congenital abnormalities</span> after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)."		191.0	191_MESH:D015474_MESH:D000013	191_5	bcv_final_eval_easy_1044		
	MESH:D015474	"<span class=""chemical"">Isotretinoin</span>"	MESH:D009901	"<span class=""disease"">optic nerve hypoplasia</span>"	"<span class=""chemical"">Isotretinoin</span> is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and <span class=""disease"">optic nerve hypoplasia</span>)."		191.0	191_MESH:D015474_MESH:D009901	191_5	bcv_final_eval_easy_1045		
	MESH:D015474	"<span class=""chemical"">Isotretinoin</span>"	MESH:D009916	"<span class=""disease"">microphthalmos, orbital hypertelorism</span>"	"<span class=""chemical"">Isotretinoin</span> is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including <span class=""disease"">microphthalmos, orbital hypertelorism</span>, and optic nerve hypoplasia)."		191.0	191_MESH:D015474_MESH:D009916	191_5	bcv_final_eval_easy_1046		
	MESH:D017265	"<span class=""chemical"">Procaterol</span>"	MESH:D001249	"<span class=""disease"">bronchial asthma</span>"	"<span class=""chemical"">Procaterol</span> and terbutaline in <span class=""disease"">bronchial asthma</span>. A double-blind, placebo-controlled, cross-over study."		192.0	192_MESH:D017265_MESH:D001249	192_0	bcv_final_eval_easy_1047		
	MESH:D013726	"<span class=""chemical"">terbutaline</span>"	MESH:D001249	"<span class=""disease"">bronchial asthma</span>"	"Procaterol and <span class=""chemical"">terbutaline</span> in <span class=""disease"">bronchial asthma</span>. A double-blind, placebo-controlled, cross-over study."		192.0	192_MESH:D013726_MESH:D001249	192_0	bcv_final_eval_easy_1048		
	MESH:D017265	"<span class=""chemical"">Procaterol</span>"	MESH:D001249	"<span class=""disease"">bronchial asthma</span>"	"<span class=""chemical"">Procaterol</span>, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with <span class=""disease"">bronchial asthma</span>."		192.0	192_MESH:D017265_MESH:D001249	192_1	bcv_final_eval_easy_1049		
	MESH:D017265	"<span class=""chemical"">procaterol</span>"	MESH:D013224	"<span class=""disease"">asthmatic</span>"	"Both anti-<span class=""disease"">asthmatic</span> and tremorgenic effects of <span class=""chemical"">procaterol</span> were dose-related."		192.0	192_MESH:D017265_MESH:D013224	192_4	bcv_final_eval_easy_1050		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D006332	"<span class=""disease"">heart hypertrophy</span>"	"Subacute effects of <span class=""chemical"">propranolol</span> and B 24/76 on isoproterenol-induced rat <span class=""disease"">heart hypertrophy</span> in correlation with blood pressure."		193.0	193_MESH:D011433_MESH:D006332	193_0	bcv_final_eval_easy_1051		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D006984	"<span class=""disease"">hypertrophied</span>"	"Neither <span class=""chemical"">propranolol</span> nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the <span class=""disease"">hypertrophied</span> rat heart."		193.0	193_MESH:D011433_MESH:D006984	193_7	bcv_final_eval_easy_1052		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D006332	"<span class=""disease"">heart hypertrophy</span>"	"Thus, the investigations did not provide any evidence that the beta-receptor blockers <span class=""chemical"">propranolol</span> and B 24/76 have the potency to prevent isoproterenol from producing <span class=""disease"">heart hypertrophy</span>."		193.0	193_MESH:D011433_MESH:D006332	193_8	bcv_final_eval_easy_1053		
	MESH:C017590	"<span class=""chemical"">oxitropium</span>"	MESH:D014202	"<span class=""disease"">tremors</span>"	"No subject reported side effects of <span class=""chemical"">oxitropium</span>, as compared to three subjects reporting nausea, vomiting and <span class=""disease"">tremors</span> after theophylline."		194.0	194_MESH:C017590_MESH:D014202	194_6	bcv_final_eval_easy_1054		
	MESH:C017590	"<span class=""chemical"">oxitropium</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"No subject reported side effects of <span class=""chemical"">oxitropium</span>, as compared to three subjects reporting <span class=""disease"">nausea</span>, vomiting and tremors after theophylline."		194.0	194_MESH:C017590_MESH:D009325	194_6	bcv_final_eval_easy_1055		
	MESH:C017590	"<span class=""chemical"">oxitropium</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"No subject reported side effects of <span class=""chemical"">oxitropium</span>, as compared to three subjects reporting nausea, <span class=""disease"">vomiting</span> and tremors after theophylline."		194.0	194_MESH:C017590_MESH:D014839	194_6	bcv_final_eval_easy_1056		
	MESH:D013806	"<span class=""chemical"">theophylline</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"No subject reported side effects of oxitropium, as compared to three subjects reporting <span class=""disease"">nausea</span>, vomiting and tremors after <span class=""chemical"">theophylline</span>."		194.0	194_MESH:D013806_MESH:D009325	194_6	bcv_final_eval_easy_1057		
	MESH:D013806	"<span class=""chemical"">theophylline</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, <span class=""disease"">vomiting</span> and tremors after <span class=""chemical"">theophylline</span>."		194.0	194_MESH:D013806_MESH:D014839	194_6	bcv_final_eval_easy_1058		
	MESH:D013806	"<span class=""chemical"">theophylline</span>"	MESH:D014202	"<span class=""disease"">tremors</span>"	"No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and <span class=""disease"">tremors</span> after <span class=""chemical"">theophylline</span>."		194.0	194_MESH:D013806_MESH:D014202	194_6	bcv_final_eval_easy_1059		
	MESH:D010406	"<span class=""chemical"">Penicillin</span>"	MESH:D000707	"<span class=""disease"">anaphylaxis</span>"	"<span class=""chemical"">Penicillin</span> <span class=""disease"">anaphylaxis</span>."		195.0	195_MESH:D010406_MESH:D000707	195_0	bcv_final_eval_easy_1060		
	MESH:D010406	"<span class=""chemical"">penicillin</span>"	MESH:D000707	"<span class=""disease"">anaphylaxis</span>"	"A case of oral <span class=""chemical"">penicillin</span> <span class=""disease"">anaphylaxis</span> is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of <span class=""disease"">anaphylaxis</span> are reviewed."		195.0	195_MESH:D010406_MESH:D000707	195_1	bcv_final_eval_easy_1061		
	MESH:D010406	"<span class=""chemical"">penicillin</span>"	MESH:D000707	"<span class=""disease"">anaphylaxis</span>"	"Emergency physicians should be aware of oral <span class=""chemical"">penicillin</span> <span class=""disease"">anaphylaxis</span> in order to prevent its occurrence by prescribing the antibiotic judiciously and knowledgeably and to offer optimal medical therapy once this life-threatening reaction has begun."		195.0	195_MESH:D010406_MESH:D000707	195_2	bcv_final_eval_easy_1062		
	MESH:D014635	"<span class=""chemical"">valproic acid</span>"	MESH:D003072	"<span class=""disease"">decline in global cognitive abilities</span>"	"Reversible <span class=""chemical"">valproic acid</span>-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive <span class=""disease"">decline in global cognitive abilities</span> documented by serial neuropsychological studies."		196.0	196_MESH:D014635_MESH:D003072	196_1	bcv_final_eval_easy_1063		
	MESH:D014635	"<span class=""chemical"">valproic acid</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"Reversible <span class=""chemical"">valproic acid</span>-induced dementia was documented in a 21-year-old man with <span class=""disease"">epilepsy</span> who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies."		196.0	196_MESH:D014635_MESH:D004827	196_1	bcv_final_eval_easy_1064		
	MESH:D009270	"<span class=""chemical"">naloxone</span>"	MESH:D000647	"<span class=""disease"">amnesia</span>"	"Reversal of scopolamine-induced <span class=""disease"">amnesia</span> of passive avoidance by pre- and post-training <span class=""chemical"">naloxone</span>."		197.0	197_MESH:D009270_MESH:D000647	197_0	bcv_final_eval_easy_1065		
	MESH:D009270	"<span class=""chemical"">naloxone</span>"	MESH:D016055	"<span class=""disease"">retention deficit</span>"	"In a series of five experiments, the modulating role of <span class=""chemical"">naloxone</span> on a scopolamine-induced <span class=""disease"">retention deficit</span> in a passive avoidance paradigm was investigated in mice."		197.0	197_MESH:D009270_MESH:D016055	197_1	bcv_final_eval_easy_1066		
	MESH:D009270	"<span class=""chemical"">Naloxone</span>"	MESH:D016055	"<span class=""disease"">retention deficit</span>"	"<span class=""chemical"">Naloxone</span> (0.3, 1, 3, and 10 mg/kg) injected prior to training attenuated the <span class=""disease"">retention deficit</span> with a peak of activity at 3 mg/kg."		197.0	197_MESH:D009270_MESH:D016055	197_3	bcv_final_eval_easy_1067		
	MESH:D009270	"<span class=""chemical"">naloxone</span>"	MESH:D000647	"<span class=""disease"">amnesia</span>"	"Post-training administration of <span class=""chemical"">naloxone</span> (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced <span class=""disease"">amnesia</span>."		197.0	197_MESH:D009270_MESH:D000647	197_5	bcv_final_eval_easy_1068		
	MESH:D009270	"<span class=""chemical"">naloxone</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"Control experiments indicated that neither an increase in <span class=""disease"">pain</span> sensitivity (pre-training <span class=""chemical"">naloxone</span>) nor an induced aversive state (post-training <span class=""chemical"">naloxone</span>) appear to be responsible for the influence of <span class=""chemical"">naloxone</span> on the scopolamine-induced retention deficit."		197.0	197_MESH:D009270_MESH:D010146	197_6	bcv_final_eval_easy_1069		
	MESH:D009270	"<span class=""chemical"">naloxone</span>"	MESH:D016055	"<span class=""disease"">retention deficit</span>"	"Control experiments indicated that neither an increase in pain sensitivity (pre-training <span class=""chemical"">naloxone</span>) nor an induced aversive state (post-training <span class=""chemical"">naloxone</span>) appear to be responsible for the influence of <span class=""chemical"">naloxone</span> on the scopolamine-induced <span class=""disease"">retention deficit</span>."		197.0	197_MESH:D009270_MESH:D016055	197_6	bcv_final_eval_easy_1070		
	MESH:D012601	"<span class=""chemical"">scopolamine</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"Control experiments indicated that neither an increase in <span class=""disease"">pain</span> sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the <span class=""chemical"">scopolamine</span>-induced retention deficit."		197.0	197_MESH:D012601_MESH:D010146	197_6	bcv_final_eval_easy_1071		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D004487	"<span class=""disease"">submucosal edema</span>"	"Fully developed <span class=""chemical"">cyclophosphamide</span>-induced cystitis is characterized by nearly complete detachment of the urothelium, severe <span class=""disease"">submucosal edema</span> owing to damage to the microvascular bed and focal muscle necroses."		198.0	198_MESH:D003520_MESH:D004487	198_1	bcv_final_eval_easy_1072		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D009135	"<span class=""disease"">muscle necroses</span>"	"Fully developed <span class=""chemical"">cyclophosphamide</span>-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal <span class=""disease"">muscle necroses</span>."		198.0	198_MESH:D003520_MESH:D009135	198_1	bcv_final_eval_easy_1073		
	MESH:D015760	"<span class=""chemical"">alfentanil</span>"	MESH:D005207	"<span class=""disease"">muscle fasciculations</span>"	"Increase in intragastric pressure during suxamethonium-induced <span class=""disease"">muscle fasciculations</span> in children: inhibition by <span class=""chemical"">alfentanil</span>."		199.0	199_MESH:D015760_MESH:D005207	199_0	bcv_final_eval_easy_1074		
	MESH:D015760	"<span class=""chemical"">alfentanil</span>"	MESH:D005207	"<span class=""disease"">muscle fasciculations</span>"	"The incidence and intensity of <span class=""disease"">muscle fasciculations</span> caused by suxamethonium were significantly greater in the control than in the <span class=""chemical"">alfentanil</span> group."		199.0	199_MESH:D015760_MESH:D005207	199_3	bcv_final_eval_easy_1075		
	MESH:D015760	"<span class=""chemical"">alfentanil</span>"	MESH:D005207	"<span class=""disease"">muscle fasciculations</span>"	"The intragastric pressure during <span class=""disease"">muscle fasciculations</span> was significantly higher in the control group (16 +/- 0.7 (SEM) cm H2O) than in the <span class=""chemical"">alfentanil</span> group (7.7 +/- 1.5 (SEM) cm H2O)."		199.0	199_MESH:D015760_MESH:D005207	199_4	bcv_final_eval_easy_1076		
	MESH:D014867	"<span class=""chemical"">H2O</span>"	MESH:D005207	"<span class=""disease"">muscle fasciculations</span>"	"The intragastric pressure during <span class=""disease"">muscle fasciculations</span> was significantly higher in the control group (16 +/- 0.7 (SEM) cm <span class=""chemical"">H2O</span>) than in the alfentanil group (7.7 +/- 1.5 (SEM) cm <span class=""chemical"">H2O</span>)."		199.0	199_MESH:D014867_MESH:D005207	199_4	bcv_final_eval_easy_1077		
	MESH:D015760	"<span class=""chemical"">Alfentanil</span>"	MESH:D005207	"<span class=""disease"">muscle fasciculations</span>"	"<span class=""chemical"">Alfentanil</span> 50 micrograms kg-1 effectively inhibits the incidence and intensity of suxamethonium-induced <span class=""disease"">muscle fasciculations</span>; moreover, intragastric pressure remains at its control value."		199.0	199_MESH:D015760_MESH:D005207	199_7	bcv_final_eval_easy_1078		
	MESH:D013311	"<span class=""chemical"">streptozotocin</span>"	MESH:D009202	"<span class=""disease"">myocardial fibrosis</span>"	"Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in <span class=""chemical"">streptozotocin</span> diabetic rats. A morphometric study of isoproterenol induced <span class=""disease"">myocardial fibrosis</span>."		200.0	200_MESH:D013311_MESH:D009202	200_0	bcv_final_eval_easy_1079		
	MESH:D013311	"<span class=""chemical"">streptozotocin</span>"	MESH:D003920	"<span class=""disease"">diabetic</span>"	"Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in <span class=""chemical"">streptozotocin</span> <span class=""disease"">diabetic</span> rats. A morphometric study of isoproterenol induced myocardial fibrosis."		200.0	200_MESH:D013311_MESH:D003920	200_0	bcv_final_eval_easy_1080		
	MESH:D013311	"<span class=""chemical"">streptozotocin</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"Acute insulin treatment normalizes the resistance to the <span class=""disease"">cardiotoxic</span> effect of isoproterenol in <span class=""chemical"">streptozotocin</span> diabetic rats. A morphometric study of isoproterenol induced myocardial fibrosis."		200.0	200_MESH:D013311_MESH:D066126	200_0	bcv_final_eval_easy_1081		
	MESH:D007545	"<span class=""chemical"">isoproterenol</span>"	MESH:D003920	"<span class=""disease"">diabetic</span>"	"Acute insulin treatment normalizes the resistance to the cardiotoxic effect of <span class=""chemical"">isoproterenol</span> in streptozotocin <span class=""disease"">diabetic</span> rats. A morphometric study of <span class=""chemical"">isoproterenol</span> induced myocardial fibrosis."		200.0	200_MESH:D007545_MESH:D003920	200_0	bcv_final_eval_easy_1082		
	MESH:D007545	"<span class=""chemical"">isoproterenol</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"Acute insulin treatment normalizes the resistance to the <span class=""disease"">cardiotoxic</span> effect of <span class=""chemical"">isoproterenol</span> in streptozotocin diabetic rats. A morphometric study of <span class=""chemical"">isoproterenol</span> induced myocardial fibrosis."		200.0	200_MESH:D007545_MESH:D066126	200_0	bcv_final_eval_easy_1083		
	MESH:D013311	"<span class=""chemical"">streptozotocin</span>"	MESH:D003920	"<span class=""disease"">diabetes against</span>"	"The acute effect of insulin treatment on the earlier reported protective effect of <span class=""chemical"">streptozotocin</span> <span class=""disease"">diabetes against</span> the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats."		200.0	200_MESH:D013311_MESH:D003920	200_1	bcv_final_eval_easy_1084		
	MESH:D013311	"<span class=""chemical"">streptozotocin</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"The acute effect of insulin treatment on the earlier reported protective effect of <span class=""chemical"">streptozotocin</span> diabetes against the <span class=""disease"">cardiotoxic</span> effect of high doses of isoproterenol (ISO) was investigated in rats."		200.0	200_MESH:D013311_MESH:D066126	200_1	bcv_final_eval_easy_1085		
	MESH:D007545	"<span class=""chemical"">isoproterenol/ISO</span>"	MESH:D003920	"<span class=""disease"">diabetes against</span>"	"The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin <span class=""disease"">diabetes against</span> the cardiotoxic effect of high doses of <span class=""chemical"">isoproterenol</span> (<span class=""chemical"">ISO</span>) was investigated in rats."		200.0	200_MESH:D007545_MESH:D003920	200_1	bcv_final_eval_easy_1086		
	MESH:D007545	"<span class=""chemical"">isoproterenol/ISO</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the <span class=""disease"">cardiotoxic</span> effect of high doses of <span class=""chemical"">isoproterenol</span> (<span class=""chemical"">ISO</span>) was investigated in rats."		200.0	200_MESH:D007545_MESH:D066126	200_1	bcv_final_eval_easy_1087		
	MESH:D007545	"<span class=""chemical"">ISO</span>"	MESH:D006402	"<span class=""disease"">blood glucose</span>"	"Thirty to 135 min after the injection of crystalline insulin, <span class=""chemical"">ISO</span> was given subcutaneously and when <span class=""chemical"">ISO</span> induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in <span class=""disease"">blood glucose</span> after insulin treatment appeared."		200.0	200_MESH:D007545_MESH:D006402	200_2	bcv_final_eval_easy_1088		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced <span class=""disease"">fibrosis</span> in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood <span class=""chemical"">glucose</span> after insulin treatment appeared."		200.0	200_MESH:D005947_MESH:D005355	200_2	bcv_final_eval_easy_1089		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D006402	"<span class=""disease"">blood glucose</span>"	"Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in <span class=""disease"">blood </span><span class=""chemical"">glucose</span> after insulin treatment appeared."		200.0	200_MESH:D005947_MESH:D006402	200_2	bcv_final_eval_easy_1090		
	MESH:D002395	"<span class=""chemical"">catecholamines</span>"	MESH:D003920	"<span class=""disease"">diabetic</span>"	"The myocardial content of <span class=""chemical"">catecholamines</span> was estimated in these 8 day <span class=""disease"">diabetic</span> rats."		200.0	200_MESH:D002395_MESH:D003920	200_3	bcv_final_eval_easy_1091		
	MESH:D013311	"<span class=""chemical"">streptozotocin</span>"	MESH:D003920	"<span class=""disease"">diabetic</span>"	"The rapid reversion after insulin treatment excludes the possibility that <span class=""chemical"">streptozotocin</span> in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in <span class=""disease"">diabetic</span> rats."		200.0	200_MESH:D013311_MESH:D003920	200_6	bcv_final_eval_easy_1092		
	MESH:D002395	"<span class=""chemical"">catecholamine</span>"	MESH:D003920	"<span class=""disease"">diabetic</span>"	"The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial <span class=""chemical"">catecholamine</span> sensitivity in <span class=""disease"">diabetic</span> rats."		200.0	200_MESH:D002395_MESH:D003920	200_6	bcv_final_eval_easy_1093		
	MESH:D007545	"<span class=""chemical"">ISO</span>"	MESH:D003920	"<span class=""disease"">diabetic</span>"	"The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the <span class=""chemical"">ISO</span> resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in <span class=""disease"">diabetic</span> rats."		200.0	200_MESH:D007545_MESH:D003920	200_6	bcv_final_eval_easy_1094		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"The muscarinic cholinergic agonist <span class=""chemical"">pilocarpine</span> induces in rats seizures and <span class=""disease"">status epilepticus</span> followed by widespread damage to the forebrain."		201.0	201_MESH:D010862_MESH:D013226	201_1	bcv_final_eval_easy_1095		
	MESH:D012980	"<span class=""chemical"">sodium salicylate</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, <span class=""chemical"">sodium salicylate</span>, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on <span class=""disease"">seizures</span> produced by pilocarpine."		201.0	201_MESH:D012980_MESH:D012640	201_2	bcv_final_eval_easy_1096		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, <span class=""chemical"">indomethacin</span>, ibuprofen and mefenamic acid, on <span class=""disease"">seizures</span> produced by pilocarpine."		201.0	201_MESH:D007213_MESH:D012640	201_2	bcv_final_eval_easy_1097		
	MESH:D010653	"<span class=""chemical"">phenylbutazone</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, <span class=""chemical"">phenylbutazone</span>, indomethacin, ibuprofen and mefenamic acid, on <span class=""disease"">seizures</span> produced by pilocarpine."		201.0	201_MESH:D010653_MESH:D012640	201_2	bcv_final_eval_easy_1098		
	MESH:D007052	"<span class=""chemical"">ibuprofen</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, <span class=""chemical"">ibuprofen</span> and mefenamic acid, on <span class=""disease"">seizures</span> produced by pilocarpine."		201.0	201_MESH:D007052_MESH:D012640	201_2	bcv_final_eval_easy_1099		
	MESH:D008528	"<span class=""chemical"">mefenamic acid</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and <span class=""chemical"">mefenamic acid</span>, on <span class=""disease"">seizures</span> produced by pilocarpine."		201.0	201_MESH:D008528_MESH:D012640	201_2	bcv_final_eval_easy_1100		
	MESH:D007213	"<span class=""chemical"">Indomethacin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"<span class=""chemical"">Indomethacin</span>, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate <span class=""disease"">seizures</span> produced by pilocarpine."		201.0	201_MESH:D007213_MESH:D012640	201_4	bcv_final_eval_easy_1101		
	MESH:D007052	"<span class=""chemical"">ibuprofen</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Indomethacin, 1-10 mg/kg, and <span class=""chemical"">ibuprofen</span>, 10-100 mg/kg, failed to modulate <span class=""disease"">seizures</span> produced by pilocarpine."		201.0	201_MESH:D007052_MESH:D012640	201_4	bcv_final_eval_easy_1102		
	MESH:D008528	"<span class=""chemical"">Mefenamic acid</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"<span class=""chemical"">Mefenamic acid</span>, 26 (22-30) mg/kg, prevented <span class=""disease"">seizures</span> and protected rats from <span class=""disease"">seizure</span>-related brain damage induced by pilocarpine, 380 mg/kg."		201.0	201_MESH:D008528_MESH:D012640	201_5	bcv_final_eval_easy_1103		
	MESH:D008528	"<span class=""chemical"">Mefenamic acid</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"<span class=""chemical"">Mefenamic acid</span>, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related <span class=""disease"">brain damage</span> induced by pilocarpine, 380 mg/kg."		201.0	201_MESH:D008528_MESH:D001927	201_5	bcv_final_eval_easy_1104		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related <span class=""disease"">brain damage</span> induced by <span class=""chemical"">pilocarpine</span>, 380 mg/kg."		201.0	201_MESH:D010862_MESH:D001927	201_5	bcv_final_eval_easy_1105		
	MESH:D005047	"<span class=""chemical"">etoposide</span>"	MESH:D005910	"<span class=""disease"">malignant glioma</span>"	"Acute neurologic dysfunction after high-dose <span class=""chemical"">etoposide</span> therapy for <span class=""disease"">malignant glioma</span>."		202.0	202_MESH:D005047_MESH:D005910	202_0	bcv_final_eval_easy_1106		
	MESH:D005047	"<span class=""chemical"">etoposide</span>"	MESH:D009461	"<span class=""disease"">Acute neurologic dysfunction</span>"	"<span class=""disease"">Acute neurologic dysfunction</span> after high-dose <span class=""chemical"">etoposide</span> therapy for malignant glioma."		202.0	202_MESH:D005047_MESH:D009461	202_0	bcv_final_eval_easy_1107		
	MESH:D005047	"<span class=""chemical"">Etoposide/VP-16-213</span>"	MESH:D009369	"<span class=""disease"">tumors</span>"	"<span class=""chemical"">Etoposide</span> (<span class=""chemical"">VP-16-213</span>) has been used in the treatment of many solid <span class=""disease"">tumors</span> and hematologic malignancies."		202.0	202_MESH:D005047_MESH:D009369	202_1	bcv_final_eval_easy_1108		
	MESH:D005047	"<span class=""chemical"">Etoposide/VP-16-213</span>"	MESH:D019337	"<span class=""disease"">hematologic malignancies</span>"	"<span class=""chemical"">Etoposide</span> (<span class=""chemical"">VP-16-213</span>) has been used in the treatment of many solid tumors and <span class=""disease"">hematologic malignancies</span>."		202.0	202_MESH:D005047_MESH:D019337	202_1	bcv_final_eval_easy_1109		
	MESH:D005047	"<span class=""chemical"">etoposide</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"This complication appears to represent a significant new <span class=""disease"">toxicity</span> of high-dose <span class=""chemical"">etoposide</span> therapy for malignant glioma."		202.0	202_MESH:D005047_MESH:D064420	202_8	bcv_final_eval_easy_1110		
	MESH:D005047	"<span class=""chemical"">etoposide</span>"	MESH:D005910	"<span class=""disease"">malignant glioma</span>"	"This complication appears to represent a significant new toxicity of high-dose <span class=""chemical"">etoposide</span> therapy for <span class=""disease"">malignant glioma</span>."		202.0	202_MESH:D005047_MESH:D005910	202_8	bcv_final_eval_easy_1111		
	MESH:D013827	"<span class=""chemical"">thiabendazole</span>"	MESH:D001649	"<span class=""disease"">bile duct injury</span>"	"Progressive <span class=""disease"">bile duct injury</span> after <span class=""chemical"">thiabendazole</span> administration."		203.0	203_MESH:D013827_MESH:D001649	203_0	bcv_final_eval_easy_1112		
	MESH:D013827	"<span class=""chemical"">thiabendazole</span>"	MESH:D007565	"<span class=""disease"">jaundice</span>"	"A 27-yr-old man developed <span class=""disease"">jaundice</span> 2 wk after exposure to <span class=""chemical"">thiabendazole</span>."		203.0	203_MESH:D013827_MESH:D007565	203_1	bcv_final_eval_easy_1113		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D002318	"<span class=""disease"">cardiovascular disease/cardiovascular diseases</span>"	"Increasing recognition of the importance of <span class=""chemical"">calcium</span> in the pathogenesis of <span class=""disease"">cardiovascular disease</span> has stimulated research into the use of <span class=""chemical"">calcium</span> channel blocking agents for treatment of a variety of <span class=""disease"">cardiovascular diseases</span>."		204.0	204_MESH:D002118_MESH:D002318	204_1	bcv_final_eval_easy_1114		
	MESH:C038806	"<span class=""chemical"">dihydropyridine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"As the first <span class=""chemical"">dihydropyridine</span> available for use in the United States, nifedipine controls angina and <span class=""disease"">hypertension</span> with minimal depression of cardiac function."		204.0	204_MESH:C038806_MESH:D006973	204_5	bcv_final_eval_easy_1115		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"As the first dihydropyridine available for use in the United States, <span class=""chemical"">nifedipine</span> controls angina and <span class=""disease"">hypertension</span> with minimal depression of cardiac function."		204.0	204_MESH:D009543_MESH:D006973	204_5	bcv_final_eval_easy_1116		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"As the first dihydropyridine available for use in the United States, <span class=""chemical"">nifedipine</span> controls angina and hypertension with minimal <span class=""disease"">depression</span> of cardiac function."		204.0	204_MESH:D009543_MESH:D003866	204_5	bcv_final_eval_easy_1117		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D000787	"<span class=""disease"">angina</span>"	"As the first dihydropyridine available for use in the United States, <span class=""chemical"">nifedipine</span> controls <span class=""disease"">angina</span> and hypertension with minimal depression of cardiac function."		204.0	204_MESH:D009543_MESH:D000787	204_5	bcv_final_eval_easy_1118		
	MESH:C038806	"<span class=""chemical"">dihydropyridine</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"As the first <span class=""chemical"">dihydropyridine</span> available for use in the United States, nifedipine controls angina and hypertension with minimal <span class=""disease"">depression</span> of cardiac function."		204.0	204_MESH:C038806_MESH:D003866	204_5	bcv_final_eval_easy_1119		
	MESH:C038806	"<span class=""chemical"">dihydropyridine</span>"	MESH:D000787	"<span class=""disease"">angina</span>"	"As the first <span class=""chemical"">dihydropyridine</span> available for use in the United States, nifedipine controls <span class=""disease"">angina</span> and hypertension with minimal depression of cardiac function."		204.0	204_MESH:C038806_MESH:D000787	204_5	bcv_final_eval_easy_1120		
	MESH:D009568	"<span class=""chemical"">nitrendipine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Once or twice daily dosage possible with <span class=""chemical"">nitrendipine</span> and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of <span class=""disease"">hypertension</span>."		204.0	204_MESH:D009568_MESH:D006973	204_7	bcv_final_eval_easy_1121		
	MESH:D015737	"<span class=""chemical"">nisoldipine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Once or twice daily dosage possible with nitrendipine and <span class=""chemical"">nisoldipine</span> offers a convenient administration schedule, which encourages patient compliance in long-term therapy of <span class=""disease"">hypertension</span>."		204.0	204_MESH:D015737_MESH:D006973	204_7	bcv_final_eval_easy_1122		
	MESH:D015737	"<span class=""chemical"">nisoldipine</span>"	MESH:D000787	"<span class=""disease"">angina</span>"	"The coronary vasodilating properties of <span class=""chemical"">nisoldipine</span> have led to the investigation of this agent for use in <span class=""disease"">angina</span>."		204.0	204_MESH:D015737_MESH:D000787	204_8	bcv_final_eval_easy_1123		
	MESH:D009553	"<span class=""chemical"">nimodipine</span>"	MESH:D003704	"<span class=""disease"">dementia</span>"	"Selectivity for the cerebrovascular bed makes <span class=""chemical"">nimodipine</span> potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, <span class=""disease"">dementia</span>, and stroke."		204.0	204_MESH:D009553_MESH:D003704	204_9	bcv_final_eval_easy_1124		
	MESH:D009553	"<span class=""chemical"">nimodipine</span>"	MESH:D013345	"<span class=""disease"">subarachnoid hemorrhage</span>"	"Selectivity for the cerebrovascular bed makes <span class=""chemical"">nimodipine</span> potentially useful in the treatment of <span class=""disease"">subarachnoid hemorrhage</span>, migraine headache, dementia, and stroke."		204.0	204_MESH:D009553_MESH:D013345	204_9	bcv_final_eval_easy_1125		
	MESH:D009553	"<span class=""chemical"">nimodipine</span>"	MESH:D008881	"<span class=""disease"">migraine headache</span>"	"Selectivity for the cerebrovascular bed makes <span class=""chemical"">nimodipine</span> potentially useful in the treatment of subarachnoid hemorrhage, <span class=""disease"">migraine headache</span>, dementia, and stroke."		204.0	204_MESH:D009553_MESH:D008881	204_9	bcv_final_eval_easy_1126		
	MESH:D009553	"<span class=""chemical"">nimodipine</span>"	MESH:D020521	"<span class=""disease"">stroke</span>"	"Selectivity for the cerebrovascular bed makes <span class=""chemical"">nimodipine</span> potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and <span class=""disease"">stroke</span>."		204.0	204_MESH:D009553_MESH:D020521	204_9	bcv_final_eval_easy_1127		
	MESH:D011692	"<span class=""chemical"">aminonucleoside</span>"	MESH:D009401	"<span class=""disease"">nephrosis</span>"	"The enhancement of <span class=""chemical"">aminonucleoside</span> <span class=""disease"">nephrosis</span> by the co-administration of protamine."		205.0	205_MESH:D011692_MESH:D009401	205_0	bcv_final_eval_easy_1128		
	MESH:D011692	"<span class=""chemical"">AMNS/puromycin-aminonucleoside</span>"	MESH:D007674	"<span class=""disease"">FSGS/focal segmental glomerular sclerosis</span>"	"An experimental model of <span class=""disease"">focal segmental glomerular sclerosis</span> (<span class=""disease"">FSGS</span>) was developed in rats by the combined administration of <span class=""chemical"">puromycin-aminonucleoside</span> (<span class=""chemical"">AMNS</span>) and protamine sulfate (PS)."		205.0	205_MESH:D011692_MESH:D007674	205_1	bcv_final_eval_easy_1129		
	MESH:D013806	"<span class=""chemical"">Theophylline</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"<span class=""chemical"">Theophylline</span> <span class=""disease"">neurotoxicity</span> in pregnant rats."		206.0	206_MESH:D013806_MESH:D020258	206_0	bcv_final_eval_easy_1130		
	MESH:D013806	"<span class=""chemical"">theophylline</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"The purpose of this investigation was to determine whether the <span class=""disease"">neurotoxicity</span> of <span class=""chemical"">theophylline</span> is altered in advanced pregnancy."		206.0	206_MESH:D013806_MESH:D020258	206_1	bcv_final_eval_easy_1131		
	MESH:D000628	"<span class=""chemical"">aminophylline</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of <span class=""chemical"">aminophylline</span> until onset of maximal <span class=""disease"">seizures</span> which occurred after 28 and 30 minutes respectively."		206.0	206_MESH:D000628_MESH:D012640	206_2	bcv_final_eval_easy_1132		
	MESH:D013806	"<span class=""chemical"">theophylline</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"It is concluded that advanced pregnancy has a negligible effect on the <span class=""disease"">neurotoxic</span> response to <span class=""chemical"">theophylline</span> in rats."		206.0	206_MESH:D013806_MESH:D020258	206_6	bcv_final_eval_easy_1133		
	MESH:D009288	"<span class=""chemical"">naproxen</span>"	MESH:D006947	"<span class=""disease"">Hyperkalemia</span>"	"<span class=""disease"">Hyperkalemia</span> induced by indomethacin and <span class=""chemical"">naproxen</span> and reversed by fludrocortisone."		207.0	207_MESH:D009288_MESH:D006947	207_0	bcv_final_eval_easy_1134		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D006947	"<span class=""disease"">Hyperkalemia</span>"	"<span class=""disease"">Hyperkalemia</span> induced by <span class=""chemical"">indomethacin</span> and naproxen and reversed by fludrocortisone."		207.0	207_MESH:D007213_MESH:D006947	207_0	bcv_final_eval_easy_1135		
	MESH:D005438	"<span class=""chemical"">fludrocortisone</span>"	MESH:D006947	"<span class=""disease"">Hyperkalemia</span>"	"<span class=""disease"">Hyperkalemia</span> induced by indomethacin and naproxen and reversed by <span class=""chemical"">fludrocortisone</span>."		207.0	207_MESH:D005438_MESH:D006947	207_0	bcv_final_eval_easy_1136		
	MESH:D008528	"<span class=""chemical"">mefenamic acid</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"We have described a patient with severe rheumatoid arthritis and a history of <span class=""chemical"">mefenamic acid</span> <span class=""disease"">nephropathy</span> in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function."		207.0	207_MESH:D008528_MESH:D007674	207_1	bcv_final_eval_easy_1137		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom <span class=""disease"">hyperkalemia</span> and inappropriate hypoaldosteronism were caused by both <span class=""chemical"">indomethacin</span> and naproxen, without major decline in renal function."		207.0	207_MESH:D007213_MESH:D006947	207_1	bcv_final_eval_easy_1138		
	MESH:D008528	"<span class=""chemical"">mefenamic acid</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"We have described a patient with severe rheumatoid arthritis and a history of <span class=""chemical"">mefenamic acid</span> nephropathy in whom <span class=""disease"">hyperkalemia</span> and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function."		207.0	207_MESH:D008528_MESH:D006947	207_1	bcv_final_eval_easy_1139		
	MESH:D008528	"<span class=""chemical"">mefenamic acid</span>"	MESH:D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"We have described a patient with severe <span class=""disease"">rheumatoid arthritis</span> and a history of <span class=""chemical"">mefenamic acid</span> nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function."		207.0	207_MESH:D008528_MESH:D001172	207_1	bcv_final_eval_easy_1140		
	MESH:D009288	"<span class=""chemical"">naproxen</span>"	MESH:D006994	"<span class=""disease"">hypoaldosteronism</span>"	"We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate <span class=""disease"">hypoaldosteronism</span> were caused by both indomethacin and <span class=""chemical"">naproxen</span>, without major decline in renal function."		207.0	207_MESH:D009288_MESH:D006994	207_1	bcv_final_eval_easy_1141		
	MESH:D009288	"<span class=""chemical"">naproxen</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid <span class=""disease"">nephropathy</span> in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and <span class=""chemical"">naproxen</span>, without major decline in renal function."		207.0	207_MESH:D009288_MESH:D007674	207_1	bcv_final_eval_easy_1142		
	MESH:D008528	"<span class=""chemical"">mefenamic acid</span>"	MESH:D006994	"<span class=""disease"">hypoaldosteronism</span>"	"We have described a patient with severe rheumatoid arthritis and a history of <span class=""chemical"">mefenamic acid</span> nephropathy in whom hyperkalemia and inappropriate <span class=""disease"">hypoaldosteronism</span> were caused by both indomethacin and naproxen, without major decline in renal function."		207.0	207_MESH:D008528_MESH:D006994	207_1	bcv_final_eval_easy_1143		
	MESH:D009288	"<span class=""chemical"">naproxen</span>"	MESH:D051437	"<span class=""disease"">decline in renal function</span>"	"We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and <span class=""chemical"">naproxen</span>, without major <span class=""disease"">decline in renal function</span>."		207.0	207_MESH:D009288_MESH:D051437	207_1	bcv_final_eval_easy_1144		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D006994	"<span class=""disease"">hypoaldosteronism</span>"	"We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate <span class=""disease"">hypoaldosteronism</span> were caused by both <span class=""chemical"">indomethacin</span> and naproxen, without major decline in renal function."		207.0	207_MESH:D007213_MESH:D006994	207_1	bcv_final_eval_easy_1145		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"We have described a patient with severe <span class=""disease"">rheumatoid arthritis</span> and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both <span class=""chemical"">indomethacin</span> and naproxen, without major decline in renal function."		207.0	207_MESH:D007213_MESH:D001172	207_1	bcv_final_eval_easy_1146		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid <span class=""disease"">nephropathy</span> in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both <span class=""chemical"">indomethacin</span> and naproxen, without major decline in renal function."		207.0	207_MESH:D007213_MESH:D007674	207_1	bcv_final_eval_easy_1147		
	MESH:D008528	"<span class=""chemical"">mefenamic acid</span>"	MESH:D051437	"<span class=""disease"">decline in renal function</span>"	"We have described a patient with severe rheumatoid arthritis and a history of <span class=""chemical"">mefenamic acid</span> nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major <span class=""disease"">decline in renal function</span>."		207.0	207_MESH:D008528_MESH:D051437	207_1	bcv_final_eval_easy_1148		
	MESH:D009288	"<span class=""chemical"">naproxen</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom <span class=""disease"">hyperkalemia</span> and inappropriate hypoaldosteronism were caused by both indomethacin and <span class=""chemical"">naproxen</span>, without major decline in renal function."		207.0	207_MESH:D009288_MESH:D006947	207_1	bcv_final_eval_easy_1149		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D051437	"<span class=""disease"">decline in renal function</span>"	"We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both <span class=""chemical"">indomethacin</span> and naproxen, without major <span class=""disease"">decline in renal function</span>."		207.0	207_MESH:D007213_MESH:D051437	207_1	bcv_final_eval_easy_1150		
	MESH:D009288	"<span class=""chemical"">naproxen</span>"	MESH:D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"We have described a patient with severe <span class=""disease"">rheumatoid arthritis</span> and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and <span class=""chemical"">naproxen</span>, without major decline in renal function."		207.0	207_MESH:D009288_MESH:D001172	207_1	bcv_final_eval_easy_1151		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the <span class=""disease"">hyperkalemia</span> and allowing <span class=""chemical"">indomethacin</span> therapy to be continued safely."		207.0	207_MESH:D007213_MESH:D006947	207_3	bcv_final_eval_easy_1152		
	MESH:D005438	"<span class=""chemical"">fludrocortisone</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, <span class=""chemical"">fludrocortisone</span> was added, correcting the <span class=""disease"">hyperkalemia</span> and allowing indomethacin therapy to be continued safely."		207.0	207_MESH:D005438_MESH:D006947	207_3	bcv_final_eval_easy_1153		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D007022	"<span class=""disease"">Hypotension</span>"	"<span class=""disease"">Hypotension</span> as a manifestation of cardiotoxicity in three patients receiving <span class=""chemical"">cisplatin</span> and 5-fluorouracil."		208.0	208_MESH:D002945_MESH:D007022	208_0	bcv_final_eval_easy_1154		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Hypotension as a manifestation of <span class=""disease"">cardiotoxicity</span> in three patients receiving <span class=""chemical"">cisplatin</span> and 5-fluorouracil."		208.0	208_MESH:D002945_MESH:D066126	208_0	bcv_final_eval_easy_1155		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D007022	"<span class=""disease"">Hypotension</span>"	"<span class=""disease"">Hypotension</span> as a manifestation of cardiotoxicity in three patients receiving cisplatin and <span class=""chemical"">5-fluorouracil</span>."		208.0	208_MESH:D005472_MESH:D007022	208_0	bcv_final_eval_easy_1156		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Hypotension as a manifestation of <span class=""disease"">cardiotoxicity</span> in three patients receiving cisplatin and <span class=""chemical"">5-fluorouracil</span>."		208.0	208_MESH:D005472_MESH:D066126	208_0	bcv_final_eval_easy_1157		
	MESH:D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	MESH:D006331	"<span class=""disease"">Cardiac symptoms</span>"	"<span class=""disease"">Cardiac symptoms</span>, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>)."		208.0	208_MESH:D005472_MESH:D006331	208_1	bcv_final_eval_easy_1158		
	MESH:D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Cardiac symptoms, including <span class=""disease"">hypotension</span>, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>)."		208.0	208_MESH:D005472_MESH:D007022	208_1	bcv_final_eval_easy_1159		
	MESH:D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	MESH:D015179	"<span class=""disease"">colorectal carcinoma</span>"	"Cardiac symptoms, including hypotension, developed in three patients with advanced <span class=""disease"">colorectal carcinoma</span> while being treated with cisplatin (CDDP) and <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>)."		208.0	208_MESH:D005472_MESH:D015179	208_1	bcv_final_eval_easy_1160		
	MESH:D002945	"<span class=""chemical"">cisplatin/CDDP</span>"	MESH:D015179	"<span class=""disease"">colorectal carcinoma</span>"	"Cardiac symptoms, including hypotension, developed in three patients with advanced <span class=""disease"">colorectal carcinoma</span> while being treated with <span class=""chemical"">cisplatin</span> (<span class=""chemical"">CDDP</span>) and 5-fluorouracil (5-FU)."		208.0	208_MESH:D002945_MESH:D015179	208_1	bcv_final_eval_easy_1161		
	MESH:D002945	"<span class=""chemical"">cisplatin/CDDP</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Cardiac symptoms, including <span class=""disease"">hypotension</span>, developed in three patients with advanced colorectal carcinoma while being treated with <span class=""chemical"">cisplatin</span> (<span class=""chemical"">CDDP</span>) and 5-fluorouracil (5-FU)."		208.0	208_MESH:D002945_MESH:D007022	208_1	bcv_final_eval_easy_1162		
	MESH:D002945	"<span class=""chemical"">cisplatin/CDDP</span>"	MESH:D006331	"<span class=""disease"">Cardiac symptoms</span>"	"<span class=""disease"">Cardiac symptoms</span>, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with <span class=""chemical"">cisplatin</span> (<span class=""chemical"">CDDP</span>) and 5-fluorouracil (5-FU)."		208.0	208_MESH:D002945_MESH:D006331	208_1	bcv_final_eval_easy_1163		
	MESH:D002945	"<span class=""chemical"">CDDP</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU <span class=""disease"">cardiotoxicity</span> that may be influenced by <span class=""chemical"">CDDP</span>."		208.0	208_MESH:D002945_MESH:D066126	208_5	bcv_final_eval_easy_1164		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of <span class=""chemical"">5-FU</span> <span class=""disease"">cardiotoxicity</span> that may be influenced by CDDP."		208.0	208_MESH:D005472_MESH:D066126	208_5	bcv_final_eval_easy_1165		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D000741	"<span class=""disease"">aplastic anemia</span>"	"Fatal <span class=""disease"">aplastic anemia</span> in a patient treated with <span class=""chemical"">carbamazepine</span>."		209.0	209_MESH:D002220_MESH:D000741	209_0	bcv_final_eval_easy_1166		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D004827	"<span class=""disease"">epileptic</span>"	"A case of fatal aplastic anemia due to <span class=""chemical"">carbamazepine</span> treatment in an <span class=""disease"">epileptic</span> woman is reported."		209.0	209_MESH:D002220_MESH:D004827	209_1	bcv_final_eval_easy_1167		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D000741	"<span class=""disease"">aplastic anemia</span>"	"A case of fatal <span class=""disease"">aplastic anemia</span> due to <span class=""chemical"">carbamazepine</span> treatment in an epileptic woman is reported."		209.0	209_MESH:D002220_MESH:D000741	209_1	bcv_final_eval_easy_1168		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D001855	"<span class=""disease"">marrow toxicity</span>"	"Despite concerns of fatal bone <span class=""disease"">marrow toxicity</span> due to <span class=""chemical"">carbamazepine</span>, this is only the fourth documented and published report."		209.0	209_MESH:D002220_MESH:D001855	209_2	bcv_final_eval_easy_1169		
	MESH:D007099	"<span class=""chemical"">imipramine</span>"	MESH:D006973	"<span class=""disease"">Hypertension</span>"	"<span class=""disease"">Hypertension</span> in neuroblastoma induced by <span class=""chemical"">imipramine</span>."		211.0	211_MESH:D007099_MESH:D006973	211_0	bcv_final_eval_easy_1170		
	MESH:D007099	"<span class=""chemical"">imipramine</span>"	MESH:D009447	"<span class=""disease"">neuroblastoma</span>"	"Hypertension in <span class=""disease"">neuroblastoma</span> induced by <span class=""chemical"">imipramine</span>."		211.0	211_MESH:D007099_MESH:D009447	211_0	bcv_final_eval_easy_1171		
	MESH:D007099	"<span class=""chemical"">Imipramine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"We report the occurrence of severe <span class=""disease"">hypertension</span> (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given <span class=""chemical"">Imipramine</span> to control a behavior disorder."		211.0	211_MESH:D007099_MESH:D006973	211_3	bcv_final_eval_easy_1172		
	MESH:D007099	"<span class=""chemical"">Imipramine</span>"	MESH:D009447	"<span class=""disease"">neuroblastoma</span>"	"We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with <span class=""disease"">neuroblastoma</span> who was given <span class=""chemical"">Imipramine</span> to control a behavior disorder."		211.0	211_MESH:D007099_MESH:D009447	211_3	bcv_final_eval_easy_1173		
	MESH:D007099	"<span class=""chemical"">Imipramine</span>"	MESH:D001523	"<span class=""disease"">behavior disorder</span>"	"We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given <span class=""chemical"">Imipramine</span> to control a <span class=""disease"">behavior disorder</span>."		211.0	211_MESH:D007099_MESH:D001523	211_3	bcv_final_eval_easy_1174		
	MESH:D007099	"<span class=""chemical"">Imipramine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the <span class=""chemical"">Imipramine</span> (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her <span class=""disease"">hypertension</span>."		211.0	211_MESH:D007099_MESH:D006973	211_5	bcv_final_eval_easy_1175		
	MESH:D001507	"<span class=""chemical"">beclomethasone dipropionate</span>"	MESH:D002180	"<span class=""disease"">oral candidiasis or hoarseness</span>"	"Rechallenge of patients who developed <span class=""disease"">oral candidiasis or hoarseness</span> with <span class=""chemical"">beclomethasone dipropionate</span>."		212.0	212_MESH:D001507_MESH:D002180	212_0	bcv_final_eval_easy_1176		
	MESH:D001507	"<span class=""chemical"">beclomethasone</span>"	MESH:D013224	"<span class=""disease"">asthmatic</span>"	"Of 158 <span class=""disease"">asthmatic</span> patients who were placed on inhaled <span class=""chemical"">beclomethasone</span>, 15 (9.5%) developed either hoarseness (8), oral thrush (6), or both (1)."		212.0	212_MESH:D001507_MESH:D013224	212_1	bcv_final_eval_easy_1177		
	MESH:D001507	"<span class=""chemical"">beclomethasone</span>"	MESH:D002180	"<span class=""disease"">hoarseness (8), oral thrush</span>"	"Of 158 asthmatic patients who were placed on inhaled <span class=""chemical"">beclomethasone</span>, 15 (9.5%) developed either <span class=""disease"">hoarseness (8), oral thrush</span> (6), or both (1)."		212.0	212_MESH:D001507_MESH:D002180	212_1	bcv_final_eval_easy_1178		
	MESH:D011241	"<span class=""chemical"">prednisone</span>"	MESH:D002177	"<span class=""disease"">candidiasis</span>"	"Concomitant use of oral <span class=""chemical"">prednisone</span> and topical beclomethasone may increase the risk of developing hoarseness or <span class=""disease"">candidiasis</span>."		212.0	212_MESH:D011241_MESH:D002177	212_7	bcv_final_eval_easy_1179		
	MESH:D001507	"<span class=""chemical"">beclomethasone</span>"	MESH:D002177	"<span class=""disease"">candidiasis</span>"	"Concomitant use of oral prednisone and topical <span class=""chemical"">beclomethasone</span> may increase the risk of developing hoarseness or <span class=""disease"">candidiasis</span>."		212.0	212_MESH:D001507_MESH:D002177	212_7	bcv_final_eval_easy_1180		
	MESH:D003520	"<span class=""chemical"">Cyclophosphamide</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"<span class=""chemical"">Cyclophosphamide</span> <span class=""disease"">cardiotoxicity</span>: an analysis of dosing as a risk factor."		213.0	213_MESH:D003520_MESH:D066126	213_0	bcv_final_eval_easy_1181		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"At these high doses of <span class=""chemical"">CYA</span>, serious <span class=""disease"">cardiotoxicity</span> may occur, but definitive risk factors for the development of such <span class=""disease"">cardiotoxicity</span> have not been described."		213.0	213_MESH:D016572_MESH:D066126	213_2	bcv_final_eval_easy_1182		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of <span class=""chemical"">CYA</span> in patients transplanted at our institution to determine whether the incidence of <span class=""chemical"">CYA</span> <span class=""disease"">cardiotoxicity</span> correlated with the dose per body surface area."		213.0	213_MESH:D016572_MESH:D066126	213_3	bcv_final_eval_easy_1183		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Since chemotherapeutic agent <span class=""disease"">toxicity</span> generally correlates with dose per body surface area, we retrospectively calculated the dose of <span class=""chemical"">CYA</span> in patients transplanted at our institution to determine whether the incidence of <span class=""chemical"">CYA</span> cardiotoxicity correlated with the dose per body surface area."		213.0	213_MESH:D016572_MESH:D064420	213_3	bcv_final_eval_easy_1184		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D000741	"<span class=""disease"">aplastic anemia</span>"	"Eighty patients who were to receive <span class=""chemical"">CYA</span> 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for <span class=""disease"">aplastic anemia</span>, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome."		213.0	213_MESH:D016572_MESH:D000741	213_4	bcv_final_eval_easy_1185		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D007153	"<span class=""disease"">combined immunodeficiency syndrome</span>"	"Eighty patients who were to receive <span class=""chemical"">CYA</span> 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe <span class=""disease"">combined immunodeficiency syndrome</span>."		213.0	213_MESH:D016572_MESH:D007153	213_4	bcv_final_eval_easy_1186		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D014923	"<span class=""disease"">Wiskott-Aldrich syndrome</span>"	"Eighty patients who were to receive <span class=""chemical"">CYA</span> 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, <span class=""disease"">Wiskott-Aldrich syndrome</span>, or severe combined immunodeficiency syndrome."		213.0	213_MESH:D016572_MESH:D014923	213_4	bcv_final_eval_easy_1187		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Fourteen of 84 (17%) patients had symptoms and signs consistent with <span class=""chemical"">CYA</span> <span class=""disease"">cardiotoxicity</span> within ten days of receiving 1 to 4 doses of <span class=""chemical"">CYA</span>."		213.0	213_MESH:D016572_MESH:D066126	213_5	bcv_final_eval_easy_1188		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D066126	"<span class=""disease"">Cardiotoxicity</span>"	"<span class=""disease"">Cardiotoxicity</span> that was thought to be related to <span class=""chemical"">CYA</span> occurred in 1/32 (3%) of patients in Group 1 and in 13/52 (25%) patients in Group 2 (P less than 0.025)."		213.0	213_MESH:D016572_MESH:D066126	213_8	bcv_final_eval_easy_1189		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D000741	"<span class=""disease"">aplastic anemia</span>"	"We conclude that the <span class=""chemical"">CYA</span> cardiotoxicity correlates with <span class=""chemical"">CYA</span> dosage as calculated by body surface area, and that patients with <span class=""disease"">aplastic anemia</span> and immunodeficiencies can be effectively prepared for bone marrow grafting at a <span class=""chemical"">CYA</span> dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose <span class=""chemical"">CYA</span> dosage is calculated based on weight."		213.0	213_MESH:D016572_MESH:D000741	213_11	bcv_final_eval_easy_1190		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"We conclude that the <span class=""chemical"">CYA</span> <span class=""disease"">cardiotoxicity</span> correlates with <span class=""chemical"">CYA</span> dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a <span class=""chemical"">CYA</span> dose of 1.55 g/m2/d for four days with a lower incidence of <span class=""disease"">cardiotoxicity</span> than patients whose <span class=""chemical"">CYA</span> dosage is calculated based on weight."		213.0	213_MESH:D016572_MESH:D066126	213_11	bcv_final_eval_easy_1191		
	MESH:D016572	"<span class=""chemical"">CYA</span>"	MESH:D007153	"<span class=""disease"">immunodeficiencies</span>"	"We conclude that the <span class=""chemical"">CYA</span> cardiotoxicity correlates with <span class=""chemical"">CYA</span> dosage as calculated by body surface area, and that patients with aplastic anemia and <span class=""disease"">immunodeficiencies</span> can be effectively prepared for bone marrow grafting at a <span class=""chemical"">CYA</span> dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose <span class=""chemical"">CYA</span> dosage is calculated based on weight."		213.0	213_MESH:D016572_MESH:D007153	213_11	bcv_final_eval_easy_1192		
	MESH:D000617	"<span class=""chemical"">aminoglycosides</span>"	MESH:D007674	"<span class=""disease"">glomerular or tubular dysfunction</span>"	"Experimental studies in healthy human volunteers indicate <span class=""chemical"">aminoglycosides</span> cause proximal tubular damage in most patients, but rarely, if ever, cause <span class=""disease"">glomerular or tubular dysfunction</span>."		214.0	214_MESH:D000617_MESH:D007674	214_2	bcv_final_eval_easy_1193		
	MESH:D000617	"<span class=""chemical"">aminoglycosides</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"Clinical trials of <span class=""chemical"">aminoglycosides</span> in seriously ill patients indicate that the relative risk for developing <span class=""disease"">acute renal failure</span> during therapy ranges from 8 to 10 and that the attributable risk is 70% to 80%."		214.0	214_MESH:D000617_MESH:D058186	214_3	bcv_final_eval_easy_1194		
	MESH:D000617	"<span class=""chemical"">aminoglycoside</span>"	MESH:D008107	"<span class=""disease"">liver disease</span>"	"Further analysis of these data suggests that the duration of therapy, plasma <span class=""chemical"">aminoglycoside</span> levels, <span class=""disease"">liver disease</span>, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity."		214.0	214_MESH:D000617_MESH:D008107	214_4	bcv_final_eval_easy_1195		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D008107	"<span class=""disease"">liver disease</span>"	"Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, <span class=""disease"">liver disease</span>, advanced age, high initial estimated <span class=""chemical"">creatinine</span> clearance and, possibly, female gender all increase the risk for nephrotoxicity."		214.0	214_MESH:D003404_MESH:D008107	214_4	bcv_final_eval_easy_1196		
	MESH:D005481	"<span class=""chemical"">Flurothyl</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">Flurothyl</span> <span class=""disease"">seizure</span> thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in <span class=""chemical"">flurothyl</span> <span class=""disease"">seizure</span> testing."		215.0	215_MESH:D005481_MESH:D012640	215_0	bcv_final_eval_easy_1197		
	MESH:D018698	"<span class=""chemical"">MSG/glutamate</span>"	MESH:D001523	"<span class=""disease"">behavioral deficits</span>"	"Monosodium <span class=""chemical"">glutamate</span> (<span class=""chemical"">MSG</span>) administration to neonatal rodents produces convulsions and results in numerous biochemical and <span class=""disease"">behavioral deficits</span>."		215.0	215_MESH:D018698_MESH:D001523	215_1	bcv_final_eval_easy_1198		
	MESH:D018698	"<span class=""chemical"">MSG/glutamate</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"Monosodium <span class=""chemical"">glutamate</span> (<span class=""chemical"">MSG</span>) administration to neonatal rodents produces <span class=""disease"">convulsions</span> and results in numerous biochemical and behavioral deficits."		215.0	215_MESH:D018698_MESH:D012640	215_1	bcv_final_eval_easy_1199		
	MESH:D018698	"<span class=""chemical"">MSG</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"These studies were undertaken to determine if neonatal administration of <span class=""chemical"">MSG</span> produced permanent alterations in <span class=""disease"">seizure</span> susceptibility, since previous investigations were inconclusive."		215.0	215_MESH:D018698_MESH:D012640	215_2	bcv_final_eval_easy_1200		
	MESH:D018698	"<span class=""chemical"">MSG</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"A flurothyl ether <span class=""disease"">seizure</span> screening technique was used to evaluate <span class=""disease"">seizure</span> susceptibility in adult mice that received neonatal injections of <span class=""chemical"">MSG</span> (4 mg/g and 1 mg/g)."		215.0	215_MESH:D018698_MESH:D012640	215_3	bcv_final_eval_easy_1201		
	MESH:D018698	"<span class=""chemical"">MSG</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">MSG</span> treatment resulted in significant reductions in whole brain weight but did not alter <span class=""disease"">seizure</span> threshold."		215.0	215_MESH:D018698_MESH:D012640	215_4	bcv_final_eval_easy_1202		
	MESH:D009270	"<span class=""chemical"">naloxone</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"A <span class=""chemical"">naloxone</span> (5 mg/kg) challenge was also ineffective in altering the <span class=""disease"">seizure</span> thresholds of either control of MSG-treated mice."		215.0	215_MESH:D009270_MESH:D012640	215_5	bcv_final_eval_easy_1203		
	MESH:D018698	"<span class=""chemical"">MSG</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"A naloxone (5 mg/kg) challenge was also ineffective in altering the <span class=""disease"">seizure</span> thresholds of either control of <span class=""chemical"">MSG</span>-treated mice."		215.0	215_MESH:D018698_MESH:D012640	215_5	bcv_final_eval_easy_1204		
	MESH:D005481	"<span class=""chemical"">flurothyl</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Flurothyl ether produced hypothermia which was correlated with the duration of <span class=""chemical"">flurothyl</span> exposure; however, the relationship of hypothermia to <span class=""disease"">seizure</span> induction was unclear."		215.0	215_MESH:D005481_MESH:D012640	215_6	bcv_final_eval_easy_1205		
	MESH:D005481	"<span class=""chemical"">flurothyl</span>"	MESH:D007035	"<span class=""disease"">hypothermia</span>"	"Flurothyl ether produced <span class=""disease"">hypothermia</span> which was correlated with the duration of <span class=""chemical"">flurothyl</span> exposure; however, the relationship of <span class=""disease"">hypothermia</span> to seizure induction was unclear."		215.0	215_MESH:D005481_MESH:D007035	215_6	bcv_final_eval_easy_1206		
	MESH:D005481	"<span class=""chemical"">Flurothyl</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">Flurothyl</span> <span class=""disease"">seizure</span> testing proved to be a rapid and reliable technique with which to evaluate <span class=""disease"">seizure</span> susceptibility."		215.0	215_MESH:D005481_MESH:D012640	215_7	bcv_final_eval_easy_1207		
	MESH:D007538	"<span class=""chemical"">isoniazid</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Susceptibility to <span class=""disease"">seizures</span> produced by pilocarpine in rats after microinjection of <span class=""chemical"">isoniazid</span> or gamma-vinyl-GABA into the substantia nigra."		216.0	216_MESH:D007538_MESH:D012640	216_0	bcv_final_eval_easy_1208		
	MESH:D020888	"<span class=""chemical"">gamma-vinyl-GABA</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Susceptibility to <span class=""disease"">seizures</span> produced by pilocarpine in rats after microinjection of isoniazid or <span class=""chemical"">gamma-vinyl-GABA</span> into the substantia nigra."		216.0	216_MESH:D020888_MESH:D012640	216_0	bcv_final_eval_easy_1209		
	MESH:D010862	"<span class=""chemical"">Pilocarpine</span>"	MESH:D004833	"<span class=""disease"">temporal lobe epilepsy</span>"	"<span class=""chemical"">Pilocarpine</span>, given intraperitoneally to rats, reproduces the neuropathological sequelae of <span class=""disease"">temporal lobe epilepsy</span> and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain."		216.0	216_MESH:D010862_MESH:D004833	216_1	bcv_final_eval_easy_1210		
	MESH:D005680	"<span class=""chemical"">gamma-aminobutyric acid/GABA</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"In the present study, the effects of manipulating the activity of the <span class=""chemical"">gamma-aminobutyric acid</span> (<span class=""chemical"">GABA</span>)-mediated synaptic inhibition within the substantia nigra on <span class=""disease"">seizures</span> produced by pilocarpine in rats, were investigated."		216.0	216_MESH:D005680_MESH:D012640	216_2	bcv_final_eval_easy_1211		
	MESH:D007538	"<span class=""chemical"">isoniazid</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"In animals pretreated with microinjections of <span class=""chemical"">isoniazid</span>, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and <span class=""disease"">status epilepticus</span>."		216.0	216_MESH:D007538_MESH:D013226	216_3	bcv_final_eval_easy_1212		
	MESH:D007538	"<span class=""chemical"">isoniazid</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"In animals pretreated with microinjections of <span class=""chemical"">isoniazid</span>, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic <span class=""disease"">seizures</span> and status epilepticus."		216.0	216_MESH:D007538_MESH:D012640	216_3	bcv_final_eval_easy_1213		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of <span class=""chemical"">pilocarpine</span>, 100 and 200 mg/kg, resulted in severe motor limbic seizures and <span class=""disease"">status epilepticus</span>."		216.0	216_MESH:D010862_MESH:D013226	216_3	bcv_final_eval_easy_1214		
	MESH:D005680	"<span class=""chemical"">GABA</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the <span class=""chemical"">GABA</span>-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and <span class=""disease"">status epilepticus</span>."		216.0	216_MESH:D005680_MESH:D013226	216_3	bcv_final_eval_easy_1215		
	MESH:D005680	"<span class=""chemical"">GABA</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the <span class=""chemical"">GABA</span>-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic <span class=""disease"">seizures</span> and status epilepticus."		216.0	216_MESH:D005680_MESH:D012640	216_3	bcv_final_eval_easy_1216		
	MESH:D007538	"<span class=""chemical"">isoniazid</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Bilateral intrastriatal injections of <span class=""chemical"">isoniazid</span> did not augment <span class=""disease"">seizures</span> produced by pilocarpine, 200 mg/kg."		216.0	216_MESH:D007538_MESH:D012640	216_6	bcv_final_eval_easy_1217		
	MESH:D020888	"<span class=""chemical"">D,L-4-amino-hex-5-enoic acid/gamma-vinyl-GABA</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Application of an irreversible inhibitor of GABA transaminase, <span class=""chemical"">gamma-vinyl-GABA</span> (<span class=""chemical"">D,L-4-amino-hex-5-enoic acid</span>), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral <span class=""disease"">seizures</span> produced by pilocarpine, 380 mg/kg."		216.0	216_MESH:D020888_MESH:D012640	216_7	bcv_final_eval_easy_1218		
	MESH:D005680	"<span class=""chemical"">GABA</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Application of an irreversible inhibitor of <span class=""chemical"">GABA</span> transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral <span class=""disease"">seizures</span> produced by pilocarpine, 380 mg/kg."		216.0	216_MESH:D005680_MESH:D012640	216_7	bcv_final_eval_easy_1219		
	MESH:D020888	"<span class=""chemical"">gamma-vinyl-GABA</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"Microinjections of <span class=""chemical"">gamma-vinyl-GABA</span>, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of <span class=""disease"">convulsions</span> produced by pilocarpine, 380 mg/kg."		216.0	216_MESH:D020888_MESH:D012640	216_9	bcv_final_eval_easy_1220		
	MESH:D005680	"<span class=""chemical"">GABA</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The results demonstrate that the threshold for pilocarpine-induced <span class=""disease"">seizures</span> in rats is subjected to the regulation of the <span class=""chemical"">GABA</span>-mediated synaptic inhibition within the substantia nigra."		216.0	216_MESH:D005680_MESH:D012640	216_10	bcv_final_eval_easy_1221		
	MESH:D004176	"<span class=""chemical"">dipyridamole</span>"	MESH:D003324	"<span class=""disease"">coronary artery disease</span>"	"Non-invasive detection of <span class=""disease"">coronary artery disease</span> by body surface electrocardiographic mapping after <span class=""chemical"">dipyridamole</span> infusion."		217.0	217_MESH:D004176_MESH:D003324	217_0	bcv_final_eval_easy_1222		
	MESH:D004176	"<span class=""chemical"">dipyridamole</span>"	MESH:D003324	"<span class=""disease"">coronary artery disease</span>"	"Electrocardiographic changes after <span class=""chemical"">dipyridamole</span> infusion (0.568 mg/kg/4 min) were studied in 41 patients with <span class=""disease"">coronary artery disease</span> and compared with those after submaximal treadmill exercise by use of the body surface mapping technique."		217.0	217_MESH:D004176_MESH:D003324	217_1	bcv_final_eval_easy_1223		
	MESH:D004176	"<span class=""chemical"">dipyridamole</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"After <span class=""chemical"">dipyridamole</span>, ischemic ST-segment <span class=""disease"">depression</span> (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population."		217.0	217_MESH:D004176_MESH:D003866	217_4	bcv_final_eval_easy_1224		
	MESH:D004176	"<span class=""chemical"">dipyridamole</span>"	MESH:D003324	"<span class=""disease"">coronary artery disease</span>"	"We conclude that the <span class=""chemical"">dipyridamole</span> ECG test is as useful as the exercise ECG test for the assessment of <span class=""disease"">coronary artery disease</span>."		217.0	217_MESH:D004176_MESH:D003324	217_9	bcv_final_eval_easy_1225		
	MESH:D008775	"<span class=""chemical"">methylprednisolone</span>"	MESH:D001919	"<span class=""disease"">Bradycardia</span>"	"<span class=""disease"">Bradycardia</span> after high-dose intravenous <span class=""chemical"">methylprednisolone</span> therapy."		218.0	218_MESH:D008775_MESH:D001919	218_0	bcv_final_eval_easy_1226		
	MESH:D008775	"<span class=""chemical"">methylprednisolone</span>"	MESH:D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"In 5 consecutive patients with <span class=""disease"">rheumatoid arthritis</span> who received intravenous high-dose <span class=""chemical"">methylprednisolone</span> (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4."		218.0	218_MESH:D008775_MESH:D001172	218_1	bcv_final_eval_easy_1227		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D009759	"<span class=""disease"">nystagmus</span>"	"Two cases of downbeat <span class=""disease"">nystagmus</span> and oscillopsia associated with <span class=""chemical"">carbamazepine</span>."		219.0	219_MESH:D002220_MESH:D009759	219_0	bcv_final_eval_easy_1228		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D009759	"<span class=""disease"">nystagmus</span>"	"We recorded the eye movements of two patients with reversible downbeat <span class=""disease"">nystagmus</span> related to <span class=""chemical"">carbamazepine</span> therapy."		219.0	219_MESH:D002220_MESH:D009759	219_2	bcv_final_eval_easy_1229		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D009759	"<span class=""disease"">nystagmus</span>"	"The <span class=""disease"">nystagmus</span> of both patients resolved after reduction of the serum <span class=""chemical"">carbamazepine</span> levels."		219.0	219_MESH:D002220_MESH:D009759	219_3	bcv_final_eval_easy_1230		
	MESH:C037293	"<span class=""chemical"">denopamine/TA-064</span>"	MESH:D006333	"<span class=""disease"">cardiac failure</span>"	"Improvement by <span class=""chemical"">denopamine</span> (<span class=""chemical"">TA-064</span>) of pentobarbital-induced <span class=""disease"">cardiac failure</span> in the dog heart-lung preparation."		220.0	220_MESH:C037293_MESH:D006333	220_0	bcv_final_eval_easy_1231		
	MESH:C037293	"<span class=""chemical"">denopamine</span>"	MESH:D006333	"<span class=""disease"">cardiac failure</span>"	"The efficacy of <span class=""chemical"">denopamine</span>, an orally active beta 1-adrenoceptor agonist, in improving <span class=""disease"">cardiac failure</span> was assessed in dog heart-lung preparations."		220.0	220_MESH:C037293_MESH:D006333	220_1	bcv_final_eval_easy_1232		
	MESH:D010424	"<span class=""chemical"">pentobarbital</span>"	MESH:D003866	"<span class=""disease"">depressed</span>"	"Cardiac functions <span class=""disease"">depressed</span> by <span class=""chemical"">pentobarbital</span> (118 +/- 28 mg; mean value +/- SD) such that cardiac output and maximum rate of rise of left ventricular pressure (LV dP/dt max) had been reduced by about 35% and 26% of the respective controls were improved by denopamine (10-300 micrograms) in a dose-dependent manner."		220.0	220_MESH:D010424_MESH:D003866	220_2	bcv_final_eval_easy_1233		
	MESH:C037293	"<span class=""chemical"">denopamine</span>"	MESH:D003866	"<span class=""disease"">depressed</span>"	"Cardiac functions <span class=""disease"">depressed</span> by pentobarbital (118 +/- 28 mg; mean value +/- SD) such that cardiac output and maximum rate of rise of left ventricular pressure (LV dP/dt max) had been reduced by about 35% and 26% of the respective controls were improved by <span class=""chemical"">denopamine</span> (10-300 micrograms) in a dose-dependent manner."		220.0	220_MESH:C037293_MESH:D003866	220_2	bcv_final_eval_easy_1234		
	MESH:C037293	"<span class=""chemical"">denopamine</span>"	MESH:D001145	"<span class=""disease"">arrhythmias</span>"	"No <span class=""disease"">arrhythmias</span> were induced by these doses of <span class=""chemical"">denopamine</span>."		220.0	220_MESH:C037293_MESH:D001145	220_4	bcv_final_eval_easy_1235		
	MESH:C037293	"<span class=""chemical"">denopamine</span>"	MESH:D006333	"<span class=""disease"">cardiac failure</span>"	"The results warrant clinical trials of <span class=""chemical"">denopamine</span> in the treatment of <span class=""disease"">cardiac failure</span>."		220.0	220_MESH:C037293_MESH:D006333	220_5	bcv_final_eval_easy_1236		
	MESH:D002998	"<span class=""chemical"">Clonazepam</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"<span class=""chemical"">Clonazepam</span> monotherapy for <span class=""disease"">epilepsy</span> in childhood."		221.0	221_MESH:D002998_MESH:D004827	221_0	bcv_final_eval_easy_1237		
	MESH:D002998	"<span class=""chemical"">clonazepam</span>"	MESH:D013036	"<span class=""disease"">infantile spasms</span>"	"Sixty patients (age-range one month to 14 years) with other types of epilepsy than <span class=""disease"">infantile spasms</span> were treated with <span class=""chemical"">clonazepam</span>."		221.0	221_MESH:D002998_MESH:D013036	221_1	bcv_final_eval_easy_1238		
	MESH:D002998	"<span class=""chemical"">clonazepam</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"Sixty patients (age-range one month to 14 years) with other types of <span class=""disease"">epilepsy</span> than infantile spasms were treated with <span class=""chemical"">clonazepam</span>."		221.0	221_MESH:D002998_MESH:D004827	221_1	bcv_final_eval_easy_1239		
	MESH:D013999	"<span class=""chemical"">timolol maleate</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of <span class=""chemical"">timolol maleate</span> and 25 mg of hydrochlorothiazide, administered twice daily for one month to <span class=""disease"">hypertensive</span> patients."		222.0	222_MESH:D013999_MESH:D006973	222_1	bcv_final_eval_easy_1240		
	MESH:D006852	"<span class=""chemical"">hydrochlorothiazide</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of <span class=""chemical"">hydrochlorothiazide</span>, administered twice daily for one month to <span class=""disease"">hypertensive</span> patients."		222.0	222_MESH:D006852_MESH:D006973	222_1	bcv_final_eval_easy_1241		
	MESH:D011453	"<span class=""chemical"">prostaglandins</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Salicylate <span class=""disease"">nephropathy</span> in the Gunn rat: potential role of <span class=""chemical"">prostaglandins</span>."		223.0	223_MESH:D011453_MESH:D007674	223_0	bcv_final_eval_easy_1242		
	MESH:D011453	"<span class=""chemical"">prostaglandins</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"We examined the potential role of <span class=""chemical"">prostaglandins</span> in the development of analgesic <span class=""disease"">nephropathy</span> in the Gunn strain of rat."		223.0	223_MESH:D011453_MESH:D007674	223_1	bcv_final_eval_easy_1243		
	MESH:D001663	"<span class=""chemical"">bilirubin</span>"	MESH:D003414	"<span class=""disease"">unconjugated hyperbilirubinemia</span>"	"The homozygous Gunn rats have <span class=""disease"">unconjugated hyperbilirubinemia</span> due to the absence of glucuronyl transferase, leading to marked <span class=""chemical"">bilirubin</span> deposition in renal medulla and papilla."		223.0	223_MESH:D001663_MESH:D003414	223_2	bcv_final_eval_easy_1244		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D007674	"<span class=""disease"">renal damage</span>"	"The changes in renal prostaglandin synthesis were accompanied by evidence of <span class=""disease"">renal damage</span> in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum <span class=""chemical"">creatinine</span> (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ)."		223.0	223_MESH:D003404_MESH:D007674	223_12	bcv_final_eval_easy_1245		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D007674	"<span class=""disease"">renal damage</span>"	"The changes in renal prostaglandin synthesis were accompanied by evidence of <span class=""disease"">renal damage</span> in <span class=""chemical"">aspirin</span>-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or <span class=""chemical"">aspirin</span>-treated jJ)."		223.0	223_MESH:D001241_MESH:D007674	223_12	bcv_final_eval_easy_1246		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D006417	"<span class=""disease"">hematuria</span>"	"The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of <span class=""disease"">hematuria</span> (p less than 0.01); increased serum <span class=""chemical"">creatinine</span> (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ)."		223.0	223_MESH:D003404_MESH:D006417	223_12	bcv_final_eval_easy_1247		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D006417	"<span class=""disease"">hematuria</span>"	"The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in <span class=""chemical"">aspirin</span>-treated jj but not jJ rats as evidenced by: increased incidence and severity of <span class=""disease"">hematuria</span> (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or <span class=""chemical"">aspirin</span>-treated jJ)."		223.0	223_MESH:D001241_MESH:D006417	223_12	bcv_final_eval_easy_1248		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Prophylactic <span class=""chemical"">lidocaine</span> in the early phase of suspected <span class=""disease"">myocardial infarction</span>."		224.0	224_MESH:D008012_MESH:D009203	224_0	bcv_final_eval_easy_1249		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Four hundred two patients with suspected <span class=""disease"">myocardial infarction</span> seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of <span class=""chemical"">lidocaine</span> vs placebo."		224.0	224_MESH:D008012_MESH:D009203	224_1	bcv_final_eval_easy_1250		
	MESH:D008012	"<span class=""chemical"">Lidocaine</span>"	MESH:D001145	"<span class=""disease"">warning arrhythmias</span>"	"<span class=""chemical"">Lidocaine</span>, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with <span class=""disease"">warning arrhythmias</span> between 15 and 45 minutes after the administration of <span class=""chemical"">lidocaine</span> (p less than 0.05)."		224.0	224_MESH:D008012_MESH:D001145	224_3	bcv_final_eval_easy_1251		
	MESH:D008012	"<span class=""chemical"">Lidocaine</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"<span class=""chemical"">Lidocaine</span>, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained <span class=""disease"">ventricular tachycardia</span>, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of <span class=""chemical"">lidocaine</span> (p less than 0.05)."		224.0	224_MESH:D008012_MESH:D017180	224_3	bcv_final_eval_easy_1252		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D007238	"<span class=""disease"">infarction</span>"	"The average plasma <span class=""chemical"">lidocaine</span> level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute <span class=""disease"">infarction</span>."		224.0	224_MESH:D008012_MESH:D007238	224_4	bcv_final_eval_easy_1253		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"The average plasma <span class=""chemical"">lidocaine</span> level 10 minutes after administration for patients without a <span class=""disease"">myocardial infarction</span> was significantly higher than that for patients with an acute infarction."		224.0	224_MESH:D008012_MESH:D009203	224_4	bcv_final_eval_easy_1254		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D006323	"<span class=""disease"">asystole</span>"	"During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the <span class=""chemical"">lidocaine</span> group, hypotension occurred in 11 patients, nine of whom had received <span class=""chemical"">lidocaine</span>, and four patients died from <span class=""disease"">asystole</span>, three of whom had had <span class=""chemical"">lidocaine</span>."		224.0	224_MESH:D008012_MESH:D006323	224_6	bcv_final_eval_easy_1255		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the <span class=""chemical"">lidocaine</span> group, <span class=""disease"">hypotension</span> occurred in 11 patients, nine of whom had received <span class=""chemical"">lidocaine</span>, and four patients died from asystole, three of whom had had <span class=""chemical"">lidocaine</span>."		224.0	224_MESH:D008012_MESH:D007022	224_6	bcv_final_eval_easy_1256		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"We cannot advocate the administration of <span class=""chemical"">lidocaine</span> prophylactically in the early hours of suspected <span class=""disease"">myocardial infarction</span>."		224.0	224_MESH:D008012_MESH:D009203	224_7	bcv_final_eval_easy_1257		
	MESH:D001285	"<span class=""chemical"">atropine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"A muscarinic receptor blocker, <span class=""chemical"">atropine</span>, disrupted haloperidol-induced <span class=""disease"">catalepsy</span>."		225.0	225_MESH:D001285_MESH:D002375	225_4	bcv_final_eval_easy_1258		
	MESH:D000109	"<span class=""chemical"">acetylcholine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Intracranial injection of an <span class=""chemical"">acetylcholine</span>-synthesis inhibitor, hemicholinium, prevented the <span class=""disease"">catalepsy</span> that is usually induced by haloperidol."		225.0	225_MESH:D000109_MESH:D002375	225_5	bcv_final_eval_easy_1259		
	MESH:D006426	"<span class=""chemical"">hemicholinium</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Intracranial injection of an acetylcholine-synthesis inhibitor, <span class=""chemical"">hemicholinium</span>, prevented the <span class=""disease"">catalepsy</span> that is usually induced by haloperidol."		225.0	225_MESH:D006426_MESH:D002375	225_5	bcv_final_eval_easy_1260		
	MESH:C024986	"<span class=""chemical"">barium chloride</span>"	MESH:D002318	"<span class=""disease"">Cardiovascular dysfunction</span>"	"<span class=""disease"">Cardiovascular dysfunction</span> and hypersensitivity to sodium pentobarbital induced by chronic <span class=""chemical"">barium chloride</span> ingestion."		226.0	226_MESH:C024986_MESH:D002318	226_0	bcv_final_eval_easy_1261		
	MESH:C024986	"<span class=""chemical"">barium chloride</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"Cardiovascular dysfunction and <span class=""disease"">hypersensitivity</span> to sodium pentobarbital induced by chronic <span class=""chemical"">barium chloride</span> ingestion."		226.0	226_MESH:C024986_MESH:D004342	226_0	bcv_final_eval_easy_1262		
	MESH:D001464	"<span class=""chemical"">Barium</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"<span class=""chemical"">Barium</span>-supplemented Long-Evans hooded rats were characterized by a persistent <span class=""disease"">hypertension</span> that was evident after 1 month of <span class=""chemical"">barium</span> (100 micrograms/ml mineral fortified water) treatment."		226.0	226_MESH:D001464_MESH:D006973	226_1	bcv_final_eval_easy_1263		
	MESH:D001464	"<span class=""chemical"">barium</span>"	MESH:D009202	"<span class=""disease"">myocardial excitability</span>"	"Analysis of in vivo <span class=""disease"">myocardial excitability</span>, contractility, and metabolic characteristics at 16 months revealed other significant <span class=""chemical"">barium</span>-induced disturbances within the cardiovascular system."		226.0	226_MESH:D001464_MESH:D009202	226_2	bcv_final_eval_easy_1264		
	MESH:D001464	"<span class=""chemical"">barium</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"The most distinctive aspect of the <span class=""chemical"">barium</span> effect was a demonstrated <span class=""disease"">hypersensitivity</span> of the cardiovascular system to sodium pentobarbital."		226.0	226_MESH:D001464_MESH:D004342	226_3	bcv_final_eval_easy_1265		
	MESH:D001464	"<span class=""chemical"">barium</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the <span class=""disease"">hypersensitivity</span> of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic <span class=""chemical"">barium</span> exposure."		226.0	226_MESH:D001464_MESH:D004342	226_10	bcv_final_eval_easy_1266		
	MESH:D001464	"<span class=""chemical"">barium</span>"	MESH:D044542	"<span class=""disease"">cardiomyopathic disorder</span>"	"Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed <span class=""disease"">cardiomyopathic disorder</span> induced by chronic <span class=""chemical"">barium</span> exposure."		226.0	226_MESH:D001464_MESH:D044542	226_10	bcv_final_eval_easy_1267		
	MESH:D011433	"<span class=""chemical"">Propranolol</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"<span class=""chemical"">Propranolol</span> antagonism of phenylpropanolamine-induced <span class=""disease"">hypertension</span>."		227.0	227_MESH:D011433_MESH:D006973	227_0	bcv_final_eval_easy_1268		
	MESH:D010665	"<span class=""chemical"">Phenylpropanolamine/PPA</span>"	MESH:D062787	"<span class=""disease"">overdose</span>"	"<span class=""chemical"">Phenylpropanolamine</span> (<span class=""chemical"">PPA</span>) <span class=""disease"">overdose</span> can cause severe hypertension, intracerebral hemorrhage, and death."		227.0	227_MESH:D010665_MESH:D062787	227_1	bcv_final_eval_easy_1269		
	MESH:D010665	"<span class=""chemical"">Phenylpropanolamine/PPA</span>"	MESH:D002543	"<span class=""disease"">intracerebral hemorrhage</span>"	"<span class=""chemical"">Phenylpropanolamine</span> (<span class=""chemical"">PPA</span>) overdose can cause severe hypertension, <span class=""disease"">intracerebral hemorrhage</span>, and death."		227.0	227_MESH:D010665_MESH:D002543	227_1	bcv_final_eval_easy_1270		
	MESH:D010665	"<span class=""chemical"">Phenylpropanolamine/PPA</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"<span class=""chemical"">Phenylpropanolamine</span> (<span class=""chemical"">PPA</span>) overdose can cause severe hypertension, intracerebral hemorrhage, and <span class=""disease"">death</span>."		227.0	227_MESH:D010665_MESH:D003643	227_1	bcv_final_eval_easy_1271		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"We studied the efficacy and safety of <span class=""chemical"">propranolol</span> in the treatment of PPA-induced <span class=""disease"">hypertension</span>."		227.0	227_MESH:D011433_MESH:D006973	227_2	bcv_final_eval_easy_1272		
	MESH:D010665	"<span class=""chemical"">PPA</span>"	MESH:D020521	"<span class=""disease"">stroke</span>"	"Left ventricular function (assessed by echocardiography) showed that <span class=""chemical"">PPA</span> increased the <span class=""disease"">stroke</span> volume 30% (from 62.5 +/- 20.9 to 80.8 +/- 22.4 ml), the ejection fraction 9% (from 64% +/- 10% to 70% +/- 7%), and cardiac output 14% (from 3.6 +/- 0.6 to 4.1 +/- 1.0 L/min)."		227.0	227_MESH:D010665_MESH:D020521	227_6	bcv_final_eval_easy_1273		
	MESH:D011692	"<span class=""chemical"">aminonucleoside</span>"	MESH:D007674	"<span class=""disease"">glomerular sclerosis</span>"	"Mesangial function and <span class=""disease"">glomerular sclerosis</span> in rats with <span class=""chemical"">aminonucleoside</span> nephrosis."		228.0	228_MESH:D011692_MESH:D007674	228_0	bcv_final_eval_easy_1274		
	MESH:D011692	"<span class=""chemical"">aminonucleoside</span>"	MESH:D009401	"<span class=""disease"">nephrosis</span>"	"Mesangial function and glomerular sclerosis in rats with <span class=""chemical"">aminonucleoside</span> <span class=""disease"">nephrosis</span>."		228.0	228_MESH:D011692_MESH:D009401	228_0	bcv_final_eval_easy_1275		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside/PAN</span>"	MESH:D007674	"<span class=""disease"">glomerular sclerosis</span>"	"The possible relationship between mesangial dysfunction and development of <span class=""disease"">glomerular sclerosis</span> was studied in the <span class=""chemical"">puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>) model."		228.0	228_MESH:D011692_MESH:D007674	228_1	bcv_final_eval_easy_1276		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside/PAN</span>"	MESH:C537346	"<span class=""disease"">mesangial dysfunction</span>"	"The possible relationship between <span class=""disease"">mesangial dysfunction</span> and development of glomerular sclerosis was studied in the <span class=""chemical"">puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>) model."		228.0	228_MESH:D011692_MESH:C537346	228_1	bcv_final_eval_easy_1277		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">glomerular sclerosis</span>"	"At 5 months <span class=""disease"">glomerular sclerosis</span> was found in 7.6 +/- 3.4% of the glomeruli of <span class=""chemical"">PAN</span> rats; glomeruli of the controls were normal."		228.0	228_MESH:D011692_MESH:D007674	228_4	bcv_final_eval_easy_1278		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D012598	"<span class=""disease"">sclerosis</span>"	"Since mesangial CC clearance from the mesangium did not change during chronic <span class=""chemical"">PAN</span> treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where <span class=""disease"">sclerosis</span> will develop subsequently."		228.0	228_MESH:D011692_MESH:D012598	228_8	bcv_final_eval_easy_1279		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">glomerular sclerosis</span>"	"Similar to the remnant kidney model in <span class=""chemical"">PAN</span> nephrosis the development of <span class=""disease"">glomerular sclerosis</span> may be related to ""mesangial overloading."""		228.0	228_MESH:D011692_MESH:D007674	228_10	bcv_final_eval_easy_1280		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D009401	"<span class=""disease"">nephrosis</span>"	"Similar to the remnant kidney model in <span class=""chemical"">PAN</span> <span class=""disease"">nephrosis</span> the development of glomerular sclerosis may be related to ""mesangial overloading."""		228.0	228_MESH:D011692_MESH:D009401	228_10	bcv_final_eval_easy_1281		
	MESH:D004229	"<span class=""chemical"">dithiothreitol</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"The binding sites from <span class=""disease"">seizure</span> sensitive and resistant mice were equally affected by treatment with <span class=""chemical"">dithiothreitol</span>, trypsin or heat."		229.0	229_MESH:D004229_MESH:D012640	229_4	bcv_final_eval_easy_1282		
	MESH:D000082	"<span class=""chemical"">APAP/Acetaminophen</span>"	MESH:D009956	"<span class=""disease"">tubular necrosis</span>"	"<span class=""chemical"">Acetaminophen</span> (<span class=""chemical"">APAP</span>) produces proximal <span class=""disease"">tubular necrosis</span> in Fischer 344 (F344) rats."		230.0	230_MESH:D000082_MESH:D009956	230_1	bcv_final_eval_easy_1283		
	MESH:C026729	"<span class=""chemical"">PAP</span>"	MESH:D007683	"<span class=""disease"">renal tubular necrosis</span>"	"It is concluded that <span class=""chemical"">PAP</span> formation, in vivo, accounts, at least in part, for APAP-induced <span class=""disease"">renal tubular necrosis</span>."		230.0	230_MESH:C026729_MESH:D007683	230_11	bcv_final_eval_easy_1284		
	MESH:D009020	"<span class=""chemical"">morphine sulfate</span>"	MESH:D000699	"<span class=""disease"">analgesia</span>"	"Two neonates suffered from generalized seizures during the course of intravenous <span class=""chemical"">morphine sulfate</span> for post-operative <span class=""disease"">analgesia</span>."		231.0	231_MESH:D009020_MESH:D000699	231_1	bcv_final_eval_easy_1285		
	MESH:D014750	"<span class=""chemical"">vincristine sulfate</span>"	MESH:D011552	"<span class=""disease"">Pseudomonas infections</span>"	"Effect of <span class=""chemical"">vincristine sulfate</span> on <span class=""disease"">Pseudomonas infections</span> in monkeys."		232.0	232_MESH:D014750_MESH:D011552	232_0	bcv_final_eval_easy_1286		
	MESH:D014750	"<span class=""chemical"">vincristine sulfate</span>"	MESH:D007970	"<span class=""disease"">leukopenia</span>"	"Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of <span class=""chemical"">vincristine sulfate</span> was followed by <span class=""disease"">leukopenia</span> in 4 to 5 days."		232.0	232_MESH:D014750_MESH:D007970	232_3	bcv_final_eval_easy_1287		
	MESH:D014750	"<span class=""chemical"">vincristine sulfate</span>"	MESH:D007239	"<span class=""disease"">infection</span>"	"Intravenous inoculation of 4.2 x 10(10) to 7.8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given <span class=""chemical"">vincristine sulfate</span> 4 days previously resulted in fatal <span class=""disease"">infection</span> in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died."		232.0	232_MESH:D014750_MESH:D007239	232_4	bcv_final_eval_easy_1288		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg <span class=""chemical"">propranolol</span> (nonselective), and placebo on both exercise- and isoproterenol-induced <span class=""disease"">tachycardia</span> in two experiments involving nine normal subjects."		234.0	234_MESH:D011433_MESH:D013610	234_1	bcv_final_eval_easy_1289		
	MESH:D001262	"<span class=""chemical"">atenolol</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"We compared the effects of single doses of 50 mg <span class=""chemical"">atenolol</span> (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced <span class=""disease"">tachycardia</span> in two experiments involving nine normal subjects."		234.0	234_MESH:D001262_MESH:D013610	234_1	bcv_final_eval_easy_1290		
	MESH:D001285	"<span class=""chemical"">atropine</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"The effects on isoproterenol <span class=""disease"">tachycardia</span> were determined before and after <span class=""chemical"">atropine</span> (0.04 mg/kg IV)."		234.0	234_MESH:D001285_MESH:D013610	234_3	bcv_final_eval_easy_1291		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D007239	"<span class=""disease"">infections</span>"	"Early <span class=""disease"">infections</span> in kidney, heart, and liver transplant recipients on <span class=""chemical"">cyclosporine</span>."		236.0	236_MESH:D016572_MESH:D007239	236_0	bcv_final_eval_easy_1292		
	MESH:D001379	"<span class=""chemical"">Aza</span>"	MESH:D007239	"<span class=""disease"">nonviral infections/overall infections</span>"	"The randomized <span class=""chemical"">Aza</span> patients had more <span class=""disease"">overall infections</span> (P less than 0.05) and more <span class=""disease"">nonviral infections</span> (P less than 0.02) than the randomized cyclosporine patients."		236.0	236_MESH:D001379_MESH:D007239	236_4	bcv_final_eval_easy_1293		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D007239	"<span class=""disease"">nonviral infections/overall infections</span>"	"The randomized Aza patients had more <span class=""disease"">overall infections</span> (P less than 0.05) and more <span class=""disease"">nonviral infections</span> (P less than 0.02) than the randomized <span class=""chemical"">cyclosporine</span> patients."		236.0	236_MESH:D016572_MESH:D007239	236_4	bcv_final_eval_easy_1294		
	MESH:D001379	"<span class=""chemical"">Aza</span>"	MESH:D007239	"<span class=""disease"">infections</span>"	"Heart and liver patients had more <span class=""disease"">infections</span> than cyclosporine renal patients but fewer <span class=""disease"">infections</span> than the <span class=""chemical"">Aza</span> renal patients."		236.0	236_MESH:D001379_MESH:D007239	236_5	bcv_final_eval_easy_1295		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D007239	"<span class=""disease"">infections</span>"	"Heart and liver patients had more <span class=""disease"">infections</span> than <span class=""chemical"">cyclosporine</span> renal patients but fewer <span class=""disease"">infections</span> than the Aza renal patients."		236.0	236_MESH:D016572_MESH:D007239	236_5	bcv_final_eval_easy_1296		
	MESH:D001379	"<span class=""chemical"">Aza</span>"	MESH:D007239	"<span class=""disease"">infection</span>"	"There were no infectious deaths in renal transplant patients on cyclosporine or <span class=""chemical"">Aza</span>, but <span class=""disease"">infection</span> played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths."		236.0	236_MESH:D001379_MESH:D007239	236_6	bcv_final_eval_easy_1297		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D007239	"<span class=""disease"">infection</span>"	"There were no infectious deaths in renal transplant patients on <span class=""chemical"">cyclosporine</span> or Aza, but <span class=""disease"">infection</span> played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths."		236.0	236_MESH:D016572_MESH:D007239	236_6	bcv_final_eval_easy_1298		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D016470	"<span class=""disease"">fewest bacteremias</span>"	"Renal patients on <span class=""chemical"">cyclosporine</span> had the <span class=""disease"">fewest bacteremias</span>."		236.0	236_MESH:D016572_MESH:D016470	236_7	bcv_final_eval_easy_1299		
	MESH:D001379	"<span class=""chemical"">Aza</span>"	MESH:D008171	"<span class=""disease"">Pulmonary infections</span>"	"<span class=""disease"">Pulmonary infections</span> were less common in cyclosporine-treated renal patients than in <span class=""chemical"">Aza</span>-treated patients (P less than 0.05)."		236.0	236_MESH:D001379_MESH:D008171	236_9	bcv_final_eval_easy_1300		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D008171	"<span class=""disease"">Pulmonary infections</span>"	"<span class=""disease"">Pulmonary infections</span> were less common in <span class=""chemical"">cyclosporine</span>-treated renal patients than in Aza-treated patients (P less than 0.05)."		236.0	236_MESH:D016572_MESH:D008171	236_9	bcv_final_eval_easy_1301		
	MESH:D001379	"<span class=""chemical"">Aza</span>"	MESH:D013203	"<span class=""disease"">staphylococcal infections</span>"	"<span class=""chemical"">Aza</span> patients had significantly more <span class=""disease"">staphylococcal infections</span> than all other transplant groups (P less than 0.005), and systemic fungal infections occurred only in the liver transplant group."		236.0	236_MESH:D001379_MESH:D013203	236_10	bcv_final_eval_easy_1302		
	MESH:D001379	"<span class=""chemical"">Aza</span>"	MESH:D009181	"<span class=""disease"">fungal infections</span>"	"<span class=""chemical"">Aza</span> patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic <span class=""disease"">fungal infections</span> occurred only in the liver transplant group."		236.0	236_MESH:D001379_MESH:D009181	236_10	bcv_final_eval_easy_1303		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D003586	"<span class=""disease"">CMV infection</span>"	"Of the <span class=""chemical"">cyclosporine</span> patients, 15% had symptoms related to <span class=""disease"">CMV infection</span>."		236.0	236_MESH:D016572_MESH:D003586	236_12	bcv_final_eval_easy_1304		
	MESH:D016572	"<span class=""chemical"">cyclosporine</span>"	MESH:D020031	"<span class=""disease"">Epstein Barr Virus infection</span>"	"Serological evidence for <span class=""disease"">Epstein Barr Virus infection</span> was found in 20% of 65 <span class=""chemical"">cyclosporine</span> patients studied."		236.0	236_MESH:D016572_MESH:D020031	236_13	bcv_final_eval_easy_1305		
	MESH:D002766	"<span class=""chemical"">cholecystokinin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced <span class=""disease"">seizures</span> by <span class=""chemical"">cholecystokinin</span>, fragments and analogues of <span class=""chemical"">cholecystokinin</span> in mice."		237.0	237_MESH:D002766_MESH:D012640	237_0	bcv_final_eval_easy_1306		
	MESH:D002766	"<span class=""chemical"">cholecystokinin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated <span class=""chemical"">cholecystokinin</span> octapeptide (CCK-8-NS) enhanced the latency of <span class=""disease"">seizures</span> induced by picrotoxin in mice."		237.0	237_MESH:D002766_MESH:D012640	237_1	bcv_final_eval_easy_1307		
	MESH:D003975	"<span class=""chemical"">diazepam</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, <span class=""chemical"">diazepam</span>, totally prevented picrotoxin-induced <span class=""disease"">seizures</span> and mortality."		237.0	237_MESH:D003975_MESH:D012640	237_4	bcv_final_eval_easy_1308		
	MESH:D014667	"<span class=""chemical"">Vasopressin</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"<span class=""chemical"">Vasopressin</span> as a possible contributor to <span class=""disease"">hypertension</span>."		238.0	238_MESH:D014667_MESH:D006973	238_0	bcv_final_eval_easy_1309		
	MESH:D014667	"<span class=""chemical"">vasopressin</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"The role of <span class=""chemical"">vasopressin</span> as a pressor agent to the <span class=""disease"">hypertensive</span> process was examined."		238.0	238_MESH:D014667_MESH:D006973	238_1	bcv_final_eval_easy_1310		
	MESH:D014667	"<span class=""chemical"">Vasopressin</span>"	MESH:D003919	"<span class=""disease"">diabetes insipidus</span>"	"<span class=""chemical"">Vasopressin</span> plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated <span class=""disease"">diabetes insipidus</span> after DOCA-salt treatment."		238.0	238_MESH:D014667_MESH:D003919	238_2	bcv_final_eval_easy_1311		
	MESH:D003900	"<span class=""chemical"">DOCA</span>"	MESH:D003919	"<span class=""disease"">diabetes insipidus</span>"	"Vasopressin plays a major role in the pathogenesis of <span class=""chemical"">DOCA</span>-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated <span class=""disease"">diabetes insipidus</span> after <span class=""chemical"">DOCA</span>-salt treatment."		238.0	238_MESH:D003900_MESH:D003919	238_2	bcv_final_eval_easy_1312		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D003919	"<span class=""disease"">diabetes insipidus</span>"	"Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with <span class=""chemical"">lithium</span>-treated <span class=""disease"">diabetes insipidus</span> after DOCA-salt treatment."		238.0	238_MESH:D008094_MESH:D003919	238_2	bcv_final_eval_easy_1313		
	MESH:D014667	"<span class=""chemical"">Vasopressin</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"<span class=""chemical"">Vasopressin</span> plays a major role in the pathogenesis of DOCA-salt <span class=""disease"">hypertension</span>, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment."		238.0	238_MESH:D014667_MESH:D006973	238_2	bcv_final_eval_easy_1314		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Vasopressin plays a major role in the pathogenesis of DOCA-salt <span class=""disease"">hypertension</span>, since the elevation of blood pressure was not substantial in the rats with <span class=""chemical"">lithium</span>-treated diabetes insipidus after DOCA-salt treatment."		238.0	238_MESH:D008094_MESH:D006973	238_2	bcv_final_eval_easy_1315		
	MESH:D003900	"<span class=""chemical"">DOCA</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Vasopressin plays a major role in the pathogenesis of <span class=""chemical"">DOCA</span>-salt <span class=""disease"">hypertension</span>, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after <span class=""chemical"">DOCA</span>-salt treatment."		238.0	238_MESH:D003900_MESH:D006973	238_2	bcv_final_eval_easy_1316		
	MESH:D014667	"<span class=""chemical"">vasopressin</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Furthermore, the pressor action of <span class=""chemical"">vasopressin</span> appears to be important in the development of this model of <span class=""disease"">hypertension</span>, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of <span class=""disease"">hypertension</span>."		238.0	238_MESH:D014667_MESH:D006973	238_4	bcv_final_eval_easy_1317		
	MESH:D014667	"<span class=""chemical"">vasopressin</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Increased secretion of <span class=""chemical"">vasopressin</span> from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in <span class=""disease"">hypertension</span>."		238.0	238_MESH:D014667_MESH:D006973	238_5	bcv_final_eval_easy_1318		
	MESH:D014667	"<span class=""chemical"">vasopressin</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"However, the role of <span class=""chemical"">vasopressin</span> remains to be determined in human essential <span class=""disease"">hypertension</span>."		238.0	238_MESH:D014667_MESH:D006973	238_7	bcv_final_eval_easy_1319		
	MESH:D004221	"<span class=""chemical"">disulfiram</span>"	MESH:D056486	"<span class=""disease"">Toxic hepatitis</span>"	"<span class=""disease"">Toxic hepatitis</span> induced by <span class=""chemical"">disulfiram</span> in a non-alcoholic."		239.0	239_MESH:D004221_MESH:D056486	239_0	bcv_final_eval_easy_1320		
	MESH:D004221	"<span class=""chemical"">disulfiram</span>"	MESH:D056486	"<span class=""disease"">toxic liver damage</span>"	"A reversible <span class=""disease"">toxic liver damage</span> was observed in a non-alcoholic woman treated with <span class=""chemical"">disulfiram</span>."		239.0	239_MESH:D004221_MESH:D056486	239_1	bcv_final_eval_easy_1321		
	MESH:D011796	"<span class=""chemical"">quinacrine hydrochloride</span>"	MESH:D013927	"<span class=""disease"">Atrial thrombosis</span>"	"<span class=""disease"">Atrial thrombosis</span> involving the heart of F-344 rats ingesting <span class=""chemical"">quinacrine hydrochloride</span>."		240.0	240_MESH:D011796_MESH:D013927	240_0	bcv_final_eval_easy_1322		
	MESH:D011796	"<span class=""chemical"">quinacrine hydrochloride</span>"	MESH:D013927	"<span class=""disease"">atrial thrombosis</span>"	"Rats treated with 500 ppm <span class=""chemical"">quinacrine hydrochloride</span> in the diet all developed a high incidence of left <span class=""disease"">atrial thrombosis</span>."		240.0	240_MESH:D011796_MESH:D013927	240_2	bcv_final_eval_easy_1323		
	MESH:D011796	"<span class=""chemical"">quinacrine hydrochloride</span>"	MESH:D013927	"<span class=""disease"">atrial thrombosis/thrombosis</span>"	"Seventy percent of rats given 250 ppm <span class=""chemical"">quinacrine hydrochloride</span> and 1,000 ppm sodium nitrite simultaneously in the diet had <span class=""disease"">thrombosis</span> of the atria of the heart, while untreated control rats in this laboratory did not have <span class=""disease"">atrial thrombosis</span>."		240.0	240_MESH:D011796_MESH:D013927	240_5	bcv_final_eval_easy_1324		
	MESH:D012977	"<span class=""chemical"">sodium nitrite</span>"	MESH:D013927	"<span class=""disease"">atrial thrombosis/thrombosis</span>"	"Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm <span class=""chemical"">sodium nitrite</span> simultaneously in the diet had <span class=""disease"">thrombosis</span> of the atria of the heart, while untreated control rats in this laboratory did not have <span class=""disease"">atrial thrombosis</span>."		240.0	240_MESH:D012977_MESH:D013927	240_5	bcv_final_eval_easy_1325		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D012848	"<span class=""disease"">sinoatrial block</span>"	"Alternating sinus rhythm and intermittent <span class=""disease"">sinoatrial block</span> induced by <span class=""chemical"">propranolol</span>."		241.0	241_MESH:D011433_MESH:D012848	241_0	bcv_final_eval_easy_1326		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D000787	"<span class=""disease"">angina</span>"	"Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for <span class=""disease"">angina</span> with 80 mg <span class=""chemical"">propranolol</span> daily."		241.0	241_MESH:D011433_MESH:D000787	241_1	bcv_final_eval_easy_1327		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D019955	"<span class=""disease"">conduction disorder</span>"	"This was accepted as evidence for <span class=""chemical"">propranolol</span> being the cause of this <span class=""disease"">conduction disorder</span>."		241.0	241_MESH:D011433_MESH:D019955	241_13	bcv_final_eval_easy_1328		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Antitumor effect, <span class=""disease"">cardiotoxicity</span>, and nephrotoxicity of <span class=""chemical"">doxorubicin</span> in the IgM solid immunocytoma-bearing LOU/M/WSL rat."		242.0	242_MESH:D004317_MESH:D066126	242_0	bcv_final_eval_easy_1329		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Antitumor activity, <span class=""disease"">cardiotoxicity</span>, and nephrotoxicity induced by <span class=""chemical"">doxorubicin</span> were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma."		242.0	242_MESH:D004317_MESH:D066126	242_1	bcv_final_eval_easy_1330		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Animals with a <span class=""disease"">tumor</span> (diameter, 15.8 +/- 3.3 mm) were treated with iv injections of <span class=""chemical"">doxorubicin</span> on 5 consecutive days, followed by 1 weekly injection for 7 weeks (dose range, 0.015-4.0 mg/kg body wt)."		242.0	242_MESH:D004317_MESH:D009369	242_2	bcv_final_eval_easy_1331		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009369	"<span class=""disease"">Tumor</span>"	"<span class=""disease"">Tumor</span> regression was observed with 0.5 mg <span class=""chemical"">doxorubicin</span>/kg."		242.0	242_MESH:D004317_MESH:D009369	242_3	bcv_final_eval_easy_1332		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Complete disappearance of the <span class=""disease"">tumor</span> was induced with 1.0 mg <span class=""chemical"">doxorubicin</span>/kg."		242.0	242_MESH:D004317_MESH:D009369	242_4	bcv_final_eval_easy_1333		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Histologic evidence of <span class=""disease"">cardiotoxicity</span> scored as grade III was only observed at a dose of 1.0 mg <span class=""chemical"">doxorubicin</span>/kg."		242.0	242_MESH:D004317_MESH:D066126	242_5	bcv_final_eval_easy_1334		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D007674	"<span class=""disease"">renal damage</span>"	"Light microscopic evidence of <span class=""disease"">renal damage</span> was seen above a dose of 0.5 mg <span class=""chemical"">doxorubicin</span>/kg, which resulted in albuminuria and very low serum albumin levels."		242.0	242_MESH:D004317_MESH:D007674	242_6	bcv_final_eval_easy_1335		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D000419	"<span class=""disease"">albuminuria</span>"	"Light microscopic evidence of renal damage was seen above a dose of 0.5 mg <span class=""chemical"">doxorubicin</span>/kg, which resulted in <span class=""disease"">albuminuria</span> and very low serum albumin levels."		242.0	242_MESH:D004317_MESH:D000419	242_6	bcv_final_eval_easy_1336		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"Intraoperative <span class=""disease"">bradycardia</span> and hypotension associated with timolol and <span class=""chemical"">pilocarpine</span> eye drops."		243.0	243_MESH:D010862_MESH:D001919	243_0	bcv_final_eval_easy_1337		
	MESH:D013999	"<span class=""chemical"">timolol</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Intraoperative bradycardia and <span class=""disease"">hypotension</span> associated with <span class=""chemical"">timolol</span> and pilocarpine eye drops."		243.0	243_MESH:D013999_MESH:D007022	243_0	bcv_final_eval_easy_1338		
	MESH:D013999	"<span class=""chemical"">timolol</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"Intraoperative <span class=""disease"">bradycardia</span> and hypotension associated with <span class=""chemical"">timolol</span> and pilocarpine eye drops."		243.0	243_MESH:D013999_MESH:D001919	243_0	bcv_final_eval_easy_1339		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Intraoperative bradycardia and <span class=""disease"">hypotension</span> associated with timolol and <span class=""chemical"">pilocarpine</span> eye drops."		243.0	243_MESH:D010862_MESH:D007022	243_0	bcv_final_eval_easy_1340		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became <span class=""disease"">hypotensive</span> during <span class=""chemical"">halothane</span> anaesthesia."		243.0	243_MESH:D006221_MESH:D007022	243_1	bcv_final_eval_easy_1341		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a <span class=""disease"">bradycardia</span> and became hypotensive during <span class=""chemical"">halothane</span> anaesthesia."		243.0	243_MESH:D006221_MESH:D001919	243_1	bcv_final_eval_easy_1342		
	MESH:D010862	"<span class=""chemical"">pilocarpine nitrate</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"A 69-yr-old man, who was concurrently being treated with <span class=""chemical"">pilocarpine nitrate</span> and timolol maleate eye drops, developed a bradycardia and became <span class=""disease"">hypotensive</span> during halothane anaesthesia."		243.0	243_MESH:D010862_MESH:D007022	243_1	bcv_final_eval_easy_1343		
	MESH:D010862	"<span class=""chemical"">pilocarpine nitrate</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"A 69-yr-old man, who was concurrently being treated with <span class=""chemical"">pilocarpine nitrate</span> and timolol maleate eye drops, developed a <span class=""disease"">bradycardia</span> and became hypotensive during halothane anaesthesia."		243.0	243_MESH:D010862_MESH:D001919	243_1	bcv_final_eval_easy_1344		
	MESH:D013999	"<span class=""chemical"">timolol maleate</span>"	MESH:D007022	"<span class=""disease"">hypotensive</span>"	"A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and <span class=""chemical"">timolol maleate</span> eye drops, developed a bradycardia and became <span class=""disease"">hypotensive</span> during halothane anaesthesia."		243.0	243_MESH:D013999_MESH:D007022	243_1	bcv_final_eval_easy_1345		
	MESH:D013999	"<span class=""chemical"">timolol maleate</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and <span class=""chemical"">timolol maleate</span> eye drops, developed a <span class=""disease"">bradycardia</span> and became hypotensive during halothane anaesthesia."		243.0	243_MESH:D013999_MESH:D001919	243_1	bcv_final_eval_easy_1346		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"It is postulated that this action may have been enhanced during <span class=""chemical"">halothane</span> anaesthesia with resultant bradycardia and <span class=""disease"">hypotension</span>."		243.0	243_MESH:D006221_MESH:D007022	243_4	bcv_final_eval_easy_1347		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"It is postulated that this action may have been enhanced during <span class=""chemical"">halothane</span> anaesthesia with resultant <span class=""disease"">bradycardia</span> and hypotension."		243.0	243_MESH:D006221_MESH:D001919	243_4	bcv_final_eval_easy_1348		
	MESH:D013390	"<span class=""chemical"">succinylcholine</span>"	MESH:D009468	"<span class=""disease"">neuromuscular blockade</span>"	"Anticholinesterases were administered in an attempt to antagonize prolonged <span class=""disease"">neuromuscular blockade</span> following the administration of <span class=""chemical"">succinylcholine</span> in a patient later found to be homozygous for atypical plasma cholinesterase."		244.0	244_MESH:D013390_MESH:D009468	244_1	bcv_final_eval_easy_1349		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009202	"<span class=""disease"">myocardial scintigraphy</span>"	"Effect of <span class=""chemical"">doxorubicin</span> on [omega-I-131]heptadecanoic acid <span class=""disease"">myocardial scintigraphy</span> and echocardiography in dogs."		245.0	245_MESH:D004317_MESH:D009202	245_0	bcv_final_eval_easy_1350		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009202	"<span class=""disease"">myocardial scintigraphy</span>"	"The effects of serial treatment with <span class=""chemical"">doxorubicin</span> on dynamic <span class=""disease"">myocardial scintigraphy</span> with [omega-I-131]heptadecanoic acid (I-131 HA), and on global left-ventricular function determined echocardiographically, were studied in a group of nine mongrel dogs."		245.0	245_MESH:D004317_MESH:D009202	245_1	bcv_final_eval_easy_1351		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D051437	"<span class=""disease"">fall in global LV function</span>"	"A significant and then progressive <span class=""disease"">fall in global LV function</span> was observed at a cumulative <span class=""chemical"">doxorubicin</span> dose of 4 mg/kg."		245.0	245_MESH:D004317_MESH:D051437	245_3	bcv_final_eval_easy_1352		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in <span class=""chemical"">doxorubicin</span> <span class=""disease"">cardiotoxicity</span>."		245.0	245_MESH:D004317_MESH:D066126	245_6	bcv_final_eval_easy_1353		
	MESH:D009599	"<span class=""chemical"">SNP/sodium nitroprusside</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Coronary blood flow, cardiac work and metabolism were studied in dogs under <span class=""chemical"">sodium nitroprusside</span> (<span class=""chemical"">SNP</span>) and trimetaphan (TMP) deliberate <span class=""disease"">hypotension</span> (20% and 40% mean pressure decrease from baseline)."		246.0	246_MESH:D009599_MESH:D007022	246_1	bcv_final_eval_easy_1354		
	MESH:D014294	"<span class=""chemical"">TMP/trimetaphan</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and <span class=""chemical"">trimetaphan</span> (<span class=""chemical"">TMP</span>) deliberate <span class=""disease"">hypotension</span> (20% and 40% mean pressure decrease from baseline)."		246.0	246_MESH:D014294_MESH:D007022	246_1	bcv_final_eval_easy_1355		
	MESH:D009599	"<span class=""chemical"">nitroprusside</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Regarding the effects of drug-induced <span class=""disease"">hypotension</span> on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that <span class=""chemical"">nitroprusside</span> <span class=""disease"">hypotension</span> could be safely used to 30% mean blood pressure decrease from control, trimetaphan <span class=""disease"">hypotension</span> to 20% mean blood pressure decrease."		246.0	246_MESH:D009599_MESH:D007022	246_2	bcv_final_eval_easy_1356		
	MESH:C093415	"<span class=""chemical"">pO2</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Regarding the effects of drug-induced <span class=""disease"">hypotension</span> on coronary blood flow, aortic and coronary sinus metabolic data (pH, <span class=""chemical"">pO2</span>, pCO2) we could confirm that nitroprusside <span class=""disease"">hypotension</span> could be safely used to 30% mean blood pressure decrease from control, trimetaphan <span class=""disease"">hypotension</span> to 20% mean blood pressure decrease."		246.0	246_MESH:C093415_MESH:D007022	246_2	bcv_final_eval_easy_1357		
	MESH:D003913	"<span class=""chemical"">D-amphetamine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"The <span class=""disease"">hyperactivity</span> induced by <span class=""chemical"">D-amphetamine</span> (10 mumol/kg) was significantly reduced by DSP4 pretreatment."		247.0	247_MESH:D003913_MESH:D006948	247_2	bcv_final_eval_easy_1358		
	MESH:C012102	"<span class=""chemical"">DSP4</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"The <span class=""disease"">hyperactivity</span> induced by D-amphetamine (10 mumol/kg) was significantly reduced by <span class=""chemical"">DSP4</span> pretreatment."		247.0	247_MESH:C012102_MESH:D006948	247_2	bcv_final_eval_easy_1359		
	MESH:C012102	"<span class=""chemical"">DSP4</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"The reduction of amphetamine hyperactivity induced by <span class=""chemical"">DSP4</span> was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the <span class=""disease"">neurotoxic</span> action of <span class=""chemical"">DSP4</span>."		247.0	247_MESH:C012102_MESH:D020258	247_4	bcv_final_eval_easy_1360		
	MESH:C012102	"<span class=""chemical"">DSP4</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"The reduction of amphetamine <span class=""disease"">hyperactivity</span> induced by <span class=""chemical"">DSP4</span> was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of <span class=""chemical"">DSP4</span>."		247.0	247_MESH:C012102_MESH:D006948	247_4	bcv_final_eval_easy_1361		
	MESH:D009638	"<span class=""chemical"">noradrenaline</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"The reduction of amphetamine <span class=""disease"">hyperactivity</span> induced by DSP4 was blocked by pretreatment with the <span class=""chemical"">noradrenaline</span>-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4."		247.0	247_MESH:D009638_MESH:D006948	247_4	bcv_final_eval_easy_1362		
	MESH:D000661	"<span class=""chemical"">amphetamine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"The reduction of <span class=""chemical"">amphetamine</span> <span class=""disease"">hyperactivity</span> induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4."		247.0	247_MESH:D000661_MESH:D006948	247_4	bcv_final_eval_easy_1363		
	MESH:D003891	"<span class=""chemical"">desipramine</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, <span class=""chemical"">desipramine</span>, which prevents the <span class=""disease"">neurotoxic</span> action of DSP4."		247.0	247_MESH:D003891_MESH:D020258	247_4	bcv_final_eval_easy_1364		
	MESH:D009638	"<span class=""chemical"">noradrenaline</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the <span class=""chemical"">noradrenaline</span>-uptake blocking agent, desipramine, which prevents the <span class=""disease"">neurotoxic</span> action of DSP4."		247.0	247_MESH:D009638_MESH:D020258	247_4	bcv_final_eval_easy_1365		
	MESH:D000661	"<span class=""chemical"">amphetamine</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"The reduction of <span class=""chemical"">amphetamine</span> hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the <span class=""disease"">neurotoxic</span> action of DSP4."		247.0	247_MESH:D000661_MESH:D020258	247_4	bcv_final_eval_easy_1366		
	MESH:D003891	"<span class=""chemical"">desipramine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"The reduction of amphetamine <span class=""disease"">hyperactivity</span> induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, <span class=""chemical"">desipramine</span>, which prevents the neurotoxic action of DSP4."		247.0	247_MESH:D003891_MESH:D006948	247_4	bcv_final_eval_easy_1367		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D020511	"<span class=""disease"">junctional rhythms</span>"	"Accelerated <span class=""disease"">junctional rhythms</span> during oral <span class=""chemical"">verapamil</span> therapy."		248.0	248_MESH:D014700_MESH:D020511	248_0	bcv_final_eval_easy_1368		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D020511	"<span class=""disease"">junctional rhythms</span>"	"This study examined the frequency of atrioventricular (AV) dissociation and accelerated <span class=""disease"">junctional rhythms</span> in 59 patients receiving oral <span class=""chemical"">verapamil</span>."		248.0	248_MESH:D014700_MESH:D020511	248_1	bcv_final_eval_easy_1369		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D006327	"<span class=""disease"">atrioventricular (AV) dissociation</span>"	"This study examined the frequency of <span class=""disease"">atrioventricular (AV) dissociation</span> and accelerated junctional rhythms in 59 patients receiving oral <span class=""chemical"">verapamil</span>."		248.0	248_MESH:D014700_MESH:D006327	248_1	bcv_final_eval_easy_1370		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D020511	"<span class=""disease"">junctional rhythms</span>"	"In patients with various chest pain syndromes, <span class=""chemical"">verapamil</span> neither increased the frequency of <span class=""disease"">junctional rhythms</span> nor suppressed their role as escape rhythms under physiologically appropriate circumstances."		248.0	248_MESH:D014700_MESH:D020511	248_4	bcv_final_eval_easy_1371		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D010146	"<span class=""disease"">pain syndromes</span>"	"In patients with various chest <span class=""disease"">pain syndromes</span>, <span class=""chemical"">verapamil</span> neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances."		248.0	248_MESH:D014700_MESH:D010146	248_4	bcv_final_eval_easy_1372		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"Treatment of <span class=""disease"">ovarian cancer</span> with a combination of cis-platinum, adriamycin, <span class=""chemical"">cyclophosphamide</span> and hexamethylmelamine."		249.0	249_MESH:D003520_MESH:D010051	249_0	bcv_final_eval_easy_1373		
	MESH:D004317	"<span class=""chemical"">adriamycin</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"Treatment of <span class=""disease"">ovarian cancer</span> with a combination of cis-platinum, <span class=""chemical"">adriamycin</span>, cyclophosphamide and hexamethylmelamine."		249.0	249_MESH:D004317_MESH:D010051	249_0	bcv_final_eval_easy_1374		
	MESH:D006585	"<span class=""chemical"">hexamethylmelamine</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"Treatment of <span class=""disease"">ovarian cancer</span> with a combination of cis-platinum, adriamycin, cyclophosphamide and <span class=""chemical"">hexamethylmelamine</span>."		249.0	249_MESH:D006585_MESH:D010051	249_0	bcv_final_eval_easy_1375		
	MESH:D002945	"<span class=""chemical"">cis-platinum</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"Treatment of <span class=""disease"">ovarian cancer</span> with a combination of <span class=""chemical"">cis-platinum</span>, adriamycin, cyclophosphamide and hexamethylmelamine."		249.0	249_MESH:D002945_MESH:D010051	249_0	bcv_final_eval_easy_1376		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"During the last 2 1/2 years, 38 patients with <span class=""disease"">ovarian cancer</span> were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, <span class=""chemical"">cyclophosphamide</span>, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days."		249.0	249_MESH:D003520_MESH:D010051	249_1	bcv_final_eval_easy_1377		
	MESH:D004317	"<span class=""chemical"">adriamycin</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"During the last 2 1/2 years, 38 patients with <span class=""disease"">ovarian cancer</span> were treated with a combination of cisplatinum (CPDD), 50 mg/m2, <span class=""chemical"">adriamycin</span>, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days."		249.0	249_MESH:D004317_MESH:D010051	249_1	bcv_final_eval_easy_1378		
	MESH:D006585	"<span class=""chemical"">HMM/hexamethylmelamine</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"During the last 2 1/2 years, 38 patients with <span class=""disease"">ovarian cancer</span> were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and <span class=""chemical"">hexamethylmelamine</span> (<span class=""chemical"">HMM</span>), 6 mg/kg daily, for 14 days."		249.0	249_MESH:D006585_MESH:D010051	249_1	bcv_final_eval_easy_1379		
	MESH:D002945	"<span class=""chemical"">cisplatinum</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"During the last 2 1/2 years, 38 patients with <span class=""disease"">ovarian cancer</span> were treated with a combination of <span class=""chemical"">cisplatinum</span> (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days."		249.0	249_MESH:D002945_MESH:D010051	249_1	bcv_final_eval_easy_1380		
	MESH:D015764	"<span class=""chemical"">bepridil</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"Studies on the <span class=""disease"">bradycardia</span> induced by <span class=""chemical"">bepridil</span>."		252.0	252_MESH:D015764_MESH:D001919	252_0	bcv_final_eval_easy_1381		
	MESH:D015764	"<span class=""chemical"">Bepridil</span>"	MESH:D001919	"<span class=""disease"">bradycardia</span>"	"<span class=""chemical"">Bepridil</span>, a novel active compound for prophylactic treatment of anginal attacks, induced persistent <span class=""disease"">bradycardia</span> and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo."		252.0	252_MESH:D015764_MESH:D001919	252_1	bcv_final_eval_easy_1382		
	MESH:D015764	"<span class=""chemical"">Bepridil</span>"	MESH:D016584	"<span class=""disease"">anginal attacks</span>"	"<span class=""chemical"">Bepridil</span>, a novel active compound for prophylactic treatment of <span class=""disease"">anginal attacks</span>, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo."		252.0	252_MESH:D015764_MESH:D016584	252_1	bcv_final_eval_easy_1383		
	MESH:D008733	"<span class=""chemical"">methoxyflurane</span>"	MESH:D007674	"<span class=""disease"">renal tubular acidosis</span>"	"Hepatitis and <span class=""disease"">renal tubular acidosis</span> after anesthesia with <span class=""chemical"">methoxyflurane</span>."		253.0	253_MESH:D008733_MESH:D007674	253_0	bcv_final_eval_easy_1384		
	MESH:D008733	"<span class=""chemical"">methoxyflurane</span>"	MESH:D056486	"<span class=""disease"">Hepatitis</span>"	"<span class=""disease"">Hepatitis</span> and renal tubular acidosis after anesthesia with <span class=""chemical"">methoxyflurane</span>."		253.0	253_MESH:D008733_MESH:D056486	253_0	bcv_final_eval_easy_1385		
	MESH:D008733	"<span class=""chemical"">methoxyflurane</span>"	MESH:D002764	"<span class=""disease"">cholecystitis</span>"	"A 69-year-old man operated for acute <span class=""disease"">cholecystitis</span> under <span class=""chemical"">methoxyflurane</span> anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis."		253.0	253_MESH:D008733_MESH:D002764	253_1	bcv_final_eval_easy_1386		
	MESH:D008733	"<span class=""chemical"">methoxyflurane</span>"	MESH:D048550	"<span class=""disease"">hepatic insufficiency syndrome</span>"	"A 69-year-old man operated for acute cholecystitis under <span class=""chemical"">methoxyflurane</span> anesthesia developed postoperatively a <span class=""disease"">hepatic insufficiency syndrome</span> and renal tubular acidosis."		253.0	253_MESH:D008733_MESH:D048550	253_1	bcv_final_eval_easy_1387		
	MESH:D008733	"<span class=""chemical"">methoxyflurane</span>"	MESH:D007674	"<span class=""disease"">renal tubular acidosis</span>"	"A 69-year-old man operated for acute cholecystitis under <span class=""chemical"">methoxyflurane</span> anesthesia developed postoperatively a hepatic insufficiency syndrome and <span class=""disease"">renal tubular acidosis</span>."		253.0	253_MESH:D008733_MESH:D007674	253_1	bcv_final_eval_easy_1388		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D051437	"<span class=""disease"">renal failure</span>"	"Antirifampicin antibodies in acute <span class=""chemical"">rifampicin</span>-associated <span class=""disease"">renal failure</span>."		255.0	255_MESH:D012293_MESH:D051437	255_0	bcv_final_eval_easy_1389		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"5 patients with <span class=""disease"">acute renal failure</span> (3 with thrombopenia and hemolysis) induced by the reintroduction of <span class=""chemical"">rifampicin</span> are described."		255.0	255_MESH:D012293_MESH:D058186	255_1	bcv_final_eval_easy_1390		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D013921	"<span class=""disease"">thrombopenia</span>"	"5 patients with acute renal failure (3 with <span class=""disease"">thrombopenia</span> and hemolysis) induced by the reintroduction of <span class=""chemical"">rifampicin</span> are described."		255.0	255_MESH:D012293_MESH:D013921	255_1	bcv_final_eval_easy_1391		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D006461	"<span class=""disease"">hemolysis</span>"	"5 patients with acute renal failure (3 with thrombopenia and <span class=""disease"">hemolysis</span>) induced by the reintroduction of <span class=""chemical"">rifampicin</span> are described."		255.0	255_MESH:D012293_MESH:D006461	255_1	bcv_final_eval_easy_1392		
	MESH:D000255	"<span class=""chemical"">adenosine triphosphate</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Cardiovascular effects of <span class=""disease"">hypotension</span> induced by <span class=""chemical"">adenosine triphosphate</span> and sodium nitroprusside on dogs with denervated hearts."		256.0	256_MESH:D000255_MESH:D007022	256_0	bcv_final_eval_easy_1393		
	MESH:D009599	"<span class=""chemical"">sodium nitroprusside</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Cardiovascular effects of <span class=""disease"">hypotension</span> induced by adenosine triphosphate and <span class=""chemical"">sodium nitroprusside</span> on dogs with denervated hearts."		256.0	256_MESH:D009599_MESH:D007022	256_0	bcv_final_eval_easy_1394		
	MESH:D000255	"<span class=""chemical"">ATP/Adenosine triphosphate</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"<span class=""chemical"">Adenosine triphosphate</span> (<span class=""chemical"">ATP</span>) and sodium nitroprusside (SNP) are administered to patients to induce and control <span class=""disease"">hypotension</span> during anesthesia."		256.0	256_MESH:D000255_MESH:D007022	256_1	bcv_final_eval_easy_1395		
	MESH:D009599	"<span class=""chemical"">SNP/sodium nitroprusside</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Adenosine triphosphate (ATP) and <span class=""chemical"">sodium nitroprusside</span> (<span class=""chemical"">SNP</span>) are administered to patients to induce and control <span class=""disease"">hypotension</span> during anesthesia."		256.0	256_MESH:D009599_MESH:D007022	256_1	bcv_final_eval_easy_1396		
	MESH:D000255	"<span class=""chemical"">ATP</span>"	MESH:D007022	"<span class=""disease"">Hypotension</span>"	"<span class=""disease"">Hypotension</span> induced by <span class=""chemical"">ATP</span> was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after <span class=""chemical"">ATP</span> was stopped."		256.0	256_MESH:D000255_MESH:D007022	256_6	bcv_final_eval_easy_1397		
	MESH:D010100	"<span class=""chemical"">oxygen</span>"	MESH:D007022	"<span class=""disease"">Hypotension</span>"	"<span class=""disease"">Hypotension</span> induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body <span class=""chemical"">oxygen</span> consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped."		256.0	256_MESH:D010100_MESH:D007022	256_6	bcv_final_eval_easy_1398		
	MESH:D009599	"<span class=""chemical"">SNP</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"During <span class=""disease"">hypotension</span> produced by <span class=""chemical"">SNP</span> similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased."		256.0	256_MESH:D009599_MESH:D007022	256_8	bcv_final_eval_easy_1399		
	MESH:D010100	"<span class=""chemical"">oxygen</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"During <span class=""disease"">hypotension</span> produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and <span class=""chemical"">oxygen</span> content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased."		256.0	256_MESH:D010100_MESH:D007022	256_8	bcv_final_eval_easy_1400		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D010146	"<span class=""disease"">Post-suxamethonium pains</span>"	"<span class=""disease"">Post-</span><span class=""chemical"">suxamethonium</span> pains in Nigerian surgical patients."		258.0	258_MESH:D013390_MESH:D010146	258_0	bcv_final_eval_easy_1401		
	MESH:C084773	"<span class=""chemical"">Fazadinium</span>"	MESH:D005207	"<span class=""disease"">muscle fasciculations</span>"	"The abolition of <span class=""disease"">muscle fasciculations</span> (by 0.075mg/kg dose of <span class=""chemical"">Fazadinium</span>) did not influence the occurrence of scoline pain."		258.0	258_MESH:C084773_MESH:D005207	258_4	bcv_final_eval_easy_1402		
	MESH:C084773	"<span class=""chemical"">Fazadinium</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"The abolition of muscle fasciculations (by 0.075mg/kg dose of <span class=""chemical"">Fazadinium</span>) did not influence the occurrence of scoline <span class=""disease"">pain</span>."		258.0	258_MESH:C084773_MESH:D010146	258_4	bcv_final_eval_easy_1403		
	MESH:D001965	"<span class=""chemical"">bromide</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or <span class=""chemical"">bromide</span>), affected the incidence of scoline <span class=""disease"">pain</span>."		258.0	258_MESH:D001965_MESH:D010146	258_5	bcv_final_eval_easy_1404		
	MESH:D013874	"<span class=""chemical"">Thiopentone</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"Neither the type of induction agent (Althesin or <span class=""chemical"">Thiopentone</span>) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline <span class=""disease"">pain</span>."		258.0	258_MESH:D013874_MESH:D010146	258_5	bcv_final_eval_easy_1405		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of <span class=""chemical"">suxamethonium</span> used (chloride or bromide), affected the incidence of scoline <span class=""disease"">pain</span>."		258.0	258_MESH:D013390_MESH:D010146	258_5	bcv_final_eval_easy_1406		
	MESH:D011803	"<span class=""chemical"">quinine sulfate</span>"	MESH:C536128	"<span class=""disease"">Total blindness</span>"	"<span class=""disease"">Total blindness</span> with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of <span class=""chemical"">quinine sulfate</span> for leg cramps."		260.0	260_MESH:D011803_MESH:C536128	260_1	bcv_final_eval_easy_1407		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in <span class=""chemical"">quinine</span> <span class=""disease"">toxicity</span>, to our knowledge, have not been previously reported."		260.0	260_MESH:D011803_MESH:D064420	260_3	bcv_final_eval_easy_1408		
	MESH:D013390	"<span class=""chemical"">Suxamethonium</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"<span class=""chemical"">Suxamethonium</span>-induced jaw stiffness and <span class=""disease"">myalgia</span> associated with atypical cholinesterase: case report."		261.0	261_MESH:D013390_MESH:D063806	261_0	bcv_final_eval_easy_1409		
	MESH:D010197	"<span class=""chemical"">pancuronium</span>"	MESH:D009127	"<span class=""disease"">jaw rigidity</span>"	"The case shows that prolonged <span class=""disease"">jaw rigidity</span> and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with <span class=""chemical"">pancuronium</span>."		261.0	261_MESH:D010197_MESH:D009127	261_6	bcv_final_eval_easy_1410		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"The case shows that prolonged jaw rigidity and <span class=""disease"">myalgia</span> may occur after <span class=""chemical"">suxamethonium</span> in patients with atypical cholinesterase despite pretreatment with pancuronium."		261.0	261_MESH:D013390_MESH:D063806	261_6	bcv_final_eval_easy_1411		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D009127	"<span class=""disease"">jaw rigidity</span>"	"The case shows that prolonged <span class=""disease"">jaw rigidity</span> and myalgia may occur after <span class=""chemical"">suxamethonium</span> in patients with atypical cholinesterase despite pretreatment with pancuronium."		261.0	261_MESH:D013390_MESH:D009127	261_6	bcv_final_eval_easy_1412		
	MESH:D010197	"<span class=""chemical"">pancuronium</span>"	MESH:D063806	"<span class=""disease"">myalgia</span>"	"The case shows that prolonged jaw rigidity and <span class=""disease"">myalgia</span> may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with <span class=""chemical"">pancuronium</span>."		261.0	261_MESH:D010197_MESH:D063806	261_6	bcv_final_eval_easy_1413		
	MESH:D007213	"<span class=""chemical"">Indomethacin</span>"	MESH:D001168	"<span class=""disease"">arthritis</span>"	"<span class=""chemical"">Indomethacin</span>-induced hyperkalemia in three patients with gouty <span class=""disease"">arthritis</span>."		262.0	262_MESH:D007213_MESH:D001168	262_0	bcv_final_eval_easy_1414		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D051437	"<span class=""disease"">renal insufficiency</span>"	"We describe three patients in whom severe, life-threatening hyperkalemia and <span class=""disease"">renal insufficiency</span> developed after treatment of acute gouty arthritis with <span class=""chemical"">indomethacin</span>."		262.0	262_MESH:D007213_MESH:D051437	262_1	bcv_final_eval_easy_1415		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D015210	"<span class=""disease"">acute gouty arthritis</span>"	"We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of <span class=""disease"">acute gouty arthritis</span> with <span class=""chemical"">indomethacin</span>."		262.0	262_MESH:D007213_MESH:D015210	262_1	bcv_final_eval_easy_1416		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D003920	"<span class=""disease"">diabetes mellitus</span>"	"Careful attention to renal function and <span class=""chemical"">potassium</span> balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with <span class=""disease"">diabetes mellitus</span> or preexisting renal disease, will help prevent this potentially serious complication."		262.0	262_MESH:D011188_MESH:D003920	262_3	bcv_final_eval_easy_1417		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D003920	"<span class=""disease"">diabetes mellitus</span>"	"Careful attention to renal function and potassium balance in patients receiving <span class=""chemical"">indomethacin</span> or other nonsteroidal anti-inflammatory agents, particularly in those patients with <span class=""disease"">diabetes mellitus</span> or preexisting renal disease, will help prevent this potentially serious complication."		262.0	262_MESH:D007213_MESH:D003920	262_3	bcv_final_eval_easy_1418		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D007674	"<span class=""disease"">renal disease</span>"	"Careful attention to renal function and potassium balance in patients receiving <span class=""chemical"">indomethacin</span> or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting <span class=""disease"">renal disease</span>, will help prevent this potentially serious complication."		262.0	262_MESH:D007213_MESH:D007674	262_3	bcv_final_eval_easy_1419		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D007674	"<span class=""disease"">renal disease</span>"	"Careful attention to renal function and <span class=""chemical"">potassium</span> balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting <span class=""disease"">renal disease</span>, will help prevent this potentially serious complication."		262.0	262_MESH:D011188_MESH:D007674	262_3	bcv_final_eval_easy_1420		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D004409	"<span class=""disease"">dyskinesias</span>"	"Levodopa-induced <span class=""disease"">dyskinesias</span> are improved by <span class=""chemical"">fluoxetine</span>."		264.0	264_MESH:D005473_MESH:D004409	264_0	bcv_final_eval_easy_1421		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D004409	"<span class=""disease"">dyskinesias</span>"	"We evaluated the severity of motor disability and <span class=""disease"">dyskinesias</span> in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of <span class=""chemical"">fluoxetine</span> (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D005473_MESH:D004409	264_1	bcv_final_eval_easy_1422		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"We evaluated the severity of <span class=""disease"">motor disability</span> and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed <span class=""chemical"">dopamine</span> agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D004298_MESH:D009069	264_1	bcv_final_eval_easy_1423		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with <span class=""disease"">Parkinson's disease</span> after an acute challenge with the mixed dopamine agonist, <span class=""chemical"">apomorphine</span>, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D001058_MESH:D010300	264_1	bcv_final_eval_easy_1424		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D004409	"<span class=""disease"">dyskinesias</span>"	"We evaluated the severity of motor disability and <span class=""disease"">dyskinesias</span> in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed <span class=""chemical"">dopamine</span> agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D004298_MESH:D004409	264_1	bcv_final_eval_easy_1425		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"We evaluated the severity of <span class=""disease"">motor disability</span> and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, <span class=""chemical"">apomorphine</span>, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D001058_MESH:D009069	264_1	bcv_final_eval_easy_1426		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"We evaluated the severity of <span class=""disease"">motor disability</span> and dyskinesias in seven <span class=""chemical"">levodopa</span>-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D007980_MESH:D009069	264_1	bcv_final_eval_easy_1427		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"We evaluated the severity of <span class=""disease"">motor disability</span> and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of <span class=""chemical"">fluoxetine</span> (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D005473_MESH:D009069	264_1	bcv_final_eval_easy_1428		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with <span class=""disease"">Parkinson's disease</span> after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of <span class=""chemical"">fluoxetine</span> (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D005473_MESH:D010300	264_1	bcv_final_eval_easy_1429		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with <span class=""disease"">Parkinson's disease</span> after an acute challenge with the mixed <span class=""chemical"">dopamine</span> agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D004298_MESH:D010300	264_1	bcv_final_eval_easy_1430		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"We evaluated the severity of motor disability and dyskinesias in seven <span class=""chemical"">levodopa</span>-responsive patients with <span class=""disease"">Parkinson's disease</span> after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days."		264.0	264_MESH:D007980_MESH:D010300	264_1	bcv_final_eval_easy_1431		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"After <span class=""chemical"">fluoxetine</span> treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of <span class=""disease"">parkinsonian</span> motor disability."		264.0	264_MESH:D005473_MESH:D010300	264_2	bcv_final_eval_easy_1432		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D004409	"<span class=""disease"">dyskinesias</span>"	"After <span class=""chemical"">fluoxetine</span> treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced <span class=""disease"">dyskinesias</span> without modification of parkinsonian motor disability."		264.0	264_MESH:D005473_MESH:D004409	264_2	bcv_final_eval_easy_1433		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"After <span class=""chemical"">fluoxetine</span> treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian <span class=""disease"">motor disability</span>."		264.0	264_MESH:D005473_MESH:D009069	264_2	bcv_final_eval_easy_1434		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of <span class=""chemical"">apomorphine</span>-induced dyskinesias without modification of parkinsonian <span class=""disease"">motor disability</span>."		264.0	264_MESH:D001058_MESH:D009069	264_2	bcv_final_eval_easy_1435		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of <span class=""chemical"">apomorphine</span>-induced dyskinesias without modification of <span class=""disease"">parkinsonian</span> motor disability."		264.0	264_MESH:D001058_MESH:D010300	264_2	bcv_final_eval_easy_1436		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D004409	"<span class=""disease"">dyskinesias</span>"	"The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or <span class=""chemical"">dopamine</span> agonist-induced <span class=""disease"">dyskinesias</span> without aggravating parkinsonian motor disability."		264.0	264_MESH:D004298_MESH:D004409	264_4	bcv_final_eval_easy_1437		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or <span class=""chemical"">dopamine</span> agonist-induced dyskinesias without aggravating parkinsonian <span class=""disease"">motor disability</span>."		264.0	264_MESH:D004298_MESH:D009069	264_4	bcv_final_eval_easy_1438		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D004409	"<span class=""disease"">dyskinesias</span>"	"The results suggest that increased brain serotoninergic transmission with <span class=""chemical"">fluoxetine</span> may reduce levodopa- or dopamine agonist-induced <span class=""disease"">dyskinesias</span> without aggravating parkinsonian motor disability."		264.0	264_MESH:D005473_MESH:D004409	264_4	bcv_final_eval_easy_1439		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce <span class=""chemical"">levodopa</span>- or dopamine agonist-induced dyskinesias without aggravating parkinsonian <span class=""disease"">motor disability</span>."		264.0	264_MESH:D007980_MESH:D009069	264_4	bcv_final_eval_easy_1440		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D009069	"<span class=""disease"">motor disability</span>"	"The results suggest that increased brain serotoninergic transmission with <span class=""chemical"">fluoxetine</span> may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian <span class=""disease"">motor disability</span>."		264.0	264_MESH:D005473_MESH:D009069	264_4	bcv_final_eval_easy_1441		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"The results suggest that increased brain serotoninergic transmission with <span class=""chemical"">fluoxetine</span> may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating <span class=""disease"">parkinsonian</span> motor disability."		264.0	264_MESH:D005473_MESH:D010300	264_4	bcv_final_eval_easy_1442		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or <span class=""chemical"">dopamine</span> agonist-induced dyskinesias without aggravating <span class=""disease"">parkinsonian</span> motor disability."		264.0	264_MESH:D004298_MESH:D010300	264_4	bcv_final_eval_easy_1443		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">parkinsonian</span>"	"The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce <span class=""chemical"">levodopa</span>- or dopamine agonist-induced dyskinesias without aggravating <span class=""disease"">parkinsonian</span> motor disability."		264.0	264_MESH:D007980_MESH:D010300	264_4	bcv_final_eval_easy_1444		
	MESH:D002506	"<span class=""chemical"">cephalexin</span>"	MESH:D064420	"<span class=""disease"">drug toxicity</span>"	"A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and <span class=""chemical"">cephalexin</span> for uncommon serious <span class=""disease"">drug toxicity</span>."		265.0	265_MESH:D002506_MESH:D064420	265_0	bcv_final_eval_easy_1445		
	MESH:D014295	"<span class=""chemical"">trimethoprim</span>"	MESH:D064420	"<span class=""disease"">drug toxicity</span>"	"A large population-based follow-up study of trimethoprim-sulfamethoxazole, <span class=""chemical"">trimethoprim</span>, and cephalexin for uncommon serious <span class=""disease"">drug toxicity</span>."		265.0	265_MESH:D014295_MESH:D064420	265_0	bcv_final_eval_easy_1446		
	MESH:D015662	"<span class=""chemical"">trimethoprim-sulfamethoxazole</span>"	MESH:D064420	"<span class=""disease"">drug toxicity</span>"	"A large population-based follow-up study of <span class=""chemical"">trimethoprim-sulfamethoxazole</span>, trimethoprim, and cephalexin for uncommon serious <span class=""disease"">drug toxicity</span>."		265.0	265_MESH:D015662_MESH:D064420	265_0	bcv_final_eval_easy_1447		
	MESH:D015662	"<span class=""chemical"">trimethoprim-sulfamethoxazole</span>"	MESH:D007674	"<span class=""disease"">renal disorders</span>"	"We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed <span class=""chemical"">trimethoprim-sulfamethoxazole</span> (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and <span class=""disease"">renal disorders</span> resulting in referral or hospitalization associated with these drugs."		265.0	265_MESH:D015662_MESH:D007674	265_1	bcv_final_eval_easy_1448		
	MESH:D002506	"<span class=""chemical"">cephalexin</span>"	MESH:D007674	"<span class=""disease"">renal disorders</span>"	"We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed <span class=""chemical"">cephalexin</span>, to estimate the risk of serious liver, blood, skin, and <span class=""disease"">renal disorders</span> resulting in referral or hospitalization associated with these drugs."		265.0	265_MESH:D002506_MESH:D007674	265_1	bcv_final_eval_easy_1449		
	MESH:D014294	"<span class=""chemical"">TMP</span>"	MESH:D007674	"<span class=""disease"">renal disorders</span>"	"We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (<span class=""chemical"">TMP</span>-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and <span class=""disease"">renal disorders</span> resulting in referral or hospitalization associated with these drugs."		265.0	265_MESH:D014294_MESH:D007674	265_1	bcv_final_eval_easy_1450		
	MESH:D014295	"<span class=""chemical"">trimethoprim</span>"	MESH:D007674	"<span class=""disease"">renal disorders</span>"	"We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed <span class=""chemical"">trimethoprim</span> alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and <span class=""disease"">renal disorders</span> resulting in referral or hospitalization associated with these drugs."		265.0	265_MESH:D014295_MESH:D007674	265_1	bcv_final_eval_easy_1451		
	MESH:D014294	"<span class=""chemical"">TMP</span>"	MESH:D008107	"<span class=""disease"">idiopathic liver disease</span>"	"The risk of clinically important <span class=""disease"">idiopathic liver disease</span> was similar for persons prescribed <span class=""chemical"">TMP</span>-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000)."		265.0	265_MESH:D014294_MESH:D008107	265_3	bcv_final_eval_easy_1452		
	MESH:D014295	"<span class=""chemical"">trimethoprim</span>"	MESH:D008107	"<span class=""disease"">idiopathic liver disease</span>"	"The risk of clinically important <span class=""disease"">idiopathic liver disease</span> was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed <span class=""chemical"">trimethoprim</span> alone (3.8/100,000)."		265.0	265_MESH:D014295_MESH:D008107	265_3	bcv_final_eval_easy_1453		
	MESH:D014294	"<span class=""chemical"">TMP</span>"	MESH:D006402	"<span class=""disease"">blood disorders</span>"	"Only five patients experienced <span class=""disease"">blood disorders</span>, one of whom was exposed to <span class=""chemical"">TMP</span>-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to <span class=""chemical"">TMP</span>-SMZ."		265.0	265_MESH:D014294_MESH:D006402	265_5	bcv_final_eval_easy_1454		
	MESH:D014294	"<span class=""chemical"">TMP</span>"	MESH:D013262	"<span class=""disease"">Stevens-Johnson syndrome</span>"	"Only five patients experienced blood disorders, one of whom was exposed to <span class=""chemical"">TMP</span>-SMZ; of seven with erythema multiforme and <span class=""disease"">Stevens-Johnson syndrome</span>, four were exposed to <span class=""chemical"">TMP</span>-SMZ."		265.0	265_MESH:D014294_MESH:D013262	265_5	bcv_final_eval_easy_1455		
	MESH:D014294	"<span class=""chemical"">TMP</span>"	MESH:D004892	"<span class=""disease"">erythema multiforme</span>"	"Only five patients experienced blood disorders, one of whom was exposed to <span class=""chemical"">TMP</span>-SMZ; of seven with <span class=""disease"">erythema multiforme</span> and Stevens-Johnson syndrome, four were exposed to <span class=""chemical"">TMP</span>-SMZ."		265.0	265_MESH:D014294_MESH:D004892	265_5	bcv_final_eval_easy_1456		
	MESH:D002506	"<span class=""chemical"">cephalexin</span>"	MESH:D064420	"<span class=""disease"">toxic epidermal necrolysis</span>"	"The one case of <span class=""disease"">toxic epidermal necrolysis</span> occurred in a patient who took <span class=""chemical"">cephalexin</span>."		265.0	265_MESH:D002506_MESH:D064420	265_6	bcv_final_eval_easy_1457		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Clinical safety of <span class=""chemical"">lidocaine</span> in patients with cocaine-associated <span class=""disease"">myocardial infarction</span>."		266.0	266_MESH:D008012_MESH:D009203	266_0	bcv_final_eval_easy_1458		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction/MI</span>"	"STUDY OBJECTIVE: To evaluate the safety of <span class=""chemical"">lidocaine</span> in the setting of cocaine-induced <span class=""disease"">myocardial infarction</span> (<span class=""disease"">MI</span>)."		266.0	266_MESH:D008012_MESH:D009203	266_1	bcv_final_eval_easy_1459		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">MI</span>"	"PARTICIPANTS: Patients with cocaine-associated <span class=""disease"">MI</span> who received <span class=""chemical"">lidocaine</span> in the emergency department."		266.0	266_MESH:D008012_MESH:D009203	266_4	bcv_final_eval_easy_1460		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D014693	"<span class=""disease"">ventricular fibrillation</span>"	"RESULTS: Of 29 patients who received lidocaine in the setting of <span class=""chemical"">cocaine</span>-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or <span class=""disease"">ventricular fibrillation</span>; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)."		266.0	266_MESH:D003042_MESH:D014693	266_5	bcv_final_eval_easy_1461		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D014693	"<span class=""disease"">ventricular fibrillation</span>"	"RESULTS: Of 29 patients who received <span class=""chemical"">lidocaine</span> in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or <span class=""disease"">ventricular fibrillation</span>; or experienced seizures after administration of <span class=""chemical"">lidocaine</span> (95% confidence interval, 0% to 11%)."		266.0	266_MESH:D008012_MESH:D014693	266_5	bcv_final_eval_easy_1462		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"RESULTS: Of 29 patients who received lidocaine in the setting of <span class=""chemical"">cocaine</span>-associated MI, no patient died; exhibited bradydysrhythmias, <span class=""disease"">ventricular tachycardia</span>, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)."		266.0	266_MESH:D003042_MESH:D017180	266_5	bcv_final_eval_easy_1463		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"RESULTS: Of 29 patients who received <span class=""chemical"">lidocaine</span> in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced <span class=""disease"">seizures</span> after administration of <span class=""chemical"">lidocaine</span> (95% confidence interval, 0% to 11%)."		266.0	266_MESH:D008012_MESH:D012640	266_5	bcv_final_eval_easy_1464		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">MI</span>"	"RESULTS: Of 29 patients who received <span class=""chemical"">lidocaine</span> in the setting of cocaine-associated <span class=""disease"">MI</span>, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of <span class=""chemical"">lidocaine</span> (95% confidence interval, 0% to 11%)."		266.0	266_MESH:D008012_MESH:D009203	266_5	bcv_final_eval_easy_1465		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"RESULTS: Of 29 patients who received lidocaine in the setting of <span class=""chemical"">cocaine</span>-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced <span class=""disease"">seizures</span> after administration of lidocaine (95% confidence interval, 0% to 11%)."		266.0	266_MESH:D003042_MESH:D012640	266_5	bcv_final_eval_easy_1466		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"RESULTS: Of 29 patients who received <span class=""chemical"">lidocaine</span> in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, <span class=""disease"">ventricular tachycardia</span>, or ventricular fibrillation; or experienced seizures after administration of <span class=""chemical"">lidocaine</span> (95% confidence interval, 0% to 11%)."		266.0	266_MESH:D008012_MESH:D017180	266_5	bcv_final_eval_easy_1467		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D064420	"<span class=""disease"">cocaine toxicity</span>"	"CONCLUSION: Despite theoretical concerns that <span class=""chemical"">lidocaine</span> may enhance <span class=""disease"">cocaine toxicity</span>, the use of <span class=""chemical"">lidocaine</span> in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity."		266.0	266_MESH:D008012_MESH:D064420	266_6	bcv_final_eval_easy_1468		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D064420	"<span class=""disease"">cocaine toxicity</span>"	"CONCLUSION: Despite theoretical concerns that lidocaine may enhance <span class=""chemical""></span><span class=""disease"">cocaine</span> toxicity, the use of lidocaine in patients with <span class=""chemical"">cocaine</span>-associated MI was not associated with significant cardiovascular or central nervous system toxicity."		266.0	266_MESH:D003042_MESH:D064420	266_6	bcv_final_eval_easy_1469		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002318	"<span class=""disease"">cardiovascular or central nervous system toxicity</span>"	"CONCLUSION: Despite theoretical concerns that lidocaine may enhance <span class=""chemical"">cocaine</span> toxicity, the use of lidocaine in patients with <span class=""chemical"">cocaine</span>-associated MI was not associated with significant <span class=""disease"">cardiovascular or central nervous system toxicity</span>."		266.0	266_MESH:D003042_MESH:D002318	266_6	bcv_final_eval_easy_1470		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D002318	"<span class=""disease"">cardiovascular or central nervous system toxicity</span>"	"CONCLUSION: Despite theoretical concerns that <span class=""chemical"">lidocaine</span> may enhance cocaine toxicity, the use of <span class=""chemical"">lidocaine</span> in patients with cocaine-associated MI was not associated with significant <span class=""disease"">cardiovascular or central nervous system toxicity</span>."		266.0	266_MESH:D008012_MESH:D002318	266_6	bcv_final_eval_easy_1471		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D009203	"<span class=""disease"">MI</span>"	"CONCLUSION: Despite theoretical concerns that <span class=""chemical"">lidocaine</span> may enhance cocaine toxicity, the use of <span class=""chemical"">lidocaine</span> in patients with cocaine-associated <span class=""disease"">MI</span> was not associated with significant cardiovascular or central nervous system toxicity."		266.0	266_MESH:D008012_MESH:D009203	266_6	bcv_final_eval_easy_1472		
	MESH:D017239	"<span class=""chemical"">Paclitaxel/Taxol</span>"	MESH:D002289	"<span class=""disease"">non-small cell lung cancer</span>"	"<span class=""chemical"">Paclitaxel</span> (<span class=""chemical"">Taxol</span>; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with <span class=""disease"">non-small cell lung cancer</span>."		267.0	267_MESH:D017239_MESH:D002289	267_1	bcv_final_eval_easy_1473		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D002289	"<span class=""disease"">non-small cell lung cancer</span>"	"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with <span class=""chemical"">carboplatin</span> in a phase I/II study directed to patients with <span class=""disease"">non-small cell lung cancer</span>."		267.0	267_MESH:D016190_MESH:D002289	267_1	bcv_final_eval_easy_1474		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D064420	"<span class=""disease"">Toxicities</span>"	"<span class=""disease"">Toxicities</span> were compared with a cohort of patients in a phase I trial of <span class=""chemical"">paclitaxel</span> alone at identical dose levels."		267.0	267_MESH:D017239_MESH:D064420	267_5	bcv_final_eval_easy_1475		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D006402	"<span class=""disease"">hematologic toxicities</span>"	"Carboplatin did not appear to add to the <span class=""disease"">hematologic toxicities</span> observed, and the <span class=""chemical"">paclitaxel</span>/carboplatin combination could be dosed every 3 weeks."		267.0	267_MESH:D017239_MESH:D006402	267_6	bcv_final_eval_easy_1476		
	MESH:D016190	"<span class=""chemical"">Carboplatin</span>"	MESH:D006402	"<span class=""disease"">hematologic toxicities</span>"	"<span class=""chemical"">Carboplatin</span> did not appear to add to the <span class=""disease"">hematologic toxicities</span> observed, and the paclitaxel/<span class=""chemical"">carboplatin</span> combination could be dosed every 3 weeks."		267.0	267_MESH:D016190_MESH:D006402	267_6	bcv_final_eval_easy_1477		
	MESH:D016595	"<span class=""chemical"">misoprostol</span>"	MESH:D007674	"<span class=""disease"">renal dysfunction</span>"	"The dose-dependent effect of <span class=""chemical"">misoprostol</span> on indomethacin-induced <span class=""disease"">renal dysfunction</span> in well compensated cirrhosis."		268.0	268_MESH:D016595_MESH:D007674	268_0	bcv_final_eval_easy_1478		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D005355	"<span class=""disease"">cirrhosis</span>"	"The dose-dependent effect of misoprostol on <span class=""chemical"">indomethacin</span>-induced renal dysfunction in well compensated <span class=""disease"">cirrhosis</span>."		268.0	268_MESH:D007213_MESH:D005355	268_0	bcv_final_eval_easy_1479		
	MESH:D016595	"<span class=""chemical"">misoprostol</span>"	MESH:D005355	"<span class=""disease"">cirrhosis</span>"	"The dose-dependent effect of <span class=""chemical"">misoprostol</span> on indomethacin-induced renal dysfunction in well compensated <span class=""disease"">cirrhosis</span>."		268.0	268_MESH:D016595_MESH:D005355	268_0	bcv_final_eval_easy_1480		
	MESH:D016595	"<span class=""chemical"">Misoprostol</span>"	MESH:D007674	"<span class=""disease"">renal dysfunction</span>"	"<span class=""chemical"">Misoprostol</span> (200 micrograms) has been shown to acutely counteract the indomethacin-induced <span class=""disease"">renal dysfunction</span> in well compensated cirrhotic patients."		268.0	268_MESH:D016595_MESH:D007674	268_1	bcv_final_eval_easy_1481		
	MESH:D007213	"<span class=""chemical"">indomethacin</span>"	MESH:D005355	"<span class=""disease"">cirrhosis</span>"	"However, until this apparent ability of 200 micrograms of misoprostol to prevent the adverse effects of <span class=""chemical"">indomethacin</span> on renal function is confirmed with chronic frequent dosing, it would be prudent to avoid nonsteroidal anti-inflammatory therapy in patients with <span class=""disease"">cirrhosis</span>."		268.0	268_MESH:D007213_MESH:D005355	268_7	bcv_final_eval_easy_1482		
	MESH:D016595	"<span class=""chemical"">misoprostol</span>"	MESH:D005355	"<span class=""disease"">cirrhosis</span>"	"However, until this apparent ability of 200 micrograms of <span class=""chemical"">misoprostol</span> to prevent the adverse effects of indomethacin on renal function is confirmed with chronic frequent dosing, it would be prudent to avoid nonsteroidal anti-inflammatory therapy in patients with <span class=""disease"">cirrhosis</span>."		268.0	268_MESH:D016595_MESH:D005355	268_7	bcv_final_eval_easy_1483		
	MESH:D000809	"<span class=""chemical"">angiotensin</span>"	MESH:D004487	"<span class=""disease"">angio-oedema</span>"	"Increased frequency and severity of <span class=""disease"">angio-oedema</span> related to long-term therapy with <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor in two patients."		269.0	269_MESH:D000809_MESH:D004487	269_0	bcv_final_eval_easy_1484		
	MESH:D008140	"<span class=""chemical"">lorazepam</span>"	MESH:D009207	"<span class=""disease"">Myoclonus</span>"	"<span class=""disease"">Myoclonus</span> associated with <span class=""chemical"">lorazepam</span> therapy in very-low-birth-weight infants."		270.0	270_MESH:D008140_MESH:D009207	270_0	bcv_final_eval_easy_1485		
	MESH:D008140	"<span class=""chemical"">lorazepam</span>"	MESH:D001724	"<span class=""disease"">low-birth-weight infants</span>"	"Myoclonus associated with <span class=""chemical"">lorazepam</span> therapy in very-<span class=""disease"">low-birth-weight infants</span>."		270.0	270_MESH:D008140_MESH:D001724	270_0	bcv_final_eval_easy_1486		
	MESH:D008140	"<span class=""chemical"">lorazepam</span>"	MESH:D009207	"<span class=""disease"">myoclonus</span>"	"Three young infants, all of birth weight < 1,500 g, experienced <span class=""disease"">myoclonus</span> following the intravenous administration of <span class=""chemical"">lorazepam</span>."		270.0	270_MESH:D008140_MESH:D009207	270_3	bcv_final_eval_easy_1487		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D012770	"<span class=""disease"">cardiogenic shock</span>"	"Three patients had acute viral myocarditis, one had a <span class=""chemical"">carbamazepine</span>-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute <span class=""disease"">cardiogenic shock</span>."		271.0	271_MESH:D002220_MESH:D012770	271_2	bcv_final_eval_easy_1488		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D006486	"<span class=""disease"">hemosiderosis</span>"	"Three patients had acute viral myocarditis, one had a <span class=""chemical"">carbamazepine</span>-induced acute eosinophilic myocarditis, and one had cardiac <span class=""disease"">hemosiderosis</span> resulting in acute cardiogenic shock."		271.0	271_MESH:D002220_MESH:D006486	271_2	bcv_final_eval_easy_1489		
	MESH:D012701	"<span class=""chemical"">5-hydroxytryptamine</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"Efficacy and safety of granisetron, a selective <span class=""chemical"">5-hydroxytryptamine</span>-3 receptor antagonist, in the prevention of <span class=""disease"">nausea</span> and vomiting induced by high-dose cisplatin."		272.0	272_MESH:D012701_MESH:D009325	272_0	bcv_final_eval_easy_1490		
	MESH:D012701	"<span class=""chemical"">5-hydroxytryptamine</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"Efficacy and safety of granisetron, a selective <span class=""chemical"">5-hydroxytryptamine</span>-3 receptor antagonist, in the prevention of nausea and <span class=""disease"">vomiting</span> induced by high-dose cisplatin."		272.0	272_MESH:D012701_MESH:D014839	272_0	bcv_final_eval_easy_1491		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and <span class=""disease"">vomiting</span> induced by high-dose <span class=""chemical"">cisplatin</span>."		272.0	272_MESH:D002945_MESH:D014839	272_0	bcv_final_eval_easy_1492		
	MESH:D017829	"<span class=""chemical"">granisetron</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"Efficacy and safety of <span class=""chemical"">granisetron</span>, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and <span class=""disease"">vomiting</span> induced by high-dose cisplatin."		272.0	272_MESH:D017829_MESH:D014839	272_0	bcv_final_eval_easy_1493		
	MESH:D017829	"<span class=""chemical"">granisetron</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"Efficacy and safety of <span class=""chemical"">granisetron</span>, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of <span class=""disease"">nausea</span> and vomiting induced by high-dose cisplatin."		272.0	272_MESH:D017829_MESH:D009325	272_0	bcv_final_eval_easy_1494		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of <span class=""chemical"">cisplatin</span>-induced nausea and <span class=""disease"">vomiting</span>."		272.0	272_MESH:D002945_MESH:D014839	272_1	bcv_final_eval_easy_1495		
	MESH:D017829	"<span class=""chemical"">granisetron</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"PURPOSE: To assess the antiemetic effects and safety profile of four different doses of <span class=""chemical"">granisetron</span> (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and <span class=""disease"">vomiting</span>."		272.0	272_MESH:D017829_MESH:D014839	272_1	bcv_final_eval_easy_1496		
	MESH:D017829	"<span class=""chemical"">granisetron</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"PURPOSE: To assess the antiemetic effects and safety profile of four different doses of <span class=""chemical"">granisetron</span> (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced <span class=""disease"">nausea</span> and vomiting."		272.0	272_MESH:D017829_MESH:D009325	272_1	bcv_final_eval_easy_1497		
	MESH:D017829	"<span class=""chemical"">granisetron</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"RESULTS: After <span class=""chemical"">granisetron</span> doses of 5, 10, 20, and 40 micrograms/kg, a major response (< or = two <span class=""disease"">vomiting</span> or retching episodes, and no antiemetic rescue) was recorded in 23%, 57%, 58%, and 60% of patients, respectively, and a complete response (no <span class=""disease"">vomiting</span> or retching, and no antiemetic rescue) in 18%, 41%, 40%, and 47% of patients, respectively."		272.0	272_MESH:D017829_MESH:D014839	272_5	bcv_final_eval_easy_1498		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling <span class=""disease"">vomiting</span> in 57% to 60% of patients who received <span class=""chemical"">cisplatin</span> at doses greater than 81 mg/m2 and totally prevented <span class=""disease"">vomiting</span> in 40% to 47% of patients."		272.0	272_MESH:D002945_MESH:D014839	272_9	bcv_final_eval_easy_1499		
	MESH:D017829	"<span class=""chemical"">granisetron</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of <span class=""chemical"">granisetron</span> was effective in controlling <span class=""disease"">vomiting</span> in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented <span class=""disease"">vomiting</span> in 40% to 47% of patients."		272.0	272_MESH:D017829_MESH:D014839	272_9	bcv_final_eval_easy_1500		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and <span class=""chemical"">verapamil</span> resulting in atrioventricular (AV) block in both patients and severe <span class=""disease"">hypotension</span> in one patient."		273.0	273_MESH:D014700_MESH:D007022	273_1	bcv_final_eval_easy_1501		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D054537	"<span class=""disease"">atrioventricular (AV) block</span>"	"OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and <span class=""chemical"">verapamil</span> resulting in <span class=""disease"">atrioventricular (AV) block</span> in both patients and severe hypotension in one patient."		273.0	273_MESH:D014700_MESH:D054537	273_1	bcv_final_eval_easy_1502		
	MESH:D003000	"<span class=""chemical"">clonidine</span>"	MESH:D054537	"<span class=""disease"">atrioventricular (AV) block</span>"	"OBJECTIVE: To report two cases of a possible adverse interaction between <span class=""chemical"">clonidine</span> and verapamil resulting in <span class=""disease"">atrioventricular (AV) block</span> in both patients and severe hypotension in one patient."		273.0	273_MESH:D003000_MESH:D054537	273_1	bcv_final_eval_easy_1503		
	MESH:D003000	"<span class=""chemical"">clonidine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"OBJECTIVE: To report two cases of a possible adverse interaction between <span class=""chemical"">clonidine</span> and verapamil resulting in atrioventricular (AV) block in both patients and severe <span class=""disease"">hypotension</span> in one patient."		273.0	273_MESH:D003000_MESH:D007022	273_1	bcv_final_eval_easy_1504		
	MESH:D013148	"<span class=""chemical"">spironolactone</span>"	MESH:D006929	"<span class=""disease"">hyperaldosteronism</span>"	"CASE SUMMARIES: A 54-year-old woman with <span class=""disease"">hyperaldosteronism</span> was treated with verapamil 480 mg/d and <span class=""chemical"">spironolactone</span> 100 mg/d."		273.0	273_MESH:D013148_MESH:D006929	273_2	bcv_final_eval_easy_1505		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D006929	"<span class=""disease"">hyperaldosteronism</span>"	"CASE SUMMARIES: A 54-year-old woman with <span class=""disease"">hyperaldosteronism</span> was treated with <span class=""chemical"">verapamil</span> 480 mg/d and spironolactone 100 mg/d."		273.0	273_MESH:D014700_MESH:D006929	273_2	bcv_final_eval_easy_1506		
	MESH:D003000	"<span class=""chemical"">clonidine</span>"	MESH:D054537	"<span class=""disease"">AV block</span>"	"After the addition of a minimal dose of <span class=""chemical"">clonidine</span> (0.15 mg bid), she developed complete <span class=""disease"">AV block</span> and severe hypotension, which resolved upon cessation of all medications."		273.0	273_MESH:D003000_MESH:D054537	273_3	bcv_final_eval_easy_1507		
	MESH:D003000	"<span class=""chemical"">clonidine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"After the addition of a minimal dose of <span class=""chemical"">clonidine</span> (0.15 mg bid), she developed complete AV block and severe <span class=""disease"">hypotension</span>, which resolved upon cessation of all medications."		273.0	273_MESH:D003000_MESH:D007022	273_3	bcv_final_eval_easy_1508		
	MESH:D003000	"<span class=""chemical"">clonidine</span>"	MESH:D054537	"<span class=""disease"">AV block</span>"	"After the addition of <span class=""chemical"">clonidine</span> 0.15 mg bid she developed complete <span class=""disease"">AV block</span>, which resolved after all therapy was stopped."		273.0	273_MESH:D003000_MESH:D054537	273_5	bcv_final_eval_easy_1509		
	MESH:D003000	"<span class=""chemical"">clonidine</span>"	MESH:D012804	"<span class=""disease"">AV node dysfunction</span>"	"CONCLUSIONS: Caution is recommended in combining <span class=""chemical"">clonidine</span> and verapamil therapy, even in patients who do not have sinus or <span class=""disease"">AV node dysfunction</span>."		273.0	273_MESH:D003000_MESH:D012804	273_9	bcv_final_eval_easy_1510		
	MESH:D014700	"<span class=""chemical"">verapamil</span>"	MESH:D012804	"<span class=""disease"">AV node dysfunction</span>"	"CONCLUSIONS: Caution is recommended in combining clonidine and <span class=""chemical"">verapamil</span> therapy, even in patients who do not have sinus or <span class=""disease"">AV node dysfunction</span>."		273.0	273_MESH:D014700_MESH:D012804	273_9	bcv_final_eval_easy_1511		
	MESH:C059447	"<span class=""chemical"">S-312</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"<span class=""chemical"">S-312</span>, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic <span class=""disease"">convulsions</span> in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o."		274.0	274_MESH:C059447_MESH:D012640	274_1	bcv_final_eval_easy_1512		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"S-312, S-312-d, but not S-312-l, L-type <span class=""chemical"">calcium</span> channel antagonists, showed anticonvulsant effects on the audiogenic tonic <span class=""disease"">convulsions</span> in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o."		274.0	274_MESH:D002118_MESH:D012640	274_1	bcv_final_eval_easy_1513		
	MESH:D005444	"<span class=""chemical"">flunarizine</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic <span class=""disease"">convulsions</span> in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of <span class=""chemical"">flunarizine</span> was 34.0 (26.0-44.8) mg/kg, p.o."		274.0	274_MESH:D005444_MESH:D012640	274_1	bcv_final_eval_easy_1514		
	MESH:D001534	"<span class=""chemical"">bemegride</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic <span class=""disease"">convulsions</span> induced by pentylenetetrazole (85 mg/kg, s.c.) or <span class=""chemical"">bemegride</span> (40 mg/kg, s.c.), no effects were observed in <span class=""disease"">convulsions</span> induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice."		274.0	274_MESH:D001534_MESH:D012640	274_2	bcv_final_eval_easy_1515		
	MESH:D010852	"<span class=""chemical"">picrotoxin</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic <span class=""disease"">convulsions</span> induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in <span class=""disease"">convulsions</span> induced by N-methyl-D-aspartate, <span class=""chemical"">picrotoxin</span>, or electroshock in Slc:ddY mice."		274.0	274_MESH:D010852_MESH:D012640	274_2	bcv_final_eval_easy_1516		
	MESH:D010433	"<span class=""chemical"">pentylenetetrazole</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic <span class=""disease"">convulsions</span> induced by <span class=""chemical"">pentylenetetrazole</span> (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in <span class=""disease"">convulsions</span> induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice."		274.0	274_MESH:D010433_MESH:D012640	274_2	bcv_final_eval_easy_1517		
	MESH:D016202	"<span class=""chemical"">N-methyl-D-aspartate</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic <span class=""disease"">convulsions</span> induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in <span class=""disease"">convulsions</span> induced by <span class=""chemical"">N-methyl-D-aspartate</span>, picrotoxin, or electroshock in Slc:ddY mice."		274.0	274_MESH:D016202_MESH:D012640	274_2	bcv_final_eval_easy_1518		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D009203	"<span class=""disease"">Transmural myocardial infarction</span>"	"<span class=""disease"">Transmural myocardial infarction</span> with <span class=""chemical"">sumatriptan</span>."		275.0	275_MESH:D018170_MESH:D009203	275_0	bcv_final_eval_easy_1519		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D003027	"<span class=""disease"">cluster headache</span>"	"We describe a 47-year-old woman with an acute myocardial infarction after administration of <span class=""chemical"">sumatriptan</span> 6 mg subcutaneously for <span class=""disease"">cluster headache</span>."		275.0	275_MESH:D018170_MESH:D003027	275_2	bcv_final_eval_easy_1520		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D009203	"<span class=""disease"">acute myocardial infarction</span>"	"We describe a 47-year-old woman with an <span class=""disease"">acute myocardial infarction</span> after administration of <span class=""chemical"">sumatriptan</span> 6 mg subcutaneously for cluster headache."		275.0	275_MESH:D018170_MESH:D009203	275_2	bcv_final_eval_easy_1521		
	MESH:D003975	"<span class=""chemical"">diazepam</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"Flumazenil induces seizures and <span class=""disease"">death</span> in mixed cocaine-<span class=""chemical"">diazepam</span> intoxications."		276.0	276_MESH:D003975_MESH:D003643	276_0	bcv_final_eval_easy_1522		
	MESH:D005442	"<span class=""chemical"">Flumazenil</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"<span class=""chemical"">Flumazenil</span> induces seizures and <span class=""disease"">death</span> in mixed cocaine-diazepam intoxications."		276.0	276_MESH:D005442_MESH:D003643	276_0	bcv_final_eval_easy_1523		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Flumazenil induces <span class=""disease"">seizures</span> and death in mixed <span class=""chemical"">cocaine</span>-diazepam intoxications."		276.0	276_MESH:D003042_MESH:D012640	276_0	bcv_final_eval_easy_1524		
	MESH:D003975	"<span class=""chemical"">diazepam</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Flumazenil induces <span class=""disease"">seizures</span> and death in mixed cocaine-<span class=""chemical"">diazepam</span> intoxications."		276.0	276_MESH:D003975_MESH:D012640	276_0	bcv_final_eval_easy_1525		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"Flumazenil induces seizures and <span class=""disease"">death</span> in mixed <span class=""chemical"">cocaine</span>-diazepam intoxications."		276.0	276_MESH:D003042_MESH:D003643	276_0	bcv_final_eval_easy_1526		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask <span class=""disease"">seizures</span> in mixed <span class=""chemical"">cocaine</span>-benzodiazepine intoxication."		276.0	276_MESH:D003042_MESH:D012640	276_1	bcv_final_eval_easy_1527		
	MESH:D001569	"<span class=""chemical"">benzodiazepine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"STUDY HYPOTHESIS: Administration of the <span class=""chemical"">benzodiazepine</span> antagonist flumazenil may unmask <span class=""disease"">seizures</span> in mixed cocaine-<span class=""chemical"">benzodiazepine</span> intoxication."		276.0	276_MESH:D001569_MESH:D012640	276_1	bcv_final_eval_easy_1528		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"CONCLUSION: Flumazenil can unmask <span class=""disease"">seizures</span> and increase the incidence of death in a model of combined <span class=""chemical"">cocaine</span>-diazepam intoxications."		276.0	276_MESH:D003042_MESH:D012640	276_18	bcv_final_eval_easy_1529		
	MESH:D005442	"<span class=""chemical"">Flumazenil</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"CONCLUSION: <span class=""chemical"">Flumazenil</span> can unmask seizures and increase the incidence of <span class=""disease"">death</span> in a model of combined cocaine-diazepam intoxications."		276.0	276_MESH:D005442_MESH:D003643	276_18	bcv_final_eval_easy_1530		
	MESH:D003975	"<span class=""chemical"">diazepam</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"CONCLUSION: Flumazenil can unmask <span class=""disease"">seizures</span> and increase the incidence of death in a model of combined cocaine-<span class=""chemical"">diazepam</span> intoxications."		276.0	276_MESH:D003975_MESH:D012640	276_18	bcv_final_eval_easy_1531		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"CONCLUSION: Flumazenil can unmask seizures and increase the incidence of <span class=""disease"">death</span> in a model of combined <span class=""chemical"">cocaine</span>-diazepam intoxications."		276.0	276_MESH:D003042_MESH:D003643	276_18	bcv_final_eval_easy_1532		
	MESH:D003975	"<span class=""chemical"">diazepam</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"CONCLUSION: Flumazenil can unmask seizures and increase the incidence of <span class=""disease"">death</span> in a model of combined cocaine-<span class=""chemical"">diazepam</span> intoxications."		276.0	276_MESH:D003975_MESH:D003643	276_18	bcv_final_eval_easy_1533		
	MESH:D005839	"<span class=""chemical"">gentamicin</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Mechanisms for protective effects of free radical scavengers on <span class=""chemical"">gentamicin</span>-mediated <span class=""disease"">nephropathy</span> in rats."		277.0	277_MESH:D005839_MESH:D007674	277_0	bcv_final_eval_easy_1534		
	MESH:D005839	"<span class=""chemical"">GM/gentamicin</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on <span class=""chemical"">gentamicin</span> (<span class=""chemical"">GM</span>)-mediated <span class=""disease"">nephropathy</span>."		277.0	277_MESH:D005839_MESH:D007674	277_1	bcv_final_eval_easy_1535		
	MESH:D005839	"<span class=""chemical"">GM</span>"	MESH:D007674	"<span class=""disease"">tubular damage/reduction in renal blood flow</span>"	"Administration of <span class=""chemical"">GM</span> at 40 mg/kg sc for 13 days to rats induced a significant <span class=""disease"">reduction in renal blood flow</span> (RBF) and inulin clearance (CIn) as well as marked <span class=""disease"">tubular damage</span>."		277.0	277_MESH:D005839_MESH:D007674	277_2	bcv_final_eval_easy_1536		
	MESH:D005839	"<span class=""chemical"">GM</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in <span class=""chemical"">GM</span>-mediated <span class=""disease"">nephropathy</span>."		277.0	277_MESH:D005839_MESH:D007674	277_3	bcv_final_eval_easy_1537		
	MESH:C038983	"<span class=""chemical"">DMTU</span>"	MESH:D007674	"<span class=""disease"">tubular damage</span>"	"In contrast, <span class=""chemical"">DMTU</span> significantly reduced the <span class=""disease"">tubular damage</span> and lipid peroxidation, but it did not affect renal hemodynamics and vasoactive substances."		277.0	277_MESH:C038983_MESH:D007674	277_7	bcv_final_eval_easy_1538		
	MESH:D005839	"<span class=""chemical"">GM</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"These results suggest that 1) both SOD and DMTU have protective effects on <span class=""chemical"">GM</span>-mediated <span class=""disease"">nephropathy</span>, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in <span class=""chemical"">GM</span>-induced renal vasoconstriction."		277.0	277_MESH:D005839_MESH:D007674	277_9	bcv_final_eval_easy_1539		
	MESH:C038983	"<span class=""chemical"">DMTU</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"These results suggest that 1) both SOD and <span class=""chemical"">DMTU</span> have protective effects on GM-mediated <span class=""disease"">nephropathy</span>, 2) the mechanisms for the protective effects differ for SOD and <span class=""chemical"">DMTU</span>, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction."		277.0	277_MESH:C038983_MESH:D007674	277_9	bcv_final_eval_easy_1540		
	MESH:D013481	"<span class=""chemical"">superoxide</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated <span class=""disease"">nephropathy</span>, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) <span class=""chemical"">superoxide</span> anions play a critical role in GM-induced renal vasoconstriction."		277.0	277_MESH:D013481_MESH:D007674	277_9	bcv_final_eval_easy_1541		
	MESH:D001127	"<span class=""chemical"">AVP</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"Central cardiovascular effects of <span class=""chemical"">AVP</span> and ANP in normotensive and spontaneously <span class=""disease"">hypertensive</span> rats."		279.0	279_MESH:D001127_MESH:D006973	279_0	bcv_final_eval_easy_1542		
	MESH:D001127	"<span class=""chemical"">arginine vasopressin/AVP</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"The purpose of the present study was to compare influence of central <span class=""chemical"">arginine vasopressin</span> (<span class=""chemical"">AVP</span>) and of atrial natriuretic peptide (ANP) on control of arterial blood pressure (MAP) and heart rate (HR) in normotensive (WKY) and spontaneously <span class=""disease"">hypertensive</span> (SHR) rats."		279.0	279_MESH:D001127_MESH:D006973	279_1	bcv_final_eval_easy_1543		
	MESH:D010656	"<span class=""chemical"">phenylephrine/Phe</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during <span class=""chemical"">phenylephrine</span> (<span class=""chemical"">Phe</span>)-induced hypertension and sodium nitroprusside (SN)-induced <span class=""disease"">hypotension</span>."		279.0	279_MESH:D010656_MESH:D007022	279_4	bcv_final_eval_easy_1544		
	MESH:D009599	"<span class=""chemical"">sodium nitroprusside</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced <span class=""disease"">hypertension</span> and <span class=""chemical"">sodium nitroprusside</span> (SN)-induced hypotension."		279.0	279_MESH:D009599_MESH:D006973	279_4	bcv_final_eval_easy_1545		
	MESH:D001127	"<span class=""chemical"">AVP</span>"	MESH:D006973	"<span class=""disease"">Increases of MAP</span>"	"<span class=""disease"">Increases of MAP</span> occurred after LV administration of 1, 10 and 50 ng of <span class=""chemical"">AVP</span> in WKY and of 10 and 50 ng in SHR."		279.0	279_MESH:D001127_MESH:D006973	279_6	bcv_final_eval_easy_1546		
	MESH:D001127	"<span class=""chemical"">AVP</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"CCB was reduced in WKY and SHR after LV administration of <span class=""chemical"">AVP</span> during SN-induced <span class=""disease"">hypotension</span>."		279.0	279_MESH:D001127_MESH:D007022	279_8	bcv_final_eval_easy_1547		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D002543	"<span class=""disease"">intracerebral hemorrhage</span>"	"Cutaneous exposure to <span class=""chemical"">warfarin</span>-like anticoagulant causing an <span class=""disease"">intracerebral hemorrhage</span>: a case report."		280.0	280_MESH:D014859_MESH:D002543	280_0	bcv_final_eval_easy_1548		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D006406	"<span class=""disease"">hematoma</span>"	"A case of intercerebral <span class=""disease"">hematoma</span> due to <span class=""chemical"">warfarin</span>-induced coagulopathy is presented."		280.0	280_MESH:D014859_MESH:D006406	280_1	bcv_final_eval_easy_1549		
	MESH:D010894	"<span class=""chemical"">piroxicam</span>"	MESH:D001778	"<span class=""disease"">coagulopathy</span>"	"An adverse drug interaction with <span class=""chemical"">piroxicam</span>, which she took occasionally, may have exacerbated the <span class=""disease"">coagulopathy</span>."		280.0	280_MESH:D010894_MESH:D001778	280_4	bcv_final_eval_easy_1550		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D002312	"<span class=""disease"">hypertrophic cardiomyopathy</span>"	"Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), <span class=""disease"">hypertrophic cardiomyopathy</span> (5%), valvular heart disease (3%), and <span class=""chemical"">doxorubicin</span> cardiomyopathy (5%)."		281.0	281_MESH:D004317_MESH:D002312	281_2	bcv_final_eval_easy_1551		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009202	"<span class=""disease"">cardiomyopathy</span>"	"Indications for transplantation were idiopathic <span class=""disease"">cardiomyopathy</span> (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and <span class=""chemical"">doxorubicin</span> <span class=""disease"">cardiomyopathy</span> (5%)."		281.0	281_MESH:D004317_MESH:D009202	281_2	bcv_final_eval_easy_1552		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D006331	"<span class=""disease"">congenital heart disease</span>"	"Indications for transplantation were idiopathic cardiomyopathy (52%), <span class=""disease"">congenital heart disease</span> (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and <span class=""chemical"">doxorubicin</span> cardiomyopathy (5%)."		281.0	281_MESH:D004317_MESH:D006331	281_2	bcv_final_eval_easy_1553		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D006349	"<span class=""disease"">valvular heart disease</span>"	"Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), <span class=""disease"">valvular heart disease</span> (3%), and <span class=""chemical"">doxorubicin</span> cardiomyopathy (5%)."		281.0	281_MESH:D004317_MESH:D006349	281_2	bcv_final_eval_easy_1554		
	MESH:D015774	"<span class=""chemical"">ganciclovir</span>"	MESH:D003586	"<span class=""disease"">Cytomegalovirus infections</span>"	"<span class=""disease"">Cytomegalovirus infections</span> were treated successfully with <span class=""chemical"">ganciclovir</span> in 11 patients."		281.0	281_MESH:D015774_MESH:D003586	281_14	bcv_final_eval_easy_1555		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D003693	"<span class=""disease"">acute hyperkinetic delirium</span>"	"In this report, we describe a patient with <span class=""disease"">acute hyperkinetic delirium</span> connected with a high serum total <span class=""chemical"">fluoxetine</span> (<span class=""chemical"">fluoxetine</span> plus desmethylfluoxetine) concentration."		282.0	282_MESH:D005473_MESH:D003693	282_5	bcv_final_eval_easy_1556		
	MESH:C036139	"<span class=""chemical"">desmethylfluoxetine</span>"	MESH:D003693	"<span class=""disease"">acute hyperkinetic delirium</span>"	"In this report, we describe a patient with <span class=""disease"">acute hyperkinetic delirium</span> connected with a high serum total fluoxetine (fluoxetine plus <span class=""chemical"">desmethylfluoxetine</span>) concentration."		282.0	282_MESH:C036139_MESH:D003693	282_5	bcv_final_eval_easy_1557		
	MESH:D003561	"<span class=""chemical"">aracytine</span>"	MESH:D008223	"<span class=""disease"">lymphoma</span>"	"Pulmonary edema and shock after high-dose <span class=""chemical"">aracytine</span>-C for <span class=""disease"">lymphoma</span>; possible role of TNF-alpha and PAF."		283.0	283_MESH:D003561_MESH:D008223	283_0	bcv_final_eval_easy_1558		
	MESH:D003561	"<span class=""chemical"">aracytine</span>"	MESH:D011654	"<span class=""disease"">Pulmonary edema</span>"	"<span class=""disease"">Pulmonary edema</span> and shock after high-dose <span class=""chemical"">aracytine</span>-C for lymphoma; possible role of TNF-alpha and PAF."		283.0	283_MESH:D003561_MESH:D011654	283_0	bcv_final_eval_easy_1559		
	MESH:D003561	"<span class=""chemical"">aracytine</span>"	MESH:D012769	"<span class=""disease"">shock</span>"	"Pulmonary edema and <span class=""disease"">shock</span> after high-dose <span class=""chemical"">aracytine</span>-C for lymphoma; possible role of TNF-alpha and PAF."		283.0	283_MESH:D003561_MESH:D012769	283_0	bcv_final_eval_easy_1560		
	MESH:D003561	"<span class=""chemical"">Ara-C</span>"	MESH:D008223	"<span class=""disease"">lymphomas</span>"	"Four out of 23 consecutive patients treated with high-dose <span class=""chemical"">Ara-C</span> for <span class=""disease"">lymphomas</span> in our institution developed a strikingly similar syndrome during the perfusion."		283.0	283_MESH:D003561_MESH:D008223	283_1	bcv_final_eval_easy_1561		
	MESH:D003561	"<span class=""chemical"">Ara-C</span>"	MESH:D012128	"<span class=""disease"">respiratory distress syndrome</span>"	"As TNF and PAF are thought to be involved in the development of septic shock and adult <span class=""disease"">respiratory distress syndrome</span>, we hypothesize that high-dose <span class=""chemical"">Ara-C</span> may be associated with cytokine release."		283.0	283_MESH:D003561_MESH:D012128	283_6	bcv_final_eval_easy_1562		
	MESH:D003561	"<span class=""chemical"">Ara-C</span>"	MESH:D012772	"<span class=""disease"">septic shock</span>"	"As TNF and PAF are thought to be involved in the development of <span class=""disease"">septic shock</span> and adult respiratory distress syndrome, we hypothesize that high-dose <span class=""chemical"">Ara-C</span> may be associated with cytokine release."		283.0	283_MESH:D003561_MESH:D012772	283_6	bcv_final_eval_easy_1563		
	MESH:C056595	"<span class=""chemical"">clentiazem</span>"	MESH:D006331	"<span class=""disease"">cardiac injury</span>"	"Protective effect of <span class=""chemical"">clentiazem</span> against epinephrine-induced <span class=""disease"">cardiac injury</span> in rats."		284.0	284_MESH:C056595_MESH:D006331	284_0	bcv_final_eval_easy_1564		
	MESH:C056595	"<span class=""chemical"">clentiazem</span>"	MESH:D009202	"<span class=""disease"">cardiomyopathy</span>"	"We investigated the effects of <span class=""chemical"">clentiazem</span>, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced <span class=""disease"">cardiomyopathy</span> in rats."		284.0	284_MESH:C056595_MESH:D009202	284_1	bcv_final_eval_easy_1565		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D002545	"<span class=""disease"">ischemic lesions</span>"	"With 2-week chronic <span class=""chemical"">epinephrine</span> infusion, 16 of 30 rats died within 4 days, and severe <span class=""disease"">ischemic lesions</span> and fibrosis of the left ventricles were observed."		284.0	284_MESH:D004837_MESH:D002545	284_2	bcv_final_eval_easy_1566		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"With 2-week chronic <span class=""chemical"">epinephrine</span> infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and <span class=""disease"">fibrosis</span> of the left ventricles were observed."		284.0	284_MESH:D004837_MESH:D005355	284_2	bcv_final_eval_easy_1567		
	MESH:C056595	"<span class=""chemical"">clentiazem</span>"	MESH:D002545	"<span class=""disease"">ventricular ischemic lesions</span>"	"Treatment with <span class=""chemical"">clentiazem</span> prevented epinephrine-induced death (P < .05), and attenuated the <span class=""disease"">ventricular ischemic lesions</span> and fibrosis, in a dose-dependent manner."		284.0	284_MESH:C056595_MESH:D002545	284_5	bcv_final_eval_easy_1568		
	MESH:C056595	"<span class=""chemical"">clentiazem</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"Treatment with <span class=""chemical"">clentiazem</span> prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and <span class=""disease"">fibrosis</span>, in a dose-dependent manner."		284.0	284_MESH:C056595_MESH:D005355	284_5	bcv_final_eval_easy_1569		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D002545	"<span class=""disease"">ventricular ischemic lesions</span>"	"Treatment with clentiazem prevented <span class=""chemical"">epinephrine</span>-induced death (P < .05), and attenuated the <span class=""disease"">ventricular ischemic lesions</span> and fibrosis, in a dose-dependent manner."		284.0	284_MESH:D004837_MESH:D002545	284_5	bcv_final_eval_easy_1570		
	MESH:C056595	"<span class=""chemical"">clentiazem</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"Treatment with <span class=""chemical"">clentiazem</span> prevented epinephrine-induced <span class=""disease"">death</span> (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner."		284.0	284_MESH:C056595_MESH:D003643	284_5	bcv_final_eval_easy_1571		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"Treatment with clentiazem prevented <span class=""chemical"">epinephrine</span>-induced death (P < .05), and attenuated the ventricular ischemic lesions and <span class=""disease"">fibrosis</span>, in a dose-dependent manner."		284.0	284_MESH:D004837_MESH:D005355	284_5	bcv_final_eval_easy_1572		
	MESH:C056595	"<span class=""chemical"">clentiazem</span>"	MESH:D006331	"<span class=""disease"">cardiac injury</span>"	"In conclusion, <span class=""chemical"">clentiazem</span> attenuated epinephrine-induced <span class=""disease"">cardiac injury</span>, possibly through its effect on the adrenergic pathway."		284.0	284_MESH:C056595_MESH:D006331	284_10	bcv_final_eval_easy_1573		
	MESH:D005996	"<span class=""chemical"">nitroglycerin</span>"	MESH:D007511	"<span class=""disease"">ischemia</span>"	"The <span class=""disease"">ischemia</span> probably induced by coronary artery spasm was reversed by <span class=""chemical"">nitroglycerin</span> and calcium blocking agents."		285.0	285_MESH:D005996_MESH:D007511	285_2	bcv_final_eval_easy_1574		
	MESH:D005996	"<span class=""chemical"">nitroglycerin</span>"	MESH:D003329	"<span class=""disease"">coronary artery spasm</span>"	"The ischemia probably induced by <span class=""disease"">coronary artery spasm</span> was reversed by <span class=""chemical"">nitroglycerin</span> and calcium blocking agents."		285.0	285_MESH:D005996_MESH:D003329	285_2	bcv_final_eval_easy_1575		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D007511	"<span class=""disease"">ischemia</span>"	"The <span class=""disease"">ischemia</span> probably induced by coronary artery spasm was reversed by nitroglycerin and <span class=""chemical"">calcium</span> blocking agents."		285.0	285_MESH:D002118_MESH:D007511	285_2	bcv_final_eval_easy_1576		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D003329	"<span class=""disease"">coronary artery spasm</span>"	"The ischemia probably induced by <span class=""disease"">coronary artery spasm</span> was reversed by nitroglycerin and <span class=""chemical"">calcium</span> blocking agents."		285.0	285_MESH:D002118_MESH:D003329	285_2	bcv_final_eval_easy_1577		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D006984	"<span class=""disease"">hypertrophic</span>"	"After sacrifice the hearts of <span class=""chemical"">doxorubicin</span>-treated animals were enlarged and the atria were <span class=""disease"">hypertrophic</span>."		286.0	286_MESH:D004317_MESH:D006984	286_7	bcv_final_eval_easy_1578		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"As this schedule exerted more <span class=""disease"">toxicity</span> than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general <span class=""disease"">toxicity</span> (6 weekly doses of 4 mg/kg <span class=""chemical"">doxorubicin</span> given i.v. plus 2 weeks of observation)."		286.0	286_MESH:D004317_MESH:D064420	286_8	bcv_final_eval_easy_1579		
	MESH:D011929	"<span class=""chemical"">ICRF-187</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"As this schedule exerted more <span class=""disease"">toxicity</span> than needed to investigate protective agents, the protection of <span class=""chemical"">ICRF-187</span> was determined using a dose schedule with lower general <span class=""disease"">toxicity</span> (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus 2 weeks of observation)."		286.0	286_MESH:D011929_MESH:D064420	286_8	bcv_final_eval_easy_1580		
	MESH:D011929	"<span class=""chemical"">ICRF-187</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"These findings result in a model that allows the testing of protectors against doxorubicin-induced <span class=""disease"">cardiotoxicity</span> as demonstrated by the protection provided by <span class=""chemical"">ICRF-187</span>."		286.0	286_MESH:D011929_MESH:D066126	286_12	bcv_final_eval_easy_1581		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D001145	"<span class=""disease"">dysrhythmias</span>"	"Since bupivacaine and <span class=""chemical"">epinephrine</span> may both precipitate <span class=""disease"">dysrhythmias</span>, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of <span class=""chemical"">epinephrine</span>."		287.0	287_MESH:D004837_MESH:D001145	287_1	bcv_final_eval_easy_1582		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D001145	"<span class=""disease"">dysrhythmias</span>"	"Since <span class=""chemical"">bupivacaine</span> and epinephrine may both precipitate <span class=""disease"">dysrhythmias</span>, circulating <span class=""chemical"">bupivacaine</span> during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine."		287.0	287_MESH:D002045_MESH:D001145	287_1	bcv_final_eval_easy_1583		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of <span class=""chemical"">epinephrine</span> in conscious, healthy dogs and in anesthetized dogs with <span class=""disease"">myocardial infarction</span>."		287.0	287_MESH:D004837_MESH:D009203	287_2	bcv_final_eval_easy_1584		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"We therefore examined whether <span class=""chemical"">bupivacaine</span> alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious, healthy dogs and in anesthetized dogs with <span class=""disease"">myocardial infarction</span>."		287.0	287_MESH:D002045_MESH:D009203	287_2	bcv_final_eval_easy_1585		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"One day after experimental <span class=""disease"">myocardial infarction</span>, six additional <span class=""chemical"">halothane</span>-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared."		287.0	287_MESH:D006221_MESH:D009203	287_9	bcv_final_eval_easy_1586		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"One day after experimental <span class=""disease"">myocardial infarction</span>, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 <span class=""chemical"">epinephrine</span> until VT appeared."		287.0	287_MESH:D004837_MESH:D009203	287_9	bcv_final_eval_easy_1587		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D017180	"<span class=""disease"">VT</span>"	"One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 <span class=""chemical"">epinephrine</span> until <span class=""disease"">VT</span> appeared."		287.0	287_MESH:D004837_MESH:D017180	287_9	bcv_final_eval_easy_1588		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D017180	"<span class=""disease"">VT</span>"	"One day after experimental myocardial infarction, six additional <span class=""chemical"">halothane</span>-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until <span class=""disease"">VT</span> appeared."		287.0	287_MESH:D006221_MESH:D017180	287_9	bcv_final_eval_easy_1589		
	MESH:D002045	"<span class=""chemical"">Bupivacaine</span>"	MESH:D017180	"<span class=""disease"">VT</span>"	"<span class=""chemical"">Bupivacaine</span> antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to <span class=""disease"">VT</span> and in anesthetized dogs with spontaneous postinfarct dysrhythmias."		287.0	287_MESH:D002045_MESH:D017180	287_12	bcv_final_eval_easy_1590		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D017180	"<span class=""disease"">VT</span>"	"Bupivacaine antagonizes <span class=""chemical"">epinephrine</span> dysrhythmogenicity in conscious dogs susceptible to <span class=""disease"">VT</span> and in anesthetized dogs with spontaneous postinfarct dysrhythmias."		287.0	287_MESH:D004837_MESH:D017180	287_12	bcv_final_eval_easy_1591		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D001145	"<span class=""disease"">postinfarct dysrhythmias</span>"	"Bupivacaine antagonizes <span class=""chemical"">epinephrine</span> dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous <span class=""disease"">postinfarct dysrhythmias</span>."		287.0	287_MESH:D004837_MESH:D001145	287_12	bcv_final_eval_easy_1592		
	MESH:D002045	"<span class=""chemical"">Bupivacaine</span>"	MESH:D001145	"<span class=""disease"">postinfarct dysrhythmias</span>"	"<span class=""chemical"">Bupivacaine</span> antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous <span class=""disease"">postinfarct dysrhythmias</span>."		287.0	287_MESH:D002045_MESH:D001145	287_12	bcv_final_eval_easy_1593		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D006934	"<span class=""disease"">Milk-alkali syndrome</span>"	"<span class=""disease"">Milk-alkali syndrome</span> was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of <span class=""chemical"">calcium</span> and alkali."		288.0	288_MESH:D002118_MESH:D006934	288_1	bcv_final_eval_easy_1594		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D010437	"<span class=""disease"">peptic ulcer disease</span>"	"Milk-alkali syndrome was first described 70 years ago in the context of the treatment of <span class=""disease"">peptic ulcer disease</span> with large amounts of <span class=""chemical"">calcium</span> and alkali."		288.0	288_MESH:D002118_MESH:D010437	288_1	bcv_final_eval_easy_1595		
	MESH:D013392	"<span class=""chemical"">sucralfate</span>"	MESH:D007674	"<span class=""disease"">renal impairment</span>"	"Although with current ulcer therapy (H-2 blockers, omeprazole, and <span class=""chemical"">sucralfate</span>), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and <span class=""disease"">renal impairment</span> remains the hallmark of the syndrome."		288.0	288_MESH:D013392_MESH:D007674	288_2	bcv_final_eval_easy_1596		
	MESH:D009853	"<span class=""chemical"">omeprazole</span>"	MESH:D000471	"<span class=""disease"">alkalosis</span>"	"Although with current ulcer therapy (H-2 blockers, <span class=""chemical"">omeprazole</span>, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, <span class=""disease"">alkalosis</span>, and renal impairment remains the hallmark of the syndrome."		288.0	288_MESH:D009853_MESH:D000471	288_2	bcv_final_eval_easy_1597		
	MESH:D013392	"<span class=""chemical"">sucralfate</span>"	MESH:D014456	"<span class=""disease"">ulcer</span>"	"Although with current <span class=""disease"">ulcer</span> therapy (H-2 blockers, omeprazole, and <span class=""chemical"">sucralfate</span>), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome."		288.0	288_MESH:D013392_MESH:D014456	288_2	bcv_final_eval_easy_1598		
	MESH:D009853	"<span class=""chemical"">omeprazole</span>"	MESH:D006934	"<span class=""disease"">milk-alkali syndrome/hypercalcemia</span>"	"Although with current ulcer therapy (H-2 blockers, <span class=""chemical"">omeprazole</span>, and sucralfate), the frequency of <span class=""disease"">milk-alkali syndrome</span> has decreased significantly, the classic triad of <span class=""disease"">hypercalcemia</span>, alkalosis, and renal impairment remains the hallmark of the syndrome."		288.0	288_MESH:D009853_MESH:D006934	288_2	bcv_final_eval_easy_1599		
	MESH:D013392	"<span class=""chemical"">sucralfate</span>"	MESH:D013577	"<span class=""disease"">hallmark of the syndrome</span>"	"Although with current ulcer therapy (H-2 blockers, omeprazole, and <span class=""chemical"">sucralfate</span>), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the <span class=""disease"">hallmark of the syndrome</span>."		288.0	288_MESH:D013392_MESH:D013577	288_2	bcv_final_eval_easy_1600		
	MESH:D009853	"<span class=""chemical"">omeprazole</span>"	MESH:D013577	"<span class=""disease"">hallmark of the syndrome</span>"	"Although with current ulcer therapy (H-2 blockers, <span class=""chemical"">omeprazole</span>, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the <span class=""disease"">hallmark of the syndrome</span>."		288.0	288_MESH:D009853_MESH:D013577	288_2	bcv_final_eval_easy_1601		
	MESH:D013392	"<span class=""chemical"">sucralfate</span>"	MESH:D006934	"<span class=""disease"">milk-alkali syndrome/hypercalcemia</span>"	"Although with current ulcer therapy (H-2 blockers, omeprazole, and <span class=""chemical"">sucralfate</span>), the frequency of <span class=""disease"">milk-alkali syndrome</span> has decreased significantly, the classic triad of <span class=""disease"">hypercalcemia</span>, alkalosis, and renal impairment remains the hallmark of the syndrome."		288.0	288_MESH:D013392_MESH:D006934	288_2	bcv_final_eval_easy_1602		
	MESH:D009853	"<span class=""chemical"">omeprazole</span>"	MESH:D007674	"<span class=""disease"">renal impairment</span>"	"Although with current ulcer therapy (H-2 blockers, <span class=""chemical"">omeprazole</span>, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and <span class=""disease"">renal impairment</span> remains the hallmark of the syndrome."		288.0	288_MESH:D009853_MESH:D007674	288_2	bcv_final_eval_easy_1603		
	MESH:D009853	"<span class=""chemical"">omeprazole</span>"	MESH:D014456	"<span class=""disease"">ulcer</span>"	"Although with current <span class=""disease"">ulcer</span> therapy (H-2 blockers, <span class=""chemical"">omeprazole</span>, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome."		288.0	288_MESH:D009853_MESH:D014456	288_2	bcv_final_eval_easy_1604		
	MESH:D013392	"<span class=""chemical"">sucralfate</span>"	MESH:D000471	"<span class=""disease"">alkalosis</span>"	"Although with current ulcer therapy (H-2 blockers, omeprazole, and <span class=""chemical"">sucralfate</span>), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, <span class=""disease"">alkalosis</span>, and renal impairment remains the hallmark of the syndrome."		288.0	288_MESH:D013392_MESH:D000471	288_2	bcv_final_eval_easy_1605		
	MESH:D002119	"<span class=""chemical"">calcium carbonate</span>"	MESH:D007011	"<span class=""disease"">hypoparathyroidism</span>"	"This article presents a patient with <span class=""disease"">hypoparathyroidism</span> who was treated with <span class=""chemical"">calcium carbonate</span> and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome."		288.0	288_MESH:D002119_MESH:D007011	288_4	bcv_final_eval_easy_1606		
	MESH:D002117	"<span class=""chemical"">calcitriol</span>"	MESH:D006934	"<span class=""disease"">milk-alkali syndrome</span>"	"This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and <span class=""chemical"">calcitriol</span> resulting in two admissions to the hospital for <span class=""disease"">milk-alkali syndrome</span>."		288.0	288_MESH:D002117_MESH:D006934	288_4	bcv_final_eval_easy_1607		
	MESH:D002119	"<span class=""chemical"">calcium carbonate</span>"	MESH:D006934	"<span class=""disease"">milk-alkali syndrome</span>"	"This article presents a patient with hypoparathyroidism who was treated with <span class=""chemical"">calcium carbonate</span> and calcitriol resulting in two admissions to the hospital for <span class=""disease"">milk-alkali syndrome</span>."		288.0	288_MESH:D002119_MESH:D006934	288_4	bcv_final_eval_easy_1608		
	MESH:D002117	"<span class=""chemical"">calcitriol</span>"	MESH:D007011	"<span class=""disease"">hypoparathyroidism</span>"	"This article presents a patient with <span class=""disease"">hypoparathyroidism</span> who was treated with calcium carbonate and <span class=""chemical"">calcitriol</span> resulting in two admissions to the hospital for milk-alkali syndrome."		288.0	288_MESH:D002117_MESH:D007011	288_4	bcv_final_eval_easy_1609		
	MESH:C019248	"<span class=""chemical"">pamidronate</span>"	MESH:D006934	"<span class=""disease"">milk-alkali syndrome</span>"	"This illustrates intravenous <span class=""chemical"">pamidronate</span> as a valuable therapeutic tool when <span class=""disease"">milk-alkali syndrome</span> presents as hypercalcemic emergency."		288.0	288_MESH:C019248_MESH:D006934	288_6	bcv_final_eval_easy_1610		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D020230	"<span class=""disease"">serotonin syndrome spectrum disorders</span>"	"Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and <span class=""chemical""></span><span class=""disease"">serotonin</span> syndrome spectrum disorders?"		289.0	289_MESH:D012701_MESH:D020230	289_0	bcv_final_eval_easy_1611		
	MESH:D000639	"<span class=""chemical"">amitriptyline</span>"	MESH:D020230	"<span class=""disease"">serotonin syndrome spectrum disorders</span>"	"Encephalopathy during <span class=""chemical"">amitriptyline</span> therapy: are neuroleptic malignant syndrome and <span class=""disease"">serotonin syndrome spectrum disorders</span>?"		289.0	289_MESH:D000639_MESH:D020230	289_0	bcv_final_eval_easy_1612		
	MESH:D000639	"<span class=""chemical"">amitriptyline</span>"	MESH:D001927	"<span class=""disease"">Encephalopathy</span>"	"<span class=""disease"">Encephalopathy</span> during <span class=""chemical"">amitriptyline</span> therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?"		289.0	289_MESH:D000639_MESH:D001927	289_0	bcv_final_eval_easy_1613		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"Encephalopathy during amitriptyline therapy: are <span class=""disease"">neuroleptic malignant syndrome</span> and <span class=""chemical"">serotonin</span> syndrome spectrum disorders?"		289.0	289_MESH:D012701_MESH:D009459	289_0	bcv_final_eval_easy_1614		
	MESH:D000639	"<span class=""chemical"">amitriptyline</span>"	MESH:D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"Encephalopathy during <span class=""chemical"">amitriptyline</span> therapy: are <span class=""disease"">neuroleptic malignant syndrome</span> and serotonin syndrome spectrum disorders?"		289.0	289_MESH:D000639_MESH:D009459	289_0	bcv_final_eval_easy_1615		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D001927	"<span class=""disease"">Encephalopathy</span>"	"<span class=""disease"">Encephalopathy</span> during amitriptyline therapy: are neuroleptic malignant syndrome and <span class=""chemical"">serotonin</span> syndrome spectrum disorders?"		289.0	289_MESH:D012701_MESH:D001927	289_0	bcv_final_eval_easy_1616		
	MESH:D000639	"<span class=""chemical"">amitriptyline</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"This report describes a case of <span class=""disease"">encephalopathy</span> developed in the course of <span class=""chemical"">amitriptyline</span> therapy, during a remission of unipolar depression."		289.0	289_MESH:D000639_MESH:D001927	289_1	bcv_final_eval_easy_1617		
	MESH:D000639	"<span class=""chemical"">amitriptyline</span>"	MESH:D003866	"<span class=""disease"">unipolar depression</span>"	"This report describes a case of encephalopathy developed in the course of <span class=""chemical"">amitriptyline</span> therapy, during a remission of <span class=""disease"">unipolar depression</span>."		289.0	289_MESH:D000639_MESH:D003866	289_1	bcv_final_eval_easy_1618		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D009459	"<span class=""disease"">NMS/neuroleptic malignant syndrome</span>"	"This patient could have been diagnosed as having either <span class=""disease"">neuroleptic malignant syndrome</span> (<span class=""disease"">NMS</span>) or <span class=""chemical"">serotonin</span> syndrome (SS)."		289.0	289_MESH:D012701_MESH:D009459	289_2	bcv_final_eval_easy_1619		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D020230	"<span class=""disease"">serotonin syndrome/SS</span>"	"This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or <span class=""chemical""></span><span class=""disease"">serotonin</span> syndrome (<span class=""disease"">SS</span>)."		289.0	289_MESH:D012701_MESH:D020230	289_2	bcv_final_eval_easy_1620		
	MESH:D004967	"<span class=""chemical"">estrogen</span>"	MESH:D006470	"<span class=""disease"">hemorrhagic</span>"	"Genetic separation of tumor growth and <span class=""disease"">hemorrhagic</span> phenotypes in an <span class=""chemical"">estrogen</span>-induced tumor."		290.0	290_MESH:D004967_MESH:D006470	290_0	bcv_final_eval_easy_1621		
	MESH:D004967	"<span class=""chemical"">estrogen</span>"	MESH:D001010	"<span class=""disease"">Genetic separation</span>"	"<span class=""disease"">Genetic separation</span> of tumor growth and hemorrhagic phenotypes in an <span class=""chemical"">estrogen</span>-induced tumor."		290.0	290_MESH:D004967_MESH:D001010	290_0	bcv_final_eval_easy_1622		
	MESH:D004967	"<span class=""chemical"">estrogen</span>"	MESH:D006470	"<span class=""disease"">hemorrhagic</span>"	"Chronic administration of <span class=""chemical"">estrogen</span> to the Fischer 344 (F344) rat induces growth of large, <span class=""disease"">hemorrhagic</span> pituitary tumors."		290.0	290_MESH:D004967_MESH:D006470	290_1	bcv_final_eval_easy_1623		
	MESH:D004967	"<span class=""chemical"">estrogen</span>"	MESH:D010911	"<span class=""disease"">pituitary tumors</span>"	"Chronic administration of <span class=""chemical"">estrogen</span> to the Fischer 344 (F344) rat induces growth of large, hemorrhagic <span class=""disease"">pituitary tumors</span>."		290.0	290_MESH:D004967_MESH:D010911	290_1	bcv_final_eval_easy_1624		
	MESH:D004054	"<span class=""chemical"">DES/diethylstilbestrol</span>"	MESH:D006470	"<span class=""disease"">hemorrhagic</span>"	"Ten weeks of <span class=""chemical"">diethylstilbestrol</span> (<span class=""chemical"">DES</span>) treatment caused female F344 rat pituitaries to grow to an average of 109.2 +/- 6.3 mg (mean +/- SE) versus 11.3 +/- 1.4 mg for untreated rats, and to become highly <span class=""disease"">hemorrhagic</span>."		290.0	290_MESH:D004054_MESH:D006470	290_2	bcv_final_eval_easy_1625		
	MESH:D004054	"<span class=""chemical"">DES</span>"	MESH:D006470	"<span class=""disease"">hemorrhagic</span>"	"However, while <span class=""chemical"">DES</span>-induced pituitary growth exhibited quantitative, additive inheritance, the <span class=""disease"">hemorrhagic</span> phenotype exhibited recessive, epistatic inheritance."		290.0	290_MESH:D004054_MESH:D006470	290_7	bcv_final_eval_easy_1626		
	MESH:D009569	"<span class=""chemical"">nitric oxide</span>"	MESH:D001749	"<span class=""disease"">bladder irritation</span>"	"Increased expression of neuronal <span class=""chemical"">nitric oxide</span> synthase in bladder afferent pathways following chronic <span class=""disease"">bladder irritation</span>."		291.0	291_MESH:D009569_MESH:D001749	291_0	bcv_final_eval_easy_1627		
	MESH:D000171	"<span class=""chemical"">acrolein</span>"	MESH:D003556	"<span class=""disease"">Chemical cystitis</span>"	"<span class=""disease"">Chemical cystitis</span> was induced by cyclophosphamide (CYP) which is metabolized to <span class=""chemical"">acrolein</span>, an irritant eliminated in the urine."		291.0	291_MESH:D000171_MESH:D003556	291_2	bcv_final_eval_easy_1628		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D003556	"<span class=""disease"">Chemical cystitis</span>"	"<span class=""disease"">Chemical cystitis</span> was induced by <span class=""chemical"">cyclophosphamide</span> (CYP) which is metabolized to acrolein, an irritant eliminated in the urine."		291.0	291_MESH:D003520_MESH:D003556	291_2	bcv_final_eval_easy_1629		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D023921	"<span class=""disease"">coronary stenosis</span>"	"Effects of a new <span class=""chemical"">calcium</span> antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial <span class=""disease"">coronary stenosis</span>."		292.0	292_MESH:D002118_MESH:D023921	292_0	bcv_final_eval_easy_1630		
	MESH:D007545	"<span class=""chemical"">isoproterenol</span>"	MESH:D023921	"<span class=""disease"">coronary stenosis</span>"	"Effects of a new calcium antagonist, CD-832, on <span class=""chemical"">isoproterenol</span>-induced myocardial ischemia in dogs with partial <span class=""disease"">coronary stenosis</span>."		292.0	292_MESH:D007545_MESH:D023921	292_0	bcv_final_eval_easy_1631		
	MESH:C082828	"<span class=""chemical"">CD-832</span>"	MESH:D023921	"<span class=""disease"">coronary stenosis</span>"	"Effects of a new calcium antagonist, <span class=""chemical"">CD-832</span>, on isoproterenol-induced myocardial ischemia in dogs with partial <span class=""disease"">coronary stenosis</span>."		292.0	292_MESH:C082828_MESH:D023921	292_0	bcv_final_eval_easy_1632		
	MESH:C082828	"<span class=""chemical"">CD-832</span>"	MESH:D017202	"<span class=""disease"">myocardial ischemia</span>"	"Effects of a new calcium antagonist, <span class=""chemical"">CD-832</span>, on isoproterenol-induced <span class=""disease"">myocardial ischemia</span> in dogs with partial coronary stenosis."		292.0	292_MESH:C082828_MESH:D017202	292_0	bcv_final_eval_easy_1633		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D017202	"<span class=""disease"">myocardial ischemia</span>"	"Effects of a new <span class=""chemical"">calcium</span> antagonist, CD-832, on isoproterenol-induced <span class=""disease"">myocardial ischemia</span> in dogs with partial coronary stenosis."		292.0	292_MESH:D002118_MESH:D017202	292_0	bcv_final_eval_easy_1634		
	MESH:C082828	"<span class=""chemical"">CD-832</span>"	MESH:D017202	"<span class=""disease"">myocardial ischemia</span>"	"Effects of <span class=""chemical"">CD-832</span> on isoproterenol (ISO)-induced <span class=""disease"">myocardial ischemia</span> were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem."		292.0	292_MESH:C082828_MESH:D017202	292_1	bcv_final_eval_easy_1635		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D017202	"<span class=""disease"">myocardial ischemia</span>"	"Effects of CD-832 on isoproterenol (ISO)-induced <span class=""disease"">myocardial ischemia</span> were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for <span class=""chemical"">nifedipine</span> or diltiazem."		292.0	292_MESH:D009543_MESH:D017202	292_1	bcv_final_eval_easy_1636		
	MESH:D004110	"<span class=""chemical"">diltiazem</span>"	MESH:D023921	"<span class=""disease"">coronary stenosis</span>"	"Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial <span class=""disease"">coronary stenosis</span> of the left circumflex coronary artery and findings were compared with those for nifedipine or <span class=""chemical"">diltiazem</span>."		292.0	292_MESH:D004110_MESH:D023921	292_1	bcv_final_eval_easy_1637		
	MESH:D007545	"<span class=""chemical"">isoproterenol/ISO</span>"	MESH:D023921	"<span class=""disease"">coronary stenosis</span>"	"Effects of CD-832 on <span class=""chemical"">isoproterenol</span> (<span class=""chemical"">ISO</span>)-induced myocardial ischemia were studied in dogs with partial <span class=""disease"">coronary stenosis</span> of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem."		292.0	292_MESH:D007545_MESH:D023921	292_1	bcv_final_eval_easy_1638		
	MESH:C082828	"<span class=""chemical"">CD-832</span>"	MESH:D023921	"<span class=""disease"">coronary stenosis</span>"	"Effects of <span class=""chemical"">CD-832</span> on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial <span class=""disease"">coronary stenosis</span> of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem."		292.0	292_MESH:C082828_MESH:D023921	292_1	bcv_final_eval_easy_1639		
	MESH:D004110	"<span class=""chemical"">diltiazem</span>"	MESH:D017202	"<span class=""disease"">myocardial ischemia</span>"	"Effects of CD-832 on isoproterenol (ISO)-induced <span class=""disease"">myocardial ischemia</span> were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or <span class=""chemical"">diltiazem</span>."		292.0	292_MESH:D004110_MESH:D017202	292_1	bcv_final_eval_easy_1640		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D023921	"<span class=""disease"">coronary stenosis</span>"	"Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial <span class=""disease"">coronary stenosis</span> of the left circumflex coronary artery and findings were compared with those for <span class=""chemical"">nifedipine</span> or diltiazem."		292.0	292_MESH:D009543_MESH:D023921	292_1	bcv_final_eval_easy_1641		
	MESH:D007545	"<span class=""chemical"">ISO</span>"	MESH:D023921	"<span class=""disease"">coronary artery stenosis</span>"	"In the presence of <span class=""disease"">coronary artery stenosis</span>, 3-min periods of intracoronary <span class=""chemical"">ISO</span> infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram."		292.0	292_MESH:D007545_MESH:D023921	292_2	bcv_final_eval_easy_1642		
	MESH:C082828	"<span class=""chemical"">CD-832</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"After the control ISO infusion with <span class=""disease"">stenosis</span> was performed, equihypotensive doses of <span class=""chemical"">CD-832</span> (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion."		292.0	292_MESH:C082828_MESH:D003251	292_3	bcv_final_eval_easy_1643		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"After the control ISO infusion with <span class=""disease"">stenosis</span> was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), <span class=""chemical"">nifedipine</span> (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion."		292.0	292_MESH:D009543_MESH:D003251	292_3	bcv_final_eval_easy_1644		
	MESH:D004110	"<span class=""chemical"">diltiazem</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"After the control ISO infusion with <span class=""disease"">stenosis</span> was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or <span class=""chemical"">diltiazem</span> (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion."		292.0	292_MESH:D004110_MESH:D003251	292_3	bcv_final_eval_easy_1645		
	MESH:D007545	"<span class=""chemical"">ISO</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"After the control <span class=""chemical"">ISO</span> infusion with <span class=""disease"">stenosis</span> was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third <span class=""chemical"">ISO</span> infusion."		292.0	292_MESH:D007545_MESH:D003251	292_3	bcv_final_eval_easy_1646		
	MESH:C082828	"<span class=""chemical"">CD-832</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"In contrast to nifedipine, <span class=""chemical"">CD-832</span> (10 micrograms/kg/min) prevented the decrease in percentage segmental shortening from 32 +/- 12% to 115 +/- 26% of the control value (P < .01) and ST-segment elevation from 5.6 +/- 1.0 mV to 1.6 +/- 1.3 mV (P < .01) at 3 min after ISO infusion with <span class=""disease"">stenosis</span>."		292.0	292_MESH:C082828_MESH:D003251	292_5	bcv_final_eval_easy_1647		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"In contrast to <span class=""chemical"">nifedipine</span>, CD-832 (10 micrograms/kg/min) prevented the decrease in percentage segmental shortening from 32 +/- 12% to 115 +/- 26% of the control value (P < .01) and ST-segment elevation from 5.6 +/- 1.0 mV to 1.6 +/- 1.3 mV (P < .01) at 3 min after ISO infusion with <span class=""disease"">stenosis</span>."		292.0	292_MESH:D009543_MESH:D003251	292_5	bcv_final_eval_easy_1648		
	MESH:D007545	"<span class=""chemical"">ISO</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"In contrast to nifedipine, CD-832 (10 micrograms/kg/min) prevented the decrease in percentage segmental shortening from 32 +/- 12% to 115 +/- 26% of the control value (P < .01) and ST-segment elevation from 5.6 +/- 1.0 mV to 1.6 +/- 1.3 mV (P < .01) at 3 min after <span class=""chemical"">ISO</span> infusion with <span class=""disease"">stenosis</span>."		292.0	292_MESH:D007545_MESH:D003251	292_5	bcv_final_eval_easy_1649		
	MESH:D004110	"<span class=""chemical"">Diltiazem</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"<span class=""chemical"">Diltiazem</span> (30 micrograms/kg/min) also prevented the decrease in percentage segmental shortening from 34 +/- 14% to 63 +/- 18% of the control value (P < .05) and ST-segment elevation from 4.7 +/- 0.7 mV to 2.1 +/- 0.7 mV (P < .01) at 3 min after ISO infusion with <span class=""disease"">stenosis</span>."		292.0	292_MESH:D004110_MESH:D003251	292_6	bcv_final_eval_easy_1650		
	MESH:D007545	"<span class=""chemical"">ISO</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"Diltiazem (30 micrograms/kg/min) also prevented the decrease in percentage segmental shortening from 34 +/- 14% to 63 +/- 18% of the control value (P < .05) and ST-segment elevation from 4.7 +/- 0.7 mV to 2.1 +/- 0.7 mV (P < .01) at 3 min after <span class=""chemical"">ISO</span> infusion with <span class=""disease"">stenosis</span>."		292.0	292_MESH:D007545_MESH:D003251	292_6	bcv_final_eval_easy_1651		
	MESH:C082828	"<span class=""chemical"">CD-832</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"These data show that <span class=""chemical"">CD-832</span> improves myocardial ischemia during ISO infusion with <span class=""disease"">stenosis</span> and suggest that the negative chronotropic property of <span class=""chemical"">CD-832</span> plays a major role in the beneficial effects of <span class=""chemical"">CD-832</span>."		292.0	292_MESH:C082828_MESH:D003251	292_7	bcv_final_eval_easy_1652		
	MESH:C082828	"<span class=""chemical"">CD-832</span>"	MESH:D017202	"<span class=""disease"">myocardial ischemia</span>"	"These data show that <span class=""chemical"">CD-832</span> improves <span class=""disease"">myocardial ischemia</span> during ISO infusion with stenosis and suggest that the negative chronotropic property of <span class=""chemical"">CD-832</span> plays a major role in the beneficial effects of <span class=""chemical"">CD-832</span>."		292.0	292_MESH:C082828_MESH:D017202	292_7	bcv_final_eval_easy_1653		
	MESH:D007545	"<span class=""chemical"">ISO</span>"	MESH:D003251	"<span class=""disease"">stenosis</span>"	"These data show that CD-832 improves myocardial ischemia during <span class=""chemical"">ISO</span> infusion with <span class=""disease"">stenosis</span> and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832."		292.0	292_MESH:D007545_MESH:D003251	292_7	bcv_final_eval_easy_1654		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"The effect of recombinant human insulin-like growth factor-I on chronic <span class=""chemical"">puromycin aminonucleoside</span> <span class=""disease"">nephropathy</span> in rats."		293.0	293_MESH:D011692_MESH:D007674	293_0	bcv_final_eval_easy_1655		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside/PAN</span>"	MESH:D001930	"<span class=""disease"">structural injury</span>"	"We recently demonstrated that recombinant hGH exacerbates renal functional and <span class=""disease"">structural injury</span> in chronic <span class=""chemical"">puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>) nephropathy, an experimental model of glomerular disease."		293.0	293_MESH:D011692_MESH:D001930	293_1	bcv_final_eval_easy_1656		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside/PAN</span>"	MESH:D007674	"<span class=""disease"">glomerular disease/nephropathy</span>"	"We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic <span class=""chemical"">puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>) <span class=""disease"">nephropathy</span>, an experimental model of <span class=""disease"">glomerular disease</span>."		293.0	293_MESH:D011692_MESH:D007674	293_1	bcv_final_eval_easy_1657		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic <span class=""chemical"">PAN</span> <span class=""disease"">nephropathy</span>."		293.0	293_MESH:D011692_MESH:D007674	293_2	bcv_final_eval_easy_1658		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D006130	"<span class=""disease"">growth failure</span>"	"Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of <span class=""disease"">growth failure</span> in rats with chronic <span class=""chemical"">PAN</span> nephropathy."		293.0	293_MESH:D011692_MESH:D006130	293_2	bcv_final_eval_easy_1659		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">glomerulopathy</span>"	"The <span class=""disease"">glomerulopathy</span> was induced by seven serial injections of <span class=""chemical"">PAN</span> over 12 wk."		293.0	293_MESH:D011692_MESH:D007674	293_3	bcv_final_eval_easy_1660		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic <span class=""chemical"">PAN</span> <span class=""disease"">nephropathy</span>."		293.0	293_MESH:D011692_MESH:D007674	293_6	bcv_final_eval_easy_1661		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"After 12 wk, the inulin clearance was higher in rhIGF-I-treated rats, 0.48 +/- 0.08 versus 0.24 +/- 0.06 mL/min/100 g of body weight in untreated <span class=""chemical"">PAN</span> <span class=""disease"">nephropathy</span> animals, p < 0.05."		293.0	293_MESH:D011692_MESH:D007674	293_7	bcv_final_eval_easy_1662		
	MESH:D008315	"<span class=""chemical"">malondialdehyde</span>"	MESH:D007674	"<span class=""disease"">glomerular hypertrophy</span>"	"The improvement in GFR was not associated with enhanced <span class=""disease"">glomerular hypertrophy</span> or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical <span class=""chemical"">malondialdehyde</span> content."		293.0	293_MESH:D008315_MESH:D007674	293_8	bcv_final_eval_easy_1663		
	MESH:D008315	"<span class=""chemical"">malondialdehyde</span>"	MESH:C538457	"<span class=""disease"">segmental glomerulosclerosis</span>"	"The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased <span class=""disease"">segmental glomerulosclerosis</span>, tubulointerstitial injury, or renal cortical <span class=""chemical"">malondialdehyde</span> content."		293.0	293_MESH:D008315_MESH:C538457	293_8	bcv_final_eval_easy_1664		
	MESH:D008315	"<span class=""chemical"">malondialdehyde</span>"	MESH:D009395	"<span class=""disease"">tubulointerstitial injury</span>"	"The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, <span class=""disease"">tubulointerstitial injury</span>, or renal cortical <span class=""chemical"">malondialdehyde</span> content."		293.0	293_MESH:D008315_MESH:D009395	293_8	bcv_final_eval_easy_1665		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"In rats with <span class=""chemical"">PAN</span> <span class=""disease"">nephropathy</span>, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA."		293.0	293_MESH:D011692_MESH:D007674	293_9	bcv_final_eval_easy_1666		
	MESH:D008315	"<span class=""chemical"">malondialdehyde</span>"	MESH:D007674	"<span class=""disease"">cortical malondialdehyde content, or glomerular or tubulointerstitial damage</span>"	"In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal <span class=""disease"">cortical </span><span class=""chemical"">malondialdehyde</span> content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4)."		293.0	293_MESH:D008315_MESH:D007674	293_10	bcv_final_eval_easy_1667		
	MESH:D008315	"<span class=""chemical"">malondialdehyde</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, <span class=""disease"">proteinuria</span>, GFR, glomerular planar area, renal cortical <span class=""chemical"">malondialdehyde</span> content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4)."		293.0	293_MESH:D008315_MESH:D011507	293_10	bcv_final_eval_easy_1668		
	MESH:D008315	"<span class=""chemical"">malondialdehyde</span>"	MESH:D015430	"<span class=""disease"">weight gain</span>"	"In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter <span class=""disease"">weight gain</span>, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical <span class=""chemical"">malondialdehyde</span> content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4)."		293.0	293_MESH:D008315_MESH:D015430	293_10	bcv_final_eval_easy_1669		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D001930	"<span class=""disease"">structural injury</span>"	"We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic <span class=""chemical"">PAN</span> nephropathy and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and <span class=""disease"">structural injury</span> in this disease model."		293.0	293_MESH:D011692_MESH:D001930	293_12	bcv_final_eval_easy_1670		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic <span class=""chemical"">PAN</span> <span class=""disease"">nephropathy</span> and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model."		293.0	293_MESH:D011692_MESH:D007674	293_12	bcv_final_eval_easy_1671		
	MESH:C058876	"<span class=""chemical"">Nefiracetam/DM-9384</span>"	MESH:D000647	"<span class=""disease"">amnesia</span>"	"<span class=""chemical"">Nefiracetam</span> (<span class=""chemical"">DM-9384</span>) reverses apomorphine-induced <span class=""disease"">amnesia</span> of a passive avoidance response: delayed emergence of the memory retention effects."		294.0	294_MESH:C058876_MESH:D000647	294_0	bcv_final_eval_easy_1672		
	MESH:C058876	"<span class=""chemical"">nefiracetam</span>"	MESH:D000647	"<span class=""disease"">amnesia</span>"	"Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <span class=""chemical"">nefiracetam</span> to attenuate <span class=""disease"">amnesia</span> induced by dopaminergic agonism."		294.0	294_MESH:C058876_MESH:D000647	294_2	bcv_final_eval_easy_1673		
	MESH:C058876	"<span class=""chemical"">nefiracetam</span>"	MESH:D000647	"<span class=""disease"">amnesic</span>"	"Co-administration of <span class=""chemical"">nefiracetam</span> and apomorphine during training or 10h thereafter produced no significant anti-<span class=""disease"">amnesic</span> effect."		294.0	294_MESH:C058876_MESH:D000647	294_4	bcv_final_eval_easy_1674		
	MESH:C058876	"<span class=""chemical"">nefiracetam</span>"	MESH:D000647	"<span class=""disease"">amnesia</span>"	"However, administration of <span class=""chemical"">nefiracetam</span> during training completely reversed the <span class=""disease"">amnesia</span> induced by apomorphine at the 10h post-training time and the converse was also true."		294.0	294_MESH:C058876_MESH:D000647	294_5	bcv_final_eval_easy_1675		
	MESH:D019259	"<span class=""chemical"">Lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"<span class=""chemical"">Lamivudine</span> is effective in suppressing <span class=""disease"">hepatitis B</span> virus DNA in Chinese <span class=""disease"">hepatitis B</span> surface antigen carriers: a placebo-controlled trial."		296.0	296_MESH:D019259_MESH:D006509	296_0	bcv_final_eval_easy_1676		
	MESH:D019259	"<span class=""chemical"">Lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"<span class=""chemical"">Lamivudine</span> is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on <span class=""disease"">hepatitis B</span> virus replication in vitro and in vivo."		296.0	296_MESH:D019259_MESH:D006509	296_1	bcv_final_eval_easy_1677		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">decrease in hepatitis B</span>"	"All 36 patients receiving <span class=""chemical"">lamivudine</span> had a <span class=""disease"">decrease in hepatitis B</span> virus (HBV) DNA values of >90% (P < .001 compared with placebo)."		296.0	296_MESH:D019259_MESH:D006509	296_6	bcv_final_eval_easy_1678		
	MESH:D003276	"<span class=""chemical"">oral contraceptives</span>"	MESH:D054556	"<span class=""disease"">venous thromboembolism</span>"	"Population-based study of risk of <span class=""disease"">venous thromboembolism</span> associated with various <span class=""chemical"">oral contraceptives</span>."		297.0	297_MESH:D003276_MESH:D054556	297_0	bcv_final_eval_easy_1679		
	MESH:D011372	"<span class=""chemical"">progestagens</span>"	MESH:D054556	"<span class=""disease"">venous thromboembolism/VTE</span>"	"BACKGROUND: Four studies published since December, 1995, reported that the incidence of <span class=""disease"">venous thromboembolism</span> (<span class=""disease"">VTE</span>) was higher in women who used oral contraceptives (OCs) containing the third-generation <span class=""chemical"">progestagens</span> gestodene or desogestrel than in users of OCs containing second-generation progestagens."		297.0	297_MESH:D011372_MESH:D054556	297_1	bcv_final_eval_easy_1680		
	MESH:D003276	"<span class=""chemical"">oral contraceptives</span>"	MESH:D054556	"<span class=""disease"">venous thromboembolism/VTE</span>"	"BACKGROUND: Four studies published since December, 1995, reported that the incidence of <span class=""disease"">venous thromboembolism</span> (<span class=""disease"">VTE</span>) was higher in women who used <span class=""chemical"">oral contraceptives</span> (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens."		297.0	297_MESH:D003276_MESH:D054556	297_1	bcv_final_eval_easy_1681		
	MESH:D017135	"<span class=""chemical"">desogestrel</span>"	MESH:D054556	"<span class=""disease"">venous thromboembolism/VTE</span>"	"BACKGROUND: Four studies published since December, 1995, reported that the incidence of <span class=""disease"">venous thromboembolism</span> (<span class=""disease"">VTE</span>) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or <span class=""chemical"">desogestrel</span> than in users of OCs containing second-generation progestagens."		297.0	297_MESH:D017135_MESH:D054556	297_1	bcv_final_eval_easy_1682		
	MESH:D017135	"<span class=""chemical"">desogestrel</span>"	MESH:D054556	"<span class=""disease"">VTE</span>"	"Among users of third-generation progestagens, the risk of <span class=""disease"">VTE</span> was higher in users of <span class=""chemical"">desogestrel</span> with 20 g ethinyloestradiol than in users of gestodene or <span class=""chemical"">desogestrel</span> with 30 g ethinyloestradiol."		297.0	297_MESH:D017135_MESH:D054556	297_15	bcv_final_eval_easy_1683		
	MESH:C033273	"<span class=""chemical"">gestodene</span>"	MESH:D054556	"<span class=""disease"">VTE</span>"	"Among users of third-generation progestagens, the risk of <span class=""disease"">VTE</span> was higher in users of desogestrel with 20 g ethinyloestradiol than in users of <span class=""chemical"">gestodene</span> or desogestrel with 30 g ethinyloestradiol."		297.0	297_MESH:C033273_MESH:D054556	297_15	bcv_final_eval_easy_1684		
	MESH:D004997	"<span class=""chemical"">ethinyloestradiol</span>"	MESH:D054556	"<span class=""disease"">VTE</span>"	"Among users of third-generation progestagens, the risk of <span class=""disease"">VTE</span> was higher in users of desogestrel with 20 g <span class=""chemical"">ethinyloestradiol</span> than in users of gestodene or desogestrel with 30 g <span class=""chemical"">ethinyloestradiol</span>."		297.0	297_MESH:D004997_MESH:D054556	297_15	bcv_final_eval_easy_1685		
	MESH:D017135	"<span class=""chemical"">desogestrel</span>"	MESH:D054556	"<span class=""disease"">VTE</span>"	"With all second-generation OCs as the reference, the odds ratios for <span class=""disease"">VTE</span> were 3.49 (1.21-10.12) for <span class=""chemical"">desogestrel</span> plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens."		297.0	297_MESH:D017135_MESH:D054556	297_16	bcv_final_eval_easy_1686		
	MESH:D004997	"<span class=""chemical"">ethinyloestradiol</span>"	MESH:D054556	"<span class=""disease"">VTE</span>"	"With all second-generation OCs as the reference, the odds ratios for <span class=""disease"">VTE</span> were 3.49 (1.21-10.12) for desogestrel plus 20 g <span class=""chemical"">ethinyloestradiol</span> and 1.18 (0.66-2.17) for the other third-generation progestagens."		297.0	297_MESH:D004997_MESH:D054556	297_16	bcv_final_eval_easy_1687		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">MK-801</span> augments pilocarpine-induced electrographic <span class=""disease"">seizure</span> but protects against brain damage in rats."		298.0	298_MESH:D016291_MESH:D012640	298_0	bcv_final_eval_easy_1688		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"<span class=""chemical"">MK-801</span> augments pilocarpine-induced electrographic seizure but protects against <span class=""disease"">brain damage</span> in rats."		298.0	298_MESH:D016291_MESH:D001927	298_0	bcv_final_eval_easy_1689		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"MK-801 augments <span class=""chemical"">pilocarpine</span>-induced electrographic seizure but protects against <span class=""disease"">brain damage</span> in rats."		298.0	298_MESH:D010862_MESH:D001927	298_0	bcv_final_eval_easy_1690		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"The authors examined the anticonvulsant effects of <span class=""chemical"">MK-801</span> on the pilocarpine-induced <span class=""disease"">seizure</span> model."		298.0	298_MESH:D016291_MESH:D012640	298_2	bcv_final_eval_easy_1691		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral <span class=""disease"">seizure</span> but <span class=""chemical"">MK-801</span> (0.5 mg/kg) did not."		298.0	298_MESH:D016291_MESH:D012640	298_4	bcv_final_eval_easy_1692		
	MESH:D010424	"<span class=""chemical"">pentobarbital</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Scopolamine (10 mg/kg) and <span class=""chemical"">pentobarbital</span> (5 mg/kg) prevented development of pilocarpine-induced behavioral <span class=""disease"">seizure</span> but MK-801 (0.5 mg/kg) did not."		298.0	298_MESH:D010424_MESH:D012640	298_4	bcv_final_eval_easy_1693		
	MESH:D012601	"<span class=""chemical"">Scopolamine</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">Scopolamine</span> (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral <span class=""disease"">seizure</span> but MK-801 (0.5 mg/kg) did not."		298.0	298_MESH:D012601_MESH:D012640	298_4	bcv_final_eval_easy_1694		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic <span class=""disease"">seizure</span>, <span class=""chemical"">MK-801</span> treatment augmented the electrographic <span class=""disease"">seizure</span> induced by pilocarpine."		298.0	298_MESH:D016291_MESH:D012640	298_7	bcv_final_eval_easy_1695		
	MESH:D010424	"<span class=""chemical"">pentobarbital</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"Scopolamine and <span class=""chemical"">pentobarbital</span> blocked the pilocarpine-induced electrographic <span class=""disease"">seizure</span>, MK-801 treatment augmented the electrographic <span class=""disease"">seizure</span> induced by pilocarpine."		298.0	298_MESH:D010424_MESH:D012640	298_7	bcv_final_eval_easy_1696		
	MESH:D012601	"<span class=""chemical"">Scopolamine</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">Scopolamine</span> and pentobarbital blocked the pilocarpine-induced electrographic <span class=""disease"">seizure</span>, MK-801 treatment augmented the electrographic <span class=""disease"">seizure</span> induced by pilocarpine."		298.0	298_MESH:D012601_MESH:D012640	298_7	bcv_final_eval_easy_1697		
	MESH:D010862	"<span class=""chemical"">Pilocarpine</span>"	MESH:D009410	"<span class=""disease"">neuronal death</span>"	"<span class=""chemical"">Pilocarpine</span> produced <span class=""disease"">neuronal death</span> in the hippocampus, which showed pyknotic changes."		298.0	298_MESH:D010862_MESH:D009410	298_10	bcv_final_eval_easy_1698		
	MESH:D012601	"<span class=""chemical"">scopolamine</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"Pentobarbital, <span class=""chemical"">scopolamine</span> and MK-801 protected the <span class=""disease"">brain damage</span> by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal."		298.0	298_MESH:D012601_MESH:D001927	298_11	bcv_final_eval_easy_1699		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"Pentobarbital, scopolamine and MK-801 protected the <span class=""disease"">brain damage</span> by <span class=""chemical"">pilocarpine</span>, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal."		298.0	298_MESH:D010862_MESH:D001927	298_11	bcv_final_eval_easy_1700		
	MESH:D016291	"<span class=""chemical"">MK-801</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"Pentobarbital, scopolamine and <span class=""chemical"">MK-801</span> protected the <span class=""disease"">brain damage</span> by pilocarpine, though in the <span class=""chemical"">MK-801</span>-treated group, the pyramidal cells of hippocampus appeared darker than normal."		298.0	298_MESH:D016291_MESH:D001927	298_11	bcv_final_eval_easy_1701		
	MESH:D010424	"<span class=""chemical"">Pentobarbital</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"<span class=""chemical"">Pentobarbital</span>, scopolamine and MK-801 protected the <span class=""disease"">brain damage</span> by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal."		298.0	298_MESH:D010424_MESH:D001927	298_11	bcv_final_eval_easy_1702		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"These results indicate that status epilepticus induced by <span class=""chemical"">pilocarpine</span> is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause <span class=""disease"">brain damage</span> through an excitatory NMDA receptor-mediated mechanism."		298.0	298_MESH:D010862_MESH:D001927	298_14	bcv_final_eval_easy_1703		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"These results indicate that <span class=""disease"">status epilepticus</span> induced by <span class=""chemical"">pilocarpine</span> is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism."		298.0	298_MESH:D010862_MESH:D013226	298_14	bcv_final_eval_easy_1704		
	MESH:D016202	"<span class=""chemical"">NMDA</span>"	MESH:D001927	"<span class=""disease"">brain damage</span>"	"These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause <span class=""disease"">brain damage</span> through an excitatory <span class=""chemical"">NMDA</span> receptor-mediated mechanism."		298.0	298_MESH:D016202_MESH:D001927	298_14	bcv_final_eval_easy_1705		
	MESH:D016202	"<span class=""chemical"">NMDA</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"These results indicate that <span class=""disease"">status epilepticus</span> induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory <span class=""chemical"">NMDA</span> receptor-mediated mechanism."		298.0	298_MESH:D016202_MESH:D013226	298_14	bcv_final_eval_easy_1706		
	MESH:D017239	"<span class=""chemical"">Paclitaxel</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"<span class=""chemical"">Paclitaxel</span>, 5-fluorouracil, and folinic acid in metastatic <span class=""disease"">breast cancer</span>: BRE-26, a phase II trial."		299.0	299_MESH:D017239_MESH:D001943	299_0	bcv_final_eval_easy_1707		
	MESH:D002955	"<span class=""chemical"">folinic acid</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"Paclitaxel, 5-fluorouracil, and <span class=""chemical"">folinic acid</span> in metastatic <span class=""disease"">breast cancer</span>: BRE-26, a phase II trial."		299.0	299_MESH:D002955_MESH:D001943	299_0	bcv_final_eval_easy_1708		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"Paclitaxel, <span class=""chemical"">5-fluorouracil</span>, and folinic acid in metastatic <span class=""disease"">breast cancer</span>: BRE-26, a phase II trial."		299.0	299_MESH:D005472_MESH:D001943	299_0	bcv_final_eval_easy_1709		
	MESH:D017239	"<span class=""chemical"">paclitaxel/Taxol</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"5-Fluorouracil plus folinic acid and <span class=""chemical"">paclitaxel</span> (<span class=""chemical"">Taxol</span>; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic <span class=""disease"">breast cancer</span> patients."		299.0	299_MESH:D017239_MESH:D001943	299_1	bcv_final_eval_easy_1710		
	MESH:D002955	"<span class=""chemical"">folinic acid</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"5-Fluorouracil plus <span class=""chemical"">folinic acid</span> and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic <span class=""disease"">breast cancer</span> patients."		299.0	299_MESH:D002955_MESH:D001943	299_1	bcv_final_eval_easy_1711		
	MESH:D005472	"<span class=""chemical"">5-Fluorouracil</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"<span class=""chemical"">5-Fluorouracil</span> plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic <span class=""disease"">breast cancer</span> patients."		299.0	299_MESH:D005472_MESH:D001943	299_1	bcv_final_eval_easy_1712		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D064420	"<span class=""disease"">cytotoxicity</span>"	"Paclitaxel and <span class=""chemical"">5-fluorouracil</span> have additive <span class=""disease"">cytotoxicity</span> in MCF-7 cell lines."		299.0	299_MESH:D005472_MESH:D064420	299_2	bcv_final_eval_easy_1713		
	MESH:D017239	"<span class=""chemical"">Paclitaxel</span>"	MESH:D064420	"<span class=""disease"">cytotoxicity</span>"	"<span class=""chemical"">Paclitaxel</span> and 5-fluorouracil have additive <span class=""disease"">cytotoxicity</span> in MCF-7 cell lines."		299.0	299_MESH:D017239_MESH:D064420	299_2	bcv_final_eval_easy_1714		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"We performed a phase II trial of <span class=""chemical"">paclitaxel</span> 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic <span class=""disease"">breast cancer</span>."		299.0	299_MESH:D017239_MESH:D001943	299_3	bcv_final_eval_easy_1715		
	MESH:D002955	"<span class=""chemical"">folinic acid</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by <span class=""chemical"">folinic acid</span> 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic <span class=""disease"">breast cancer</span>."		299.0	299_MESH:D002955_MESH:D001943	299_3	bcv_final_eval_easy_1716		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D001943	"<span class=""disease"">breast cancer</span>"	"We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before <span class=""chemical"">5-fluorouracil</span> 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic <span class=""disease"">breast cancer</span>."		299.0	299_MESH:D005472_MESH:D001943	299_3	bcv_final_eval_easy_1717		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"Chronic <span class=""disease"">hyperprolactinemia</span> and changes in <span class=""chemical"">dopamine</span> neurons."		301.0	301_MESH:D004298_MESH:D006966	301_0	bcv_final_eval_easy_1718		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D006966	"<span class=""disease"">Hyperprolactinemia</span>"	"<span class=""disease"">Hyperprolactinemia</span> was induced by treatment with haloperidol, a <span class=""chemical"">dopamine</span> receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain."		301.0	301_MESH:D004298_MESH:D006966	301_5	bcv_final_eval_easy_1719		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"After 6 months of <span class=""disease"">hyperprolactinemia</span>, <span class=""chemical"">dopamine</span> (DA) concentrations in the median eminence (ME) increased by 84% over the control group."		301.0	301_MESH:D004298_MESH:D006966	301_6	bcv_final_eval_easy_1720		
	MESH:D009638	"<span class=""chemical"">norepinephrine</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"There was no change in the levels of DA, <span class=""chemical"">norepinephrine</span> (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of <span class=""disease"">hyperprolactinemia</span> and an increase in DA concentrations in the AN after 9-months of <span class=""disease"">hyperprolactinemia</span>."		301.0	301_MESH:D009638_MESH:D006966	301_9	bcv_final_eval_easy_1721		
	MESH:D012701	"<span class=""chemical"">serotonin/5-HT</span>"	MESH:D012607	"<span class=""disease"">arcuate nucleus/AN</span>"	"There was no change in the levels of DA, norepinephrine (NE), <span class=""chemical"">serotonin</span> (<span class=""chemical"">5-HT</span>), or their metabolites in the <span class=""disease"">arcuate nucleus</span> (<span class=""disease"">AN</span>), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the <span class=""disease"">AN</span> after 6-months of hyperprolactinemia and an increase in DA concentrations in the <span class=""disease"">AN</span> after 9-months of hyperprolactinemia."		301.0	301_MESH:D012701_MESH:D012607	301_9	bcv_final_eval_easy_1722		
	MESH:D009638	"<span class=""chemical"">norepinephrine</span>"	MESH:D012607	"<span class=""disease"">arcuate nucleus/AN</span>"	"There was no change in the levels of DA, <span class=""chemical"">norepinephrine</span> (NE), serotonin (5-HT), or their metabolites in the <span class=""disease"">arcuate nucleus</span> (<span class=""disease"">AN</span>), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the <span class=""disease"">AN</span> after 6-months of hyperprolactinemia and an increase in DA concentrations in the <span class=""disease"">AN</span> after 9-months of hyperprolactinemia."		301.0	301_MESH:D009638_MESH:D012607	301_9	bcv_final_eval_easy_1723		
	MESH:D012701	"<span class=""chemical"">serotonin/5-HT</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"There was no change in the levels of DA, norepinephrine (NE), <span class=""chemical"">serotonin</span> (<span class=""chemical"">5-HT</span>), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of <span class=""disease"">hyperprolactinemia</span> and an increase in DA concentrations in the AN after 9-months of <span class=""disease"">hyperprolactinemia</span>."		301.0	301_MESH:D012701_MESH:D006966	301_9	bcv_final_eval_easy_1724		
	MESH:D006897	"<span class=""chemical"">5-HIAA</span>"	MESH:D006966	"<span class=""disease"">hyperprolactinemia</span>"	"There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (<span class=""chemical"">5-HIAA</span>) in the AN after 6-months of <span class=""disease"">hyperprolactinemia</span> and an increase in DA concentrations in the AN after 9-months of <span class=""disease"">hyperprolactinemia</span>."		301.0	301_MESH:D006897_MESH:D006966	301_9	bcv_final_eval_easy_1725		
	MESH:D006897	"<span class=""chemical"">5-HIAA</span>"	MESH:D012607	"<span class=""disease"">arcuate nucleus/AN</span>"	"There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the <span class=""disease"">arcuate nucleus</span> (<span class=""disease"">AN</span>), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (<span class=""chemical"">5-HIAA</span>) in the <span class=""disease"">AN</span> after 6-months of hyperprolactinemia and an increase in DA concentrations in the <span class=""disease"">AN</span> after 9-months of hyperprolactinemia."		301.0	301_MESH:D006897_MESH:D012607	301_9	bcv_final_eval_easy_1726		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D054198	"<span class=""disease"">acute lymphoblastic leukemia</span>"	"This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from <span class=""disease"">acute lymphoblastic leukemia</span> treated with high-dose <span class=""chemical"">methotrexate</span>."		302.0	302_MESH:D008727_MESH:D054198	302_1	bcv_final_eval_easy_1727		
	MESH:D008727	"<span class=""chemical"">methotrexate</span>"	MESH:D009336	"<span class=""disease"">disseminated necrotizing leukoencephalopathy</span>"	"This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with <span class=""disease"">disseminated necrotizing leukoencephalopathy</span>, which developed from acute lymphoblastic leukemia treated with high-dose <span class=""chemical"">methotrexate</span>."		302.0	302_MESH:D008727_MESH:D009336	302_1	bcv_final_eval_easy_1728		
	MESH:D014212	"<span class=""chemical"">all-trans-retinoic acid</span>"	MESH:D015473	"<span class=""disease"">acute promyelocytic leukemia</span>"	"Thrombotic complications in <span class=""disease"">acute promyelocytic leukemia</span> during <span class=""chemical"">all-trans-retinoic acid</span> therapy."		303.0	303_MESH:D014212_MESH:D015473	303_0	bcv_final_eval_easy_1729		
	MESH:D014212	"<span class=""chemical"">all-trans-retinoic acid</span>"	MESH:D013927	"<span class=""disease"">Thrombotic</span>"	"<span class=""disease"">Thrombotic</span> complications in acute promyelocytic leukemia during <span class=""chemical"">all-trans-retinoic acid</span> therapy."		303.0	303_MESH:D014212_MESH:D013927	303_0	bcv_final_eval_easy_1730		
	MESH:D014212	"<span class=""chemical"">ATRA/all-trans-retinoic acid</span>"	MESH:D015473	"<span class=""disease"">APL/acute promyelocytic leukemia</span>"	"A case of acute renal failure, due to occlusion of renal vessels in a patient with <span class=""disease"">acute promyelocytic leukemia</span> (<span class=""disease"">APL</span>) treated with <span class=""chemical"">all-trans-retinoic acid</span> (<span class=""chemical"">ATRA</span>) and tranexamic acid has been described recently."		303.0	303_MESH:D014212_MESH:D015473	303_1	bcv_final_eval_easy_1731		
	MESH:D014148	"<span class=""chemical"">tranexamic acid</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"A case of <span class=""disease"">acute renal failure</span>, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and <span class=""chemical"">tranexamic acid</span> has been described recently."		303.0	303_MESH:D014148_MESH:D058186	303_1	bcv_final_eval_easy_1732		
	MESH:D014212	"<span class=""chemical"">ATRA/all-trans-retinoic acid</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"A case of <span class=""disease"">acute renal failure</span>, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with <span class=""chemical"">all-trans-retinoic acid</span> (<span class=""chemical"">ATRA</span>) and tranexamic acid has been described recently."		303.0	303_MESH:D014212_MESH:D058186	303_1	bcv_final_eval_easy_1733		
	MESH:D014148	"<span class=""chemical"">tranexamic acid</span>"	MESH:D015473	"<span class=""disease"">APL/acute promyelocytic leukemia</span>"	"A case of acute renal failure, due to occlusion of renal vessels in a patient with <span class=""disease"">acute promyelocytic leukemia</span> (<span class=""disease"">APL</span>) treated with all-trans-retinoic acid (ATRA) and <span class=""chemical"">tranexamic acid</span> has been described recently."		303.0	303_MESH:D014148_MESH:D015473	303_1	bcv_final_eval_easy_1734		
	MESH:D014212	"<span class=""chemical"">ATRA</span>"	MESH:D015473	"<span class=""disease"">APL</span>"	"We report a case of acute renal failure in an <span class=""disease"">APL</span> patient treated with <span class=""chemical"">ATRA</span> alone."		303.0	303_MESH:D014212_MESH:D015473	303_2	bcv_final_eval_easy_1735		
	MESH:D014212	"<span class=""chemical"">ATRA</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"We report a case of <span class=""disease"">acute renal failure</span> in an APL patient treated with <span class=""chemical"">ATRA</span> alone."		303.0	303_MESH:D014212_MESH:D058186	303_2	bcv_final_eval_easy_1736		
	MESH:D014212	"<span class=""chemical"">ATRA</span>"	MESH:D015473	"<span class=""disease"">APL</span>"	"This case further supports the concern about thromboembolic complications associated with <span class=""chemical"">ATRA</span> therapy in <span class=""disease"">APL</span> patients."		303.0	303_MESH:D014212_MESH:D015473	303_3	bcv_final_eval_easy_1737		
	MESH:D014212	"<span class=""chemical"">ATRA</span>"	MESH:D013923	"<span class=""disease"">thromboembolic</span>"	"This case further supports the concern about <span class=""disease"">thromboembolic</span> complications associated with <span class=""chemical"">ATRA</span> therapy in APL patients."		303.0	303_MESH:D014212_MESH:D013923	303_3	bcv_final_eval_easy_1738		
	MESH:D014212	"<span class=""chemical"">ATRA</span>"	MESH:D015473	"<span class=""disease"">APL</span>"	"The patients, a 43-year-old man, presented all the signs and symptoms of <span class=""disease"">APL</span> and was included in a treatment protocol with <span class=""chemical"">ATRA</span>."		303.0	303_MESH:D014212_MESH:D015473	303_4	bcv_final_eval_easy_1739		
	MESH:D014212	"<span class=""chemical"">ATRA</span>"	MESH:D015473	"<span class=""disease"">APL</span>"	"We conclude that <span class=""chemical"">ATRA</span> is a valid therapeutic choice for patients with <span class=""disease"">APL</span>, although the procoagulant tendency is not completely corrected."		303.0	303_MESH:D014212_MESH:D015473	303_6	bcv_final_eval_easy_1740		
	MESH:D004053	"<span class=""chemical"">diethylpropion</span>"	MESH:D001714	"<span class=""disease"">manic</span>"	"A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication <span class=""chemical"">diethylpropion</span> (DEP) became <span class=""disease"">manic</span> during his second week on the study drug."		304.0	304_MESH:D004053_MESH:D001714	304_1	bcv_final_eval_easy_1741		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D001714	"<span class=""disease"">manic</span>"	"A 30-year-old <span class=""chemical"">cocaine</span>-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became <span class=""disease"">manic</span> during his second week on the study drug."		304.0	304_MESH:D003042_MESH:D001714	304_1	bcv_final_eval_easy_1742		
	MESH:D002245	"<span class=""chemical"">CO2</span>"	MESH:D010146	"<span class=""disease"">tonic pain/pain</span>"	"Phasic <span class=""disease"">pain</span> was applied by means of short pulses of <span class=""chemical"">CO2</span> to the nasal mucosa (stimulus duration 500 ms, interval approximately 60 s), and <span class=""disease"">tonic pain</span> was induced in the nasal cavity by means of dry air of controlled temperature, humidity and flow rate (22 degrees C, 0% relative humidity, 145 ml.s-1)."		305.0	305_MESH:D002245_MESH:D010146	305_4	bcv_final_eval_easy_1743		
	MESH:D002245	"<span class=""chemical"">CO2</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"Both CSSEPs as central and NMPs as peripheral correlates of <span class=""disease"">pain</span> were obtained in response to the <span class=""chemical"">CO2</span> stimuli."		305.0	305_MESH:D002245_MESH:D010146	305_5	bcv_final_eval_easy_1744		
	MESH:D007052	"<span class=""chemical"">ibuprofen</span>"	MESH:D010146	"<span class=""disease"">tonic pain/pain</span>"	"RESULTS: As described earlier, administration of <span class=""chemical"">ibuprofen</span> was followed by a decrease in <span class=""disease"">tonic pain</span> but-relative to placebo-an increase in correlates of phasic <span class=""disease"">pain</span>, indicating a specific effect of <span class=""chemical"">ibuprofen</span> on the interaction between the <span class=""disease"">pain</span> stimuli under these special experimental conditions."		305.0	305_MESH:D007052_MESH:D010146	305_7	bcv_final_eval_easy_1745		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D003866	"<span class=""disease"">depression disorder</span>"	"She had developed a severe acute major <span class=""disease"">depression disorder</span> almost immediately thereafter, possibly related to the use of a <span class=""chemical"">serotonin</span> antagonist."		306.0	306_MESH:D012701_MESH:D003866	306_2	bcv_final_eval_easy_1746		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"Anaesthesia with a propofol infusion and avoidance of <span class=""chemical"">serotonin</span> antagonists provided a <span class=""disease"">nausea</span>-free postoperative course without exacerbation of the depression disorder."		306.0	306_MESH:D012701_MESH:D009325	306_4	bcv_final_eval_easy_1747		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D003866	"<span class=""disease"">depression disorder</span>"	"Anaesthesia with a propofol infusion and avoidance of <span class=""chemical"">serotonin</span> antagonists provided a nausea-free postoperative course without exacerbation of the <span class=""disease"">depression disorder</span>."		306.0	306_MESH:D012701_MESH:D003866	306_4	bcv_final_eval_easy_1748		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D003866	"<span class=""disease"">depression disorder</span>"	"Anaesthesia with a <span class=""chemical"">propofol</span> infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the <span class=""disease"">depression disorder</span>."		306.0	306_MESH:D015742_MESH:D003866	306_4	bcv_final_eval_easy_1749		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D009325	"<span class=""disease"">nausea</span>"	"Anaesthesia with a <span class=""chemical"">propofol</span> infusion and avoidance of serotonin antagonists provided a <span class=""disease"">nausea</span>-free postoperative course without exacerbation of the depression disorder."		306.0	306_MESH:D015742_MESH:D009325	306_4	bcv_final_eval_easy_1750		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D006973	"<span class=""disease"">Hypertensive</span>"	"<span class=""disease"">Hypertensive</span> response during <span class=""chemical"">dobutamine</span> stress echocardiography."		307.0	307_MESH:D004280_MESH:D006973	307_0	bcv_final_eval_easy_1751		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"Among 3,129 <span class=""chemical"">dobutamine</span> stress echocardiographic studies, a <span class=""disease"">hypertensive</span> response, defined as systolic blood pressure (BP) > or = 220 mm Hg and/or diastolic BP > or = 110 mm Hg, occurred in 30 patients (1%)."		307.0	307_MESH:D004280_MESH:D006973	307_1	bcv_final_eval_easy_1752		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Patients with this response more often had a history of <span class=""disease"">hypertension</span> and had higher resting systolic and diastolic BP before <span class=""chemical"">dobutamine</span> infusion."		307.0	307_MESH:D004280_MESH:D006973	307_2	bcv_final_eval_easy_1753		
	MESH:D000420	"<span class=""chemical"">albuterol</span>"	MESH:D001249	"<span class=""disease"">asthma</span>"	"Continuously nebulized <span class=""chemical"">albuterol</span> in severe exacerbations of <span class=""disease"">asthma</span> in adults: a case-controlled study."		308.0	308_MESH:D000420_MESH:D001249	308_0	bcv_final_eval_easy_1754		
	MESH:D000420	"<span class=""chemical"">albuterol</span>"	MESH:D001249	"<span class=""disease"">asthma</span>"	"A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of <span class=""disease"">asthma</span> who received continuously nebulized <span class=""chemical"">albuterol</span> (CNA) versus intermittent <span class=""chemical"">albuterol</span> (INA) treatments is reported."		308.0	308_MESH:D000420_MESH:D001249	308_1	bcv_final_eval_easy_1755		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D006944	"<span class=""disease"">Hyperosmolar nonketotic coma</span>"	"<span class=""disease"">Hyperosmolar nonketotic coma</span> precipitated by <span class=""chemical"">lithium</span>-induced nephrogenic diabetes insipidus."		309.0	309_MESH:D008094_MESH:D006944	309_0	bcv_final_eval_easy_1756		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D003128	"<span class=""disease"">coma</span>"	"A 45-year-old man, with a 10-year history of manic depression treated with <span class=""chemical"">lithium</span>, was admitted with hyperosmolar, nonketotic <span class=""disease"">coma</span>."		309.0	309_MESH:D008094_MESH:D003128	309_1	bcv_final_eval_easy_1757		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D003866	"<span class=""disease"">manic depression</span>"	"A 45-year-old man, with a 10-year history of <span class=""disease"">manic depression</span> treated with <span class=""chemical"">lithium</span>, was admitted with hyperosmolar, nonketotic coma."		309.0	309_MESH:D008094_MESH:D003866	309_1	bcv_final_eval_easy_1758		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D006944	"<span class=""disease"">hyperosmolar</span>"	"A 45-year-old man, with a 10-year history of manic depression treated with <span class=""chemical"">lithium</span>, was admitted with <span class=""disease"">hyperosmolar</span>, nonketotic coma."		309.0	309_MESH:D008094_MESH:D006944	309_1	bcv_final_eval_easy_1759		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D011141	"<span class=""disease"">polyuria</span>"	"He gave a five-year history of <span class=""disease"">polyuria</span> and polydipsia, during which time urinalysis had been negative for <span class=""chemical"">glucose</span>."		309.0	309_MESH:D005947_MESH:D011141	309_2	bcv_final_eval_easy_1760		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D059606	"<span class=""disease"">polydipsia</span>"	"He gave a five-year history of polyuria and <span class=""disease"">polydipsia</span>, during which time urinalysis had been negative for <span class=""chemical"">glucose</span>."		309.0	309_MESH:D005947_MESH:D059606	309_2	bcv_final_eval_easy_1761		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D018500	"<span class=""disease"">nephrogenic diabetes insipidus</span>"	"After recovery from hyperglycaemia, he remained polyuric despite normal blood <span class=""chemical"">glucose</span> concentrations; water deprivation testing indicated <span class=""disease"">nephrogenic diabetes insipidus</span>, likely to be lithium-induced."		309.0	309_MESH:D005947_MESH:D018500	309_3	bcv_final_eval_easy_1762		
	MESH:D003042	"<span class=""chemical"">cocaine hydrochloride</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of <span class=""disease"">chest pain</span>, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or <span class=""chemical"">cocaine hydrochloride</span> 1 mg/min (n=10)."		310.0	310_MESH:D003042_MESH:D002637	310_3	bcv_final_eval_easy_1763		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D019970	"<span class=""disease"">cocaine intoxication</span>"	"With <span class=""chemical"">cocaine</span>, the drug concentration in blood obtained from the coronary sinus was 3.0+/-0.4 (mean+/-SD) mg/L, similar in magnitude to the blood <span class=""chemical"">cocaine</span> concentration reported in abusers dying of <span class=""chemical""></span><span class=""disease"">cocaine</span> intoxication."		310.0	310_MESH:D003042_MESH:D019970	310_5	bcv_final_eval_easy_1764		
	MESH:D006493	"<span class=""chemical"">Heparin</span>"	MESH:D013923	"<span class=""disease"">thromboembolism</span>"	"<span class=""chemical"">Heparin</span>-induced thrombocytopenia, paradoxical <span class=""disease"">thromboembolism</span>, and other side effects of <span class=""chemical"">heparin</span> therapy."		311.0	311_MESH:D006493_MESH:D013923	311_0	bcv_final_eval_easy_1765		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D004342	"<span class=""disease"">allergic reactions</span>"	"Important untoward effects of <span class=""chemical"">heparin</span> therapy including <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, eosinophilia, skin reactions, <span class=""disease"">allergic reactions</span> other than thrombocytopenia and alopecia will be discussed in this article."		311.0	311_MESH:D006493_MESH:D004342	311_3	bcv_final_eval_easy_1766		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D004802	"<span class=""disease"">eosinophilia</span>"	"Important untoward effects of <span class=""chemical"">heparin</span> therapy including <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, <span class=""disease"">eosinophilia</span>, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article."		311.0	311_MESH:D006493_MESH:D004802	311_3	bcv_final_eval_easy_1767		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D010024	"<span class=""disease"">osteoporosis</span>"	"Important untoward effects of <span class=""chemical"">heparin</span> therapy including <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated <span class=""disease"">osteoporosis</span>, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article."		311.0	311_MESH:D006493_MESH:D010024	311_3	bcv_final_eval_easy_1768		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D000505	"<span class=""disease"">alopecia</span>"	"Important untoward effects of <span class=""chemical"">heparin</span> therapy including <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and <span class=""disease"">alopecia</span> will be discussed in this article."		311.0	311_MESH:D006493_MESH:D000505	311_3	bcv_final_eval_easy_1769		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D015658	"<span class=""disease"">HIV</span>"	"Nonopaque crystal deposition causing ureteric obstruction in patients with <span class=""disease"">HIV</span> undergoing <span class=""chemical"">indinavir</span> therapy."		312.0	312_MESH:D019469_MESH:D015658	312_0	bcv_final_eval_easy_1770		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D014517	"<span class=""disease"">ureteric obstruction</span>"	"Nonopaque crystal deposition causing <span class=""disease"">ureteric obstruction</span> in patients with HIV undergoing <span class=""chemical"">indinavir</span> therapy."		312.0	312_MESH:D019469_MESH:D014517	312_0	bcv_final_eval_easy_1771		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D015658	"<span class=""disease"">HIV/HIV-infected</span>"	"OBJECTIVE: We describe the unique CT features of ureteric calculi in six <span class=""disease"">HIV-infected</span> patients receiving <span class=""chemical"">indinavir</span>, the most commonly used <span class=""disease"">HIV</span> protease inhibitor, which is associated with an increased incidence of urolithiasis."		312.0	312_MESH:D019469_MESH:D015658	312_1	bcv_final_eval_easy_1772		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D052878	"<span class=""disease"">urolithiasis</span>"	"OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving <span class=""chemical"">indinavir</span>, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of <span class=""disease"">urolithiasis</span>."		312.0	312_MESH:D019469_MESH:D052878	312_1	bcv_final_eval_easy_1773		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D014517	"<span class=""disease"">Ureteric obstruction</span>"	"CONCLUSION: <span class=""disease"">Ureteric obstruction</span> caused by precipitated <span class=""chemical"">indinavir</span> crystals may be difficult to diagnose with unenhanced CT."		312.0	312_MESH:D019469_MESH:D014517	312_2	bcv_final_eval_easy_1774		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D015658	"<span class=""disease"">HIV infection</span>"	"Images may need to be obtained using i.v. contrast material to enable diagnosis of ureteric stones or obstruction in patients with <span class=""disease"">HIV infection</span> who receive <span class=""chemical"">indinavir</span> therapy."		312.0	312_MESH:D019469_MESH:D015658	312_4	bcv_final_eval_easy_1775		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D014517	"<span class=""disease"">ureteric stones or obstruction</span>"	"Images may need to be obtained using i.v. contrast material to enable diagnosis of <span class=""disease"">ureteric stones or obstruction</span> in patients with HIV infection who receive <span class=""chemical"">indinavir</span> therapy."		312.0	312_MESH:D019469_MESH:D014517	312_4	bcv_final_eval_easy_1776		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D017091	"<span class=""disease"">Ischemic colitis</span>"	"<span class=""disease"">Ischemic colitis</span> and <span class=""chemical"">sumatriptan</span> use."		313.0	313_MESH:D018170_MESH:D017091	313_0	bcv_final_eval_easy_1777		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D003329	"<span class=""disease"">coronary vasospasm</span>"	"Cases have been published of <span class=""disease"">coronary vasospasm</span>, myocardial ischemia, and myocardial infarction occurring after <span class=""chemical"">sumatriptan</span> use."		313.0	313_MESH:D018170_MESH:D003329	313_3	bcv_final_eval_easy_1778		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D017202	"<span class=""disease"">myocardial ischemia</span>"	"Cases have been published of coronary vasospasm, <span class=""disease"">myocardial ischemia</span>, and myocardial infarction occurring after <span class=""chemical"">sumatriptan</span> use."		313.0	313_MESH:D018170_MESH:D017202	313_3	bcv_final_eval_easy_1779		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Cases have been published of coronary vasospasm, myocardial ischemia, and <span class=""disease"">myocardial infarction</span> occurring after <span class=""chemical"">sumatriptan</span> use."		313.0	313_MESH:D018170_MESH:D009203	313_3	bcv_final_eval_easy_1780		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D017091	"<span class=""disease"">ischemic colitis</span>"	"We report on the development of 8 serious cases of <span class=""disease"">ischemic colitis</span> in patients with migraine treated with <span class=""chemical"">sumatriptan</span>."		313.0	313_MESH:D018170_MESH:D017091	313_4	bcv_final_eval_easy_1781		
	MESH:D018170	"<span class=""chemical"">sumatriptan</span>"	MESH:D008881	"<span class=""disease"">migraine</span>"	"We report on the development of 8 serious cases of ischemic colitis in patients with <span class=""disease"">migraine</span> treated with <span class=""chemical"">sumatriptan</span>."		313.0	313_MESH:D018170_MESH:D008881	313_4	bcv_final_eval_easy_1782		
	MESH:D007980	"<span class=""chemical"">L-DOPA</span>"	MESH:D018476	"<span class=""disease"">bradykinesia</span>"	"51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of <span class=""disease"">bradykinesia</span>, rigidity, and <span class=""chemical"">L-DOPA</span>-induced dyskinesias."		314.0	314_MESH:D007980_MESH:D018476	314_1	bcv_final_eval_easy_1783		
	MESH:D007980	"<span class=""chemical"">L-DOPA</span>"	MESH:D009127	"<span class=""disease"">rigidity</span>"	"51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, <span class=""disease"">rigidity</span>, and <span class=""chemical"">L-DOPA</span>-induced dyskinesias."		314.0	314_MESH:D007980_MESH:D009127	314_1	bcv_final_eval_easy_1784		
	MESH:D007980	"<span class=""chemical"">L-DOPA</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"51 patients with medically refractory <span class=""disease"">Parkinson's disease</span> underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and <span class=""chemical"">L-DOPA</span>-induced dyskinesias."		314.0	314_MESH:D007980_MESH:D010300	314_1	bcv_final_eval_easy_1785		
	MESH:D008774	"<span class=""chemical"">methylphenidate</span>"	MESH:D009459	"<span class=""disease"">Neuroleptic malignant syndrome</span>"	"<span class=""disease"">Neuroleptic malignant syndrome</span> and <span class=""chemical"">methylphenidate</span>."		315.0	315_MESH:D008774_MESH:D009459	315_0	bcv_final_eval_easy_1786		
	MESH:D008774	"<span class=""chemical"">methylphenidate</span>"	MESH:D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"A 1-year-old female presented with <span class=""disease"">neuroleptic malignant syndrome</span> probably caused by <span class=""chemical"">methylphenidate</span>."		315.0	315_MESH:D008774_MESH:D009459	315_1	bcv_final_eval_easy_1787		
	MESH:D003975	"<span class=""chemical"">diazepam</span>"	MESH:D015223	"<span class=""disease"">acid-ergic deficiency</span>"	"A relative gamma-aminobutyric <span class=""disease"">acid-ergic deficiency</span> might occur because <span class=""chemical"">diazepam</span>, a gamma-aminobutyric acid-mimetic agent, was strikingly effective."		315.0	315_MESH:D003975_MESH:D015223	315_5	bcv_final_eval_easy_1788		
	MESH:D005680	"<span class=""chemical"">gamma-aminobutyric acid</span>"	MESH:D015223	"<span class=""disease"">acid-ergic deficiency</span>"	"A relative <span class=""chemical"">gamma-aminobutyric </span><span class=""disease"">acid</span>-ergic deficiency might occur because diazepam, a <span class=""chemical"">gamma-aminobutyric acid</span>-mimetic agent, was strikingly effective."		315.0	315_MESH:D005680_MESH:D015223	315_5	bcv_final_eval_easy_1789		
	MESH:D008774	"<span class=""chemical"">methylphenidate</span>"	MESH:D009459	"<span class=""disease"">neuroleptic malignant syndrome</span>"	"This is the first reported patient with <span class=""disease"">neuroleptic malignant syndrome</span> probably caused by <span class=""chemical"">methylphenidate</span>."		315.0	315_MESH:D008774_MESH:D009459	315_6	bcv_final_eval_easy_1790		
	MESH:D005905	"<span class=""chemical"">Glibenclamide</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"<span class=""chemical"">Glibenclamide</span>-sensitive <span class=""disease"">hypotension</span> produced by helodermin assessed in the rat."		317.0	317_MESH:D005905_MESH:D007022	317_0	bcv_final_eval_easy_1791		
	MESH:D005905	"<span class=""chemical"">glibenclamide</span>"	MESH:D007022	"<span class=""disease"">Hypotension</span>"	"<span class=""disease"">Hypotension</span> induced by both peptides was significantly attenuated by <span class=""chemical"">glibenclamide</span>, which abolished a levcromakalim-produced decrease in arterial blood pressure."		317.0	317_MESH:D005905_MESH:D007022	317_4	bcv_final_eval_easy_1792		
	MESH:D000109	"<span class=""chemical"">ACh/acetylcholine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Oxyhemoglobin did not affect helodermin-induced <span class=""disease"">hypotension</span>, whereas it shortened the duration of <span class=""chemical"">acetylcholine</span> (<span class=""chemical"">ACh</span>)-produced <span class=""disease"">hypotension</span>."		317.0	317_MESH:D000109_MESH:D007022	317_5	bcv_final_eval_easy_1793		
	MESH:D005905	"<span class=""chemical"">glibenclamide</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"These findings suggest that helodermin-produced <span class=""disease"">hypotension</span> is partly attributable to the activation of <span class=""chemical"">glibenclamide</span>-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells."		317.0	317_MESH:D005905_MESH:D007022	317_6	bcv_final_eval_easy_1794		
	MESH:D000255	"<span class=""chemical"">ATP</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"These findings suggest that helodermin-produced <span class=""disease"">hypotension</span> is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(<span class=""chemical"">ATP</span>) channels), which presumably exist on arterial smooth muscle cells."		317.0	317_MESH:D000255_MESH:D007022	317_6	bcv_final_eval_easy_1795		
	MESH:D011188	"<span class=""chemical"">K+/K</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"These findings suggest that helodermin-produced <span class=""disease"">hypotension</span> is partly attributable to the activation of glibenclamide-sensitive <span class=""chemical"">K+</span> channels (<span class=""chemical"">K</span>(ATP) channels), which presumably exist on arterial smooth muscle cells."		317.0	317_MESH:D011188_MESH:D007022	317_6	bcv_final_eval_easy_1796		
	MESH:D009569	"<span class=""chemical"">nitric oxide</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"EDRF (endothelium-derived relaxing factor)/<span class=""chemical"">nitric oxide</span> does not seem to play an important role in the peptide-produced <span class=""disease"">hypotension</span>."		317.0	317_MESH:D009569_MESH:D007022	317_7	bcv_final_eval_easy_1797		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D011565	"<span class=""disease"">psoriasis</span>"	"Long-term efficacy and adverse event of <span class=""chemical"">nifedipine</span> sustained-release tablets for cyclosporin A-induced hypertension in patients with <span class=""disease"">psoriasis</span>."		318.0	318_MESH:D009543_MESH:D011565	318_0	bcv_final_eval_easy_1798		
	MESH:D016572	"<span class=""chemical"">cyclosporin A</span>"	MESH:D011565	"<span class=""disease"">psoriasis</span>"	"Long-term efficacy and adverse event of nifedipine sustained-release tablets for <span class=""chemical"">cyclosporin A</span>-induced hypertension in patients with <span class=""disease"">psoriasis</span>."		318.0	318_MESH:D016572_MESH:D011565	318_0	bcv_final_eval_easy_1799		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Long-term efficacy and adverse event of <span class=""chemical"">nifedipine</span> sustained-release tablets for cyclosporin A-induced <span class=""disease"">hypertension</span> in patients with psoriasis."		318.0	318_MESH:D009543_MESH:D006973	318_0	bcv_final_eval_easy_1800		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D015535	"<span class=""disease"">psoriatic</span>"	"Thirteen <span class=""disease"">psoriatic</span> patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release <span class=""chemical"">nifedipine</span>, to study the clinical antihypertensive effects and adverse events during treatment with both drugs."		318.0	318_MESH:D009543_MESH:D015535	318_1	bcv_final_eval_easy_1801		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Thirteen psoriatic patients with <span class=""disease"">hypertension</span> during the course of cyclosporin A therapy were treated for 25 months with a <span class=""chemical"">calcium</span> channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs."		318.0	318_MESH:D002118_MESH:D006973	318_1	bcv_final_eval_easy_1802		
	MESH:D002118	"<span class=""chemical"">calcium</span>"	MESH:D015535	"<span class=""disease"">psoriatic</span>"	"Thirteen <span class=""disease"">psoriatic</span> patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a <span class=""chemical"">calcium</span> channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs."		318.0	318_MESH:D002118_MESH:D015535	318_1	bcv_final_eval_easy_1803		
	MESH:D016572	"<span class=""chemical"">cyclosporin A</span>"	MESH:D015535	"<span class=""disease"">psoriatic</span>"	"Thirteen <span class=""disease"">psoriatic</span> patients with hypertension during the course of <span class=""chemical"">cyclosporin A</span> therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs."		318.0	318_MESH:D016572_MESH:D015535	318_1	bcv_final_eval_easy_1804		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Thirteen psoriatic patients with <span class=""disease"">hypertension</span> during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release <span class=""chemical"">nifedipine</span>, to study the clinical antihypertensive effects and adverse events during treatment with both drugs."		318.0	318_MESH:D009543_MESH:D006973	318_1	bcv_final_eval_easy_1805		
	MESH:D016572	"<span class=""chemical"">cyclosporin A</span>"	MESH:D005885	"<span class=""disease"">gingival hyperplasia</span>"	"The adverse events during combined therapy with <span class=""chemical"">cyclosporin A</span> and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of <span class=""disease"">gingival hyperplasia</span> in 2 of the 13 patients."		318.0	318_MESH:D016572_MESH:D005885	318_4	bcv_final_eval_easy_1806		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D005885	"<span class=""disease"">gingival hyperplasia</span>"	"The adverse events during combined therapy with cyclosporin A and <span class=""chemical"">nifedipine</span> included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of <span class=""disease"">gingival hyperplasia</span> in 2 of the 13 patients."		318.0	318_MESH:D009543_MESH:D005885	318_4	bcv_final_eval_easy_1807		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D015535	"<span class=""disease"">psoriatic</span>"	"Our findings indicate that sustained-release <span class=""chemical"">nifedipine</span> is useful for hypertensive <span class=""disease"">psoriatic</span> patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia."		318.0	318_MESH:D009543_MESH:D015535	318_5	bcv_final_eval_easy_1808		
	MESH:D016572	"<span class=""chemical"">cyclosporin A</span>"	MESH:D005885	"<span class=""disease"">gingival hyperplasia</span>"	"Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with <span class=""chemical"">cyclosporin A</span>, but that these patients should be monitored for <span class=""disease"">gingival hyperplasia</span>."		318.0	318_MESH:D016572_MESH:D005885	318_5	bcv_final_eval_easy_1809		
	MESH:D016572	"<span class=""chemical"">cyclosporin A</span>"	MESH:D015535	"<span class=""disease"">psoriatic</span>"	"Our findings indicate that sustained-release nifedipine is useful for hypertensive <span class=""disease"">psoriatic</span> patients under long-term treatment with <span class=""chemical"">cyclosporin A</span>, but that these patients should be monitored for gingival hyperplasia."		318.0	318_MESH:D016572_MESH:D015535	318_5	bcv_final_eval_easy_1810		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D005885	"<span class=""disease"">gingival hyperplasia</span>"	"Our findings indicate that sustained-release <span class=""chemical"">nifedipine</span> is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for <span class=""disease"">gingival hyperplasia</span>."		318.0	318_MESH:D009543_MESH:D005885	318_5	bcv_final_eval_easy_1811		
	MESH:D009543	"<span class=""chemical"">nifedipine</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"Our findings indicate that sustained-release <span class=""chemical"">nifedipine</span> is useful for <span class=""disease"">hypertensive</span> psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia."		318.0	318_MESH:D009543_MESH:D006973	318_5	bcv_final_eval_easy_1812		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"Torsade de pointes <span class=""disease"">ventricular tachycardia</span> during low dose intermittent <span class=""chemical"">dobutamine</span> treatment in a patient with dilated cardiomyopathy and congestive heart failure."		319.0	319_MESH:D004280_MESH:D017180	319_0	bcv_final_eval_easy_1813		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D009202	"<span class=""disease"">cardiomyopathy</span>"	"Torsade de pointes ventricular tachycardia during low dose intermittent <span class=""chemical"">dobutamine</span> treatment in a patient with dilated <span class=""disease"">cardiomyopathy</span> and congestive heart failure."		319.0	319_MESH:D004280_MESH:D009202	319_0	bcv_final_eval_easy_1814		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D006333	"<span class=""disease"">congestive heart failure</span>"	"Torsade de pointes ventricular tachycardia during low dose intermittent <span class=""chemical"">dobutamine</span> treatment in a patient with dilated cardiomyopathy and <span class=""disease"">congestive heart failure</span>."		319.0	319_MESH:D004280_MESH:D006333	319_0	bcv_final_eval_easy_1815		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes <span class=""disease"">ventricular tachycardia</span> during one cycle of intermittent low dose (2.5 mcg/kg per min) <span class=""chemical"">dobutamine</span>."		319.0	319_MESH:D004280_MESH:D017180	319_1	bcv_final_eval_easy_1816		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D001145	"<span class=""disease"">ventricular arrhythmias</span>"	"The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant <span class=""disease"">ventricular arrhythmias</span> who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <span class=""chemical"">dobutamine</span>."		319.0	319_MESH:D004280_MESH:D001145	319_1	bcv_final_eval_easy_1817		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D008133	"<span class=""disease"">QT prolongation</span>"	"The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed <span class=""disease"">QT prolongation</span> and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <span class=""chemical"">dobutamine</span>."		319.0	319_MESH:D004280_MESH:D008133	319_1	bcv_final_eval_easy_1818		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D006333	"<span class=""disease"">heart failure</span>"	"The authors describe the case of a 56-year-old woman with chronic, severe <span class=""disease"">heart failure</span> secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <span class=""chemical"">dobutamine</span>."		319.0	319_MESH:D004280_MESH:D006333	319_1	bcv_final_eval_easy_1819		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D009202	"<span class=""disease"">cardiomyopathy</span>"	"The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated <span class=""disease"">cardiomyopathy</span> and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <span class=""chemical"">dobutamine</span>."		319.0	319_MESH:D004280_MESH:D009202	319_1	bcv_final_eval_easy_1820		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"This report of torsade de pointes <span class=""disease"">ventricular tachycardia</span> during intermittent <span class=""chemical"">dobutamine</span> supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances."		319.0	319_MESH:D004280_MESH:D017180	319_2	bcv_final_eval_easy_1821		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D001145	"<span class=""disease"">arrhythmias</span>"	"This report of torsade de pointes ventricular tachycardia during intermittent <span class=""chemical"">dobutamine</span> supports the hypothesis that unpredictable fatal <span class=""disease"">arrhythmias</span> may occur even with low doses and in patients with no history of significant rhythm disturbances."		319.0	319_MESH:D004280_MESH:D001145	319_2	bcv_final_eval_easy_1822		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D010468	"<span class=""disease"">rhythm disturbances</span>"	"This report of torsade de pointes ventricular tachycardia during intermittent <span class=""chemical"">dobutamine</span> supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant <span class=""disease"">rhythm disturbances</span>."		319.0	319_MESH:D004280_MESH:D010468	319_2	bcv_final_eval_easy_1823		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"Risk of transient hyperammonemic <span class=""disease"">encephalopathy</span> in cancer patients who received continuous infusion of <span class=""chemical"">5-fluorouracil</span> with the complication of dehydration and infection."		321.0	321_MESH:D005472_MESH:D001927	321_0	bcv_final_eval_easy_1824		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D003681	"<span class=""disease"">dehydration</span>"	"Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of <span class=""chemical"">5-fluorouracil</span> with the complication of <span class=""disease"">dehydration</span> and infection."		321.0	321_MESH:D005472_MESH:D003681	321_0	bcv_final_eval_easy_1825		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"Risk of transient hyperammonemic encephalopathy in <span class=""disease"">cancer</span> patients who received continuous infusion of <span class=""chemical"">5-fluorouracil</span> with the complication of dehydration and infection."		321.0	321_MESH:D005472_MESH:D009369	321_0	bcv_final_eval_easy_1826		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D007239	"<span class=""disease"">infection</span>"	"Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of <span class=""chemical"">5-fluorouracil</span> with the complication of dehydration and <span class=""disease"">infection</span>."		321.0	321_MESH:D005472_MESH:D007239	321_0	bcv_final_eval_easy_1827		
	MESH:D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"From 1986 to 1998, 29 <span class=""disease"">cancer</span> patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) were identified."		321.0	321_MESH:D005472_MESH:D009369	321_1	bcv_final_eval_easy_1828		
	MESH:D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic <span class=""disease"">encephalopathy</span> related to continuous infusion of <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) were identified."		321.0	321_MESH:D005472_MESH:D001927	321_1	bcv_final_eval_easy_1829		
	MESH:D000644	"<span class=""chemical"">ammonium</span>"	MESH:D001424	"<span class=""disease"">bacterial infections</span>"	"Higher plasma <span class=""chemical"">ammonium</span> levels and more rapid onset of hyperammonemia were seen in 18 patients with <span class=""disease"">bacterial infections</span> (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively)."		321.0	321_MESH:D000644_MESH:D001424	321_6	bcv_final_eval_easy_1830		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D022124	"<span class=""disease"">hyperammonemia</span>"	"Higher plasma ammonium levels and more rapid onset of <span class=""disease"">hyperammonemia</span> were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of <span class=""chemical"">5-FU</span> (p=0.0001 and < 0.0001, respectively)."		321.0	321_MESH:D005472_MESH:D022124	321_6	bcv_final_eval_easy_1831		
	MESH:D000644	"<span class=""chemical"">ammonium</span>"	MESH:D022124	"<span class=""disease"">hyperammonemia</span>"	"Higher plasma <span class=""chemical"">ammonium</span> levels and more rapid onset of <span class=""disease"">hyperammonemia</span> were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively)."		321.0	321_MESH:D000644_MESH:D022124	321_6	bcv_final_eval_easy_1832		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D001424	"<span class=""disease"">bacterial infections</span>"	"Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with <span class=""disease"">bacterial infections</span> (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of <span class=""chemical"">5-FU</span> (p=0.0001 and < 0.0001, respectively)."		321.0	321_MESH:D005472_MESH:D001424	321_6	bcv_final_eval_easy_1833		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"In conclusion, hyperammonemic <span class=""disease"">encephalopathy</span> can occur in patients receiving continuous infusion of <span class=""chemical"">5-FU</span>."		321.0	321_MESH:D005472_MESH:D001927	321_8	bcv_final_eval_easy_1834		
	MESH:D011188	"<span class=""chemical"">K(+)</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"In the motor activity test measured with an Animex-activity meter neither of the <span class=""chemical"">K(+)</span>-channel blockers affected morphine-induced hypoactivity, but both <span class=""chemical"">K(+)</span>-channel blockers prevented morphine-induced secondary <span class=""disease"">hyperactivity</span>."		322.0	322_MESH:D011188_MESH:D006948	322_6	bcv_final_eval_easy_1835		
	MESH:D011188	"<span class=""chemical"">K(+)</span>"	MESH:D020018	"<span class=""disease"">hypoactivity</span>"	"In the motor activity test measured with an Animex-activity meter neither of the <span class=""chemical"">K(+)</span>-channel blockers affected morphine-induced <span class=""disease"">hypoactivity</span>, but both <span class=""chemical"">K(+)</span>-channel blockers prevented morphine-induced secondary hyperactivity."		322.0	322_MESH:D011188_MESH:D020018	322_6	bcv_final_eval_easy_1836		
	MESH:D015761	"<span class=""chemical"">4-aminopyridine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced <span class=""disease"">hyperactivity</span> seems to be connected to both quinine- and <span class=""chemical"">4-aminopyridine</span>-sensitive K(+)-channels."		322.0	322_MESH:D015761_MESH:D006948	322_9	bcv_final_eval_easy_1837		
	MESH:D011188	"<span class=""chemical"">K(+)</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"It is also suggested that the blockade of <span class=""chemical"">K(+)</span>-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced <span class=""disease"">hyperactivity</span> seems to be connected to both quinine- and 4-aminopyridine-sensitive <span class=""chemical"">K(+)</span>-channels."		322.0	322_MESH:D011188_MESH:D006948	322_9	bcv_final_eval_easy_1838		
	MESH:D011188	"<span class=""chemical"">K(+)</span>"	MESH:D020018	"<span class=""disease"">hypoactivity</span>"	"It is also suggested that the blockade of <span class=""chemical"">K(+)</span>-channels sensitive to these blockers is not sufficient to prevent morphine-induced <span class=""disease"">hypoactivity</span> whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive <span class=""chemical"">K(+)</span>-channels."		322.0	322_MESH:D011188_MESH:D020018	322_9	bcv_final_eval_easy_1839		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D020018	"<span class=""disease"">hypoactivity</span>"	"It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced <span class=""disease"">hypoactivity</span> whereas morphine-induced hyperactivity seems to be connected to both <span class=""chemical"">quinine</span>- and 4-aminopyridine-sensitive K(+)-channels."		322.0	322_MESH:D011803_MESH:D020018	322_9	bcv_final_eval_easy_1840		
	MESH:D015761	"<span class=""chemical"">4-aminopyridine</span>"	MESH:D020018	"<span class=""disease"">hypoactivity</span>"	"It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced <span class=""disease"">hypoactivity</span> whereas morphine-induced hyperactivity seems to be connected to both quinine- and <span class=""chemical"">4-aminopyridine</span>-sensitive K(+)-channels."		322.0	322_MESH:D015761_MESH:D020018	322_9	bcv_final_eval_easy_1841		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced <span class=""disease"">hyperactivity</span> seems to be connected to both <span class=""chemical"">quinine</span>- and 4-aminopyridine-sensitive K(+)-channels."		322.0	322_MESH:D011803_MESH:D006948	322_9	bcv_final_eval_easy_1842		
	MESH:C111148	"<span class=""chemical"">nocistatin</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"Nociceptin/orphanin FQ and <span class=""chemical"">nocistatin</span> on learning and <span class=""disease"">memory impairment</span> induced by scopolamine in mice."		323.0	323_MESH:C111148_MESH:D008569	323_0	bcv_final_eval_easy_1843		
	MESH:C096012	"<span class=""chemical"">Nociceptin</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"<span class=""chemical"">Nociceptin</span>/orphanin FQ and nocistatin on learning and <span class=""disease"">memory impairment</span> induced by scopolamine in mice."		323.0	323_MESH:C096012_MESH:D008569	323_0	bcv_final_eval_easy_1844		
	MESH:D012601	"<span class=""chemical"">scopolamine</span>"	MESH:D008569	"<span class=""disease"">memory impairment</span>"	"Nociceptin/orphanin FQ and nocistatin on learning and <span class=""disease"">memory impairment</span> induced by <span class=""chemical"">scopolamine</span> in mice."		323.0	323_MESH:D012601_MESH:D008569	323_0	bcv_final_eval_easy_1845		
	MESH:C111148	"<span class=""chemical"">nocistatin</span>"	MESH:D006930	"<span class=""disease"">allodynia/hyperalgesia</span>"	"On the other hand, <span class=""chemical"">nocistatin</span> is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced <span class=""disease"">allodynia</span> and <span class=""disease"">hyperalgesia</span>."		323.0	323_MESH:C111148_MESH:D006930	323_3	bcv_final_eval_easy_1846		
	MESH:C111148	"<span class=""chemical"">nocistatin</span>"	MESH:D008569	"<span class=""disease"">impairment of learning and memory</span>"	"The present study was designed to investigate whether nociceptin/orphanin FQ and <span class=""chemical"">nocistatin</span> could modulate <span class=""disease"">impairment of learning and memory</span> induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice."		323.0	323_MESH:C111148_MESH:D008569	323_7	bcv_final_eval_easy_1847		
	MESH:C096012	"<span class=""chemical"">nociceptin</span>"	MESH:D008569	"<span class=""disease"">impairment of learning and memory</span>"	"The present study was designed to investigate whether <span class=""chemical"">nociceptin</span>/orphanin FQ and nocistatin could modulate <span class=""disease"">impairment of learning and memory</span> induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice."		323.0	323_MESH:C096012_MESH:D008569	323_7	bcv_final_eval_easy_1848		
	MESH:D012601	"<span class=""chemical"">scopolamine</span>"	MESH:D008569	"<span class=""disease"">impairment of learning and memory</span>"	"The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate <span class=""disease"">impairment of learning and memory</span> induced by <span class=""chemical"">scopolamine</span>, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice."		323.0	323_MESH:D012601_MESH:D008569	323_7	bcv_final_eval_easy_1849		
	MESH:C111148	"<span class=""chemical"">nocistatin</span>"	MESH:D003072	"<span class=""disease"">impairment of spontaneous alternation and passive avoidance behaviours</span>"	"Administration of <span class=""chemical"">nocistatin</span> (1.5 and/or 5.0 nmol mouse-1, i.c.v.) 30 min before spontaneous alternation performance or the training session of the passive avoidance task, attenuated the scopolamine-induced <span class=""disease"">impairment of spontaneous alternation and passive avoidance behaviours</span>."		323.0	323_MESH:C111148_MESH:D003072	323_11	bcv_final_eval_easy_1850		
	MESH:C111148	"<span class=""chemical"">nocistatin</span>"	MESH:D003072	"<span class=""disease"">ameliorates impairments</span>"	"These results indicated that <span class=""chemical"">nocistatin</span>, a new biologically active peptide, <span class=""disease"">ameliorates impairments</span> of spontaneous alternation and passive avoidance induced by scopolamine, and suggested that these peptides play opposite roles in learning and memory."		323.0	323_MESH:C111148_MESH:D003072	323_13	bcv_final_eval_easy_1851		
	MESH:C065757	"<span class=""chemical"">meloxicam</span>"	MESH:D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"We report the case of a female patient with <span class=""disease"">rheumatoid arthritis</span> who developed acute cytolytic hepatitis due to <span class=""chemical"">meloxicam</span>."		324.0	324_MESH:C065757_MESH:D001172	324_1	bcv_final_eval_easy_1852		
	MESH:C065757	"<span class=""chemical"">meloxicam</span>"	MESH:D056486	"<span class=""disease"">acute cytolytic hepatitis</span>"	"We report the case of a female patient with rheumatoid arthritis who developed <span class=""disease"">acute cytolytic hepatitis</span> due to <span class=""chemical"">meloxicam</span>."		324.0	324_MESH:C065757_MESH:D056486	324_1	bcv_final_eval_easy_1853		
	MESH:C065757	"<span class=""chemical"">meloxicam</span>"	MESH:D056486	"<span class=""disease"">acute cytolytic hepatitis</span>"	"The <span class=""disease"">acute cytolytic hepatitis</span> occurred rapidly after <span class=""chemical"">meloxicam</span> administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism."		324.0	324_MESH:C065757_MESH:D056486	324_3	bcv_final_eval_easy_1854		
	MESH:C065757	"<span class=""chemical"">meloxicam</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"The acute cytolytic hepatitis occurred rapidly after <span class=""chemical"">meloxicam</span> administration and was associated with the development of antinuclear antibodies suggesting a <span class=""disease"">hypersensitivity</span> mechanism."		324.0	324_MESH:C065757_MESH:D004342	324_3	bcv_final_eval_easy_1855		
	MESH:C065757	"<span class=""chemical"">meloxicam</span>"	MESH:D056486	"<span class=""disease"">hepatic damage</span>"	"This first case of <span class=""chemical"">meloxicam</span> related liver toxicity demonstrates the potential of this drug to induce <span class=""disease"">hepatic damage</span>."		324.0	324_MESH:C065757_MESH:D056486	324_4	bcv_final_eval_easy_1856		
	MESH:C112341	"<span class=""chemical"">NCQ344</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"No <span class=""disease"">necrosis</span> was observed in cells treated with NCQ436 but <span class=""chemical"">NCQ344</span> had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and <span class=""disease"">necrosis</span> at higher concentrations."		325.0	325_MESH:C112341_MESH:D009336	325_7	bcv_final_eval_easy_1857		
	MESH:C084325	"<span class=""chemical"">NCQ436</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"No <span class=""disease"">necrosis</span> was observed in cells treated with <span class=""chemical"">NCQ436</span> but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and <span class=""disease"">necrosis</span> at higher concentrations."		325.0	325_MESH:C084325_MESH:D009336	325_7	bcv_final_eval_easy_1858		
	MESH:C084325	"<span class=""chemical"">NCQ436</span>"	MESH:D000741	"<span class=""disease"">aplastic anemia</span>"	"We propose that remoxipride and benzene may induce <span class=""disease"">aplastic anemia</span> via production of similar reactive metabolites and that the ability of <span class=""chemical"">NCQ436</span> and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired <span class=""disease"">aplastic anemia</span> that has been associated with remoxipride."		325.0	325_MESH:C084325_MESH:D000741	325_10	bcv_final_eval_easy_1859		
	MESH:C112341	"<span class=""chemical"">NCQ344</span>"	MESH:D000741	"<span class=""disease"">aplastic anemia</span>"	"We propose that remoxipride and benzene may induce <span class=""disease"">aplastic anemia</span> via production of similar reactive metabolites and that the ability of NCQ436 and <span class=""chemical"">NCQ344</span> to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired <span class=""disease"">aplastic anemia</span> that has been associated with remoxipride."		325.0	325_MESH:C112341_MESH:D000741	325_10	bcv_final_eval_easy_1860		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"7e exhibits a high reversal of <span class=""disease"">catalepsy</span> induced by <span class=""chemical"">haloperidol</span> indicating its atypical antipsychotic nature."		326.0	326_MESH:D006220_MESH:D002375	326_4	bcv_final_eval_easy_1861		
	MESH:D009249	"<span class=""chemical"">NADPH</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced <span class=""disease"">catalepsy</span> and the number of <span class=""chemical"">NADPH</span>-diaphorase neurons in mice."		327.0	327_MESH:D009249_MESH:D002375	327_0	bcv_final_eval_easy_1862		
	MESH:D009569	"<span class=""chemical"">nitric-oxide</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Sub-chronic inhibition of <span class=""chemical"">nitric-oxide</span> synthesis modifies haloperidol-induced <span class=""disease"">catalepsy</span> and the number of NADPH-diaphorase neurons in mice."		327.0	327_MESH:D009569_MESH:D002375	327_0	bcv_final_eval_easy_1863		
	MESH:D009569	"<span class=""chemical"">nitric-oxide</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of <span class=""chemical"">nitric-oxide</span> synthase (NOS), induces <span class=""disease"">catalepsy</span> in mice."		327.0	327_MESH:D009569_MESH:D002375	327_1	bcv_final_eval_easy_1864		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Neuroleptic drugs such as haloperidol, which block <span class=""chemical"">dopamine</span> receptors, also cause <span class=""disease"">catalepsy</span> in rodents."		327.0	327_MESH:D004298_MESH:D002375	327_4	bcv_final_eval_easy_1865		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D018487	"<span class=""disease"">Prolonged left ventricular dysfunction</span>"	"<span class=""disease"">Prolonged left ventricular dysfunction</span> occurs in patients with coronary artery disease after both <span class=""chemical"">dobutamine</span> and exercise induced myocardial ischaemia."		328.0	328_MESH:D004280_MESH:D018487	328_0	bcv_final_eval_easy_1866		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D009202	"<span class=""disease"">myocardial ischaemia</span>"	"Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both <span class=""chemical"">dobutamine</span> and exercise induced <span class=""disease"">myocardial ischaemia</span>."		328.0	328_MESH:D004280_MESH:D009202	328_0	bcv_final_eval_easy_1867		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D003324	"<span class=""disease"">coronary artery disease</span>"	"Prolonged left ventricular dysfunction occurs in patients with <span class=""disease"">coronary artery disease</span> after both <span class=""chemical"">dobutamine</span> and exercise induced myocardial ischaemia."		328.0	328_MESH:D004280_MESH:D003324	328_0	bcv_final_eval_easy_1868		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D018487	"<span class=""disease"">left ventricular dysfunction</span>"	"CONCLUSIONS: In patients with coronary artery disease, <span class=""chemical"">dobutamine</span> induced ischaemia results in prolonged reversible <span class=""disease"">left ventricular dysfunction</span>, presumed to be myocardial stunning, similar to that seen after exercise."		328.0	328_MESH:D004280_MESH:D018487	328_13	bcv_final_eval_easy_1869		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D003324	"<span class=""disease"">coronary artery disease</span>"	"CONCLUSIONS: In patients with <span class=""disease"">coronary artery disease</span>, <span class=""chemical"">dobutamine</span> induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise."		328.0	328_MESH:D004280_MESH:D003324	328_13	bcv_final_eval_easy_1870		
	MESH:D004280	"<span class=""chemical"">dobutamine</span>"	MESH:D017682	"<span class=""disease"">myocardial stunning</span>"	"CONCLUSIONS: In patients with coronary artery disease, <span class=""chemical"">dobutamine</span> induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be <span class=""disease"">myocardial stunning</span>, similar to that seen after exercise."		328.0	328_MESH:D004280_MESH:D017682	328_13	bcv_final_eval_easy_1871		
	MESH:D004280	"<span class=""chemical"">Dobutamine</span>"	MESH:D003324	"<span class=""disease"">coronary artery disease</span>"	"<span class=""chemical"">Dobutamine</span> induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with <span class=""disease"">coronary artery disease</span>."		328.0	328_MESH:D004280_MESH:D003324	328_14	bcv_final_eval_easy_1872		
	MESH:D001067	"<span class=""chemical"">appetite suppressants</span>"	MESH:D006976	"<span class=""disease"">primary pulmonary hypertension/PPH</span>"	"BACKGROUND: The use of <span class=""chemical"">appetite suppressants</span> in Europe has been associated with the development of <span class=""disease"">primary pulmonary hypertension</span> (<span class=""disease"">PPH</span>)."		329.0	329_MESH:D001067_MESH:D006976	329_1	bcv_final_eval_easy_1873		
	MESH:D005277	"<span class=""chemical"">fenfluramines</span>"	MESH:D006976	"<span class=""disease"">SPH/PPH</span>"	"However, of the medications surveyed, only the <span class=""chemical"">fenfluramines</span> had a significant preferential association with <span class=""disease"">PPH</span> as compared with <span class=""disease"">SPH</span> (adjusted odds ratio for use > 6 months, 7.5; 95% confidence interval, 1.7 to 32.4)."		329.0	329_MESH:D005277_MESH:D006976	329_9	bcv_final_eval_easy_1874		
	MESH:D005277	"<span class=""chemical"">fenfluramines</span>"	MESH:D006976	"<span class=""disease"">PPH</span>"	"CONCLUSION: The magnitude of the association with <span class=""disease"">PPH</span>, the increase of association with increasing duration of use, and the specificity for <span class=""chemical"">fenfluramines</span> are consistent with previous studies indicating that <span class=""chemical"">fenfluramines</span> are causally related to <span class=""disease"">PPH</span>."		329.0	329_MESH:D005277_MESH:D006976	329_12	bcv_final_eval_easy_1875		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013927	"<span class=""disease"">thrombosis</span>"	"Clinical aspects of <span class=""chemical"">heparin</span>-induced thrombocytopenia and <span class=""disease"">thrombosis</span> and other side effects of <span class=""chemical"">heparin</span> therapy."		330.0	330_MESH:D006493_MESH:D013927	330_0	bcv_final_eval_easy_1876		
	MESH:D006493	"<span class=""chemical"">Heparin</span>"	MESH:D013927	"<span class=""disease"">thrombosis</span>"	"<span class=""chemical"">Heparin</span>, first used to prevent the clotting of blood in vitro, has been clinically used to treat <span class=""disease"">thrombosis</span> for more than 50 years."		330.0	330_MESH:D006493_MESH:D013927	330_1	bcv_final_eval_easy_1877		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013927	"<span class=""disease"">thrombotic</span>"	"Although several new anticoagulant drugs are in development, <span class=""chemical"">heparin</span> remains the anticoagulant of choice to treat acute <span class=""disease"">thrombotic</span> episodes."		330.0	330_MESH:D006493_MESH:D013927	330_2	bcv_final_eval_easy_1878		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D006470	"<span class=""disease"">Bleeding</span>"	"<span class=""disease"">Bleeding</span> is the primary untoward effect of <span class=""chemical"">heparin</span>."		330.0	330_MESH:D006493_MESH:D006470	330_4	bcv_final_eval_easy_1879		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D006470	"<span class=""disease"">Major bleeding</span>"	"<span class=""disease"">Major bleeding</span> is of primary concern in patients receiving <span class=""chemical"">heparin</span> therapy."		330.0	330_MESH:D006493_MESH:D006470	330_5	bcv_final_eval_easy_1880		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D004342	"<span class=""disease"">allergic reactions</span>"	"However, additional important untoward effects of <span class=""chemical"">heparin</span> therapy include <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, eosinophilia, skin reactions, <span class=""disease"">allergic reactions</span> other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism."		330.0	330_MESH:D006493_MESH:D004342	330_6	bcv_final_eval_easy_1881		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"However, additional important untoward effects of <span class=""chemical"">heparin</span> therapy include <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, <span class=""disease"">hyperkalemia</span>, hypoaldosteronism, and priapism."		330.0	330_MESH:D006493_MESH:D006947	330_6	bcv_final_eval_easy_1882		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D000505	"<span class=""disease"">alopecia</span>"	"However, additional important untoward effects of <span class=""chemical"">heparin</span> therapy include <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, <span class=""disease"">alopecia</span>, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism."		330.0	330_MESH:D006493_MESH:D000505	330_6	bcv_final_eval_easy_1883		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D004802	"<span class=""disease"">eosinophilia</span>"	"However, additional important untoward effects of <span class=""chemical"">heparin</span> therapy include <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, <span class=""disease"">eosinophilia</span>, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism."		330.0	330_MESH:D006493_MESH:D004802	330_6	bcv_final_eval_easy_1884		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D010024	"<span class=""disease"">osteoporosis</span>"	"However, additional important untoward effects of <span class=""chemical"">heparin</span> therapy include <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated <span class=""disease"">osteoporosis</span>, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism."		330.0	330_MESH:D006493_MESH:D010024	330_6	bcv_final_eval_easy_1885		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D011317	"<span class=""disease"">priapism</span>"	"However, additional important untoward effects of <span class=""chemical"">heparin</span> therapy include <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and <span class=""disease"">priapism</span>."		330.0	330_MESH:D006493_MESH:D011317	330_6	bcv_final_eval_easy_1886		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D006994	"<span class=""disease"">hypoaldosteronism</span>"	"However, additional important untoward effects of <span class=""chemical"">heparin</span> therapy include <span class=""chemical"">heparin</span>-induced thrombocytopenia, <span class=""chemical"">heparin</span>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, <span class=""disease"">hypoaldosteronism</span>, and priapism."		330.0	330_MESH:D006493_MESH:D006994	330_6	bcv_final_eval_easy_1887		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D010024	"<span class=""disease"">osteoporosis</span>"	"These side effects are relatively rare in a given individual, but given the extremely widespread use of <span class=""chemical"">heparin</span>, some are quite common, particularly HITT and <span class=""disease"">osteoporosis</span>."		330.0	330_MESH:D006493_MESH:D010024	330_7	bcv_final_eval_easy_1888		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:C567116	"<span class=""disease"">low molecular weight heparins</span>"	"Although reasonable incidences of many of these side effects can be ""softly"" deduced from current reports dealing with unfractionated <span class=""chemical"">heparin</span>, at present the incidences of these side effects with newer <span class=""disease"">low molecular weight heparins</span> appear to be much less common."		330.0	330_MESH:D006493_MESH:C567116	330_8	bcv_final_eval_easy_1889		
	MESH:D016559	"<span class=""chemical"">FK506/tacrolimus</span>"	MESH:D009901	"<span class=""disease"">bilateral optic neuropathy</span>"	"A case of <span class=""disease"">bilateral optic neuropathy</span> in a patient on <span class=""chemical"">tacrolimus</span> (<span class=""chemical"">FK506</span>) therapy after liver transplantation."		331.0	331_MESH:D016559_MESH:D009901	331_0	bcv_final_eval_easy_1890		
	MESH:D016559	"<span class=""chemical"">FK 506/tacrolimus</span>"	MESH:D009901	"<span class=""disease"">bilateral optic neuropathy</span>"	"PURPOSE: To report a case of <span class=""disease"">bilateral optic neuropathy</span> in a patient receiving <span class=""chemical"">tacrolimus</span> (<span class=""chemical"">FK 506</span>, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation."		331.0	331_MESH:D016559_MESH:D009901	331_1	bcv_final_eval_easy_1891		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D014786	"<span class=""disease"">Deterioration of vision</span>"	"<span class=""disease"">Deterioration of vision</span> occurred despite discontinuation of the <span class=""chemical"">tacrolimus</span>."		331.0	331_MESH:D016559_MESH:D014786	331_5	bcv_final_eval_easy_1892		
	MESH:D016559	"<span class=""chemical"">Tacrolimus</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"CONCLUSION: <span class=""chemical"">Tacrolimus</span> and other immunosuppressive agents may be associated with optic nerve <span class=""disease"">toxicity</span>."		331.0	331_MESH:D016559_MESH:D064420	331_6	bcv_final_eval_easy_1893		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D001714	"<span class=""disease"">bipolar</span>"	"Recent findings in a <span class=""disease"">bipolar</span> patient receiving maintenance <span class=""chemical"">lithium</span> therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of <span class=""disease"">bipolar</span> patients with <span class=""chemical"">lithium</span>-associated hypercalcemia."		332.0	332_MESH:D008094_MESH:D001714	332_1	bcv_final_eval_easy_1894		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D006934	"<span class=""disease"">hypercalcemia</span>"	"Recent findings in a bipolar patient receiving maintenance <span class=""chemical"">lithium</span> therapy who developed <span class=""disease"">hypercalcemia</span> and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with <span class=""chemical"">lithium</span>-associated <span class=""disease"">hypercalcemia</span>."		332.0	332_MESH:D008094_MESH:D006934	332_1	bcv_final_eval_easy_1895		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D001919	"<span class=""disease"">bradyarrhythmia</span>"	"Recent findings in a bipolar patient receiving maintenance <span class=""chemical"">lithium</span> therapy who developed hypercalcemia and severe <span class=""disease"">bradyarrhythmia</span> prompted the authors to conduct a retrospective study of bipolar patients with <span class=""chemical"">lithium</span>-associated hypercalcemia."		332.0	332_MESH:D008094_MESH:D001919	332_1	bcv_final_eval_easy_1896		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D009369	"<span class=""disease"">malignancies</span>"	"After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-<span class=""chemical"">lithium</span>-treated patients with hypercalcemias related to <span class=""disease"">malignancies</span> and other medical conditions (group A) and 12 patients with <span class=""chemical"">lithium</span>-associated hypercalcemia (group B)."		332.0	332_MESH:D008094_MESH:D009369	332_3	bcv_final_eval_easy_1897		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D006934	"<span class=""disease"">hypercalcemia/hypercalcemias</span>"	"After eliminating spurious <span class=""disease"">hypercalcemias</span> or those associated with intravenous fluids, the authors identified 18 non-<span class=""chemical"">lithium</span>-treated patients with <span class=""disease"">hypercalcemias</span> related to malignancies and other medical conditions (group A) and 12 patients with <span class=""chemical"">lithium</span>-associated <span class=""disease"">hypercalcemia</span> (group B)."		332.0	332_MESH:D008094_MESH:D006934	332_3	bcv_final_eval_easy_1898		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D001714	"<span class=""disease"">bipolar normocalcemic</span>"	"Thus, two control groups were generated: group C1, which included age- and sex-comparable <span class=""chemical"">lithium</span>-treated <span class=""disease"">bipolar normocalcemic</span> patients, and group C2, which included <span class=""disease"">bipolar normocalcemic</span> patients treated with anticonvulsant mood stabilizers."		332.0	332_MESH:D008094_MESH:D001714	332_5	bcv_final_eval_easy_1899		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D001714	"<span class=""disease"">bipolar</span>"	"Patients with hypercalcemia resulting from medical diseases and <span class=""disease"">bipolar</span> patients with <span class=""chemical"">lithium</span>-associated hypercalcemia had significantly higher frequencies of conduction defects."		332.0	332_MESH:D008094_MESH:D001714	332_8	bcv_final_eval_easy_1900		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D006934	"<span class=""disease"">hypercalcemia</span>"	"Patients with <span class=""disease"">hypercalcemia</span> resulting from medical diseases and bipolar patients with <span class=""chemical"">lithium</span>-associated <span class=""disease"">hypercalcemia</span> had significantly higher frequencies of conduction defects."		332.0	332_MESH:D008094_MESH:D006934	332_8	bcv_final_eval_easy_1901		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:C566238	"<span class=""disease"">conduction defects</span>"	"Patients with hypercalcemia resulting from medical diseases and bipolar patients with <span class=""chemical"">lithium</span>-associated hypercalcemia had significantly higher frequencies of <span class=""disease"">conduction defects</span>."		332.0	332_MESH:D008094_MESH:C566238	332_8	bcv_final_eval_easy_1902		
	MESH:D000666	"<span class=""chemical"">amphotericin B</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"NS-718, a lipid nanosphere incorporating <span class=""chemical"">amphotericin B</span>, is effective against pathogenic fungi and has low <span class=""disease"">toxicity</span>."		333.0	333_MESH:D000666_MESH:D064420	333_1	bcv_final_eval_easy_1903		
	MESH:D000666	"<span class=""chemical"">Fungizone/amphotericin B</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"We compared the <span class=""disease"">toxicity</span> of NS-718 with that of <span class=""chemical"">Fungizone</span> (<span class=""chemical"">amphotericin B</span>-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of <span class=""chemical"">amphotericin B</span> following intravenous infusion of the formulation in rats."		333.0	333_MESH:D000666_MESH:D064420	333_2	bcv_final_eval_easy_1904		
	MESH:D003840	"<span class=""chemical"">sodium deoxycholate</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"We compared the <span class=""disease"">toxicity</span> of NS-718 with that of Fungizone (amphotericin B-<span class=""chemical"">sodium deoxycholate</span>; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats."		333.0	333_MESH:D003840_MESH:D064420	333_2	bcv_final_eval_easy_1905		
	MESH:D013411	"<span class=""chemical"">sulfadiazine</span>"	MESH:D015746	"<span class=""disease"">abdominal pain</span>"	"Under treatment with <span class=""chemical"">sulfadiazine</span> they developed oliguria, <span class=""disease"">abdominal pain</span>, renal failure and showed multiple radiolucent renal calculi in echography."		334.0	334_MESH:D013411_MESH:D015746	334_3	bcv_final_eval_easy_1906		
	MESH:D013411	"<span class=""chemical"">sulfadiazine</span>"	MESH:D051437	"<span class=""disease"">renal failure</span>"	"Under treatment with <span class=""chemical"">sulfadiazine</span> they developed oliguria, abdominal pain, <span class=""disease"">renal failure</span> and showed multiple radiolucent renal calculi in echography."		334.0	334_MESH:D013411_MESH:D051437	334_3	bcv_final_eval_easy_1907		
	MESH:D013411	"<span class=""chemical"">sulfadiazine</span>"	MESH:D009846	"<span class=""disease"">oliguria</span>"	"Under treatment with <span class=""chemical"">sulfadiazine</span> they developed <span class=""disease"">oliguria</span>, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography."		334.0	334_MESH:D013411_MESH:D009846	334_3	bcv_final_eval_easy_1908		
	MESH:D013411	"<span class=""chemical"">sulfadiazine</span>"	MESH:D007669	"<span class=""disease"">renal calculi</span>"	"Under treatment with <span class=""chemical"">sulfadiazine</span> they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent <span class=""disease"">renal calculi</span> in echography."		334.0	334_MESH:D013411_MESH:D007669	334_3	bcv_final_eval_easy_1909		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D009759	"<span class=""disease"">nystagmus</span>"	"Downbeat <span class=""disease"">nystagmus</span> associated with intravenous patient-controlled administration of <span class=""chemical"">morphine</span>."		335.0	335_MESH:D009020_MESH:D009759	335_0	bcv_final_eval_easy_1910		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D004244	"<span class=""disease"">dizziness</span>"	"IMPLICATIONS: This case documents a patient who developed <span class=""disease"">dizziness</span> with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia <span class=""chemical"">morphine</span>."		335.0	335_MESH:D009020_MESH:D004244	335_1	bcv_final_eval_easy_1911		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D009759	"<span class=""disease"">nystagmus</span>"	"IMPLICATIONS: This case documents a patient who developed dizziness with downbeating <span class=""disease"">nystagmus</span> while receiving a relatively large dose of IV patient-controlled analgesia <span class=""chemical"">morphine</span>."		335.0	335_MESH:D009020_MESH:D009759	335_1	bcv_final_eval_easy_1912		
	MESH:C118667	"<span class=""chemical"">dronedarone</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Hemodynamic and antiadrenergic effects of <span class=""chemical"">dronedarone</span> and amiodarone in animals with a healed <span class=""disease"">myocardial infarction</span>."		336.0	336_MESH:C118667_MESH:D009203	336_0	bcv_final_eval_easy_1913		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"Hemodynamic and antiadrenergic effects of dronedarone and <span class=""chemical"">amiodarone</span> in animals with a healed <span class=""disease"">myocardial infarction</span>."		336.0	336_MESH:D000638_MESH:D009203	336_0	bcv_final_eval_easy_1914		
	MESH:C118667	"<span class=""chemical"">dronedarone</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"The hemodynamic and antiadrenergic effects of <span class=""chemical"">dronedarone</span>, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed <span class=""disease"">myocardial infarction</span>."		336.0	336_MESH:C118667_MESH:D009203	336_1	bcv_final_eval_easy_1915		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to <span class=""chemical"">amiodarone</span>, were compared with those of <span class=""chemical"">amiodarone</span> after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed <span class=""disease"">myocardial infarction</span>."		336.0	336_MESH:D000638_MESH:D009203	336_1	bcv_final_eval_easy_1916		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"Both dronedarone and <span class=""chemical"">amiodarone</span> significantly reduced the exercise-induced <span class=""disease"">tachycardia</span> and, at the highest dose, decreased the isoproterenol-induced <span class=""disease"">tachycardia</span>."		336.0	336_MESH:D000638_MESH:D013610	336_5	bcv_final_eval_easy_1917		
	MESH:C118667	"<span class=""chemical"">dronedarone</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"Both <span class=""chemical"">dronedarone</span> and amiodarone significantly reduced the exercise-induced <span class=""disease"">tachycardia</span> and, at the highest dose, decreased the isoproterenol-induced <span class=""disease"">tachycardia</span>."		336.0	336_MESH:C118667_MESH:D013610	336_5	bcv_final_eval_easy_1918		
	MESH:C118667	"<span class=""chemical"">dronedarone</span>"	MESH:D001145	"<span class=""disease"">arrhythmias</span>"	"Consequently, <span class=""chemical"">dronedarone</span> might be particularly suitable for the treatment and prevention of various clinical <span class=""disease"">arrhythmias</span>, without compromising the left ventricular function."		336.0	336_MESH:C118667_MESH:D001145	336_7	bcv_final_eval_easy_1919		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D002277	"<span class=""disease"">primary carcinoma</span>"	"Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in <span class=""chemical"">platinum</span>/paclitaxel-refractory ovarian and fallopian tube cancers and <span class=""disease"">primary carcinoma</span> of the peritoneum."		337.0	337_MESH:D010984_MESH:D002277	337_0	bcv_final_eval_easy_1920		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D009369	"<span class=""disease"">tube cancers</span>"	"Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in <span class=""chemical"">platinum</span>/paclitaxel-refractory ovarian and fallopian <span class=""disease"">tube cancers</span> and primary carcinoma of the peritoneum."		337.0	337_MESH:D010984_MESH:D009369	337_0	bcv_final_eval_easy_1921		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D002277	"<span class=""disease"">primary carcinoma</span>"	"Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/<span class=""chemical"">paclitaxel</span>-refractory ovarian and fallopian tube cancers and <span class=""disease"">primary carcinoma</span> of the peritoneum."		337.0	337_MESH:D017239_MESH:D002277	337_0	bcv_final_eval_easy_1922		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D009369	"<span class=""disease"">tube cancers</span>"	"Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/<span class=""chemical"">paclitaxel</span>-refractory ovarian and fallopian <span class=""disease"">tube cancers</span> and primary carcinoma of the peritoneum."		337.0	337_MESH:D017239_MESH:D009369	337_0	bcv_final_eval_easy_1923		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D002277	"<span class=""disease"">primary carcinoma</span>"	"Phase 2 trial of liposomal <span class=""chemical"">doxorubicin</span> (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and <span class=""disease"">primary carcinoma</span> of the peritoneum."		337.0	337_MESH:D004317_MESH:D002277	337_0	bcv_final_eval_easy_1924		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009369	"<span class=""disease"">tube cancers</span>"	"Phase 2 trial of liposomal <span class=""chemical"">doxorubicin</span> (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian <span class=""disease"">tube cancers</span> and primary carcinoma of the peritoneum."		337.0	337_MESH:D004317_MESH:D009369	337_0	bcv_final_eval_easy_1925		
	MESH:D004317	"<span class=""chemical"">doxorubicin/Doxil</span>"	MESH:D013280	"<span class=""disease"">stomatitis</span>"	"BACKGROUND: Several studies have demonstrated liposomal <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">Doxil</span>) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (""hand-foot syndrome"") and <span class=""disease"">stomatitis</span>."		337.0	337_MESH:D004317_MESH:D013280	337_1	bcv_final_eval_easy_1926		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in <span class=""chemical"">platinum</span>-resistant ovarian cancer, with dose limiting <span class=""disease"">toxicity</span> of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (""hand-foot syndrome"") and stomatitis."		337.0	337_MESH:D010984_MESH:D064420	337_1	bcv_final_eval_easy_1927		
	MESH:D004317	"<span class=""chemical"">doxorubicin/Doxil</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"BACKGROUND: Several studies have demonstrated liposomal <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">Doxil</span>) to be an active antineoplastic agent in platinum-resistant <span class=""disease"">ovarian cancer</span>, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (""hand-foot syndrome"") and stomatitis."		337.0	337_MESH:D004317_MESH:D010051	337_1	bcv_final_eval_easy_1928		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D060831	"<span class=""disease"">hand-foot syndrome</span>"	"BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in <span class=""chemical"">platinum</span>-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (""<span class=""disease"">hand-foot syndrome</span>"") and stomatitis."		337.0	337_MESH:D010984_MESH:D060831	337_1	bcv_final_eval_easy_1929		
	MESH:D004317	"<span class=""chemical"">doxorubicin/Doxil</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: Several studies have demonstrated liposomal <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">Doxil</span>) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting <span class=""disease"">toxicity</span> of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (""hand-foot syndrome"") and stomatitis."		337.0	337_MESH:D004317_MESH:D064420	337_1	bcv_final_eval_easy_1930		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D013280	"<span class=""disease"">stomatitis</span>"	"BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in <span class=""chemical"">platinum</span>-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (""hand-foot syndrome"") and <span class=""disease"">stomatitis</span>."		337.0	337_MESH:D010984_MESH:D013280	337_1	bcv_final_eval_easy_1931		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in <span class=""chemical"">platinum</span>-resistant <span class=""disease"">ovarian cancer</span>, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (""hand-foot syndrome"") and stomatitis."		337.0	337_MESH:D010984_MESH:D010051	337_1	bcv_final_eval_easy_1932		
	MESH:D004317	"<span class=""chemical"">doxorubicin/Doxil</span>"	MESH:D060831	"<span class=""disease"">hand-foot syndrome</span>"	"BACKGROUND: Several studies have demonstrated liposomal <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">Doxil</span>) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (""<span class=""disease"">hand-foot syndrome</span>"") and stomatitis."		337.0	337_MESH:D004317_MESH:D060831	337_1	bcv_final_eval_easy_1933		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D010051	"<span class=""disease"">ovarian or fallopian tube cancers</span>"	"METHODS AND MATERIALS: Patients with <span class=""disease"">ovarian or fallopian tube cancers</span> or primary peritoneal carcinoma with platinum/<span class=""chemical"">paclitaxel</span>-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks."		337.0	337_MESH:D017239_MESH:D010051	337_3	bcv_final_eval_easy_1934		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D002277	"<span class=""disease"">carcinoma</span>"	"METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal <span class=""disease"">carcinoma</span> with <span class=""chemical"">platinum</span>/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks."		337.0	337_MESH:D010984_MESH:D002277	337_3	bcv_final_eval_easy_1935		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D010051	"<span class=""disease"">ovarian or fallopian tube cancers</span>"	"METHODS AND MATERIALS: Patients with <span class=""disease"">ovarian or fallopian tube cancers</span> or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal <span class=""chemical"">doxorubicin</span> at a dose of 40 mg/m(2) q 4 weeks."		337.0	337_MESH:D004317_MESH:D010051	337_3	bcv_final_eval_easy_1936		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D002277	"<span class=""disease"">carcinoma</span>"	"METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal <span class=""disease"">carcinoma</span> with platinum/<span class=""chemical"">paclitaxel</span>-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks."		337.0	337_MESH:D017239_MESH:D002277	337_3	bcv_final_eval_easy_1937		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D002277	"<span class=""disease"">carcinoma</span>"	"METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal <span class=""disease"">carcinoma</span> with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal <span class=""chemical"">doxorubicin</span> at a dose of 40 mg/m(2) q 4 weeks."		337.0	337_MESH:D004317_MESH:D002277	337_3	bcv_final_eval_easy_1938		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D010051	"<span class=""disease"">ovarian or fallopian tube cancers</span>"	"METHODS AND MATERIALS: Patients with <span class=""disease"">ovarian or fallopian tube cancers</span> or primary peritoneal carcinoma with <span class=""chemical"">platinum</span>/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks."		337.0	337_MESH:D010984_MESH:D010051	337_3	bcv_final_eval_easy_1939		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D013280	"<span class=""disease"">stomatitis</span>"	"CONCLUSION: This modified liposomal <span class=""chemical"">doxorubicin</span> regimen results in less toxicity (<span class=""disease"">stomatitis</span>, hand-foot syndrome) than the standard FDA-approved dose schedule."		337.0	337_MESH:D004317_MESH:D013280	337_11	bcv_final_eval_easy_1940		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"CONCLUSION: This modified liposomal <span class=""chemical"">doxorubicin</span> regimen results in less <span class=""disease"">toxicity</span> (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule."		337.0	337_MESH:D004317_MESH:D064420	337_11	bcv_final_eval_easy_1941		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D060831	"<span class=""disease"">hand-foot syndrome</span>"	"CONCLUSION: This modified liposomal <span class=""chemical"">doxorubicin</span> regimen results in less toxicity (stomatitis, <span class=""disease"">hand-foot syndrome</span>) than the standard FDA-approved dose schedule."		337.0	337_MESH:D004317_MESH:D060831	337_11	bcv_final_eval_easy_1942		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"Definite, although limited, antineoplastic activity is observed in patients with well-defined <span class=""chemical"">platinum</span>- and paclitaxel-refractory <span class=""disease"">ovarian cancer</span>."		337.0	337_MESH:D010984_MESH:D010051	337_12	bcv_final_eval_easy_1943		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D010051	"<span class=""disease"">ovarian cancer</span>"	"Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and <span class=""chemical"">paclitaxel</span>-refractory <span class=""disease"">ovarian cancer</span>."		337.0	337_MESH:D017239_MESH:D010051	337_12	bcv_final_eval_easy_1944		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D001714	"<span class=""disease"">bipolar mania</span>"	"Efficacy of <span class=""chemical"">olanzapine</span> in acute <span class=""disease"">bipolar mania</span>: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group."		338.0	338_MESH:C076029_MESH:D001714	338_0	bcv_final_eval_easy_1945		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D001714	"<span class=""disease"">bipolar mania</span>"	"BACKGROUND: We compared the efficacy and safety of <span class=""chemical"">olanzapine</span> vs placebo for the treatment of acute <span class=""disease"">bipolar mania</span>."		338.0	338_MESH:C076029_MESH:D001714	338_1	bcv_final_eval_easy_1946		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D001714	"<span class=""disease"">manic/bipolar disorder</span>"	"A total of 115 patients with a DSM-IV diagnosis of <span class=""disease"">bipolar disorder</span>, <span class=""disease"">manic</span> or mixed, were randomized to <span class=""chemical"">olanzapine</span>, 5 to 20 mg/d (n = 55), or placebo (n = 60)."		338.0	338_MESH:C076029_MESH:D001714	338_3	bcv_final_eval_easy_1947		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D006970	"<span class=""disease"">treatment-emergent somnolence</span>"	"However, <span class=""chemical"">olanzapine</span>-treated patients had a statistically significant greater mean (+/- SD) weight gain than placebo-treated patients (2.1 +/- 2.8 vs 0.45 +/- 2.3 kg, respectively) and also experienced more <span class=""disease"">treatment-emergent somnolence</span> (21 patients [38.2%] vs 5 [8.3% ], respectively)."		338.0	338_MESH:C076029_MESH:D006970	338_10	bcv_final_eval_easy_1948		
	MESH:C076029	"<span class=""chemical"">Olanzapine</span>"	MESH:D001714	"<span class=""disease"">bipolar mania</span>"	"CONCLUSION: <span class=""chemical"">Olanzapine</span> demonstrated greater efficacy than placebo in the treatment of acute <span class=""disease"">bipolar mania</span> and was generally well tolerated."		338.0	338_MESH:C076029_MESH:D001714	338_11	bcv_final_eval_easy_1949		
	MESH:D014331	"<span class=""chemical"">tropicamide</span>"	MESH:D002311	"<span class=""disease"">pupil dilation</span>"	"The effect of <span class=""disease"">pupil dilation</span> with <span class=""chemical"">tropicamide</span> on vision and driving simulator performance."		339.0	339_MESH:D014331_MESH:D002311	339_0	bcv_final_eval_easy_1950		
	MESH:D015474	"<span class=""chemical"">isotretinoin</span>"	MESH:C535670	"<span class=""disease"">isotretinoin embryopathy</span>"	"A case of <span class=""chemical""></span><span class=""disease"">isotretinoin</span> embryopathy with bilateral anotia and Taussig-Bing malformation."		340.0	340_MESH:D015474_MESH:C535670	340_0	bcv_final_eval_easy_1951		
	MESH:D015474	"<span class=""chemical"">isotretinoin</span>"	MESH:D065817	"<span class=""disease"">bilateral anotia</span>"	"A case of <span class=""chemical"">isotretinoin</span> embryopathy with <span class=""disease"">bilateral anotia</span> and Taussig-Bing malformation."		340.0	340_MESH:D015474_MESH:D065817	340_0	bcv_final_eval_easy_1952		
	MESH:D015474	"<span class=""chemical"">isotretinoin</span>"	MESH:D000014	"<span class=""disease"">Bing malformation</span>"	"A case of <span class=""chemical"">isotretinoin</span> embryopathy with bilateral anotia and Taussig-<span class=""disease"">Bing malformation</span>."		340.0	340_MESH:D015474_MESH:D000014	340_0	bcv_final_eval_easy_1953		
	MESH:D015474	"<span class=""chemical"">isotretinoin</span>"	MESH:D000013	"<span class=""disease"">multiple congenital anomalies</span>"	"We report a newborn infant with <span class=""disease"">multiple congenital anomalies</span> (anotia and Taussig-Bing malformation) due to exposure to <span class=""chemical"">isotretinoin</span> within the first trimester."		340.0	340_MESH:D015474_MESH:D000013	340_1	bcv_final_eval_easy_1954		
	MESH:D015474	"<span class=""chemical"">isotretinoin</span>"	MESH:D065817	"<span class=""disease"">anotia</span>"	"We report a newborn infant with multiple congenital anomalies (<span class=""disease"">anotia</span> and Taussig-Bing malformation) due to exposure to <span class=""chemical"">isotretinoin</span> within the first trimester."		340.0	340_MESH:D015474_MESH:D065817	340_1	bcv_final_eval_easy_1955		
	MESH:D015474	"<span class=""chemical"">isotretinoin</span>"	MESH:D000014	"<span class=""disease"">Bing malformation</span>"	"We report a newborn infant with multiple congenital anomalies (anotia and Taussig-<span class=""disease"">Bing malformation</span>) due to exposure to <span class=""chemical"">isotretinoin</span> within the first trimester."		340.0	340_MESH:D015474_MESH:D000014	340_1	bcv_final_eval_easy_1956		
	MESH:D008729	"<span class=""chemical"">methoxamine</span>"	MESH:D014550	"<span class=""disease"">genuine stress incontinence</span>"	"Effect of <span class=""chemical"">methoxamine</span> on maximum urethral pressure in women with <span class=""disease"">genuine stress incontinence</span>: a placebo-controlled, double-blind crossover study."		341.0	341_MESH:D008729_MESH:D014550	341_0	bcv_final_eval_easy_1957		
	MESH:D008729	"<span class=""chemical"">methoxamine</span>"	MESH:D014550	"<span class=""disease"">genuine stress incontinence</span>"	"Half log incremental doses of intravenous <span class=""chemical"">methoxamine</span> or placebo (saline) were administered to a group of women with <span class=""disease"">genuine stress incontinence</span> while measuring maximum urethral pressure (MUP), blood pressure, heart rate, and symptomatic side effects."		341.0	341_MESH:D008729_MESH:D014550	341_3	bcv_final_eval_easy_1958		
	MESH:D008729	"<span class=""chemical"">Methoxamine</span>"	MESH:D007022	"<span class=""disease"">increases in MUP and diastolic blood pressure/rise in systolic blood pressure</span>"	"<span class=""chemical"">Methoxamine</span> evoked non-significant <span class=""disease"">increases in MUP and diastolic blood pressure</span> but caused a significant <span class=""disease"">rise in systolic blood pressure</span> and significant fall in heart rate at maximum dosage."		341.0	341_MESH:D008729_MESH:D007022	341_4	bcv_final_eval_easy_1959		
	MESH:D017706	"<span class=""chemical"">Lisinopril</span>"	MESH:D006333	"<span class=""disease"">chronic heart failure</span>"	"Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with <span class=""disease"">chronic heart failure</span>: results from the ATLAS trial. The Assessment of Treatment with <span class=""chemical"">Lisinopril</span> and Survival."		342.0	342_MESH:D017706_MESH:D006333	342_0	bcv_final_eval_easy_1960		
	MESH:D000809	"<span class=""chemical"">angiotensin</span>"	MESH:D006333	"<span class=""disease"">chronic heart failure</span>"	"Toleration of high doses of <span class=""chemical"">angiotensin</span>-converting enzyme inhibitors in patients with <span class=""disease"">chronic heart failure</span>: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival."		342.0	342_MESH:D000809_MESH:D006333	342_0	bcv_final_eval_easy_1961		
	MESH:D000806	"<span class=""chemical"">angiotensin-converting enzyme (ACE) inhibitors</span>"	MESH:D006333	"<span class=""disease"">chronic heart failure/CHF</span>"	"BACKGROUND: Treatment with <span class=""chemical"">angiotensin-converting enzyme (ACE) inhibitors</span> reduces mortality and morbidity in patients with <span class=""disease"">chronic heart failure</span> (<span class=""disease"">CHF</span>), but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials, primarily because of concerns about the safety and tolerability of these agents, especially at the recommended doses."		342.0	342_MESH:D000806_MESH:D006333	342_1	bcv_final_eval_easy_1962		
	MESH:D017706	"<span class=""chemical"">lisinopril</span>"	MESH:D006333	"<span class=""disease"">CHF</span>"	"The present study examines the safety and tolerability of high- compared with low-dose <span class=""chemical"">lisinopril</span> in <span class=""disease"">CHF</span>."		342.0	342_MESH:D017706_MESH:D006333	342_2	bcv_final_eval_easy_1963		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D003920	"<span class=""disease"">diabetes</span>"	"Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; <span class=""chemical"">creatinine</span>, > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with <span class=""disease"">diabetes</span>) generally tolerated the high-dose strategy."		342.0	342_MESH:D003404_MESH:D003920	342_9	bcv_final_eval_easy_1964		
	MESH:D003042	"<span class=""chemical"">Cocaine</span>"	MESH:D066126	"<span class=""disease"">cardiotoxity</span>"	"<span class=""chemical"">Cocaine</span>, ethanol, and cocaethylene <span class=""disease"">cardiotoxity</span> in an animal model of <span class=""chemical"">cocaine</span> and ethanol abuse."		343.0	343_MESH:D003042_MESH:D066126	343_0	bcv_final_eval_easy_1965		
	MESH:D000431	"<span class=""chemical"">ethanol</span>"	MESH:D066126	"<span class=""disease"">cardiotoxity</span>"	"Cocaine, <span class=""chemical"">ethanol</span>, and cocaethylene <span class=""disease"">cardiotoxity</span> in an animal model of cocaine and <span class=""chemical"">ethanol</span> abuse."		343.0	343_MESH:D000431_MESH:D066126	343_0	bcv_final_eval_easy_1966		
	MESH:C066444	"<span class=""chemical"">cocaethylene</span>"	MESH:D066126	"<span class=""disease"">cardiotoxity</span>"	"Cocaine, ethanol, and <span class=""chemical"">cocaethylene</span> <span class=""disease"">cardiotoxity</span> in an animal model of cocaine and ethanol abuse."		343.0	343_MESH:C066444_MESH:D066126	343_0	bcv_final_eval_easy_1967		
	MESH:C066444	"<span class=""chemical"">cocaethylene</span>"	MESH:D066126	"<span class=""disease"">cardiac toxicity</span>"	"Their combined <span class=""disease"">cardiac toxicity</span> may be due to independent effects of each drug; however, they may also be due to <span class=""chemical"">cocaethylene</span> (CE), a cocaine metabolite formed only in the presence of ethanol."		343.0	343_MESH:C066444_MESH:D066126	343_3	bcv_final_eval_easy_1968		
	MESH:D000431	"<span class=""chemical"">ethanol</span>"	MESH:D066126	"<span class=""disease"">cardiac toxicity</span>"	"Their combined <span class=""disease"">cardiac toxicity</span> may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of <span class=""chemical"">ethanol</span>."		343.0	343_MESH:D000431_MESH:D066126	343_3	bcv_final_eval_easy_1969		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D066126	"<span class=""disease"">cardiac toxicity</span>"	"Their combined <span class=""disease"">cardiac toxicity</span> may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a <span class=""chemical"">cocaine</span> metabolite formed only in the presence of ethanol."		343.0	343_MESH:D003042_MESH:D066126	343_3	bcv_final_eval_easy_1970		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The purpose of this study was to delineate the role of CE in the combined <span class=""disease"">cardiotoxicity</span> of <span class=""chemical"">cocaine</span> and ethanol in a model simulating their abuse."		343.0	343_MESH:D003042_MESH:D066126	343_4	bcv_final_eval_easy_1971		
	MESH:D000431	"<span class=""chemical"">ethanol</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The purpose of this study was to delineate the role of CE in the combined <span class=""disease"">cardiotoxicity</span> of cocaine and <span class=""chemical"">ethanol</span> in a model simulating their abuse."		343.0	343_MESH:D000431_MESH:D066126	343_4	bcv_final_eval_easy_1972		
	MESH:C066444	"<span class=""chemical"">cocaethylene</span>"	MESH:D003866	"<span class=""disease"">prolonged myocardial depression</span>"	"Peak serum <span class=""chemical"">cocaethylene</span> concentrations were associated with <span class=""disease"">prolonged myocardial depression</span>."		343.0	343_MESH:C066444_MESH:D003866	343_13	bcv_final_eval_easy_1973		
	MESH:C027429	"<span class=""chemical"">veralipride</span>"	MESH:D010302	"<span class=""disease"">Parkinsonism</span>"	"Worsening of <span class=""disease"">Parkinsonism</span> after the use of <span class=""chemical"">veralipride</span> for treatment of menopause: case report."		344.0	344_MESH:C027429_MESH:D010302	344_0	bcv_final_eval_easy_1974		
	MESH:C027429	"<span class=""chemical"">veralipride</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"We describe a female patient with stable <span class=""disease"">Parkinson's disease</span> who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with <span class=""chemical"">veralipride</span>, as well as the improvement of her symptoms back to baseline after discontinuation of the drug."		344.0	344_MESH:C027429_MESH:D010300	344_1	bcv_final_eval_easy_1975		
	MESH:D011441	"<span class=""chemical"">propylthiouracil</span>"	MESH:D006111	"<span class=""disease"">Graves' disease</span>"	"Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in <span class=""disease"">Graves' disease</span> patients treated with <span class=""chemical"">propylthiouracil</span> and the relationship between MPO-ANCA and clinical manifestations."		346.0	346_MESH:D011441_MESH:D006111	346_0	bcv_final_eval_easy_1976		
	MESH:D011441	"<span class=""chemical"">PTU/propylthiouracil</span>"	MESH:D006111	"<span class=""disease"">Graves' disease</span>"	"OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with <span class=""disease"">Graves' disease</span> who were treated with <span class=""chemical"">propylthiouracil</span> (<span class=""chemical"">PTU</span>)."		346.0	346_MESH:D011441_MESH:D006111	346_1	bcv_final_eval_easy_1977		
	MESH:D011441	"<span class=""chemical"">PTU/propylthiouracil</span>"	MESH:D014657	"<span class=""disease"">vasculitis</span>"	"OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive <span class=""disease"">vasculitis</span> has been reported in patients with Graves' disease who were treated with <span class=""chemical"">propylthiouracil</span> (<span class=""chemical"">PTU</span>)."		346.0	346_MESH:D011441_MESH:D014657	346_1	bcv_final_eval_easy_1978		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D006111	"<span class=""disease"">Graves' disease</span>"	"Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and vasculitis during <span class=""chemical"">PTU</span> therapy, or on the incidence of MPO-ANCA in untreated <span class=""disease"">Graves' disease</span> patients."		346.0	346_MESH:D011441_MESH:D006111	346_3	bcv_final_eval_easy_1979		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D014657	"<span class=""disease"">vasculitis</span>"	"Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and <span class=""disease"">vasculitis</span> during <span class=""chemical"">PTU</span> therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients."		346.0	346_MESH:D011441_MESH:D014657	346_3	bcv_final_eval_easy_1980		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D006980	"<span class=""disease"">hyperthyroidism</span>"	"PATIENTS: We investigated 102 untreated patients with <span class=""disease"">hyperthyroidism</span> due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting <span class=""chemical"">PTU</span> therapy."		346.0	346_MESH:D011441_MESH:D006980	346_5	bcv_final_eval_easy_1981		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D006111	"<span class=""disease"">Graves' disease</span>"	"PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to <span class=""disease"">Graves' disease</span> for the presence of MPO-ANCA, and for the development vasculitis after starting <span class=""chemical"">PTU</span> therapy."		346.0	346_MESH:D011441_MESH:D006111	346_5	bcv_final_eval_easy_1982		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D014657	"<span class=""disease"">vasculitis</span>"	"PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development <span class=""disease"">vasculitis</span> after starting <span class=""chemical"">PTU</span> therapy."		346.0	346_MESH:D011441_MESH:D014657	346_5	bcv_final_eval_easy_1983		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D001523	"<span class=""disease"">vasculitic disorders</span>"	"In two of them, the MPO-ANCA titres transiently increased to 12.8 and 15.0 U/ml, respectively, despite continued <span class=""chemical"">PTU</span> therapy, but no <span class=""disease"">vasculitic disorders</span> developed."		346.0	346_MESH:D011441_MESH:D001523	346_12	bcv_final_eval_easy_1984		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D018771	"<span class=""disease"">polyarthralgia</span>"	"In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and <span class=""disease"">polyarthralgia</span>, but the symptoms resolved 2 weeks after stopping <span class=""chemical"">PTU</span> therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing <span class=""chemical"">PTU</span>."		346.0	346_MESH:D011441_MESH:D018771	346_13	bcv_final_eval_easy_1985		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D019226	"<span class=""disease"">fever, oral ulcers</span>"	"In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher <span class=""disease"">fever, oral ulcers</span> and polyarthralgia, but the symptoms resolved 2 weeks after stopping <span class=""chemical"">PTU</span> therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing <span class=""chemical"">PTU</span>."		346.0	346_MESH:D011441_MESH:D019226	346_13	bcv_final_eval_easy_1986		
	MESH:D011441	"<span class=""chemical"">PTU</span>"	MESH:D014657	"<span class=""disease"">vasculitis</span>"	"CONCLUSIONS: <span class=""chemical"">PTU</span> therapy may be related to the appearance of MPO-ANCA, but MPO-ANCA does not appear to be closely related to <span class=""disease"">vasculitis</span>."		346.0	346_MESH:D011441_MESH:D014657	346_14	bcv_final_eval_easy_1987		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D006331	"<span class=""disease"">heart disease</span>"	"Prevalence of <span class=""disease"">heart disease</span> in asymptomatic chronic <span class=""chemical"">cocaine</span> users."		347.0	347_MESH:D003042_MESH:D006331	347_0	bcv_final_eval_easy_1988		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D006331	"<span class=""disease"">heart disease</span>"	"To determine the prevalence of <span class=""disease"">heart disease</span> in outpatient young asymptomatic chronic <span class=""chemical"">cocaine</span> users, 35 <span class=""chemical"">cocaine</span> users and 32 age-matched controls underwent resting and exercise electrocardiography (ECG) and Doppler echocardiography."		347.0	347_MESH:D003042_MESH:D006331	347_1	bcv_final_eval_easy_1989		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D009202	"<span class=""disease"">myocardial disease</span>"	"We conclude that coronary artery or <span class=""disease"">myocardial disease</span> is common (38%) in young asymptomatic chronic <span class=""chemical"">cocaine</span> users."		347.0	347_MESH:D003042_MESH:D009202	347_5	bcv_final_eval_easy_1990		
	MESH:D000431	"<span class=""chemical"">ethanol</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"The cardioprotective effect of the <span class=""chemical"">ethanol</span> extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced <span class=""disease"">myocardial infarction</span> in rats with respect to lipid metabolism in serum and heart tissue has been investigated."		348.0	348_MESH:D000431_MESH:D009203	348_1	bcv_final_eval_easy_1991		
	MESH:C086123	"<span class=""chemical"">azimilide</span>"	MESH:D016171	"<span class=""disease"">torsade de pointes/TdP</span>"	"BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate <span class=""disease"">torsade de pointes</span> (<span class=""disease"">TdP</span>) with QT prolongation induced by dl-sotalol and <span class=""chemical"">azimilide</span>."		349.0	349_MESH:C086123_MESH:D016171	349_1	bcv_final_eval_easy_1992		
	MESH:C086123	"<span class=""chemical"">azimilide</span>"	MESH:D008133	"<span class=""disease"">QT prolongation</span>"	"BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with <span class=""disease"">QT prolongation</span> induced by dl-sotalol and <span class=""chemical"">azimilide</span>."		349.0	349_MESH:C086123_MESH:D008133	349_1	bcv_final_eval_easy_1993		
	MESH:C086123	"<span class=""chemical"">azimilide</span>"	MESH:D008133	"<span class=""disease"">QT prolongation</span>"	"Although both dl-sotalol and <span class=""chemical"">azimilide</span> rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced <span class=""disease"">QT prolongation</span> was seen."		349.0	349_MESH:C086123_MESH:D008133	349_7	bcv_final_eval_easy_1994		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D006470	"<span class=""disease"">subependymal hemorrhage</span>"	"PURPOSE: Prenatal <span class=""chemical"">cocaine</span> exposure has been linked with <span class=""disease"">subependymal hemorrhage</span> and the formation of cysts that are detectable on cranial sonography in neonates born at term."		350.0	350_MESH:D003042_MESH:D006470	350_1	bcv_final_eval_easy_1995		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D018315	"<span class=""disease"">subependymal cysts</span>"	"We sought to determine if prenatal <span class=""chemical"">cocaine</span> exposure increases the incidence of <span class=""disease"">subependymal cysts</span> in preterm infants."		350.0	350_MESH:D003042_MESH:D018315	350_2	bcv_final_eval_easy_1996		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D019970	"<span class=""disease"">cocaine abuse</span>"	"Infants were assigned to the <span class=""chemical"">cocaine</span>-exposed group if there was a maternal history of <span class=""chemical""></span><span class=""disease"">cocaine</span> abuse during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery."		350.0	350_MESH:D003042_MESH:D019970	350_5	bcv_final_eval_easy_1997		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D018315	"<span class=""disease"">subependymal cysts</span>"	"The incidence of <span class=""disease"">subependymal cysts</span> in infants exposed to <span class=""chemical"">cocaine</span> prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0.01)."		350.0	350_MESH:D003042_MESH:D018315	350_8	bcv_final_eval_easy_1998		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D018315	"<span class=""disease"">subependymal cyst</span>"	"CONCLUSIONS: We found an increased incidence of <span class=""disease"">subependymal cyst</span> formation in preterm infants who were exposed to <span class=""chemical"">cocaine</span> prenatally."		350.0	350_MESH:D003042_MESH:D018315	350_9	bcv_final_eval_easy_1999		
	MESH:D013792	"<span class=""chemical"">Thalidomide</span>"	MESH:D011471	"<span class=""disease"">prostate cancer</span>"	"<span class=""chemical"">Thalidomide</span> neuropathy in patients treated for metastatic <span class=""disease"">prostate cancer</span>."		351.0	351_MESH:D013792_MESH:D011471	351_0	bcv_final_eval_easy_2000		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D011471	"<span class=""disease"">prostate cancer</span>"	"Sixty-seven men with metastatic androgen-independent <span class=""disease"">prostate cancer</span> in an open-label trial of oral <span class=""chemical"">thalidomide</span> underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment."		351.0	351_MESH:D013792_MESH:D011471	351_2	bcv_final_eval_easy_2001		
	MESH:D015032	"<span class=""chemical"">zinc</span>"	MESH:D034381	"<span class=""disease"">hearing loss</span>"	"Overexpression of copper/<span class=""chemical"">zinc</span>-superoxide dismutase protects from kanamycin-induced <span class=""disease"">hearing loss</span>."		352.0	352_MESH:D015032_MESH:D034381	352_0	bcv_final_eval_easy_2002		
	MESH:D003300	"<span class=""chemical"">copper</span>"	MESH:D034381	"<span class=""disease"">hearing loss</span>"	"Overexpression of <span class=""chemical"">copper</span>/zinc-superoxide dismutase protects from kanamycin-induced <span class=""disease"">hearing loss</span>."		352.0	352_MESH:D003300_MESH:D034381	352_0	bcv_final_eval_easy_2003		
	MESH:D013481	"<span class=""chemical"">superoxide</span>"	MESH:D034381	"<span class=""disease"">hearing loss</span>"	"Overexpression of copper/zinc-<span class=""chemical"">superoxide</span> dismutase protects from kanamycin-induced <span class=""disease"">hearing loss</span>."		352.0	352_MESH:D013481_MESH:D034381	352_0	bcv_final_eval_easy_2004		
	MESH:D013481	"<span class=""chemical"">superoxide</span>"	MESH:D006311	"<span class=""disease"">ototoxicity</span>"	"The participation of reactive oxygen species in aminoglycoside-induced <span class=""disease"">ototoxicity</span> has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of <span class=""chemical"">superoxide</span> radicals in vitro and that antioxidants attenuate <span class=""disease"">ototoxicity</span> in vivo."		352.0	352_MESH:D013481_MESH:D006311	352_1	bcv_final_eval_easy_2005		
	MESH:D010100	"<span class=""chemical"">oxygen</span>"	MESH:D006311	"<span class=""disease"">ototoxicity</span>"	"The participation of reactive <span class=""chemical"">oxygen</span> species in aminoglycoside-induced <span class=""disease"">ototoxicity</span> has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate <span class=""disease"">ototoxicity</span> in vivo."		352.0	352_MESH:D010100_MESH:D006311	352_1	bcv_final_eval_easy_2006		
	MESH:D007501	"<span class=""chemical"">iron</span>"	MESH:D006311	"<span class=""disease"">ototoxicity</span>"	"The participation of reactive oxygen species in aminoglycoside-induced <span class=""disease"">ototoxicity</span> has been deduced from observations that aminoglycoside-<span class=""chemical"">iron</span> complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate <span class=""disease"">ototoxicity</span> in vivo."		352.0	352_MESH:D007501_MESH:D006311	352_1	bcv_final_eval_easy_2007		
	MESH:D013481	"<span class=""chemical"">superoxide</span>"	MESH:D006311	"<span class=""disease"">ototoxicity</span>"	"We therefore hypothesized that overexpression of Cu/Zn-<span class=""chemical"">superoxide</span> dismutase (h-SOD1) should protect transgenic mice from <span class=""disease"">ototoxicity</span>."		352.0	352_MESH:D013481_MESH:D006311	352_2	bcv_final_eval_easy_2008		
	MESH:D013481	"<span class=""chemical"">superoxide</span>"	MESH:D006311	"<span class=""disease"">ototoxicity</span>"	"The protection by overexpression of <span class=""chemical"">superoxide</span> dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside-induced <span class=""disease"">ototoxicity</span>."		352.0	352_MESH:D013481_MESH:D006311	352_9	bcv_final_eval_easy_2009		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D002294	"<span class=""disease"">squamous cell carcinoma of the cervix</span>"	"Phase II study of <span class=""chemical"">carboplatin</span> and liposomal doxorubicin in patients with recurrent <span class=""disease"">squamous cell carcinoma of the cervix</span>."		354.0	354_MESH:D016190_MESH:D002294	354_0	bcv_final_eval_easy_2010		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D002294	"<span class=""disease"">squamous cell carcinoma of the cervix</span>"	"Phase II study of carboplatin and liposomal <span class=""chemical"">doxorubicin</span> in patients with recurrent <span class=""disease"">squamous cell carcinoma of the cervix</span>."		354.0	354_MESH:D004317_MESH:D002294	354_0	bcv_final_eval_easy_2011		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D002277	"<span class=""disease"">carcinoma</span>"	"BACKGROUND: The activity of the combination of carboplatin and liposomal <span class=""chemical"">doxorubicin</span> was tested in a Phase II study of patients with recurrent cervical <span class=""disease"">carcinoma</span>."		354.0	354_MESH:D004317_MESH:D002277	354_1	bcv_final_eval_easy_2012		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D002277	"<span class=""disease"">carcinoma</span>"	"BACKGROUND: The activity of the combination of <span class=""chemical"">carboplatin</span> and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical <span class=""disease"">carcinoma</span>."		354.0	354_MESH:D016190_MESH:D002277	354_1	bcv_final_eval_easy_2013		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"METHODS: The combination of <span class=""chemical"">carboplatin</span> (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and <span class=""disease"">toxicity</span> profile."		354.0	354_MESH:D016190_MESH:D064420	354_2	bcv_final_eval_easy_2014		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D002294	"<span class=""disease"">squamous cell cervical carcinoma</span>"	"METHODS: The combination of <span class=""chemical"">carboplatin</span> (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent <span class=""disease"">squamous cell cervical carcinoma</span> to determine antitumor activity and toxicity profile."		354.0	354_MESH:D016190_MESH:D002294	354_2	bcv_final_eval_easy_2015		
	MESH:D004317	"<span class=""chemical"">doxorubicin/Doxil</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">Doxil</span>; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and <span class=""disease"">toxicity</span> profile."		354.0	354_MESH:D004317_MESH:D064420	354_2	bcv_final_eval_easy_2016		
	MESH:D004317	"<span class=""chemical"">doxorubicin/Doxil</span>"	MESH:D002294	"<span class=""disease"">squamous cell cervical carcinoma</span>"	"METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">Doxil</span>; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent <span class=""disease"">squamous cell cervical carcinoma</span> to determine antitumor activity and toxicity profile."		354.0	354_MESH:D004317_MESH:D002294	354_2	bcv_final_eval_easy_2017		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D002277	"<span class=""disease"">carcinoma</span>"	"CONCLUSIONS: The combination of carboplatin and liposomal <span class=""chemical"">doxorubicin</span> has modest activity in patients with recurrent cervical <span class=""disease"">carcinoma</span>."		354.0	354_MESH:D004317_MESH:D002277	354_8	bcv_final_eval_easy_2018		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D002277	"<span class=""disease"">carcinoma</span>"	"CONCLUSIONS: The combination of <span class=""chemical"">carboplatin</span> and liposomal doxorubicin has modest activity in patients with recurrent cervical <span class=""disease"">carcinoma</span>."		354.0	354_MESH:D016190_MESH:D002277	354_8	bcv_final_eval_easy_2019		
	MESH:D004917	"<span class=""chemical"">erythromycin</span>"	MESH:D001714	"<span class=""disease"">manic</span>"	"Cotrimoxazole, metronidazole, and <span class=""chemical"">erythromycin</span> were involved in 15 reported <span class=""disease"">manic</span> episodes."		355.0	355_MESH:D004917_MESH:D001714	355_7	bcv_final_eval_easy_2020		
	MESH:D015662	"<span class=""chemical"">Cotrimoxazole</span>"	MESH:D001714	"<span class=""disease"">manic</span>"	"<span class=""chemical"">Cotrimoxazole</span>, metronidazole, and erythromycin were involved in 15 reported <span class=""disease"">manic</span> episodes."		355.0	355_MESH:D015662_MESH:D001714	355_7	bcv_final_eval_easy_2021		
	MESH:D008795	"<span class=""chemical"">metronidazole</span>"	MESH:D001714	"<span class=""disease"">manic</span>"	"Cotrimoxazole, <span class=""chemical"">metronidazole</span>, and erythromycin were involved in 15 reported <span class=""disease"">manic</span> episodes."		355.0	355_MESH:D008795_MESH:D001714	355_7	bcv_final_eval_easy_2022		
	MESH:D017291	"<span class=""chemical"">clarithromycin</span>"	MESH:D001714	"<span class=""disease"">mania</span>"	"Cases reported by the FDA showed <span class=""chemical"">clarithromycin</span> and ciprofloxacin to be the most frequently associated with the development of <span class=""disease"">mania</span>."		355.0	355_MESH:D017291_MESH:D001714	355_8	bcv_final_eval_easy_2023		
	MESH:D002939	"<span class=""chemical"">ciprofloxacin</span>"	MESH:D001714	"<span class=""disease"">mania</span>"	"Cases reported by the FDA showed clarithromycin and <span class=""chemical"">ciprofloxacin</span> to be the most frequently associated with the development of <span class=""disease"">mania</span>."		355.0	355_MESH:D002939_MESH:D001714	355_8	bcv_final_eval_easy_2024		
	MESH:D007980	"<span class=""chemical"">Levodopa</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Levodopa</span>-induced ocular dyskinesias in <span class=""disease"">Parkinson's disease</span>."		356.0	356_MESH:D007980_MESH:D010300	356_0	bcv_final_eval_easy_2025		
	MESH:D004008	"<span class=""chemical"">diclofenac</span>"	MESH:D004412	"<span class=""disease"">primary dysmenorrhea</span>"	"A comparison of glyceryl trinitrate with <span class=""chemical"">diclofenac</span> for the treatment of <span class=""disease"">primary dysmenorrhea</span>: an open, randomized, cross-over trial."		357.0	357_MESH:D004008_MESH:D004412	357_0	bcv_final_eval_easy_2026		
	MESH:D005996	"<span class=""chemical"">glyceryl trinitrate</span>"	MESH:D004412	"<span class=""disease"">primary dysmenorrhea</span>"	"A comparison of <span class=""chemical"">glyceryl trinitrate</span> with diclofenac for the treatment of <span class=""disease"">primary dysmenorrhea</span>: an open, randomized, cross-over trial."		357.0	357_MESH:D005996_MESH:D004412	357_0	bcv_final_eval_easy_2027		
	MESH:D011453	"<span class=""chemical"">prostaglandins</span>"	MESH:D004412	"<span class=""disease"">dysmenorrhea</span>"	"Primary <span class=""disease"">dysmenorrhea</span> is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial <span class=""chemical"">prostaglandins</span>; non-steroidal anti-inflammatory drugs are the first choice for its treatment."		357.0	357_MESH:D011453_MESH:D004412	357_1	bcv_final_eval_easy_2028		
	MESH:D004008	"<span class=""chemical"">DCF/diclofenac</span>"	MESH:D004412	"<span class=""disease"">primary dysmenorrhea</span>"	"The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of <span class=""disease"">primary dysmenorrhea</span> in comparison with <span class=""chemical"">diclofenac</span> (<span class=""chemical"">DCF</span>)."		357.0	357_MESH:D004008_MESH:D004412	357_3	bcv_final_eval_easy_2029		
	MESH:D005996	"<span class=""chemical"">glyceryl trinitrate/GTN</span>"	MESH:D004412	"<span class=""disease"">primary dysmenorrhea</span>"	"The aim of the present study was to determine the efficacy of <span class=""chemical"">glyceryl trinitrate</span> (<span class=""chemical"">GTN</span>), an NO donor, in the resolution of <span class=""disease"">primary dysmenorrhea</span> in comparison with diclofenac (DCF)."		357.0	357_MESH:D005996_MESH:D004412	357_3	bcv_final_eval_easy_2030		
	MESH:D004008	"<span class=""chemical"">DCF</span>"	MESH:D017699	"<span class=""disease"">pelvic pain</span>"	"However, <span class=""chemical"">DCF</span> continued to be effective in reducing <span class=""disease"">pelvic pain</span> for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/- 17.9; DFC, -18.9 +/- 16.6 and after two hours: GTN, -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001)."		357.0	357_MESH:D004008_MESH:D017699	357_11	bcv_final_eval_easy_2031		
	MESH:D005996	"<span class=""chemical"">GTN</span>"	MESH:D017699	"<span class=""disease"">pelvic pain</span>"	"However, DCF continued to be effective in reducing <span class=""disease"">pelvic pain</span> for two hours, whereas <span class=""chemical"">GTN</span> scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: <span class=""chemical"">GTN</span>, -12.8 +/- 17.9; DFC, -18.9 +/- 16.6 and after two hours: <span class=""chemical"">GTN</span>, -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001)."		357.0	357_MESH:D005996_MESH:D017699	357_11	bcv_final_eval_easy_2032		
	MESH:D005996	"<span class=""chemical"">GTN</span>"	MESH:D006261	"<span class=""disease"">headache</span>"	"Eight patients stopped using <span class=""chemical"">GTN</span> because <span class=""disease"">headache</span>--attributed to its use--became intolerable."		357.0	357_MESH:D005996_MESH:D006261	357_14	bcv_final_eval_easy_2033		
	MESH:D004008	"<span class=""chemical"">DCF</span>"	MESH:D004412	"<span class=""disease"">primary dysmenorrhea</span>"	"These findings indicate that GTN has a reduced efficacy and tolerability by comparison with <span class=""chemical"">DCF</span> in the treatment of <span class=""disease"">primary dysmenorrhea</span>."		357.0	357_MESH:D004008_MESH:D004412	357_15	bcv_final_eval_easy_2034		
	MESH:D005996	"<span class=""chemical"">GTN</span>"	MESH:D004412	"<span class=""disease"">primary dysmenorrhea</span>"	"These findings indicate that <span class=""chemical"">GTN</span> has a reduced efficacy and tolerability by comparison with DCF in the treatment of <span class=""disease"">primary dysmenorrhea</span>."		357.0	357_MESH:D005996_MESH:D004412	357_15	bcv_final_eval_easy_2035		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside</span>"	MESH:D007674	"<span class=""disease"">glomerular injury</span>"	"Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates <span class=""disease"">glomerular injury</span> in chronic <span class=""chemical"">puromycin aminonucleoside</span> nephrosis."		358.0	358_MESH:D011692_MESH:D007674	358_0	bcv_final_eval_easy_2036		
	MESH:C055603	"<span class=""chemical"">Temocapril</span>"	MESH:D009401	"<span class=""disease"">nephrosis</span>"	"<span class=""chemical"">Temocapril</span>, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside <span class=""disease"">nephrosis</span>."		358.0	358_MESH:C055603_MESH:D009401	358_0	bcv_final_eval_easy_2037		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside</span>"	MESH:D009401	"<span class=""disease"">nephrosis</span>"	"Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic <span class=""chemical"">puromycin aminonucleoside</span> <span class=""disease"">nephrosis</span>."		358.0	358_MESH:D011692_MESH:D009401	358_0	bcv_final_eval_easy_2038		
	MESH:C055603	"<span class=""chemical"">Temocapril</span>"	MESH:D007674	"<span class=""disease"">glomerular injury</span>"	"<span class=""chemical"">Temocapril</span>, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates <span class=""disease"">glomerular injury</span> in chronic puromycin aminonucleoside nephrosis."		358.0	358_MESH:C055603_MESH:D007674	358_0	bcv_final_eval_easy_2039		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside/PAN</span>"	MESH:D007674	"<span class=""disease"">glomerular hypertrophy</span>"	"The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited <span class=""disease"">glomerular hypertrophy</span> and prevented glomerulosclerosis in chronic <span class=""chemical"">puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>) - induced nephrotic rats."		358.0	358_MESH:D011692_MESH:D007674	358_1	bcv_final_eval_easy_2040		
	MESH:C055603	"<span class=""chemical"">temocapril</span>"	MESH:D009404	"<span class=""disease"">nephrotic</span>"	"The purpose of the present study was to determine whether chronic administration of <span class=""chemical"">temocapril</span>, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced <span class=""disease"">nephrotic</span> rats."		358.0	358_MESH:C055603_MESH:D009404	358_1	bcv_final_eval_easy_2041		
	MESH:C055603	"<span class=""chemical"">temocapril</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"The purpose of the present study was to determine whether chronic administration of <span class=""chemical"">temocapril</span>, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced <span class=""disease"">proteinuria</span>, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats."		358.0	358_MESH:C055603_MESH:D011507	358_1	bcv_final_eval_easy_2042		
	MESH:C055603	"<span class=""chemical"">temocapril</span>"	MESH:D007674	"<span class=""disease"">glomerular hypertrophy</span>"	"The purpose of the present study was to determine whether chronic administration of <span class=""chemical"">temocapril</span>, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited <span class=""disease"">glomerular hypertrophy</span> and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats."		358.0	358_MESH:C055603_MESH:D007674	358_1	bcv_final_eval_easy_2043		
	MESH:C055603	"<span class=""chemical"">temocapril</span>"	MESH:D005921	"<span class=""disease"">glomerulosclerosis</span>"	"The purpose of the present study was to determine whether chronic administration of <span class=""chemical"">temocapril</span>, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented <span class=""disease"">glomerulosclerosis</span> in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats."		358.0	358_MESH:C055603_MESH:D005921	358_1	bcv_final_eval_easy_2044		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside/PAN</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced <span class=""disease"">proteinuria</span>, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic <span class=""chemical"">puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>) - induced nephrotic rats."		358.0	358_MESH:D011692_MESH:D011507	358_1	bcv_final_eval_easy_2045		
	MESH:D011692	"<span class=""chemical"">puromycin aminonucleoside/PAN</span>"	MESH:D005921	"<span class=""disease"">glomerulosclerosis</span>"	"The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented <span class=""disease"">glomerulosclerosis</span> in chronic <span class=""chemical"">puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>) - induced nephrotic rats."		358.0	358_MESH:D011692_MESH:D005921	358_1	bcv_final_eval_easy_2046		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D009401	"<span class=""disease"">Nephrosis</span>"	"<span class=""disease"">Nephrosis</span> was induced by injection of <span class=""chemical"">PAN</span> (15mg/100g body weight) in male Sprague-Dawley (SD) rats."		358.0	358_MESH:D011692_MESH:D009401	358_2	bcv_final_eval_easy_2047		
	MESH:C055603	"<span class=""chemical"">Temocapril</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"<span class=""chemical"">Temocapril</span> did not attenuate <span class=""disease"">proteinuria</span> at 8 days, but it did markedly lower it from weeks 4 to 20."		358.0	358_MESH:C055603_MESH:D011507	358_8	bcv_final_eval_easy_2048		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D005921	"<span class=""disease"">glomerulosclerosis</span>"	"The <span class=""disease"">glomerulosclerosis</span> index (GSI) was 6.21 % at 4 weeks and respectively 25.35 % and 30.49 % at 14 and 20 weeks in the <span class=""chemical"">PAN</span> group."		358.0	358_MESH:D011692_MESH:D005921	358_9	bcv_final_eval_easy_2049		
	MESH:D011692	"<span class=""chemical"">PAN</span>"	MESH:D007674	"<span class=""disease"">retarding renal progression</span>"	"It appears that temocapril was effective in <span class=""disease"">retarding renal progression</span> and protected renal function in <span class=""chemical"">PAN</span> neprotic rats."		358.0	358_MESH:D011692_MESH:D007674	358_12	bcv_final_eval_easy_2050		
	MESH:C055603	"<span class=""chemical"">temocapril</span>"	MESH:D007674	"<span class=""disease"">retarding renal progression</span>"	"It appears that <span class=""chemical"">temocapril</span> was effective in <span class=""disease"">retarding renal progression</span> and protected renal function in PAN neprotic rats."		358.0	358_MESH:C055603_MESH:D007674	358_12	bcv_final_eval_easy_2051		
	MESH:D007052	"<span class=""chemical"">ibuprofen</span>"	MESH:D006976	"<span class=""disease"">Pulmonary hypertension</span>"	"<span class=""disease"">Pulmonary hypertension</span> after <span class=""chemical"">ibuprofen</span> prophylaxis in very preterm infants."		359.0	359_MESH:D007052_MESH:D006976	359_0	bcv_final_eval_easy_2052		
	MESH:D007052	"<span class=""chemical"">ibuprofen</span>"	MESH:D004374	"<span class=""disease"">patent ductus arteriosus</span>"	"We report three cases of severe hypoxaemia after <span class=""chemical"">ibuprofen</span> administration during a randomised controlled trial of prophylactic treatment of <span class=""disease"">patent ductus arteriosus</span> with <span class=""chemical"">ibuprofen</span> in premature infants born at less than 28 weeks of gestation."		359.0	359_MESH:D007052_MESH:D004374	359_1	bcv_final_eval_easy_2053		
	MESH:D014750	"<span class=""chemical"">Vincristine</span>"	MESH:D007010	"<span class=""disease"">Hyponatremia</span>"	"<span class=""disease"">Hyponatremia</span> and syndrome of inappropriate anti-diuretic hormone reported with the use of <span class=""chemical"">Vincristine</span>: an over-representation of Asians?"		360.0	360_MESH:D014750_MESH:D007010	360_0	bcv_final_eval_easy_2054		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007010	"<span class=""disease"">hyponatremia</span>"	"PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of <span class=""disease"">hyponatremia</span> and/or syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) among <span class=""chemical"">vincristine</span>-treated patients and to explore the possibility of at-risk population subgroups."		360.0	360_MESH:D014750_MESH:D007010	360_1	bcv_final_eval_easy_2055		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007177	"<span class=""disease"">SIADH/secretion of anti-diuretic hormone</span>"	"PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate <span class=""disease"">secretion of anti-diuretic hormone</span> (<span class=""disease"">SIADH</span>) among <span class=""chemical"">vincristine</span>-treated patients and to explore the possibility of at-risk population subgroups."		360.0	360_MESH:D014750_MESH:D007177	360_1	bcv_final_eval_easy_2056		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007010	"<span class=""disease"">hyponatremia</span>"	"METHOD: We searched the Eli Lilly and Company's computerized adverse event database for all reported cases of <span class=""disease"">hyponatremia</span> and/or SIADH as of 1 November 1999 that had been reported during the use of <span class=""chemical"">vincristine</span>."		360.0	360_MESH:D014750_MESH:D007010	360_2	bcv_final_eval_easy_2057		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007177	"<span class=""disease"">SIADH</span>"	"METHOD: We searched the Eli Lilly and Company's computerized adverse event database for all reported cases of hyponatremia and/or <span class=""disease"">SIADH</span> as of 1 November 1999 that had been reported during the use of <span class=""chemical"">vincristine</span>."		360.0	360_MESH:D014750_MESH:D007177	360_2	bcv_final_eval_easy_2058		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007010	"<span class=""disease"">hyponatremia</span>"	"RESULTS: A total of 76 cases of <span class=""disease"">hyponatremia</span> and/or SIADH associated with <span class=""chemical"">vincristine</span> use were identified."		360.0	360_MESH:D014750_MESH:D007010	360_3	bcv_final_eval_easy_2059		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007177	"<span class=""disease"">SIADH</span>"	"RESULTS: A total of 76 cases of hyponatremia and/or <span class=""disease"">SIADH</span> associated with <span class=""chemical"">vincristine</span> use were identified."		360.0	360_MESH:D014750_MESH:D007177	360_3	bcv_final_eval_easy_2060		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007010	"<span class=""disease"">hyponatremia</span>"	"CONCLUSION: Our data suggest that Asian patients may be at increased risk of <span class=""disease"">hyponatremia</span> and/or SIADH associated with <span class=""chemical"">vincristine</span> use."		360.0	360_MESH:D014750_MESH:D007010	360_8	bcv_final_eval_easy_2061		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007177	"<span class=""disease"">SIADH</span>"	"CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or <span class=""disease"">SIADH</span> associated with <span class=""chemical"">vincristine</span> use."		360.0	360_MESH:D014750_MESH:D007177	360_8	bcv_final_eval_easy_2062		
	MESH:D014750	"<span class=""chemical"">vincristine</span>"	MESH:D007177	"<span class=""disease"">SIADH</span>"	"Although the overall reported rate of <span class=""disease"">SIADH</span> associated with <span class=""chemical"">vincristine</span> is very low, physicians caring for Asian oncology patients should be aware of this potential serious but reversible adverse event."		360.0	360_MESH:D014750_MESH:D007177	360_9	bcv_final_eval_easy_2063		
	MESH:D003520	"<span class=""chemical"">cyclophosphamide</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Delayed <span class=""disease"">toxicity</span> of <span class=""chemical"">cyclophosphamide</span> on the bladder of DBA/2 and C57BL/6 female mouse."		361.0	361_MESH:D003520_MESH:D064420	361_0	bcv_final_eval_easy_2064		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D013274	"<span class=""disease"">gastric cancer</span>"	"High-dose <span class=""chemical"">5-fluorouracil</span> / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced <span class=""disease"">gastric cancer</span>. A phase II study."		362.0	362_MESH:D005472_MESH:D013274	362_0	bcv_final_eval_easy_2065		
	MESH:D002955	"<span class=""chemical"">folinic acid</span>"	MESH:D013274	"<span class=""disease"">gastric cancer</span>"	"High-dose 5-fluorouracil / <span class=""chemical"">folinic acid</span> in combination with three-weekly mitomycin C in the treatment of advanced <span class=""disease"">gastric cancer</span>. A phase II study."		362.0	362_MESH:D002955_MESH:D013274	362_0	bcv_final_eval_easy_2066		
	MESH:D016685	"<span class=""chemical"">mitomycin C</span>"	MESH:D013274	"<span class=""disease"">gastric cancer</span>"	"High-dose 5-fluorouracil / folinic acid in combination with three-weekly <span class=""chemical"">mitomycin C</span> in the treatment of advanced <span class=""disease"">gastric cancer</span>. A phase II study."		362.0	362_MESH:D016685_MESH:D013274	362_0	bcv_final_eval_easy_2067		
	MESH:D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	MESH:D013274	"<span class=""disease"">gastric cancer</span>"	"BACKGROUND: The 24-hour continuous infusion of <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced <span class=""disease"">gastric cancer</span> (AGC) has shown to be effective, with low toxicity."		362.0	362_MESH:D005472_MESH:D013274	362_1	bcv_final_eval_easy_2068		
	MESH:D002955	"<span class=""chemical"">folinic acid</span>"	MESH:D013274	"<span class=""disease"">gastric cancer</span>"	"BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and <span class=""chemical"">folinic acid</span> (FA) as part of several new multidrug chemotherapy regimens in advanced <span class=""disease"">gastric cancer</span> (AGC) has shown to be effective, with low toxicity."		362.0	362_MESH:D002955_MESH:D013274	362_1	bcv_final_eval_easy_2069		
	MESH:D002955	"<span class=""chemical"">folinic acid</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and <span class=""chemical"">folinic acid</span> (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low <span class=""disease"">toxicity</span>."		362.0	362_MESH:D002955_MESH:D064420	362_1	bcv_final_eval_easy_2070		
	MESH:D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: The 24-hour continuous infusion of <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low <span class=""disease"">toxicity</span>."		362.0	362_MESH:D005472_MESH:D064420	362_1	bcv_final_eval_easy_2071		
	MESH:D016685	"<span class=""chemical"">MMC/mitomycin C</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"In a previous phase II study with 3-weekly bolus 5-FU, FA and <span class=""chemical"">mitomycin C</span> (<span class=""chemical"">MMC</span>) we found a low <span class=""disease"">toxicity</span> rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival."		362.0	362_MESH:D016685_MESH:D064420	362_2	bcv_final_eval_easy_2072		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"In a previous phase II study with 3-weekly bolus <span class=""chemical"">5-FU</span>, FA and mitomycin C (MMC) we found a low <span class=""disease"">toxicity</span> rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival."		362.0	362_MESH:D005472_MESH:D064420	362_2	bcv_final_eval_easy_2073		
	MESH:D002945	"<span class=""chemical"">cisplatin</span>"	MESH:D006463	"<span class=""disease"">HUS</span>"	"It may serve as an alternative to <span class=""chemical"">cisplatin</span>-containing regimens; however, it has to be considered that possibly <span class=""disease"">HUS</span> may occur."		362.0	362_MESH:D002945_MESH:D006463	362_15	bcv_final_eval_easy_2074		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D007153	"<span class=""disease"">immunodeficiency</span>"	"Persistent sterile leukocyturia is associated with impaired renal function in human <span class=""disease"">immunodeficiency</span> virus type 1-infected children treated with <span class=""chemical"">indinavir</span>."		363.0	363_MESH:D019469_MESH:D007153	363_0	bcv_final_eval_easy_2075		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D051437	"<span class=""disease"">impaired renal function</span>"	"Persistent sterile leukocyturia is associated with <span class=""disease"">impaired renal function</span> in human immunodeficiency virus type 1-infected children treated with <span class=""chemical"">indinavir</span>."		363.0	363_MESH:D019469_MESH:D051437	363_0	bcv_final_eval_easy_2076		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D007674	"<span class=""disease"">renal complications</span>"	"BACKGROUND: Prolonged administration of <span class=""chemical"">indinavir</span> is associated with the occurrence of a variety of <span class=""disease"">renal complications</span> in adults."		363.0	363_MESH:D019469_MESH:D007674	363_1	bcv_final_eval_easy_2077		
	MESH:D019469	"<span class=""chemical"">indinavir</span>"	MESH:D007153	"<span class=""disease"">immunodeficiency</span>"	"DESIGN: A prospective study to monitor <span class=""chemical"">indinavir</span>-related nephrotoxicity in a cohort of 30 human <span class=""disease"">immunodeficiency</span> virus type 1-infected children treated with <span class=""chemical"">indinavir</span>."		363.0	363_MESH:D019469_MESH:D007153	363_3	bcv_final_eval_easy_2078		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D006417	"<span class=""disease"">hematuria</span>"	"Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/<span class=""chemical"">creatinine</span> ratio and by microscopic <span class=""disease"">hematuria</span>."		363.0	363_MESH:D003404_MESH:D006417	363_8	bcv_final_eval_easy_2079		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"Utility of troponin I in patients with <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span>."		364.0	364_MESH:D003042_MESH:D002637	364_0	bcv_final_eval_easy_2080		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction/MI</span>"	"Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of <span class=""disease"">myocardial infarction</span> (<span class=""disease"">MI</span>) difficult in patients with <span class=""chemical"">cocaine</span>-associated chest pain."		364.0	364_MESH:D003042_MESH:D009203	364_1	bcv_final_eval_easy_2081		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D009202	"<span class=""disease"">myocardial necrosis</span>"	"Baseline electrocardiogram abnormalities and market elevations not associated with <span class=""disease"">myocardial necrosis</span> make accurate diagnosis of myocardial infarction (MI) difficult in patients with <span class=""chemical"">cocaine</span>-associated chest pain."		364.0	364_MESH:D003042_MESH:D009202	364_1	bcv_final_eval_easy_2082		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span>."		364.0	364_MESH:D003042_MESH:D002637	364_1	bcv_final_eval_easy_2083		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D009203	"<span class=""disease"">MI</span>"	"OBJECTIVE: To assess outcomes based on troponin positivity in patients with <span class=""chemical"">cocaine</span> chest pain admitted for exclusion of <span class=""disease"">MI</span>."		364.0	364_MESH:D003042_MESH:D009203	364_3	bcv_final_eval_easy_2084		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"OBJECTIVE: To assess outcomes based on troponin positivity in patients with <span class=""chemical"">cocaine</span> <span class=""disease"">chest pain</span> admitted for exclusion of MI."		364.0	364_MESH:D003042_MESH:D002637	364_3	bcv_final_eval_easy_2085		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D009203	"<span class=""disease"">MI</span>"	"METHODS: Outcomes were examined in patients admitted for possible <span class=""disease"">MI</span> after <span class=""chemical"">cocaine</span> use."		364.0	364_MESH:D003042_MESH:D009203	364_4	bcv_final_eval_easy_2086		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D009203	"<span class=""disease"">MI</span>"	"Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing necrosis in patients with <span class=""chemical"">cocaine</span>-associated chest pain and suspected <span class=""disease"">MI</span>."		364.0	364_MESH:D003042_MESH:D009203	364_12	bcv_final_eval_easy_2087		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing necrosis in patients with <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span> and suspected MI."		364.0	364_MESH:D003042_MESH:D002637	364_12	bcv_final_eval_easy_2088		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing <span class=""disease"">necrosis</span> in patients with <span class=""chemical"">cocaine</span>-associated chest pain and suspected MI."		364.0	364_MESH:D003042_MESH:D009336	364_12	bcv_final_eval_easy_2089		
	MESH:D009530	"<span class=""chemical"">nicergoline</span>"	MESH:D009395	"<span class=""disease"">interstitial nephritis</span>"	"Acute <span class=""disease"">interstitial nephritis</span> due to <span class=""chemical"">nicergoline</span> (Sermion)."		365.0	365_MESH:D009530_MESH:D009395	365_0	bcv_final_eval_easy_2090		
	MESH:D009530	"<span class=""chemical"">nicergoline</span>"	MESH:D009395	"<span class=""disease"">AIN/acute interstitial nephritis</span>"	"We report a case of <span class=""disease"">acute interstitial nephritis</span> (<span class=""disease"">AIN</span>) due to <span class=""chemical"">nicergoline</span> (Sermion)."		365.0	365_MESH:D009530_MESH:D009395	365_1	bcv_final_eval_easy_2091		
	MESH:D009530	"<span class=""chemical"">nicergoline</span>"	MESH:D012170	"<span class=""disease"">retinal vein occlusion</span>"	"Before admission, he had been taking <span class=""chemical"">nicergoline</span> and bendazac lysine due to <span class=""disease"">retinal vein occlusion</span> at ophthalmologic department."		365.0	365_MESH:D009530_MESH:D012170	365_3	bcv_final_eval_easy_2092		
	MESH:D009530	"<span class=""chemical"">nicergoline</span>"	MESH:D009395	"<span class=""disease"">AIN</span>"	"To our knowledge, this is the first report of <span class=""chemical"">nicergoline</span>-associated <span class=""disease"">AIN</span>."		365.0	365_MESH:D009530_MESH:D009395	365_8	bcv_final_eval_easy_2093		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D007676	"<span class=""disease"">chronic renal failure/CRF</span>"	"A patient with <span class=""disease"">chronic renal failure</span> (<span class=""disease"">CRF</span>) developed neuroleptic malignant syndrome (NMS) after administration of <span class=""chemical"">risperidone</span> and levomepromazine."		366.0	366_MESH:D018967_MESH:D007676	366_1	bcv_final_eval_easy_2094		
	MESH:D008728	"<span class=""chemical"">levomepromazine</span>"	MESH:D007676	"<span class=""disease"">chronic renal failure/CRF</span>"	"A patient with <span class=""disease"">chronic renal failure</span> (<span class=""disease"">CRF</span>) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and <span class=""chemical"">levomepromazine</span>."		366.0	366_MESH:D008728_MESH:D007676	366_1	bcv_final_eval_easy_2095		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D009459	"<span class=""disease"">NMS/neuroleptic malignant syndrome</span>"	"A patient with chronic renal failure (CRF) developed <span class=""disease"">neuroleptic malignant syndrome</span> (<span class=""disease"">NMS</span>) after administration of <span class=""chemical"">risperidone</span> and levomepromazine."		366.0	366_MESH:D018967_MESH:D009459	366_1	bcv_final_eval_easy_2096		
	MESH:D008728	"<span class=""chemical"">levomepromazine</span>"	MESH:D009459	"<span class=""disease"">NMS/neuroleptic malignant syndrome</span>"	"A patient with chronic renal failure (CRF) developed <span class=""disease"">neuroleptic malignant syndrome</span> (<span class=""disease"">NMS</span>) after administration of risperidone and <span class=""chemical"">levomepromazine</span>."		366.0	366_MESH:D008728_MESH:D009459	366_1	bcv_final_eval_easy_2097		
	MESH:C009591	"<span class=""chemical"">triphenyltetrazolium</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Adrenaline-induced <span class=""disease"">hypertension</span> was used to destroy the BBB, which was evaluated using <span class=""chemical"">triphenyltetrazolium</span> (TTC) staining of the brain slices just after giving adrenaline for 30 s."		367.0	367_MESH:C009591_MESH:D006973	367_3	bcv_final_eval_easy_2098		
	MESH:C043211	"<span class=""chemical"">Carvedilol</span>"	MESH:D009202	"<span class=""disease"">mitochondrial cardiomyopathy</span>"	"<span class=""chemical"">Carvedilol</span> protects against doxorubicin-induced <span class=""disease"">mitochondrial cardiomyopathy</span>."		368.0	368_MESH:C043211_MESH:D009202	368_0	bcv_final_eval_easy_2099		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic <span class=""chemical"">doxorubicin</span> <span class=""disease"">toxicity</span>."		368.0	368_MESH:D004317_MESH:D064420	368_3	bcv_final_eval_easy_2100		
	MESH:C043211	"<span class=""chemical"">carvedilol</span>"	MESH:D006331	"<span class=""disease"">cardiac and hepatic mitochondrial bioenergetic dysfunction</span>"	"The objective of this investigation was to test the hypothesis that <span class=""chemical"">carvedilol</span>, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the <span class=""disease"">cardiac and hepatic mitochondrial bioenergetic dysfunction</span> associated with subchronic doxorubicin toxicity."		368.0	368_MESH:C043211_MESH:D006331	368_3	bcv_final_eval_easy_2101		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D006331	"<span class=""disease"">cardiac and hepatic mitochondrial bioenergetic dysfunction</span>"	"The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the <span class=""disease"">cardiac and hepatic mitochondrial bioenergetic dysfunction</span> associated with subchronic <span class=""chemical"">doxorubicin</span> toxicity."		368.0	368_MESH:D004317_MESH:D006331	368_3	bcv_final_eval_easy_2102		
	MESH:C043211	"<span class=""chemical"">carvedilol</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"The objective of this investigation was to test the hypothesis that <span class=""chemical"">carvedilol</span>, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin <span class=""disease"">toxicity</span>."		368.0	368_MESH:C043211_MESH:D064420	368_3	bcv_final_eval_easy_2103		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D008107	"<span class=""disease"">liver mitochondria</span>"	"Heart and <span class=""disease"">liver mitochondria</span> were isolated from rats treated for 7 weeks with <span class=""chemical"">doxorubicin</span> (2 mg/kg sc/week), carvedilol (1 mg/kg ip/week), or the combination of the two drugs."		368.0	368_MESH:D004317_MESH:D008107	368_4	bcv_final_eval_easy_2104		
	MESH:C043211	"<span class=""chemical"">carvedilol</span>"	MESH:D008107	"<span class=""disease"">liver mitochondria</span>"	"Heart and <span class=""disease"">liver mitochondria</span> were isolated from rats treated for 7 weeks with doxorubicin (2 mg/kg sc/week), <span class=""chemical"">carvedilol</span> (1 mg/kg ip/week), or the combination of the two drugs."		368.0	368_MESH:C043211_MESH:D008107	368_4	bcv_final_eval_easy_2105		
	MESH:D004317	"<span class=""chemical"">Doxorubicin</span>"	MESH:D008107	"<span class=""disease"">liver mitochondria</span>"	"<span class=""chemical"">Doxorubicin</span> treatment also caused a decrease in RCR for <span class=""disease"">liver mitochondria</span> (3.9 +/- 0.9 versus 5.6 +/- 0.7 for control rats) and inhibition of hepatic cytochrome oxidase activity."		368.0	368_MESH:D004317_MESH:D008107	368_7	bcv_final_eval_easy_2106		
	MESH:C043211	"<span class=""chemical"">Carvedilol</span>"	MESH:D006331	"<span class=""disease"">heart mitochondria</span>"	"<span class=""chemical"">Carvedilol</span> also prevented the decrease in mitochondrial Ca(2+) loading capacity and the inhibition of the respiratory complexes of <span class=""disease"">heart mitochondria</span> caused by doxorubicin."		368.0	368_MESH:C043211_MESH:D006331	368_9	bcv_final_eval_easy_2107		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D006331	"<span class=""disease"">heart mitochondria</span>"	"Carvedilol also prevented the decrease in mitochondrial Ca(2+) loading capacity and the inhibition of the respiratory complexes of <span class=""disease"">heart mitochondria</span> caused by <span class=""chemical"">doxorubicin</span>."		368.0	368_MESH:D004317_MESH:D006331	368_9	bcv_final_eval_easy_2108		
	MESH:C043211	"<span class=""chemical"">Carvedilol</span>"	MESH:D008107	"<span class=""disease"">liver mitochondria</span>"	"<span class=""chemical"">Carvedilol</span> by itself did not affect any of the parameters measured for heart or <span class=""disease"">liver mitochondria</span>."		368.0	368_MESH:C043211_MESH:D008107	368_10	bcv_final_eval_easy_2109		
	MESH:C043211	"<span class=""chemical"">carvedilol</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"It is concluded that this protection by <span class=""chemical"">carvedilol</span> against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in <span class=""disease"">cancer</span> patients."		368.0	368_MESH:C043211_MESH:D009369	368_11	bcv_final_eval_easy_2110		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D028361	"<span class=""disease"">mitochondrial dysfunction</span>"	"It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting <span class=""disease"">mitochondrial dysfunction</span> and cardiomyopathy that accompanies long-term <span class=""chemical"">doxorubicin</span> therapy in cancer patients."		368.0	368_MESH:D004317_MESH:D028361	368_11	bcv_final_eval_easy_2111		
	MESH:C043211	"<span class=""chemical"">carvedilol</span>"	MESH:D028361	"<span class=""disease"">mitochondrial dysfunction</span>"	"It is concluded that this protection by <span class=""chemical"">carvedilol</span> against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting <span class=""disease"">mitochondrial dysfunction</span> and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients."		368.0	368_MESH:C043211_MESH:D028361	368_11	bcv_final_eval_easy_2112		
	MESH:C043211	"<span class=""chemical"">carvedilol</span>"	MESH:D009202	"<span class=""disease"">cardiomyopathy</span>"	"It is concluded that this protection by <span class=""chemical"">carvedilol</span> against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and <span class=""disease"">cardiomyopathy</span> that accompanies long-term doxorubicin therapy in cancer patients."		368.0	368_MESH:C043211_MESH:D009202	368_11	bcv_final_eval_easy_2113		
	MESH:D004317	"<span class=""chemical"">doxorubicin</span>"	MESH:D009369	"<span class=""disease"">cancer</span>"	"It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term <span class=""chemical"">doxorubicin</span> therapy in <span class=""disease"">cancer</span> patients."		368.0	368_MESH:D004317_MESH:D009369	368_11	bcv_final_eval_easy_2114		
	MESH:D000241	"<span class=""chemical"">adenosine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"Cocaine-induced <span class=""disease"">hyperactivity</span> is more influenced by <span class=""chemical"">adenosine</span> receptor agonists than amphetamine-induced <span class=""disease"">hyperactivity</span>."		369.0	369_MESH:D000241_MESH:D006948	369_0	bcv_final_eval_easy_2115		
	MESH:D000241	"<span class=""chemical"">adenosine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"The influence of <span class=""chemical"">adenosine</span> receptor agonists and antagonists on cocaine-and amphetamine-induced <span class=""disease"">hyperactivity</span> was examined in mice."		369.0	369_MESH:D000241_MESH:D006948	369_1	bcv_final_eval_easy_2116		
	MESH:D000241	"<span class=""chemical"">adenosine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"Similarly, all <span class=""chemical"">adenosine</span> receptor agonists decreased amphetamine-induced <span class=""disease"">hyperactivity</span>, but at the higher doses than those which were active in cocaine-induced <span class=""disease"">hyperactivity</span>."		369.0	369_MESH:D000241_MESH:D006948	369_10	bcv_final_eval_easy_2117		
	MESH:D000241	"<span class=""chemical"">adenosine</span>"	MESH:D006948	"<span class=""disease"">hyperactivity</span>"	"Our results have shown that all <span class=""chemical"">adenosine</span> receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced <span class=""disease"">hyperactivity</span> is more influenced by <span class=""chemical"">adenosine</span> receptor agonists (particularly A1 receptors) than amphetamine-induced <span class=""disease"">hyperactivity</span>."		369.0	369_MESH:D000241_MESH:D006948	369_12	bcv_final_eval_easy_2118		
	MESH:D000638	"<span class=""chemical"">Amiodarone</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"<span class=""chemical"">Amiodarone</span> and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior <span class=""disease"">myocardial infarction</span>."		370.0	370_MESH:D000638_MESH:D009203	370_0	bcv_final_eval_easy_2119		
	MESH:D000638	"<span class=""chemical"">Amiodarone</span>"	MESH:D001919	"<span class=""disease"">bradyarrhythmia</span>"	"<span class=""chemical"">Amiodarone</span> and the risk of <span class=""disease"">bradyarrhythmia</span> requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction."		370.0	370_MESH:D000638_MESH:D001919	370_0	bcv_final_eval_easy_2120		
	MESH:D000638	"<span class=""chemical"">Amiodarone</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"<span class=""chemical"">Amiodarone</span> and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with <span class=""disease"">atrial fibrillation</span> and prior myocardial infarction."		370.0	370_MESH:D000638_MESH:D001281	370_0	bcv_final_eval_easy_2121		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation/AF</span>"	"OBJECTIVES: The aim of this study was to determine whether the use of <span class=""chemical"">amiodarone</span> in patients with <span class=""disease"">atrial fibrillation</span> (<span class=""disease"">AF</span>) increases the risk of bradyarrhythmia requiring a permanent pacemaker."		370.0	370_MESH:D000638_MESH:D001281	370_1	bcv_final_eval_easy_2122		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D001919	"<span class=""disease"">bradyarrhythmia</span>"	"OBJECTIVES: The aim of this study was to determine whether the use of <span class=""chemical"">amiodarone</span> in patients with atrial fibrillation (AF) increases the risk of <span class=""disease"">bradyarrhythmia</span> requiring a permanent pacemaker."		370.0	370_MESH:D000638_MESH:D001919	370_1	bcv_final_eval_easy_2123		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D001919	"<span class=""disease"">bradyarrhythmia</span>"	"BACKGROUND: Reports of severe <span class=""disease"">bradyarrhythmia</span> during <span class=""chemical"">amiodarone</span> therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias."		370.0	370_MESH:D000638_MESH:D001919	370_2	bcv_final_eval_easy_2124		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D001145	"<span class=""disease"">ventricular arrhythmias</span>"	"BACKGROUND: Reports of severe bradyarrhythmia during <span class=""chemical"">amiodarone</span> therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with <span class=""disease"">ventricular arrhythmias</span>."		370.0	370_MESH:D000638_MESH:D001145	370_2	bcv_final_eval_easy_2125		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D009203	"<span class=""disease"">MI</span>"	"CONCLUSIONS: This study suggests that the use of <span class=""chemical"">amiodarone</span> in elderly patients with AF and a previous <span class=""disease"">MI</span> increases the risk of bradyarrhythmia requiring a permanent pacemaker."		370.0	370_MESH:D000638_MESH:D009203	370_9	bcv_final_eval_easy_2126		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D001281	"<span class=""disease"">AF</span>"	"CONCLUSIONS: This study suggests that the use of <span class=""chemical"">amiodarone</span> in elderly patients with <span class=""disease"">AF</span> and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker."		370.0	370_MESH:D000638_MESH:D001281	370_9	bcv_final_eval_easy_2127		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D001919	"<span class=""disease"">bradyarrhythmia</span>"	"CONCLUSIONS: This study suggests that the use of <span class=""chemical"">amiodarone</span> in elderly patients with AF and a previous MI increases the risk of <span class=""disease"">bradyarrhythmia</span> requiring a permanent pacemaker."		370.0	370_MESH:D000638_MESH:D001919	370_9	bcv_final_eval_easy_2128		
	MESH:D007213	"<span class=""chemical"">Indomethacin</span>"	MESH:D018856	"<span class=""disease"">interstitial cystitis</span>"	"CONCLUSIONS: <span class=""chemical"">Indomethacin</span> resulted in histopathologic findings typical of <span class=""disease"">interstitial cystitis</span>, such as leaky bladder epithelium and mucosal mastocytosis."		371.0	371_MESH:D007213_MESH:D018856	371_9	bcv_final_eval_easy_2129		
	MESH:D007213	"<span class=""chemical"">Indomethacin</span>"	MESH:D008415	"<span class=""disease"">mucosal mastocytosis</span>"	"CONCLUSIONS: <span class=""chemical"">Indomethacin</span> resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and <span class=""disease"">mucosal mastocytosis</span>."		371.0	371_MESH:D007213_MESH:D008415	371_9	bcv_final_eval_easy_2130		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D011471	"<span class=""disease"">prostate cancer</span>"	"An open-label phase II study of low-dose <span class=""chemical"">thalidomide</span> in androgen-independent <span class=""disease"">prostate cancer</span>."		372.0	372_MESH:D013792_MESH:D011471	372_0	bcv_final_eval_easy_2131		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D009369	"<span class=""disease"">malignancies</span>"	"The antiangiogenic effects of <span class=""chemical"">thalidomide</span> have been assessed in clinical trials in patients with various solid and haematological <span class=""disease"">malignancies</span>."		372.0	372_MESH:D013792_MESH:D009369	372_1	bcv_final_eval_easy_2132		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D011471	"<span class=""disease"">prostate cancer</span>"	"We undertook an open-label study using <span class=""chemical"">thalidomide</span> 100 mg once daily for up to 6 months in 20 men with androgen-independent <span class=""disease"">prostate cancer</span>."		372.0	372_MESH:D013792_MESH:D011471	372_3	bcv_final_eval_easy_2133		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D010523	"<span class=""disease"">peripheral neuropathy</span>"	"In the seven men who completed six months on <span class=""chemical"">thalidomide</span>, subclinical evidence of <span class=""disease"">peripheral neuropathy</span> was found in four before treatment, but in all seven at repeat testing."		372.0	372_MESH:D013792_MESH:D010523	372_11	bcv_final_eval_easy_2134		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D010523	"<span class=""disease"">peripheral neuropathy</span>"	"The findings indicate that <span class=""chemical"">thalidomide</span> may be an option for patients who have failed other forms of therapy, provided close follow-up is maintained for development of <span class=""disease"">peripheral neuropathy</span>."		372.0	372_MESH:D013792_MESH:D010523	372_12	bcv_final_eval_easy_2135		
	MESH:C476513	"<span class=""chemical"">levobupivacaine</span>"	MESH:D002493	"<span class=""disease"">Central nervous system toxicity</span>"	"<span class=""disease"">Central nervous system toxicity</span> following the administration of <span class=""chemical"">levobupivacaine</span> for lumbar plexus block: A report of two cases."		373.0	373_MESH:C476513_MESH:D002493	373_0	bcv_final_eval_easy_2136		
	MESH:C476513	"<span class=""chemical"">levobupivacaine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"We describe 2 cases of grand mal <span class=""disease"">seizures</span> following accidental intravascular injection of <span class=""chemical"">levobupivacaine</span>."		373.0	373_MESH:C476513_MESH:D012640	373_3	bcv_final_eval_easy_2137		
	MESH:C476513	"<span class=""chemical"">levobupivacaine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Immediately after the administration of <span class=""chemical"">levobupivacaine</span> 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal <span class=""disease"">seizures</span>, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration."		373.0	373_MESH:C476513_MESH:D012640	373_5	bcv_final_eval_easy_2138		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Immediately after the administration of levobupivacaine 0.5% with <span class=""chemical"">epinephrine</span> 2.5 microgram/mL, the patients developed grand mal <span class=""disease"">seizures</span>, despite negative aspiration for blood and no clinical signs of intravenous <span class=""chemical"">epinephrine</span> administration."		373.0	373_MESH:D004837_MESH:D012640	373_5	bcv_final_eval_easy_2139		
	MESH:D013390	"<span class=""chemical"">succinylcholine</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"The <span class=""disease"">seizures</span> were successfully treated with sodium thiopental in addition to <span class=""chemical"">succinylcholine</span> in 1 patient."		373.0	373_MESH:D013390_MESH:D012640	373_6	bcv_final_eval_easy_2140		
	MESH:C476513	"<span class=""chemical"">levobupivacaine</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"CONCLUSIONS: Although <span class=""chemical"">levobupivacaine</span> may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of <span class=""chemical"">levobupivacaine</span> reach the circulation, it will result in <span class=""disease"">convulsions</span>."		373.0	373_MESH:C476513_MESH:D012640	373_9	bcv_final_eval_easy_2141		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D066126	"<span class=""disease"">cardiac toxicity</span>"	"CONCLUSIONS: Although levobupivacaine may have a safer <span class=""disease"">cardiac toxicity</span> profile than racemic <span class=""chemical"">bupivacaine</span>, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions."		373.0	373_MESH:D002045_MESH:D066126	373_9	bcv_final_eval_easy_2142		
	MESH:C476513	"<span class=""chemical"">levobupivacaine</span>"	MESH:D066126	"<span class=""disease"">cardiac toxicity</span>"	"CONCLUSIONS: Although <span class=""chemical"">levobupivacaine</span> may have a safer <span class=""disease"">cardiac toxicity</span> profile than racemic bupivacaine, if adequate amounts of <span class=""chemical"">levobupivacaine</span> reach the circulation, it will result in convulsions."		373.0	373_MESH:C476513_MESH:D066126	373_9	bcv_final_eval_easy_2143		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic <span class=""chemical"">bupivacaine</span>, if adequate amounts of levobupivacaine reach the circulation, it will result in <span class=""disease"">convulsions</span>."		373.0	373_MESH:D002045_MESH:D012640	373_9	bcv_final_eval_easy_2144		
	MESH:D013390	"<span class=""chemical"">suxamethonium</span>"	MESH:D013035	"<span class=""disease"">spasm</span>"	"We describe a previously healthy 32-year-old woman who developed a life-threatening muscle <span class=""disease"">spasm</span> and secondary ventilation difficulties following a preoperative injection of <span class=""chemical"">suxamethonium</span>."		374.0	374_MESH:D013390_MESH:D013035	374_2	bcv_final_eval_easy_2145		
	MESH:D000082	"<span class=""chemical"">paracetamol</span>"	MESH:D017114	"<span class=""disease"">acute liver failure</span>"	"Increased serum soluble Fas in patients with <span class=""disease"">acute liver failure</span> due to <span class=""chemical"">paracetamol</span> overdose."		376.0	376_MESH:D000082_MESH:D017114	376_0	bcv_final_eval_easy_2146		
	MESH:D000082	"<span class=""chemical"">paracetamol</span>"	MESH:D062787	"<span class=""disease"">overdose</span>"	"Increased serum soluble Fas in patients with acute liver failure due to <span class=""chemical"">paracetamol</span> <span class=""disease"">overdose</span>."		376.0	376_MESH:D000082_MESH:D062787	376_0	bcv_final_eval_easy_2147		
	MESH:D000082	"<span class=""chemical"">paracetamol</span>"	MESH:D056486	"<span class=""disease"">hepatitis</span>"	"Levels were significantly greater in patients with acute liver failure due to <span class=""chemical"">paracetamol</span> overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E <span class=""disease"">hepatitis</span> (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01)."		376.0	376_MESH:D000082_MESH:D056486	376_6	bcv_final_eval_easy_2148		
	MESH:D000082	"<span class=""chemical"">paracetamol</span>"	MESH:D017114	"<span class=""disease"">acute liver failure</span>"	"Levels were significantly greater in patients with <span class=""disease"">acute liver failure</span> due to <span class=""chemical"">paracetamol</span> overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01)."		376.0	376_MESH:D000082_MESH:D017114	376_6	bcv_final_eval_easy_2149		
	MESH:D000082	"<span class=""chemical"">paracetamol</span>"	MESH:D062787	"<span class=""disease"">overdose</span>"	"Levels were significantly greater in patients with acute liver failure due to <span class=""chemical"">paracetamol</span> <span class=""disease"">overdose</span> (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01)."		376.0	376_MESH:D000082_MESH:D062787	376_6	bcv_final_eval_easy_2150		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D018476	"<span class=""disease"">bradykinesia</span>"	"METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly <span class=""disease"">bradykinesia</span>, rigidity, and <span class=""chemical"">levodopa</span>-induced dyskinesias underwent bilateral implantation of electrodes in the STN."		377.0	377_MESH:D007980_MESH:D018476	377_3	bcv_final_eval_easy_2151		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D009127	"<span class=""disease"">rigidity</span>"	"METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, <span class=""disease"">rigidity</span>, and <span class=""chemical"">levodopa</span>-induced dyskinesias underwent bilateral implantation of electrodes in the STN."		377.0	377_MESH:D007980_MESH:D009127	377_3	bcv_final_eval_easy_2152		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"METHOD: Twenty-three patients suffering from severe <span class=""disease"">Parkinson's disease</span> (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and <span class=""chemical"">levodopa</span>-induced dyskinesias underwent bilateral implantation of electrodes in the STN."		377.0	377_MESH:D007980_MESH:D010300	377_3	bcv_final_eval_easy_2153		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D012175	"<span class=""disease"">retinoblastoma</span>"	"Ocular motility changes after subtenon <span class=""chemical"">carboplatin</span> chemotherapy for <span class=""disease"">retinoblastoma</span>."		378.0	378_MESH:D016190_MESH:D012175	378_0	bcv_final_eval_easy_2154		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: Focal subtenon <span class=""chemical"">carboplatin</span> injections have recently been used as a presumably <span class=""disease"">toxicity</span>-free adjunct to systemic chemotherapy for intraocular retinoblastoma."		378.0	378_MESH:D016190_MESH:D064420	378_1	bcv_final_eval_easy_2155		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D012175	"<span class=""disease"">intraocular retinoblastoma</span>"	"BACKGROUND: Focal subtenon <span class=""chemical"">carboplatin</span> injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for <span class=""disease"">intraocular retinoblastoma</span>."		378.0	378_MESH:D016190_MESH:D012175	378_1	bcv_final_eval_easy_2156		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D015835	"<span class=""disease"">abnormal ocular motility</span>"	"METHODS: We noted <span class=""disease"">abnormal ocular motility</span> in 10 consecutive patients with retinoblastoma who had received subtenon <span class=""chemical"">carboplatin</span>."		378.0	378_MESH:D016190_MESH:D015835	378_3	bcv_final_eval_easy_2157		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D012175	"<span class=""disease"">retinoblastoma</span>"	"METHODS: We noted abnormal ocular motility in 10 consecutive patients with <span class=""disease"">retinoblastoma</span> who had received subtenon <span class=""chemical"">carboplatin</span>."		378.0	378_MESH:D016190_MESH:D012175	378_3	bcv_final_eval_easy_2158		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D012175	"<span class=""disease"">intraocular retinoblastoma</span>"	"RESULTS: Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for <span class=""disease"">intraocular retinoblastoma</span> with 1 to 6 injections of subtenon <span class=""chemical"">carboplatin</span> as part of multimodality therapy."		378.0	378_MESH:D016190_MESH:D012175	378_6	bcv_final_eval_easy_2159		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"CONCLUSIONS: Subtenon <span class=""chemical"">carboplatin</span> chemotherapy is associated with significant <span class=""disease"">fibrosis</span> of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult."		378.0	378_MESH:D016190_MESH:D005355	378_9	bcv_final_eval_easy_2160		
	MESH:D016190	"<span class=""chemical"">carboplatin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Subtenon <span class=""chemical"">carboplatin</span> is not free of <span class=""disease"">toxicity</span>, and its use is best restricted to specific indications."		378.0	378_MESH:D016190_MESH:D064420	378_10	bcv_final_eval_easy_2161		
	MESH:D004977	"<span class=""chemical"">Ethambutol</span>"	MESH:D009901	"<span class=""disease"">optic neuropathy</span>"	"<span class=""chemical"">Ethambutol</span> and <span class=""disease"">optic neuropathy</span>."		379.0	379_MESH:D004977_MESH:D009901	379_0	bcv_final_eval_easy_2162		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D009901	"<span class=""disease"">optic neuropathy</span>"	"PURPOSE: To demonstrate the association between <span class=""chemical"">ethambutol</span> and <span class=""disease"">optic neuropathy</span>."		379.0	379_MESH:D004977_MESH:D009901	379_1	bcv_final_eval_easy_2163		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D014376	"<span class=""disease"">tuberculosis</span>"	"METHOD: Thirteen patients who developed optic neuropathy after being treated with <span class=""chemical"">ethambutol</span> for <span class=""disease"">tuberculosis</span> of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed."		379.0	379_MESH:D004977_MESH:D014376	379_2	bcv_final_eval_easy_2164		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D009901	"<span class=""disease"">optic neuropathy</span>"	"METHOD: Thirteen patients who developed <span class=""disease"">optic neuropathy</span> after being treated with <span class=""chemical"">ethambutol</span> for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed."		379.0	379_MESH:D004977_MESH:D009901	379_2	bcv_final_eval_easy_2165		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D009901	"<span class=""disease"">optic neuropathy</span>"	"RESULTS: All patients had <span class=""disease"">optic neuropathy</span> between 1 to 6 months (mean = 2.9 months) after starting <span class=""chemical"">ethambutol</span> therapy at a dosage ranging from 13 to 20 mg/kg/day (mean = 17 mg/kg/day)."		379.0	379_MESH:D004977_MESH:D009901	379_4	bcv_final_eval_easy_2166		
	MESH:D004977	"<span class=""chemical"">ethambutol</span>"	MESH:D009901	"<span class=""disease"">optic neuropathy</span>"	"CONCLUSION: Early recognition of <span class=""disease"">optic neuropathy</span> should be considered in patients with <span class=""chemical"">ethambutol</span> therapy."		379.0	379_MESH:D004977_MESH:D009901	379_7	bcv_final_eval_easy_2167		
	MESH:D006024	"<span class=""chemical"">glycopyrrolate</span>"	MESH:D013547	"<span class=""disease"">gustatory hyperhidrosis</span>"	"Treatment of compensatory <span class=""disease"">gustatory hyperhidrosis</span> with topical <span class=""chemical"">glycopyrrolate</span>."		380.0	380_MESH:D006024_MESH:D013547	380_0	bcv_final_eval_easy_2168		
	MESH:D006024	"<span class=""chemical"">glycopyrrolate</span>"	MESH:D014987	"<span class=""disease"">dry mouth</span>"	"Adverse effects included a mildly <span class=""disease"">dry mouth</span> and a sore throat in 2 patients (2% <span class=""chemical"">glycopyrrolate</span>), a light headache in 1 patient (1.5% <span class=""chemical"">glycopyrrolate</span>)."		380.0	380_MESH:D006024_MESH:D014987	380_7	bcv_final_eval_easy_2169		
	MESH:D006024	"<span class=""chemical"">glycopyrrolate</span>"	MESH:D006261	"<span class=""disease"">headache</span>"	"Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% <span class=""chemical"">glycopyrrolate</span>), a light <span class=""disease"">headache</span> in 1 patient (1.5% <span class=""chemical"">glycopyrrolate</span>)."		380.0	380_MESH:D006024_MESH:D006261	380_7	bcv_final_eval_easy_2170		
	MESH:D006024	"<span class=""chemical"">glycopyrrolate</span>"	MESH:D013547	"<span class=""disease"">gustatory hyperhidrosis</span>"	"The topical application of a <span class=""chemical"">glycopyrrolate</span> pad appeared to be safe, efficacious, well tolerated, and a convenient method of treatment for moderate to severe symptoms of <span class=""disease"">gustatory hyperhidrosis</span> in post transthoracic endoscopic sympathectomy or sympathicotomy patients, with few side effects."		380.0	380_MESH:D006024_MESH:D013547	380_8	bcv_final_eval_easy_2171		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D054080	"<span class=""disease"">galenic</span>"	"Pharmacological characteristics and side effects of a new <span class=""disease"">galenic</span> formulation of <span class=""chemical"">propofol</span> without soyabean oil."		381.0	381_MESH:D015742_MESH:D054080	381_0	bcv_final_eval_easy_2172		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D054080	"<span class=""disease"">galenic</span>"	"We compared the pharmacokinetics, pharmacodynamics and safety profile of a new <span class=""disease"">galenic</span> formulation of <span class=""chemical"">propofol</span> (AM149 1%), which does not contain soyabean oil, with a standard formulation of <span class=""chemical"">propofol</span> (Disoprivan 1%)."		381.0	381_MESH:D015742_MESH:D054080	381_1	bcv_final_eval_easy_2173		
	MESH:D015742	"<span class=""chemical"">Disoprivan</span>"	MESH:D010146	"<span class=""disease"">Pain</span>"	"<span class=""disease"">Pain</span> on injection (80 vs. 20%, p < 0.01) and thrombophlebitis (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with <span class=""chemical"">Disoprivan</span>."		381.0	381_MESH:D015742_MESH:D010146	381_9	bcv_final_eval_easy_2174		
	MESH:D015742	"<span class=""chemical"">Disoprivan</span>"	MESH:D013924	"<span class=""disease"">thrombophlebitis</span>"	"Pain on injection (80 vs. 20%, p < 0.01) and <span class=""disease"">thrombophlebitis</span> (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with <span class=""chemical"">Disoprivan</span>."		381.0	381_MESH:D015742_MESH:D013924	381_9	bcv_final_eval_easy_2175		
	MESH:C030852	"<span class=""chemical"">Vinorelbine</span>"	MESH:D006331	"<span class=""disease"">cardiac events</span>"	"<span class=""chemical"">Vinorelbine</span>-related <span class=""disease"">cardiac events</span>: a meta-analysis of randomized clinical trials."		382.0	382_MESH:C030852_MESH:D006331	382_0	bcv_final_eval_easy_2176		
	MESH:D014751	"<span class=""chemical"">vindesine</span>"	MESH:D006331	"<span class=""disease"">cardiac events</span>"	"The risk of VNR <span class=""disease"">cardiac events</span> was similar to <span class=""chemical"">vindesine</span> (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]."		382.0	382_MESH:D014751_MESH:D006331	382_8	bcv_final_eval_easy_2177		
	MESH:C056507	"<span class=""chemical"">GEM/gemcitabine</span>"	MESH:D006331	"<span class=""disease"">cardiac events</span>"	"The risk of VNR <span class=""disease"">cardiac events</span> was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, <span class=""chemical"">gemcitabine</span> (<span class=""chemical"">GEM</span>) em leader ]."		382.0	382_MESH:C056507_MESH:D006331	382_8	bcv_final_eval_easy_2178		
	MESH:D005472	"<span class=""chemical"">fluorouracil</span>"	MESH:D006331	"<span class=""disease"">cardiac events</span>"	"The risk of VNR <span class=""disease"">cardiac events</span> was similar to vindesine (VDS) and other cardiotoxic drugs [<span class=""chemical"">fluorouracil</span>, anthracyclines, gemcitabine (GEM) em leader ]."		382.0	382_MESH:D005472_MESH:D006331	382_8	bcv_final_eval_easy_2179		
	MESH:D014751	"<span class=""chemical"">vindesine</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"The risk of VNR cardiac events was similar to <span class=""chemical"">vindesine</span> (VDS) and other <span class=""disease"">cardiotoxic</span> drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]."		382.0	382_MESH:D014751_MESH:D066126	382_8	bcv_final_eval_easy_2180		
	MESH:C056507	"<span class=""chemical"">GEM/gemcitabine</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"The risk of VNR cardiac events was similar to vindesine (VDS) and other <span class=""disease"">cardiotoxic</span> drugs [fluorouracil, anthracyclines, <span class=""chemical"">gemcitabine</span> (<span class=""chemical"">GEM</span>) em leader ]."		382.0	382_MESH:C056507_MESH:D066126	382_8	bcv_final_eval_easy_2181		
	MESH:D005472	"<span class=""chemical"">fluorouracil</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"The risk of VNR cardiac events was similar to vindesine (VDS) and other <span class=""disease"">cardiotoxic</span> drugs [<span class=""chemical"">fluorouracil</span>, anthracyclines, gemcitabine (GEM) em leader ]."		382.0	382_MESH:D005472_MESH:D066126	382_8	bcv_final_eval_easy_2182		
	MESH:D018943	"<span class=""chemical"">anthracyclines</span>"	MESH:D066126	"<span class=""disease"">cardiotoxic</span>"	"The risk of VNR cardiac events was similar to vindesine (VDS) and other <span class=""disease"">cardiotoxic</span> drugs [fluorouracil, <span class=""chemical"">anthracyclines</span>, gemcitabine (GEM) em leader ]."		382.0	382_MESH:D018943_MESH:D066126	382_8	bcv_final_eval_easy_2183		
	MESH:D018943	"<span class=""chemical"">anthracyclines</span>"	MESH:D006331	"<span class=""disease"">cardiac events</span>"	"The risk of VNR <span class=""disease"">cardiac events</span> was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, <span class=""chemical"">anthracyclines</span>, gemcitabine (GEM) em leader ]."		382.0	382_MESH:D018943_MESH:D006331	382_8	bcv_final_eval_easy_2184		
	MESH:C030852	"<span class=""chemical"">Vinorelbine</span>"	MESH:D006331	"<span class=""disease"">cardiac events</span>"	"<span class=""chemical"">Vinorelbine</span>-related <span class=""disease"">cardiac events</span> concern about 1% of treated patients in clinical trials."		382.0	382_MESH:C030852_MESH:D006331	382_10	bcv_final_eval_easy_2185		
	MESH:D014295	"<span class=""chemical"">trimethoprim</span>"	MESH:D000743	"<span class=""disease"">hemolytic anemia</span>"	"We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing <span class=""disease"">hemolytic anemia</span> crisis induced by <span class=""chemical"">trimethoprim</span>-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage."		383.0	383_MESH:D014295_MESH:D000743	383_1	bcv_final_eval_easy_2186		
	MESH:D014295	"<span class=""chemical"">trimethoprim</span>"	MESH:D002534	"<span class=""disease"">cerebral anoxia</span>"	"We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by <span class=""chemical"">trimethoprim</span>-sulfomethoxazole, resulting in <span class=""disease"">cerebral anoxia</span> leading to permanent damage."		383.0	383_MESH:D014295_MESH:D002534	383_1	bcv_final_eval_easy_2187		
	MESH:D020888	"<span class=""chemical"">Vigabatrin</span>"	MESH:D014786	"<span class=""disease"">visual field defects</span>"	"The natural history of <span class=""chemical"">Vigabatrin</span> associated <span class=""disease"">visual field defects</span> in patients electing to continue their medication."		384.0	384_MESH:D020888_MESH:D014786	384_0	bcv_final_eval_easy_2188		
	MESH:D020888	"<span class=""chemical"">Vigabatrin</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"PURPOSE: To determine the natural history of visual field defects in a group of patients known to have <span class=""chemical"">Vigabatrin</span>-associated changes who elected to continue the medication because of good <span class=""disease"">seizure</span> control."		384.0	384_MESH:D020888_MESH:D012640	384_1	bcv_final_eval_easy_2189		
	MESH:D020888	"<span class=""chemical"">Vigabatrin</span>"	MESH:D014786	"<span class=""disease"">visual field defects</span>"	"PURPOSE: To determine the natural history of <span class=""disease"">visual field defects</span> in a group of patients known to have <span class=""chemical"">Vigabatrin</span>-associated changes who elected to continue the medication because of good seizure control."		384.0	384_MESH:D020888_MESH:D014786	384_1	bcv_final_eval_easy_2190		
	MESH:D020888	"<span class=""chemical"">Vigabatrin</span>"	MESH:D014786	"<span class=""disease"">visual field defects</span>"	"CONCLUSION: Established <span class=""disease"">visual field defects</span> presumed to be due to <span class=""chemical"">Vigabatrin</span> therapy did not usually progress in spite of continuing use of the medication."		384.0	384_MESH:D020888_MESH:D014786	384_8	bcv_final_eval_easy_2191		
	MESH:D020888	"<span class=""chemical"">Vigabatrin</span>"	MESH:D014786	"<span class=""disease"">visual field defects</span>"	"These data give support to the hypothesis that the pathogenesis of <span class=""chemical"">Vigabatrin</span>-associated <span class=""disease"">visual field defects</span> may be an idiosyncratic adverse drug reaction rather than dose-dependent toxicity."		384.0	384_MESH:D020888_MESH:D014786	384_9	bcv_final_eval_easy_2192		
	MESH:D020888	"<span class=""chemical"">Vigabatrin</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"These data give support to the hypothesis that the pathogenesis of <span class=""chemical"">Vigabatrin</span>-associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent <span class=""disease"">toxicity</span>."		384.0	384_MESH:D020888_MESH:D064420	384_9	bcv_final_eval_easy_2193		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D003872	"<span class=""disease"">dermatitis</span>"	"Induction of rosaceiform <span class=""disease"">dermatitis</span> during treatment of facial inflammatory dermatoses with <span class=""chemical"">tacrolimus</span> ointment."		385.0	385_MESH:D016559_MESH:D003872	385_0	bcv_final_eval_easy_2194		
	MESH:D013256	"<span class=""chemical"">steroid</span>"	MESH:D012393	"<span class=""disease"">rosacea</span>"	"BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in <span class=""chemical"">steroid</span>-aggravated <span class=""disease"">rosacea</span> and perioral dermatitis."		385.0	385_MESH:D013256_MESH:D012393	385_1	bcv_final_eval_easy_2195		
	MESH:D013256	"<span class=""chemical"">steroid</span>"	MESH:D003872	"<span class=""disease"">dermatitis</span>"	"BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in <span class=""chemical"">steroid</span>-aggravated rosacea and perioral <span class=""disease"">dermatitis</span>."		385.0	385_MESH:D013256_MESH:D003872	385_1	bcv_final_eval_easy_2196		
	MESH:D016559	"<span class=""chemical"">Tacrolimus</span>"	MESH:D012393	"<span class=""disease"">rosacea</span>"	"BACKGROUND: <span class=""chemical"">Tacrolimus</span> ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated <span class=""disease"">rosacea</span> and perioral dermatitis."		385.0	385_MESH:D016559_MESH:D012393	385_1	bcv_final_eval_easy_2197		
	MESH:D016559	"<span class=""chemical"">Tacrolimus</span>"	MESH:D003872	"<span class=""disease"">dermatitis</span>"	"BACKGROUND: <span class=""chemical"">Tacrolimus</span> ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral <span class=""disease"">dermatitis</span>."		385.0	385_MESH:D016559_MESH:D003872	385_1	bcv_final_eval_easy_2198		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D003872	"<span class=""disease"">dermatitis</span>"	"We report on rosaceiform <span class=""disease"">dermatitis</span> as a complication of treatment with <span class=""chemical"">tacrolimus</span> ointment."		385.0	385_MESH:D016559_MESH:D003872	385_2	bcv_final_eval_easy_2199		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D005148	"<span class=""disease"">facial dermatoses</span>"	"OBSERVATIONS: Six adult patients with inflammatory <span class=""disease"">facial dermatoses</span> were treated with <span class=""chemical"">tacrolimus</span> ointment because of the ineffectiveness of standard treatments."		385.0	385_MESH:D016559_MESH:D005148	385_3	bcv_final_eval_easy_2200		
	MESH:D016559	"<span class=""chemical"">tacrolimus</span>"	MESH:D003872	"<span class=""disease"">dermatitis</span>"	"CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform <span class=""disease"">dermatitis</span> as a complication of treatment with <span class=""chemical"">tacrolimus</span> ointment is heterogeneous."		385.0	385_MESH:D016559_MESH:D003872	385_8	bcv_final_eval_easy_2201		
	MESH:D008694	"<span class=""chemical"">methamphetamine</span>"	MESH:D028361	"<span class=""disease"">Structural abnormalities</span>"	"<span class=""disease"">Structural abnormalities</span> in the brains of human subjects who use <span class=""chemical"">methamphetamine</span>."		386.0	386_MESH:D008694_MESH:D028361	386_0	bcv_final_eval_easy_2202		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D006529	"<span class=""disease"">hepatomegaly</span>"	"Amiodarone induced <span class=""disease"">hepatomegaly</span>, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and <span class=""chemical"">glucose</span>."		387.0	387_MESH:D005947_MESH:D006529	387_3	bcv_final_eval_easy_2203		
	MESH:D014280	"<span class=""chemical"">triglycerides</span>"	MESH:D006529	"<span class=""disease"">hepatomegaly</span>"	"Amiodarone induced <span class=""disease"">hepatomegaly</span>, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum <span class=""chemical"">triglycerides</span> and glucose."		387.0	387_MESH:D014280_MESH:D006529	387_3	bcv_final_eval_easy_2204		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D015431	"<span class=""disease"">weight loss</span>"	"Compared to wild-type mice, treatment of PPARalpha-/- mice with <span class=""chemical"">amiodarone</span> resulted in an increased rate and extent of total body <span class=""disease"">weight loss</span>."		387.0	387_MESH:D000638_MESH:D015431	387_7	bcv_final_eval_easy_2205		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D006528	"<span class=""disease"">hepatoma</span>"	"The inability of <span class=""chemical"">amiodarone</span> to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 <span class=""disease"">hepatoma</span> cells indicates that the effects of <span class=""chemical"">amiodarone</span> on the function of this receptor were indirect."		387.0	387_MESH:D000638_MESH:D006528	387_8	bcv_final_eval_easy_2206		
	MESH:D009525	"<span class=""chemical"">Niacin</span>"	MESH:D050171	"<span class=""disease"">dyslipidemia</span>"	"<span class=""chemical"">Niacin</span> extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed <span class=""disease"">dyslipidemia</span>."		388.0	388_MESH:D009525_MESH:D050171	388_1	bcv_final_eval_easy_2207		
	MESH:D008148	"<span class=""chemical"">lovastatin</span>"	MESH:D050171	"<span class=""disease"">dyslipidemia</span>"	"Niacin extended-release/<span class=""chemical"">lovastatin</span> is a new combination product approved for treatment of primary hypercholesterolemia and mixed <span class=""disease"">dyslipidemia</span>."		388.0	388_MESH:D008148_MESH:D050171	388_1	bcv_final_eval_easy_2208		
	MESH:D009525	"<span class=""chemical"">Niacin</span>"	MESH:D006937	"<span class=""disease"">hypercholesterolemia</span>"	"<span class=""chemical"">Niacin</span> extended-release/lovastatin is a new combination product approved for treatment of primary <span class=""disease"">hypercholesterolemia</span> and mixed dyslipidemia."		388.0	388_MESH:D009525_MESH:D006937	388_1	bcv_final_eval_easy_2209		
	MESH:D008148	"<span class=""chemical"">lovastatin</span>"	MESH:D006937	"<span class=""disease"">hypercholesterolemia</span>"	"Niacin extended-release/<span class=""chemical"">lovastatin</span> is a new combination product approved for treatment of primary <span class=""disease"">hypercholesterolemia</span> and mixed dyslipidemia."		388.0	388_MESH:D008148_MESH:D006937	388_1	bcv_final_eval_easy_2210		
	MESH:D009525	"<span class=""chemical"">niacin</span>"	MESH:D050171	"<span class=""disease"">dyslipidemia</span>"	"Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about <span class=""disease"">dyslipidemia</span> and <span class=""chemical"">niacin</span> extended-release/lovastatin."		388.0	388_MESH:D009525_MESH:D050171	388_5	bcv_final_eval_easy_2211		
	MESH:D008148	"<span class=""chemical"">lovastatin</span>"	MESH:D050171	"<span class=""disease"">dyslipidemia</span>"	"Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about <span class=""disease"">dyslipidemia</span> and niacin extended-release/<span class=""chemical"">lovastatin</span>."		388.0	388_MESH:D008148_MESH:D050171	388_5	bcv_final_eval_easy_2212		
	MESH:D003401	"<span class=""chemical"">creatine</span>"	MESH:D009135	"<span class=""disease"">drug-induced myopathy</span>"	"An increase of <span class=""chemical"">creatine</span> phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of <span class=""disease"">drug-induced myopathy</span> were observed."		388.0	388_MESH:D003401_MESH:D009135	388_12	bcv_final_eval_easy_2213		
	MESH:D007545	"<span class=""chemical"">isoproterenol</span>"	MESH:D009202	"<span class=""disease"">myocardial injury</span>"	"Protective effect of Terminalia chebula against experimental <span class=""disease"">myocardial injury</span> induced by <span class=""chemical"">isoproterenol</span>."		389.0	389_MESH:D007545_MESH:D009202	389_0	bcv_final_eval_easy_2214		
	MESH:D007545	"<span class=""chemical"">isoproterenol</span>"	MESH:D009202	"<span class=""disease"">myocardial damage</span>"	"Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in <span class=""chemical"">isoproterenol</span> (200 mg/kg body wt) induced <span class=""disease"">myocardial damage</span> in rats."		389.0	389_MESH:D007545_MESH:D009202	389_1	bcv_final_eval_easy_2215		
	MESH:D004329	"<span class=""chemical"">droperidol</span>"	MESH:D019106	"<span class=""disease"">postoperative anxiety</span>"	"A case of <span class=""disease"">postoperative anxiety</span> due to low dose <span class=""chemical"">droperidol</span> used with patient-controlled analgesia."		390.0	390_MESH:D004329_MESH:D019106	390_0	bcv_final_eval_easy_2216		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D059606	"<span class=""disease"">polydipsia</span>"	"The nursing staff, by reviewing the patient's health history with his family, discovered a history of <span class=""disease"">polydipsia</span> and long-standing <span class=""chemical"">lithium</span> use."		391.0	391_MESH:D008094_MESH:D059606	391_3	bcv_final_eval_easy_2217		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D001930	"<span class=""disease"">brain trauma</span>"	"By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his <span class=""chemical"">lithium</span>-induced nephrogenic DI and developed neurogenic DI secondary to <span class=""disease"">brain trauma</span>."		391.0	391_MESH:D008094_MESH:D001930	391_5	bcv_final_eval_easy_2218		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D003919	"<span class=""disease"">DI</span>"	"By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his <span class=""chemical"">lithium</span>-induced nephrogenic DI and developed neurogenic <span class=""disease"">DI</span> secondary to brain trauma."		391.0	391_MESH:D008094_MESH:D003919	391_5	bcv_final_eval_easy_2219		
	MESH:D012254	"<span class=""chemical"">ribavirin</span>"	MESH:D019698	"<span class=""disease"">chronic hepatitis C</span>"	"BACKGROUND AND AIM: Interferon and <span class=""chemical"">ribavirin</span> combination therapy for <span class=""disease"">chronic hepatitis C</span> produces hemolytic anemia."		392.0	392_MESH:D012254_MESH:D019698	392_1	bcv_final_eval_easy_2220		
	MESH:D012254	"<span class=""chemical"">ribavirin</span>"	MESH:D000743	"<span class=""disease"">hemolytic anemia</span>"	"BACKGROUND AND AIM: Interferon and <span class=""chemical"">ribavirin</span> combination therapy for chronic hepatitis C produces <span class=""disease"">hemolytic anemia</span>."		392.0	392_MESH:D012254_MESH:D000743	392_1	bcv_final_eval_easy_2221		
	MESH:D012254	"<span class=""chemical"">ribavirin</span>"	MESH:D019698	"<span class=""disease"">chronic hepatitis C</span>"	"METHODS: Eighty-eight patients with <span class=""disease"">chronic hepatitis C</span> who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with <span class=""chemical"">ribavirin</span> administered orally at a dose of 600 mg or 800 mg participated in the study."		392.0	392_MESH:D012254_MESH:D019698	392_3	bcv_final_eval_easy_2222		
	MESH:D010100	"<span class=""chemical"">oxygen</span>"	MESH:C535282	"<span class=""disease"">RNS</span>"	"The purpose of the present study was to determine if elevated reactive <span class=""chemical"">oxygen</span> (ROS)/nitrogen species (<span class=""disease"">RNS</span>) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach."		393.0	393_MESH:D010100_MESH:C535282	393_1	bcv_final_eval_easy_2223		
	MESH:D010100	"<span class=""chemical"">oxygen</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The purpose of the present study was to determine if elevated reactive <span class=""chemical"">oxygen</span> (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced <span class=""disease"">cardiotoxicity</span> actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach."		393.0	393_MESH:D010100_MESH:D066126	393_1	bcv_final_eval_easy_2224		
	MESH:D009584	"<span class=""chemical"">nitrogen</span>"	MESH:C535282	"<span class=""disease"">RNS</span>"	"The purpose of the present study was to determine if elevated reactive oxygen (ROS)/<span class=""chemical"">nitrogen</span> species (<span class=""disease"">RNS</span>) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach."		393.0	393_MESH:D009584_MESH:C535282	393_1	bcv_final_eval_easy_2225		
	MESH:D009584	"<span class=""chemical"">nitrogen</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The purpose of the present study was to determine if elevated reactive oxygen (ROS)/<span class=""chemical"">nitrogen</span> species (RNS) reported to be present in adriamycin (ADR)-induced <span class=""disease"">cardiotoxicity</span> actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach."		393.0	393_MESH:D009584_MESH:D066126	393_1	bcv_final_eval_easy_2226		
	MESH:D004317	"<span class=""chemical"">ADR/adriamycin</span>"	MESH:C535282	"<span class=""disease"">RNS</span>"	"The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (<span class=""disease"">RNS</span>) reported to be present in <span class=""chemical"">adriamycin</span> (<span class=""chemical"">ADR</span>)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach."		393.0	393_MESH:D004317_MESH:C535282	393_1	bcv_final_eval_easy_2227		
	MESH:C027576	"<span class=""chemical"">4-hydroxy-2-nonenal/4HNE</span>"	MESH:D009422	"<span class=""disease"">Ultrastructural damage</span>"	"<span class=""disease"">Ultrastructural damage</span> and levels of <span class=""chemical"">4-hydroxy-2-nonenal</span> (<span class=""chemical"">4HNE</span>)-protein adducts and 3-nitrotyrosine (3NT) were analyzed."		393.0	393_MESH:C027576_MESH:D009422	393_3	bcv_final_eval_easy_2228		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D028361	"<span class=""disease"">mitochondrial injury</span>"	"Our data showed <span class=""chemical"">ADR</span> induced 4HNE-protein adducts in mitochondria at the same time point as when <span class=""disease"">mitochondrial injury</span> initially appeared."		393.0	393_MESH:D004317_MESH:D028361	393_7	bcv_final_eval_easy_2229		
	MESH:D013015	"<span class=""chemical"">Sotalol</span>"	MESH:D002311	"<span class=""disease"">dilated cardiomyopathy</span>"	"<span class=""chemical"">Sotalol</span>-induced coronary spasm in a patient with <span class=""disease"">dilated cardiomyopathy</span> associated with sustained ventricular tachycardia."		394.0	394_MESH:D013015_MESH:D002311	394_0	bcv_final_eval_easy_2230		
	MESH:D013015	"<span class=""chemical"">Sotalol</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"<span class=""chemical"">Sotalol</span>-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained <span class=""disease"">ventricular tachycardia</span>."		394.0	394_MESH:D013015_MESH:D017180	394_0	bcv_final_eval_easy_2231		
	MESH:D013015	"<span class=""chemical"">sotalol</span>"	MESH:D017180	"<span class=""disease"">VT</span>"	"An alternate class III agent, <span class=""chemical"">sotalol</span>, was also effective for the prevention of <span class=""disease"">VT</span>."		394.0	394_MESH:D013015_MESH:D017180	394_3	bcv_final_eval_easy_2232		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on <span class=""disease"">catalepsy</span> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and <span class=""chemical"">fluoxetine</span>-induced penile erections was studied in rats."		395.0	395_MESH:D005473_MESH:D002375	395_4	bcv_final_eval_easy_2233		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on <span class=""disease"">catalepsy</span> induced by <span class=""chemical"">haloperidol</span> and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats."		395.0	395_MESH:D006220_MESH:D002375	395_4	bcv_final_eval_easy_2234		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and <span class=""chemical"">apomorphine</span>-induced oral stereotypies, on <span class=""disease"">catalepsy</span> induced by haloperidol and <span class=""chemical"">apomorphine</span> (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats."		395.0	395_MESH:D001058_MESH:D002375	395_4	bcv_final_eval_easy_2235		
	MESH:D003913	"<span class=""chemical"">dexamphetamine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"METHODS: The effect of pretreatment with trazodone on <span class=""chemical"">dexamphetamine</span>- and apomorphine-induced oral stereotypies, on <span class=""disease"">catalepsy</span> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats."		395.0	395_MESH:D003913_MESH:D002375	395_4	bcv_final_eval_easy_2236		
	MESH:D004874	"<span class=""chemical"">ergometrine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on <span class=""disease"">catalepsy</span> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on <span class=""chemical"">ergometrine</span>-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats."		395.0	395_MESH:D004874_MESH:D002375	395_4	bcv_final_eval_easy_2237		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce <span class=""disease"">catalepsy</span>, and did not antagonize <span class=""chemical"">apomorphine</span> (1.5 and 3 mg/kg) stereotypy and <span class=""chemical"">apomorphine</span> (0.05 mg/kg)-induced <span class=""disease"">catalepsy</span>."		395.0	395_MESH:D001058_MESH:D002375	395_6	bcv_final_eval_easy_2238		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol <span class=""disease"">catalepsy</span>, ergometrine-induced WDS behavior and <span class=""chemical"">fluoxetine</span>-induced penile erections."		395.0	395_MESH:D005473_MESH:D002375	395_7	bcv_final_eval_easy_2239		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized <span class=""chemical"">haloperidol</span> <span class=""disease"">catalepsy</span>, ergometrine-induced WDS behavior and fluoxetine-induced penile erections."		395.0	395_MESH:D006220_MESH:D002375	395_7	bcv_final_eval_easy_2240		
	MESH:D003913	"<span class=""chemical"">dexamphetamine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced <span class=""chemical"">dexamphetamine</span> stereotypy, and antagonized haloperidol <span class=""disease"">catalepsy</span>, ergometrine-induced WDS behavior and fluoxetine-induced penile erections."		395.0	395_MESH:D003913_MESH:D002375	395_7	bcv_final_eval_easy_2241		
	MESH:D004874	"<span class=""chemical"">ergometrine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol <span class=""disease"">catalepsy</span>, <span class=""chemical"">ergometrine</span>-induced WDS behavior and fluoxetine-induced penile erections."		395.0	395_MESH:D004874_MESH:D002375	395_7	bcv_final_eval_easy_2242		
	MESH:D001058	"<span class=""chemical"">apomorphine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Trazodone at 30, 40 and 50 mg/kg i.p. induced <span class=""disease"">catalepsy</span> and antagonized <span class=""chemical"">apomorphine</span> and dexamphetamine stereotypies."		395.0	395_MESH:D001058_MESH:D002375	395_8	bcv_final_eval_easy_2243		
	MESH:D003913	"<span class=""chemical"">dexamphetamine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"Trazodone at 30, 40 and 50 mg/kg i.p. induced <span class=""disease"">catalepsy</span> and antagonized apomorphine and <span class=""chemical"">dexamphetamine</span> stereotypies."		395.0	395_MESH:D003913_MESH:D002375	395_8	bcv_final_eval_easy_2244		
	MESH:D006220	"<span class=""chemical"">haloperidol</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes <span class=""chemical"">haloperidol</span> <span class=""disease"">catalepsy</span>."		395.0	395_MESH:D006220_MESH:D002375	395_11	bcv_final_eval_easy_2245		
	MESH:D003913	"<span class=""chemical"">dexamphetamine</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates <span class=""chemical"">dexamphetamine</span> stereotypy and antagonizes haloperidol <span class=""disease"">catalepsy</span>."		395.0	395_MESH:D003913_MESH:D002375	395_11	bcv_final_eval_easy_2246		
	MESH:D012701	"<span class=""chemical"">5-HT</span>"	MESH:D002375	"<span class=""disease"">catalepsy</span>"	"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by <span class=""chemical"">5-HT</span>, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol <span class=""disease"">catalepsy</span>."		395.0	395_MESH:D012701_MESH:D002375	395_11	bcv_final_eval_easy_2247		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">PD</span>"	"The aim of this study was to characterize the oropharyngeal dynamics in <span class=""disease"">PD</span> patients with and without <span class=""chemical"">levodopa</span>-induced dyskinesia."		396.0	396_MESH:D007980_MESH:D010300	396_2	bcv_final_eval_easy_2248		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D003680	"<span class=""disease"">dysphagia</span>"	"Our results suggest a role for <span class=""chemical"">levodopa</span> in the oral phase of deglutition and confirm that <span class=""disease"">dysphagia</span> is not a good predictor of deglutition alterations in PD."		396.0	396_MESH:D007980_MESH:D003680	396_11	bcv_final_eval_easy_2249		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">PD</span>"	"Our results suggest a role for <span class=""chemical"">levodopa</span> in the oral phase of deglutition and confirm that dysphagia is not a good predictor of deglutition alterations in <span class=""disease"">PD</span>."		396.0	396_MESH:D007980_MESH:D010300	396_11	bcv_final_eval_easy_2250		
	MESH:D005839	"<span class=""chemical"">gentamicin</span>"	MESH:D009395	"<span class=""disease"">tubulointerstitial nephritis</span>"	"Inhibition of nuclear factor-kappaB activation attenuates <span class=""disease"">tubulointerstitial nephritis</span> induced by <span class=""chemical"">gentamicin</span>."		397.0	397_MESH:D005839_MESH:D009395	397_0	bcv_final_eval_easy_2251		
	MESH:D005839	"<span class=""chemical"">gentamicin</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"BACKGROUND: Animals treated with <span class=""chemical"">gentamicin</span> can show residual areas of interstitial <span class=""disease"">fibrosis</span> in the renal cortex."		397.0	397_MESH:D005839_MESH:D005355	397_1	bcv_final_eval_easy_2252		
	MESH:D005839	"<span class=""chemical"">gentamicin</span>"	MESH:D009395	"<span class=""disease"">tubulointerstitial nephritis</span>"	"CONCLUSIONS: These data show that inhibition of NF-kappaB activation attenuates <span class=""disease"">tubulointerstitial nephritis</span> induced by <span class=""chemical"">gentamicin</span>."		397.0	397_MESH:D005839_MESH:D009395	397_11	bcv_final_eval_easy_2253		
	MESH:D005947	"<span class=""chemical"">Glucose</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"<span class=""chemical"">Glucose</span> metabolism in patients with <span class=""disease"">schizophrenia</span> treated with atypical antipsychotic agents: a frequently sampled intravenous <span class=""chemical"">glucose</span> tolerance test and minimal model analysis."		398.0	398_MESH:D005947_MESH:D012559	398_0	bcv_final_eval_easy_2254		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with <span class=""disease"">schizophrenia</span> treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting <span class=""chemical"">glucose</span> metabolism or simply increasing known risk factors for diabetes."		398.0	398_MESH:D005947_MESH:D012559	398_1	bcv_final_eval_easy_2255		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D003920	"<span class=""disease"">diabetes/new-onset diabetes mellitus</span>"	"BACKGROUND: While the incidence of <span class=""disease"">new-onset diabetes mellitus</span> may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting <span class=""chemical"">glucose</span> metabolism or simply increasing known risk factors for <span class=""disease"">diabetes</span>."		398.0	398_MESH:D005947_MESH:D003920	398_1	bcv_final_eval_easy_2256		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"DESIGN: A cross-sectional design in stable, treated patients with <span class=""disease"">schizophrenia</span> evaluated using a frequently sampled intravenous <span class=""chemical"">glucose</span> tolerance test and the Bergman minimal model analysis."		398.0	398_MESH:D005947_MESH:D012559	398_3	bcv_final_eval_easy_2257		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D011618	"<span class=""disease"">schizoaffective disorder</span>"	"Thirty-six nonobese subjects with schizophrenia or <span class=""disease"">schizoaffective disorder</span>, matched by body mass index and treated with either clozapine, olanzapine, or <span class=""chemical"">risperidone</span>, were included in the analysis."		398.0	398_MESH:D018967_MESH:D011618	398_6	bcv_final_eval_easy_2258		
	MESH:D003024	"<span class=""chemical"">clozapine</span>"	MESH:D011618	"<span class=""disease"">schizoaffective disorder</span>"	"Thirty-six nonobese subjects with schizophrenia or <span class=""disease"">schizoaffective disorder</span>, matched by body mass index and treated with either <span class=""chemical"">clozapine</span>, olanzapine, or risperidone, were included in the analysis."		398.0	398_MESH:D003024_MESH:D011618	398_6	bcv_final_eval_easy_2259		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"Thirty-six nonobese subjects with <span class=""disease"">schizophrenia</span> or schizoaffective disorder, matched by body mass index and treated with either clozapine, <span class=""chemical"">olanzapine</span>, or risperidone, were included in the analysis."		398.0	398_MESH:C076029_MESH:D012559	398_6	bcv_final_eval_easy_2260		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D011618	"<span class=""disease"">schizoaffective disorder</span>"	"Thirty-six nonobese subjects with schizophrenia or <span class=""disease"">schizoaffective disorder</span>, matched by body mass index and treated with either clozapine, <span class=""chemical"">olanzapine</span>, or risperidone, were included in the analysis."		398.0	398_MESH:C076029_MESH:D011618	398_6	bcv_final_eval_easy_2261		
	MESH:D003024	"<span class=""chemical"">clozapine</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"Thirty-six nonobese subjects with <span class=""disease"">schizophrenia</span> or schizoaffective disorder, matched by body mass index and treated with either <span class=""chemical"">clozapine</span>, olanzapine, or risperidone, were included in the analysis."		398.0	398_MESH:D003024_MESH:D012559	398_6	bcv_final_eval_easy_2262		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"Thirty-six nonobese subjects with <span class=""disease"">schizophrenia</span> or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or <span class=""chemical"">risperidone</span>, were included in the analysis."		398.0	398_MESH:D018967_MESH:D012559	398_6	bcv_final_eval_easy_2263		
	MESH:D010656	"<span class=""chemical"">phenylephrine</span>"	MESH:D002545	"<span class=""disease"">cerebral ischemia</span>"	"Focal <span class=""disease"">cerebral ischemia</span> in rats: effect of <span class=""chemical"">phenylephrine</span>-induced hypertension during reperfusion."		399.0	399_MESH:D010656_MESH:D002545	399_0	bcv_final_eval_easy_2264		
	MESH:D010656	"<span class=""chemical"">phenylephrine</span>"	MESH:D002545	"<span class=""disease"">ischemic brain injury</span>"	"After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of <span class=""chemical"">phenylephrine</span>-induced hypertension on <span class=""disease"">ischemic brain injury</span> and blood-brain barrier permeability was determined."		399.0	399_MESH:D010656_MESH:D002545	399_1	bcv_final_eval_easy_2265		
	MESH:D010656	"<span class=""chemical"">phenylephrine</span>"	MESH:D020244	"<span class=""disease"">temporary middle cerebral artery occlusion</span>"	"After 180 min of <span class=""disease"">temporary middle cerebral artery occlusion</span> in spontaneously hypertensive rats, the effect of <span class=""chemical"">phenylephrine</span>-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined."		399.0	399_MESH:D010656_MESH:D020244	399_1	bcv_final_eval_easy_2266		
	MESH:C009591	"<span class=""chemical"">2,3,5-triphenyltetrazolium chloride</span>"	MESH:D004487	"<span class=""disease"">edema</span>"	"Part A, for eight rats in each group brain injury was evaluated by staining tissue using <span class=""chemical"">2,3,5-triphenyltetrazolium chloride</span> and <span class=""disease"">edema</span> was evaluated by microgravimetry."		399.0	399_MESH:C009591_MESH:D004487	399_3	bcv_final_eval_easy_2267		
	MESH:C009591	"<span class=""chemical"">2,3,5-triphenyltetrazolium chloride</span>"	MESH:D001930	"<span class=""disease"">brain injury</span>"	"Part A, for eight rats in each group <span class=""disease"">brain injury</span> was evaluated by staining tissue using <span class=""chemical"">2,3,5-triphenyltetrazolium chloride</span> and edema was evaluated by microgravimetry."		399.0	399_MESH:C009591_MESH:D001930	399_3	bcv_final_eval_easy_2268		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D020521	"<span class=""disease"">stroke</span>"	"People aged over 75 in atrial fibrillation on <span class=""chemical"">warfarin</span>: the rate of major hemorrhage and <span class=""disease"">stroke</span> in more than 500 patient-years of follow-up."		400.0	400_MESH:D014859_MESH:D020521	400_0	bcv_final_eval_easy_2269		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D006470	"<span class=""disease"">hemorrhage</span>"	"People aged over 75 in atrial fibrillation on <span class=""chemical"">warfarin</span>: the rate of major <span class=""disease"">hemorrhage</span> and stroke in more than 500 patient-years of follow-up."		400.0	400_MESH:D014859_MESH:D006470	400_0	bcv_final_eval_easy_2270		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"People aged over 75 in <span class=""disease"">atrial fibrillation</span> on <span class=""chemical"">warfarin</span>: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up."		400.0	400_MESH:D014859_MESH:D001281	400_0	bcv_final_eval_easy_2271		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D020521	"<span class=""disease"">stroke</span>"	"OBJECTIVES: To determine the incidence of major hemorrhage and <span class=""disease"">stroke</span> in people aged 76 and older with atrial fibrillation on adjusted-dose <span class=""chemical"">warfarin</span> who had been recently been admitted to hospital."		400.0	400_MESH:D014859_MESH:D020521	400_1	bcv_final_eval_easy_2272		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D006470	"<span class=""disease"">hemorrhage</span>"	"OBJECTIVES: To determine the incidence of major <span class=""disease"">hemorrhage</span> and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose <span class=""chemical"">warfarin</span> who had been recently been admitted to hospital."		400.0	400_MESH:D014859_MESH:D006470	400_1	bcv_final_eval_easy_2273		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with <span class=""disease"">atrial fibrillation</span> on adjusted-dose <span class=""chemical"">warfarin</span> who had been recently been admitted to hospital."		400.0	400_MESH:D014859_MESH:D001281	400_1	bcv_final_eval_easy_2274		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"PARTICIPANTS: Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with <span class=""disease"">atrial fibrillation</span> on <span class=""chemical"">warfarin</span> were enrolled."		400.0	400_MESH:D014859_MESH:D001281	400_4	bcv_final_eval_easy_2275		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D020521	"<span class=""disease"">strokes</span>"	"MEASUREMENTS: Information regarding major bleeding episodes, <span class=""disease"">strokes</span>, and <span class=""chemical"">warfarin</span> use was obtained from patients, relatives, primary physicians, and medical records."		400.0	400_MESH:D014859_MESH:D020521	400_5	bcv_final_eval_easy_2276		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D006470	"<span class=""disease"">bleeding</span>"	"MEASUREMENTS: Information regarding major <span class=""disease"">bleeding</span> episodes, strokes, and <span class=""chemical"">warfarin</span> use was obtained from patients, relatives, primary physicians, and medical records."		400.0	400_MESH:D014859_MESH:D006470	400_5	bcv_final_eval_easy_2277		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D020521	"<span class=""disease"">annual stroke</span>"	"The <span class=""disease"">annual stroke</span> rate after initiation of <span class=""chemical"">warfarin</span> was 2.6%."		400.0	400_MESH:D014859_MESH:D020521	400_9	bcv_final_eval_easy_2278		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D020521	"<span class=""disease"">stroke</span>"	"CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the <span class=""disease"">stroke</span> rate on <span class=""chemical"">warfarin</span> was low, demonstrating how effective <span class=""chemical"">warfarin</span> treatment is."		400.0	400_MESH:D014859_MESH:D020521	400_10	bcv_final_eval_easy_2279		
	MESH:D014859	"<span class=""chemical"">warfarin</span>"	MESH:D006470	"<span class=""disease"">hemorrhage</span>"	"CONCLUSION: The rate of major <span class=""disease"">hemorrhage</span> was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on <span class=""chemical"">warfarin</span> was low, demonstrating how effective <span class=""chemical"">warfarin</span> treatment is."		400.0	400_MESH:D014859_MESH:D006470	400_10	bcv_final_eval_easy_2280		
	MESH:C012655	"<span class=""chemical"">N</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"METHODS: We studied 9 patients with <span class=""disease"">hypersensitivity</span> to P and <span class=""chemical"">N</span> with or without associated reactions to classic NSAIDs."		401.0	401_MESH:C012655_MESH:D004342	401_6	bcv_final_eval_easy_2281		
	MESH:C012655	"<span class=""chemical"">N</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"CONCLUSION: Only one <span class=""disease"">hypersensitivity</span> reaction to CE was documented among 9 P and <span class=""chemical"">N</span>-highly NSAIDs intolerant patients."		401.0	401_MESH:C012655_MESH:D004342	401_15	bcv_final_eval_easy_2282		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D007676	"<span class=""disease"">ESRD/end-stage renal disease</span>"	"BACKGROUND: Studies on the association between the long-term use of <span class=""chemical"">aspirin</span> and other analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) and <span class=""disease"">end-stage renal disease</span> (<span class=""disease"">ESRD</span>) have given conflicting results."		402.0	402_MESH:D001241_MESH:D007676	402_1	bcv_final_eval_easy_2283		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D007676	"<span class=""disease"">ESRD</span>"	"The risk of <span class=""disease"">ESRD</span> associated with <span class=""chemical"">aspirin</span> was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)]."		402.0	402_MESH:D001241_MESH:D007676	402_10	bcv_final_eval_easy_2284		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"The risk of ESRD associated with <span class=""chemical"">aspirin</span> was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular <span class=""disease"">nephropathy</span> as underlying disease [2.35 (1.17-4.72)]."		402.0	402_MESH:D001241_MESH:D007674	402_10	bcv_final_eval_easy_2285		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D007676	"<span class=""disease"">ESRD</span>"	"However, the chronic use of <span class=""chemical"">aspirin</span> may increase the risk of <span class=""disease"">ESRD</span>."		402.0	402_MESH:D001241_MESH:D007676	402_12	bcv_final_eval_easy_2286		
	MESH:C012052	"<span class=""chemical"">amisulpride</span>"	MESH:D062787	"<span class=""disease"">overdose</span>"	"Two cases of <span class=""chemical"">amisulpride</span> <span class=""disease"">overdose</span>: a cause for prolonged QT syndrome."		403.0	403_MESH:C012052_MESH:D062787	403_0	bcv_final_eval_easy_2287		
	MESH:C012052	"<span class=""chemical"">amisulpride</span>"	MESH:D008133	"<span class=""disease"">prolonged QT syndrome</span>"	"Two cases of <span class=""chemical"">amisulpride</span> overdose: a cause for <span class=""disease"">prolonged QT syndrome</span>."		403.0	403_MESH:C012052_MESH:D008133	403_0	bcv_final_eval_easy_2288		
	MESH:D002125	"<span class=""chemical"">calcium gluconate</span>"	MESH:D008133	"<span class=""disease"">QT prolongation</span>"	"The <span class=""disease"">QT prolongation</span> appeared to respond to administration of i.v. <span class=""chemical"">calcium gluconate</span>."		403.0	403_MESH:D002125_MESH:D008133	403_3	bcv_final_eval_easy_2289		
	MESH:D003513	"<span class=""chemical"">cycloheximide</span>"	MESH:D004827	"<span class=""disease"">epileptic</span>"	"Growth-associated protein 43 expression in hippocampal molecular layer of chronic <span class=""disease"">epileptic</span> rats treated with <span class=""chemical"">cycloheximide</span>."		404.0	404_MESH:D003513_MESH:D004827	404_0	bcv_final_eval_easy_2290		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D004604	"<span class=""disease"">MFS</span>"	"To investigate how GAP43 expression (GAP43-ir) correlates with <span class=""disease"">MFS</span>, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by <span class=""chemical"">pilocarpine</span> (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit <span class=""disease"">MFS</span>."		404.0	404_MESH:D010862_MESH:D004604	404_2	bcv_final_eval_easy_2291		
	MESH:D003513	"<span class=""chemical"">CHX/cycloheximide</span>"	MESH:D004604	"<span class=""disease"">MFS</span>"	"To investigate how GAP43 expression (GAP43-ir) correlates with <span class=""disease"">MFS</span>, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with <span class=""chemical"">cycloheximide</span> (<span class=""chemical"">CHX</span>), which has been shown to inhibit <span class=""disease"">MFS</span>."		404.0	404_MESH:D003513_MESH:D004604	404_2	bcv_final_eval_easy_2292		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to <span class=""disease"">status epilepticus</span> induced by <span class=""chemical"">pilocarpine</span> (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS."		404.0	404_MESH:D010862_MESH:D013226	404_2	bcv_final_eval_easy_2293		
	MESH:D003513	"<span class=""chemical"">CHX/cycloheximide</span>"	MESH:D013226	"<span class=""disease"">status epilepticus</span>"	"To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to <span class=""disease"">status epilepticus</span> induced by pilocarpine (Pilo), previously injected or not with <span class=""chemical"">cycloheximide</span> (<span class=""chemical"">CHX</span>), which has been shown to inhibit MFS."		404.0	404_MESH:D003513_MESH:D013226	404_2	bcv_final_eval_easy_2294		
	MESH:D003513	"<span class=""chemical"">CHX</span>"	MESH:D004604	"<span class=""disease"">MFS</span>"	"CONCLUSIONS: Our current finding that animals in the <span class=""chemical"">CHX</span>+Pilo group have a GAP43-ir band in the IML, similar to that of controls, reinforces prior data on the blockade of <span class=""disease"">MFS</span> in these animals."		404.0	404_MESH:D003513_MESH:D004604	404_8	bcv_final_eval_easy_2295		
	MESH:D009538	"<span class=""chemical"">nicotine</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"OBJECTIVES: The present study investigates the effects of <span class=""chemical"">nicotine</span> on <span class=""disease"">anxiety</span> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice."		405.0	405_MESH:D009538_MESH:D001008	405_4	bcv_final_eval_easy_2296		
	MESH:D009538	"<span class=""chemical"">Nicotine</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"<span class=""chemical"">Nicotine</span> (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced <span class=""disease"">anxiety</span>."		405.0	405_MESH:D009538_MESH:D001008	405_10	bcv_final_eval_easy_2297		
	MESH:D009538	"<span class=""chemical"">nicotine</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"CONCLUSIONS: Our results suggest that the antagonistic effect of <span class=""chemical"">nicotine</span> on caffeine-induced <span class=""disease"">anxiety</span> is specific to caffeine, instead of a non-specific anxiolytic effect."		405.0	405_MESH:D009538_MESH:D001008	405_12	bcv_final_eval_easy_2298		
	MESH:D001663	"<span class=""chemical"">bilirubin</span>"	MESH:D017114	"<span class=""disease"">fulminant hepatic failure</span>"	"Factors associated with the development of <span class=""disease"">fulminant hepatic failure</span> were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma <span class=""chemical"">bilirubin</span> value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001)."		407.0	407_MESH:D001663_MESH:D017114	407_9	bcv_final_eval_easy_2299		
	MESH:D001663	"<span class=""chemical"">bilirubin</span>"	MESH:D056486	"<span class=""disease"">hepatocellular damage</span>"	"Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), <span class=""disease"">hepatocellular damage</span> (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma <span class=""chemical"">bilirubin</span> value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001)."		407.0	407_MESH:D001663_MESH:D056486	407_9	bcv_final_eval_easy_2300		
	MESH:D004317	"<span class=""chemical"">adriamycin</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Morphological evaluation of the effect of d-ribose on <span class=""chemical"">adriamycin</span>-evoked <span class=""disease"">cardiotoxicity</span> in rats."		408.0	408_MESH:D004317_MESH:D066126	408_0	bcv_final_eval_easy_2301		
	MESH:D012266	"<span class=""chemical"">d-ribose</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"Morphological evaluation of the effect of <span class=""chemical"">d-ribose</span> on adriamycin-evoked <span class=""disease"">cardiotoxicity</span> in rats."		408.0	408_MESH:D012266_MESH:D066126	408_0	bcv_final_eval_easy_2302		
	MESH:D012266	"<span class=""chemical"">d-ribose</span>"	MESH:D009202	"<span class=""disease"">myocardiopathy</span>"	"The influence of <span class=""chemical"">d-ribose</span> on adriamycin-induced <span class=""disease"">myocardiopathy</span> in rats was studied."		408.0	408_MESH:D012266_MESH:D009202	408_1	bcv_final_eval_easy_2303		
	MESH:D004317	"<span class=""chemical"">Adriamycin</span>"	MESH:D066126	"<span class=""disease"">cardiac toxicity</span>"	"<span class=""chemical"">Adriamycin</span> in the cumulative dose of 25 mg/kg evoked fully developed <span class=""disease"">cardiac toxicity</span>."		408.0	408_MESH:D004317_MESH:D066126	408_2	bcv_final_eval_easy_2304		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"D-ribose in the multiple doses of 200 mg/kg did not influence <span class=""chemical"">ADR</span> <span class=""disease"">cardiotoxicity</span>."		408.0	408_MESH:D004317_MESH:D066126	408_3	bcv_final_eval_easy_2305		
	MESH:D012266	"<span class=""chemical"">D-ribose</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"<span class=""chemical"">D-ribose</span> in the multiple doses of 200 mg/kg did not influence ADR <span class=""disease"">cardiotoxicity</span>."		408.0	408_MESH:D012266_MESH:D066126	408_3	bcv_final_eval_easy_2306		
	MESH:D010100	"<span class=""chemical"">oxygen</span>"	MESH:D007674	"<span class=""disease"">renal impairment</span>"	"The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive <span class=""chemical"">oxygen</span> species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <span class=""disease"">renal impairment</span> in rats."		409.0	409_MESH:D010100_MESH:D007674	409_1	bcv_final_eval_easy_2307		
	MESH:C048498	"<span class=""chemical"">erdosteine</span>"	MESH:D007674	"<span class=""disease"">renal impairment</span>"	"The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <span class=""chemical"">erdosteine</span>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <span class=""disease"">renal impairment</span> in rats."		409.0	409_MESH:C048498_MESH:D007674	409_1	bcv_final_eval_easy_2308		
	MESH:D008315	"<span class=""chemical"">MDA/malondialdehyde</span>"	MESH:D007674	"<span class=""disease"">renal tubular injury/renal malondialdehyde</span>"	"VCM administration to control rats significantly increased <span class=""disease"">renal </span><span class=""chemical"">malondialdehyde</span> (<span class=""chemical"">MDA</span>) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of <span class=""disease"">renal tubular injury</span>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities."		409.0	409_MESH:D008315_MESH:D007674	409_5	bcv_final_eval_easy_2309		
	MESH:D013481	"<span class=""chemical"">superoxide</span>"	MESH:D007674	"<span class=""disease"">renal tubular injury/renal malondialdehyde</span>"	"VCM administration to control rats significantly increased <span class=""disease"">renal malondialdehyde</span> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of <span class=""disease"">renal tubular injury</span>) excretion but decreased <span class=""chemical"">superoxide</span> dismutase (SOD) and catalase (CAT) activities."		409.0	409_MESH:D013481_MESH:D007674	409_5	bcv_final_eval_easy_2310		
	MESH:D008315	"<span class=""chemical"">MDA</span>"	MESH:D051437	"<span class=""disease"">decreased renal MDA</span>"	"Erdosteine administration with VCM injections caused significantly <span class=""disease"">decreased renal </span><span class=""chemical"">MDA</span> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone."		409.0	409_MESH:D008315_MESH:D051437	409_6	bcv_final_eval_easy_2311		
	MESH:C048498	"<span class=""chemical"">Erdosteine</span>"	MESH:D051437	"<span class=""disease"">decreased renal MDA</span>"	"<span class=""chemical"">Erdosteine</span> administration with VCM injections caused significantly <span class=""disease"">decreased renal MDA</span> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone."		409.0	409_MESH:C048498_MESH:D051437	409_6	bcv_final_eval_easy_2312		
	MESH:D014640	"<span class=""chemical"">VCM</span>"	MESH:D051437	"<span class=""disease"">decreased renal MDA</span>"	"Erdosteine administration with <span class=""chemical"">VCM</span> injections caused significantly <span class=""disease"">decreased renal MDA</span> and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with <span class=""chemical"">VCM</span> alone."		409.0	409_MESH:D014640_MESH:D051437	409_6	bcv_final_eval_easy_2313		
	MESH:C048498	"<span class=""chemical"">erdosteine</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <span class=""disease"">necrosis</span> in VCM-treated rats more than those of the control and the <span class=""chemical"">erdosteine</span> groups."		409.0	409_MESH:C048498_MESH:D009336	409_8	bcv_final_eval_easy_2314		
	MESH:D014640	"<span class=""chemical"">VCM</span>"	MESH:D001284	"<span class=""disease"">atrophy</span>"	"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <span class=""disease"">atrophy</span>, desquamation, and necrosis in <span class=""chemical"">VCM</span>-treated rats more than those of the control and the erdosteine groups."		409.0	409_MESH:D014640_MESH:D001284	409_8	bcv_final_eval_easy_2315		
	MESH:C048498	"<span class=""chemical"">erdosteine</span>"	MESH:D001284	"<span class=""disease"">atrophy</span>"	"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, <span class=""disease"">atrophy</span>, desquamation, and necrosis in VCM-treated rats more than those of the control and the <span class=""chemical"">erdosteine</span> groups."		409.0	409_MESH:C048498_MESH:D001284	409_8	bcv_final_eval_easy_2316		
	MESH:D014640	"<span class=""chemical"">VCM</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and <span class=""disease"">necrosis</span> in <span class=""chemical"">VCM</span>-treated rats more than those of the control and the erdosteine groups."		409.0	409_MESH:D014640_MESH:D009336	409_8	bcv_final_eval_easy_2317		
	MESH:C048498	"<span class=""chemical"">Erdosteine</span>"	MESH:D007674	"<span class=""disease"">reduction in the extent of tubular damage</span>"	"<span class=""chemical"">Erdosteine</span> caused a marked <span class=""disease"">reduction in the extent of tubular damage</span>."		409.0	409_MESH:C048498_MESH:D007674	409_9	bcv_final_eval_easy_2318		
	MESH:C048498	"<span class=""chemical"">erdosteine</span>"	MESH:D007674	"<span class=""disease"">kidney damage</span>"	"It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with <span class=""chemical"">erdosteine</span> reduces the VCM-induced <span class=""disease"">kidney damage</span> both at the biochemical and histological levels."		409.0	409_MESH:C048498_MESH:D007674	409_10	bcv_final_eval_easy_2319		
	MESH:C035133	"<span class=""chemical"">mirtazapine</span>"	MESH:D012148	"<span class=""disease"">restless legs syndrome</span>"	"Does domperidone potentiate <span class=""chemical"">mirtazapine</span>-associated <span class=""disease"">restless legs syndrome</span>?"		410.0	410_MESH:C035133_MESH:D012148	410_0	bcv_final_eval_easy_2320		
	MESH:D004294	"<span class=""chemical"">domperidone</span>"	MESH:D012148	"<span class=""disease"">restless legs syndrome</span>"	"Does <span class=""chemical"">domperidone</span> potentiate mirtazapine-associated <span class=""disease"">restless legs syndrome</span>?"		410.0	410_MESH:D004294_MESH:D012148	410_0	bcv_final_eval_easy_2321		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"For example, the symptoms of <span class=""disease"">RLS</span> can be dramatically improved by levodopa and <span class=""chemical"">dopamine</span> agonists, whereas central <span class=""chemical"">dopamine</span> D2 receptor antagonists can induce or aggravate <span class=""disease"">RLS</span> symptoms."		410.0	410_MESH:D004298_MESH:D012148	410_2	bcv_final_eval_easy_2322		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"For example, the symptoms of <span class=""disease"">RLS</span> can be dramatically improved by <span class=""chemical"">levodopa</span> and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate <span class=""disease"">RLS</span> symptoms."		410.0	410_MESH:D007980_MESH:D012148	410_2	bcv_final_eval_easy_2323		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"To our knowledge, there is no previous report regarding whether domperidone, a peripheral <span class=""chemical"">dopamine</span> D2 receptor antagonist, can also induce or aggravate symptoms of <span class=""disease"">RLS</span>."		410.0	410_MESH:D004298_MESH:D012148	410_3	bcv_final_eval_easy_2324		
	MESH:D004294	"<span class=""chemical"">domperidone</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"To our knowledge, there is no previous report regarding whether <span class=""chemical"">domperidone</span>, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of <span class=""disease"">RLS</span>."		410.0	410_MESH:D004294_MESH:D012148	410_3	bcv_final_eval_easy_2325		
	MESH:C035133	"<span class=""chemical"">Mirtazapine</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"<span class=""chemical"">Mirtazapine</span>, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with <span class=""disease"">RLS</span> in several recent publications."		410.0	410_MESH:C035133_MESH:D012148	410_4	bcv_final_eval_easy_2326		
	MESH:C035133	"<span class=""chemical"">mirtazapine</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"The authors report here a depressed patient comorbid with postprandial dyspepsia who developed <span class=""disease"">RLS</span> after <span class=""chemical"">mirtazapine</span> had been added to his domperidone therapy."		410.0	410_MESH:C035133_MESH:D012148	410_5	bcv_final_eval_easy_2327		
	MESH:D004294	"<span class=""chemical"">domperidone</span>"	MESH:D003866	"<span class=""disease"">depressed</span>"	"The authors report here a <span class=""disease"">depressed</span> patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his <span class=""chemical"">domperidone</span> therapy."		410.0	410_MESH:D004294_MESH:D003866	410_5	bcv_final_eval_easy_2328		
	MESH:C035133	"<span class=""chemical"">mirtazapine</span>"	MESH:D003866	"<span class=""disease"">depressed</span>"	"The authors report here a <span class=""disease"">depressed</span> patient comorbid with postprandial dyspepsia who developed RLS after <span class=""chemical"">mirtazapine</span> had been added to his domperidone therapy."		410.0	410_MESH:C035133_MESH:D003866	410_5	bcv_final_eval_easy_2329		
	MESH:D004294	"<span class=""chemical"">domperidone</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"The authors report here a depressed patient comorbid with postprandial dyspepsia who developed <span class=""disease"">RLS</span> after mirtazapine had been added to his <span class=""chemical"">domperidone</span> therapy."		410.0	410_MESH:D004294_MESH:D012148	410_5	bcv_final_eval_easy_2330		
	MESH:C035133	"<span class=""chemical"">mirtazapine</span>"	MESH:D004415	"<span class=""disease"">dyspepsia</span>"	"The authors report here a depressed patient comorbid with postprandial <span class=""disease"">dyspepsia</span> who developed RLS after <span class=""chemical"">mirtazapine</span> had been added to his domperidone therapy."		410.0	410_MESH:C035133_MESH:D004415	410_5	bcv_final_eval_easy_2331		
	MESH:D004294	"<span class=""chemical"">domperidone</span>"	MESH:D004415	"<span class=""disease"">dyspepsia</span>"	"The authors report here a depressed patient comorbid with postprandial <span class=""disease"">dyspepsia</span> who developed RLS after mirtazapine had been added to his <span class=""chemical"">domperidone</span> therapy."		410.0	410_MESH:D004294_MESH:D004415	410_5	bcv_final_eval_easy_2332		
	MESH:C035133	"<span class=""chemical"">mirtazapine</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"Our patient started to have symptoms of <span class=""disease"">RLS</span> only after he had been treated with <span class=""chemical"">mirtazapine</span>, and his <span class=""disease"">RLS</span> symptoms resolved completely upon discontinuation of his <span class=""chemical"">mirtazapine</span>."		410.0	410_MESH:C035133_MESH:D012148	410_6	bcv_final_eval_easy_2333		
	MESH:C035133	"<span class=""chemical"">mirtazapine</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"Such a temporal relationship between the use of <span class=""chemical"">mirtazapine</span> and the symptoms of <span class=""disease"">RLS</span> in our patient did not support a potentiating effect of domperione on <span class=""chemical"">mirtazapine</span>-associated <span class=""disease"">RLS</span>."		410.0	410_MESH:C035133_MESH:D012148	410_7	bcv_final_eval_easy_2334		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"However, physicians should be aware of the possibility that mirtazapine can be associated with <span class=""disease"">RLS</span> in some individuals, especially those receiving concomitant <span class=""chemical"">dopamine</span> D2 receptor antagonists."		410.0	410_MESH:D004298_MESH:D012148	410_8	bcv_final_eval_easy_2335		
	MESH:C035133	"<span class=""chemical"">mirtazapine</span>"	MESH:D012148	"<span class=""disease"">RLS</span>"	"However, physicians should be aware of the possibility that <span class=""chemical"">mirtazapine</span> can be associated with <span class=""disease"">RLS</span> in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists."		410.0	410_MESH:C035133_MESH:D012148	410_8	bcv_final_eval_easy_2336		
	MESH:D014280	"<span class=""chemical"">triglycerides</span>"	MESH:D011471	"<span class=""disease"">low risk prostate cancer</span>"	"MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), <span class=""chemical"">triglycerides</span> (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with <span class=""disease"">low risk prostate cancer</span> (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy."		411.0	411_MESH:D014280_MESH:D011471	411_2	bcv_final_eval_easy_2337		
	MESH:D017373	"<span class=""chemical"">cyproterone acetate</span>"	MESH:D011471	"<span class=""disease"">low risk prostate cancer</span>"	"MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with <span class=""disease"">low risk prostate cancer</span> (stage: T1cN0M0, Gleason score: 2-5) during treatment with <span class=""chemical"">cyproterone acetate</span> (CPA) without surgical management or radiation therapy."		411.0	411_MESH:D017373_MESH:D011471	411_2	bcv_final_eval_easy_2338		
	MESH:D017373	"<span class=""chemical"">cyproterone acetate</span>"	MESH:C566031	"<span class=""disease"">TG/triglycerides</span>"	"MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), <span class=""disease"">triglycerides</span> (<span class=""disease"">TG</span>), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with <span class=""chemical"">cyproterone acetate</span> (CPA) without surgical management or radiation therapy."		411.0	411_MESH:D017373_MESH:C566031	411_2	bcv_final_eval_easy_2339		
	MESH:C048599	"<span class=""chemical"">CPA</span>"	MESH:C566031	"<span class=""disease"">TG/triglycerides</span>"	"MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), <span class=""disease"">triglycerides</span> (<span class=""disease"">TG</span>), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (<span class=""chemical"">CPA</span>) without surgical management or radiation therapy."		411.0	411_MESH:C048599_MESH:C566031	411_2	bcv_final_eval_easy_2340		
	MESH:D014280	"<span class=""chemical"">triglycerides</span>"	MESH:C566031	"<span class=""disease"">TG/triglycerides</span>"	"MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), <span class=""chemical""></span><span class=""disease"">triglycerides</span> (<span class=""disease"">TG</span>), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy."		411.0	411_MESH:D014280_MESH:C566031	411_2	bcv_final_eval_easy_2341		
	MESH:C048599	"<span class=""chemical"">CPA</span>"	MESH:D011471	"<span class=""disease"">low risk prostate cancer</span>"	"MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with <span class=""disease"">low risk prostate cancer</span> (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (<span class=""chemical"">CPA</span>) without surgical management or radiation therapy."		411.0	411_MESH:C048599_MESH:D011471	411_2	bcv_final_eval_easy_2342		
	MESH:D002784	"<span class=""chemical"">cholesterol</span>"	MESH:D003324	"<span class=""disease"">coronary arteriosclerosis</span>"	"CONCLUSIONS: Ischaemic <span class=""disease"">coronary arteriosclerosis</span> with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL <span class=""chemical"">cholesterol</span>, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen."		411.0	411_MESH:D002784_MESH:D003324	411_5	bcv_final_eval_easy_2343		
	MESH:D004967	"<span class=""chemical"">estrogen</span>"	MESH:D003324	"<span class=""disease"">coronary arteriosclerosis</span>"	"CONCLUSIONS: Ischaemic <span class=""disease"">coronary arteriosclerosis</span> with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by <span class=""chemical"">estrogen</span>."		411.0	411_MESH:D004967_MESH:D003324	411_5	bcv_final_eval_easy_2344		
	MESH:D005472	"<span class=""chemical"">5-Fluorouracil</span>"	MESH:D009081	"<span class=""disease"">alpha-fluoro-beta-alanine</span>"	"<span class=""chemical"">5-Fluorouracil</span> cardiotoxicity induced by <span class=""disease"">alpha-fluoro-beta-alanine</span>."		412.0	412_MESH:D005472_MESH:D009081	412_0	bcv_final_eval_easy_2345		
	MESH:D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"	MESH:D009369	"<span class=""disease"">malignancies</span>"	"Cardiotoxicity is a rare complication occurring during <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) treatment for <span class=""disease"">malignancies</span>."		412.0	412_MESH:D005472_MESH:D009369	412_1	bcv_final_eval_easy_2346		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D009081	"<span class=""disease"">alpha-fluoro-beta-alanine/FBAL</span>"	"We herein report the case of a 70-year-old man with <span class=""chemical"">5-FU</span>-induced cardiotoxicity, in whom a high serum level of <span class=""disease"">alpha-fluoro-beta-alanine</span> (<span class=""disease"">FBAL</span>) was observed."		412.0	412_MESH:D005472_MESH:D009081	412_2	bcv_final_eval_easy_2347		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D002037	"<span class=""disease"">right bundle branch block</span>"	"After admission, the patient received a continuous intravenous infusion of <span class=""chemical"">5-FU</span> (1000 mg/day), during which precordial pain with <span class=""disease"">right bundle branch block</span> occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml."		412.0	412_MESH:D005472_MESH:D002037	412_4	bcv_final_eval_easy_2348		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D009081	"<span class=""disease"">FBAL</span>"	"After admission, the patient received a continuous intravenous infusion of <span class=""chemical"">5-FU</span> (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum <span class=""disease"">FBAL</span> concentration of 1955 ng/ml."		412.0	412_MESH:D005472_MESH:D009081	412_4	bcv_final_eval_easy_2349		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D010146	"<span class=""disease"">precordial pain</span>"	"After admission, the patient received a continuous intravenous infusion of <span class=""chemical"">5-FU</span> (1000 mg/day), during which <span class=""disease"">precordial pain</span> with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml."		412.0	412_MESH:D005472_MESH:D010146	412_4	bcv_final_eval_easy_2350		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D010146	"<span class=""disease"">precordial pain</span>"	"Both the <span class=""disease"">precordial pain</span> and the electrocardiographic changes disappeared spontaneously after the discontinuation of <span class=""chemical"">5-FU</span>."		412.0	412_MESH:D005472_MESH:D010146	412_5	bcv_final_eval_easy_2351		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D010146	"<span class=""disease"">precordial pain</span>"	"As the <span class=""disease"">precordial pain</span> in this patient was considered to have been due to <span class=""chemical"">5-FU</span>-induced cardiotoxicity, the administration of <span class=""chemical"">5-FU</span> was abandoned."		412.0	412_MESH:D005472_MESH:D010146	412_6	bcv_final_eval_easy_2352		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D009081	"<span class=""disease"">FBAL</span>"	"Instead, oral administration of S-1 (a derivative of <span class=""chemical"">5-FU</span>), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of <span class=""chemical"">5-FU</span> into <span class=""disease"">FBAL</span>."		412.0	412_MESH:D005472_MESH:D009081	412_7	bcv_final_eval_easy_2353		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D009081	"<span class=""disease"">FBAL</span>"	"The experience of this case, together with a review of the literature, suggests that <span class=""disease"">FBAL</span> is related to <span class=""chemical"">5-FU</span>-induced cardiotoxicity."		412.0	412_MESH:D005472_MESH:D009081	412_11	bcv_final_eval_easy_2354		
	MESH:C522803	"<span class=""chemical"">monoHER</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The influence of the time interval between <span class=""chemical"">monoHER</span> and doxorubicin administration on the protection against doxorubicin-induced <span class=""disease"">cardiotoxicity</span> in mice."		413.0	413_MESH:C522803_MESH:D066126	413_0	bcv_final_eval_easy_2355		
	MESH:C522803	"<span class=""chemical"">monoHER</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The semisynthetic flavonoid monohydroxyethylrutoside (<span class=""chemical"">monoHER</span>) showed cardioprotection against DOX-induced <span class=""disease"">cardiotoxicity</span> through its radical scavenging and iron chelating properties."		413.0	413_MESH:C522803_MESH:D066126	413_4	bcv_final_eval_easy_2356		
	MESH:D007501	"<span class=""chemical"">iron</span>"	MESH:D066126	"<span class=""disease"">cardiotoxicity</span>"	"The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced <span class=""disease"">cardiotoxicity</span> through its radical scavenging and <span class=""chemical"">iron</span> chelating properties."		413.0	413_MESH:D007501_MESH:D066126	413_4	bcv_final_eval_easy_2357		
	MESH:D015764	"<span class=""chemical"">bepridil</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"Clinical evaluation of adverse effects during <span class=""chemical"">bepridil</span> administration for <span class=""disease"">atrial fibrillation</span> and flutter."		414.0	414_MESH:D015764_MESH:D001281	414_0	bcv_final_eval_easy_2358		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D008133	"<span class=""disease"">long QT syndrome</span>"	"Drug-induced <span class=""disease"">long QT syndrome</span> in injection drug users receiving <span class=""chemical"">methadone</span>: high frequency in hospitalized patients and risk factors."		416.0	416_MESH:D008691_MESH:D008133	416_0	bcv_final_eval_easy_2359		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D008133	"<span class=""disease"">QT prolongation</span>"	"In addition to <span class=""chemical"">methadone</span> dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for <span class=""disease"">QT prolongation</span>."		416.0	416_MESH:D008691_MESH:D008133	416_6	bcv_final_eval_easy_2360		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D008133	"<span class=""disease"">QTc prolongation</span>"	"RESULTS: Among 167 <span class=""chemical"">methadone</span> maintenance patients, the prevalence of <span class=""disease"">QTc prolongation</span> to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects."		416.0	416_MESH:D008691_MESH:D008133	416_7	bcv_final_eval_easy_2361		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D016171	"<span class=""disease"">torsades de pointes</span>"	"Six patients (3.6%) in the <span class=""chemical"">methadone</span> group presented <span class=""disease"">torsades de pointes</span>."		416.0	416_MESH:D008691_MESH:D016171	416_8	bcv_final_eval_easy_2362		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"Multivariate regression analysis allowed attribution of 31.8% of QTc variability to <span class=""chemical"">methadone</span> dose, cytochrome P-450 3A4 drug-drug interactions, <span class=""disease"">hypokalemia</span>, and altered liver function."		416.0	416_MESH:D008691_MESH:D007008	416_10	bcv_final_eval_easy_2363		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D008133	"<span class=""disease"">QT prolongation</span>"	"Methadone dose, presence of cytochrome P-450 3A4 inhibitors, <span class=""chemical"">potassium</span> level, and liver function contribute to <span class=""disease"">QT prolongation</span>."		416.0	416_MESH:D011188_MESH:D008133	416_12	bcv_final_eval_easy_2364		
	MESH:D008691	"<span class=""chemical"">Methadone</span>"	MESH:D008133	"<span class=""disease"">QT prolongation</span>"	"<span class=""chemical"">Methadone</span> dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to <span class=""disease"">QT prolongation</span>."		416.0	416_MESH:D008691_MESH:D008133	416_12	bcv_final_eval_easy_2365		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D008133	"<span class=""disease"">Long QT syndrome</span>"	"<span class=""disease"">Long QT syndrome</span> can occur with low doses of <span class=""chemical"">methadone</span>."		416.0	416_MESH:D008691_MESH:D008133	416_13	bcv_final_eval_easy_2366		
	MESH:D009569	"<span class=""chemical"">nitric oxide</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Mechanisms of <span class=""disease"">hypertension</span> induced by <span class=""chemical"">nitric oxide</span> (NO) deficiency: focus on venous function."		417.0	417_MESH:D009569_MESH:D006973	417_0	bcv_final_eval_easy_2367		
	MESH:D009569	"<span class=""chemical"">nitric oxide</span>"	MESH:D014652	"<span class=""disease"">arterial dysfunction</span>"	"Loss of endothelial cell-derived <span class=""chemical"">nitric oxide</span> (NO) in hypertension is a hallmark of <span class=""disease"">arterial dysfunction</span>."		417.0	417_MESH:D009569_MESH:D014652	417_1	bcv_final_eval_easy_2368		
	MESH:D009569	"<span class=""chemical"">nitric oxide</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Loss of endothelial cell-derived <span class=""chemical"">nitric oxide</span> (NO) in <span class=""disease"">hypertension</span> is a hallmark of arterial dysfunction."		417.0	417_MESH:D009569_MESH:D006973	417_1	bcv_final_eval_easy_2369		
	MESH:D018738	"<span class=""chemical"">hexamethonium</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"Similarly, ganglionic blockade with <span class=""chemical"">hexamethonium</span> caused a significantly greater fall in LNNA <span class=""disease"">hypertensive</span> rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg)."		417.0	417_MESH:D018738_MESH:D006973	417_12	bcv_final_eval_easy_2370		
	MESH:D002746	"<span class=""chemical"">chlorpromazine</span>"	MESH:D012559	"<span class=""disease"">schizophrenic</span>"	"Association of DRD2 polymorphisms and <span class=""chemical"">chlorpromazine</span>-induced extrapyramidal syndrome in Chinese <span class=""disease"">schizophrenic</span> patients."		418.0	418_MESH:D002746_MESH:D012559	418_0	bcv_final_eval_easy_2371		
	MESH:D002746	"<span class=""chemical"">chlorpromazine</span>"	MESH:D012559	"<span class=""disease"">schizophrenic</span>"	"In this study, we evaluate the role DRD2 plays in <span class=""chemical"">chlorpromazine</span>-induced EPS in <span class=""disease"">schizophrenic</span> patients."		418.0	418_MESH:D002746_MESH:D012559	418_3	bcv_final_eval_easy_2372		
	MESH:D002746	"<span class=""chemical"">chlorpromazine</span>"	MESH:D012559	"<span class=""disease"">schizophrenic</span>"	"METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 <span class=""disease"">schizophrenic</span> inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with <span class=""chemical"">chlorpromazine</span> after 8 weeks."		418.0	418_MESH:D002746_MESH:D012559	418_4	bcv_final_eval_easy_2373		
	MESH:D002746	"<span class=""chemical"">chlorpromazine</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by <span class=""chemical"">chlorpromazine</span>, at least in Chinese patients with <span class=""disease"">schizophrenia</span>."		418.0	418_MESH:D002746_MESH:D012559	418_8	bcv_final_eval_easy_2374		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D020521	"<span class=""disease"">stroke</span>"	"Administration of the <span class=""chemical"">dopamine</span> precursor levodopa enhances learning in healthy subjects and <span class=""disease"">stroke</span> patients."		420.0	420_MESH:D004298_MESH:D020521	420_2	bcv_final_eval_easy_2375		
	MESH:D004298	"<span class=""chemical"">dopamine</span>"	MESH:D020521	"<span class=""disease"">stroke</span>"	"Thus, phasic signaling seems to be the critical mechanism by which <span class=""chemical"">dopamine</span> enhances associative learning in healthy subjects and <span class=""disease"">stroke</span> patients."		420.0	420_MESH:D004298_MESH:D020521	420_12	bcv_final_eval_easy_2376		
	MESH:D008911	"<span class=""chemical"">Minocycline</span>"	MESH:D010488	"<span class=""disease"">polyarteritis nodosa</span>"	"<span class=""chemical"">Minocycline</span>-induced vasculitis fulfilling the criteria of <span class=""disease"">polyarteritis nodosa</span>."		421.0	421_MESH:D008911_MESH:D010488	421_0	bcv_final_eval_easy_2377		
	MESH:D008911	"<span class=""chemical"">minocycline</span>"	MESH:D010146	"<span class=""disease"">testicular pain</span>"	"A 47-year-old man who had been taking <span class=""chemical"">minocycline</span> for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and <span class=""disease"">testicular pain</span>, with elevated C-reactive protein (CRP)."		421.0	421_MESH:D008911_MESH:D010146	421_1	bcv_final_eval_easy_2378		
	MESH:D008911	"<span class=""chemical"">minocycline</span>"	MESH:D005334	"<span class=""disease"">fever</span>"	"A 47-year-old man who had been taking <span class=""chemical"">minocycline</span> for palmoplantar pustulosis developed <span class=""disease"">fever</span>, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)."		421.0	421_MESH:D008911_MESH:D005334	421_1	bcv_final_eval_easy_2379		
	MESH:D008911	"<span class=""chemical"">minocycline</span>"	MESH:D011565	"<span class=""disease"">palmoplantar pustulosis</span>"	"A 47-year-old man who had been taking <span class=""chemical"">minocycline</span> for <span class=""disease"">palmoplantar pustulosis</span> developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)."		421.0	421_MESH:D008911_MESH:D011565	421_1	bcv_final_eval_easy_2380		
	MESH:D008911	"<span class=""chemical"">minocycline</span>"	MESH:D011115	"<span class=""disease"">polyneuropathy</span>"	"A 47-year-old man who had been taking <span class=""chemical"">minocycline</span> for palmoplantar pustulosis developed fever, myalgias, <span class=""disease"">polyneuropathy</span>, and testicular pain, with elevated C-reactive protein (CRP)."		421.0	421_MESH:D008911_MESH:D011115	421_1	bcv_final_eval_easy_2381		
	MESH:D008911	"<span class=""chemical"">minocycline</span>"	MESH:D063806	"<span class=""disease"">myalgias</span>"	"A 47-year-old man who had been taking <span class=""chemical"">minocycline</span> for palmoplantar pustulosis developed fever, <span class=""disease"">myalgias</span>, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)."		421.0	421_MESH:D008911_MESH:D063806	421_1	bcv_final_eval_easy_2382		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"Intramuscular <span class=""disease"">hepatitis B</span> immune globulin combined with <span class=""chemical"">lamivudine</span> in prevention of <span class=""disease"">hepatitis B</span> recurrence after liver transplantation."		422.0	422_MESH:D019259_MESH:D006509	422_0	bcv_final_eval_easy_2383		
	MESH:D006514	"<span class=""chemical"">HBsAg</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"BACKGROUND: Combined <span class=""disease"">hepatitis B</span> immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of <span class=""disease"">hepatitis B</span> after liver transplantation has significantly improved the survival of <span class=""chemical"">HBsAg</span> positive patients."		422.0	422_MESH:D006514_MESH:D006509	422_1	bcv_final_eval_easy_2384		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"BACKGROUND: Combined <span class=""disease"">hepatitis B</span> immune globulin (HBIg) and <span class=""chemical"">lamivudine</span> in prophylaxis of the recurrence of <span class=""disease"">hepatitis B</span> after liver transplantation has significantly improved the survival of HBsAg positive patients."		422.0	422_MESH:D019259_MESH:D006509	422_1	bcv_final_eval_easy_2385		
	MESH:D006513	"<span class=""chemical"">HBeAg</span>"	MESH:D006509	"<span class=""disease"">HBV</span>"	"A daily oral dose of 100 mg lamivudine for 2 weeks before transplantation for 10 patients enabled 57.1% (4/7) and 62.5% (5/8) of <span class=""disease"">HBV</span>-DNA and <span class=""chemical"">HBeAg</span> positive patients respectively to convert to be negative."		422.0	422_MESH:D006513_MESH:D006509	422_7	bcv_final_eval_easy_2386		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">HBV</span>"	"A daily oral dose of 100 mg <span class=""chemical"">lamivudine</span> for 2 weeks before transplantation for 10 patients enabled 57.1% (4/7) and 62.5% (5/8) of <span class=""disease"">HBV</span>-DNA and HBeAg positive patients respectively to convert to be negative."		422.0	422_MESH:D019259_MESH:D006509	422_7	bcv_final_eval_easy_2387		
	MESH:D019259	"<span class=""chemical"">Lamivudine</span>"	MESH:D006509	"<span class=""disease"">HBV</span>"	"CONCLUSION: <span class=""chemical"">Lamivudine</span> combined with intramuscular HBIg can effectively prevent allograft from the recurrence of <span class=""disease"">HBV</span> after liver transplantation."		422.0	422_MESH:D019259_MESH:D006509	422_9	bcv_final_eval_easy_2388		
	MESH:D010852	"<span class=""chemical"">picrotoxin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on <span class=""disease"">seizures</span> induced by microperfusion of <span class=""chemical"">picrotoxin</span> in the hippocampus of freely moving rats."		423.0	423_MESH:D010852_MESH:D012640	423_0	bcv_final_eval_easy_2389		
	MESH:C416835	"<span class=""chemical"">BIA 2-093/eslicarbazepine acetate</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Anticonvulsant effect of <span class=""chemical"">eslicarbazepine acetate</span> (<span class=""chemical"">BIA 2-093</span>) on <span class=""disease"">seizures</span> induced by microperfusion of picrotoxin in the hippocampus of freely moving rats."		423.0	423_MESH:C416835_MESH:D012640	423_0	bcv_final_eval_easy_2390		
	MESH:C416835	"<span class=""chemical"">eslicarbazepine acetate</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"We have studied the effects of oral treatment with <span class=""chemical"">eslicarbazepine acetate</span> on a whole-animal model in which partial <span class=""disease"">seizures</span> can be elicited repeatedly on different days without changes in threshold or <span class=""disease"">seizure</span> patterns."		423.0	423_MESH:C416835_MESH:D012640	423_2	bcv_final_eval_easy_2391		
	MESH:D010852	"<span class=""chemical"">picrotoxin</span>"	MESH:D012640	"<span class=""disease"">seizures/seizure</span>"	"In the animals treated with threshold doses of <span class=""chemical"">picrotoxin</span>, the average number of <span class=""disease"">seizures</span> was 2.3+/-1.2, and average <span class=""disease"">seizure</span> duration was 39.5+/-8.4s."		423.0	423_MESH:D010852_MESH:D012640	423_3	bcv_final_eval_easy_2392		
	MESH:D010852	"<span class=""chemical"">picrotoxin</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"Pre-treatment with a dose of 30 mg/kg 2h before <span class=""chemical"">picrotoxin</span> microperfusion prevented <span class=""disease"">seizures</span> in the 75% of the rats."		423.0	423_MESH:D010852_MESH:D012640	423_4	bcv_final_eval_easy_2393		
	MESH:D000880	"<span class=""chemical"">anthraquinones</span>"	MESH:D058186	"<span class=""disease"">Acute renal failure</span>"	"<span class=""disease"">Acute renal failure</span> associated with prolonged intake of slimming pills containing <span class=""chemical"">anthraquinones</span>."		424.0	424_MESH:D000880_MESH:D058186	424_0	bcv_final_eval_easy_2394		
	MESH:D004008	"<span class=""chemical"">diclofenac</span>"	MESH:D007674	"<span class=""disease"">renal injury</span>"	"The <span class=""disease"">renal injury</span> was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, <span class=""chemical"">diclofenac</span>."		424.0	424_MESH:D004008_MESH:D007674	424_4	bcv_final_eval_easy_2395		
	MESH:C004656	"<span class=""chemical"">Chloroacetaldehyde</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"<span class=""chemical"">Chloroacetaldehyde</span> as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide <span class=""disease"">nephropathy</span>."		425.0	425_MESH:C004656_MESH:D007674	425_0	bcv_final_eval_easy_2396		
	MESH:D007069	"<span class=""chemical"">ifosfamide</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in <span class=""chemical"">ifosfamide</span> <span class=""disease"">nephropathy</span>."		425.0	425_MESH:D007069_MESH:D007674	425_0	bcv_final_eval_easy_2397		
	MESH:C004656	"<span class=""chemical"">CAA/Chloroacetaldehyde</span>"	MESH:D007674	"<span class=""disease"">renal damage</span>"	"<span class=""chemical"">Chloroacetaldehyde</span> (<span class=""chemical"">CAA</span>) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for <span class=""disease"">renal damage</span> following anti-tumor therapy with IFO."		425.0	425_MESH:C004656_MESH:D007674	425_1	bcv_final_eval_easy_2398		
	MESH:C004656	"<span class=""chemical"">CAA/Chloroacetaldehyde</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"<span class=""chemical"">Chloroacetaldehyde</span> (<span class=""chemical"">CAA</span>) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-<span class=""disease"">tumor</span> therapy with IFO."		425.0	425_MESH:C004656_MESH:D009369	425_1	bcv_final_eval_easy_2399		
	MESH:D007069	"<span class=""chemical"">ifosfamide/IFO</span>"	MESH:D007674	"<span class=""disease"">renal damage</span>"	"Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent <span class=""chemical"">ifosfamide</span> (<span class=""chemical"">IFO</span>) and putatively responsible for <span class=""disease"">renal damage</span> following anti-tumor therapy with <span class=""chemical"">IFO</span>."		425.0	425_MESH:D007069_MESH:D007674	425_1	bcv_final_eval_easy_2400		
	MESH:D007069	"<span class=""chemical"">ifosfamide/IFO</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent <span class=""chemical"">ifosfamide</span> (<span class=""chemical"">IFO</span>) and putatively responsible for renal damage following anti-<span class=""disease"">tumor</span> therapy with <span class=""chemical"">IFO</span>."		425.0	425_MESH:D007069_MESH:D009369	425_1	bcv_final_eval_easy_2401		
	MESH:D014343	"<span class=""chemical"">trypan blue</span>"	MESH:D064420	"<span class=""disease"">Toxicity</span>"	"<span class=""disease"">Toxicity</span> of CAA was determined by protein content, cell number, LDH release, <span class=""chemical"">trypan blue</span> exclusion assay and caspase-3 activity."		425.0	425_MESH:D014343_MESH:D064420	425_4	bcv_final_eval_easy_2402		
	MESH:C004656	"<span class=""chemical"">CAA</span>"	MESH:D064420	"<span class=""disease"">Toxicity</span>"	"<span class=""disease"">Toxicity</span> of <span class=""chemical"">CAA</span> was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity."		425.0	425_MESH:C004656_MESH:D064420	425_4	bcv_final_eval_easy_2403		
	MESH:C004656	"<span class=""chemical"">CAA</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"<span class=""chemical"">CAA</span> reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in <span class=""disease"">necrosis</span> markers."		425.0	425_MESH:C004656_MESH:D009336	425_6	bcv_final_eval_easy_2404		
	MESH:D013438	"<span class=""chemical"">thiols</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular <span class=""chemical"">thiols</span> and an increase in <span class=""disease"">necrosis</span> markers."		425.0	425_MESH:D013438_MESH:D009336	425_6	bcv_final_eval_easy_2405		
	MESH:C004656	"<span class=""chemical"">CAA</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Acidification, which slowed the reaction of <span class=""chemical"">CAA</span> with thiol donors, could also attenuate effects of <span class=""chemical"">CAA</span> on <span class=""disease"">necrosis</span> markers, thiol depletion and cysteine protease inhibition in living cells."		425.0	425_MESH:C004656_MESH:D009336	425_11	bcv_final_eval_easy_2406		
	MESH:D003545	"<span class=""chemical"">cysteine</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on <span class=""disease"">necrosis</span> markers, thiol depletion and <span class=""chemical"">cysteine</span> protease inhibition in living cells."		425.0	425_MESH:D003545_MESH:D009336	425_11	bcv_final_eval_easy_2407		
	MESH:D013438	"<span class=""chemical"">thiols</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Thus, CAA directly reacts with cellular protein and non-protein <span class=""chemical"">thiols</span>, mediating its <span class=""disease"">toxicity</span> on hRPTEC."		425.0	425_MESH:D013438_MESH:D064420	425_12	bcv_final_eval_easy_2408		
	MESH:C004656	"<span class=""chemical"">CAA</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Thus, <span class=""chemical"">CAA</span> directly reacts with cellular protein and non-protein thiols, mediating its <span class=""disease"">toxicity</span> on hRPTEC."		425.0	425_MESH:C004656_MESH:D064420	425_12	bcv_final_eval_easy_2409		
	MESH:D007069	"<span class=""chemical"">IFO</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Therefore, urinary acidification could be an option to prevent <span class=""chemical"">IFO</span> <span class=""disease"">nephropathy</span> in patients."		425.0	425_MESH:D007069_MESH:D007674	425_14	bcv_final_eval_easy_2410		
	MESH:D010862	"<span class=""chemical"">pilocarpine</span>"	MESH:D004833	"<span class=""disease"">temporal lobe epilepsy</span>"	"The results provide new insight into the potential role of ectopic hilar granule cells in the <span class=""chemical"">pilocarpine</span> model of <span class=""disease"">temporal lobe epilepsy</span>."		426.0	426_MESH:D010862_MESH:D004833	426_9	bcv_final_eval_easy_2411		
	MESH:D005702	"<span class=""chemical"">galantamine</span>"	MESH:D001321	"<span class=""disease"">autistic disorder</span>"	"A prospective, open-label trial of <span class=""chemical"">galantamine</span> in <span class=""disease"">autistic disorder</span>."		427.0	427_MESH:D005702_MESH:D001321	427_0	bcv_final_eval_easy_2412		
	MESH:D005702	"<span class=""chemical"">galantamine</span>"	MESH:D001321	"<span class=""disease"">autism</span>"	"The purpose of this study was to assess the use of <span class=""chemical"">galantamine</span>, an acetylcholinesterase inhibitor and nicotinic receptor modulator, in the treatment of interfering behaviors in children with <span class=""disease"">autism</span>."		427.0	427_MESH:D005702_MESH:D001321	427_2	bcv_final_eval_easy_2413		
	MESH:D005702	"<span class=""chemical"">galantamine</span>"	MESH:D001321	"<span class=""disease"">autism</span>"	"METHODS: Thirteen medication-free children with <span class=""disease"">autism</span> (mean age, 8.8 +/- 3.5 years) participated in a 12-week, open-label trial of <span class=""chemical"">galantamine</span>."		427.0	427_MESH:D005702_MESH:D001321	427_3	bcv_final_eval_easy_2414		
	MESH:D005702	"<span class=""chemical"">galantamine</span>"	MESH:D006261	"<span class=""disease"">headaches</span>"	"Overall, <span class=""chemical"">galantamine</span> was well-tolerated, with no significant adverse effects apart from <span class=""disease"">headaches</span> in one patient."		427.0	427_MESH:D005702_MESH:D006261	427_8	bcv_final_eval_easy_2415		
	MESH:D005702	"<span class=""chemical"">galantamine</span>"	MESH:D001321	"<span class=""disease"">autism</span>"	"CONCLUSION: In this open trial, <span class=""chemical"">galantamine</span> was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with <span class=""disease"">autism</span>, particularly aggression, behavioral dyscontrol, and inattention."		427.0	427_MESH:D005702_MESH:D001321	427_9	bcv_final_eval_easy_2416		
	MESH:D005702	"<span class=""chemical"">galantamine</span>"	MESH:D001523	"<span class=""disease"">aggression</span>"	"CONCLUSION: In this open trial, <span class=""chemical"">galantamine</span> was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly <span class=""disease"">aggression</span>, behavioral dyscontrol, and inattention."		427.0	427_MESH:D005702_MESH:D001523	427_9	bcv_final_eval_easy_2417		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"Randomized comparison of olanzapine versus <span class=""chemical"">risperidone</span> for the treatment of first-episode <span class=""disease"">schizophrenia</span>: 4-month outcomes."		428.0	428_MESH:D018967_MESH:D012559	428_0	bcv_final_eval_easy_2418		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"Randomized comparison of <span class=""chemical"">olanzapine</span> versus risperidone for the treatment of first-episode <span class=""disease"">schizophrenia</span>: 4-month outcomes."		428.0	428_MESH:C076029_MESH:D012559	428_0	bcv_final_eval_easy_2419		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus <span class=""chemical"">risperidone</span> in patients with first-episode <span class=""disease"">schizophrenia</span> spectrum disorders."		428.0	428_MESH:D018967_MESH:D012559	428_1	bcv_final_eval_easy_2420		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"OBJECTIVE: The authors compared 4-month treatment outcomes for <span class=""chemical"">olanzapine</span> versus risperidone in patients with first-episode <span class=""disease"">schizophrenia</span> spectrum disorders."		428.0	428_MESH:C076029_MESH:D012559	428_1	bcv_final_eval_easy_2421		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode <span class=""disease"">schizophrenia</span> (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <span class=""chemical"">risperidone</span> (1-6 mg/day)."		428.0	428_MESH:D018967_MESH:D012559	428_2	bcv_final_eval_easy_2422		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D011618	"<span class=""disease"">or schizoaffective disorder/schizophreniform disorder</span>"	"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), <span class=""disease"">schizophreniform disorder</span> (17%), <span class=""disease"">or schizoaffective disorder</span> (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <span class=""chemical"">risperidone</span> (1-6 mg/day)."		428.0	428_MESH:D018967_MESH:D011618	428_2	bcv_final_eval_easy_2423		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D012559	"<span class=""disease"">schizophrenia</span>"	"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode <span class=""disease"">schizophrenia</span> (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with <span class=""chemical"">olanzapine</span> (2.5-20 mg/day) or risperidone (1-6 mg/day)."		428.0	428_MESH:C076029_MESH:D012559	428_2	bcv_final_eval_easy_2424		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D011618	"<span class=""disease"">or schizoaffective disorder/schizophreniform disorder</span>"	"METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), <span class=""disease"">schizophreniform disorder</span> (17%), <span class=""disease"">or schizoaffective disorder</span> (8%) were randomly assigned to treatment with <span class=""chemical"">olanzapine</span> (2.5-20 mg/day) or risperidone (1-6 mg/day)."		428.0	428_MESH:C076029_MESH:D011618	428_2	bcv_final_eval_easy_2425		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D015430	"<span class=""disease"">weight gain</span>"	"Significantly more <span class=""disease"">weight gain</span> occurred with <span class=""chemical"">olanzapine</span> than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with <span class=""chemical"">olanzapine</span> and 11.3% (95% CI=8.4%-14.3%) with risperidone."		428.0	428_MESH:C076029_MESH:D015430	428_7	bcv_final_eval_easy_2426		
	MESH:D018967	"<span class=""chemical"">risperidone</span>"	MESH:D015430	"<span class=""disease"">weight gain</span>"	"Significantly more <span class=""disease"">weight gain</span> occurred with olanzapine than with <span class=""chemical"">risperidone</span>: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with <span class=""chemical"">risperidone</span>."		428.0	428_MESH:D018967_MESH:D015430	428_7	bcv_final_eval_easy_2427		
	MESH:C076029	"<span class=""chemical"">olanzapine</span>"	MESH:D015430	"<span class=""disease"">weight gain</span>"	"Both medications caused substantial rapid <span class=""disease"">weight gain</span>, but <span class=""disease"">weight gain</span> was greater with <span class=""chemical"">olanzapine</span>."		428.0	428_MESH:C076029_MESH:D015430	428_11	bcv_final_eval_easy_2428		
	MESH:D006886	"<span class=""chemical"">hydroxychloroquine</span>"	MESH:D014786	"<span class=""disease"">visual field loss</span>"	"Early paracentral <span class=""disease"">visual field loss</span> in patients taking <span class=""chemical"">hydroxychloroquine</span>."		429.0	429_MESH:D006886_MESH:D014786	429_0	bcv_final_eval_easy_2429		
	MESH:D006886	"<span class=""chemical"">hydroxychloroquine</span>"	MESH:D014786	"<span class=""disease"">visual field abnormalities</span>"	"Thirty-five patients (13.4%) had <span class=""disease"">visual field abnormalities</span>, which were attributed to <span class=""chemical"">hydroxychloroquine</span> treatment in 4 patients (1.5%)."		429.0	429_MESH:D006886_MESH:D014786	429_6	bcv_final_eval_easy_2430		
	MESH:D015251	"<span class=""chemical"">epirubicin</span>"	MESH:D054537	"<span class=""disease"">atrioventricular block</span>"	"Peri-operative <span class=""disease"">atrioventricular block</span> as a result of chemotherapy with <span class=""chemical"">epirubicin</span> and paclitaxel."		430.0	430_MESH:D015251_MESH:D054537	430_0	bcv_final_eval_easy_2431		
	MESH:D017239	"<span class=""chemical"">paclitaxel</span>"	MESH:D054537	"<span class=""disease"">atrioventricular block</span>"	"Peri-operative <span class=""disease"">atrioventricular block</span> as a result of chemotherapy with epirubicin and <span class=""chemical"">paclitaxel</span>."		430.0	430_MESH:D017239_MESH:D054537	430_0	bcv_final_eval_easy_2432		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"We aimed to compare the risks of hospitalization for <span class=""disease"">AMI</span> and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <span class=""chemical"">acetaminophen</span>."		431.0	431_MESH:D000082_MESH:D009203	431_2	bcv_final_eval_easy_2433		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D005767	"<span class=""disease"">GI bleeding</span>"	"We aimed to compare the risks of hospitalization for AMI and <span class=""disease"">GI bleeding</span> among elderly patients using COX-2 inhibitors, NS-NSAIDs and <span class=""chemical"">acetaminophen</span>."		431.0	431_MESH:D000082_MESH:D005767	431_2	bcv_final_eval_easy_2434		
	MESH:D004008	"<span class=""chemical"">diclofenac</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <span class=""disease"">AMI</span>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), <span class=""chemical"">diclofenac</span> 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."		431.0	431_MESH:D004008_MESH:D009203	431_7	bcv_final_eval_easy_2435		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <span class=""disease"">AMI</span>/GI vs the <span class=""chemical"">acetaminophen</span> (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."		431.0	431_MESH:D000082_MESH:D009203	431_7	bcv_final_eval_easy_2436		
	MESH:C105934	"<span class=""chemical"">celecoxib</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <span class=""disease"">AMI</span>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <span class=""chemical"">celecoxib</span> 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."		431.0	431_MESH:C105934_MESH:D009203	431_7	bcv_final_eval_easy_2437		
	MESH:C116926	"<span class=""chemical"">rofecoxib</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <span class=""disease"">AMI</span>/GI vs the acetaminophen (with no aspirin) group were: <span class=""chemical"">rofecoxib</span> 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."		431.0	431_MESH:C116926_MESH:D009203	431_7	bcv_final_eval_easy_2438		
	MESH:D007052	"<span class=""chemical"">ibuprofen</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <span class=""disease"">AMI</span>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and <span class=""chemical"">ibuprofen</span> 1.05 (0.74, 1.51)."		431.0	431_MESH:D007052_MESH:D009203	431_7	bcv_final_eval_easy_2439		
	MESH:D009288	"<span class=""chemical"">naproxen</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <span class=""disease"">AMI</span>/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), <span class=""chemical"">naproxen</span> 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."		431.0	431_MESH:D009288_MESH:D009203	431_7	bcv_final_eval_easy_2440		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"Among non-users of <span class=""chemical"">aspirin</span>, the adjusted hazard ratios (95% confidence interval) of hospitalization for <span class=""disease"">AMI</span>/GI vs the acetaminophen (with no <span class=""chemical"">aspirin</span>) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51)."		431.0	431_MESH:D001241_MESH:D009203	431_7	bcv_final_eval_easy_2441		
	MESH:D009288	"<span class=""chemical"">naproxen</span>"	MESH:D009203	"<span class=""disease"">AMI/GI bleeding</span>"	"CONCLUSION: Among non-users of aspirin, <span class=""chemical"">naproxen</span> seemed to carry the highest risk for <span class=""disease"">AMI/GI bleeding</span>."		431.0	431_MESH:D009288_MESH:D009203	431_9	bcv_final_eval_easy_2442		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D009203	"<span class=""disease"">AMI/GI bleeding</span>"	"CONCLUSION: Among non-users of <span class=""chemical"">aspirin</span>, naproxen seemed to carry the highest risk for <span class=""disease"">AMI/GI bleeding</span>."		431.0	431_MESH:D001241_MESH:D009203	431_9	bcv_final_eval_easy_2443		
	MESH:C105934	"<span class=""chemical"">celecoxib</span>"	MESH:D005767	"<span class=""disease"">GI toxicity</span>"	"The AMI/<span class=""disease"">GI toxicity</span> of <span class=""chemical"">celecoxib</span> was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs."		431.0	431_MESH:C105934_MESH:D005767	431_10	bcv_final_eval_easy_2444		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D005767	"<span class=""disease"">GI toxicity</span>"	"The AMI/<span class=""disease"">GI toxicity</span> of celecoxib was similar to that of <span class=""chemical"">acetaminophen</span> and seemed to be better than those of rofecoxib and NS-NSAIDs."		431.0	431_MESH:D000082_MESH:D005767	431_10	bcv_final_eval_easy_2445		
	MESH:C116926	"<span class=""chemical"">rofecoxib</span>"	MESH:D005767	"<span class=""disease"">GI toxicity</span>"	"The AMI/<span class=""disease"">GI toxicity</span> of celecoxib was similar to that of acetaminophen and seemed to be better than those of <span class=""chemical"">rofecoxib</span> and NS-NSAIDs."		431.0	431_MESH:C116926_MESH:D005767	431_10	bcv_final_eval_easy_2446		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"The <span class=""disease"">AMI</span>/GI toxicity of celecoxib was similar to that of <span class=""chemical"">acetaminophen</span> and seemed to be better than those of rofecoxib and NS-NSAIDs."		431.0	431_MESH:D000082_MESH:D009203	431_10	bcv_final_eval_easy_2447		
	MESH:C105934	"<span class=""chemical"">celecoxib</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"The <span class=""disease"">AMI</span>/GI toxicity of <span class=""chemical"">celecoxib</span> was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs."		431.0	431_MESH:C105934_MESH:D009203	431_10	bcv_final_eval_easy_2448		
	MESH:C116926	"<span class=""chemical"">rofecoxib</span>"	MESH:D009203	"<span class=""disease"">AMI</span>"	"The <span class=""disease"">AMI</span>/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of <span class=""chemical"">rofecoxib</span> and NS-NSAIDs."		431.0	431_MESH:C116926_MESH:D009203	431_10	bcv_final_eval_easy_2449		
	MESH:D011803	"<span class=""chemical"">Quinine</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"<span class=""chemical"">Quinine</span>-induced arrhythmia in a patient with severe <span class=""disease"">malaria</span>."		432.0	432_MESH:D011803_MESH:D008288	432_0	bcv_final_eval_easy_2450		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D007565	"<span class=""disease"">jaundice</span>"	"It was reported that there was a case of severe malaria patient with <span class=""disease"">jaundice</span> who presented with arrhythmia (premature ventricular contraction) while getting <span class=""chemical"">quinine</span> infusion was reported."		432.0	432_MESH:D011803_MESH:D007565	432_1	bcv_final_eval_easy_2451		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D018879	"<span class=""disease"">premature ventricular contraction</span>"	"It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (<span class=""disease"">premature ventricular contraction</span>) while getting <span class=""chemical"">quinine</span> infusion was reported."		432.0	432_MESH:D011803_MESH:D018879	432_1	bcv_final_eval_easy_2452		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"It was reported that there was a case of severe <span class=""disease"">malaria</span> patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <span class=""chemical"">quinine</span> infusion was reported."		432.0	432_MESH:D011803_MESH:D008288	432_1	bcv_final_eval_easy_2453		
	MESH:D001663	"<span class=""chemical"">bilirubin</span>"	MESH:D007565	"<span class=""disease"">jaundice</span>"	"On admission, laboratory examination showed Plasmodium falciparum (++++), total <span class=""chemical"">bilirubin</span> 8.25 mg/dL, conjugated <span class=""chemical"">bilirubin</span> 4.36 mg/dL, unconjugated <span class=""chemical"">bilirubin</span> 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with <span class=""disease"">jaundice</span> and got quinine infusion in dextrose 5% 500 mg/8 hour."		432.0	432_MESH:D001663_MESH:D007565	432_4	bcv_final_eval_easy_2454		
	MESH:D001663	"<span class=""chemical"">bilirubin</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"On admission, laboratory examination showed Plasmodium falciparum (++++), total <span class=""chemical"">bilirubin</span> 8.25 mg/dL, conjugated <span class=""chemical"">bilirubin</span> 4.36 mg/dL, unconjugated <span class=""chemical"">bilirubin</span> 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe <span class=""disease"">malaria</span> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour."		432.0	432_MESH:D001663_MESH:D008288	432_4	bcv_final_eval_easy_2455		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe <span class=""disease"">malaria</span> with jaundice and got <span class=""chemical"">quinine</span> infusion in dextrose 5% 500 mg/8 hour."		432.0	432_MESH:D011803_MESH:D008288	432_4	bcv_final_eval_easy_2456		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D007565	"<span class=""disease"">jaundice</span>"	"On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with <span class=""disease"">jaundice</span> and got <span class=""chemical"">quinine</span> infusion in dextrose 5% 500 mg/8 hour."		432.0	432_MESH:D011803_MESH:D007565	432_4	bcv_final_eval_easy_2457		
	MESH:D005947	"<span class=""chemical"">dextrose</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe <span class=""disease"">malaria</span> with jaundice and got quinine infusion in <span class=""chemical"">dextrose</span> 5% 500 mg/8 hour."		432.0	432_MESH:D005947_MESH:D008288	432_4	bcv_final_eval_easy_2458		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, <span class=""chemical"">potassium</span> 3.52 meq/L Patient was diagnosed as severe <span class=""disease"">malaria</span> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour."		432.0	432_MESH:D011188_MESH:D008288	432_4	bcv_final_eval_easy_2459		
	MESH:D005947	"<span class=""chemical"">dextrose</span>"	MESH:D007565	"<span class=""disease"">jaundice</span>"	"On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with <span class=""disease"">jaundice</span> and got quinine infusion in <span class=""chemical"">dextrose</span> 5% 500 mg/8 hour."		432.0	432_MESH:D005947_MESH:D007565	432_4	bcv_final_eval_easy_2460		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D007565	"<span class=""disease"">jaundice</span>"	"On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, <span class=""chemical"">potassium</span> 3.52 meq/L Patient was diagnosed as severe malaria with <span class=""disease"">jaundice</span> and got quinine infusion in dextrose 5% 500 mg/8 hour."		432.0	432_MESH:D011188_MESH:D007565	432_4	bcv_final_eval_easy_2461		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D018879	"<span class=""disease"">premature ventricular contraction/PVC</span>"	"After 30 hours of <span class=""chemical"">quinine</span> infusion the patient felt palpitation and electrocardiography (ECG) recording showed <span class=""disease"">premature ventricular contraction</span> (<span class=""disease"">PVC</span>) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave."		432.0	432_MESH:D011803_MESH:D018879	432_6	bcv_final_eval_easy_2462		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D018879	"<span class=""disease"">PVC</span>"	"Three hours later the patient felt better, the frequency of <span class=""disease"">PVC</span> reduced to 4 - 5 x/minute and on the third day ECG was normal, <span class=""chemical"">potassium</span> level was 3.34 meq/L."		432.0	432_MESH:D011188_MESH:D018879	432_9	bcv_final_eval_easy_2463		
	MESH:D011803	"<span class=""chemical"">Quinine</span>"	MESH:D018879	"<span class=""disease"">PVC</span>"	"<span class=""chemical"">Quinine</span>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple <span class=""disease"">PVC</span>."		432.0	432_MESH:D011803_MESH:D018879	432_11	bcv_final_eval_easy_2464		
	MESH:D011802	"<span class=""chemical"">quinidine</span>"	MESH:D001145	"<span class=""disease"">various arrhythmias/arrhythmia</span>"	"Quinine, like <span class=""chemical"">quinidine</span>, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause <span class=""disease"">various arrhythmias</span>, including severe <span class=""disease"">arrhythmia</span> such as multiple PVC."		432.0	432_MESH:D011802_MESH:D001145	432_11	bcv_final_eval_easy_2465		
	MESH:D011802	"<span class=""chemical"">quinidine</span>"	MESH:D018879	"<span class=""disease"">PVC</span>"	"Quinine, like <span class=""chemical"">quinidine</span>, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple <span class=""disease"">PVC</span>."		432.0	432_MESH:D011802_MESH:D018879	432_11	bcv_final_eval_easy_2466		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"Administration of parenteral <span class=""chemical"">quinine</span> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (<span class=""disease"">hypokalemia</span>) which frequently occurs due to vomiting and or diarrhea in malaria cases."		432.0	432_MESH:D011803_MESH:D007008	432_12	bcv_final_eval_easy_2467		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D008288	"<span class=""disease"">malaria</span>"	"Administration of parenteral <span class=""chemical"">quinine</span> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in <span class=""disease"">malaria</span> cases."		432.0	432_MESH:D011803_MESH:D008288	432_12	bcv_final_eval_easy_2468		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D006331	"<span class=""disease"">heart diseases</span>"	"Administration of parenteral <span class=""chemical"">quinine</span> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have <span class=""disease"">heart diseases</span> or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases."		432.0	432_MESH:D011803_MESH:D006331	432_12	bcv_final_eval_easy_2469		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D014883	"<span class=""disease"">electrolyte disorder</span>"	"Administration of parenteral <span class=""chemical"">quinine</span> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with <span class=""disease"">electrolyte disorder</span> (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases."		432.0	432_MESH:D011803_MESH:D014883	432_12	bcv_final_eval_easy_2470		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D014839	"<span class=""disease"">vomiting</span>"	"Administration of parenteral <span class=""chemical"">quinine</span> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to <span class=""disease"">vomiting</span> and or diarrhea in malaria cases."		432.0	432_MESH:D011803_MESH:D014839	432_12	bcv_final_eval_easy_2471		
	MESH:D011803	"<span class=""chemical"">quinine</span>"	MESH:D003967	"<span class=""disease"">diarrhea</span>"	"Administration of parenteral <span class=""chemical"">quinine</span> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or <span class=""disease"">diarrhea</span> in malaria cases."		432.0	432_MESH:D011803_MESH:D003967	432_12	bcv_final_eval_easy_2472		
	MESH:D010396	"<span class=""chemical"">Penicillamine</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"<span class=""chemical"">Penicillamine</span>-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, <span class=""disease"">anxiety</span> and SPECT abnormalities."		433.0	433_MESH:D010396_MESH:D001008	433_0	bcv_final_eval_easy_2473		
	MESH:D010396	"<span class=""chemical"">Penicillamine</span>"	MESH:D006527	"<span class=""disease"">Wilson disease</span>"	"<span class=""chemical"">Penicillamine</span>-related lichenoid dermatitis and utility of zinc acetate in a <span class=""disease"">Wilson disease</span> patient with hepatic presentation, anxiety and SPECT abnormalities."		433.0	433_MESH:D010396_MESH:D006527	433_0	bcv_final_eval_easy_2474		
	MESH:D019345	"<span class=""chemical"">zinc acetate</span>"	MESH:D003872	"<span class=""disease"">lichenoid dermatitis</span>"	"Penicillamine-related <span class=""disease"">lichenoid dermatitis</span> and utility of <span class=""chemical"">zinc acetate</span> in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities."		433.0	433_MESH:D019345_MESH:D003872	433_0	bcv_final_eval_easy_2475		
	MESH:D010396	"<span class=""chemical"">Penicillamine</span>"	MESH:D003872	"<span class=""disease"">lichenoid dermatitis</span>"	"<span class=""chemical"">Penicillamine</span>-related <span class=""disease"">lichenoid dermatitis</span> and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities."		433.0	433_MESH:D010396_MESH:D003872	433_0	bcv_final_eval_easy_2476		
	MESH:D019345	"<span class=""chemical"">zinc acetate</span>"	MESH:D006527	"<span class=""disease"">Wilson disease</span>"	"Penicillamine-related lichenoid dermatitis and utility of <span class=""chemical"">zinc acetate</span> in a <span class=""disease"">Wilson disease</span> patient with hepatic presentation, anxiety and SPECT abnormalities."		433.0	433_MESH:D019345_MESH:D006527	433_0	bcv_final_eval_easy_2477		
	MESH:D019345	"<span class=""chemical"">zinc acetate</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"Penicillamine-related lichenoid dermatitis and utility of <span class=""chemical"">zinc acetate</span> in a Wilson disease patient with hepatic presentation, <span class=""disease"">anxiety</span> and SPECT abnormalities."		433.0	433_MESH:D019345_MESH:D001008	433_0	bcv_final_eval_easy_2478		
	MESH:D003300	"<span class=""chemical"">copper</span>"	MESH:D001523	"<span class=""disease"">psychiatric disorders</span>"	"Wilson's disease is an autosomal recessive disorder of hepatic <span class=""chemical"">copper</span> metabolism with consequent <span class=""chemical"">copper</span> accumulation and toxicity in many tissues and consequent hepatic, neurologic and <span class=""disease"">psychiatric disorders</span>."		433.0	433_MESH:D003300_MESH:D001523	433_1	bcv_final_eval_easy_2479		
	MESH:D003300	"<span class=""chemical"">copper</span>"	MESH:D006527	"<span class=""disease"">Wilson's disease</span>"	"<span class=""disease"">Wilson's disease</span> is an autosomal recessive disorder of hepatic <span class=""chemical"">copper</span> metabolism with consequent <span class=""chemical"">copper</span> accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders."		433.0	433_MESH:D003300_MESH:D006527	433_1	bcv_final_eval_easy_2480		
	MESH:D003300	"<span class=""chemical"">copper</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Wilson's disease is an autosomal recessive disorder of hepatic <span class=""chemical"">copper</span> metabolism with consequent <span class=""chemical"">copper</span> accumulation and <span class=""disease"">toxicity</span> in many tissues and consequent hepatic, neurologic and psychiatric disorders."		433.0	433_MESH:D003300_MESH:D064420	433_1	bcv_final_eval_easy_2481		
	MESH:D010396	"<span class=""chemical"">penicillamine</span>"	MESH:D003872	"<span class=""disease"">lichenoid dermatitis</span>"	"During the follow-up of our patient, <span class=""chemical"">penicillamine</span> was interrupted after the appearance of a <span class=""disease"">lichenoid dermatitis</span>, and zinc acetate permitted to continue the successful treatment of the patient without side-effects."		433.0	433_MESH:D010396_MESH:D003872	433_3	bcv_final_eval_easy_2482		
	MESH:D019345	"<span class=""chemical"">zinc acetate</span>"	MESH:D003872	"<span class=""disease"">lichenoid dermatitis</span>"	"During the follow-up of our patient, penicillamine was interrupted after the appearance of a <span class=""disease"">lichenoid dermatitis</span>, and <span class=""chemical"">zinc acetate</span> permitted to continue the successful treatment of the patient without side-effects."		433.0	433_MESH:D019345_MESH:D003872	433_3	bcv_final_eval_easy_2483		
	MESH:D019345	"<span class=""chemical"">zinc acetate</span>"	MESH:D006527	"<span class=""disease"">Wilson's disease</span>"	"In our case the therapy with <span class=""chemical"">zinc acetate</span> represented an effective treatment for a <span class=""disease"">Wilson's disease</span> patient in which penicillamine-related side effects appeared."		433.0	433_MESH:D019345_MESH:D006527	433_4	bcv_final_eval_easy_2484		
	MESH:D010396	"<span class=""chemical"">penicillamine</span>"	MESH:D006527	"<span class=""disease"">Wilson's disease</span>"	"In our case the therapy with zinc acetate represented an effective treatment for a <span class=""disease"">Wilson's disease</span> patient in which <span class=""chemical"">penicillamine</span>-related side effects appeared."		433.0	433_MESH:D010396_MESH:D006527	433_4	bcv_final_eval_easy_2485		
	MESH:D019345	"<span class=""chemical"">zinc acetate</span>"	MESH:D006527	"<span class=""disease"">Wilson's disease</span>"	"The safety of the <span class=""chemical"">zinc acetate</span> allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of <span class=""disease"">Wilson's disease</span>."		433.0	433_MESH:D019345_MESH:D006527	433_5	bcv_final_eval_easy_2486		
	MESH:D010396	"<span class=""chemical"">penicillamine</span>"	MESH:D012871	"<span class=""disease"">skin lesion</span>"	"Since most of Wilson's disease <span class=""chemical"">penicillamine</span>-treated patients do not seem to develop this <span class=""disease"">skin lesion</span>, it could be conceivable that a specific genetic factor is involved in drug response."		433.0	433_MESH:D010396_MESH:D012871	433_6	bcv_final_eval_easy_2487		
	MESH:D010396	"<span class=""chemical"">penicillamine</span>"	MESH:D006527	"<span class=""disease"">Wilson's disease</span>"	"Since most of <span class=""disease"">Wilson's disease</span> <span class=""chemical"">penicillamine</span>-treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response."		433.0	433_MESH:D010396_MESH:D006527	433_6	bcv_final_eval_easy_2488		
	MESH:D003561	"<span class=""chemical"">cytarabine</span>"	MESH:D020301	"<span class=""disease"">cerebral vasospasm</span>"	"Acute encephalopathy and <span class=""disease"">cerebral vasospasm</span> after multiagent chemotherapy including PEG-asparaginase and intrathecal <span class=""chemical"">cytarabine</span> for the treatment of acute lymphoblastic leukemia."		435.0	435_MESH:D003561_MESH:D020301	435_0	bcv_final_eval_easy_2489		
	MESH:D003561	"<span class=""chemical"">cytarabine</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"Acute <span class=""disease"">encephalopathy</span> and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal <span class=""chemical"">cytarabine</span> for the treatment of acute lymphoblastic leukemia."		435.0	435_MESH:D003561_MESH:D001927	435_0	bcv_final_eval_easy_2490		
	MESH:D003561	"<span class=""chemical"">cytarabine</span>"	MESH:D054198	"<span class=""disease"">acute lymphoblastic leukemia</span>"	"Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal <span class=""chemical"">cytarabine</span> for the treatment of <span class=""disease"">acute lymphoblastic leukemia</span>."		435.0	435_MESH:D003561_MESH:D054198	435_0	bcv_final_eval_easy_2491		
	MESH:D003561	"<span class=""chemical"">cytarabine</span>"	MESH:D001037	"<span class=""disease"">aphasia</span>"	"The patient developed acute encephalopathy evidenced by behavioral changes, <span class=""disease"">aphasia</span>, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <span class=""chemical"">cytarabine</span>."		435.0	435_MESH:D003561_MESH:D001037	435_2	bcv_final_eval_easy_2492		
	MESH:D003561	"<span class=""chemical"">cytarabine</span>"	MESH:D020301	"<span class=""disease"">cerebral vasospasm</span>"	"The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse <span class=""disease"">cerebral vasospasm</span> on magnetic resonance angiography after the administration of intrathecal <span class=""chemical"">cytarabine</span>."		435.0	435_MESH:D003561_MESH:D020301	435_2	bcv_final_eval_easy_2493		
	MESH:D003561	"<span class=""chemical"">cytarabine</span>"	MESH:D001927	"<span class=""disease"">encephalopathy</span>"	"The patient developed acute <span class=""disease"">encephalopathy</span> evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <span class=""chemical"">cytarabine</span>."		435.0	435_MESH:D003561_MESH:D001927	435_2	bcv_final_eval_easy_2494		
	MESH:D003561	"<span class=""chemical"">cytarabine</span>"	MESH:D006212	"<span class=""disease"">visual hallucinations</span>"	"The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, <span class=""disease"">visual hallucinations</span>, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <span class=""chemical"">cytarabine</span>."		435.0	435_MESH:D003561_MESH:D006212	435_2	bcv_final_eval_easy_2495		
	MESH:D006852	"<span class=""chemical"">hydrochlorothiazide</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"Comparison of valsartan/<span class=""chemical"">hydrochlorothiazide</span> combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in <span class=""disease"">hypertensive</span> adults."		436.0	436_MESH:D006852_MESH:D006973	436_0	bcv_final_eval_easy_2496		
	MESH:C081489	"<span class=""chemical"">valsartan</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"Comparison of <span class=""chemical"">valsartan</span>/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in <span class=""disease"">hypertensive</span> adults."		436.0	436_MESH:C081489_MESH:D006973	436_0	bcv_final_eval_easy_2497		
	MESH:D006852	"<span class=""chemical"">HCTZ/hydrochlorothiazide</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or <span class=""chemical"">hydrochlorothiazide</span> (<span class=""chemical"">HCTZ</span>)-monotherapy and higher-dose combinations in patients with essential <span class=""disease"">hypertension</span>."		436.0	436_MESH:D006852_MESH:D006973	436_3	bcv_final_eval_easy_2498		
	MESH:C081489	"<span class=""chemical"">VAL/valsartan</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"OBJECTIVE: This study investigated the efficacy and tolerability of <span class=""chemical"">valsartan</span> (<span class=""chemical"">VAL</span>) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential <span class=""disease"">hypertension</span>."		436.0	436_MESH:C081489_MESH:D006973	436_3	bcv_final_eval_easy_2499		
	MESH:D006852	"<span class=""chemical"">HCTZ</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Patients with essential <span class=""disease"">hypertension</span> (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; <span class=""chemical"">HCTZ</span> 12.5 or 25 mg; VAL/<span class=""chemical"">HCTZ</span> 160/12.5, 320/12.5, or 320/25 mg; or placebo."		436.0	436_MESH:D006852_MESH:D006973	436_5	bcv_final_eval_easy_2500		
	MESH:C081489	"<span class=""chemical"">VAL</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Patients with essential <span class=""disease"">hypertension</span> (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: <span class=""chemical"">VAL</span> 160 or 320 mg; HCTZ 12.5 or 25 mg; <span class=""chemical"">VAL</span>/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo."		436.0	436_MESH:C081489_MESH:D006973	436_5	bcv_final_eval_easy_2501		
	MESH:D006852	"<span class=""chemical"">HCTZ</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"The incidence of <span class=""disease"">hypokalemia</span> was lower with VAL/<span class=""chemical"">HCTZ</span> combinations (1.8%-6.1%) than with <span class=""chemical"">HCTZ</span> monotherapies (7.1%-13.3%)."		436.0	436_MESH:D006852_MESH:D007008	436_17	bcv_final_eval_easy_2502		
	MESH:C081489	"<span class=""chemical"">VAL</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"The incidence of <span class=""disease"">hypokalemia</span> was lower with <span class=""chemical"">VAL</span>/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%)."		436.0	436_MESH:C081489_MESH:D007008	436_17	bcv_final_eval_easy_2503		
	MESH:D006852	"<span class=""chemical"">HCTZ</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"CONCLUSIONS: In this study population, combination therapies with VAL/<span class=""chemical"">HCTZ</span> were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less <span class=""disease"">hypokalemia</span> than <span class=""chemical"">HCTZ</span> alone."		436.0	436_MESH:D006852_MESH:D007008	436_20	bcv_final_eval_easy_2504		
	MESH:C081489	"<span class=""chemical"">VAL</span>"	MESH:D007008	"<span class=""disease"">hypokalemia</span>"	"CONCLUSIONS: In this study population, combination therapies with <span class=""chemical"">VAL</span>/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less <span class=""disease"">hypokalemia</span> than HCTZ alone."		436.0	436_MESH:C081489_MESH:D007008	436_20	bcv_final_eval_easy_2505		
	MESH:D002110	"<span class=""chemical"">Caffeine</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"<span class=""chemical"">Caffeine</span> challenge test in panic disorder and <span class=""disease"">depression</span> with panic attacks."		438.0	438_MESH:D002110_MESH:D003866	438_0	bcv_final_eval_easy_2506		
	MESH:D002110	"<span class=""chemical"">Caffeine</span>"	MESH:D016584	"<span class=""disease"">panic disorder/panic attacks</span>"	"<span class=""chemical"">Caffeine</span> challenge test in <span class=""disease"">panic disorder</span> and depression with <span class=""disease"">panic attacks</span>."		438.0	438_MESH:D002110_MESH:D016584	438_0	bcv_final_eval_easy_2507		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D003866	"<span class=""disease"">MDP/major depression with panic attacks</span>"	"Our aim was to observe if patients with panic disorder (PD) and patients with <span class=""disease"">major depression with panic attacks</span> (<span class=""disease"">MDP</span>) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <span class=""chemical"">caffeine</span> challenge test."		438.0	438_MESH:D002110_MESH:D003866	438_1	bcv_final_eval_easy_2508		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D001523	"<span class=""disease"">Mental Disorders</span>"	"Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of <span class=""disease"">Mental Disorders</span>, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <span class=""chemical"">caffeine</span> challenge test."		438.0	438_MESH:D002110_MESH:D001523	438_1	bcv_final_eval_easy_2509		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">panic disorder/PD/panic attacks</span>"	"Our aim was to observe if patients with <span class=""disease"">panic disorder</span> (<span class=""disease"">PD</span>) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of <span class=""disease"">panic attacks</span> by an oral <span class=""chemical"">caffeine</span> challenge test."		438.0	438_MESH:D002110_MESH:D016584	438_1	bcv_final_eval_easy_2510		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D001008	"<span class=""disease"">anxiety</span>"	"In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg <span class=""chemical"">caffeine</span> and a <span class=""chemical"">caffeine</span>-free (placebo) solution were administered in a coffee form and <span class=""disease"">anxiety</span> scales were applied before and after each test."		438.0	438_MESH:D002110_MESH:D001008	438_4	bcv_final_eval_easy_2511		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D009436	"<span class=""disease"">MD</span>"	"A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with <span class=""disease"">MD</span>, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg <span class=""chemical"">caffeine</span> challenge test (chi(2)(3) = 16.22, P = .001)."		438.0	438_MESH:D002110_MESH:D009436	438_5	bcv_final_eval_easy_2512		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D003866	"<span class=""disease"">MDP</span>"	"A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with <span class=""disease"">MDP</span>, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg <span class=""chemical"">caffeine</span> challenge test (chi(2)(3) = 16.22, P = .001)."		438.0	438_MESH:D002110_MESH:D003866	438_5	bcv_final_eval_easy_2513		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">panic/PD</span>"	"A total of 58.6% (n = 17) of patients with <span class=""disease"">PD</span>, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a <span class=""disease"">panic</span> attack after the 480-mg <span class=""chemical"">caffeine</span> challenge test (chi(2)(3) = 16.22, P = .001)."		438.0	438_MESH:D002110_MESH:D016584	438_5	bcv_final_eval_easy_2514		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D009436	"<span class=""disease"">MD</span>"	"The patients with PD and MDP were more sensitive to <span class=""chemical"">caffeine</span> than were patients with <span class=""disease"">MD</span> and healthy volunteers."		438.0	438_MESH:D002110_MESH:D009436	438_6	bcv_final_eval_easy_2515		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D003866	"<span class=""disease"">MDP</span>"	"The patients with PD and <span class=""disease"">MDP</span> were more sensitive to <span class=""chemical"">caffeine</span> than were patients with MD and healthy volunteers."		438.0	438_MESH:D002110_MESH:D003866	438_6	bcv_final_eval_easy_2516		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">PD</span>"	"The patients with <span class=""disease"">PD</span> and MDP were more sensitive to <span class=""chemical"">caffeine</span> than were patients with MD and healthy volunteers."		438.0	438_MESH:D002110_MESH:D016584	438_6	bcv_final_eval_easy_2517		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">panic</span>"	"No <span class=""disease"">panic</span> attack was observed after the <span class=""chemical"">caffeine</span>-free solution intake."		438.0	438_MESH:D002110_MESH:D016584	438_7	bcv_final_eval_easy_2518		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D003866	"<span class=""disease"">MDP</span>"	"Our data suggest that there is an association between panic attacks, no matter if associated with PD or <span class=""disease"">MDP</span>, and hyperreactivity to an oral <span class=""chemical"">caffeine</span> challenge test."		438.0	438_MESH:D002110_MESH:D003866	438_9	bcv_final_eval_easy_2519		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016535	"<span class=""disease"">hyperreactivity</span>"	"Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and <span class=""disease"">hyperreactivity</span> to an oral <span class=""chemical"">caffeine</span> challenge test."		438.0	438_MESH:D002110_MESH:D016535	438_9	bcv_final_eval_easy_2520		
	MESH:D002110	"<span class=""chemical"">caffeine</span>"	MESH:D016584	"<span class=""disease"">PD/panic attacks</span>"	"Our data suggest that there is an association between <span class=""disease"">panic attacks</span>, no matter if associated with <span class=""disease"">PD</span> or MDP, and hyperreactivity to an oral <span class=""chemical"">caffeine</span> challenge test."		438.0	438_MESH:D002110_MESH:D016584	438_9	bcv_final_eval_easy_2521		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D008944	"<span class=""disease"">MR</span>"	"Acute heart failure was induced by <span class=""chemical"">propranolol</span> and volume loading after weaning from cardiopulmonary bypass; an absence of <span class=""disease"">MR</span> was confirmed by echocardiography."		439.0	439_MESH:D011433_MESH:D008944	439_7	bcv_final_eval_easy_2522		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D006333	"<span class=""disease"">Acute heart failure</span>"	"<span class=""disease"">Acute heart failure</span> was induced by <span class=""chemical"">propranolol</span> and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography."		439.0	439_MESH:D011433_MESH:D006333	439_7	bcv_final_eval_easy_2523		
	MESH:D010878	"<span class=""chemical"">Piperacillin</span>"	MESH:D012640	"<span class=""disease"">seizure</span>"	"<span class=""chemical"">Piperacillin</span>/tazobactam-induced <span class=""disease"">seizure</span> rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis."		440.0	440_MESH:D010878_MESH:D012640	440_0	bcv_final_eval_easy_2524		
	MESH:D010878	"<span class=""chemical"">piperacillin</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"Despite popular use of <span class=""chemical"">piperacillin</span>, the dire <span class=""disease"">neurotoxicity</span> associated with <span class=""chemical"">piperacillin</span> still goes unrecognized, leading to a delay in appropriate management."		440.0	440_MESH:D010878_MESH:D020258	440_1	bcv_final_eval_easy_2525		
	MESH:C043265	"<span class=""chemical"">tazobactam</span>"	MESH:D001987	"<span class=""disease"">bronchiectasis</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/<span class=""chemical"">tazobactam</span> (2 g/250 mg) were given for <span class=""disease"">bronchiectasis</span> with secondary infection."		440.0	440_MESH:C043265_MESH:D001987	440_2	bcv_final_eval_easy_2526		
	MESH:D010878	"<span class=""chemical"">piperacillin</span>"	MESH:D014202	"<span class=""disease"">tremor</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, <span class=""disease"">tremor</span>, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <span class=""chemical"">piperacillin</span>/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection."		440.0	440_MESH:D010878_MESH:D014202	440_2	bcv_final_eval_easy_2527		
	MESH:D010878	"<span class=""chemical"">piperacillin</span>"	MESH:D007676	"<span class=""disease"">end-stage renal disease</span>"	"We report a 57-year-old woman with <span class=""disease"">end-stage renal disease</span> receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <span class=""chemical"">piperacillin</span>/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection."		440.0	440_MESH:D010878_MESH:D007676	440_2	bcv_final_eval_easy_2528		
	MESH:C043265	"<span class=""chemical"">tazobactam</span>"	MESH:D007676	"<span class=""disease"">end-stage renal disease</span>"	"We report a 57-year-old woman with <span class=""disease"">end-stage renal disease</span> receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/<span class=""chemical"">tazobactam</span> (2 g/250 mg) were given for bronchiectasis with secondary infection."		440.0	440_MESH:C043265_MESH:D007676	440_2	bcv_final_eval_easy_2529		
	MESH:D010878	"<span class=""chemical"">piperacillin</span>"	MESH:D007239	"<span class=""disease"">infection</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <span class=""chemical"">piperacillin</span>/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary <span class=""disease"">infection</span>."		440.0	440_MESH:D010878_MESH:D007239	440_2	bcv_final_eval_easy_2530		
	MESH:C043265	"<span class=""chemical"">tazobactam</span>"	MESH:D014202	"<span class=""disease"">tremor</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, <span class=""disease"">tremor</span>, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/<span class=""chemical"">tazobactam</span> (2 g/250 mg) were given for bronchiectasis with secondary infection."		440.0	440_MESH:C043265_MESH:D014202	440_2	bcv_final_eval_easy_2531		
	MESH:D010878	"<span class=""chemical"">piperacillin</span>"	MESH:D012640	"<span class=""disease"">tonic-clonic seizure</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized <span class=""disease"">tonic-clonic seizure</span> (GTCS) after 5 doses of <span class=""chemical"">piperacillin</span>/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection."		440.0	440_MESH:D010878_MESH:D012640	440_2	bcv_final_eval_easy_2532		
	MESH:D010878	"<span class=""chemical"">piperacillin</span>"	MESH:D001987	"<span class=""disease"">bronchiectasis</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <span class=""chemical"">piperacillin</span>/tazobactam (2 g/250 mg) were given for <span class=""disease"">bronchiectasis</span> with secondary infection."		440.0	440_MESH:D010878_MESH:D001987	440_2	bcv_final_eval_easy_2533		
	MESH:C043265	"<span class=""chemical"">tazobactam</span>"	MESH:D007239	"<span class=""disease"">infection</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/<span class=""chemical"">tazobactam</span> (2 g/250 mg) were given for bronchiectasis with secondary <span class=""disease"">infection</span>."		440.0	440_MESH:C043265_MESH:D007239	440_2	bcv_final_eval_easy_2534		
	MESH:C043265	"<span class=""chemical"">tazobactam</span>"	MESH:D003221	"<span class=""disease"">confusion</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental <span class=""disease"">confusion</span>, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/<span class=""chemical"">tazobactam</span> (2 g/250 mg) were given for bronchiectasis with secondary infection."		440.0	440_MESH:C043265_MESH:D003221	440_2	bcv_final_eval_easy_2535		
	MESH:D010878	"<span class=""chemical"">piperacillin</span>"	MESH:D003221	"<span class=""disease"">confusion</span>"	"We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental <span class=""disease"">confusion</span>, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <span class=""chemical"">piperacillin</span>/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection."		440.0	440_MESH:D010878_MESH:D003221	440_2	bcv_final_eval_easy_2536		
	MESH:D000641	"<span class=""chemical"">ammonia</span>"	MESH:D007964	"<span class=""disease"">leukocytosis</span>"	"The laboratory data revealed normal plasma electrolyte and <span class=""chemical"">ammonia</span> levels but <span class=""disease"">leukocytosis</span>."		440.0	440_MESH:D000641_MESH:D007964	440_3	bcv_final_eval_easy_2537		
	MESH:D008550	"<span class=""chemical"">melatonin</span>"	MESH:D054220	"<span class=""disease"">cortical dysplasia</span>"	"Neuroprotective effects of <span class=""chemical"">melatonin</span> upon the offspring cerebellar cortex in the rat model of BCNU-induced <span class=""disease"">cortical dysplasia</span>."		442.0	442_MESH:D008550_MESH:D054220	442_0	bcv_final_eval_easy_2538		
	MESH:D008550	"<span class=""chemical"">melatonin</span>"	MESH:D054220	"<span class=""disease"">cortical dysplasia</span>"	"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous <span class=""chemical"">melatonin</span> upon cerebellar BCNU-induced <span class=""disease"">cortical dysplasia</span>, using histological and biochemical analyses."		442.0	442_MESH:D008550_MESH:D054220	442_2	bcv_final_eval_easy_2539		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"This study shows that MIP synthase inhibition does not replicate or augment the effects of <span class=""chemical"">lithium</span> in the inositol sensitive pilocarpine-induced <span class=""disease"">seizures</span> model."		443.0	443_MESH:D008094_MESH:D012640	443_4	bcv_final_eval_easy_2540		
	MESH:D007294	"<span class=""chemical"">inositol</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the <span class=""chemical"">inositol</span> sensitive pilocarpine-induced <span class=""disease"">seizures</span> model."		443.0	443_MESH:D007294_MESH:D012640	443_4	bcv_final_eval_easy_2541		
	MESH:D012293	"<span class=""chemical"">Rifampicin</span>"	MESH:D004696	"<span class=""disease"">staphylococcal endocarditis</span>"	"<span class=""chemical"">Rifampicin</span>-associated segmental necrotizing glomerulonephritis in <span class=""disease"">staphylococcal endocarditis</span>."		445.0	445_MESH:D012293_MESH:D004696	445_0	bcv_final_eval_easy_2542		
	MESH:D012293	"<span class=""chemical"">Rifampicin</span>"	MESH:D005921	"<span class=""disease"">glomerulonephritis</span>"	"<span class=""chemical"">Rifampicin</span>-associated segmental necrotizing <span class=""disease"">glomerulonephritis</span> in staphylococcal endocarditis."		445.0	445_MESH:D012293_MESH:D005921	445_0	bcv_final_eval_easy_2543		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D005921	"<span class=""disease"">glomerulonephritis</span>"	"Segmental necrotising <span class=""disease"">glomerulonephritis</span> has been reported as complication of <span class=""chemical"">rifampicin</span> therapy in patients receiving treatment for tuberculosis."		445.0	445_MESH:D012293_MESH:D005921	445_1	bcv_final_eval_easy_2544		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D014376	"<span class=""disease"">tuberculosis</span>"	"Segmental necrotising glomerulonephritis has been reported as complication of <span class=""chemical"">rifampicin</span> therapy in patients receiving treatment for <span class=""disease"">tuberculosis</span>."		445.0	445_MESH:D012293_MESH:D014376	445_1	bcv_final_eval_easy_2545		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D004696	"<span class=""disease"">IE/infective endocarditis</span>"	"Changing epidemiology of infections such as <span class=""disease"">infective endocarditis</span> (<span class=""disease"">IE</span>) has led to an increase in the use of <span class=""chemical"">rifampicin</span> for Staphylococcal infections."		445.0	445_MESH:D012293_MESH:D004696	445_2	bcv_final_eval_easy_2546		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D013203	"<span class=""disease"">Staphylococcal infections</span>"	"Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of <span class=""chemical"">rifampicin</span> for <span class=""disease"">Staphylococcal infections</span>."		445.0	445_MESH:D012293_MESH:D013203	445_2	bcv_final_eval_easy_2547		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D007239	"<span class=""disease"">infections</span>"	"Changing epidemiology of <span class=""disease"">infections</span> such as infective endocarditis (IE) has led to an increase in the use of <span class=""chemical"">rifampicin</span> for Staphylococcal infections."		445.0	445_MESH:D012293_MESH:D007239	445_2	bcv_final_eval_easy_2548		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D004696	"<span class=""disease"">IE</span>"	"We describe a case of a patient with Staphylococcal <span class=""disease"">IE</span> who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with <span class=""chemical"">rifampicin</span>, and review the literature regarding this complication of <span class=""chemical"">rifampicin</span> therapy."		445.0	445_MESH:D012293_MESH:D004696	445_3	bcv_final_eval_easy_2549		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"We describe a case of a patient with Staphylococcal IE who developed <span class=""disease"">acute renal failure</span> secondary to a segmental necrotising glomerulonephritis while being treated with <span class=""chemical"">rifampicin</span>, and review the literature regarding this complication of <span class=""chemical"">rifampicin</span> therapy."		445.0	445_MESH:D012293_MESH:D058186	445_3	bcv_final_eval_easy_2550		
	MESH:D012293	"<span class=""chemical"">rifampicin</span>"	MESH:D005921	"<span class=""disease"">glomerulonephritis</span>"	"We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising <span class=""disease"">glomerulonephritis</span> while being treated with <span class=""chemical"">rifampicin</span>, and review the literature regarding this complication of <span class=""chemical"">rifampicin</span> therapy."		445.0	445_MESH:D012293_MESH:D005921	445_3	bcv_final_eval_easy_2551		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B virus infection</span>"	"Rate of YMDD motif mutants in <span class=""chemical"">lamivudine</span>-untreated Iranian patients with chronic <span class=""disease"">hepatitis B virus infection</span>."		446.0	446_MESH:D019259_MESH:D006509	446_0	bcv_final_eval_easy_2552		
	MESH:D019259	"<span class=""chemical"">Lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"BACKGROUND: <span class=""chemical"">Lamivudine</span> is used for the treatment of chronic <span class=""disease"">hepatitis B</span> patients."		446.0	446_MESH:D019259_MESH:D006509	446_1	bcv_final_eval_easy_2553		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"Recent studies show that the YMDD motif mutants (resistant <span class=""disease"">hepatitis B</span> virus) occur as natural genome variability in <span class=""chemical"">lamivudine</span>-untreated chronic <span class=""disease"">hepatitis B</span> patients."		446.0	446_MESH:D019259_MESH:D006509	446_2	bcv_final_eval_easy_2554		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"In this study we aimed to determine the rate of YMDD motif mutants in <span class=""chemical"">lamivudine</span>-untreated chronic <span class=""disease"">hepatitis B</span> patients in Iran."		446.0	446_MESH:D019259_MESH:D006509	446_3	bcv_final_eval_easy_2555		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"PATIENTS AND METHODS: A total of 77 chronic <span class=""disease"">hepatitis B</span> patients who had not been treated with <span class=""chemical"">lamivudine</span> were included in the study."		446.0	446_MESH:D019259_MESH:D006509	446_4	bcv_final_eval_easy_2556		
	MESH:D019259	"<span class=""chemical"">lamivudine</span>"	MESH:D006509	"<span class=""disease"">hepatitis B</span>"	"CONCLUSION: Although the natural occurrence of YMDD motif mutants in <span class=""chemical"">lamivudine</span>-untreated patients with chronic <span class=""disease"">hepatitis B</span> has been reported, these mutants were not detected in Iranian <span class=""chemical"">lamivudine</span>-untreated chronic <span class=""disease"">hepatitis B</span> patients."		446.0	446_MESH:D019259_MESH:D006509	446_12	bcv_final_eval_easy_2557		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D012170	"<span class=""disease"">Branch retinal vein occlusion</span>"	"<span class=""disease"">Branch retinal vein occlusion</span> and <span class=""chemical"">fluoxetine</span>."		447.0	447_MESH:D005473_MESH:D012170	447_0	bcv_final_eval_easy_2558		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D012170	"<span class=""disease"">branch retinal vein occlusion</span>"	"A case of <span class=""disease"">branch retinal vein occlusion</span> associated with <span class=""chemical"">fluoxetine</span>-induced secondary hypertension is described."		447.0	447_MESH:D005473_MESH:D012170	447_1	bcv_final_eval_easy_2559		
	MESH:D005473	"<span class=""chemical"">fluoxetine</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"A case of branch retinal vein occlusion associated with <span class=""chemical"">fluoxetine</span>-induced secondary <span class=""disease"">hypertension</span> is described."		447.0	447_MESH:D005473_MESH:D006973	447_1	bcv_final_eval_easy_2560		
	MESH:D012701	"<span class=""chemical"">serotonin</span>"	MESH:D006973	"<span class=""disease"">hypertension</span>"	"Although an infrequent complication of selective <span class=""chemical"">serotonin</span> reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause <span class=""disease"">hypertension</span> because this class of drugs is widely prescribed."		447.0	447_MESH:D012701_MESH:D006973	447_2	bcv_final_eval_easy_2561		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"The differential effects of <span class=""chemical"">bupivacaine</span> and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and <span class=""disease"">pain</span> in a clinical <span class=""disease"">pain</span> model."		448.0	448_MESH:D002045_MESH:D010146	448_0	bcv_final_eval_easy_2562		
	MESH:D008012	"<span class=""chemical"">lidocaine</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"The differential effects of bupivacaine and <span class=""chemical"">lidocaine</span> on prostaglandin E2 release, cyclooxygenase gene expression and <span class=""disease"">pain</span> in a clinical <span class=""disease"">pain</span> model."		448.0	448_MESH:D008012_MESH:D010146	448_0	bcv_final_eval_easy_2563		
	MESH:D015232	"<span class=""chemical"">prostaglandin E2</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"The differential effects of bupivacaine and lidocaine on <span class=""chemical"">prostaglandin E2</span> release, cyclooxygenase gene expression and <span class=""disease"">pain</span> in a clinical <span class=""disease"">pain</span> model."		448.0	448_MESH:D015232_MESH:D010146	448_0	bcv_final_eval_easy_2564		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D010149	"<span class=""disease"">postoperative pain</span>"	"In the present study, we describe the proinflammatory effects of <span class=""chemical"">bupivacaine</span> on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases <span class=""disease"">postoperative pain</span> in human subjects."		448.0	448_MESH:D002045_MESH:D010149	448_2	bcv_final_eval_easy_2565		
	MESH:D015232	"<span class=""chemical"">PGE2/prostaglandin E2</span>"	MESH:D010149	"<span class=""disease"">postoperative pain</span>"	"In the present study, we describe the proinflammatory effects of bupivacaine on local <span class=""chemical"">prostaglandin E2</span> (<span class=""chemical"">PGE2</span>) production and cyclooxygenase (COX) gene expression that increases <span class=""disease"">postoperative pain</span> in human subjects."		448.0	448_MESH:D015232_MESH:D010149	448_2	bcv_final_eval_easy_2566		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D010146	"<span class=""disease"">less pain</span>"	"RESULTS: The <span class=""chemical"">bupivacaine</span>/rofecoxib group reported significantly <span class=""disease"">less pain</span>, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h."		448.0	448_MESH:D002045_MESH:D010146	448_6	bcv_final_eval_easy_2567		
	MESH:C116926	"<span class=""chemical"">rofecoxib</span>"	MESH:D010146	"<span class=""disease"">less pain</span>"	"RESULTS: The bupivacaine/<span class=""chemical"">rofecoxib</span> group reported significantly <span class=""disease"">less pain</span>, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h."		448.0	448_MESH:C116926_MESH:D010146	448_6	bcv_final_eval_easy_2568		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"However, the <span class=""chemical"">bupivacaine</span>/placebo group reported significantly more <span class=""disease"">pain</span> at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups."		448.0	448_MESH:D002045_MESH:D010146	448_7	bcv_final_eval_easy_2569		
	MESH:D015232	"<span class=""chemical"">PGE2</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"However, the bupivacaine/placebo group reported significantly more <span class=""disease"">pain</span> at 24 h and <span class=""chemical"">PGE2</span> levels during the first 4 h were significantly higher than the other three treatment groups."		448.0	448_MESH:D015232_MESH:D010146	448_7	bcv_final_eval_easy_2570		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"CONCLUSIONS: These results suggest that <span class=""chemical"">bupivacaine</span> stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and <span class=""disease"">pain</span> after the local anesthetic effect dissipates."		448.0	448_MESH:D002045_MESH:D010146	448_10	bcv_final_eval_easy_2571		
	MESH:D015232	"<span class=""chemical"">PGE2</span>"	MESH:D017695	"<span class=""disease"">tissue injury</span>"	"CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after <span class=""disease"">tissue injury</span>, which is associated with higher <span class=""chemical"">PGE2</span> production and pain after the local anesthetic effect dissipates."		448.0	448_MESH:D015232_MESH:D017695	448_10	bcv_final_eval_easy_2572		
	MESH:D015232	"<span class=""chemical"">PGE2</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher <span class=""chemical"">PGE2</span> production and <span class=""disease"">pain</span> after the local anesthetic effect dissipates."		448.0	448_MESH:D015232_MESH:D010146	448_10	bcv_final_eval_easy_2573		
	MESH:D002045	"<span class=""chemical"">bupivacaine</span>"	MESH:D017695	"<span class=""disease"">tissue injury</span>"	"CONCLUSIONS: These results suggest that <span class=""chemical"">bupivacaine</span> stimulates COX-2 gene expression after <span class=""disease"">tissue injury</span>, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates."		448.0	448_MESH:D002045_MESH:D017695	448_10	bcv_final_eval_easy_2574		
	MESH:D014443	"<span class=""chemical"">tyrosine</span>"	MESH:D001749	"<span class=""disease"">urinary bladder inflammation</span>"	"Previous studies have examined the expression and regulation of <span class=""chemical"">tyrosine</span> kinase receptors (Trks) in micturition reflexes with <span class=""disease"">urinary bladder inflammation</span>."		449.0	449_MESH:D014443_MESH:D001749	449_2	bcv_final_eval_easy_2575		
	MESH:D003520	"<span class=""chemical"">CYP/cyclophosphamide</span>"	MESH:D001749	"<span class=""disease"">bladder inflammation</span>"	"The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of <span class=""disease"">bladder inflammation</span> induced by <span class=""chemical"">cyclophosphamide</span> (<span class=""chemical"">CYP</span>)."		449.0	449_MESH:D003520_MESH:D001749	449_3	bcv_final_eval_easy_2576		
	MESH:D001379	"<span class=""chemical"">azathioprine</span>"	MESH:D001855	"<span class=""disease"">bone marrow suppression</span>"	"The side effects of <span class=""chemical"">azathioprine</span> include anemia, which has been attributed to <span class=""disease"">bone marrow suppression</span>."		450.0	450_MESH:D001379_MESH:D001855	450_2	bcv_final_eval_easy_2577		
	MESH:D004837	"<span class=""chemical"">epinephrine</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"Four (10.8%) patients in the conventional group and 1 (2.7%) in the unilateral group, P= 0.17 required <span class=""chemical"">epinephrine</span> infusion to treat <span class=""disease"">hypotension</span>."		451.0	451_MESH:D004837_MESH:D007022	451_9	bcv_final_eval_easy_2578		
	MESH:D000409	"<span class=""chemical"">alanine</span>"	MESH:D056486	"<span class=""disease"">hepatitis</span>"	"Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and <span class=""disease"">hepatitis</span> (clinical jaundice with <span class=""chemical"">alanine</span> aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL)."		452.0	452_MESH:D000409_MESH:D056486	452_4	bcv_final_eval_easy_2579		
	MESH:D000409	"<span class=""chemical"">alanine</span>"	MESH:D007565	"<span class=""disease"">jaundice</span>"	"Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical <span class=""disease"">jaundice</span> with <span class=""chemical"">alanine</span> aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL)."		452.0	452_MESH:D000409_MESH:D007565	452_4	bcv_final_eval_easy_2580		
	MESH:D000409	"<span class=""chemical"">alanine</span>"	MESH:D000740	"<span class=""disease"">anemia</span>"	"Clinically significant <span class=""disease"">anemia</span> (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with <span class=""chemical"">alanine</span> aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL)."		452.0	452_MESH:D000409_MESH:D000740	452_4	bcv_final_eval_easy_2581		
	MESH:D019829	"<span class=""chemical"">NVP</span>"	MESH:D005076	"<span class=""disease"">rash</span>"	"Among the patients with 1 year of follow-up, <span class=""chemical"">NVP</span> therapy was significantly associated with developing <span class=""disease"">rash</span> and d4T therapy with developing peripheral neuropathy (p < 0.05)."		452.0	452_MESH:D019829_MESH:D005076	452_6	bcv_final_eval_easy_2582		
	MESH:D018119	"<span class=""chemical"">d4T</span>"	MESH:D010523	"<span class=""disease"">peripheral neuropathy</span>"	"Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and <span class=""chemical"">d4T</span> therapy with developing <span class=""disease"">peripheral neuropathy</span> (p < 0.05)."		452.0	452_MESH:D018119_MESH:D010523	452_6	bcv_final_eval_easy_2583		
	MESH:D019829	"<span class=""chemical"">NVP</span>"	MESH:D010523	"<span class=""disease"">peripheral neuropathy</span>"	"Among the patients with 1 year of follow-up, <span class=""chemical"">NVP</span> therapy was significantly associated with developing rash and d4T therapy with developing <span class=""disease"">peripheral neuropathy</span> (p < 0.05)."		452.0	452_MESH:D019829_MESH:D010523	452_6	bcv_final_eval_easy_2584		
	MESH:D018119	"<span class=""chemical"">d4T</span>"	MESH:D005076	"<span class=""disease"">rash</span>"	"Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing <span class=""disease"">rash</span> and <span class=""chemical"">d4T</span> therapy with developing peripheral neuropathy (p < 0.05)."		452.0	452_MESH:D018119_MESH:D005076	452_6	bcv_final_eval_easy_2585		
	MESH:D013792	"<span class=""chemical"">Thalidomide</span>"	MESH:D020258	"<span class=""disease"">neurotoxicity</span>"	"<span class=""chemical"">Thalidomide</span> and sensory <span class=""disease"">neurotoxicity</span>: a neurophysiological study."		453.0	453_MESH:D013792_MESH:D020258	453_0	bcv_final_eval_easy_2586		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D009422	"<span class=""disease"">sensory axonal neuropathy</span>"	"BACKGROUND: Recent studies confirmed a high incidence of <span class=""disease"">sensory axonal neuropathy</span> in patients treated with different doses of <span class=""chemical"">thalidomide</span>."		453.0	453_MESH:D013792_MESH:D009422	453_1	bcv_final_eval_easy_2587		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with <span class=""chemical"">thalidomide</span> and use these findings to identify the <span class=""disease"">neurotoxic</span> potential of <span class=""chemical"">thalidomide</span> and the recovery capacity of sensory fibres after discontinuation of treatment."		453.0	453_MESH:D013792_MESH:D020258	453_2	bcv_final_eval_easy_2588		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D008178	"<span class=""disease"">CLE/cutaneous lupus erythematosus</span>"	"The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory <span class=""disease"">cutaneous lupus erythematosus</span> (<span class=""disease"">CLE</span>) treated with <span class=""chemical"">thalidomide</span> and use these findings to identify the neurotoxic potential of <span class=""chemical"">thalidomide</span> and the recovery capacity of sensory fibres after discontinuation of treatment."		453.0	453_MESH:D013792_MESH:D008178	453_2	bcv_final_eval_easy_2589		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D008178	"<span class=""disease"">CLE</span>"	"PATIENTS AND METHODS: Clinical and electrophysiological data in 12 female patients with <span class=""disease"">CLE</span> during treatment with <span class=""chemical"">thalidomide</span> and up to 47 months after discontinuation of treatment were analysed."		453.0	453_MESH:D013792_MESH:D008178	453_3	bcv_final_eval_easy_2590		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D005155	"<span class=""disease"">reduction in sural nerve SAP amplitude</span>"	"At detection of <span class=""disease"">reduction in sural nerve SAP amplitude</span>, the median <span class=""chemical"">thalidomide</span> cumulative dose was 21.4 g."		453.0	453_MESH:D013792_MESH:D005155	453_9	bcv_final_eval_easy_2591		
	MESH:D013792	"<span class=""chemical"">thalidomide</span>"	MESH:D020258	"<span class=""disease"">neurotoxic</span>"	"This electrophysiological parameter provides information about subclinical <span class=""disease"">neurotoxic</span> potential of <span class=""chemical"">thalidomide</span> but is not helpful in predicting the appearance of sensory symptoms."		453.0	453_MESH:D013792_MESH:D020258	453_12	bcv_final_eval_easy_2592		
	MESH:D000638	"<span class=""chemical"">Amiodarone</span>"	MESH:D006349	"<span class=""disease"">valvular heart disease</span>"	"<span class=""chemical"">Amiodarone</span>-related pulmonary mass and unique membranous glomerulonephritis in a patient with <span class=""disease"">valvular heart disease</span>: Diagnostic pitfall and new findings."		454.0	454_MESH:D000638_MESH:D006349	454_0	bcv_final_eval_easy_2593		
	MESH:D000638	"<span class=""chemical"">Amiodarone</span>"	MESH:D015433	"<span class=""disease"">membranous glomerulonephritis</span>"	"<span class=""chemical"">Amiodarone</span>-related pulmonary mass and unique <span class=""disease"">membranous glomerulonephritis</span> in a patient with valvular heart disease: Diagnostic pitfall and new findings."		454.0	454_MESH:D000638_MESH:D015433	454_0	bcv_final_eval_easy_2594		
	MESH:D000638	"<span class=""chemical"">Amiodarone</span>"	MESH:D013610	"<span class=""disease"">tachycardia</span>"	"<span class=""chemical"">Amiodarone</span> is an anti-arrhythmic drug for life-threatening <span class=""disease"">tachycardia</span>, but various adverse effects have been reported."		454.0	454_MESH:D000638_MESH:D013610	454_1	bcv_final_eval_easy_2595		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D006349	"<span class=""disease"">valvular heart disease</span>"	"Reported herein is an autopsy case of <span class=""disease"">valvular heart disease</span>, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with <span class=""chemical"">amiodarone</span> for a long time."		454.0	454_MESH:D000638_MESH:D006349	454_2	bcv_final_eval_easy_2596		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and <span class=""disease"">proteinuria</span> (2.76 g/day) after treatment with <span class=""chemical"">amiodarone</span> for a long time."		454.0	454_MESH:D000638_MESH:D011507	454_2	bcv_final_eval_easy_2597		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D008175	"<span class=""disease"">lung cancer</span>"	"The lung mass was highly suspected to be <span class=""disease"">lung cancer</span> on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an <span class=""chemical"">amiodarone</span>-related lesion."		454.0	454_MESH:D000638_MESH:D008175	454_3	bcv_final_eval_easy_2598		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D008171	"<span class=""disease"">pulmonary lesion</span>"	"The present case highlights the possibility that differential diagnosis between an <span class=""chemical"">amiodarone</span>-related <span class=""disease"">pulmonary lesion</span> and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of <span class=""chemical"">amiodarone</span> treatment."		454.0	454_MESH:D000638_MESH:D008171	454_7	bcv_final_eval_easy_2599		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D009369	"<span class=""disease"">neoplasm</span>"	"The present case highlights the possibility that differential diagnosis between an <span class=""chemical"">amiodarone</span>-related pulmonary lesion and a <span class=""disease"">neoplasm</span> can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of <span class=""chemical"">amiodarone</span> treatment."		454.0	454_MESH:D000638_MESH:D009369	454_7	bcv_final_eval_easy_2600		
	MESH:D000638	"<span class=""chemical"">amiodarone</span>"	MESH:D015433	"<span class=""disease"">membranous glomerulonephritis</span>"	"The present case highlights the possibility that differential diagnosis between an <span class=""chemical"">amiodarone</span>-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that <span class=""disease"">membranous glomerulonephritis</span> might be another possible complication of <span class=""chemical"">amiodarone</span> treatment."		454.0	454_MESH:D000638_MESH:D015433	454_7	bcv_final_eval_easy_2601		
	MESH:D008687	"<span class=""chemical"">metformin</span>"	MESH:D003324	"<span class=""disease"">CAD</span>"	"The hazard of developing <span class=""disease"">CAD</span> (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with <span class=""chemical"">metformin</span>."		455.0	455_MESH:D008687_MESH:D003324	455_5	bcv_final_eval_easy_2602		
	MESH:D005905	"<span class=""chemical"">glibenclamide</span>"	MESH:D003324	"<span class=""disease"">CAD</span>"	"The hazard of developing <span class=""disease"">CAD</span> (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with <span class=""chemical"">glibenclamide</span>; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin."		455.0	455_MESH:D005905_MESH:D003324	455_5	bcv_final_eval_easy_2603		
	MESH:D005913	"<span class=""chemical"">glipizide</span>"	MESH:D003324	"<span class=""disease"">CAD</span>"	"The hazard of developing <span class=""disease"">CAD</span> (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with <span class=""chemical"">glipizide</span>; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin."		455.0	455_MESH:D005913_MESH:D003324	455_5	bcv_final_eval_easy_2604		
	MESH:C057619	"<span class=""chemical"">glimepiride</span>"	MESH:C537389	"<span class=""disease"">type</span>"	"CONCLUSIONS: Initiating treatment of <span class=""disease"">type</span> 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or <span class=""chemical"">glimepiride</span>."		455.0	455_MESH:C057619_MESH:C537389	455_7	bcv_final_eval_easy_2605		
	MESH:D005907	"<span class=""chemical"">gliclazide</span>"	MESH:C537389	"<span class=""disease"">type</span>"	"CONCLUSIONS: Initiating treatment of <span class=""disease"">type</span> 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to <span class=""chemical"">gliclazide</span> or glimepiride."		455.0	455_MESH:D005907_MESH:C537389	455_7	bcv_final_eval_easy_2606		
	MESH:D005913	"<span class=""chemical"">glipizide</span>"	MESH:D003324	"<span class=""disease"">CAD</span>"	"CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or <span class=""chemical"">glipizide</span> is associated with increased risk of <span class=""disease"">CAD</span> in comparison to gliclazide or glimepiride."		455.0	455_MESH:D005913_MESH:D003324	455_7	bcv_final_eval_easy_2607		
	MESH:D005905	"<span class=""chemical"">glibenclamide</span>"	MESH:D003324	"<span class=""disease"">CAD</span>"	"CONCLUSIONS: Initiating treatment of type 2 diabetes with <span class=""chemical"">glibenclamide</span> or glipizide is associated with increased risk of <span class=""disease"">CAD</span> in comparison to gliclazide or glimepiride."		455.0	455_MESH:D005905_MESH:D003324	455_7	bcv_final_eval_easy_2608		
	MESH:D005905	"<span class=""chemical"">glibenclamide</span>"	MESH:D003920	"<span class=""disease"">diabetes</span>"	"CONCLUSIONS: Initiating treatment of type 2 <span class=""disease"">diabetes</span> with <span class=""chemical"">glibenclamide</span> or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride."		455.0	455_MESH:D005905_MESH:D003920	455_7	bcv_final_eval_easy_2609		
	MESH:D005907	"<span class=""chemical"">gliclazide</span>"	MESH:D003920	"<span class=""disease"">diabetes</span>"	"CONCLUSIONS: Initiating treatment of type 2 <span class=""disease"">diabetes</span> with glibenclamide or glipizide is associated with increased risk of CAD in comparison to <span class=""chemical"">gliclazide</span> or glimepiride."		455.0	455_MESH:D005907_MESH:D003920	455_7	bcv_final_eval_easy_2610		
	MESH:C057619	"<span class=""chemical"">glimepiride</span>"	MESH:D003324	"<span class=""disease"">CAD</span>"	"CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of <span class=""disease"">CAD</span> in comparison to gliclazide or <span class=""chemical"">glimepiride</span>."		455.0	455_MESH:C057619_MESH:D003324	455_7	bcv_final_eval_easy_2611		
	MESH:D005907	"<span class=""chemical"">gliclazide</span>"	MESH:D003324	"<span class=""disease"">CAD</span>"	"CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of <span class=""disease"">CAD</span> in comparison to <span class=""chemical"">gliclazide</span> or glimepiride."		455.0	455_MESH:D005907_MESH:D003324	455_7	bcv_final_eval_easy_2612		
	MESH:D005913	"<span class=""chemical"">glipizide</span>"	MESH:D003920	"<span class=""disease"">diabetes</span>"	"CONCLUSIONS: Initiating treatment of type 2 <span class=""disease"">diabetes</span> with glibenclamide or <span class=""chemical"">glipizide</span> is associated with increased risk of CAD in comparison to gliclazide or glimepiride."		455.0	455_MESH:D005913_MESH:D003920	455_7	bcv_final_eval_easy_2613		
	MESH:D005913	"<span class=""chemical"">glipizide</span>"	MESH:C537389	"<span class=""disease"">type</span>"	"CONCLUSIONS: Initiating treatment of <span class=""disease"">type</span> 2 diabetes with glibenclamide or <span class=""chemical"">glipizide</span> is associated with increased risk of CAD in comparison to gliclazide or glimepiride."		455.0	455_MESH:D005913_MESH:C537389	455_7	bcv_final_eval_easy_2614		
	MESH:C057619	"<span class=""chemical"">glimepiride</span>"	MESH:D003920	"<span class=""disease"">diabetes</span>"	"CONCLUSIONS: Initiating treatment of type 2 <span class=""disease"">diabetes</span> with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or <span class=""chemical"">glimepiride</span>."		455.0	455_MESH:C057619_MESH:D003920	455_7	bcv_final_eval_easy_2615		
	MESH:D005905	"<span class=""chemical"">glibenclamide</span>"	MESH:C537389	"<span class=""disease"">type</span>"	"CONCLUSIONS: Initiating treatment of <span class=""disease"">type</span> 2 diabetes with <span class=""chemical"">glibenclamide</span> or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride."		455.0	455_MESH:D005905_MESH:C537389	455_7	bcv_final_eval_easy_2616		
	MESH:D004317	"<span class=""chemical"">adriamycin</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Reduced progression of <span class=""chemical"">adriamycin</span> <span class=""disease"">nephropathy</span> in spontaneously hypertensive rats treated by losartan."		456.0	456_MESH:D004317_MESH:D007674	456_0	bcv_final_eval_easy_2617		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Reduced progression of adriamycin <span class=""disease"">nephropathy</span> in spontaneously hypertensive rats treated by <span class=""chemical"">losartan</span>."		456.0	456_MESH:D019808_MESH:D007674	456_0	bcv_final_eval_easy_2618		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"Reduced progression of adriamycin nephropathy in spontaneously <span class=""disease"">hypertensive</span> rats treated by <span class=""chemical"">losartan</span>."		456.0	456_MESH:D019808_MESH:D006973	456_0	bcv_final_eval_easy_2619		
	MESH:D004317	"<span class=""chemical"">adriamycin</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"Reduced progression of <span class=""chemical"">adriamycin</span> nephropathy in spontaneously <span class=""disease"">hypertensive</span> rats treated by losartan."		456.0	456_MESH:D004317_MESH:D006973	456_0	bcv_final_eval_easy_2620		
	MESH:D004317	"<span class=""chemical"">ADR/adriamycin</span>"	MESH:D007674	"<span class=""disease"">down renal disease progression/nephropathy</span>"	"BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing <span class=""disease"">down renal disease progression</span> in spontaneously hypertensive rats (SHR) with <span class=""chemical"">adriamycin</span> (<span class=""chemical"">ADR</span>) <span class=""disease"">nephropathy</span>."		456.0	456_MESH:D004317_MESH:D007674	456_1	bcv_final_eval_easy_2621		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D007674	"<span class=""disease"">down renal disease progression/nephropathy</span>"	"BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, <span class=""chemical"">losartan</span>, and its potential in slowing <span class=""disease"">down renal disease progression</span> in spontaneously hypertensive rats (SHR) with adriamycin (ADR) <span class=""disease"">nephropathy</span>."		456.0	456_MESH:D019808_MESH:D007674	456_1	bcv_final_eval_easy_2622		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, <span class=""chemical"">losartan</span>, and its potential in slowing down renal disease progression in spontaneously <span class=""disease"">hypertensive</span> rats (SHR) with adriamycin (ADR) nephropathy."		456.0	456_MESH:D019808_MESH:D006973	456_1	bcv_final_eval_easy_2623		
	MESH:D004317	"<span class=""chemical"">ADR/adriamycin</span>"	MESH:D006973	"<span class=""disease"">hypertensive</span>"	"BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously <span class=""disease"">hypertensive</span> rats (SHR) with <span class=""chemical"">adriamycin</span> (<span class=""chemical"">ADR</span>) nephropathy."		456.0	456_MESH:D004317_MESH:D006973	456_1	bcv_final_eval_easy_2624		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D005921	"<span class=""disease"">glomerulosclerosis</span>"	"RESULTS: Short-term <span class=""chemical"">losartan</span> treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated <span class=""disease"">glomerulosclerosis</span> resulting in decreased proteinuria."		456.0	456_MESH:D019808_MESH:D005921	456_8	bcv_final_eval_easy_2625		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"RESULTS: Short-term <span class=""chemical"">losartan</span> treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased <span class=""disease"">proteinuria</span>."		456.0	456_MESH:D019808_MESH:D011507	456_8	bcv_final_eval_easy_2626		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D005921	"<span class=""disease"">glomerulosclerosis</span>"	"Prolonged treatment with <span class=""chemical"">losartan</span> showed further reduction of <span class=""disease"">glomerulosclerosis</span> associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure."		456.0	456_MESH:D019808_MESH:D005921	456_9	bcv_final_eval_easy_2627		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D001284	"<span class=""disease"">tubular atrophy</span>"	"Prolonged treatment with <span class=""chemical"">losartan</span> showed further reduction of glomerulosclerosis associated with reduced progression of <span class=""disease"">tubular atrophy</span> and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure."		456.0	456_MESH:D019808_MESH:D001284	456_9	bcv_final_eval_easy_2628		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D011507	"<span class=""disease"">proteinuria</span>"	"Prolonged treatment with <span class=""chemical"">losartan</span> showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy <span class=""disease"">proteinuria</span> and chronic renal failure."		456.0	456_MESH:D019808_MESH:D011507	456_9	bcv_final_eval_easy_2629		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"Prolonged treatment with <span class=""chemical"">losartan</span> showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial <span class=""disease"">fibrosis</span>, thus preventing heavy proteinuria and chronic renal failure."		456.0	456_MESH:D019808_MESH:D005355	456_9	bcv_final_eval_easy_2630		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D007676	"<span class=""disease"">chronic renal failure</span>"	"Prolonged treatment with <span class=""chemical"">losartan</span> showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and <span class=""disease"">chronic renal failure</span>."		456.0	456_MESH:D019808_MESH:D007676	456_9	bcv_final_eval_easy_2631		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Losartan reduced uraemia and increased urea clearance in advanced <span class=""chemical"">ADR</span> <span class=""disease"">nephropathy</span> in SHR."		456.0	456_MESH:D004317_MESH:D007674	456_10	bcv_final_eval_easy_2632		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D001523	"<span class=""disease"">Losartan reduced uraemia</span>"	"<span class=""disease"">Losartan reduced uraemia</span> and increased urea clearance in advanced <span class=""chemical"">ADR</span> nephropathy in SHR."		456.0	456_MESH:D004317_MESH:D001523	456_10	bcv_final_eval_easy_2633		
	MESH:D014508	"<span class=""chemical"">urea</span>"	MESH:D001523	"<span class=""disease"">Losartan reduced uraemia</span>"	"<span class=""disease"">Losartan reduced uraemia</span> and increased <span class=""chemical"">urea</span> clearance in advanced ADR nephropathy in SHR."		456.0	456_MESH:D014508_MESH:D001523	456_10	bcv_final_eval_easy_2634		
	MESH:D014508	"<span class=""chemical"">urea</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Losartan reduced uraemia and increased <span class=""chemical"">urea</span> clearance in advanced ADR <span class=""disease"">nephropathy</span> in SHR."		456.0	456_MESH:D014508_MESH:D007674	456_10	bcv_final_eval_easy_2635		
	MESH:D019808	"<span class=""chemical"">Losartan</span>"	MESH:D001523	"<span class=""disease"">Losartan reduced uraemia</span>"	"<span class=""chemical""></span><span class=""disease"">Losartan</span> reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR."		456.0	456_MESH:D019808_MESH:D001523	456_10	bcv_final_eval_easy_2636		
	MESH:D019808	"<span class=""chemical"">Losartan</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"<span class=""chemical"">Losartan</span> reduced uraemia and increased urea clearance in advanced ADR <span class=""disease"">nephropathy</span> in SHR."		456.0	456_MESH:D019808_MESH:D007674	456_10	bcv_final_eval_easy_2637		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in <span class=""chemical"">ADR</span> <span class=""disease"">nephropathy</span>."		456.0	456_MESH:D004317_MESH:D007674	456_11	bcv_final_eval_easy_2638		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D001284	"<span class=""disease"">tubular atrophy</span>"	"Histological examination showed that losartan could prevent <span class=""disease"">tubular atrophy</span>, interstitial infiltration and fibrosis in <span class=""chemical"">ADR</span> nephropathy."		456.0	456_MESH:D004317_MESH:D001284	456_11	bcv_final_eval_easy_2639		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"Histological examination showed that <span class=""chemical"">losartan</span> could prevent tubular atrophy, interstitial infiltration and <span class=""disease"">fibrosis</span> in ADR nephropathy."		456.0	456_MESH:D019808_MESH:D005355	456_11	bcv_final_eval_easy_2640		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D009395	"<span class=""disease"">interstitial infiltration</span>"	"Histological examination showed that <span class=""chemical"">losartan</span> could prevent tubular atrophy, <span class=""disease"">interstitial infiltration</span> and fibrosis in ADR nephropathy."		456.0	456_MESH:D019808_MESH:D009395	456_11	bcv_final_eval_easy_2641		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D009395	"<span class=""disease"">interstitial infiltration</span>"	"Histological examination showed that losartan could prevent tubular atrophy, <span class=""disease"">interstitial infiltration</span> and fibrosis in <span class=""chemical"">ADR</span> nephropathy."		456.0	456_MESH:D004317_MESH:D009395	456_11	bcv_final_eval_easy_2642		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D001284	"<span class=""disease"">tubular atrophy</span>"	"Histological examination showed that <span class=""chemical"">losartan</span> could prevent <span class=""disease"">tubular atrophy</span>, interstitial infiltration and fibrosis in ADR nephropathy."		456.0	456_MESH:D019808_MESH:D001284	456_11	bcv_final_eval_easy_2643		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D005355	"<span class=""disease"">fibrosis</span>"	"Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and <span class=""disease"">fibrosis</span> in <span class=""chemical"">ADR</span> nephropathy."		456.0	456_MESH:D004317_MESH:D005355	456_11	bcv_final_eval_easy_2644		
	MESH:D019808	"<span class=""chemical"">losartan</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Histological examination showed that <span class=""chemical"">losartan</span> could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR <span class=""disease"">nephropathy</span>."		456.0	456_MESH:D019808_MESH:D007674	456_11	bcv_final_eval_easy_2645		
	MESH:D019808	"<span class=""chemical"">Losartan</span>"	MESH:D005923	"<span class=""disease"">focal segmental glomerulosclerosis</span>"	"CONCLUSION: <span class=""chemical"">Losartan</span> reduces the rate of progression of ADR-induced <span class=""disease"">focal segmental glomerulosclerosis</span> to end-stage renal disease in SHR."		456.0	456_MESH:D019808_MESH:D005923	456_12	bcv_final_eval_easy_2646		
	MESH:D004317	"<span class=""chemical"">ADR</span>"	MESH:D007676	"<span class=""disease"">end-stage renal disease</span>"	"CONCLUSION: Losartan reduces the rate of progression of <span class=""chemical"">ADR</span>-induced focal segmental glomerulosclerosis to <span class=""disease"">end-stage renal disease</span> in SHR."		456.0	456_MESH:D004317_MESH:D007676	456_12	bcv_final_eval_easy_2647		
	MESH:D019808	"<span class=""chemical"">Losartan</span>"	MESH:D007676	"<span class=""disease"">end-stage renal disease</span>"	"CONCLUSION: <span class=""chemical"">Losartan</span> reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to <span class=""disease"">end-stage renal disease</span> in SHR."		456.0	456_MESH:D019808_MESH:D007676	456_12	bcv_final_eval_easy_2648		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D001145	"<span class=""disease"">cardiac arrhythmias</span>"	"The biological properties of the optical isomers of <span class=""chemical"">propranolol</span> and their effects on <span class=""disease"">cardiac arrhythmias</span>."		458.0	458_MESH:D011433_MESH:D001145	458_0	bcv_final_eval_easy_2649		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D009135	"<span class=""disease"">atrial muscle</span>"	"Both isomers of <span class=""chemical"">propranolol</span> possessed similar depressant potency on isolated <span class=""disease"">atrial muscle</span> taken from guinea-pigs.5."		458.0	458_MESH:D011433_MESH:D009135	458_7	bcv_final_eval_easy_2650		
	MESH:D006221	"<span class=""chemical"">halothane</span>"	MESH:D001145	"<span class=""disease"">cardiac arrhythmias</span>"	"Both isomers of propranolol were capable of preventing adrenaline-induced <span class=""disease"">cardiac arrhythmias</span> in cats anaesthetized with <span class=""chemical"">halothane</span>, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg."		458.0	458_MESH:D006221_MESH:D001145	458_10	bcv_final_eval_easy_2651		
	MESH:D011433	"<span class=""chemical"">(+)-propranolol/(-)-propranolol/propranolol</span>"	MESH:D001145	"<span class=""disease"">cardiac arrhythmias</span>"	"Both isomers of <span class=""chemical"">propranolol</span> were capable of preventing adrenaline-induced <span class=""disease"">cardiac arrhythmias</span> in cats anaesthetized with halothane, but the mean dose of <span class=""chemical"">(-)-propranolol</span> was 0.09+/-0.02 mg/kg whereas that of <span class=""chemical"">(+)-propranolol</span> was 4.2+/-1.2 mg/kg."		458.0	458_MESH:D011433_MESH:D001145	458_10	bcv_final_eval_easy_2652		
	MESH:D010042	"<span class=""chemical"">ouabain</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"Both isomers of propranolol were also capable of reversing <span class=""disease"">ventricular tachycardia</span> caused by <span class=""chemical"">ouabain</span> in anaesthetized cats and dogs."		458.0	458_MESH:D010042_MESH:D017180	458_13	bcv_final_eval_easy_2653		
	MESH:D011433	"<span class=""chemical"">propranolol</span>"	MESH:D017180	"<span class=""disease"">ventricular tachycardia</span>"	"Both isomers of <span class=""chemical"">propranolol</span> were also capable of reversing <span class=""disease"">ventricular tachycardia</span> caused by ouabain in anaesthetized cats and dogs."		458.0	458_MESH:D011433_MESH:D017180	458_13	bcv_final_eval_easy_2654		
	MESH:D019772	"<span class=""chemical"">Topotecan</span>"	MESH:D005909	"<span class=""disease"">glioblastoma</span>"	"<span class=""chemical"">Topotecan</span> in combination with radiotherapy in unresectable <span class=""disease"">glioblastoma</span>: a phase 2 study."		459.0	459_MESH:D019772_MESH:D005909	459_0	bcv_final_eval_easy_2655		
	MESH:D019772	"<span class=""chemical"">Topotecan</span>"	MESH:D005910	"<span class=""disease"">glioma</span>"	"<span class=""chemical"">Topotecan</span> is an attractive option as it exhibits growth inhibition of human <span class=""disease"">glioma</span> as well as brain penetration."		459.0	459_MESH:D019772_MESH:D005910	459_2	bcv_final_eval_easy_2656		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D006961	"<span class=""disease"">hyperparathyroidism</span>"	"Long-term <span class=""chemical"">lithium</span> therapy leading to <span class=""disease"">hyperparathyroidism</span>: a case report."		460.0	460_MESH:D008094_MESH:D006961	460_0	bcv_final_eval_easy_2657		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D006934	"<span class=""disease"">hypercalcemia</span>"	"We examined the case of a <span class=""chemical"">lithium</span>-treated patient who had recurrent <span class=""disease"">hypercalcemia</span> to better understand the disease process."		460.0	460_MESH:D008094_MESH:D006934	460_2	bcv_final_eval_easy_2658		
	MESH:D008094	"<span class=""chemical"">lithium</span>"	MESH:D049950	"<span class=""disease"">Primary hyperparathyroidism</span>"	"CONCLUSION: <span class=""disease"">Primary hyperparathyroidism</span> is a rare but potentially life-threatening side effect of long-term <span class=""chemical"">lithium</span> therapy."		460.0	460_MESH:D008094_MESH:D049950	460_3	bcv_final_eval_easy_2659		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled <span class=""disease"">hypotension</span> anesthesia induced by <span class=""chemical"">propofol</span>-remifentanil total i.v. anesthesia (TIVA)."		461.0	461_MESH:D015742_MESH:D007022	461_1	bcv_final_eval_easy_2660		
	MESH:C071741	"<span class=""chemical"">remifentanil</span>"	MESH:D016063	"<span class=""disease"">intraoperative bleeding</span>"	"BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of <span class=""disease"">intraoperative bleeding</span> as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-<span class=""chemical"">remifentanil</span> total i.v. anesthesia (TIVA)."		461.0	461_MESH:C071741_MESH:D016063	461_1	bcv_final_eval_easy_2661		
	MESH:C071741	"<span class=""chemical"">remifentanil</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled <span class=""disease"">hypotension</span> anesthesia induced by propofol-<span class=""chemical"">remifentanil</span> total i.v. anesthesia (TIVA)."		461.0	461_MESH:C071741_MESH:D007022	461_1	bcv_final_eval_easy_2662		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D016063	"<span class=""disease"">intraoperative bleeding</span>"	"BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of <span class=""disease"">intraoperative bleeding</span> as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by <span class=""chemical"">propofol</span>-remifentanil total i.v. anesthesia (TIVA)."		461.0	461_MESH:D015742_MESH:D016063	461_1	bcv_final_eval_easy_2663		
	MESH:D015742	"<span class=""chemical"">propofol</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled <span class=""disease"">hypotension</span> anesthesia caused by <span class=""chemical"">propofol</span>-remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT."		461.0	461_MESH:D015742_MESH:D007022	461_2	bcv_final_eval_easy_2664		
	MESH:C071741	"<span class=""chemical"">remifentanil</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled <span class=""disease"">hypotension</span> anesthesia caused by propofol-<span class=""chemical"">remifentanil</span>-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT."		461.0	461_MESH:C071741_MESH:D007022	461_2	bcv_final_eval_easy_2665		
	MESH:C071741	"<span class=""chemical"">remifentanil</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"RESULTS: Controlled <span class=""disease"">hypotension</span> was achieved within a shorter period using laryngeal mask using lower rates of <span class=""chemical"">remifentanil</span> infusion and lower total dose of <span class=""chemical"">remifentanil</span>."		461.0	461_MESH:C071741_MESH:D007022	461_4	bcv_final_eval_easy_2666		
	MESH:C071741	"<span class=""chemical"">remifentanil</span>"	MESH:D006473	"<span class=""disease"">blood loss</span>"	"CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and <span class=""disease"">blood loss</span> and allowed for convenient induced hypotension with low doses of <span class=""chemical"">remifentanil</span> during TIVA in patients undergoing FESS."		461.0	461_MESH:C071741_MESH:D006473	461_5	bcv_final_eval_easy_2667		
	MESH:C071741	"<span class=""chemical"">remifentanil</span>"	MESH:D007022	"<span class=""disease"">hypotension</span>"	"CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled <span class=""disease"">hypotension</span> anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced <span class=""disease"">hypotension</span> with low doses of <span class=""chemical"">remifentanil</span> during TIVA in patients undergoing FESS."		461.0	461_MESH:C071741_MESH:D007022	461_5	bcv_final_eval_easy_2668		
	MESH:D014635	"<span class=""chemical"">valproate</span>"	MESH:D065626	"<span class=""disease"">Nonalcoholic fatty liver disease</span>"	"<span class=""disease"">Nonalcoholic fatty liver disease</span> during <span class=""chemical"">valproate</span> therapy."		462.0	462_MESH:D014635_MESH:D065626	462_0	bcv_final_eval_easy_2669		
	MESH:D014635	"<span class=""chemical"">Valproic acid/VPA</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"<span class=""chemical"">Valproic acid</span> (<span class=""chemical"">VPA</span>) is effective for the treatment of many types of <span class=""disease"">epilepsy</span>, but its use can be associated with an increase in body weight."		462.0	462_MESH:D014635_MESH:D004827	462_1	bcv_final_eval_easy_2670		
	MESH:D014635	"<span class=""chemical"">VPA</span>"	MESH:D009765	"<span class=""disease"">obesity</span>"	"We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed <span class=""disease"">obesity</span> during <span class=""chemical"">VPA</span> treatment."		462.0	462_MESH:D014635_MESH:D009765	462_2	bcv_final_eval_easy_2671		
	MESH:D014635	"<span class=""chemical"">VPA</span>"	MESH:D065626	"<span class=""disease"">NAFLD/nonalcoholic fatty liver disease</span>"	"We report a case of <span class=""disease"">nonalcoholic fatty liver disease</span> (<span class=""disease"">NAFLD</span>) arising in a child who developed obesity during <span class=""chemical"">VPA</span> treatment."		462.0	462_MESH:D014635_MESH:D065626	462_2	bcv_final_eval_easy_2672		
	MESH:D014635	"<span class=""chemical"">VPA</span>"	MESH:D015431	"<span class=""disease"">weight loss</span>"	"After the withdrawal of <span class=""chemical"">VPA</span> therapy, our patient showed a significant <span class=""disease"">weight loss</span>, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization."		462.0	462_MESH:D014635_MESH:D015431	462_4	bcv_final_eval_easy_2673		
	MESH:D014635	"<span class=""chemical"">VPA</span>"	MESH:D006946	"<span class=""disease"">hyperinsulinemia</span>"	"The present case suggests that obesity, <span class=""disease"">hyperinsulinemia</span>, insulin resistance, and long-term treatment with <span class=""chemical"">VPA</span> may be all associated with the development of NAFLD; this side effect is reversible after <span class=""chemical"">VPA</span> withdrawal."		462.0	462_MESH:D014635_MESH:D006946	462_5	bcv_final_eval_easy_2674		
	MESH:D014635	"<span class=""chemical"">VPA</span>"	MESH:D009765	"<span class=""disease"">obesity</span>"	"The present case suggests that <span class=""disease"">obesity</span>, hyperinsulinemia, insulin resistance, and long-term treatment with <span class=""chemical"">VPA</span> may be all associated with the development of NAFLD; this side effect is reversible after <span class=""chemical"">VPA</span> withdrawal."		462.0	462_MESH:D014635_MESH:D009765	462_5	bcv_final_eval_easy_2675		
	MESH:D014635	"<span class=""chemical"">VPA</span>"	MESH:D065626	"<span class=""disease"">NAFLD</span>"	"The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with <span class=""chemical"">VPA</span> may be all associated with the development of <span class=""disease"">NAFLD</span>; this side effect is reversible after <span class=""chemical"">VPA</span> withdrawal."		462.0	462_MESH:D014635_MESH:D065626	462_5	bcv_final_eval_easy_2676		
	MESH:D002231	"<span class=""chemical"">carbimazole</span>"	MESH:D006980	"<span class=""disease"">hyperthyroidism</span>"	"Anti-thyroid drugs, like <span class=""chemical"">carbimazole</span> and propylthiouracil (PTU) are commonly prescribed for the treatment of <span class=""disease"">hyperthyroidism</span>."		463.0	463_MESH:D002231_MESH:D006980	463_1	bcv_final_eval_easy_2677		
	MESH:D011441	"<span class=""chemical"">PTU/propylthiouracil</span>"	MESH:D006980	"<span class=""disease"">hyperthyroidism</span>"	"Anti-thyroid drugs, like carbimazole and <span class=""chemical"">propylthiouracil</span> (<span class=""chemical"">PTU</span>) are commonly prescribed for the treatment of <span class=""disease"">hyperthyroidism</span>."		463.0	463_MESH:D011441_MESH:D006980	463_1	bcv_final_eval_easy_2678		
	MESH:D002231	"<span class=""chemical"">carbimazole</span>"	MESH:D006111	"<span class=""disease"">Graves' disease</span>"	"We report a patient with <span class=""disease"">Graves' disease</span> who developed ANCA positive <span class=""chemical"">carbimazole</span> induced vasculitis."		463.0	463_MESH:D002231_MESH:D006111	463_4	bcv_final_eval_easy_2679		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D003327	"<span class=""disease"">coronary heart disease</span>"	"Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss <span class=""chemical"">aspirin</span> with adults who are at increased risk for <span class=""disease"">coronary heart disease</span>."		464.0	464_MESH:D001241_MESH:D003327	464_3	bcv_final_eval_easy_2680		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D009203	"<span class=""disease"">myocardial infarctions</span>"	"PURPOSE: To determine the benefits and harms of taking <span class=""chemical"">aspirin</span> for the primary prevention of <span class=""disease"">myocardial infarctions</span>, strokes, and death."		464.0	464_MESH:D001241_MESH:D009203	464_4	bcv_final_eval_easy_2681		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"PURPOSE: To determine the benefits and harms of taking <span class=""chemical"">aspirin</span> for the primary prevention of myocardial infarctions, strokes, and <span class=""disease"">death</span>."		464.0	464_MESH:D001241_MESH:D003643	464_4	bcv_final_eval_easy_2682		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D020521	"<span class=""disease"">strokes</span>"	"PURPOSE: To determine the benefits and harms of taking <span class=""chemical"">aspirin</span> for the primary prevention of myocardial infarctions, <span class=""disease"">strokes</span>, and death."		464.0	464_MESH:D001241_MESH:D020521	464_4	bcv_final_eval_easy_2683		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D002318	"<span class=""disease"">CVD/cardiovascular disease</span>"	"STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <span class=""chemical"">aspirin</span> versus control for the primary prevention of <span class=""disease"">cardiovascular disease</span> (<span class=""disease"">CVD</span>) were selected to answer the following questions: Does <span class=""chemical"">aspirin</span> decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known <span class=""disease"">CVD</span>?"		464.0	464_MESH:D001241_MESH:D002318	464_6	bcv_final_eval_easy_2684		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D020521	"<span class=""disease"">strokes/stroke</span>"	"STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <span class=""chemical"">aspirin</span> versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does <span class=""chemical"">aspirin</span> decrease coronary heart events, <span class=""disease"">strokes</span>, death from coronary heart events or <span class=""disease"">stroke</span>, or all-cause mortality in adults without known CVD?"		464.0	464_MESH:D001241_MESH:D020521	464_6	bcv_final_eval_easy_2685		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <span class=""chemical"">aspirin</span> versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does <span class=""chemical"">aspirin</span> decrease coronary heart events, strokes, <span class=""disease"">death</span> from coronary heart events or stroke, or all-cause mortality in adults without known CVD?"		464.0	464_MESH:D001241_MESH:D003643	464_6	bcv_final_eval_easy_2686		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D020521	"<span class=""disease"">hemorrhagic strokes</span>"	"Does <span class=""chemical"">aspirin</span> increase gastrointestinal bleeding or <span class=""disease"">hemorrhagic strokes</span>?"		464.0	464_MESH:D001241_MESH:D020521	464_7	bcv_final_eval_easy_2687		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D005767	"<span class=""disease"">gastrointestinal bleeding</span>"	"Does <span class=""chemical"">aspirin</span> increase <span class=""disease"">gastrointestinal bleeding</span> or hemorrhagic strokes?"		464.0	464_MESH:D001241_MESH:D005767	464_7	bcv_final_eval_easy_2688		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D002318	"<span class=""disease"">CVD</span>"	"DATA SYNTHESIS: New evidence from 1 good-quality RCT, 1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates that <span class=""chemical"">aspirin</span> use reduces the number of <span class=""disease"">CVD</span> events in patients without known <span class=""disease"">CVD</span>."		464.0	464_MESH:D001241_MESH:D002318	464_9	bcv_final_eval_easy_2689		
	MESH:D001241	"<span class=""chemical"">Aspirin</span>"	MESH:D002318	"<span class=""disease"">CVD</span>"	"<span class=""chemical"">Aspirin</span> does not seem to affect <span class=""disease"">CVD</span> mortality or all-cause mortality in either men or women."		464.0	464_MESH:D001241_MESH:D002318	464_11	bcv_final_eval_easy_2690		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D006470	"<span class=""disease"">bleeding</span>"	"The use of <span class=""chemical"">aspirin</span> for primary prevention increases the risk for major <span class=""disease"">bleeding</span> events, primarily gastrointestinal bleeding events, in both men and women."		464.0	464_MESH:D001241_MESH:D006470	464_12	bcv_final_eval_easy_2691		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D005767	"<span class=""disease"">gastrointestinal bleeding</span>"	"The use of <span class=""chemical"">aspirin</span> for primary prevention increases the risk for major bleeding events, primarily <span class=""disease"">gastrointestinal bleeding</span> events, in both men and women."		464.0	464_MESH:D001241_MESH:D005767	464_12	bcv_final_eval_easy_2692		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D020521	"<span class=""disease"">hemorrhagic strokes</span>"	"Men have an increased risk for <span class=""disease"">hemorrhagic strokes</span> with <span class=""chemical"">aspirin</span> use."		464.0	464_MESH:D001241_MESH:D020521	464_13	bcv_final_eval_easy_2693		
	MESH:D001241	"<span class=""chemical"">aspirin</span>"	MESH:D002318	"<span class=""disease"">CVD</span>"	"LIMITATIONS: New evidence on <span class=""chemical"">aspirin</span> for the primary prevention of <span class=""disease"">CVD</span> is limited."		464.0	464_MESH:D001241_MESH:D002318	464_15	bcv_final_eval_easy_2694		
	MESH:D001241	"<span class=""chemical"">Aspirin</span>"	MESH:D020521	"<span class=""disease"">strokes</span>"	"CONCLUSION: <span class=""chemical"">Aspirin</span> reduces the risk for myocardial infarction in men and <span class=""disease"">strokes</span> in women."		464.0	464_MESH:D001241_MESH:D020521	464_18	bcv_final_eval_easy_2695		
	MESH:D001241	"<span class=""chemical"">Aspirin</span>"	MESH:D009203	"<span class=""disease"">myocardial infarction</span>"	"CONCLUSION: <span class=""chemical"">Aspirin</span> reduces the risk for <span class=""disease"">myocardial infarction</span> in men and strokes in women."		464.0	464_MESH:D001241_MESH:D009203	464_18	bcv_final_eval_easy_2696		
	MESH:D001241	"<span class=""chemical"">Aspirin</span>"	MESH:D006470	"<span class=""disease"">bleeding</span>"	"<span class=""chemical"">Aspirin</span> use increases the risk for serious <span class=""disease"">bleeding</span> events."		464.0	464_MESH:D001241_MESH:D006470	464_19	bcv_final_eval_easy_2697		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013921	"<span class=""disease"">heparin-induced thrombocytopenia</span>"	"Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in <span class=""chemical""></span><span class=""disease"">heparin</span>-induced thrombocytopenia."		465.0	465_MESH:D006493_MESH:D013921	465_0	bcv_final_eval_easy_2698		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013921	"<span class=""disease"">heparin-induced thrombocytopenia</span>"	"Reducing harm associated with anticoagulation: practical considerations of <span class=""chemical"">argatroban</span> therapy in <span class=""disease"">heparin-induced thrombocytopenia</span>."		465.0	465_MESH:C031942_MESH:D013921	465_0	bcv_final_eval_easy_2699		
	MESH:C031942	"<span class=""chemical"">Argatroban</span>"	MESH:D013927	"<span class=""disease"">thrombosis</span>"	"<span class=""chemical"">Argatroban</span> is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of <span class=""disease"">thrombosis</span> in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)."		465.0	465_MESH:C031942_MESH:D013927	465_1	bcv_final_eval_easy_2700		
	MESH:C031942	"<span class=""chemical"">Argatroban</span>"	MESH:D013921	"<span class=""disease"">HIT/heparin-induced thrombocytopenia</span>"	"<span class=""chemical"">Argatroban</span> is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in <span class=""disease"">heparin-induced thrombocytopenia</span> (<span class=""disease"">HIT</span>) and for patients with or at risk of <span class=""disease"">HIT</span> undergoing percutaneous coronary intervention (PCI)."		465.0	465_MESH:C031942_MESH:D013921	465_1	bcv_final_eval_easy_2701		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013927	"<span class=""disease"">thrombosis</span>"	"Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of <span class=""disease"">thrombosis</span> in <span class=""chemical"">heparin</span>-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)."		465.0	465_MESH:D006493_MESH:D013927	465_1	bcv_final_eval_easy_2702		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013921	"<span class=""disease"">HIT/heparin-induced thrombocytopenia</span>"	"Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in <span class=""chemical""></span><span class=""disease"">heparin</span>-induced thrombocytopenia (<span class=""disease"">HIT</span>) and for patients with or at risk of <span class=""disease"">HIT</span> undergoing percutaneous coronary intervention (PCI)."		465.0	465_MESH:D006493_MESH:D013921	465_1	bcv_final_eval_easy_2703		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013921	"<span class=""disease"">HIT</span>"	"The objective of this review is to summarize practical considerations of <span class=""chemical"">argatroban</span> therapy in <span class=""disease"">HIT</span>."		465.0	465_MESH:C031942_MESH:D013921	465_2	bcv_final_eval_easy_2704		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D056486	"<span class=""disease"">hepatic impairment</span>"	"The US FDA-recommended <span class=""chemical"">argatroban</span> dose in HIT is 2 microg/kg/min (reduced in patients with <span class=""disease"">hepatic impairment</span> and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds)."		465.0	465_MESH:C031942_MESH:D056486	465_3	bcv_final_eval_easy_2705		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013921	"<span class=""disease"">HIT</span>"	"The US FDA-recommended <span class=""chemical"">argatroban</span> dose in <span class=""disease"">HIT</span> is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds)."		465.0	465_MESH:C031942_MESH:D013921	465_3	bcv_final_eval_easy_2706		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D056486	"<span class=""disease"">hepatically impaired</span>"	"For PCI, <span class=""chemical"">argatroban</span> has not been investigated in <span class=""disease"">hepatically impaired</span> patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition."		465.0	465_MESH:C031942_MESH:D056486	465_7	bcv_final_eval_easy_2707		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D009765	"<span class=""disease"">obesity</span>"	"For PCI, <span class=""chemical"">argatroban</span> has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or <span class=""disease"">obesity</span>, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition."		465.0	465_MESH:C031942_MESH:D009765	465_7	bcv_final_eval_easy_2708		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D006470	"<span class=""disease"">Major bleeding</span>"	"<span class=""disease"">Major bleeding</span> with <span class=""chemical"">argatroban</span> is 0-10% in the non-interventional setting and 0-5.8% periprocedurally."		465.0	465_MESH:C031942_MESH:D006470	465_9	bcv_final_eval_easy_2709		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013927	"<span class=""disease"">thromboses</span>"	"Improved familiarity of healthcare professionals with <span class=""chemical"">argatroban</span> therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer <span class=""disease"">thromboses</span>) or its treatment (e.g. fewer <span class=""chemical"">argatroban</span> medication errors)."		465.0	465_MESH:C031942_MESH:D013927	465_11	bcv_final_eval_easy_2710		
	MESH:C031942	"<span class=""chemical"">argatroban</span>"	MESH:D013921	"<span class=""disease"">HIT</span>"	"Improved familiarity of healthcare professionals with <span class=""chemical"">argatroban</span> therapy in <span class=""disease"">HIT</span>, including in special populations and during PCI, may facilitate reduction of harm associated with <span class=""disease"">HIT</span> (e.g. fewer thromboses) or its treatment (e.g. fewer <span class=""chemical"">argatroban</span> medication errors)."		465.0	465_MESH:C031942_MESH:D013921	465_11	bcv_final_eval_easy_2711		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D002544	"<span class=""disease"">ischemic stroke</span>"	"Rhabdomyolysis and brain <span class=""disease"">ischemic stroke</span> in a heroin-dependent male under <span class=""chemical"">methadone</span> maintenance therapy."		466.0	466_MESH:D008691_MESH:D002544	466_0	bcv_final_eval_easy_2712		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D012206	"<span class=""disease"">Rhabdomyolysis</span>"	"<span class=""disease"">Rhabdomyolysis</span> and brain ischemic stroke in a <span class=""chemical"">heroin</span>-dependent male under methadone maintenance therapy."		466.0	466_MESH:D003932_MESH:D012206	466_0	bcv_final_eval_easy_2713		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D012206	"<span class=""disease"">Rhabdomyolysis</span>"	"<span class=""disease"">Rhabdomyolysis</span> and brain ischemic stroke in a heroin-dependent male under <span class=""chemical"">methadone</span> maintenance therapy."		466.0	466_MESH:D008691_MESH:D012206	466_0	bcv_final_eval_easy_2714		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D002544	"<span class=""disease"">ischemic stroke</span>"	"Rhabdomyolysis and brain <span class=""disease"">ischemic stroke</span> in a <span class=""chemical"">heroin</span>-dependent male under methadone maintenance therapy."		466.0	466_MESH:D003932_MESH:D002544	466_0	bcv_final_eval_easy_2715		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D006556	"<span class=""disease"">heroin abuse</span>"	"OBJECTIVE: There are several complications associated with <span class=""chemical""></span><span class=""disease"">heroin</span> abuse, some of which are life-threatening."		466.0	466_MESH:D003932_MESH:D006556	466_1	bcv_final_eval_easy_2716		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D012206	"<span class=""disease"">rhabdomyolysis</span>"	"RESULTS: A 33-year-old man presented with <span class=""disease"">rhabdomyolysis</span> and cerebral ischemic stroke after intravenous <span class=""chemical"">heroin</span>."		466.0	466_MESH:D003932_MESH:D012206	466_4	bcv_final_eval_easy_2717		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D002544	"<span class=""disease"">ischemic stroke</span>"	"RESULTS: A 33-year-old man presented with rhabdomyolysis and cerebral <span class=""disease"">ischemic stroke</span> after intravenous <span class=""chemical"">heroin</span>."		466.0	466_MESH:D003932_MESH:D002544	466_4	bcv_final_eval_easy_2718		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D002544	"<span class=""disease"">ischemic stroke</span>"	"CONCLUSION: Those using <span class=""chemical"">methadone</span> and heroin simultaneously may increase risk of rhabdomyolysis and <span class=""disease"">ischemic stroke</span>."		466.0	466_MESH:D008691_MESH:D002544	466_11	bcv_final_eval_easy_2719		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D012206	"<span class=""disease"">rhabdomyolysis</span>"	"CONCLUSION: Those using methadone and <span class=""chemical"">heroin</span> simultaneously may increase risk of <span class=""disease"">rhabdomyolysis</span> and ischemic stroke."		466.0	466_MESH:D003932_MESH:D012206	466_11	bcv_final_eval_easy_2720		
	MESH:D008691	"<span class=""chemical"">methadone</span>"	MESH:D012206	"<span class=""disease"">rhabdomyolysis</span>"	"CONCLUSION: Those using <span class=""chemical"">methadone</span> and heroin simultaneously may increase risk of <span class=""disease"">rhabdomyolysis</span> and ischemic stroke."		466.0	466_MESH:D008691_MESH:D012206	466_11	bcv_final_eval_easy_2721		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D002544	"<span class=""disease"">ischemic stroke</span>"	"CONCLUSION: Those using methadone and <span class=""chemical"">heroin</span> simultaneously may increase risk of rhabdomyolysis and <span class=""disease"">ischemic stroke</span>."		466.0	466_MESH:D003932_MESH:D002544	466_11	bcv_final_eval_easy_2722		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D020521	"<span class=""disease"">stroke</span>"	"Hypotheses of <span class=""chemical"">heroin</span>-related rhabdomyolysis and <span class=""disease"">stroke</span> in <span class=""chemical"">heroin</span> abusers are discussed."		466.0	466_MESH:D003932_MESH:D020521	466_13	bcv_final_eval_easy_2723		
	MESH:D003932	"<span class=""chemical"">heroin</span>"	MESH:D012206	"<span class=""disease"">rhabdomyolysis</span>"	"Hypotheses of <span class=""chemical"">heroin</span>-related <span class=""disease"">rhabdomyolysis</span> and stroke in <span class=""chemical"">heroin</span> abusers are discussed."		466.0	466_MESH:D003932_MESH:D012206	466_13	bcv_final_eval_easy_2724		
	MESH:D016627	"<span class=""chemical"">6-hydroxydopamine</span>"	MESH:D004409	"<span class=""disease"">dyskinesias</span>"	"Increased vulnerability to <span class=""chemical"">6-hydroxydopamine</span> lesion and reduced development of <span class=""disease"">dyskinesias</span> in mice lacking CB1 cannabinoid receptors."		467.0	467_MESH:D016627_MESH:D004409	467_0	bcv_final_eval_easy_2725		
	MESH:D007980	"<span class=""chemical"">L-DOPA</span>"	MESH:D003072	"<span class=""disease"">motor impairment</span>"	"The results revealed that the lack of cannabinoid CB1 receptors increased the severity of <span class=""disease"">motor impairment</span> and DA lesion, and reduced <span class=""chemical"">L-DOPA</span>-induced dyskinesias."		467.0	467_MESH:D007980_MESH:D003072	467_6	bcv_final_eval_easy_2726		
	MESH:D011188	"<span class=""chemical"">K(+)</span>"	MESH:D001714	"<span class=""disease"">bipolar mania</span>"	"The intracerebroventricular (ICV) administration of ouabain (a Na(+)/<span class=""chemical"">K(+)</span>-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human <span class=""disease"">bipolar mania</span>."		468.0	468_MESH:D011188_MESH:D001714	468_1	bcv_final_eval_easy_2727		
	MESH:D012964	"<span class=""chemical"">Na(+)</span>"	MESH:D001714	"<span class=""disease"">bipolar mania</span>"	"The intracerebroventricular (ICV) administration of ouabain (a <span class=""chemical"">Na(+)</span>/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human <span class=""disease"">bipolar mania</span>."		468.0	468_MESH:D012964_MESH:D001714	468_1	bcv_final_eval_easy_2728		
	MESH:C102006	"<span class=""chemical"">citrate</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Systemic anticoagulation is unsafe and regional <span class=""chemical"">citrate</span> anticoagulation in the absence of a functional liver carries the risk of <span class=""chemical"">citrate</span> <span class=""disease"">toxicity</span>."		469.0	469_MESH:C102006_MESH:D064420	469_4	bcv_final_eval_easy_2729		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D058186	"<span class=""disease"">AKI</span>"	"We report a case of a 40-year-old female with <span class=""chemical"">acetaminophen</span>-induced fulminant liver failure with associated <span class=""disease"">AKI</span> who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure."		469.0	469_MESH:D000082_MESH:D058186	469_6	bcv_final_eval_easy_2730		
	MESH:C102006	"<span class=""chemical"">citrate</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"The patient tolerated the procedure well without any signs of <span class=""chemical"">citrate</span> <span class=""disease"">toxicity</span> and maintained adequate anticoagulation for patency of the dialysis circuit."		469.0	469_MESH:C102006_MESH:D064420	469_7	bcv_final_eval_easy_2731		
	MESH:C102006	"<span class=""chemical"">Citrate</span>"	MESH:D017114	"<span class=""disease"">fulminant liver failure</span>"	"<span class=""chemical"">Citrate</span> dialysate is a safe alternative for intradialytic support of liver transplantation in <span class=""disease"">fulminant liver failure</span>."		469.0	469_MESH:C102006_MESH:D017114	469_8	bcv_final_eval_easy_2732		
	MESH:D017374	"<span class=""chemical"">paroxetine</span>"	MESH:D003693	"<span class=""disease"">Delirium</span>"	"<span class=""disease"">Delirium</span> in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with <span class=""chemical"">paroxetine</span>."		470.0	470_MESH:D017374_MESH:D003693	470_0	bcv_final_eval_easy_2733		
	MESH:D017374	"<span class=""chemical"">paroxetine</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"OBJECTIVE: To describe a case of flecainide-induced <span class=""disease"">delirium</span> associated with a pharmacokinetic drug interaction with <span class=""chemical"">paroxetine</span>."		470.0	470_MESH:D017374_MESH:D003693	470_1	bcv_final_eval_easy_2734		
	MESH:D005424	"<span class=""chemical"">Flecainide</span>"	MESH:D001281	"<span class=""disease"">atrial fibrillation</span>"	"<span class=""chemical"">Flecainide</span> had been started 2 weeks prior for <span class=""disease"">atrial fibrillation</span>."		470.0	470_MESH:D005424_MESH:D001281	470_4	bcv_final_eval_easy_2735		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"DISCUSSION: Flecainide and pharmacologically similar agents that interact with <span class=""chemical"">sodium</span> channels may cause <span class=""disease"">delirium</span> in susceptible patients."		470.0	470_MESH:D012964_MESH:D003693	470_9	bcv_final_eval_easy_2736		
	MESH:D017374	"<span class=""chemical"">paroxetine</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and <span class=""chemical"">paroxetine</span>, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced <span class=""disease"">delirium</span>."		470.0	470_MESH:D017374_MESH:D003693	470_10	bcv_final_eval_easy_2737		
	MESH:D017374	"<span class=""chemical"">paroxetine</span>"	MESH:D003693	"<span class=""disease"">delirium</span>"	"According to the Naranjo probability scale, flecainide was the probable cause of the patient's <span class=""disease"">delirium</span>; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and <span class=""chemical"">paroxetine</span>."		470.0	470_MESH:D017374_MESH:D003693	470_11	bcv_final_eval_easy_2738		
	MESH:D005424	"<span class=""chemical"">flecainide</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Because <span class=""disease"">toxicity</span> may occur when <span class=""chemical"">flecainide</span> is prescribed with paroxetine and other potent CYP2D6 inhibitors, <span class=""chemical"">flecainide</span> plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors."		470.0	470_MESH:D005424_MESH:D064420	470_13	bcv_final_eval_easy_2739		
	MESH:D017374	"<span class=""chemical"">paroxetine</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"Because <span class=""disease"">toxicity</span> may occur when flecainide is prescribed with <span class=""chemical"">paroxetine</span> and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors."		470.0	470_MESH:D017374_MESH:D064420	470_13	bcv_final_eval_easy_2740		
	MESH:C107135	"<span class=""chemical"">RAD001/everolimus</span>"	MESH:D002289	"<span class=""disease"">NSCLC</span>"	"Efficacy of <span class=""chemical"">everolimus</span> (<span class=""chemical"">RAD001</span>) in patients with advanced <span class=""disease"">NSCLC</span> previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors."		471.0	471_MESH:C107135_MESH:D002289	471_0	bcv_final_eval_easy_2741		
	MESH:C107135	"<span class=""chemical"">RAD001</span>"	MESH:D002289	"<span class=""disease"">NSCLC</span>"	"<span class=""chemical"">RAD001</span>, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in <span class=""disease"">NSCLC</span>."		471.0	471_MESH:C107135_MESH:D002289	471_2	bcv_final_eval_easy_2742		
	MESH:D020123	"<span class=""chemical"">rapamycin</span>"	MESH:D002289	"<span class=""disease"">NSCLC</span>"	"RAD001, an oral inhibitor of the mammalian target of <span class=""chemical"">rapamycin</span> (mTOR), has shown phase I efficacy in <span class=""disease"">NSCLC</span>."		471.0	471_MESH:D020123_MESH:D002289	471_2	bcv_final_eval_easy_2743		
	MESH:C107135	"<span class=""chemical"">RAD001</span>"	MESH:D002289	"<span class=""disease"">NSCLC</span>"	"METHODS: Stage IIIb or IV <span class=""disease"">NSCLC</span> patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received <span class=""chemical"">RAD001</span> 10 mg/day until progression or unacceptable toxicity."		471.0	471_MESH:C107135_MESH:D002289	471_3	bcv_final_eval_easy_2744		
	MESH:D014443	"<span class=""chemical"">tyrosine</span>"	MESH:D002289	"<span class=""disease"">NSCLC</span>"	"METHODS: Stage IIIb or IV <span class=""disease"">NSCLC</span> patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor <span class=""chemical"">tyrosine</span> kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity."		471.0	471_MESH:D014443_MESH:D002289	471_3	bcv_final_eval_easy_2745		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one <span class=""chemical"">platinum</span> based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable <span class=""disease"">toxicity</span>."		471.0	471_MESH:D010984_MESH:D064420	471_3	bcv_final_eval_easy_2746		
	MESH:D010984	"<span class=""chemical"">platinum</span>"	MESH:D002289	"<span class=""disease"">NSCLC</span>"	"METHODS: Stage IIIb or IV <span class=""disease"">NSCLC</span> patients, with two or fewer prior chemotherapy regimens, one <span class=""chemical"">platinum</span> based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity."		471.0	471_MESH:D010984_MESH:D002289	471_3	bcv_final_eval_easy_2747		
	MESH:C107135	"<span class=""chemical"">RAD001</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received <span class=""chemical"">RAD001</span> 10 mg/day until progression or unacceptable <span class=""disease"">toxicity</span>."		471.0	471_MESH:C107135_MESH:D064420	471_3	bcv_final_eval_easy_2748		
	MESH:D014443	"<span class=""chemical"">tyrosine</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor <span class=""chemical"">tyrosine</span> kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable <span class=""disease"">toxicity</span>."		471.0	471_MESH:D014443_MESH:D064420	471_3	bcv_final_eval_easy_2749		
	MESH:C107135	"<span class=""chemical"">RAD001</span>"	MESH:D002289	"<span class=""disease"">NSCLC</span>"	"CONCLUSIONS: <span class=""chemical"">RAD001</span> 10 mg/day was well tolerated, showing modest clinical activity in pretreated <span class=""disease"">NSCLC</span>."		471.0	471_MESH:C107135_MESH:D002289	471_13	bcv_final_eval_easy_2750		
	MESH:C107135	"<span class=""chemical"">RAD001</span>"	MESH:D002289	"<span class=""disease"">NSCLC</span>"	"Evaluation of <span class=""chemical"">RAD001</span> plus standard therapy for metastatic <span class=""disease"">NSCLC</span> continues."		471.0	471_MESH:C107135_MESH:D002289	471_14	bcv_final_eval_easy_2751		
	MESH:D020123	"<span class=""chemical"">sirolimus</span>"	MESH:D000740	"<span class=""disease"">Posttransplant anemia</span>"	"<span class=""disease"">Posttransplant anemia</span>: the role of <span class=""chemical"">sirolimus</span>."		472.0	472_MESH:D020123_MESH:D000740	472_0	bcv_final_eval_easy_2752		
	MESH:D020123	"<span class=""chemical"">Sirolimus/rapamycin</span>"	MESH:D000740	"<span class=""disease"">posttransplant anemia</span>"	"<span class=""chemical"">Sirolimus</span>, a mammalian target of <span class=""chemical"">rapamycin</span> inhibitor, has been implicated as playing a special role in <span class=""disease"">posttransplant anemia</span>."		472.0	472_MESH:D020123_MESH:D000740	472_4	bcv_final_eval_easy_2753		
	MESH:D020123	"<span class=""chemical"">sirolimus</span>"	MESH:D000740	"<span class=""disease"">anemia</span>"	"This review considers <span class=""disease"">anemia</span> associated with <span class=""chemical"">sirolimus</span>, including its presentation, mechanisms, and management."		472.0	472_MESH:D020123_MESH:D000740	472_5	bcv_final_eval_easy_2754		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"Coronary computerized tomography angiography for rapid discharge of low-risk patients with <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span>."		473.0	473_MESH:D003042_MESH:D002637	473_0	bcv_final_eval_easy_2755		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D003327	"<span class=""disease"">coronary syndrome</span>"	"BACKGROUND: Most patients presenting to emergency departments (EDs) with <span class=""chemical"">cocaine</span>-associated chest pain are admitted for at least 12 hours and receive a ""rule out acute <span class=""disease"">coronary syndrome</span>"" protocol, often with noninvasive testing prior to discharge."		473.0	473_MESH:D003042_MESH:D003327	473_1	bcv_final_eval_easy_2756		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"BACKGROUND: Most patients presenting to emergency departments (EDs) with <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span> are admitted for at least 12 hours and receive a ""rule out acute coronary syndrome"" protocol, often with noninvasive testing prior to discharge."		473.0	473_MESH:D003042_MESH:D002637	473_1	bcv_final_eval_easy_2757		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D006331	"<span class=""disease"">cardiac events</span>"	"In patients without <span class=""chemical"">cocaine</span> use, coronary computerized tomography angiography (CTA) has been shown to be useful for identifying a group of patients at low risk for <span class=""disease"">cardiac events</span> who can be safely discharged."		473.0	473_MESH:D003042_MESH:D006331	473_2	bcv_final_eval_easy_2758		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D007511	"<span class=""disease"">ischemia</span>"	"It is unclear whether a coronary CTA strategy would be efficacious in <span class=""chemical"">cocaine</span>-associated chest pain, as coronary vasospasm may account for some of the <span class=""disease"">ischemia</span>."		473.0	473_MESH:D003042_MESH:D007511	473_3	bcv_final_eval_easy_2759		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D003329	"<span class=""disease"">coronary vasospasm</span>"	"It is unclear whether a coronary CTA strategy would be efficacious in <span class=""chemical"">cocaine</span>-associated chest pain, as <span class=""disease"">coronary vasospasm</span> may account for some of the ischemia."		473.0	473_MESH:D003042_MESH:D003329	473_3	bcv_final_eval_easy_2760		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"It is unclear whether a coronary CTA strategy would be efficacious in <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span>, as coronary vasospasm may account for some of the ischemia."		473.0	473_MESH:D003042_MESH:D002637	473_3	bcv_final_eval_easy_2761		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"We studied whether a negative coronary CTA in patients with <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span> could identify a subset safe for discharge."		473.0	473_MESH:D003042_MESH:D002637	473_4	bcv_final_eval_easy_2762		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"RESULTS: A total of 59 patients with <span class=""chemical"">cocaine</span>-associated <span class=""disease"">chest pain</span> were evaluated."		473.0	473_MESH:D003042_MESH:D002637	473_9	bcv_final_eval_easy_2763		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D017202	"<span class=""disease"">myocardial ischemia</span>"	"CONCLUSIONS: Although <span class=""chemical"">cocaine</span>-associated <span class=""disease"">myocardial ischemia</span> can result from coronary vasoconstriction, patients with <span class=""chemical"">cocaine</span> associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events."		473.0	473_MESH:D003042_MESH:D017202	473_16	bcv_final_eval_easy_2764		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D002637	"<span class=""disease"">chest pain</span>"	"CONCLUSIONS: Although <span class=""chemical"">cocaine</span>-associated myocardial ischemia can result from coronary vasoconstriction, patients with <span class=""chemical"">cocaine</span> associated <span class=""disease"">chest pain</span>, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events."		473.0	473_MESH:D003042_MESH:D002637	473_16	bcv_final_eval_easy_2765		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D001929	"<span class=""disease"">cerebral edema</span>"	"METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from <span class=""chemical"">acetaminophen</span> and resultant <span class=""disease"">cerebral edema</span>."		475.0	475_MESH:D000082_MESH:D001929	475_2	bcv_final_eval_easy_2766		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D017114	"<span class=""disease"">FHF</span>"	"METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with <span class=""disease"">FHF</span> from <span class=""chemical"">acetaminophen</span> and resultant cerebral edema."		475.0	475_MESH:D000082_MESH:D017114	475_2	bcv_final_eval_easy_2767		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed <span class=""disease"">toxicity</span> from <span class=""chemical"">acetaminophen</span> which was ingested over a 2-day period."		475.0	475_MESH:D000082_MESH:D064420	475_3	bcv_final_eval_easy_2768		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D001929	"<span class=""disease"">cerebral edema</span>"	"Initial evaluation confirmed FHF from <span class=""chemical"">acetaminophen</span> and <span class=""disease"">cerebral edema</span>."		475.0	475_MESH:D000082_MESH:D001929	475_5	bcv_final_eval_easy_2769		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D017114	"<span class=""disease"">FHF</span>"	"Initial evaluation confirmed <span class=""disease"">FHF</span> from <span class=""chemical"">acetaminophen</span> and cerebral edema."		475.0	475_MESH:D000082_MESH:D017114	475_5	bcv_final_eval_easy_2770		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D007035	"<span class=""disease"">therapeutic hypothermia</span>"	"CONCLUSION: In patients with FHF and cerebral edema from <span class=""chemical"">acetaminophen</span> overdose, prolonged <span class=""disease"">therapeutic hypothermia</span> could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery."		475.0	475_MESH:D000082_MESH:D007035	475_11	bcv_final_eval_easy_2771		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D001929	"<span class=""disease"">cerebral edema</span>"	"CONCLUSION: In patients with FHF and <span class=""disease"">cerebral edema</span> from <span class=""chemical"">acetaminophen</span> overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery."		475.0	475_MESH:D000082_MESH:D001929	475_11	bcv_final_eval_easy_2772		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D017114	"<span class=""disease"">FHF</span>"	"CONCLUSION: In patients with <span class=""disease"">FHF</span> and cerebral edema from <span class=""chemical"">acetaminophen</span> overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery."		475.0	475_MESH:D000082_MESH:D017114	475_11	bcv_final_eval_easy_2773		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D062787	"<span class=""disease"">overdose</span>"	"CONCLUSION: In patients with FHF and cerebral edema from <span class=""chemical"">acetaminophen</span> <span class=""disease"">overdose</span>, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery."		475.0	475_MESH:D000082_MESH:D062787	475_11	bcv_final_eval_easy_2774		
	MESH:D020888	"<span class=""chemical"">vigabatrin</span>"	MESH:D014786	"<span class=""disease"">Binasal visual field defects</span>"	"<span class=""disease"">Binasal visual field defects</span> are not specific to <span class=""chemical"">vigabatrin</span>."		476.0	476_MESH:D020888_MESH:D014786	476_0	bcv_final_eval_easy_2775		
	MESH:D020888	"<span class=""chemical"">vigabatrin</span>"	MESH:D014786	"<span class=""disease"">visual defects</span>"	"This study investigated the <span class=""disease"">visual defects</span> associated with the antiepileptic drug <span class=""chemical"">vigabatrin</span> (VGB)."		476.0	476_MESH:D020888_MESH:D014786	476_1	bcv_final_eval_easy_2776		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D015658	"<span class=""disease"">HIV infection</span>"	"Smoking of crack <span class=""chemical"">cocaine</span> as a risk factor for <span class=""disease"">HIV infection</span> among people who use injection drugs."		477.0	477_MESH:D003042_MESH:D015658	477_0	bcv_final_eval_easy_2777		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D015658	"<span class=""disease"">HIV infection</span>"	"BACKGROUND: Little is known about the possible role that smoking crack <span class=""chemical"">cocaine</span> has on the incidence of <span class=""disease"">HIV infection</span>."		477.0	477_MESH:D003042_MESH:D015658	477_1	bcv_final_eval_easy_2778		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D015658	"<span class=""disease"">HIV infection</span>"	"Given the increasing use of crack <span class=""chemical"">cocaine</span>, we sought to examine whether use of this illicit drug has become a risk factor for <span class=""disease"">HIV infection</span>."		477.0	477_MESH:D003042_MESH:D015658	477_2	bcv_final_eval_easy_2779		
	MESH:D005472	"<span class=""chemical"">5-fluorouracil</span>"	MESH:D008569	"<span class=""disease"">memory deficits</span>"	"Fluoxetine improves the <span class=""disease"">memory deficits</span> caused by the chemotherapy agent <span class=""chemical"">5-fluorouracil</span>."		478.0	478_MESH:D005472_MESH:D008569	478_0	bcv_final_eval_easy_2780		
	MESH:D005473	"<span class=""chemical"">Fluoxetine</span>"	MESH:D008569	"<span class=""disease"">memory deficits</span>"	"<span class=""chemical"">Fluoxetine</span> improves the <span class=""disease"">memory deficits</span> caused by the chemotherapy agent 5-fluorouracil."		478.0	478_MESH:D005473_MESH:D008569	478_0	bcv_final_eval_easy_2781		
	MESH:D005472	"<span class=""chemical"">5-FU</span>"	MESH:D008569	"<span class=""disease"">hippocampal dependent working memory</span>"	"These findings suggest that <span class=""chemical"">5-FU</span> can negatively affect both cell proliferation and <span class=""disease"">hippocampal dependent working memory</span> and that these deficits can be reversed by the simultaneous administration of the antidepressant Fluoxetine."		478.0	478_MESH:D005472_MESH:D008569	478_12	bcv_final_eval_easy_2782		
	MESH:D005473	"<span class=""chemical"">Fluoxetine</span>"	MESH:D008569	"<span class=""disease"">hippocampal dependent working memory</span>"	"These findings suggest that 5-FU can negatively affect both cell proliferation and <span class=""disease"">hippocampal dependent working memory</span> and that these deficits can be reversed by the simultaneous administration of the antidepressant <span class=""chemical"">Fluoxetine</span>."		478.0	478_MESH:D005473_MESH:D008569	478_12	bcv_final_eval_easy_2783		
	MESH:D010634	"<span class=""chemical"">phenobarbital</span>"	MESH:D006529	"<span class=""disease"">hepatomegaly</span>"	"Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and <span class=""disease"">hepatomegaly</span> after <span class=""chemical"">phenobarbital</span> administration."		479.0	479_MESH:D010634_MESH:D006529	479_0	bcv_final_eval_easy_2784		
	MESH:D010634	"<span class=""chemical"">PB/phenobarbital</span>"	MESH:D006529	"<span class=""disease"">liver enlargement</span>"	"This study investigates the role of ILK in <span class=""disease"">liver enlargement</span> induced by <span class=""chemical"">phenobarbital</span> (<span class=""chemical"">PB</span>)."		479.0	479_MESH:D010634_MESH:D006529	479_2	bcv_final_eval_easy_2785		
	MESH:D010634	"<span class=""chemical"">PB</span>"	MESH:D008107	"<span class=""disease"">liver regeneration</span>"	"Lack of ILK in the hepatocytes imparts prolonged proliferative response not only to stimuli related to <span class=""disease"">liver regeneration</span> but also to xenobiotic chemical mitogens, such as <span class=""chemical"">PB</span>."		479.0	479_MESH:D010634_MESH:D008107	479_12	bcv_final_eval_easy_2786		
	MESH:D012964	"<span class=""chemical"">Na</span>"	MESH:D015799	"<span class=""disease"">OAT</span>"	"Decreased Expression of <span class=""chemical"">Na</span>/K-ATPase, NHE3, NBC1, AQP1 and <span class=""disease"">OAT</span> in Gentamicin-induced Nephropathy."		480.0	480_MESH:D012964_MESH:D015799	480_0	bcv_final_eval_easy_2787		
	MESH:D012964	"<span class=""chemical"">Na</span>"	MESH:D007674	"<span class=""disease"">Nephropathy</span>"	"Decreased Expression of <span class=""chemical"">Na</span>/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced <span class=""disease"">Nephropathy</span>."		480.0	480_MESH:D012964_MESH:D007674	480_0	bcv_final_eval_easy_2788		
	MESH:D011188	"<span class=""chemical"">K</span>"	MESH:D007674	"<span class=""disease"">Nephropathy</span>"	"Decreased Expression of Na/<span class=""chemical"">K</span>-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced <span class=""disease"">Nephropathy</span>."		480.0	480_MESH:D011188_MESH:D007674	480_0	bcv_final_eval_easy_2789		
	MESH:D011188	"<span class=""chemical"">K</span>"	MESH:D015799	"<span class=""disease"">OAT</span>"	"Decreased Expression of Na/<span class=""chemical"">K</span>-ATPase, NHE3, NBC1, AQP1 and <span class=""disease"">OAT</span> in Gentamicin-induced Nephropathy."		480.0	480_MESH:D011188_MESH:D015799	480_0	bcv_final_eval_easy_2790		
	MESH:D005839	"<span class=""chemical"">Gentamicin</span>"	MESH:D015799	"<span class=""disease"">OAT</span>"	"Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and <span class=""disease"">OAT</span> in <span class=""chemical"">Gentamicin</span>-induced Nephropathy."		480.0	480_MESH:D005839_MESH:D015799	480_0	bcv_final_eval_easy_2791		
	MESH:D012964	"<span class=""chemical"">Na(+)</span>"	MESH:D015799	"<span class=""disease"">OAT</span>"	"Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of <span class=""chemical"">Na(+)</span>/K(+)-ATPase, NHE3, NBC1, AQP1 and <span class=""disease"">OAT</span>."		480.0	480_MESH:D012964_MESH:D015799	480_9	bcv_final_eval_easy_2792		
	MESH:D012964	"<span class=""chemical"">Na(+)</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Gentamicin-induced <span class=""disease"">nephropathy</span> may at least in part be causally related with a decreased expression of <span class=""chemical"">Na(+)</span>/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT."		480.0	480_MESH:D012964_MESH:D007674	480_9	bcv_final_eval_easy_2793		
	MESH:D011188	"<span class=""chemical"">K(+)</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"Gentamicin-induced <span class=""disease"">nephropathy</span> may at least in part be causally related with a decreased expression of Na(+)/<span class=""chemical"">K(+)</span>-ATPase, NHE3, NBC1, AQP1 and OAT."		480.0	480_MESH:D011188_MESH:D007674	480_9	bcv_final_eval_easy_2794		
	MESH:D011188	"<span class=""chemical"">K(+)</span>"	MESH:D015799	"<span class=""disease"">OAT</span>"	"Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/<span class=""chemical"">K(+)</span>-ATPase, NHE3, NBC1, AQP1 and <span class=""disease"">OAT</span>."		480.0	480_MESH:D011188_MESH:D015799	480_9	bcv_final_eval_easy_2795		
	MESH:D005839	"<span class=""chemical"">Gentamicin</span>"	MESH:D015799	"<span class=""disease"">OAT</span>"	"<span class=""chemical"">Gentamicin</span>-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and <span class=""disease"">OAT</span>."		480.0	480_MESH:D005839_MESH:D015799	480_9	bcv_final_eval_easy_2796		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D015658	"<span class=""disease"">HIV disease progression/psychological health of women with HIV</span>"	"Longitudinal association of <span class=""chemical"">alcohol</span> use with <span class=""disease"">HIV disease progression</span> and <span class=""disease"">psychological health of women with HIV</span>."		481.0	481_MESH:D000431_MESH:D015658	481_0	bcv_final_eval_easy_2797		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"We evaluated the association of <span class=""chemical"">alcohol</span> consumption and <span class=""disease"">depression</span>, and their effects on HIV disease progression among women with HIV."		481.0	481_MESH:D000431_MESH:D003866	481_1	bcv_final_eval_easy_2798		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D015658	"<span class=""disease"">HIV disease progression/HIV</span>"	"We evaluated the association of <span class=""chemical"">alcohol</span> consumption and depression, and their effects on <span class=""disease"">HIV disease progression</span> among women with <span class=""disease"">HIV</span>."		481.0	481_MESH:D000431_MESH:D015658	481_1	bcv_final_eval_easy_2799		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of <span class=""disease"">depression</span> symptoms (using the self-report Center for Epidemiological Studies-<span class=""disease"">Depression</span> Scale), and <span class=""chemical"">alcohol</span> use assessment at enrollment, and semiannually until March 2000."		481.0	481_MESH:D000431_MESH:D003866	481_3	bcv_final_eval_easy_2800		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"The association between <span class=""chemical"">alcohol</span> consumption and <span class=""disease"">depression</span> was significant (p<0.001)."		481.0	481_MESH:D000431_MESH:D003866	481_7	bcv_final_eval_easy_2801		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D003866	"<span class=""disease"">depression</span>"	"Our findings suggest that <span class=""chemical"">alcohol</span> consumption has a direct association with <span class=""disease"">depression</span>."		481.0	481_MESH:D000431_MESH:D003866	481_9	bcv_final_eval_easy_2802		
	MESH:D000431	"<span class=""chemical"">alcohol</span>"	MESH:D015658	"<span class=""disease"">HIV</span>"	"Our findings have implications for the provision of <span class=""chemical"">alcohol</span> use interventions and psychological resources to improve the health of women with <span class=""disease"">HIV</span>."		481.0	481_MESH:D000431_MESH:D015658	481_11	bcv_final_eval_easy_2803		
	MESH:D002330	"<span class=""chemical"">carmustine</span>"	MESH:D003072	"<span class=""disease"">preservation of cognitive function</span>"	"Metallothionein induction reduces caspase-3 activity and TNFalpha levels with <span class=""disease"">preservation of cognitive function</span> and intact hippocampal neurons in <span class=""chemical"">carmustine</span>-treated rats."		483.0	483_MESH:D002330_MESH:D003072	483_0	bcv_final_eval_easy_2804		
	MESH:D002330	"<span class=""chemical"">BCNU/carmustine</span>"	MESH:D003072	"<span class=""disease"">cognitive dysfunction</span>"	"The present study aimed to explore the effect of MT induction on <span class=""chemical"">carmustine</span> (<span class=""chemical"">BCNU</span>)-induced hippocampal <span class=""disease"">cognitive dysfunction</span> in rats."		483.0	483_MESH:D002330_MESH:D003072	483_3	bcv_final_eval_easy_2805		
	MESH:D002330	"<span class=""chemical"">BCNU</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Also, <span class=""chemical"">BCNU</span> administration increased serum <span class=""disease"">tumor</span> necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations."		483.0	483_MESH:D002330_MESH:D009369	483_9	bcv_final_eval_easy_2806		
	MESH:D002330	"<span class=""chemical"">BCNU</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Also, <span class=""chemical"">BCNU</span> administration increased serum tumor <span class=""disease"">necrosis</span> factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations."		483.0	483_MESH:D002330_MESH:D009336	483_9	bcv_final_eval_easy_2807		
	MESH:D008315	"<span class=""chemical"">MDA/malondialdehyde</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Also, BCNU administration increased serum <span class=""disease"">tumor</span> necrosis factor-alpha (TNFalpha), hippocampal MT and <span class=""chemical"">malondialdehyde</span> (<span class=""chemical"">MDA</span>) contents as well as caspase-3 activity in addition to histological alterations."		483.0	483_MESH:D008315_MESH:D009369	483_9	bcv_final_eval_easy_2808		
	MESH:D008315	"<span class=""chemical"">MDA/malondialdehyde</span>"	MESH:D009336	"<span class=""disease"">necrosis</span>"	"Also, BCNU administration increased serum tumor <span class=""disease"">necrosis</span> factor-alpha (TNFalpha), hippocampal MT and <span class=""chemical"">malondialdehyde</span> (<span class=""chemical"">MDA</span>) contents as well as caspase-3 activity in addition to histological alterations."		483.0	483_MESH:D008315_MESH:D009336	483_9	bcv_final_eval_easy_2809		
	MESH:D008315	"<span class=""chemical"">MDA</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"In conclusion, MT induction halts BCNU-induced hippocampal <span class=""disease"">toxicity</span> as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, <span class=""chemical"">MDA</span> and caspase-3 activity with subsequent preservation of cognition."		483.0	483_MESH:D008315_MESH:D064420	483_12	bcv_final_eval_easy_2810		
	MESH:D002330	"<span class=""chemical"">BCNU</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"In conclusion, MT induction halts <span class=""chemical"">BCNU</span>-induced hippocampal <span class=""disease"">toxicity</span> as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition."		483.0	483_MESH:D002330_MESH:D064420	483_12	bcv_final_eval_easy_2811		
	MESH:D005978	"<span class=""chemical"">GSH</span>"	MESH:D064420	"<span class=""disease"">toxicity</span>"	"In conclusion, MT induction halts BCNU-induced hippocampal <span class=""disease"">toxicity</span> as it prevented GR inhibition and <span class=""chemical"">GSH</span> depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition."		483.0	483_MESH:D005978_MESH:D064420	483_12	bcv_final_eval_easy_2812		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"Fatal <span class=""chemical"">carbamazepine</span> induced fulminant eosinophilic (<span class=""disease"">hypersensitivity</span>) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug <span class=""disease"">hypersensitivity</span> and differential diagnosis."		484.0	484_MESH:D002220_MESH:D004342	484_0	bcv_final_eval_easy_2813		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D004802	"<span class=""disease"">eosinophilic</span>"	"Fatal <span class=""chemical"">carbamazepine</span> induced fulminant <span class=""disease"">eosinophilic</span> (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis."		484.0	484_MESH:D002220_MESH:D004802	484_0	bcv_final_eval_easy_2814		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D004342	"<span class=""disease"">hypersensitivity</span>"	"A frequently fatal, although exceptionally rare side effect of <span class=""chemical"">carbamazepine</span> is necrotizing eosinophilic (<span class=""disease"">hypersensitivity</span>) myocarditis."		484.0	484_MESH:D002220_MESH:D004342	484_2	bcv_final_eval_easy_2815		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D004802	"<span class=""disease"">eosinophilic</span>"	"A frequently fatal, although exceptionally rare side effect of <span class=""chemical"">carbamazepine</span> is necrotizing <span class=""disease"">eosinophilic</span> (hypersensitivity) myocarditis."		484.0	484_MESH:D002220_MESH:D004802	484_2	bcv_final_eval_easy_2816		
	MESH:D002220	"<span class=""chemical"">carbamazepine</span>"	MESH:D009336	"<span class=""disease"">necrotizing</span>"	"A frequently fatal, although exceptionally rare side effect of <span class=""chemical"">carbamazepine</span> is <span class=""disease"">necrotizing</span> eosinophilic (hypersensitivity) myocarditis."		484.0	484_MESH:D002220_MESH:D009336	484_2	bcv_final_eval_easy_2817		
	MESH:D015632	"<span class=""chemical"">MPTP</span>"	MESH:D010300	"<span class=""disease"">Parkinson's disease</span>"	"Neuropsychiatric behaviors in the <span class=""chemical"">MPTP</span> marmoset model of <span class=""disease"">Parkinson's disease</span>."		485.0	485_MESH:D015632_MESH:D010300	485_0	bcv_final_eval_easy_2818		
	MESH:D015632	"<span class=""chemical"">MPTP</span>"	MESH:D001523	"<span class=""disease"">Neuropsychiatric behaviors</span>"	"<span class=""disease"">Neuropsychiatric behaviors</span> in the <span class=""chemical"">MPTP</span> marmoset model of Parkinson's disease."		485.0	485_MESH:D015632_MESH:D001523	485_0	bcv_final_eval_easy_2819		
	MESH:D015632	"<span class=""chemical"">MPTP</span>"	MESH:D010300	"<span class=""disease"">PD</span>"	"The levodopa-treated <span class=""chemical"">MPTP</span>-lesioned marmoset was used as a model of neuropsychiatric symptoms in <span class=""disease"">PD</span> patients."		485.0	485_MESH:D015632_MESH:D010300	485_3	bcv_final_eval_easy_2820		
	MESH:D015632	"<span class=""chemical"">MPTP</span>"	MESH:D001523	"<span class=""disease"">neuropsychiatric symptoms</span>"	"The levodopa-treated <span class=""chemical"">MPTP</span>-lesioned marmoset was used as a model of <span class=""disease"">neuropsychiatric symptoms</span> in PD patients."		485.0	485_MESH:D015632_MESH:D001523	485_3	bcv_final_eval_easy_2821		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">PD</span>"	"The <span class=""chemical"">levodopa</span>-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in <span class=""disease"">PD</span> patients."		485.0	485_MESH:D007980_MESH:D010300	485_3	bcv_final_eval_easy_2822		
	MESH:D015632	"<span class=""chemical"">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</span>"	MESH:D010302	"<span class=""disease"">parkinsonism</span>"	"METHODS: Marmosets were administered <span class=""chemical"">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</span> (2.0 mg/kg s.c.) for five days, resulting in stable <span class=""disease"">parkinsonism</span>."		485.0	485_MESH:D015632_MESH:D010302	485_5	bcv_final_eval_easy_2823		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D004409	"<span class=""disease"">dyskinesia</span>"	"Animals were evaluated for parkinsonian disability, <span class=""disease"">dyskinesia</span> and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to <span class=""chemical"">levodopa</span>) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day."		485.0	485_MESH:D007980_MESH:D004409	485_8	bcv_final_eval_easy_2824		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">parkinsonian disability</span>"	"Animals were evaluated for <span class=""disease"">parkinsonian disability</span>, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to <span class=""chemical"">levodopa</span>) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day."		485.0	485_MESH:D007980_MESH:D010300	485_8	bcv_final_eval_easy_2825		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D004409	"<span class=""disease"">dyskinesia</span>"	"As anticipated, animals exhibited a progressive increase in <span class=""chemical"">levodopa</span>-induced motor fluctuations, <span class=""disease"">dyskinesia</span> and wearing-off, that correlated with the duration of <span class=""chemical"">levodopa</span> therapy."		485.0	485_MESH:D007980_MESH:D004409	485_10	bcv_final_eval_easy_2826		
	MESH:D007980	"<span class=""chemical"">levodopa</span>"	MESH:D010300	"<span class=""disease"">PD</span>"	"CONCLUSIONS: The data suggest that neuropsychiatric disorders in <span class=""disease"">PD</span> are more likely an interaction between <span class=""chemical"">levodopa</span> and the disease state than a consequence of sensitisation to repeated dopaminergic therapy."		485.0	485_MESH:D007980_MESH:D010300	485_12	bcv_final_eval_easy_2827		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D001523	"<span class=""disease"">psychiatric</span>"	"Medical and <span class=""disease"">psychiatric</span> outcomes for patients transplanted for <span class=""chemical"">acetaminophen</span>-induced acute liver failure: a case-control study."		487.0	487_MESH:D000082_MESH:D001523	487_0	bcv_final_eval_easy_2828		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D005067	"<span class=""disease"">pretransplant illness</span>"	"AIMS AND METHODS: We compared the severity of <span class=""disease"">pretransplant illness</span>, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for <span class=""chemical"">acetaminophen</span>-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-<span class=""chemical"">acetaminophen</span>-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34)."		487.0	487_MESH:D000082_MESH:D005067	487_3	bcv_final_eval_easy_2829		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D001523	"<span class=""disease"">psychiatric</span>"	"AIMS AND METHODS: We compared the severity of pretransplant illness, <span class=""disease"">psychiatric</span> co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for <span class=""chemical"">acetaminophen</span>-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-<span class=""chemical"">acetaminophen</span>-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34)."		487.0	487_MESH:D000082_MESH:D001523	487_3	bcv_final_eval_easy_2830		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D008107	"<span class=""disease"">CLD/chronic liver disease</span>"	"AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for <span class=""chemical"">acetaminophen</span>-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-<span class=""chemical"">acetaminophen</span>-induced ALF (n=35) and elective LT for <span class=""disease"">chronic liver disease</span> (<span class=""disease"">CLD</span>, n=34)."		487.0	487_MESH:D000082_MESH:D008107	487_3	bcv_final_eval_easy_2831		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D008107	"<span class=""disease"">CLD</span>"	"Twenty (56%) <span class=""chemical"">acetaminophen</span>-induced ALF patients had a formal psychiatric diagnosis before LT (non-<span class=""chemical"">acetaminophen</span>-induced ALF=0/35, <span class=""disease"">CLD</span>=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt."		487.0	487_MESH:D000082_MESH:D008107	487_5	bcv_final_eval_easy_2832		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D001523	"<span class=""disease"">psychiatric diagnosis</span>"	"Twenty (56%) <span class=""chemical"">acetaminophen</span>-induced ALF patients had a formal <span class=""disease"">psychiatric diagnosis</span> before LT (non-<span class=""chemical"">acetaminophen</span>-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt."		487.0	487_MESH:D000082_MESH:D001523	487_5	bcv_final_eval_easy_2833		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D008107	"<span class=""disease"">CLD</span>"	"During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (<span class=""chemical"">acetaminophen</span>-induced ALF 1 year 87%, 5 years 75%; non-<span class=""chemical"">acetaminophen</span>-induced ALF 88%, 78%; <span class=""disease"">CLD</span> 93%, 82%: P>0.6 log rank)."		487.0	487_MESH:D000082_MESH:D008107	487_6	bcv_final_eval_easy_2834		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D008107	"<span class=""disease"">CLD</span>"	"CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for <span class=""chemical"">acetaminophen</span>-induced ALF were comparable to those transplanted for non-<span class=""chemical"">acetaminophen</span>-induced ALF and electively for <span class=""disease"">CLD</span>."		487.0	487_MESH:D000082_MESH:D008107	487_8	bcv_final_eval_easy_2835		
	MESH:D000082	"<span class=""chemical"">acetaminophen</span>"	MESH:D001523	"<span class=""disease"">psychiatric</span>"	"CONCLUSIONS: Despite a high prevalence of <span class=""disease"">psychiatric</span> disturbance, outcomes for patients transplanted emergently for <span class=""chemical"">acetaminophen</span>-induced ALF were comparable to those transplanted for non-<span class=""chemical"">acetaminophen</span>-induced ALF and electively for CLD."		487.0	487_MESH:D000082_MESH:D001523	487_8	bcv_final_eval_easy_2836		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D009437	"<span class=""disease"">inflammatory and neuropathic pain</span>"	"Studies of synergy between morphine and a novel sodium channel blocker, <span class=""chemical"">CNSB002</span>, in rat models of <span class=""disease"">inflammatory and neuropathic pain</span>."		488.0	488_MESH:C401121_MESH:D009437	488_0	bcv_final_eval_easy_2837		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D009437	"<span class=""disease"">inflammatory and neuropathic pain</span>"	"Studies of synergy between morphine and a novel <span class=""chemical"">sodium</span> channel blocker, CNSB002, in rat models of <span class=""disease"">inflammatory and neuropathic pain</span>."		488.0	488_MESH:D012964_MESH:D009437	488_0	bcv_final_eval_easy_2838		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D009437	"<span class=""disease"">inflammatory and neuropathic pain</span>"	"Studies of synergy between <span class=""chemical"">morphine</span> and a novel sodium channel blocker, CNSB002, in rat models of <span class=""disease"">inflammatory and neuropathic pain</span>."		488.0	488_MESH:D009020_MESH:D009437	488_0	bcv_final_eval_easy_2839		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D009437	"<span class=""disease"">inflammatory and neuropathic pain</span>"	"OBJECTIVE: This study determined the antihyperalgesic effect of <span class=""chemical"">CNSB002</span>, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of <span class=""disease"">inflammatory and neuropathic pain</span>."		488.0	488_MESH:C401121_MESH:D009437	488_1	bcv_final_eval_easy_2840		
	MESH:D012964	"<span class=""chemical"">sodium</span>"	MESH:D009437	"<span class=""disease"">inflammatory and neuropathic pain</span>"	"OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a <span class=""chemical"">sodium</span> channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of <span class=""disease"">inflammatory and neuropathic pain</span>."		488.0	488_MESH:D012964_MESH:D009437	488_1	bcv_final_eval_easy_2841		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D009437	"<span class=""disease"">inflammatory and neuropathic pain</span>"	"OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with <span class=""chemical"">morphine</span> in rat models of <span class=""disease"">inflammatory and neuropathic pain</span>."		488.0	488_MESH:D009020_MESH:D009437	488_1	bcv_final_eval_easy_2842		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D003929	"<span class=""disease"">diabetic neuropathy</span>"	"DESIGN: Dose response curves for nonsedating doses of morphine and <span class=""chemical"">CNSB002</span> given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced <span class=""disease"">diabetic neuropathy</span>."		488.0	488_MESH:C401121_MESH:D003929	488_2	bcv_final_eval_easy_2843		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D010146	"<span class=""disease"">rat pain</span>"	"DESIGN: Dose response curves for nonsedating doses of <span class=""chemical"">morphine</span> and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two <span class=""disease"">rat pain</span> models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy."		488.0	488_MESH:D009020_MESH:D010146	488_2	bcv_final_eval_easy_2844		
	MESH:D013311	"<span class=""chemical"">streptozotocin/STZ</span>"	MESH:D010146	"<span class=""disease"">rat pain</span>"	"DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two <span class=""disease"">rat pain</span> models: carrageenan-induced paw inflammation and <span class=""chemical"">streptozotocin</span> (<span class=""chemical"">STZ</span>)-induced diabetic neuropathy."		488.0	488_MESH:D013311_MESH:D010146	488_2	bcv_final_eval_easy_2845		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D010146	"<span class=""disease"">rat pain</span>"	"DESIGN: Dose response curves for nonsedating doses of morphine and <span class=""chemical"">CNSB002</span> given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two <span class=""disease"">rat pain</span> models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy."		488.0	488_MESH:C401121_MESH:D010146	488_2	bcv_final_eval_easy_2846		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D003929	"<span class=""disease"">diabetic neuropathy</span>"	"DESIGN: Dose response curves for nonsedating doses of <span class=""chemical"">morphine</span> and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced <span class=""disease"">diabetic neuropathy</span>."		488.0	488_MESH:D009020_MESH:D003929	488_2	bcv_final_eval_easy_2847		
	MESH:D013311	"<span class=""chemical"">streptozotocin/STZ</span>"	MESH:D007249	"<span class=""disease"">inflammation</span>"	"DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw <span class=""disease"">inflammation</span> and <span class=""chemical"">streptozotocin</span> (<span class=""chemical"">STZ</span>)-induced diabetic neuropathy."		488.0	488_MESH:D013311_MESH:D007249	488_2	bcv_final_eval_easy_2848		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D007249	"<span class=""disease"">inflammation</span>"	"DESIGN: Dose response curves for nonsedating doses of <span class=""chemical"">morphine</span> and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw <span class=""disease"">inflammation</span> and streptozotocin (STZ)-induced diabetic neuropathy."		488.0	488_MESH:D009020_MESH:D007249	488_2	bcv_final_eval_easy_2849		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D007249	"<span class=""disease"">inflammation</span>"	"DESIGN: Dose response curves for nonsedating doses of morphine and <span class=""chemical"">CNSB002</span> given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw <span class=""disease"">inflammation</span> and streptozotocin (STZ)-induced diabetic neuropathy."		488.0	488_MESH:C401121_MESH:D007249	488_2	bcv_final_eval_easy_2850		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D009422	"<span class=""disease"">neuropathy</span>"	"The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced <span class=""disease"">neuropathy</span> model for <span class=""chemical"">CNSB002</span> and morphine, respectively (mg/kg; mean, SEM)."		488.0	488_MESH:C401121_MESH:D009422	488_4	bcv_final_eval_easy_2851		
	MESH:D013311	"<span class=""chemical"">STZ</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia</span>"	"The doses calculated to cause 50% reversal of <span class=""disease"">hyperalgesia</span> (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the <span class=""chemical"">STZ</span>-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM)."		488.0	488_MESH:D013311_MESH:D006930	488_4	bcv_final_eval_easy_2852		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia</span>"	"The doses calculated to cause 50% reversal of <span class=""disease"">hyperalgesia</span> (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for <span class=""chemical"">CNSB002</span> and morphine, respectively (mg/kg; mean, SEM)."		488.0	488_MESH:C401121_MESH:D006930	488_4	bcv_final_eval_easy_2853		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia</span>"	"The doses calculated to cause 50% reversal of <span class=""disease"">hyperalgesia</span> (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and <span class=""chemical"">morphine</span>, respectively (mg/kg; mean, SEM)."		488.0	488_MESH:D009020_MESH:D006930	488_4	bcv_final_eval_easy_2854		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D009422	"<span class=""disease"">neuropathy</span>"	"The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced <span class=""disease"">neuropathy</span> model for CNSB002 and <span class=""chemical"">morphine</span>, respectively (mg/kg; mean, SEM)."		488.0	488_MESH:D009020_MESH:D009422	488_4	bcv_final_eval_easy_2855		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D009422	"<span class=""disease"">neuropathy</span>"	"The ED50 values for <span class=""chemical"">morphine</span> when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the <span class=""disease"">neuropathy</span> model (mg/kg; mean, SEM)."		488.0	488_MESH:D009020_MESH:D009422	488_6	bcv_final_eval_easy_2856		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D009422	"<span class=""disease"">neuropathy</span>"	"The ED50 values for morphine when given in combination with <span class=""chemical"">CNSB002</span> (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the <span class=""disease"">neuropathy</span> model (mg/kg; mean, SEM)."		488.0	488_MESH:C401121_MESH:D009422	488_6	bcv_final_eval_easy_2857		
	MESH:C401121	"<span class=""chemical"">CNSB002</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia</span>"	"The antinociception after morphine (3.2 mg/kg) was increased by co-administration with <span class=""chemical"">CNSB002</span> from 28.0 and 31.7% to 114.6 and 56.9% reversal of <span class=""disease"">hyperalgesia</span> in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone)."		488.0	488_MESH:C401121_MESH:D006930	488_7	bcv_final_eval_easy_2858		
	MESH:D009020	"<span class=""chemical"">morphine</span>"	MESH:D006930	"<span class=""disease"">hyperalgesia</span>"	"The antinociception after <span class=""chemical"">morphine</span> (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of <span class=""disease"">hyperalgesia</span> in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone)."		488.0	488_MESH:D009020_MESH:D006930	488_7	bcv_final_eval_easy_2859		
	MESH:D006493	"<span class=""chemical"">Heparin</span>"	MESH:D013921	"<span class=""disease"">Heparin-induced thrombocytopenia</span>"	"<span class=""chemical""></span><span class=""disease"">Heparin</span>-induced thrombocytopenia: a practical review."		489.0	489_MESH:D006493_MESH:D013921	489_0	bcv_final_eval_easy_2860		
	MESH:D006493	"<span class=""chemical"">Heparin</span>"	MESH:D013921	"<span class=""disease"">HIT/Heparin-induced thrombocytopenia</span>"	"<span class=""chemical""></span><span class=""disease"">Heparin</span>-induced thrombocytopenia (<span class=""disease"">HIT</span>) remains under-recognized despite its potentially devastating outcomes."		489.0	489_MESH:D006493_MESH:D013921	489_1	bcv_final_eval_easy_2861		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013921	"<span class=""disease"">HIT</span>"	"<span class=""disease"">HIT</span> must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after <span class=""chemical"">heparin</span> exposure."		489.0	489_MESH:D006493_MESH:D013921	489_5	bcv_final_eval_easy_2862		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013927	"<span class=""disease"">thrombosis</span>"	"HIT must be acknowledged for its intense predilection for <span class=""disease"">thrombosis</span> and suspected whenever <span class=""disease"">thrombosis</span> occurs after <span class=""chemical"">heparin</span> exposure."		489.0	489_MESH:D006493_MESH:D013927	489_5	bcv_final_eval_easy_2863		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013921	"<span class=""disease"">HIT</span>"	"The treatment of <span class=""disease"">HIT</span> mandates an immediate cessation of all <span class=""chemical"">heparin</span> exposure and the institution of an antithrombotic therapy, most commonly using a direct thrombin inhibitor."		489.0	489_MESH:D006493_MESH:D013921	489_7	bcv_final_eval_easy_2864		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013921	"<span class=""disease"">HIT</span>"	"Direct thrombin inhibitors are appropriate, evidence-based alternatives to <span class=""chemical"">heparin</span> in patients with a history of <span class=""disease"">HIT</span>, who need to undergo percutaneous coronary intervention."		489.0	489_MESH:D006493_MESH:D013921	489_10	bcv_final_eval_easy_2865		
	MESH:D006493	"<span class=""chemical"">heparin</span>"	MESH:D013921	"<span class=""disease"">HIT</span>"	"As <span class=""chemical"">heparin</span> remains one of the most frequently used medications today with potential for <span class=""disease"">HIT</span> with every <span class=""chemical"">heparin</span> exposure, a close vigilance of platelet counts must be practiced whenever <span class=""chemical"">heparin</span> is initiated."		489.0	489_MESH:D006493_MESH:D013921	489_11	bcv_final_eval_easy_2866		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D028361	"<span class=""disease"">Mitochondrial impairment</span>"	"<span class=""disease"">Mitochondrial impairment</span> contributes to <span class=""chemical"">cocaine</span>-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ."		491.0	491_MESH:D003042_MESH:D028361	491_0	bcv_final_eval_easy_2867		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D019970	"<span class=""disease"">cocaine abuse</span>"	"We hypothesized that <span class=""chemical""></span><span class=""disease"">cocaine</span> abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction."		491.0	491_MESH:D003042_MESH:D019970	491_2	bcv_final_eval_easy_2868		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D018487	"<span class=""disease"">left ventricular dysfunction</span>"	"We hypothesized that <span class=""chemical"">cocaine</span> abuse may lead to altered mitochondrial function that in turn may cause <span class=""disease"">left ventricular dysfunction</span>."		491.0	491_MESH:D003042_MESH:D018487	491_2	bcv_final_eval_easy_2869		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D028361	"<span class=""disease"">mitochondrial abnormalities</span>"	"This uncoupling effect on oxidative phosphorylation was not detectable after short-term exposure to <span class=""chemical"">cocaine</span>, suggesting that these <span class=""disease"">mitochondrial abnormalities</span> were a late rather than a primary event in the pathological response to <span class=""chemical"">cocaine</span>."		491.0	491_MESH:D003042_MESH:D028361	491_6	bcv_final_eval_easy_2870		
	MESH:D003042	"<span class=""chemical"">cocaine</span>"	MESH:D028361	"<span class=""disease"">mitochondrial defect</span>"	"Taken together, these results extend previous studies and demonstrate that <span class=""chemical"">cocaine</span>-induced cardiac dysfunction may be due to a <span class=""disease"">mitochondrial defect</span>."		491.0	491_MESH:D003042_MESH:D028361	491_8	bcv_final_eval_easy_2871		
	MESH:D014295	"<span class=""chemical"">Trimethoprim</span>"	MESH:D000743	"<span class=""disease"">hemolytic anemia</span>"	"<span class=""chemical"">Trimethoprim</span>-induced immune <span class=""disease"">hemolytic anemia</span> in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction."		492.0	492_MESH:D014295_MESH:D000743	492_0	bcv_final_eval_easy_2872		
	MESH:D014295	"<span class=""chemical"">Trimethoprim</span>"	MESH:D065227	"<span class=""disease"">acute hemolytic transfusion reaction</span>"	"<span class=""chemical"">Trimethoprim</span>-induced immune hemolytic anemia in a pediatric oncology patient presenting as an <span class=""disease"">acute hemolytic transfusion reaction</span>."		492.0	492_MESH:D014295_MESH:D065227	492_0	bcv_final_eval_easy_2873		
	MESH:D000809	"<span class=""chemical"">angiotensin</span>"	MESH:D007674	"<span class=""disease"">nephropathy</span>"	"OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-<span class=""chemical"">angiotensin</span> system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of <span class=""disease"">nephropathy</span>, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)."		493.0	493_MESH:D000809_MESH:D007674	493_1	bcv_final_eval_easy_2874		
	MESH:D000809	"<span class=""chemical"">angiotensin</span>"	MESH:D003920	"<span class=""disease"">diabetes</span>"	"OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-<span class=""chemical"">angiotensin</span> system in patients with type 1 <span class=""disease"">diabetes</span> and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)."		493.0	493_MESH:D000809_MESH:D003920	493_1	bcv_final_eval_easy_2875		
	MESH:D000809	"<span class=""chemical"">angiotensin</span>"	MESH:D003928	"<span class=""disease"">diabetic nephropathy</span>"	"OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-<span class=""chemical"">angiotensin</span> system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early <span class=""disease"">diabetic nephropathy</span> (<span class=""disease"">diabetic nephropathy</span>)."		493.0	493_MESH:D000809_MESH:D003928	493_1	bcv_final_eval_easy_2876		
	MESH:D013311	"<span class=""chemical"">streptozotocin/STZ</span>"	MESH:D007674	"<span class=""disease"">renal interstitial fibrosis</span>"	"We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of <span class=""disease"">renal interstitial fibrosis</span> independently of microalbuminuria in mice with <span class=""chemical"">streptozotocin</span> (<span class=""chemical"">STZ</span>)-induced diabetes."		493.0	493_MESH:D013311_MESH:D007674	493_2	bcv_final_eval_easy_2877		
	MESH:C401859	"<span class=""chemical"">temsirolimus</span>"	MESH:D020522	"<span class=""disease"">refractory mantle cell lymphoma</span>"	"Cytostatic and anti-angiogenic effects of <span class=""chemical"">temsirolimus</span> in <span class=""disease"">refractory mantle cell lymphoma</span>."		494.0	494_MESH:C401859_MESH:D020522	494_0	bcv_final_eval_easy_2878		
	MESH:C401859	"<span class=""chemical"">temsirolimus</span>"	MESH:D020522	"<span class=""disease"">MCL</span>"	"However, a 38% remission rate has been recently reported in refractory <span class=""disease"">MCL</span> treated with <span class=""chemical"">temsirolimus</span>, a mTOR inhibitor.Here we had the opportunity to study a case of refractory <span class=""disease"">MCL</span> who had tumor regression two months after <span class=""chemical"">temsirolimus</span> treatment, and a progression-free survival of 10 months."		494.0	494_MESH:C401859_MESH:D020522	494_3	bcv_final_eval_easy_2879		
	MESH:C401859	"<span class=""chemical"">temsirolimus</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"However, a 38% remission rate has been recently reported in refractory MCL treated with <span class=""chemical"">temsirolimus</span>, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had <span class=""disease"">tumor</span> regression two months after <span class=""chemical"">temsirolimus</span> treatment, and a progression-free survival of 10 months."		494.0	494_MESH:C401859_MESH:D009369	494_3	bcv_final_eval_easy_2880		
	MESH:C401859	"<span class=""chemical"">temsirolimus</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Comparison of the two biopsies showed that <span class=""chemical"">temsirolimus</span> inhibited <span class=""disease"">tumor</span> cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic <span class=""disease"">tumor</span> cells."		494.0	494_MESH:C401859_MESH:D009369	494_5	bcv_final_eval_easy_2881		
	MESH:C401859	"<span class=""chemical"">temsirolimus</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Apart from this cytostatic effect, <span class=""chemical"">temsirolimus</span> had an antiangiogenic effect with decrease of <span class=""disease"">tumor</span> microvessel density and of VEGF expression."		494.0	494_MESH:C401859_MESH:D009369	494_6	bcv_final_eval_easy_2882		
	MESH:C401859	"<span class=""chemical"">temsirolimus</span>"	MESH:D009336	"<span class=""disease"">necrotic</span>"	"Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-<span class=""disease"">necrotic</span> tissue repair, were found after 6-month <span class=""chemical"">temsirolimus</span> therapy."		494.0	494_MESH:C401859_MESH:D009336	494_7	bcv_final_eval_easy_2883		
	MESH:C401859	"<span class=""chemical"">temsirolimus</span>"	MESH:D009369	"<span class=""disease"">tumor</span>"	"Thus, <span class=""chemical"">temsirolimus</span> reduced <span class=""disease"">tumor</span> burden through associated cytostatic and anti-angiogenic effects.This dual effect of <span class=""chemical"">temsirolimus</span> on <span class=""disease"">tumor</span> tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy."		494.0	494_MESH:C401859_MESH:D009369	494_8	bcv_final_eval_easy_2884		
	MESH:C401859	"<span class=""chemical"">temsirolimus</span>"	MESH:D020522	"<span class=""disease"">MCL</span>"	"Thus, <span class=""chemical"">temsirolimus</span> reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of <span class=""chemical"">temsirolimus</span> on tumor tissue could contribute to its recently reported efficiency in refractory <span class=""disease"">MCL</span> resistant to conventional chemotherapy."		494.0	494_MESH:C401859_MESH:D020522	494_8	bcv_final_eval_easy_2885		
	MESH:D000809	"<span class=""chemical"">angiotensin</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"Syncope caused by <span class=""disease"">hyperkalemia</span> during use of a combined therapy with the <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor and spironolactone."		495.0	495_MESH:D000809_MESH:D006947	495_0	bcv_final_eval_easy_2886		
	MESH:D000809	"<span class=""chemical"">angiotensin</span>"	MESH:D013575	"<span class=""disease"">Syncope</span>"	"<span class=""disease"">Syncope</span> caused by hyperkalemia during use of a combined therapy with the <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor and spironolactone."		495.0	495_MESH:D000809_MESH:D013575	495_0	bcv_final_eval_easy_2887		
	MESH:D013148	"<span class=""chemical"">spironolactone</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"Syncope caused by <span class=""disease"">hyperkalemia</span> during use of a combined therapy with the angiotensin-converting enzyme inhibitor and <span class=""chemical"">spironolactone</span>."		495.0	495_MESH:D013148_MESH:D006947	495_0	bcv_final_eval_easy_2888		
	MESH:D013148	"<span class=""chemical"">spironolactone</span>"	MESH:D013575	"<span class=""disease"">Syncope</span>"	"<span class=""disease"">Syncope</span> caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and <span class=""chemical"">spironolactone</span>."		495.0	495_MESH:D013148_MESH:D013575	495_0	bcv_final_eval_easy_2889		
	MESH:D000450	"<span class=""chemical"">aldosterone</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"The cause of <span class=""disease"">hyperkalemia</span> was considered to be several doses of spiranolactone, an <span class=""chemical"">aldosterone</span> antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor."		495.0	495_MESH:D000450_MESH:D006947	495_3	bcv_final_eval_easy_2890		
	MESH:D017257	"<span class=""chemical"">ramipril</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"The cause of <span class=""disease"">hyperkalemia</span> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of <span class=""chemical"">ramipril</span>, an ACE inhibitor."		495.0	495_MESH:D017257_MESH:D006947	495_3	bcv_final_eval_easy_2891		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D007674	"<span class=""disease"">renal disturbance</span>"	"Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with <span class=""chemical"">potassium</span> sparing agents and who have mild <span class=""disease"">renal disturbance</span>."		495.0	495_MESH:D011188_MESH:D007674	495_5	bcv_final_eval_easy_2892		
	MESH:D011188	"<span class=""chemical"">potassium</span>"	MESH:D006947	"<span class=""disease"">hyperkalemia</span>"	"Clinicians should be alert to the possibility of <span class=""disease"">hyperkalemia</span>, especially in elderly patients using ACE/ARB in combination with <span class=""chemical"">potassium</span> sparing agents and who have mild renal disturbance."		495.0	495_MESH:D011188_MESH:D006947	495_5	bcv_final_eval_easy_2893		
	MESH:D019386	"<span class=""chemical"">alendronate</span>"	MESH:D010146	"<span class=""disease"">skeletal pain</span>"	"Diffuse <span class=""disease"">skeletal pain</span> after administration of <span class=""chemical"">alendronate</span>."		496.0	496_MESH:D019386_MESH:D010146	496_0	bcv_final_eval_easy_2894		
	MESH:D004164	"<span class=""chemical"">bisphosphonates</span>"	MESH:D010024	"<span class=""disease"">Osteoporosis</span>"	"BACKGROUND: <span class=""disease"">Osteoporosis</span> is caused by bone resorption in excess of bone formation, and <span class=""chemical"">bisphosphonates</span>, are used to inhibit bone resorption."		496.0	496_MESH:D004164_MESH:D010024	496_1	bcv_final_eval_easy_2895		
	MESH:D019386	"<span class=""chemical"">Alendronate</span>"	MESH:D010024	"<span class=""disease"">osteoporosis</span>"	"<span class=""chemical"">Alendronate</span>, a biphosphonate, is effective for both the treatment and prevention of <span class=""disease"">osteoporosis</span> in postmenopausal women."		496.0	496_MESH:D019386_MESH:D010024	496_2	bcv_final_eval_easy_2896		
	MESH:D019386	"<span class=""chemical"">alendronate</span>"	MESH:D010146	"<span class=""disease"">skeletal pain</span>"	"We presented a patient admitted to our out-patient clinic with diffuse <span class=""disease"">skeletal pain</span> after three consecutive administration of <span class=""chemical"">alendronate</span>."		496.0	496_MESH:D019386_MESH:D010146	496_5	bcv_final_eval_easy_2897		
	MESH:D004164	"<span class=""chemical"">bisphosphonate</span>"	MESH:D010146	"<span class=""disease"">pain</span>"	"CONCLUSION: We conclude that patients with osteoporosis can report <span class=""disease"">pain</span>, and <span class=""chemical"">bisphosphonate</span>-related <span class=""disease"">pain</span> should also be considered before ascribing this complaint to osteoporosis."		496.0	496_MESH:D004164_MESH:D010146	496_6	bcv_final_eval_easy_2898		
	MESH:D004164	"<span class=""chemical"">bisphosphonate</span>"	MESH:D010024	"<span class=""disease"">osteoporosis</span>"	"CONCLUSION: We conclude that patients with <span class=""disease"">osteoporosis</span> can report pain, and <span class=""chemical"">bisphosphonate</span>-related pain should also be considered before ascribing this complaint to <span class=""disease"">osteoporosis</span>."		496.0	496_MESH:D004164_MESH:D010024	496_6	bcv_final_eval_easy_2899		
	MESH:D017576	"<span class=""chemical"">daptomycin</span>"	MESH:D008581	"<span class=""disease"">meningitis</span>"	"Cerebrospinal fluid penetration of high-dose <span class=""chemical"">daptomycin</span> in suspected Staphylococcus aureus <span class=""disease"">meningitis</span>."		497.0	497_MESH:D017576_MESH:D008581	497_0	bcv_final_eval_easy_2900		
	MESH:D008712	"<span class=""chemical"">methicillin</span>"	MESH:D013203	"<span class=""disease"">Staphylococcus aureus (MSSA) bacteremia</span>"	"OBJECTIVE: To report a case of <span class=""chemical"">methicillin</span>-sensitive <span class=""disease"">Staphylococcus aureus (MSSA) bacteremia</span> with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations."		497.0	497_MESH:D008712_MESH:D013203	497_1	bcv_final_eval_easy_2901		
	MESH:D017576	"<span class=""chemical"">daptomycin</span>"	MESH:D013203	"<span class=""disease"">Staphylococcus aureus (MSSA) bacteremia</span>"	"OBJECTIVE: To report a case of methicillin-sensitive <span class=""disease"">Staphylococcus aureus (MSSA) bacteremia</span> with suspected MSSA meningitis treated with high-dose <span class=""chemical"">daptomycin</span> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations."		497.0	497_MESH:D017576_MESH:D013203	497_1	bcv_final_eval_easy_2902		
	MESH:D008712	"<span class=""chemical"">methicillin</span>"	MESH:D008581	"<span class=""disease"">meningitis</span>"	"OBJECTIVE: To report a case of <span class=""chemical"">methicillin</span>-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA <span class=""disease"">meningitis</span> treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations."		497.0	497_MESH:D008712_MESH:D008581	497_1	bcv_final_eval_easy_2903		
	MESH:D017576	"<span class=""chemical"">daptomycin</span>"	MESH:D008581	"<span class=""disease"">meningitis</span>"	"OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA <span class=""disease"">meningitis</span> treated with high-dose <span class=""chemical"">daptomycin</span> assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations."		497.0	497_MESH:D017576_MESH:D008581	497_1	bcv_final_eval_easy_2904		
	MESH:D003404	"<span class=""chemical"">creatinine</span>"	MESH:D058186	"<span class=""disease"">acute renal failure</span>"	"On day 8, the patient developed <span class=""disease"">acute renal failure</span> (serum <span class=""chemical"">creatinine</span> 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission)."		497.0	497_MESH:D003404_MESH:D058186	497_6	bcv_final_eval_easy_2905		
	MESH:D009254	"<span class=""chemical"">Nafcillin</span>"	MESH:D008581	"<span class=""disease"">meningitis</span>"	"<span class=""chemical"">Nafcillin</span> was discontinued and daptomycin 9 mg/kg daily was initiated for suspected <span class=""disease"">meningitis</span> and was continued until the patient's death on day 16."		497.0	497_MESH:D009254_MESH:D008581	497_9	bcv_final_eval_easy_2906		
	MESH:D009254	"<span class=""chemical"">Nafcillin</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"<span class=""chemical"">Nafcillin</span> was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's <span class=""disease"">death</span> on day 16."		497.0	497_MESH:D009254_MESH:D003643	497_9	bcv_final_eval_easy_2907		
	MESH:D017576	"<span class=""chemical"">daptomycin</span>"	MESH:D003643	"<span class=""disease"">death</span>"	"Nafcillin was discontinued and <span class=""chemical"">daptomycin</span> 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's <span class=""disease"">death</span> on day 16."		497.0	497_MESH:D017576_MESH:D003643	497_9	bcv_final_eval_easy_2908		
	MESH:D017576	"<span class=""chemical"">daptomycin</span>"	MESH:D008581	"<span class=""disease"">meningitis</span>"	"Nafcillin was discontinued and <span class=""chemical"">daptomycin</span> 9 mg/kg daily was initiated for suspected <span class=""disease"">meningitis</span> and was continued until the patient's death on day 16."		497.0	497_MESH:D017576_MESH:D008581	497_9	bcv_final_eval_easy_2909		
	MESH:D017576	"<span class=""chemical"">Daptomycin</span>"	MESH:D009395	"<span class=""disease"">interstitial nephritis</span>"	"DISCUSSION: <span class=""chemical"">Daptomycin</span> was initiated in our patient secondary to possible nafcillin-induced acute <span class=""disease"">interstitial nephritis</span> and relapsing bacteremia."		497.0	497_MESH:D017576_MESH:D009395	497_13	bcv_final_eval_easy_2910		
	MESH:D009254	"<span class=""chemical"">nafcillin</span>"	MESH:D016470	"<span class=""disease"">bacteremia</span>"	"DISCUSSION: Daptomycin was initiated in our patient secondary to possible <span class=""chemical"">nafcillin</span>-induced acute interstitial nephritis and relapsing <span class=""disease"">bacteremia</span>."		497.0	497_MESH:D009254_MESH:D016470	497_13	bcv_final_eval_easy_2911		
	MESH:D017576	"<span class=""chemical"">Daptomycin</span>"	MESH:D016470	"<span class=""disease"">bacteremia</span>"	"DISCUSSION: <span class=""chemical"">Daptomycin</span> was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing <span class=""disease"">bacteremia</span>."		497.0	497_MESH:D017576_MESH:D016470	497_13	bcv_final_eval_easy_2912		
	MESH:D017576	"<span class=""chemical"">daptomycin</span>"	MESH:D016470	"<span class=""disease"">bacteremia</span>"	"CONCLUSIONS: High-dose <span class=""chemical"">daptomycin</span> may be an alternative option for MSSA <span class=""disease"">bacteremia</span> with or without a CNS source in patients who have failed or cannot tolerate standard therapy."		497.0	497_MESH:D017576_MESH:D016470	497_15	bcv_final_eval_easy_2913		
	MESH:D001556	"<span class=""chemical"">lindane</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"The role of nitric oxide in <span class=""disease"">convulsions</span> induced by <span class=""chemical"">lindane</span> in rats."		498.0	498_MESH:D001556_MESH:D012640	498_0	bcv_final_eval_easy_2914		
	MESH:D009569	"<span class=""chemical"">nitric oxide</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"The role of <span class=""chemical"">nitric oxide</span> in <span class=""disease"">convulsions</span> induced by lindane in rats."		498.0	498_MESH:D009569_MESH:D012640	498_0	bcv_final_eval_easy_2915		
	MESH:D005680	"<span class=""chemical"">GABA</span>"	MESH:D012640	"<span class=""disease"">convulsions</span>"	"It evokes <span class=""disease"">convulsions</span> mainly trough the blockage of <span class=""chemical"">GABA</span>(A) receptors."		498.0	498_MESH:D005680_MESH:D012640	498_2	bcv_final_eval_easy_2916		
	MESH:D009569	"<span class=""chemical"">Nitric oxide</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"<span class=""chemical"">Nitric oxide</span> (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different <span class=""disease"">epilepsy</span> models."		498.0	498_MESH:D009569_MESH:D004827	498_3	bcv_final_eval_easy_2917		
	MESH:D001120	"<span class=""chemical"">L-arginine</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of <span class=""chemical"">L-arginine</span>, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different <span class=""disease"">epilepsy</span> models."		498.0	498_MESH:D001120_MESH:D004827	498_3	bcv_final_eval_easy_2918		
	MESH:D019331	"<span class=""chemical"">L-NAME</span>"	MESH:D004827	"<span class=""disease"">epilepsy</span>"	"Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and <span class=""chemical"">L-NAME</span> (NOS inhibitor) observed in different <span class=""disease"">epilepsy</span> models."		498.0	498_MESH:D019331_MESH:D004827	498_3	bcv_final_eval_easy_2919		
	MESH:D001556	"<span class=""chemical"">lindane</span>"	MESH:D012640	"<span class=""disease"">convulsion</span>"	"The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased <span class=""disease"">convulsion</span> incidence and severity and shortened latency time to first <span class=""disease"">convulsion</span> elicited by lower <span class=""chemical"">lindane</span> dose (4 mg/kg, i.p.)."		498.0	498_MESH:D001556_MESH:D012640	498_5	bcv_final_eval_easy_2920		
	MESH:D001120	"<span class=""chemical"">L-arginine</span>"	MESH:D012640	"<span class=""disease"">convulsion</span>"	"The administration of <span class=""chemical"">L-arginine</span> (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased <span class=""disease"">convulsion</span> incidence and severity and shortened latency time to first <span class=""disease"">convulsion</span> elicited by lower lindane dose (4 mg/kg, i.p.)."		498.0	498_MESH:D001120_MESH:D012640	498_5	bcv_final_eval_easy_2921		
	MESH:D001556	"<span class=""chemical"">lindane</span>"	MESH:D012640	"<span class=""disease"">convulsive/convulsion</span>"	"On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased <span class=""disease"">convulsion</span> incidence and severity and prolonged latency time to <span class=""disease"">convulsion</span> following injection with a <span class=""disease"">convulsive</span> dose of <span class=""chemical"">lindane</span> (8 mg/kg, i.p.)."		498.0	498_MESH:D001556_MESH:D012640	498_6	bcv_final_eval_easy_2922		
	MESH:D019331	"<span class=""chemical"">L-NAME</span>"	MESH:D012640	"<span class=""disease"">convulsive/convulsion</span>"	"On the contrary, pretreatment with <span class=""chemical"">L-NAME</span> (500, 700 and 900 mg/kg, i.p.) decreased <span class=""disease"">convulsion</span> incidence and severity and prolonged latency time to <span class=""disease"">convulsion</span> following injection with a <span class=""disease"">convulsive</span> dose of lindane (8 mg/kg, i.p.)."		498.0	498_MESH:D019331_MESH:D012640	498_6	bcv_final_eval_easy_2923		
	MESH:D001556	"<span class=""chemical"">lindane</span>"	MESH:D012640	"<span class=""disease"">seizures</span>"	"These results support the conclusion that NO plays a role of endogenous convulsant in rat model of <span class=""chemical"">lindane</span> <span class=""disease"">seizures</span>."		498.0	498_MESH:D001556_MESH:D012640	498_8	bcv_final_eval_easy_2924		
	MESH:D005690	"<span class=""chemical"">galactose</span>"	MESH:D003072	"<span class=""disease"">cognitive deficits</span>"	"Long-term oral <span class=""chemical"">galactose</span> treatment prevents <span class=""disease"">cognitive deficits</span> in male Wistar rats treated intracerebroventricularly with streptozotocin."		499.0	499_MESH:D005690_MESH:D003072	499_0	bcv_final_eval_easy_2925		
	MESH:D013311	"<span class=""chemical"">streptozotocin</span>"	MESH:D003072	"<span class=""disease"">cognitive deficits</span>"	"Long-term oral galactose treatment prevents <span class=""disease"">cognitive deficits</span> in male Wistar rats treated intracerebroventricularly with <span class=""chemical"">streptozotocin</span>."		499.0	499_MESH:D013311_MESH:D003072	499_0	bcv_final_eval_easy_2926		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D000544	"<span class=""disease"">Alzheimer's disease</span>"	"Basic and clinical research has demonstrated that dementia of sporadic <span class=""disease"">Alzheimer's disease</span> (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased <span class=""chemical"">glucose</span> transport via <span class=""chemical"">glucose</span> transporter GLUT4 and decreased <span class=""chemical"">glucose</span> metabolism in brain cells."		499.0	499_MESH:D005947_MESH:D000544	499_1	bcv_final_eval_easy_2927		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D003704	"<span class=""disease"">dementia</span>"	"Basic and clinical research has demonstrated that <span class=""disease"">dementia</span> of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased <span class=""chemical"">glucose</span> transport via <span class=""chemical"">glucose</span> transporter GLUT4 and decreased <span class=""chemical"">glucose</span> metabolism in brain cells."		499.0	499_MESH:D005947_MESH:D003704	499_1	bcv_final_eval_easy_2928		
	MESH:D005690	"<span class=""chemical"">galactose</span>"	MESH:D008569	"<span class=""disease"">galactose induce memory deterioration</span>"	"Exclusively parenteral daily injections of <span class=""chemical""></span><span class=""disease"">galactose</span> induce memory deterioration in rodents and are used to generate animal aging model, but the effects of oral <span class=""chemical"">galactose</span> treatment on cognitive functions have never been tested."		499.0	499_MESH:D005690_MESH:D008569	499_3	bcv_final_eval_easy_2929		
	MESH:D005690	"<span class=""chemical"">galactose</span>"	MESH:D003072	"<span class=""disease"">cognitive deficits</span>"	"We have investigated the effects of continuous daily oral <span class=""chemical"">galactose</span> (200 mg/kg/day) treatment on <span class=""disease"">cognitive deficits</span> in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively."		499.0	499_MESH:D005690_MESH:D003072	499_4	bcv_final_eval_easy_2930		
	MESH:D013311	"<span class=""chemical"">streptozotocin</span>"	MESH:D003072	"<span class=""disease"">cognitive deficits</span>"	"We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on <span class=""disease"">cognitive deficits</span> in <span class=""chemical"">streptozotocin</span>-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively."		499.0	499_MESH:D013311_MESH:D003072	499_4	bcv_final_eval_easy_2931		
	MESH:D005690	"<span class=""chemical"">galactose</span>"	MESH:D003072	"<span class=""disease"">cognitive deficits</span>"	"One month of oral <span class=""chemical"">galactose</span> treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced <span class=""disease"">cognitive deficits</span>."		499.0	499_MESH:D005690_MESH:D003072	499_5	bcv_final_eval_easy_2932		
	MESH:D005690	"<span class=""chemical"">galactose</span>"	MESH:D006402	"<span class=""disease"">galactose in the blood</span>"	"Additionally, oral <span class=""chemical"">galactose</span> administration led to the appearance of <span class=""chemical""></span><span class=""disease"">galactose</span> in the blood."		499.0	499_MESH:D005690_MESH:D006402	499_7	bcv_final_eval_easy_2933		
	MESH:D005690	"<span class=""chemical"">galactose</span>"	MESH:D000544	"<span class=""disease"">AD</span>"	"Oral <span class=""chemical"">galactose</span> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in <span class=""disease"">AD</span>."		499.0	499_MESH:D005690_MESH:D000544	499_9	bcv_final_eval_easy_2934		
	MESH:D005690	"<span class=""chemical"">galactose</span>"	MESH:D009062	"<span class=""disease"">Oral galactose exposure</span>"	"<span class=""disease"">Oral </span><span class=""chemical"">galactose</span> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD."		499.0	499_MESH:D005690_MESH:D009062	499_9	bcv_final_eval_easy_2935		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D009062	"<span class=""disease"">Oral galactose exposure</span>"	"<span class=""disease"">Oral galactose exposure</span> might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with <span class=""chemical"">glucose</span> hypometabolism in AD."		499.0	499_MESH:D005947_MESH:D009062	499_9	bcv_final_eval_easy_2936		
	MESH:D005690	"<span class=""chemical"">galactose</span>"	MESH:D003072	"<span class=""disease"">cognitive deficits</span>"	"Oral <span class=""chemical"">galactose</span> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of <span class=""disease"">cognitive deficits</span> associated with glucose hypometabolism in AD."		499.0	499_MESH:D005690_MESH:D003072	499_9	bcv_final_eval_easy_2937		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D003072	"<span class=""disease"">cognitive deficits</span>"	"Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of <span class=""disease"">cognitive deficits</span> associated with <span class=""chemical"">glucose</span> hypometabolism in AD."		499.0	499_MESH:D005947_MESH:D003072	499_9	bcv_final_eval_easy_2938		
	MESH:D005947	"<span class=""chemical"">glucose</span>"	MESH:D000544	"<span class=""disease"">AD</span>"	"Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with <span class=""chemical"">glucose</span> hypometabolism in <span class=""disease"">AD</span>."		499.0	499_MESH:D005947_MESH:D000544	499_9	bcv_final_eval_easy_2939		
